{"683534226be567902b10272655d2973d7ddc1f91": [["management involved antibiotic therapy, debridement and wound dressings.", [["wound", "ANATOMY", 56, 61], ["wound", "PATHOLOGICAL_FORMATION", 56, 61], ["management", "TREATMENT", 0, 10], ["antibiotic therapy", "TREATMENT", 20, 38], ["debridement", "TREATMENT", 40, 51], ["wound dressings", "TREATMENT", 56, 71], ["antibiotic therapy", "OBSERVATION", 20, 38], ["wound dressings", "OBSERVATION", 56, 71]]], ["Further breakdown ensued, exposing the bone and mandibular reconstruction plate ( Figure 1 ).", [["bone", "ANATOMY", 39, 43], ["mandibular", "ANATOMY", 48, 58], ["bone", "TISSUE", 39, 43], ["Further breakdown", "PROBLEM", 0, 17], ["the bone and mandibular reconstruction plate", "TREATMENT", 35, 79], ["breakdown", "OBSERVATION_MODIFIER", 8, 17], ["bone", "ANATOMY", 39, 43], ["mandibular", "ANATOMY", 48, 58]]], ["We debrided the wound, sectioned the exposed plate at the wound edges and covered with an Integra\u00ae dermal regeneration template and a sponge bolster dressing; this was unsuccessful.", [["wound", "ANATOMY", 16, 21], ["wound", "ANATOMY", 58, 63], ["dermal", "ANATOMY", 99, 105], ["wound", "PATHOLOGICAL_FORMATION", 16, 21], ["wound edges", "PATHOLOGICAL_FORMATION", 58, 69], ["dermal", "TISSUE", 99, 105], ["the wound", "PROBLEM", 12, 21], ["the wound edges", "TREATMENT", 54, 69], ["an Integra\u00ae dermal regeneration template", "TREATMENT", 87, 127], ["a sponge bolster dressing", "TREATMENT", 132, 157], ["wound", "OBSERVATION", 16, 21], ["plate", "OBSERVATION_MODIFIER", 45, 50], ["wound", "ANATOMY", 58, 63], ["edges", "OBSERVATION_MODIFIER", 64, 69], ["Integra\u00ae dermal", "OBSERVATION", 90, 105], ["regeneration template", "OBSERVATION", 106, 127]]]], "PMC7274937": [["Problems with General AnaesthesiaIn a recent report related to 138 confirmed COVID-19 cases, 41.3% were considered hospital acquired infection, and more than 70% were healthcare providers [2].", [["infection", "DISEASE", 133, 142], ["COVID", "TEST", 77, 82], ["hospital acquired infection", "PROBLEM", 115, 142]]], ["In anaesthesia practice, it is important to reduce exposure to patient\u2019s respiratory secretion and minimize the aerosol-generating procedures performed in general anaesthesia (GA) like bag mask ventilation, open airway ventilation, open airway suctioning, and endotracheal intubation.", [["respiratory", "ANATOMY", 73, 84], ["airway", "ANATOMY", 212, 218], ["airway", "ANATOMY", 237, 243], ["endotracheal", "ANATOMY", 260, 272], ["patient", "ORGANISM", 63, 70], ["airway", "MULTI-TISSUE_STRUCTURE", 212, 218], ["airway", "MULTI-TISSUE_STRUCTURE", 237, 243], ["patient", "SPECIES", 63, 70], ["the aerosol-generating procedures", "TREATMENT", 108, 141], ["general anaesthesia (GA)", "TREATMENT", 155, 179], ["bag mask ventilation", "TREATMENT", 185, 205], ["open airway ventilation", "TREATMENT", 207, 230], ["open airway suctioning", "TREATMENT", 232, 254], ["endotracheal intubation", "TREATMENT", 260, 283], ["airway ventilation", "OBSERVATION", 212, 230], ["airway", "ANATOMY", 237, 243], ["suctioning", "OBSERVATION", 244, 254], ["endotracheal intubation", "OBSERVATION", 260, 283]]], ["A systemic literature review and meta-analysis that evaluated the transmission of Severe Acute Respiratory Syndrome Corona Virus 1 (SARS\u2013COV-1) to health care personnel in association with exposure to aerosol generating procedure found a significantly increased odds ratio of 6.6 [3].", [["Acute Respiratory Syndrome", "DISEASE", 89, 115], ["SARS\u2013COV-1", "CHEMICAL", 132, 142], ["Severe Acute Respiratory Syndrome Corona Virus 1", "SPECIES", 82, 130], ["SARS\u2013COV-1", "SPECIES", 132, 142], ["A systemic literature review", "TEST", 0, 28], ["meta-analysis", "TEST", 33, 46], ["Severe Acute Respiratory Syndrome Corona Virus", "PROBLEM", 82, 128], ["aerosol generating procedure", "TREATMENT", 201, 229], ["a significantly increased odds ratio", "PROBLEM", 236, 272], ["Severe", "OBSERVATION_MODIFIER", 82, 88], ["Acute", "OBSERVATION_MODIFIER", 89, 94], ["Respiratory Syndrome", "OBSERVATION", 95, 115]]], ["The authors concluded that the ensemble of personal protective equipment (PPE) used in the simulation may not fully prevent exposure of personnel performing endotracheal intubation in emergency department settings.", [["endotracheal", "ANATOMY", 157, 169], ["personal protective equipment (PPE)", "TREATMENT", 43, 78], ["endotracheal intubation", "TREATMENT", 157, 180]]], ["GA in a COVID-19 patient is a high-risk procedure owing to the proximity of the health care workers to the patient\u2019s oropharynx, which carries a high viral load.", [["oropharynx", "ANATOMY", 117, 127], ["GA", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 17, 24], ["patient", "ORGANISM", 107, 114], ["oropharynx", "ORGAN", 117, 127], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 107, 114], ["a high-risk procedure", "TREATMENT", 28, 49], ["a high viral load", "PROBLEM", 143, 160], ["oropharynx", "ANATOMY", 117, 127], ["viral load", "OBSERVATION", 150, 160]]], ["Moreover, another situation, which poses a huge threat to ICU and operation theatre staff, is most often performed by anaesthesiologists, is cardiopulmonary resuscitation (CPR).Advantages of Regional AnaesthesiaIn order to avoid any airway manipulation during COVID-19, the use of RA may be preferred.", [["airway", "ANATOMY", 233, 239], ["RA", "DISEASE", 281, 283], ["COVID-19", "CHEMICAL", 260, 268], ["airway", "MULTI-TISSUE_STRUCTURE", 233, 239], ["cardiopulmonary resuscitation", "TREATMENT", 141, 170], ["Regional AnaesthesiaIn order", "TREATMENT", 191, 219], ["any airway manipulation", "TREATMENT", 229, 252], ["COVID", "TEST", 260, 265], ["RA", "TREATMENT", 281, 283], ["cardiopulmonary", "ANATOMY", 141, 156], ["airway", "ANATOMY", 233, 239], ["RA", "ANATOMY", 281, 283]]], ["There is general benefit of reduced pain and opioid consumption, reduced postoperative pulmonary complication, reduced postoperative nausea and vomiting, and reduced postoperative cognitive dysfunction and delirium during RA for laparoscopic surgery.", [["pulmonary", "ANATOMY", 87, 96], ["pain", "DISEASE", 36, 40], ["postoperative pulmonary complication", "DISEASE", 73, 109], ["postoperative nausea and vomiting", "DISEASE", 119, 152], ["postoperative cognitive dysfunction", "DISEASE", 166, 201], ["delirium", "DISEASE", 206, 214], ["RA", "DISEASE", 222, 224], ["opioid", "SIMPLE_CHEMICAL", 45, 51], ["pulmonary", "ORGAN", 87, 96], ["reduced pain", "PROBLEM", 28, 40], ["opioid consumption", "PROBLEM", 45, 63], ["reduced postoperative pulmonary complication", "PROBLEM", 65, 109], ["reduced postoperative nausea", "PROBLEM", 111, 139], ["vomiting", "PROBLEM", 144, 152], ["reduced postoperative cognitive dysfunction", "PROBLEM", 158, 201], ["delirium", "PROBLEM", 206, 214], ["laparoscopic surgery", "TREATMENT", 229, 249], ["reduced", "OBSERVATION_MODIFIER", 28, 35], ["pain", "OBSERVATION", 36, 40], ["pulmonary", "ANATOMY", 87, 96], ["complication", "OBSERVATION", 97, 109], ["postoperative nausea", "OBSERVATION", 119, 139], ["postoperative cognitive dysfunction", "OBSERVATION", 166, 201]]], ["The avoidance of airway instrumentation also prevents patient coughing during intubation and extubation [4].", [["airway", "ANATOMY", 17, 23], ["airway", "MULTI-TISSUE_STRUCTURE", 17, 23], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["airway instrumentation", "TREATMENT", 17, 39], ["patient coughing", "PROBLEM", 54, 70], ["intubation", "TREATMENT", 78, 88], ["extubation", "TREATMENT", 93, 103], ["airway", "ANATOMY", 17, 23], ["instrumentation", "OBSERVATION", 24, 39]]], ["RA has fewer effects on respiratory function and dynamics compared with GA with or without muscle paralysis.", [["respiratory", "ANATOMY", 24, 35], ["muscle", "ANATOMY", 91, 97], ["RA", "DISEASE", 0, 2], ["GA", "CHEMICAL", 72, 74], ["muscle paralysis", "DISEASE", 91, 107], ["muscle", "ORGAN", 91, 97], ["respiratory function", "TEST", 24, 44], ["muscle paralysis", "PROBLEM", 91, 107], ["fewer", "OBSERVATION_MODIFIER", 7, 12], ["effects", "OBSERVATION_MODIFIER", 13, 20], ["respiratory function", "OBSERVATION", 24, 44], ["without", "UNCERTAINTY", 83, 90], ["muscle", "ANATOMY", 91, 97], ["paralysis", "OBSERVATION", 98, 107]]], ["This relative preservation of respiratory function could theoretically reduce postoperative pulmonary complications in COVID-19 patients who may already have reduced respiratory function from COVID-19-associated pneumonia or acute respiratory distress syndrome.", [["respiratory", "ANATOMY", 30, 41], ["pulmonary", "ANATOMY", 92, 101], ["respiratory", "ANATOMY", 166, 177], ["respiratory", "ANATOMY", 231, 242], ["postoperative pulmonary complications", "DISEASE", 78, 115], ["COVID-19", "CHEMICAL", 192, 200], ["pneumonia", "DISEASE", 212, 221], ["acute respiratory distress syndrome", "DISEASE", 225, 260], ["pulmonary", "ORGAN", 92, 101], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["respiratory function", "PROBLEM", 30, 50], ["postoperative pulmonary complications", "PROBLEM", 78, 115], ["reduced respiratory function", "PROBLEM", 158, 186], ["COVID", "TEST", 192, 197], ["pneumonia", "PROBLEM", 212, 221], ["acute respiratory distress syndrome", "PROBLEM", 225, 260], ["respiratory function", "OBSERVATION", 30, 50], ["postoperative", "OBSERVATION_MODIFIER", 78, 91], ["pulmonary", "ANATOMY", 92, 101], ["complications", "OBSERVATION", 102, 115], ["reduced", "OBSERVATION_MODIFIER", 158, 165], ["respiratory function", "OBSERVATION", 166, 186], ["pneumonia", "OBSERVATION", 212, 221], ["acute", "OBSERVATION_MODIFIER", 225, 230], ["respiratory distress syndrome", "OBSERVATION", 231, 260]]], ["However, this approach requires a co-operative patient, an experienced surgeon, and an enthusiastic anaesthesiologist ever prepared to supplement it with intravenous adjuncts and if needed with general anaesthesia.", [["intravenous", "ANATOMY", 154, 165], ["patient", "ORGANISM", 47, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 154, 165], ["patient", "SPECIES", 47, 54], ["intravenous adjuncts", "TREATMENT", 154, 174], ["general anaesthesia", "TREATMENT", 194, 213]]], ["From these, we conclude that with proper application and with suitable improvements, regional anaesthesia has got the potential to emerge as the novel gold standard anaesthetic technique for elective laparoscopic surgeries [5].Advantages of Regional AnaesthesiaHaving a well-thought-out RA plan to manage infected patients in this new normal will ensure the best possible outcome for both the patient and the perioperative management team during laparoscopy.", [["patients", "ORGANISM", 314, 322], ["patient", "ORGANISM", 393, 400], ["patients", "SPECIES", 314, 322], ["patient", "SPECIES", 393, 400], ["regional anaesthesia", "TREATMENT", 85, 105], ["the novel gold standard anaesthetic technique", "TREATMENT", 141, 186], ["elective laparoscopic surgeries", "TREATMENT", 191, 222], ["the perioperative management", "TREATMENT", 405, 433], ["laparoscopy", "TEST", 446, 457]]]], "4072d963e777819e01f6bc7af1f24f419cb67e93": [["IntroductionNitric oxide ( \u2022 NO) mediates innate and adaptive immunity by inhibiting viral replication and modulating T-helper (Th) 1/Th2 responses, respectively (Akaike and Maeda, 2000; Davis and Matalon, 2001; Xu et al., 2006) .", [["IntroductionNitric oxide", "CHEMICAL", 0, 24], ["NO", "CHEMICAL", 29, 31], ["IntroductionNitric oxide", "CHEMICAL", 0, 24], ["NO", "CHEMICAL", 29, 31], ["IntroductionNitric oxide", "SIMPLE_CHEMICAL", 0, 24], ["\u2022 NO", "SIMPLE_CHEMICAL", 27, 31], ["T-helper", "GENE_OR_GENE_PRODUCT", 118, 126], ["Th) 1", "GENE_OR_GENE_PRODUCT", 128, 133], ["Th2", "GENE_OR_GENE_PRODUCT", 134, 137], ["IntroductionNitric oxide", "TREATMENT", 0, 24], ["adaptive immunity", "TREATMENT", 53, 70], ["viral replication", "TREATMENT", 85, 102]]], ["During immune responses to respiratory viral infections, such as influenza A, \u2022 NO is generated by inducible nitric oxide synthase (iNOS) in alveolar macrophages (AMs), pulmonary epithelial cells, and neutrophils.", [["alveolar macrophages", "ANATOMY", 141, 161], ["AMs", "ANATOMY", 163, 166], ["pulmonary epithelial cells", "ANATOMY", 169, 195], ["neutrophils", "ANATOMY", 201, 212], ["respiratory viral infections", "DISEASE", 27, 55], ["NO", "CHEMICAL", 80, 82], ["nitric oxide", "CHEMICAL", 109, 121], ["NO", "CHEMICAL", 80, 82], ["nitric oxide", "CHEMICAL", 109, 121], ["NO", "SIMPLE_CHEMICAL", 80, 82], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 99, 130], ["iNOS", "GENE_OR_GENE_PRODUCT", 132, 136], ["alveolar macrophages", "CELL", 141, 161], ["AMs", "CELL", 163, 166], ["pulmonary epithelial cells", "CELL", 169, 195], ["neutrophils", "CELL", 201, 212], ["nitric oxide synthase", "PROTEIN", 109, 130], ["iNOS", "PROTEIN", 132, 136], ["alveolar macrophages", "CELL_TYPE", 141, 161], ["AMs", "CELL_TYPE", 163, 166], ["pulmonary epithelial cells", "CELL_TYPE", 169, 195], ["neutrophils", "CELL_TYPE", 201, 212], ["respiratory viral infections", "PROBLEM", 27, 55], ["influenza A", "PROBLEM", 65, 76], ["inducible nitric oxide synthase", "TREATMENT", 99, 130], ["alveolar macrophages", "TEST", 141, 161], ["pulmonary epithelial cells", "PROBLEM", 169, 195], ["neutrophils", "TEST", 201, 212], ["respiratory", "ANATOMY", 27, 38], ["viral infections", "OBSERVATION", 39, 55], ["alveolar macrophages", "ANATOMY", 141, 161], ["pulmonary", "ANATOMY", 169, 178], ["epithelial cells", "OBSERVATION", 179, 195], ["neutrophils", "ANATOMY", 201, 212]]], ["To produce \u2022 NO, IFN\u03b1/\u03b2 and the dsRNA-activated protein kinase (PKR) system is required which triggers the iNOS gene at an early stage of viral infection.", [["NO", "CHEMICAL", 13, 15], ["viral infection", "DISEASE", 138, 153], ["NO", "CHEMICAL", 13, 15], ["NO", "GENE_OR_GENE_PRODUCT", 13, 15], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 17, 21], ["\u03b2", "GENE_OR_GENE_PRODUCT", 22, 23], ["dsRNA-activated protein kinase", "GENE_OR_GENE_PRODUCT", 32, 62], ["PKR", "GENE_OR_GENE_PRODUCT", 64, 67], ["iNOS", "GENE_OR_GENE_PRODUCT", 107, 111], ["IFN\u03b1", "PROTEIN", 17, 21], ["\u03b2", "PROTEIN", 22, 23], ["dsRNA-activated protein kinase", "PROTEIN", 32, 62], ["PKR", "PROTEIN", 64, 67], ["iNOS gene", "DNA", 107, 116], ["IFN", "TEST", 17, 20], ["the dsRNA", "TEST", 28, 37], ["the iNOS gene", "PROBLEM", 103, 116], ["viral infection", "PROBLEM", 138, 153], ["viral", "OBSERVATION_MODIFIER", 138, 143], ["infection", "OBSERVATION", 144, 153]]], ["Subsequently, IFN-\u03b3 through the signal transducer and activator of transcription (STAT) pathway induces persistent \u2022 NO production at the later stages of infection (Xu et al., 2006) .", [["NO", "CHEMICAL", 117, 119], ["infection", "DISEASE", 154, 163], ["NO", "CHEMICAL", 117, 119], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 14, 19], ["signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 32, 80], ["STAT", "GENE_OR_GENE_PRODUCT", 82, 86], ["NO", "GENE_OR_GENE_PRODUCT", 117, 119], ["IFN-\u03b3", "PROTEIN", 14, 19], ["STAT", "PROTEIN", 82, 86], ["IFN", "TREATMENT", 14, 17], ["infection", "PROBLEM", 154, 163], ["persistent", "OBSERVATION_MODIFIER", 104, 114], ["infection", "OBSERVATION", 154, 163]]], ["The \u2022 NO likely functions as a signalling molecule in initiation and progression of immune responses to viral infections.IntroductionThe \u2022 NO is known to inhibit viral protein and/or RNA synthesis by modification of target molecules essential for viral replication, such as ribonucleotide reductase and viral protease (Davis and Matalon, 2001; Xu et al., 2006) .", [["NO", "CHEMICAL", 6, 8], ["viral infections", "DISEASE", 104, 120], ["NO", "CHEMICAL", 139, 141], ["NO", "CHEMICAL", 6, 8], ["NO", "CHEMICAL", 139, 141], ["ribonucleotide", "CHEMICAL", 274, 288], ["NO", "SIMPLE_CHEMICAL", 6, 8], ["NO", "SIMPLE_CHEMICAL", 139, 141], ["ribonucleotide reductase", "GENE_OR_GENE_PRODUCT", 274, 298], ["viral protein", "PROTEIN", 162, 175], ["target molecules", "PROTEIN", 216, 232], ["ribonucleotide reductase", "PROTEIN", 274, 298], ["viral protease", "PROTEIN", 303, 317], ["a signalling molecule", "PROBLEM", 29, 50], ["immune responses", "PROBLEM", 84, 100], ["viral infections", "PROBLEM", 104, 120], ["viral protein", "PROBLEM", 162, 175], ["RNA synthesis", "PROBLEM", 183, 196], ["target molecules", "PROBLEM", 216, 232], ["viral replication", "PROBLEM", 247, 264], ["ribonucleotide reductase", "TREATMENT", 274, 298], ["viral protease", "TREATMENT", 303, 317], ["NO likely", "UNCERTAINTY", 6, 15], ["viral infections", "OBSERVATION", 104, 120]]], ["The \u2022 NO has antiviral effects on RNA viruses, such as influenza A virus, and DNA viruses, such as human herpes virus (Davis and Matalon, 2001) .", [["NO", "CHEMICAL", 6, 8], ["influenza A", "DISEASE", 55, 66], ["human herpes virus", "DISEASE", 99, 117], ["NO", "CHEMICAL", 6, 8], ["NO", "SIMPLE_CHEMICAL", 6, 8], ["influenza A virus", "ORGANISM", 55, 72], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["human", "ORGANISM", 99, 104], ["herpes virus", "ORGANISM", 105, 117], ["influenza A virus", "SPECIES", 55, 72], ["human", "SPECIES", 99, 104], ["herpes virus", "SPECIES", 105, 117], ["influenza A virus", "SPECIES", 55, 72], ["human herpes virus", "SPECIES", 99, 117], ["antiviral effects", "PROBLEM", 13, 30], ["RNA viruses", "PROBLEM", 34, 45], ["influenza A virus", "PROBLEM", 55, 72], ["DNA viruses", "PROBLEM", 78, 89], ["human herpes virus", "PROBLEM", 99, 117], ["NO", "UNCERTAINTY", 6, 8], ["antiviral", "OBSERVATION", 13, 22]]], ["However, studies exploiting immortalized cell lines may not fully elucidate the roles of \u2022 NO in the host.", [["cell lines", "ANATOMY", 41, 51], ["NO", "CHEMICAL", 91, 93], ["NO", "CHEMICAL", 91, 93], ["cell lines", "CELL", 41, 51], ["NO", "GENE_OR_GENE_PRODUCT", 91, 93], ["immortalized cell lines", "CELL_LINE", 28, 51], ["immortalized cell lines", "PROBLEM", 28, 51], ["immortalized cell lines", "OBSERVATION", 28, 51]]], ["In addition, since \u2022 NO is a highly reactive nitrogen/oxygen radical, in cases of its excessive generation during viral infection, it may be detrimental by damaging uninfected host cells rather than inhibiting viral replication in infected cells (Davis and Matalon, 2001) .IntroductionPorcine respiratory coronavirus (PRCV) is a positive-strand RNA virus which belongs to group 1 coronaviruses (CoVs) in the family Coronaviridae, order Nidovirales (Saif, 2004) .", [["cells", "ANATOMY", 181, 186], ["cells", "ANATOMY", 240, 245], ["NO", "CHEMICAL", 21, 23], ["oxygen", "CHEMICAL", 54, 60], ["viral infection", "DISEASE", 114, 129], ["respiratory coronavirus", "DISEASE", 293, 316], ["NO", "CHEMICAL", 21, 23], ["nitrogen", "CHEMICAL", 45, 53], ["oxygen", "CHEMICAL", 54, 60], ["NO", "SIMPLE_CHEMICAL", 21, 23], ["nitrogen", "SIMPLE_CHEMICAL", 45, 53], ["oxygen", "SIMPLE_CHEMICAL", 54, 60], ["radical", "SIMPLE_CHEMICAL", 61, 68], ["host cells", "CELL", 176, 186], ["cells", "CELL", 240, 245], ["IntroductionPorcine respiratory coronavirus", "ORGANISM", 273, 316], ["PRCV", "GENE_OR_GENE_PRODUCT", 318, 322], ["group 1 coronaviruses", "ORGANISM", 372, 393], ["CoVs", "CANCER", 395, 399], ["uninfected host cells", "CELL_TYPE", 165, 186], ["infected cells", "CELL_TYPE", 231, 245], ["IntroductionPorcine respiratory coronavirus", "SPECIES", 273, 316], ["PRCV", "SPECIES", 318, 322], ["a highly reactive nitrogen/oxygen radical", "TREATMENT", 27, 68], ["its excessive generation", "PROBLEM", 82, 106], ["viral infection", "PROBLEM", 114, 129], ["damaging uninfected host cells", "PROBLEM", 156, 186], ["viral replication in infected cells", "PROBLEM", 210, 245], ["IntroductionPorcine respiratory coronavirus", "PROBLEM", 273, 316], ["a positive-strand RNA virus", "PROBLEM", 327, 354], ["reactive", "OBSERVATION_MODIFIER", 36, 44], ["oxygen radical", "OBSERVATION", 54, 68], ["viral infection", "OBSERVATION", 114, 129], ["host cells", "OBSERVATION", 176, 186], ["infected cells", "OBSERVATION", 231, 245], ["respiratory coronavirus", "OBSERVATION", 293, 316]]], ["In pigs, PRCV induces upper and lower respiratory tract disease.", [["lower respiratory tract", "ANATOMY", 32, 55], ["PRCV", "CHEMICAL", 9, 13], ["upper and lower respiratory tract disease", "DISEASE", 22, 63], ["pigs", "ORGANISM", 3, 7], ["PRCV", "ORGANISM", 9, 13], ["upper", "ORGANISM_SUBDIVISION", 22, 27], ["lower", "ORGANISM_SUBDIVISION", 32, 37], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["PRCV", "SPECIES", 9, 13], ["upper and lower respiratory tract disease", "PROBLEM", 22, 63], ["upper", "ANATOMY_MODIFIER", 22, 27], ["lower", "ANATOMY_MODIFIER", 32, 37], ["respiratory tract", "ANATOMY", 38, 55], ["disease", "OBSERVATION", 56, 63]]], ["The virus mainly damages pulmonary epithelial cells at the onset of infection and thereafter induces lymphohistiocytic interstitial pneumonia (Cox et al., 1990; Jung et al., 2007) .", [["pulmonary epithelial cells", "ANATOMY", 25, 51], ["lymphohistiocytic interstitial", "ANATOMY", 101, 131], ["infection", "DISEASE", 68, 77], ["interstitial pneumonia", "DISEASE", 119, 141], ["pulmonary epithelial cells", "CELL", 25, 51], ["pulmonary epithelial cells", "CELL_TYPE", 25, 51], ["The virus mainly damages pulmonary epithelial cells", "PROBLEM", 0, 51], ["infection", "PROBLEM", 68, 77], ["lymphohistiocytic interstitial pneumonia", "PROBLEM", 101, 141], ["virus", "OBSERVATION", 4, 9], ["pulmonary", "ANATOMY", 25, 34], ["epithelial cells", "OBSERVATION", 35, 51], ["infection", "OBSERVATION", 68, 77], ["lymphohistiocytic", "OBSERVATION_MODIFIER", 101, 118], ["interstitial", "ANATOMY_MODIFIER", 119, 131], ["pneumonia", "OBSERVATION", 132, 141]]], ["The pulmonary lymphohistiocytic inflammation induced coincided with increased Th1 (IFN-\u03b3) cytokines in serum and lung (bronchoalveolar lavage) and large numbers of IFN-\u03b3 secreting T cells infiltrating the lungs and regional lymph nodes (Jung et al., 2007; Zhang et al., 2008) .IntroductionPorcine reproductive and respiratory syndrome virus (PRRSV) is a positive-strand RNA virus in the family Arteriviridae, and like CoVs, it belongs to the order Nidovirales.", [["pulmonary lymphohistiocytic", "ANATOMY", 4, 31], ["serum", "ANATOMY", 103, 108], ["lung", "ANATOMY", 113, 117], ["bronchoalveolar lavage", "ANATOMY", 119, 141], ["T cells", "ANATOMY", 180, 187], ["lungs", "ANATOMY", 205, 210], ["lymph nodes", "ANATOMY", 224, 235], ["inflammation", "DISEASE", 32, 44], ["Porcine reproductive and respiratory syndrome virus", "DISEASE", 289, 340], ["pulmonary lymphohistiocytic", "PATHOLOGICAL_FORMATION", 4, 31], ["Th1", "GENE_OR_GENE_PRODUCT", 78, 81], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 83, 88], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["lung", "ORGAN", 113, 117], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 119, 141], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 164, 169], ["T cells", "CELL", 180, 187], ["lungs", "ORGAN", 205, 210], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 224, 235], ["Porcine reproductive and respiratory syndrome virus", "ORGANISM", 289, 340], ["PRRSV", "ORGANISM", 342, 347], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 394, 407], ["CoVs", "GENE_OR_GENE_PRODUCT", 418, 422], ["Th1 (IFN-\u03b3) cytokines", "PROTEIN", 78, 99], ["IFN-\u03b3 secreting T cells", "CELL_TYPE", 164, 187], ["Porcine", "SPECIES", 289, 296], ["PRRSV", "SPECIES", 342, 347], ["Porcine reproductive and respiratory syndrome virus", "SPECIES", 289, 340], ["PRRSV", "SPECIES", 342, 347], ["The pulmonary lymphohistiocytic inflammation", "PROBLEM", 0, 44], ["increased Th1 (IFN-\u03b3) cytokines in serum and lung", "PROBLEM", 68, 117], ["bronchoalveolar lavage", "TEST", 119, 141], ["IFN", "TEST", 164, 167], ["secreting T cells infiltrating the lungs and regional lymph nodes", "PROBLEM", 170, 235], ["IntroductionPorcine reproductive", "TREATMENT", 277, 309], ["respiratory syndrome virus", "PROBLEM", 314, 340], ["a positive-strand RNA virus", "PROBLEM", 352, 379], ["Arteriviridae", "TREATMENT", 394, 407], ["pulmonary", "ANATOMY", 4, 13], ["lymphohistiocytic inflammation", "OBSERVATION", 14, 44], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["Th1", "OBSERVATION_MODIFIER", 78, 81], ["serum", "ANATOMY", 103, 108], ["lung", "ANATOMY", 113, 117], ["bronchoalveolar lavage", "OBSERVATION", 119, 141], ["large", "OBSERVATION_MODIFIER", 147, 152], ["numbers", "OBSERVATION_MODIFIER", 153, 160], ["IFN", "OBSERVATION_MODIFIER", 164, 167], ["secreting T cells", "OBSERVATION", 170, 187], ["lungs", "ANATOMY", 205, 210], ["regional", "ANATOMY_MODIFIER", 215, 223], ["lymph nodes", "OBSERVATION", 224, 235], ["respiratory syndrome", "OBSERVATION", 314, 334]]], ["The virus replicates in AMs in lung resulting in apoptotic death of infected cells, and it also increases Th1 (IFN-\u03b3) serum (systemic) and lung (local) cytokine responses (Costers et al., 2008; Mateu and Diaz, 2008) .", [["AMs", "ANATOMY", 24, 27], ["lung", "ANATOMY", 31, 35], ["cells", "ANATOMY", 77, 82], ["serum", "ANATOMY", 118, 123], ["lung", "ANATOMY", 139, 143], ["death", "DISEASE", 59, 64], ["AMs", "CELL", 24, 27], ["lung", "ORGAN", 31, 35], ["cells", "CELL", 77, 82], ["Th1", "GENE_OR_GENE_PRODUCT", 106, 109], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 111, 116], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["lung", "ORGAN", 139, 143], ["AMs", "CELL_TYPE", 24, 27], ["infected cells", "CELL_TYPE", 68, 82], ["IFN", "PROTEIN", 111, 114], ["cytokine", "PROTEIN", 152, 160], ["The virus", "PROBLEM", 0, 9], ["AMs in lung", "PROBLEM", 24, 35], ["apoptotic death of infected cells", "PROBLEM", 49, 82], ["Th1", "TEST", 106, 109], ["IFN", "TEST", 111, 114], ["serum (systemic) and lung (local) cytokine responses", "PROBLEM", 118, 170], ["virus", "OBSERVATION", 4, 9], ["lung", "ANATOMY", 31, 35], ["apoptotic death", "OBSERVATION", 49, 64], ["infected cells", "OBSERVATION", 68, 82], ["increases", "OBSERVATION_MODIFIER", 96, 105], ["Th1", "OBSERVATION_MODIFIER", 106, 109], ["lung", "ANATOMY", 139, 143]]], ["We previously reported that co-infection by PRRSV and PRCV increased Th1 (IFN-\u03b3) serum cytokine responses and enhanced apoptosis of AMs in dual-infected pigs compared to single PRCV or PRRSV-infected pigs (Jung et al., 2009 ).", [["serum", "ANATOMY", 81, 86], ["AMs", "ANATOMY", 132, 135], ["co-infection", "DISEASE", 28, 40], ["PRRSV-infected", "DISEASE", 185, 199], ["PRRSV", "ORGANISM", 44, 49], ["PRCV", "GENE_OR_GENE_PRODUCT", 54, 58], ["Th1", "GENE_OR_GENE_PRODUCT", 69, 72], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 74, 79], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["AMs", "CELL", 132, 135], ["pigs", "ORGANISM", 153, 157], ["PRCV", "ORGANISM", 177, 181], ["PRRSV", "ORGANISM", 185, 190], ["pigs", "ORGANISM", 200, 204], ["Th1 (IFN-\u03b3", "PROTEIN", 69, 79], ["cytokine", "PROTEIN", 87, 95], ["AMs", "CELL_TYPE", 132, 135], ["PRRSV", "SPECIES", 44, 49], ["pigs", "SPECIES", 153, 157], ["PRRSV", "SPECIES", 185, 190], ["pigs", "SPECIES", 200, 204], ["PRRSV", "SPECIES", 44, 49], ["PRCV", "SPECIES", 54, 58], ["pigs", "SPECIES", 153, 157], ["PRCV", "SPECIES", 177, 181], ["PRRSV", "SPECIES", 185, 190], ["pigs", "SPECIES", 200, 204], ["co-infection", "PROBLEM", 28, 40], ["PRRSV", "TEST", 44, 49], ["PRCV", "TEST", 54, 58], ["Th1", "TEST", 69, 72], ["IFN", "TEST", 74, 77], ["serum cytokine responses", "TEST", 81, 105], ["enhanced apoptosis of AMs", "PROBLEM", 110, 135], ["dual-infected pigs", "TREATMENT", 139, 157], ["single PRCV", "PROBLEM", 170, 181], ["PRRSV", "PROBLEM", 185, 190], ["co-infection", "OBSERVATION", 28, 40]]], ["The cytokine IFN-\u03b3 is also known to promote \u2022 NO production, resulting in enhanced cell apoptosis (Akaike and Maeda, 2000; Schroder et al., 2006) .IntroductionThe aims of our study were two-fold: first, to examine \u2022 NO levels in the lungs of pigs infected with either PRCV or PRRSV, or co-infected with PRRSV and PRCV over the time course of the infection; and second, to analyze the antiviral effects of \u2022 NO on these two viruses in an in vitro system using a \u2022 NO donor, S-nitroso-N-acetylpenicillamine (SNAP).", [["cell", "ANATOMY", 83, 87], ["lungs", "ANATOMY", 233, 238], ["NO", "CHEMICAL", 46, 48], ["NO", "CHEMICAL", 216, 218], ["infection", "DISEASE", 346, 355], ["NO", "CHEMICAL", 407, 409], ["NO", "CHEMICAL", 463, 465], ["S-nitroso-N-acetylpenicillamine", "CHEMICAL", 473, 504], ["SNAP", "CHEMICAL", 506, 510], ["NO", "CHEMICAL", 46, 48], ["NO", "CHEMICAL", 216, 218], ["NO", "CHEMICAL", 407, 409], ["NO", "CHEMICAL", 463, 465], ["S-nitroso-N-acetylpenicillamine", "CHEMICAL", 473, 504], ["SNAP", "CHEMICAL", 506, 510], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 13, 18], ["NO", "SIMPLE_CHEMICAL", 46, 48], ["cell", "CELL", 83, 87], ["NO", "GENE_OR_GENE_PRODUCT", 216, 218], ["lungs", "ORGAN", 233, 238], ["pigs", "ORGANISM", 242, 246], ["PRRSV", "ORGANISM", 276, 281], ["PRRSV", "ORGANISM", 303, 308], ["NO", "SIMPLE_CHEMICAL", 407, 409], ["NO", "SIMPLE_CHEMICAL", 463, 465], ["S-nitroso-N-acetylpenicillamine", "SIMPLE_CHEMICAL", 473, 504], ["SNAP", "SIMPLE_CHEMICAL", 506, 510], ["cytokine", "PROTEIN", 4, 12], ["IFN-\u03b3", "PROTEIN", 13, 18], ["pigs", "SPECIES", 242, 246], ["PRRSV", "SPECIES", 276, 281], ["PRRSV", "SPECIES", 303, 308], ["pigs", "SPECIES", 242, 246], ["PRCV", "SPECIES", 268, 272], ["PRRSV", "SPECIES", 276, 281], ["PRRSV", "SPECIES", 303, 308], ["PRCV", "SPECIES", 313, 317], ["The cytokine IFN", "TEST", 0, 16], ["enhanced cell apoptosis", "PROBLEM", 74, 97], ["our study", "TEST", 171, 180], ["PRRSV", "PROBLEM", 276, 281], ["PRRSV", "PROBLEM", 303, 308], ["PRCV", "TREATMENT", 313, 317], ["the infection", "PROBLEM", 342, 355], ["donor", "TREATMENT", 466, 471], ["S-nitroso", "TREATMENT", 473, 482], ["N-acetylpenicillamine (SNAP", "TREATMENT", 483, 510], ["enhanced cell apoptosis", "OBSERVATION", 74, 97], ["lungs", "ANATOMY", 233, 238], ["infection", "OBSERVATION", 346, 355], ["antiviral", "OBSERVATION", 384, 393]]], ["We further investigated if the induced \u2022 NO coincides with the increased Th1 (IFN-\u03b3) serum and lung cytokine responses after PRCV, PRRSV, or PRRSV/PRCV co-infections, as reported in an earlier publication (Jung et al., 2009 ).Animal infection and sample collectionBased on the availability of different bronchoalveolar lavage (BAL) fluids, the \u2022 NO was estimated in BAL fluids obtained during 4 of 5 independent animal trials that were conducted earlier (Jung et al., 2009) .", [["serum", "ANATOMY", 85, 90], ["lung", "ANATOMY", 95, 99], ["sample", "ANATOMY", 247, 253], ["bronchoalveolar lavage", "ANATOMY", 303, 325], ["BAL", "ANATOMY", 327, 330], ["BAL fluids", "ANATOMY", 366, 376], ["NO", "CHEMICAL", 41, 43], ["PRRSV/PRCV co-infections", "DISEASE", 141, 165], ["infection", "DISEASE", 233, 242], ["NO", "CHEMICAL", 346, 348], ["NO", "CHEMICAL", 41, 43], ["NO", "CHEMICAL", 346, 348], ["NO", "SIMPLE_CHEMICAL", 41, 43], ["Th1", "GENE_OR_GENE_PRODUCT", 73, 76], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 78, 83], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["lung", "ORGAN", 95, 99], ["PRCV", "GENE_OR_GENE_PRODUCT", 125, 129], ["PRRSV", "ORGANISM", 131, 136], ["PRRSV", "ORGANISM", 141, 146], ["PRCV", "GENE_OR_GENE_PRODUCT", 147, 151], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 303, 325], ["NO", "SIMPLE_CHEMICAL", 346, 348], ["Th1 (IFN-\u03b3", "PROTEIN", 73, 83], ["cytokine", "PROTEIN", 100, 108], ["PRCV", "SPECIES", 125, 129], ["PRRSV", "SPECIES", 131, 136], ["PRRSV", "SPECIES", 141, 146], ["PRCV", "SPECIES", 147, 151], ["the increased Th1", "PROBLEM", 59, 76], ["IFN", "TEST", 78, 81], ["serum", "TEST", 85, 90], ["lung cytokine responses", "TEST", 95, 118], ["PRCV", "TEST", 125, 129], ["PRRSV", "PROBLEM", 131, 136], ["PRRSV", "PROBLEM", 141, 146], ["PRCV co-infections", "PROBLEM", 147, 165], ["Animal infection", "PROBLEM", 226, 242], ["different bronchoalveolar lavage (BAL) fluids", "TREATMENT", 293, 338], ["BAL fluids", "TEST", 366, 376], ["lung", "ANATOMY", 95, 99], ["infection", "OBSERVATION", 233, 242], ["bronchoalveolar lavage", "OBSERVATION", 303, 325]]], ["Specific-pathogen-free, 20-to 25-day-old, Large White-Duroc crossbred weaned pigs (n=92) were randomly assigned to one of four groups: PRCV single-infection (n = 26), PRRSV single-infection (n = 20), PRRSV/PRCV dualinfection (n = 26), and mock control (n = 20).", [["infection", "DISEASE", 147, 156], ["PRRSV single-infection", "DISEASE", 167, 189], ["pigs", "ORGANISM", 77, 81], ["PRRSV", "ORGANISM", 167, 172], ["PRRSV", "ORGANISM", 200, 205], ["pigs", "SPECIES", 77, 81], ["PRRSV", "SPECIES", 167, 172], ["PRRSV", "SPECIES", 200, 205], ["Large White-Duroc crossbred weaned pigs", "SPECIES", 42, 81], ["PRRSV", "SPECIES", 167, 172], ["PRRSV", "SPECIES", 200, 205], ["PRCV", "SPECIES", 206, 210], ["Specific-pathogen", "TEST", 0, 17], ["Large White-Duroc crossbred weaned pigs", "TREATMENT", 42, 81], ["PRCV single-infection", "PROBLEM", 135, 156], ["PRRSV single-infection", "PROBLEM", 167, 189], ["PRRSV/PRCV dualinfection", "PROBLEM", 200, 224], ["Large", "OBSERVATION_MODIFIER", 42, 47], ["infection", "OBSERVATION", 147, 156], ["infection", "OBSERVATION", 180, 189]]], ["As reported previously (Jung et al., 2009 ), subsets of pigs were first inoculated intranasally (IN) with 3\u00d710 4 50% tissue culture infectious dose (TCID 50 ) and intramuscularly with 2\u00d710 4 TCID 50 of PRRSV (North American SD23983 strain) or mock and, 10 days later, inoculated IN with 4\u00d710 6 plaqueforming units (PFU) and intratracheally with 6\u00d710 6 PFU of PRCV (ISU-1 strain) or mock.", [["intranasally", "ANATOMY", 83, 95], ["tissue", "ANATOMY", 117, 123], ["intramuscularly", "ANATOMY", 163, 178], ["2\u00d710 4 TCID 50 of PRRSV", "CHEMICAL", 184, 207], ["pigs", "ORGANISM", 56, 60], ["tissue", "TISSUE", 117, 123], ["PRRSV", "ORGANISM", 202, 207], ["pigs", "SPECIES", 56, 60], ["PRRSV", "SPECIES", 202, 207], ["pigs", "SPECIES", 56, 60], ["PRRSV", "SPECIES", 202, 207], ["PRCV", "SPECIES", 359, 363], ["pigs", "TREATMENT", 56, 60], ["PRRSV", "PROBLEM", 202, 207], ["PRCV", "TEST", 359, 363]]], ["At early [post-inoculation day (PID) 2 and 4], middle (PID 8 and 10), and late (PID 14) stages of PRCV infection, 4 to 6 pigs per group were euthanized to collect BAL samples, as described previously (Jung et al., 2007; Jung et al., 2009; Zhang et al., 2008) .", [["BAL samples", "ANATOMY", 163, 174], ["PRCV infection", "DISEASE", 98, 112], ["pigs", "ORGANISM", 121, 125], ["BAL samples", "CANCER", 163, 174], ["pigs", "SPECIES", 121, 125], ["PRCV", "SPECIES", 98, 102], ["PRCV infection", "PROBLEM", 98, 112], ["BAL samples", "TEST", 163, 174], ["middle", "ANATOMY_MODIFIER", 47, 53], ["infection", "OBSERVATION", 103, 112]]], ["The BAL (25-30 ml) was centrifuged at 800 \u00d7 g for 10 min at 4 \u00b0C to separate the BAL cells.", [["BAL", "ANATOMY", 4, 7], ["BAL cells", "ANATOMY", 81, 90], ["BAL", "ORGANISM_SUBSTANCE", 4, 7], ["BAL cells", "CELL", 81, 90], ["BAL cells", "CELL_TYPE", 81, 90], ["The BAL", "TEST", 0, 7], ["BAL", "ANATOMY", 4, 7], ["BAL cells", "OBSERVATION", 81, 90]]], ["The \u2022 NO concentrations were determined only in BAL fluids, devoid of BAL cells.Determination of \u2022 NO concentration in BAL fluidsThe BAL samples were stored at \u221270 \u00b0C until tested.", [["BAL fluids", "ANATOMY", 48, 58], ["BAL cells", "ANATOMY", 70, 79], ["BAL fluids", "ANATOMY", 119, 129], ["BAL samples", "ANATOMY", 133, 144], ["NO", "CHEMICAL", 6, 8], ["NO", "CHEMICAL", 99, 101], ["NO", "CHEMICAL", 6, 8], ["NO", "CHEMICAL", 99, 101], ["NO", "SIMPLE_CHEMICAL", 6, 8], ["BAL fluids", "ORGANISM_SUBSTANCE", 48, 58], ["BAL cells", "CELL", 70, 79], ["NO", "SIMPLE_CHEMICAL", 99, 101], ["BAL samples", "CANCER", 133, 144], ["BAL cells", "CELL_TYPE", 70, 79], ["BAL fluids", "TEST", 48, 58], ["BAL cells", "PROBLEM", 70, 79], ["concentration in BAL fluids", "TREATMENT", 102, 129], ["The BAL samples", "TEST", 129, 144], ["BAL cells", "OBSERVATION", 70, 79]]], ["Since the final products of \u2022 NO in vivo are nitrite (NO 2 \u2212 ) and nitrate (NO 3 \u2212 ), the sum of both nitrite and nitrate were measured by the Griess method using a commercially available kit (Cayman Chemical Co., MI).", [["NO", "CHEMICAL", 30, 32], ["nitrite", "CHEMICAL", 45, 52], ["NO 2 \u2212", "CHEMICAL", 54, 60], ["nitrate", "CHEMICAL", 67, 74], ["NO", "CHEMICAL", 76, 78], ["nitrite", "CHEMICAL", 102, 109], ["nitrate", "CHEMICAL", 114, 121], ["NO", "CHEMICAL", 30, 32], ["nitrite", "CHEMICAL", 45, 52], ["NO 2 \u2212 )", "CHEMICAL", 54, 62], ["nitrate", "CHEMICAL", 67, 74], ["NO 3 \u2212", "CHEMICAL", 76, 82], ["nitrite", "CHEMICAL", 102, 109], ["nitrate", "CHEMICAL", 114, 121], ["NO", "SIMPLE_CHEMICAL", 30, 32], ["nitrite", "SIMPLE_CHEMICAL", 45, 52], ["NO 2 \u2212", "SIMPLE_CHEMICAL", 54, 60], ["nitrate", "SIMPLE_CHEMICAL", 67, 74], ["NO 3 \u2212", "SIMPLE_CHEMICAL", 76, 82], ["nitrite", "SIMPLE_CHEMICAL", 102, 109], ["nitrate", "SIMPLE_CHEMICAL", 114, 121], ["nitrite", "TEST", 45, 52], ["nitrate", "TREATMENT", 67, 74], ["both nitrite and nitrate", "TREATMENT", 97, 121], ["MI", "PROBLEM", 214, 216]]], ["All assays were performed in duplicate.In vitro evaluation of antiviral effects of \u2022 NO on PRCV and PRRSVThe antiviral effects of \u2022 NO on PRCV and PRRSV replication were tested in viralreplication competent ST and MARC145 cells, respectively.", [["ST", "ANATOMY", 207, 209], ["MARC145 cells", "ANATOMY", 214, 227], ["NO", "CHEMICAL", 85, 87], ["NO", "CHEMICAL", 132, 134], ["NO", "CHEMICAL", 85, 87], ["NO", "CHEMICAL", 132, 134], ["NO", "SIMPLE_CHEMICAL", 85, 87], ["PRCV", "SIMPLE_CHEMICAL", 91, 95], ["PRRSVThe", "SIMPLE_CHEMICAL", 100, 108], ["NO", "SIMPLE_CHEMICAL", 132, 134], ["PRCV", "CELL", 138, 142], ["PRRSV", "ORGANISM", 147, 152], ["ST", "CELL", 207, 209], ["MARC145 cells", "CELL", 214, 227], ["viralreplication competent ST and MARC145 cells", "CELL_LINE", 180, 227], ["PRRSV", "SPECIES", 147, 152], ["PRCV", "SPECIES", 91, 95], ["PRCV", "SPECIES", 138, 142], ["PRRSV", "SPECIES", 147, 152], ["All assays", "TEST", 0, 10], ["vitro evaluation", "TEST", 42, 58], ["antiviral effects", "TREATMENT", 62, 79], ["PRCV", "TREATMENT", 91, 95], ["PRRSVThe antiviral effects", "TREATMENT", 100, 126], ["PRCV", "TREATMENT", 138, 142], ["PRRSV replication", "TREATMENT", 147, 164], ["antiviral effects", "OBSERVATION", 62, 79]]], ["Based on previous similar studies (Akerstrom et al., 2005; Davis and Matalon, 2001) , the confluent cell monolayers seeded in 6 well plates were treated with SNAP at different concentrations (0, 50, 100, 200, 400, and 800 \u03bcM; Sigma-Aldrich) to select an optimal concentration that produced maximum \u2022 NO without affecting cell viability.", [["cell monolayers", "ANATOMY", 100, 115], ["cell", "ANATOMY", 321, 325], ["SNAP", "CHEMICAL", 158, 162], ["NO", "CHEMICAL", 300, 302], ["NO", "CHEMICAL", 300, 302], ["cell monolayers", "CELL", 100, 115], ["SNAP", "SIMPLE_CHEMICAL", 158, 162], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 226, 239], ["NO", "SIMPLE_CHEMICAL", 300, 302], ["cell", "CELL", 321, 325], ["confluent cell monolayers", "CELL_LINE", 90, 115], ["previous similar studies", "TEST", 9, 33], ["the confluent cell monolayers seeded", "TREATMENT", 86, 122], ["SNAP", "TREATMENT", 158, 162], ["affecting cell viability", "PROBLEM", 311, 335], ["confluent", "OBSERVATION_MODIFIER", 90, 99], ["cell monolayers seeded", "OBSERVATION", 100, 122], ["NO without", "UNCERTAINTY", 300, 310], ["affecting cell viability", "OBSERVATION", 311, 335]]], ["Based on cell toxicity observed, 400 \u03bcM and 800 \u03bcM SNAP were added to MARC145 and ST cells, respectively.", [["cell", "ANATOMY", 9, 13], ["MARC145", "ANATOMY", 70, 77], ["ST cells", "ANATOMY", 82, 90], ["toxicity", "DISEASE", 14, 22], ["SNAP", "CHEMICAL", 51, 55], ["cell", "CELL", 9, 13], ["SNAP", "SIMPLE_CHEMICAL", 51, 55], ["MARC145", "CELL", 70, 77], ["ST cells", "CELL", 82, 90], ["MARC145 and ST cells", "CELL_LINE", 70, 90], ["cell toxicity", "PROBLEM", 9, 22], ["800 \u03bcM SNAP", "TREATMENT", 44, 55], ["cell toxicity", "OBSERVATION", 9, 22]]], ["The SNAP-treated, virus-infected and SNAP-untreated, virus-infected cells were infected with PRCV or PRRSV (10 5~6 TCID 50 /ml), with or without SNAP, respectively.", [["cells", "ANATOMY", 68, 73], ["SNAP", "CHEMICAL", 4, 8], ["SNAP", "CHEMICAL", 37, 41], ["SNAP", "CHEMICAL", 145, 149], ["SNAP", "SIMPLE_CHEMICAL", 4, 8], ["SNAP", "SIMPLE_CHEMICAL", 37, 41], ["cells", "CELL", 68, 73], ["PRRSV", "ORGANISM", 101, 106], ["SNAP", "SIMPLE_CHEMICAL", 145, 149], ["SNAP-untreated, virus-infected cells", "CELL_LINE", 37, 73], ["PRCV", "SPECIES", 93, 97], ["PRRSV", "SPECIES", 101, 106], ["The SNAP", "TEST", 0, 8], ["virus", "PROBLEM", 18, 23], ["infected", "PROBLEM", 24, 32], ["SNAP", "TEST", 37, 41], ["virus", "PROBLEM", 53, 58], ["infected cells", "PROBLEM", 59, 73], ["PRCV", "TREATMENT", 93, 97], ["PRRSV", "PROBLEM", 101, 106], ["infected cells", "OBSERVATION", 59, 73]]], ["At PTH 24 and 48, the cells were fixed in 95% ethanol and the TCID 50 /ml was determined by evaluating virus infectivity in cells by immunofluorescent staining using virus-specific monoclonal antibodies (SDOW-17 for PRRSV and 25H7/14E3 for PRCV) (Jung et al., 2009 ).", [["cells", "ANATOMY", 22, 27], ["cells", "ANATOMY", 124, 129], ["ethanol", "CHEMICAL", 46, 53], ["ethanol", "CHEMICAL", 46, 53], ["cells", "CELL", 22, 27], ["ethanol", "SIMPLE_CHEMICAL", 46, 53], ["cells", "CELL", 124, 129], ["PRRSV", "ORGANISM", 216, 221], ["monoclonal antibodies", "PROTEIN", 181, 202], ["SDOW", "PROTEIN", 204, 208], ["25H7", "PROTEIN", 226, 230], ["14E3", "PROTEIN", 231, 235], ["PRRSV", "SPECIES", 216, 221], ["PRCV", "SPECIES", 240, 244], ["PTH", "TEST", 3, 6], ["the cells", "TEST", 18, 27], ["the TCID", "TEST", 58, 66], ["virus infectivity in cells", "PROBLEM", 103, 129], ["immunofluorescent staining", "TEST", 133, 159], ["virus", "TEST", 166, 171], ["specific monoclonal antibodies", "TEST", 172, 202], ["SDOW", "TEST", 204, 208], ["PRRSV", "PROBLEM", 216, 221]]], ["The TCID 50 /ml was calculated according to the Reed and Muench method (Reed and Muench, 1938) .", [["The TCID", "TREATMENT", 0, 8]]], ["All assays were performed independently three times.Statistical analysisFor \u2022 NO levels in BAL, all data are expressed as the means \u00b1 standard deviation of the means (SDM) or standard error of the means (SEM).", [["BAL", "ANATOMY", 91, 94], ["NO", "CHEMICAL", 78, 80], ["NO", "CHEMICAL", 78, 80], ["NO", "SIMPLE_CHEMICAL", 78, 80], ["All assays", "TEST", 0, 10], ["Statistical analysis", "TEST", 52, 72], ["levels in BAL", "TEST", 81, 94]]], ["For comparison of viral titers between SNAP-treated, virus-infected and SNAP-untreated, virus-infected cells, all data are expressed as the means \u00b1 SDM and analyzed by unpaired Student's t-test.", [["cells", "ANATOMY", 103, 108], ["SNAP", "CHEMICAL", 39, 43], ["SNAP", "CHEMICAL", 72, 76], ["SNAP", "SIMPLE_CHEMICAL", 39, 43], ["SNAP", "SIMPLE_CHEMICAL", 72, 76], ["cells", "CELL", 103, 108], ["SNAP-untreated, virus-infected cells", "CELL_LINE", 72, 108], ["viral titers", "PROBLEM", 18, 30], ["SNAP", "TEST", 39, 43], ["virus", "PROBLEM", 53, 58], ["infected", "PROBLEM", 59, 67], ["SNAP", "TEST", 72, 76], ["virus", "PROBLEM", 88, 93], ["infected cells", "PROBLEM", 94, 108], ["infected cells", "OBSERVATION", 94, 108]]], ["A value of P<0.05 was considered statistically significant.Results and DiscussionThe Griess assay results revealed a large increase in BAL \u2022 NO levels of PRCV-infected pigs, but not in PRRSV single-infected pigs.", [["BAL", "ANATOMY", 135, 138], ["NO", "CHEMICAL", 141, 143], ["NO", "CHEMICAL", 141, 143], ["BAL", "ORGANISM_SUBSTANCE", 135, 138], ["NO", "SIMPLE_CHEMICAL", 141, 143], ["PRCV", "SIMPLE_CHEMICAL", 154, 158], ["pigs", "ORGANISM", 168, 172], ["PRRSV", "ORGANISM", 185, 190], ["single", "ORGANISM", 191, 197], ["pigs", "ORGANISM", 207, 211], ["pigs", "SPECIES", 168, 172], ["PRRSV", "SPECIES", 185, 190], ["pigs", "SPECIES", 207, 211], ["pigs", "SPECIES", 168, 172], ["PRRSV", "SPECIES", 185, 190], ["pigs", "SPECIES", 207, 211], ["A value", "TEST", 0, 7], ["The Griess assay", "TEST", 81, 97], ["a large increase in BAL", "PROBLEM", 115, 138], ["levels of PRCV", "PROBLEM", 144, 158], ["infected pigs", "PROBLEM", 159, 172], ["large", "OBSERVATION_MODIFIER", 117, 122], ["increase", "OBSERVATION_MODIFIER", 123, 131], ["BAL", "OBSERVATION", 135, 138], ["infected pigs", "OBSERVATION", 159, 172], ["infected", "OBSERVATION", 198, 206]]], ["The PRRSV/PRCV dual-and PRCV singleinfected pigs had 2.4 to 14 times higher BAL \u2022 NO levels at PRCV PID 2 to 10 than the mock control pigs ( Figure 1A to C), although there were no significant differences in mean \u2022 NO levels among treatment groups due to high variability among pigs.", [["NO", "CHEMICAL", 82, 84], ["NO", "CHEMICAL", 215, 217], ["NO", "CHEMICAL", 82, 84], ["NO", "CHEMICAL", 215, 217], ["PRRSV", "ORGANISM", 4, 9], ["PRCV", "GENE_OR_GENE_PRODUCT", 10, 14], ["PRCV singleinfected", "ORGANISM", 24, 43], ["pigs", "ORGANISM", 44, 48], ["NO", "SIMPLE_CHEMICAL", 82, 84], ["pigs", "ORGANISM", 134, 138], ["NO", "SIMPLE_CHEMICAL", 215, 217], ["pigs", "ORGANISM", 278, 282], ["pigs", "SPECIES", 44, 48], ["pigs", "SPECIES", 134, 138], ["pigs", "SPECIES", 278, 282], ["PRRSV", "SPECIES", 4, 9], ["PRCV", "SPECIES", 10, 14], ["PRCV", "SPECIES", 24, 28], ["pigs", "SPECIES", 44, 48], ["pigs", "SPECIES", 134, 138], ["pigs", "SPECIES", 278, 282], ["The PRRSV/PRCV dual", "TEST", 0, 19], ["PRCV singleinfected pigs", "TREATMENT", 24, 48], ["significant differences", "PROBLEM", 181, 204], ["treatment groups", "TREATMENT", 231, 247], ["no", "UNCERTAINTY", 178, 180], ["significant", "OBSERVATION_MODIFIER", 181, 192]]], ["In our Greiss assays, large variability in BAL \u2022 NO levels was observed among the 4 independent animal trials.", [["NO", "CHEMICAL", 49, 51], ["NO", "CHEMICAL", 49, 51], ["BAL", "ORGANISM_SUBSTANCE", 43, 46], ["NO", "SIMPLE_CHEMICAL", 49, 51], ["our Greiss assays", "TEST", 3, 20], ["large variability in BAL", "PROBLEM", 22, 46], ["large", "OBSERVATION_MODIFIER", 22, 27], ["variability", "OBSERVATION_MODIFIER", 28, 39], ["BAL", "ANATOMY", 43, 46]]], ["In mock control pigs, mean BAL \u2022 NO levels showed a wide range from 2.5 to 16.63 \u03bcM/ml among the 4 trials.", [["NO", "CHEMICAL", 33, 35], ["NO", "CHEMICAL", 33, 35], ["pigs", "ORGANISM", 16, 20], ["NO", "SIMPLE_CHEMICAL", 33, 35], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["mean BAL", "TEST", 22, 30], ["levels", "TEST", 36, 42], ["wide", "OBSERVATION_MODIFIER", 52, 56]]], ["For this reason, no significant differences were detected in mean BAL \u2022 NO levels among the 4 experimental groups in our study.", [["NO", "CHEMICAL", 72, 74], ["NO", "CHEMICAL", 72, 74], ["NO", "SIMPLE_CHEMICAL", 72, 74], ["significant differences", "PROBLEM", 20, 43], ["mean BAL", "TEST", 61, 69], ["our study", "TEST", 117, 126]]], ["These results also might be explained by use of outbred pigs and different storage times for the BAL samples after collection, because of large intervals between each animal trial.", [["BAL samples", "ANATOMY", 97, 108], ["pigs", "ORGANISM", 56, 60], ["pigs", "SPECIES", 56, 60], ["pigs", "SPECIES", 56, 60], ["outbred pigs", "TREATMENT", 48, 60], ["different storage times", "TREATMENT", 65, 88], ["the BAL samples", "TEST", 93, 108], ["large", "OBSERVATION_MODIFIER", 138, 143]]], ["However, the trend toward increased BAL \u2022 NO levels in PRCV-infected pigs at PRCV PID 2 to 10 was consistent and reproducible ( Figure 1A to C).Results and DiscussionAs verified by others (Cox et al., 1990) and in our previous studies using the PRCV ISU-1 strain (Jung et al., 2007; Jung et al., 2009) , at PRCV PID 2 and 4 (acute stage of infection), PRCV mainly infected upper and lower pulmonary epithelial cells (bronchial/bronchiolar epithelial cells and type 2 pneumocytes) and caused cytolysis, which coincided with the highest BAL \u2022 NO levels among all PIDs.", [["BAL", "ANATOMY", 36, 39], ["upper", "ANATOMY", 373, 378], ["pulmonary epithelial cells", "ANATOMY", 389, 415], ["bronchial", "ANATOMY", 417, 426], ["bronchiolar epithelial cells", "ANATOMY", 427, 455], ["type 2 pneumocytes", "ANATOMY", 460, 478], ["NO", "CHEMICAL", 42, 44], ["infection", "DISEASE", 340, 349], ["NO", "CHEMICAL", 541, 543], ["NO", "CHEMICAL", 42, 44], ["NO", "CHEMICAL", 541, 543], ["NO", "SIMPLE_CHEMICAL", 42, 44], ["PRCV", "ORGANISM", 55, 59], ["pigs", "ORGANISM", 69, 73], ["upper", "ORGANISM_SUBDIVISION", 373, 378], ["pulmonary epithelial cells", "CELL", 389, 415], ["bronchial", "CELL", 417, 426], ["bronchiolar epithelial cells", "CELL", 427, 455], ["type 2 pneumocytes", "CELL", 460, 478], ["NO", "SIMPLE_CHEMICAL", 541, 543], ["PIDs", "PATHOLOGICAL_FORMATION", 561, 565], ["pulmonary epithelial cells", "CELL_TYPE", 389, 415], ["bronchial/bronchiolar epithelial cells", "CELL_TYPE", 417, 455], ["type 2 pneumocytes", "CELL_TYPE", 460, 478], ["pigs", "SPECIES", 69, 73], ["PRCV", "SPECIES", 55, 59], ["pigs", "SPECIES", 69, 73], ["PRCV", "SPECIES", 77, 81], ["PRCV", "SPECIES", 352, 356], ["increased BAL", "TEST", 26, 39], ["levels", "TEST", 45, 51], ["PRCV", "TEST", 55, 59], ["acute stage of infection", "PROBLEM", 325, 349], ["PRCV mainly infected upper and lower pulmonary epithelial cells", "PROBLEM", 352, 415], ["bronchial/bronchiolar epithelial cells", "PROBLEM", 417, 455], ["type 2 pneumocytes", "PROBLEM", 460, 478], ["cytolysis", "PROBLEM", 491, 500], ["the highest BAL", "TEST", 523, 538], ["infected", "OBSERVATION", 60, 68], ["acute", "OBSERVATION_MODIFIER", 325, 330], ["infection", "OBSERVATION", 340, 349], ["infected", "OBSERVATION", 364, 372], ["upper", "ANATOMY_MODIFIER", 373, 378], ["lower", "ANATOMY_MODIFIER", 383, 388], ["pulmonary epithelial", "ANATOMY", 389, 409], ["cells", "OBSERVATION", 410, 415], ["bronchial", "ANATOMY", 417, 426], ["bronchiolar", "ANATOMY_MODIFIER", 427, 438], ["epithelial cells", "OBSERVATION", 439, 455], ["cytolysis", "OBSERVATION", 491, 500]]], ["Pulmonary epithelial cells are known to contribute to substantial increased levels of \u2022 NO in respiratory viral infections (Xu et al., 2006) , whereas porcine AMs are likely to be less involved in induction of \u2022 NO production in the respiratory tract (Pampusch et al., 1998) .", [["Pulmonary epithelial cells", "ANATOMY", 0, 26], ["AMs", "ANATOMY", 159, 162], ["respiratory tract", "ANATOMY", 233, 250], ["NO", "CHEMICAL", 88, 90], ["respiratory viral infections", "DISEASE", 94, 122], ["NO", "CHEMICAL", 212, 214], ["NO", "CHEMICAL", 88, 90], ["NO", "CHEMICAL", 212, 214], ["Pulmonary epithelial cells", "CELL", 0, 26], ["NO", "GENE_OR_GENE_PRODUCT", 88, 90], ["porcine", "ORGANISM", 151, 158], ["AMs", "CELL", 159, 162], ["NO", "SIMPLE_CHEMICAL", 212, 214], ["respiratory tract", "ORGANISM_SUBDIVISION", 233, 250], ["Pulmonary epithelial cells", "CELL_TYPE", 0, 26], ["porcine AMs", "CELL_TYPE", 151, 162], ["porcine", "SPECIES", 151, 158], ["Pulmonary epithelial cells", "PROBLEM", 0, 26], ["substantial increased levels", "PROBLEM", 54, 82], ["respiratory viral infections", "PROBLEM", 94, 122], ["production in the respiratory tract", "PROBLEM", 215, 250], ["epithelial cells", "OBSERVATION", 10, 26], ["substantial", "OBSERVATION_MODIFIER", 54, 65], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["levels", "OBSERVATION_MODIFIER", 76, 82], ["NO in", "UNCERTAINTY", 88, 93], ["respiratory", "OBSERVATION", 94, 105], ["viral infections", "OBSERVATION", 106, 122], ["likely to be", "UNCERTAINTY", 167, 179], ["respiratory tract", "ANATOMY", 233, 250]]], ["Thus, the elevated BAL NO levels following PRCV infection might originate as a result of viral-induced damage to pulmonary epithelial cells; subsequently, the increased \u2022 NO might also contribute to further damage to the pulmonary epithelial cells.", [["BAL", "ANATOMY", 19, 22], ["pulmonary epithelial cells", "ANATOMY", 113, 139], ["pulmonary epithelial cells", "ANATOMY", 221, 247], ["NO", "CHEMICAL", 23, 25], ["PRCV", "CHEMICAL", 43, 47], ["infection", "DISEASE", 48, 57], ["NO", "CHEMICAL", 171, 173], ["NO", "CHEMICAL", 23, 25], ["NO", "CHEMICAL", 171, 173], ["BAL", "ORGANISM_SUBSTANCE", 19, 22], ["NO", "GENE_OR_GENE_PRODUCT", 23, 25], ["pulmonary epithelial cells", "CELL", 113, 139], ["NO", "SIMPLE_CHEMICAL", 171, 173], ["pulmonary epithelial cells", "CELL", 221, 247], ["pulmonary epithelial cells", "CELL_TYPE", 113, 139], ["pulmonary epithelial cells", "CELL_TYPE", 221, 247], ["PRCV", "SPECIES", 43, 47], ["the elevated BAL NO levels", "PROBLEM", 6, 32], ["PRCV infection", "PROBLEM", 43, 57], ["viral-induced damage to pulmonary epithelial cells", "PROBLEM", 89, 139], ["further damage to the pulmonary epithelial cells", "PROBLEM", 199, 247], ["elevated", "OBSERVATION_MODIFIER", 10, 18], ["BAL", "OBSERVATION", 19, 22], ["viral", "OBSERVATION", 89, 94], ["pulmonary", "ANATOMY", 113, 122], ["epithelial cells", "OBSERVATION", 123, 139], ["NO might also contribute", "UNCERTAINTY", 171, 195], ["pulmonary", "ANATOMY", 221, 230], ["epithelial cells", "OBSERVATION", 231, 247]]], ["In addition, we speculate that the persisting, increased BAL \u2022 NO levels at PRCV PID 8 and 10 also might be associated with the large numbers of AMs and lymphocytes infiltrating the lungs in parallel with necrosis of respiratory epithelial cells occurring during the same period.", [["BAL", "ANATOMY", 57, 60], ["AMs", "ANATOMY", 145, 148], ["lymphocytes", "ANATOMY", 153, 164], ["lungs", "ANATOMY", 182, 187], ["respiratory epithelial cells", "ANATOMY", 217, 245], ["NO", "CHEMICAL", 63, 65], ["necrosis", "DISEASE", 205, 213], ["NO", "CHEMICAL", 63, 65], ["NO", "GENE_OR_GENE_PRODUCT", 63, 65], ["AMs", "CELL", 145, 148], ["lymphocytes", "CELL", 153, 164], ["lungs", "ORGAN", 182, 187], ["respiratory epithelial cells", "CELL", 217, 245], ["AMs", "CELL_TYPE", 145, 148], ["lymphocytes", "CELL_TYPE", 153, 164], ["respiratory epithelial cells", "CELL_TYPE", 217, 245], ["increased BAL", "PROBLEM", 47, 60], ["levels at PRCV PID", "TEST", 66, 84], ["AMs", "PROBLEM", 145, 148], ["lymphocytes infiltrating the lungs", "PROBLEM", 153, 187], ["necrosis of respiratory epithelial cells", "PROBLEM", 205, 245], ["persisting", "OBSERVATION_MODIFIER", 35, 45], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["BAL", "OBSERVATION", 57, 60], ["large", "OBSERVATION_MODIFIER", 128, 133], ["numbers", "OBSERVATION_MODIFIER", 134, 141], ["lymphocytes infiltrating", "OBSERVATION", 153, 177], ["lungs", "ANATOMY", 182, 187], ["necrosis", "OBSERVATION", 205, 213], ["respiratory epithelial cells", "OBSERVATION", 217, 245]]], ["However, further studies are needed to identify if iNOS gene expression or if \u2022 NO amounts are increased in AMs and lymphocytes following PRCV infection, although unlike murine macrophages, porcine macrophages stimulated by either IFN-\u03b3 or lipopolysaccharide (LPS) did not induce \u2022 NO production (Pampusch et al., 1998) .", [["AMs", "ANATOMY", 108, 111], ["lymphocytes", "ANATOMY", 116, 127], ["macrophages", "ANATOMY", 177, 188], ["macrophages", "ANATOMY", 198, 209], ["NO", "CHEMICAL", 80, 82], ["infection", "DISEASE", 143, 152], ["IFN-\u03b3", "CHEMICAL", 231, 236], ["lipopolysaccharide", "CHEMICAL", 240, 258], ["LPS", "CHEMICAL", 260, 263], ["NO", "CHEMICAL", 282, 284], ["NO", "CHEMICAL", 80, 82], ["NO", "CHEMICAL", 282, 284], ["iNOS", "GENE_OR_GENE_PRODUCT", 51, 55], ["NO", "GENE_OR_GENE_PRODUCT", 80, 82], ["AMs", "CELL", 108, 111], ["lymphocytes", "CELL", 116, 127], ["PRCV", "CELL", 138, 142], ["murine", "ORGANISM", 170, 176], ["macrophages", "CELL", 177, 188], ["porcine", "ORGANISM", 190, 197], ["macrophages", "CELL", 198, 209], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 231, 236], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 240, 258], ["LPS", "SIMPLE_CHEMICAL", 260, 263], ["NO", "SIMPLE_CHEMICAL", 282, 284], ["iNOS", "PROTEIN", 51, 55], ["AMs", "CELL_TYPE", 108, 111], ["lymphocytes", "CELL_TYPE", 116, 127], ["murine macrophages", "CELL_TYPE", 170, 188], ["porcine macrophages", "CELL_TYPE", 190, 209], ["IFN", "PROTEIN", 231, 234], ["murine", "SPECIES", 170, 176], ["porcine", "SPECIES", 190, 197], ["PRCV", "SPECIES", 138, 142], ["porcine", "SPECIES", 190, 197], ["further studies", "TEST", 9, 24], ["iNOS gene expression", "PROBLEM", 51, 71], ["amounts", "PROBLEM", 83, 90], ["AMs", "PROBLEM", 108, 111], ["lymphocytes", "PROBLEM", 116, 127], ["PRCV infection", "PROBLEM", 138, 152], ["porcine macrophages", "TREATMENT", 190, 209], ["IFN", "TEST", 231, 234], ["lipopolysaccharide", "PROBLEM", 240, 258], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["murine macrophages", "OBSERVATION", 170, 188]]], ["We suggest that respiratory CoVs such as PRCV that infect pulmonary epithelial cells and cause cytolysis, induce \u2022 NO production in the lungs.", [["respiratory CoVs", "ANATOMY", 16, 32], ["pulmonary epithelial cells", "ANATOMY", 58, 84], ["lungs", "ANATOMY", 136, 141], ["cytolysis", "DISEASE", 95, 104], ["NO", "CHEMICAL", 115, 117], ["NO", "CHEMICAL", 115, 117], ["CoVs", "GENE_OR_GENE_PRODUCT", 28, 32], ["PRCV", "GENE_OR_GENE_PRODUCT", 41, 45], ["pulmonary epithelial cells", "CELL", 58, 84], ["NO", "GENE_OR_GENE_PRODUCT", 115, 117], ["lungs", "ORGAN", 136, 141], ["pulmonary epithelial cells", "CELL_TYPE", 58, 84], ["PRCV", "SPECIES", 41, 45], ["respiratory CoVs", "PROBLEM", 16, 32], ["PRCV", "TREATMENT", 41, 45], ["pulmonary epithelial cells", "PROBLEM", 58, 84], ["cytolysis", "PROBLEM", 95, 104], ["production in the lungs", "PROBLEM", 118, 141], ["respiratory CoVs", "OBSERVATION", 16, 32], ["pulmonary", "ANATOMY", 58, 67], ["epithelial cells", "OBSERVATION", 68, 84], ["lungs", "ANATOMY", 136, 141]]], ["Based on the results, SARS-CoV that caused massive necrosis of pulmonary epithelial cells such as type 1 and 2 pneumocytes, similar to that observed in lungs of PRCV-infected pigs (Gu and Korteweg, 2007; Jung et al., 2007) , might also induce \u2022 NO production in the respiratory tract.", [["pulmonary epithelial cells", "ANATOMY", 63, 89], ["type 1", "ANATOMY", 98, 104], ["2 pneumocytes", "ANATOMY", 109, 122], ["lungs", "ANATOMY", 152, 157], ["respiratory tract", "ANATOMY", 266, 283], ["SARS", "DISEASE", 22, 26], ["necrosis", "DISEASE", 51, 59], ["NO", "CHEMICAL", 245, 247], ["NO", "CHEMICAL", 245, 247], ["SARS-CoV", "ORGANISM", 22, 30], ["pulmonary epithelial cells", "CELL", 63, 89], ["type 1", "GENE_OR_GENE_PRODUCT", 98, 104], ["2 pneumocytes", "CELL", 109, 122], ["lungs", "ORGAN", 152, 157], ["PRCV", "ORGANISM", 161, 165], ["pigs", "ORGANISM", 175, 179], ["NO", "SIMPLE_CHEMICAL", 245, 247], ["respiratory tract", "ORGANISM_SUBDIVISION", 266, 283], ["pulmonary epithelial cells", "CELL_TYPE", 63, 89], ["type 1 and 2 pneumocytes", "CELL_TYPE", 98, 122], ["pigs", "SPECIES", 175, 179], ["SARS-CoV", "SPECIES", 22, 30], ["PRCV", "SPECIES", 161, 165], ["pigs", "SPECIES", 175, 179], ["SARS-CoV", "PROBLEM", 22, 30], ["massive necrosis of pulmonary epithelial cells", "PROBLEM", 43, 89], ["type 1 and 2 pneumocytes", "PROBLEM", 98, 122], ["PRCV", "TEST", 161, 165], ["production in the respiratory tract", "PROBLEM", 248, 283], ["massive", "OBSERVATION_MODIFIER", 43, 50], ["necrosis", "OBSERVATION", 51, 59], ["pulmonary", "ANATOMY", 63, 72], ["epithelial cells", "OBSERVATION", 73, 89], ["pneumocytes", "OBSERVATION", 111, 122], ["lungs", "ANATOMY", 152, 157], ["infected", "OBSERVATION_MODIFIER", 166, 174], ["pigs", "OBSERVATION_MODIFIER", 175, 179], ["NO", "UNCERTAINTY", 245, 247], ["production", "OBSERVATION", 248, 258], ["respiratory tract", "ANATOMY", 266, 283]]], ["It is unknown whether SARS-CoV induces \u2022 NO production in the lungs and serum of patients (Akerstrom et al., 2005) .", [["lungs", "ANATOMY", 62, 67], ["serum", "ANATOMY", 72, 77], ["SARS", "DISEASE", 22, 26], ["NO", "CHEMICAL", 41, 43], ["NO", "CHEMICAL", 41, 43], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["\u2022 NO", "SIMPLE_CHEMICAL", 39, 43], ["lungs", "ORGAN", 62, 67], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 22, 30], ["SARS", "PROBLEM", 22, 26], ["production in the lungs", "PROBLEM", 44, 67], ["lungs", "ANATOMY", 62, 67]]], ["In humans, concentrations of exhaled \u2022 NO are measured in some clinical cases to monitor the progress of pulmonary diseases, such as asthma and viral pneumonia (Xu et al., 2006) .", [["pulmonary", "ANATOMY", 105, 114], ["NO", "CHEMICAL", 39, 41], ["pulmonary diseases", "DISEASE", 105, 123], ["asthma", "DISEASE", 133, 139], ["viral pneumonia", "DISEASE", 144, 159], ["NO", "CHEMICAL", 39, 41], ["humans", "ORGANISM", 3, 9], ["NO", "SIMPLE_CHEMICAL", 39, 41], ["pulmonary", "ORGAN", 105, 114], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["pulmonary diseases", "PROBLEM", 105, 123], ["asthma", "PROBLEM", 133, 139], ["viral pneumonia", "PROBLEM", 144, 159], ["pulmonary", "ANATOMY", 105, 114], ["diseases", "OBSERVATION", 115, 123], ["asthma", "OBSERVATION", 133, 139], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["pneumonia", "OBSERVATION", 150, 159]]], ["Our study demonstrated that as compared with earlier PIDs, BAL \u2022 NO levels decreased dramatically on PRCV PID 14 by which time PRCV-induced pneumonia had mostly resolved ( Figure 1A and B) (Jung et al., 2009 ).", [["NO", "CHEMICAL", 65, 67], ["PRCV", "CHEMICAL", 127, 131], ["pneumonia", "DISEASE", 140, 149], ["NO", "CHEMICAL", 65, 67], ["NO", "GENE_OR_GENE_PRODUCT", 65, 67], ["PRCV", "SPECIES", 101, 105], ["Our study", "TEST", 0, 9], ["earlier PIDs", "TEST", 45, 57], ["BAL", "TEST", 59, 62], ["levels", "PROBLEM", 68, 74], ["PRCV PID", "TEST", 101, 109], ["PRCV", "TEST", 127, 131], ["pneumonia", "PROBLEM", 140, 149], ["NO", "UNCERTAINTY", 65, 67], ["levels", "OBSERVATION_MODIFIER", 68, 74], ["decreased", "OBSERVATION_MODIFIER", 75, 84], ["dramatically", "OBSERVATION_MODIFIER", 85, 97], ["pneumonia", "OBSERVATION", 140, 149]]], ["Thus, \u2022 NO levels might be monitored as an indicator of the progression of bronchopneumonia induced by PRCV, or possibly other respiratory CoVs, and to monitor the effectiveness of treatment.Results and DiscussionThe IFN-\u03b3 contributes to \u2022 NO production by inducing iNOS gene expression in AMs and pulmonary epithelial cells during the late stages of viral infection (Xu et al., 2006) .", [["AMs", "ANATOMY", 290, 293], ["pulmonary epithelial cells", "ANATOMY", 298, 324], ["NO", "CHEMICAL", 8, 10], ["bronchopneumonia", "DISEASE", 75, 91], ["NO", "CHEMICAL", 240, 242], ["viral infection", "DISEASE", 351, 366], ["NO", "CHEMICAL", 8, 10], ["NO", "CHEMICAL", 240, 242], ["NO", "SIMPLE_CHEMICAL", 8, 10], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 217, 222], ["NO", "SIMPLE_CHEMICAL", 240, 242], ["iNOS", "GENE_OR_GENE_PRODUCT", 266, 270], ["AMs", "CELL", 290, 293], ["pulmonary epithelial cells", "CELL", 298, 324], ["IFN", "PROTEIN", 217, 220], ["iNOS", "PROTEIN", 266, 270], ["AMs", "CELL_TYPE", 290, 293], ["pulmonary epithelial cells", "CELL_TYPE", 298, 324], ["PRCV", "SPECIES", 103, 107], ["bronchopneumonia", "PROBLEM", 75, 91], ["PRCV", "TREATMENT", 103, 107], ["other respiratory CoVs", "PROBLEM", 121, 143], ["treatment", "TREATMENT", 181, 190], ["inducing iNOS gene expression in AMs", "PROBLEM", 257, 293], ["pulmonary epithelial cells", "PROBLEM", 298, 324], ["viral infection", "PROBLEM", 351, 366], ["bronchopneumonia", "OBSERVATION", 75, 91], ["respiratory CoVs", "OBSERVATION", 127, 143], ["pulmonary", "ANATOMY", 298, 307], ["epithelial cells", "OBSERVATION", 308, 324], ["late stages", "OBSERVATION_MODIFIER", 336, 347], ["viral", "OBSERVATION_MODIFIER", 351, 356], ["infection", "OBSERVATION", 357, 366]]], ["In our previous study, we noted elevated IFN-\u03b3 serum levels beyond PRCV PID 10 in PRRSV/ PRCV dual-infected pigs compared to either group of PRRSV or PRCV single-infected pigs, which might be associated with the more severe pneumonia in dual-infected pigs (Jung et al., 2009) .", [["serum", "ANATOMY", 47, 52], ["pneumonia", "DISEASE", 224, 233], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 41, 46], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["PRRSV", "ORGANISM", 82, 87], ["PRCV dual", "ORGANISM", 89, 98], ["pigs", "ORGANISM", 108, 112], ["PRRSV", "ORGANISM", 141, 146], ["PRCV single", "ORGANISM", 150, 161], ["pigs", "ORGANISM", 171, 175], ["pigs", "ORGANISM", 251, 255], ["IFN", "PROTEIN", 41, 44], ["pigs", "SPECIES", 108, 112], ["PRRSV", "SPECIES", 141, 146], ["pigs", "SPECIES", 171, 175], ["pigs", "SPECIES", 251, 255], ["PRRSV", "SPECIES", 82, 87], ["PRCV", "SPECIES", 89, 93], ["pigs", "SPECIES", 108, 112], ["PRRSV", "SPECIES", 141, 146], ["PRCV", "SPECIES", 150, 154], ["pigs", "SPECIES", 171, 175], ["pigs", "SPECIES", 251, 255], ["our previous study", "TEST", 3, 21], ["elevated IFN", "PROBLEM", 32, 44], ["serum levels", "TEST", 47, 59], ["PRCV PID", "TEST", 67, 75], ["PRRSV", "TEST", 82, 87], ["infected pigs", "PROBLEM", 99, 112], ["PRRSV", "PROBLEM", 141, 146], ["PRCV", "PROBLEM", 150, 154], ["the more severe pneumonia", "PROBLEM", 208, 233], ["infected pigs", "OBSERVATION", 162, 175], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["pneumonia", "OBSERVATION", 224, 233]]], ["Therefore, we hypothesized that increased IFN-\u03b3 serum levels followed by elevated \u2022 NO production in lung of the dual-infected pigs might be related to the exacerbated pneumonic lesions.", [["serum", "ANATOMY", 48, 53], ["lung", "ANATOMY", 101, 105], ["pneumonic lesions", "ANATOMY", 168, 185], ["NO", "CHEMICAL", 84, 86], ["pneumonic", "DISEASE", 168, 177], ["NO", "CHEMICAL", 84, 86], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 42, 47], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["NO", "SIMPLE_CHEMICAL", 84, 86], ["lung", "ORGAN", 101, 105], ["pigs", "ORGANISM", 127, 131], ["pneumonic lesions", "PATHOLOGICAL_FORMATION", 168, 185], ["IFN", "PROTEIN", 42, 45], ["pigs", "SPECIES", 127, 131], ["pigs", "SPECIES", 127, 131], ["increased IFN", "PROBLEM", 32, 45], ["serum levels", "TEST", 48, 60], ["elevated \u2022", "PROBLEM", 73, 83], ["the exacerbated pneumonic lesions", "PROBLEM", 152, 185], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["lung", "ANATOMY", 101, 105], ["exacerbated", "OBSERVATION_MODIFIER", 156, 167], ["pneumonic", "OBSERVATION_MODIFIER", 168, 177], ["lesions", "OBSERVATION", 178, 185]]], ["In pigs infected with the influenza H1N2 virus, increased BAL IFN-\u03b3 levels at PID 7 to 10 coincided with increased BAL \u2022 NO levels during the same period, possibly promoting viral clearance from the lungs during the middle and late stages of infection (Jung et al., 2004) .", [["BAL", "ANATOMY", 115, 118], ["lungs", "ANATOMY", 199, 204], ["NO", "CHEMICAL", 121, 123], ["infection", "DISEASE", 242, 251], ["NO", "CHEMICAL", 121, 123], ["pigs", "ORGANISM", 3, 7], ["influenza H1N2 virus", "ORGANISM", 26, 46], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 62, 67], ["NO", "SIMPLE_CHEMICAL", 121, 123], ["lungs", "ORGAN", 199, 204], ["IFN", "PROTEIN", 62, 65], ["pigs", "SPECIES", 3, 7], ["influenza H1N2 virus", "SPECIES", 26, 46], ["pigs", "SPECIES", 3, 7], ["influenza H1N2 virus", "SPECIES", 26, 46], ["the influenza H1N2 virus", "PROBLEM", 22, 46], ["increased BAL IFN", "TREATMENT", 48, 65], ["levels at PID", "TEST", 68, 81], ["increased BAL", "PROBLEM", 105, 118], ["viral clearance from the lungs", "PROBLEM", 174, 204], ["infection", "PROBLEM", 242, 251], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["BAL", "OBSERVATION", 115, 118], ["viral clearance", "OBSERVATION", 174, 189], ["lungs", "ANATOMY", 199, 204], ["middle", "ANATOMY_MODIFIER", 216, 222], ["late stages", "OBSERVATION_MODIFIER", 227, 238], ["infection", "OBSERVATION", 242, 251]]], ["In contrast, our study demonstrated that the trend toward increased Th1 (IFN-\u03b3) serum cytokine responses beyond 14 days after PRCV single or PRRSV/PRCV co-infection resulted in the reverse trend of decreased BAL \u2022 NO levels in the PRCV single and PRRSV/PRCV dual-infected pigs.", [["serum", "ANATOMY", 80, 85], ["BAL", "ANATOMY", 208, 211], ["PRCV", "CHEMICAL", 126, 130], ["PRCV", "CHEMICAL", 147, 151], ["NO", "CHEMICAL", 214, 216], ["NO", "CHEMICAL", 214, 216], ["Th1", "GENE_OR_GENE_PRODUCT", 68, 71], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 73, 78], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["PRRSV", "ORGANISM", 141, 146], ["NO", "SIMPLE_CHEMICAL", 214, 216], ["PRCV", "ORGANISM", 231, 235], ["PRRSV/PRCV dual", "ORGANISM", 247, 262], ["pigs", "ORGANISM", 272, 276], ["Th1 (IFN-\u03b3", "PROTEIN", 68, 78], ["cytokine", "PROTEIN", 86, 94], ["PRRSV", "SPECIES", 247, 252], ["pigs", "SPECIES", 272, 276], ["PRCV", "SPECIES", 126, 130], ["PRRSV", "SPECIES", 141, 146], ["PRCV", "SPECIES", 147, 151], ["PRCV", "SPECIES", 231, 235], ["PRRSV", "SPECIES", 247, 252], ["PRCV", "SPECIES", 253, 257], ["pigs", "SPECIES", 272, 276], ["our study", "TEST", 13, 22], ["increased Th1", "PROBLEM", 58, 71], ["IFN", "TEST", 73, 76], ["serum cytokine responses", "TEST", 80, 104], ["PRCV", "TREATMENT", 126, 130], ["PRRSV/PRCV co-infection", "PROBLEM", 141, 164], ["decreased BAL", "PROBLEM", 198, 211], ["the PRCV", "TEST", 227, 235], ["infected pigs", "OBSERVATION", 263, 276]]], ["Thus, the induced \u2022 NO levels in BAL of PRCV singly and PRCV/PRRSV dually infected pigs might not be related to the increased Th1 (IFN-\u03b3) serum and lung cytokine responses.Results and DiscussionIn PRRSV single-infected pigs, BAL \u2022 NO levels were unchanged at PRCV PID 2 to 14 (PRRSV PID 12 to 24) compared to mock control pigs ( Figure 1A-C) .", [["BAL", "ANATOMY", 33, 36], ["serum", "ANATOMY", 138, 143], ["lung", "ANATOMY", 148, 152], ["BAL", "ANATOMY", 225, 228], ["NO", "CHEMICAL", 20, 22], ["NO", "CHEMICAL", 231, 233], ["NO", "CHEMICAL", 20, 22], ["NO", "CHEMICAL", 231, 233], ["NO", "GENE_OR_GENE_PRODUCT", 20, 22], ["BAL", "ORGANISM_SUBSTANCE", 33, 36], ["PRCV", "GENE_OR_GENE_PRODUCT", 40, 44], ["PRCV/PRRSV", "ORGANISM", 56, 66], ["pigs", "ORGANISM", 83, 87], ["Th1", "GENE_OR_GENE_PRODUCT", 126, 129], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 131, 136], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["lung", "ORGAN", 148, 152], ["DiscussionIn PRRSV", "ORGANISM", 184, 202], ["pigs", "ORGANISM", 219, 223], ["NO", "GENE_OR_GENE_PRODUCT", 231, 233], ["pigs", "ORGANISM", 322, 326], ["Th1 (IFN-\u03b3", "PROTEIN", 126, 136], ["cytokine", "PROTEIN", 153, 161], ["pigs", "SPECIES", 83, 87], ["pigs", "SPECIES", 219, 223], ["pigs", "SPECIES", 322, 326], ["PRCV", "SPECIES", 40, 44], ["PRCV", "SPECIES", 56, 60], ["PRRSV", "SPECIES", 61, 66], ["pigs", "SPECIES", 83, 87], ["pigs", "SPECIES", 219, 223], ["pigs", "SPECIES", 322, 326], ["PRCV", "TEST", 40, 44], ["PRCV", "TEST", 56, 60], ["PRRSV dually infected pigs", "PROBLEM", 61, 87], ["the increased Th1", "PROBLEM", 112, 129], ["IFN", "TEST", 131, 134], ["serum", "TEST", 138, 143], ["lung cytokine responses", "TEST", 148, 171], ["BAL \u2022 NO levels", "TEST", 225, 240], ["PRRSV PID", "TEST", 277, 286], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["Th1", "OBSERVATION", 126, 129], ["lung", "ANATOMY", 148, 152], ["cytokine", "OBSERVATION", 153, 161]]], ["Nevertheless, during the test period, high PRRSV titers in lungs and severe pneumonia were observed in PRRSV single-infected pigs as reported earlier (Jung et al., 2009) .", [["lungs", "ANATOMY", 59, 64], ["pneumonia", "DISEASE", 76, 85], ["PRRSV single-infected", "DISEASE", 103, 124], ["PRRSV", "ORGANISM", 43, 48], ["lungs", "ORGAN", 59, 64], ["PRRSV", "ORGANISM", 103, 108], ["pigs", "ORGANISM", 125, 129], ["pigs", "SPECIES", 125, 129], ["PRRSV", "SPECIES", 43, 48], ["PRRSV", "SPECIES", 103, 108], ["pigs", "SPECIES", 125, 129], ["the test period", "TEST", 21, 36], ["high PRRSV titers in lungs", "PROBLEM", 38, 64], ["severe pneumonia", "PROBLEM", 69, 85], ["PRRSV", "PROBLEM", 103, 108], ["high", "OBSERVATION_MODIFIER", 38, 42], ["PRRSV titers", "OBSERVATION", 43, 55], ["lungs", "ANATOMY", 59, 64], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["pneumonia", "OBSERVATION", 76, 85]]], ["Our results concur with a prior report showing that \u2022 NO levels in BAL of experimentally PRRSV (strain VR2332)-infected pigs were not increased at PID 2 and 9 (Pampusch et al., 1998) , although the infected pigs had viremia at these PIDs.", [["BAL", "ANATOMY", 67, 70], ["NO", "CHEMICAL", 54, 56], ["viremia", "DISEASE", 216, 223], ["NO", "CHEMICAL", 54, 56], ["NO", "GENE_OR_GENE_PRODUCT", 54, 56], ["BAL", "ORGANISM_SUBSTANCE", 67, 70], ["PRRSV", "ORGANISM", 89, 94], ["strain VR2332)", "ORGANISM", 96, 110], ["pigs", "ORGANISM", 120, 124], ["pigs", "ORGANISM", 207, 211], ["PIDs", "PATHOLOGICAL_FORMATION", 233, 237], ["PRRSV", "SPECIES", 89, 94], ["pigs", "SPECIES", 120, 124], ["pigs", "SPECIES", 207, 211], ["PRRSV", "SPECIES", 89, 94], ["pigs", "SPECIES", 120, 124], ["pigs", "SPECIES", 207, 211], ["infected pigs", "PROBLEM", 111, 124], ["the infected pigs", "PROBLEM", 194, 211], ["viremia", "PROBLEM", 216, 223], ["infected", "OBSERVATION_MODIFIER", 198, 206], ["viremia", "OBSERVATION", 216, 223]]], ["Our study was expanded to confirm whether PRRSV induces \u2022 NO production in AMs, the major target cells for viral replication.", [["AMs", "ANATOMY", 75, 78], ["cells", "ANATOMY", 97, 102], ["NO", "CHEMICAL", 58, 60], ["NO", "CHEMICAL", 58, 60], ["PRRSV", "ORGANISM", 42, 47], ["NO", "GENE_OR_GENE_PRODUCT", 58, 60], ["AMs", "CELL", 75, 78], ["cells", "CELL", 97, 102], ["AMs", "CELL_TYPE", 75, 78], ["PRRSV", "SPECIES", 42, 47], ["Our study", "TEST", 0, 9], ["PRRSV", "PROBLEM", 42, 47], ["production in AMs", "PROBLEM", 61, 78], ["viral replication", "TREATMENT", 107, 124]]], ["Briefly, AMsrich BAL cells (1\u00d710 6 cells/ml) collected from the lungs of a five-day-old gnotobiotic pig were infected with either North American PRRSV VR2332 (10 5 TCID 50 /ml) or MN184 (10 5 TCID 50 /ml).", [["AMsrich BAL cells", "ANATOMY", 9, 26], ["cells", "ANATOMY", 35, 40], ["lungs", "ANATOMY", 64, 69], ["VR2332", "CHEMICAL", 151, 157], ["MN184", "CHEMICAL", 180, 185], ["MN184", "CHEMICAL", 180, 185], ["AMsrich BAL cells", "CELL", 9, 26], ["1\u00d710 6 cells", "CELL", 28, 40], ["lungs", "ORGAN", 64, 69], ["gnotobiotic", "ORGANISM", 88, 99], ["pig", "ORGANISM", 100, 103], ["PRRSV", "ORGANISM", 145, 150], ["AMsrich BAL cells", "CELL_LINE", 9, 26], ["gnotobiotic pig", "SPECIES", 88, 103], ["pig", "SPECIES", 100, 103], ["North American PRRSV VR2332", "SPECIES", 130, 157], ["AMsrich BAL cells", "TEST", 9, 26], ["gnotobiotic pig", "TREATMENT", 88, 103], ["BAL cells", "OBSERVATION", 17, 26], ["lungs", "ANATOMY", 64, 69]]], ["At PTH 24, 48 and 60, the cell culture medium was harvested for the Greiss assay.", [["cell", "ANATOMY", 26, 30], ["cell", "CELL", 26, 30], ["PTH", "TEST", 3, 6], ["the cell culture medium", "TEST", 22, 45], ["the Greiss assay", "TEST", 64, 80]]], ["There were no statistically significant differences in \u2022 NO levels in the cell culture medium between PRRSV-and mock-infected AMs, although large numbers of PRRSV antigen-containing AMs were confirmed by immunofluorescent staining during the test period (data not shown).", [["cell", "ANATOMY", 74, 78], ["AMs", "ANATOMY", 126, 129], ["AMs", "ANATOMY", 182, 185], ["NO", "CHEMICAL", 57, 59], ["NO", "CHEMICAL", 57, 59], ["NO", "SIMPLE_CHEMICAL", 57, 59], ["cell", "CELL", 74, 78], ["PRRSV", "ORGANISM", 102, 107], ["AMs", "CELL", 126, 129], ["PRRSV", "ORGANISM", 157, 162], ["antigen", "GENE_OR_GENE_PRODUCT", 163, 170], ["AMs", "CELL", 182, 185], ["AMs", "CELL_TYPE", 126, 129], ["PRRSV antigen", "PROTEIN", 157, 170], ["AMs", "CELL_TYPE", 182, 185], ["PRRSV", "SPECIES", 102, 107], ["PRRSV", "SPECIES", 157, 162], ["statistically significant differences", "PROBLEM", 14, 51], ["the cell culture", "TEST", 70, 86], ["PRRSV", "TEST", 102, 107], ["infected AMs", "PROBLEM", 117, 129], ["PRRSV antigen", "TEST", 157, 170], ["AMs", "PROBLEM", 182, 185], ["immunofluorescent staining", "TEST", 204, 230], ["the test period", "TEST", 238, 253], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["differences", "OBSERVATION", 40, 51], ["large", "OBSERVATION_MODIFIER", 140, 145], ["numbers", "OBSERVATION_MODIFIER", 146, 153]]], ["Therefore, we conclude that although PRRSV induces severe apoptotic death of AMs in lungs, it may not induce \u2022 NO in the respiratory tract, and that \u2022 NO might not play a critical role in the pathogenesis of PRRSV.Results and DiscussionFrom antiviral assays of \u2022 NO induced by PRCV infection, treatment with 800 \u03bcM SNAP in ST cells produced maximum \u2022 NO levels of 1.07 and 1.51 mM/ml in a dose-dependent manner at PTH 24 and 48, respectively.", [["AMs", "ANATOMY", 77, 80], ["lungs", "ANATOMY", 84, 89], ["respiratory tract", "ANATOMY", 121, 138], ["ST cells", "ANATOMY", 323, 331], ["death", "DISEASE", 68, 73], ["NO", "CHEMICAL", 111, 113], ["NO", "CHEMICAL", 151, 153], ["PRRSV", "DISEASE", 208, 213], ["NO", "CHEMICAL", 263, 265], ["PRCV infection", "DISEASE", 277, 291], ["SNAP", "CHEMICAL", 315, 319], ["NO", "CHEMICAL", 351, 353], ["PTH", "CHEMICAL", 414, 417], ["NO", "CHEMICAL", 111, 113], ["NO", "CHEMICAL", 151, 153], ["NO", "CHEMICAL", 263, 265], ["NO", "CHEMICAL", 351, 353], ["PRRSV", "ORGANISM", 37, 42], ["AMs", "CELL", 77, 80], ["lungs", "ORGAN", 84, 89], ["NO", "GENE_OR_GENE_PRODUCT", 111, 113], ["respiratory tract", "ORGANISM_SUBDIVISION", 121, 138], ["NO", "GENE_OR_GENE_PRODUCT", 151, 153], ["PRRSV", "ORGANISM", 208, 213], ["NO", "SIMPLE_CHEMICAL", 263, 265], ["PRCV", "SIMPLE_CHEMICAL", 277, 281], ["SNAP", "SIMPLE_CHEMICAL", 315, 319], ["ST cells", "CELL", 323, 331], ["NO", "SIMPLE_CHEMICAL", 351, 353], ["AMs", "CELL_TYPE", 77, 80], ["ST cells", "CELL_LINE", 323, 331], ["PRRSV", "SPECIES", 37, 42], ["PRRSV", "SPECIES", 208, 213], ["PRCV", "SPECIES", 277, 281], ["PRRSV", "PROBLEM", 37, 42], ["severe apoptotic death of AMs in lungs", "PROBLEM", 51, 89], ["PRRSV", "PROBLEM", 208, 213], ["antiviral assays", "TEST", 241, 257], ["PRCV infection", "PROBLEM", 277, 291], ["treatment", "TREATMENT", 293, 302], ["800 \u03bcM SNAP in ST cells", "TREATMENT", 308, 331], ["levels", "TEST", 354, 360], ["PTH", "TEST", 414, 417], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["apoptotic", "OBSERVATION_MODIFIER", 58, 67], ["lungs", "ANATOMY", 84, 89], ["respiratory tract", "ANATOMY", 121, 138], ["infection", "OBSERVATION", 282, 291]]], ["The \u2022 NO significantly inhibited PRCV replication in ST cells at PTH 24 (P<0.05) and 48 (P<0.01) compared to SNAP-free, virus-infected cells (Figure 2A and B) .", [["PRCV", "ANATOMY", 33, 37], ["ST cells", "ANATOMY", 53, 61], ["cells", "ANATOMY", 135, 140], ["NO", "CHEMICAL", 6, 8], ["SNAP", "CHEMICAL", 109, 113], ["NO", "CHEMICAL", 6, 8], ["NO", "SIMPLE_CHEMICAL", 6, 8], ["PRCV", "SIMPLE_CHEMICAL", 33, 37], ["ST cells", "CELL", 53, 61], ["SNAP-free", "SIMPLE_CHEMICAL", 109, 118], ["cells", "CELL", 135, 140], ["B", "CELL", 156, 157], ["ST cells", "CELL_TYPE", 53, 61], ["virus-infected cells", "CELL_TYPE", 120, 140], ["PRCV", "SPECIES", 33, 37], ["significantly inhibited PRCV replication in ST cells", "PROBLEM", 9, 61], ["PTH", "TEST", 65, 68], ["P", "TEST", 73, 74], ["P", "TEST", 89, 90], ["SNAP", "TEST", 109, 113], ["virus", "PROBLEM", 120, 125], ["infected cells", "PROBLEM", 126, 140], ["NO", "UNCERTAINTY", 6, 8], ["infected cells", "OBSERVATION", 126, 140]]], ["Similarly, a group 2a CoV, mouse hepatitis virus (MHV) was also susceptible to the antiviral effects of \u2022 NO, which reduced viral replication in OBL21a cells.", [["OBL21a cells", "ANATOMY", 145, 157], ["hepatitis virus", "DISEASE", 33, 48], ["NO", "CHEMICAL", 106, 108], ["NO", "CHEMICAL", 106, 108], ["CoV", "ORGANISM", 22, 25], ["mouse hepatitis virus", "ORGANISM", 27, 48], ["MHV", "ORGANISM", 50, 53], ["\u2022 NO", "SIMPLE_CHEMICAL", 104, 108], ["OBL21a cells", "CELL", 145, 157], ["OBL21a cells", "CELL_LINE", 145, 157], ["mouse", "SPECIES", 27, 32], ["hepatitis virus", "SPECIES", 33, 48], ["mouse hepatitis virus", "SPECIES", 27, 48], ["MHV", "SPECIES", 50, 53], ["mouse hepatitis virus", "PROBLEM", 27, 48], ["the antiviral effects", "TREATMENT", 79, 100], ["hepatitis virus", "OBSERVATION", 33, 48], ["viral replication", "OBSERVATION", 124, 141], ["OBL21a cells", "OBSERVATION", 145, 157]]], ["However, \u2022 NO production was not a determinant in viral clearance from the lesions (Lane et al., 1997) .", [["lesions", "ANATOMY", 75, 82], ["NO", "CHEMICAL", 11, 13], ["NO", "CHEMICAL", 11, 13], ["NO", "SIMPLE_CHEMICAL", 11, 13], ["lesions", "PATHOLOGICAL_FORMATION", 75, 82], ["the lesions", "PROBLEM", 71, 82], ["lesions", "OBSERVATION", 75, 82]]], ["Also the group 2b CoV, SARS-CoV was inhibited in Vero E6 cells treated with 400 \u03bcM SNAP (Akerstrom et al., 2005) ; however, as noted earlier, there is no information about \u2022 NO levels in SARS patients (Akerstrom et al., 2005) .", [["Vero E6 cells", "ANATOMY", 49, 62], ["SNAP", "CHEMICAL", 83, 87], ["NO", "CHEMICAL", 174, 176], ["SARS", "DISEASE", 187, 191], ["SNAP", "CHEMICAL", 83, 87], ["NO", "CHEMICAL", 174, 176], ["CoV", "ORGANISM", 18, 21], ["SARS-CoV", "ORGANISM", 23, 31], ["Vero E6 cells", "CELL", 49, 62], ["SNAP", "SIMPLE_CHEMICAL", 83, 87], ["NO", "SIMPLE_CHEMICAL", 174, 176], ["patients", "ORGANISM", 192, 200], ["Vero E6 cells", "CELL_LINE", 49, 62], ["patients", "SPECIES", 192, 200], ["SARS-CoV", "SPECIES", 23, 31], ["Vero E6", "SPECIES", 49, 56], ["SARS", "PROBLEM", 23, 27], ["Vero E6 cells", "TREATMENT", 49, 62]]], ["On the other hand, \u2022 NO did not significantly inhibit PRRSV replication in MARC145 cells at PTH 24 and 48 compared to SNAP-free, virus-infected cells ( Figure 2C and D) .", [["MARC145 cells", "ANATOMY", 75, 88], ["cells", "ANATOMY", 144, 149], ["NO", "CHEMICAL", 21, 23], ["SNAP", "CHEMICAL", 118, 122], ["NO", "CHEMICAL", 21, 23], ["NO", "SIMPLE_CHEMICAL", 21, 23], ["PRRSV", "ORGANISM", 54, 59], ["MARC145 cells", "CELL", 75, 88], ["SNAP-free", "SIMPLE_CHEMICAL", 118, 127], ["cells", "CELL", 144, 149], ["MARC145 cells", "CELL_LINE", 75, 88], ["virus-infected cells", "CELL_TYPE", 129, 149], ["PRRSV", "SPECIES", 54, 59], ["PRRSV replication", "PROBLEM", 54, 71], ["PTH", "TEST", 92, 95], ["SNAP", "TEST", 118, 122], ["infected cells", "PROBLEM", 135, 149], ["infected cells", "OBSERVATION", 135, 149]]], ["Moreover, treatment with 400 \u03bcM SNAP in MARC145 cells produced as much \u2022 NO (1.31 and 1.41 mM/ml in MARC145 cells at PTH 24 and 48, respectively) as in ST cells treated with 800 \u03bcM SNAP (Figure 2A and C).", [["MARC145 cells", "ANATOMY", 40, 53], ["MARC145 cells", "ANATOMY", 100, 113], ["ST cells", "ANATOMY", 152, 160], ["SNAP", "CHEMICAL", 32, 36], ["NO", "CHEMICAL", 73, 75], ["SNAP", "CHEMICAL", 181, 185], ["SNAP", "CHEMICAL", 32, 36], ["NO", "CHEMICAL", 73, 75], ["SNAP", "SIMPLE_CHEMICAL", 32, 36], ["MARC145 cells", "CELL", 40, 53], ["NO", "SIMPLE_CHEMICAL", 73, 75], ["MARC145 cells", "CELL", 100, 113], ["ST cells", "CELL", 152, 160], ["MARC145 cells", "CELL_LINE", 40, 53], ["MARC145 cells", "CELL_LINE", 100, 113], ["ST cells", "CELL_TYPE", 152, 160], ["treatment", "TREATMENT", 10, 19], ["400 \u03bcM SNAP in MARC145 cells", "TREATMENT", 25, 53], ["PTH", "TEST", 117, 120], ["800 \u03bcM SNAP", "TREATMENT", 174, 185]]], ["Therefore, our results imply that PRRSV is not susceptible to \u2022 NO under the conditions tested.Results and DiscussionCollectively, we suggest that unlike PRRSV, respiratory CoVs such as PRCV that infect pulmonary epithelial cells, cause cytolysis, and stimulate IFN-\u03b1 secretion, induce \u2022 NO production in the lungs.", [["pulmonary epithelial cells", "ANATOMY", 203, 229], ["lungs", "ANATOMY", 309, 314], ["NO", "CHEMICAL", 64, 66], ["cytolysis", "DISEASE", 237, 246], ["NO", "CHEMICAL", 288, 290], ["NO", "CHEMICAL", 64, 66], ["NO", "CHEMICAL", 288, 290], ["PRRSV", "ORGANISM", 34, 39], ["NO", "SIMPLE_CHEMICAL", 64, 66], ["PRRSV", "ORGANISM", 154, 159], ["CoVs", "GENE_OR_GENE_PRODUCT", 173, 177], ["PRCV", "GENE_OR_GENE_PRODUCT", 186, 190], ["pulmonary epithelial cells", "CELL", 203, 229], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 262, 267], ["NO", "SIMPLE_CHEMICAL", 288, 290], ["lungs", "ORGAN", 309, 314], ["pulmonary epithelial cells", "CELL_TYPE", 203, 229], ["IFN", "PROTEIN", 262, 265], ["PRRSV", "SPECIES", 34, 39], ["PRRSV", "SPECIES", 154, 159], ["PRCV", "SPECIES", 186, 190], ["PRRSV", "PROBLEM", 34, 39], ["PRRSV", "PROBLEM", 154, 159], ["respiratory CoVs", "PROBLEM", 161, 177], ["PRCV", "TREATMENT", 186, 190], ["pulmonary epithelial cells", "PROBLEM", 203, 229], ["cytolysis", "PROBLEM", 237, 246], ["IFN", "TEST", 262, 265], ["secretion", "PROBLEM", 268, 277], ["production in the lungs", "PROBLEM", 291, 314], ["respiratory CoVs", "OBSERVATION", 161, 177], ["pulmonary", "ANATOMY", 203, 212], ["epithelial cells", "OBSERVATION", 213, 229], ["lungs", "ANATOMY", 309, 314]]], ["Based on the in vivo and in vitro data, we conclude that \u2022 NO may play a role in innate immunity to respiratory CoV infections by inhibiting viral replication, but not in PRRSV infections, at least based on the conditions tested.Figure 1.", [["NO", "CHEMICAL", 59, 61], ["respiratory CoV infections", "DISEASE", 100, 126], ["PRRSV infections", "DISEASE", 171, 187], ["NO", "CHEMICAL", 59, 61], ["NO", "SIMPLE_CHEMICAL", 59, 61], ["respiratory CoV", "ORGANISM", 100, 115], ["PRRSV", "ORGANISM", 171, 176], ["respiratory CoV", "SPECIES", 100, 115], ["PRRSV", "SPECIES", 171, 176], ["respiratory CoV infections", "PROBLEM", 100, 126], ["viral replication", "TREATMENT", 141, 158], ["PRRSV infections", "PROBLEM", 171, 187]]], ["PRCV, but not PRRSV, induced increased \u2022 NO levels in BAL during the early and middle stages of infection (PRCV PID 2 to 10)(A and B) BAL \u2022 NO levels in different independent animal trials.", [["BAL", "ANATOMY", 54, 57], ["NO", "CHEMICAL", 41, 43], ["infection", "DISEASE", 96, 105], ["NO", "CHEMICAL", 140, 142], ["NO", "CHEMICAL", 41, 43], ["NO", "CHEMICAL", 140, 142], ["PRCV", "GENE_OR_GENE_PRODUCT", 0, 4], ["PRRSV", "ORGANISM", 14, 19], ["NO", "SIMPLE_CHEMICAL", 41, 43], ["BAL", "ORGANISM_SUBSTANCE", 54, 57], ["NO", "SIMPLE_CHEMICAL", 140, 142], ["PRCV", "PROTEIN", 0, 4], ["PRCV", "SPECIES", 0, 4], ["PRRSV", "SPECIES", 14, 19], ["PRRSV", "PROBLEM", 14, 19], ["levels in BAL", "PROBLEM", 44, 57], ["infection", "PROBLEM", 96, 105], ["PRCV PID", "TEST", 107, 115], ["A and B) BAL", "TEST", 125, 137], ["not", "UNCERTAINTY", 10, 13], ["PRRSV", "OBSERVATION", 14, 19], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["BAL", "OBSERVATION", 54, 57], ["middle stages", "OBSERVATION_MODIFIER", 79, 92], ["infection", "OBSERVATION", 96, 105]]], ["BAL samples were collected from each pig (n=1 at all PIDs for mock and PRRSV single-infected pigs, n=1-2 at each PID for PRRSV/PRCV dual-and PRCV single-infected pigs).", [["BAL samples", "ANATOMY", 0, 11], ["BAL samples", "ORGANISM_SUBSTANCE", 0, 11], ["pig", "ORGANISM", 37, 40], ["PRRSV", "ORGANISM", 71, 76], ["pigs", "ORGANISM", 93, 97], ["PRRSV", "ORGANISM", 121, 126], ["PRCV", "ORGANISM", 141, 145], ["pigs", "ORGANISM", 162, 166], ["pig", "SPECIES", 37, 40], ["pigs", "SPECIES", 93, 97], ["pigs", "SPECIES", 162, 166], ["pig", "SPECIES", 37, 40], ["PRRSV", "SPECIES", 71, 76], ["PRRSV", "SPECIES", 121, 126], ["PRCV", "SPECIES", 127, 131], ["PRCV", "SPECIES", 141, 145], ["BAL samples", "TEST", 0, 11], ["mock", "TEST", 62, 66], ["PRRSV single-infected pigs", "TREATMENT", 71, 97], ["PRRSV/PRCV dual", "TREATMENT", 121, 136], ["PRCV single-infected pigs", "TREATMENT", 141, 166]]], ["(C) Mean BAL \u2022 NO levels in 4 independent animal trials.", [["NO", "CHEMICAL", 15, 17], ["NO", "CHEMICAL", 15, 17], ["NO", "SIMPLE_CHEMICAL", 15, 17], ["Mean BAL \u2022", "TEST", 4, 14]]], ["BAL samples were collected from each pig (n=4 at all PIDs for mock and PRRSV single-infected pigs, n=4-6 at each PID for PRRSV/PRCV dual-and PRCV single-infected pigs).", [["BAL samples", "ANATOMY", 0, 11], ["BAL samples", "ORGANISM_SUBSTANCE", 0, 11], ["pig", "ORGANISM", 37, 40], ["PRRSV", "ORGANISM", 71, 76], ["pigs", "ORGANISM", 93, 97], ["PRRSV", "ORGANISM", 121, 126], ["PRCV", "ORGANISM", 141, 145], ["pigs", "ORGANISM", 162, 166], ["pig", "SPECIES", 37, 40], ["pigs", "SPECIES", 93, 97], ["pigs", "SPECIES", 162, 166], ["pig", "SPECIES", 37, 40], ["PRRSV", "SPECIES", 71, 76], ["PRRSV", "SPECIES", 121, 126], ["PRCV", "SPECIES", 127, 131], ["PRCV", "SPECIES", 141, 145], ["BAL samples", "TEST", 0, 11], ["mock", "TEST", 62, 66], ["PRRSV single-infected pigs", "TREATMENT", 71, 97], ["PRRSV/PRCV dual", "TREATMENT", 121, 136], ["PRCV", "TREATMENT", 141, 145]]], ["Pigs were first inoculated with PRRSV or mock and, 10 days later, inoculated with PRCV or mock.", [["Pigs", "ORGANISM", 0, 4], ["PRRSV", "ORGANISM", 32, 37], ["Pigs", "SPECIES", 0, 4], ["PRRSV", "SPECIES", 32, 37], ["Pigs", "SPECIES", 0, 4], ["PRRSV", "SPECIES", 32, 37], ["PRCV", "SPECIES", 82, 86], ["Pigs", "TREATMENT", 0, 4]]], ["Total \u2022 NO (nitrite and nitrate) in BAL fluids were measured by the Griess method.", [["BAL fluids", "ANATOMY", 36, 46], ["NO", "CHEMICAL", 8, 10], ["nitrite", "CHEMICAL", 12, 19], ["nitrate", "CHEMICAL", 24, 31], ["NO", "CHEMICAL", 8, 10], ["nitrite", "CHEMICAL", 12, 19], ["nitrate", "CHEMICAL", 24, 31], ["NO", "SIMPLE_CHEMICAL", 8, 10], ["nitrite", "SIMPLE_CHEMICAL", 12, 19], ["nitrate", "SIMPLE_CHEMICAL", 24, 31], ["BAL fluids", "ORGANISM_SUBSTANCE", 36, 46], ["Total \u2022 NO (nitrite and nitrate", "TREATMENT", 0, 31], ["BAL fluids", "TREATMENT", 36, 46]]], ["All assays were performed in duplicate.Figure 2. \u2022 NO significantly inhibited PRCV replication in ST cells, whereas PRRSV was not susceptible to \u2022 NO(A and C) \u2022 NO production in ST and MARC145 cells, respectively.", [["PRCV", "ANATOMY", 78, 82], ["ST cells", "ANATOMY", 98, 106], ["ST", "ANATOMY", 178, 180], ["MARC145 cells", "ANATOMY", 185, 198], ["NO", "CHEMICAL", 51, 53], ["NO", "CHEMICAL", 147, 149], ["NO", "CHEMICAL", 161, 163], ["NO", "CHEMICAL", 51, 53], ["NO(A and C", "CHEMICAL", 147, 157], ["NO", "CHEMICAL", 161, 163], ["NO", "SIMPLE_CHEMICAL", 51, 53], ["PRCV", "SIMPLE_CHEMICAL", 78, 82], ["ST cells", "CELL", 98, 106], ["PRRSV", "ORGANISM", 116, 121], ["NO", "SIMPLE_CHEMICAL", 147, 149], ["A and C) \u2022 NO", "SIMPLE_CHEMICAL", 150, 163], ["ST", "CELL", 178, 180], ["MARC145 cells", "CELL", 185, 198], ["ST cells", "CELL_TYPE", 98, 106], ["ST and MARC145 cells", "CELL_LINE", 178, 198], ["PRCV", "SPECIES", 78, 82], ["PRRSV", "SPECIES", 116, 121], ["All assays", "TEST", 0, 10], ["significantly inhibited PRCV replication in ST cells", "PROBLEM", 54, 106], ["PRRSV", "PROBLEM", 116, 121], ["production in ST and MARC145 cells", "PROBLEM", 164, 198], ["NO", "UNCERTAINTY", 51, 53], ["significantly inhibited", "OBSERVATION_MODIFIER", 54, 77], ["PRCV replication", "OBSERVATION", 78, 94]]], ["ST and MARC145 cells were treated with SNAP at different concentrations (0, 50, 100, 200, 400, and 800 \u03bcM), and cell supernatants were harvested at PTH 24 and 48 for the Griess assay.", [["MARC145 cells", "ANATOMY", 7, 20], ["cell supernatants", "ANATOMY", 112, 129], ["SNAP", "CHEMICAL", 39, 43], ["ST", "CELL", 0, 2], ["MARC145 cells", "CELL", 7, 20], ["SNAP", "SIMPLE_CHEMICAL", 39, 43], ["cell", "CELL", 112, 116], ["MARC145 cells", "CELL_LINE", 7, 20], ["ST and MARC145 cells", "PROBLEM", 0, 20], ["SNAP", "TREATMENT", 39, 43], ["cell supernatants", "TREATMENT", 112, 129], ["PTH", "TEST", 148, 151], ["the Griess assay", "TEST", 166, 182]]], ["(B and D) The antiviral effects of \u2022 NO on PRCV replication in ST cells and PRRSV replication in MARC145 cells, respectively.", [["PRCV", "ANATOMY", 43, 47], ["ST cells", "ANATOMY", 63, 71], ["MARC145 cells", "ANATOMY", 97, 110], ["NO", "CHEMICAL", 37, 39], ["(B and D)", "CHEMICAL", 0, 9], ["NO", "CHEMICAL", 37, 39], ["\u2022", "SIMPLE_CHEMICAL", 35, 36], ["NO", "SIMPLE_CHEMICAL", 37, 39], ["PRCV", "CELL", 43, 47], ["ST cells", "CELL", 63, 71], ["PRRSV", "ORGANISM", 76, 81], ["MARC145 cells", "CELL", 97, 110], ["ST cells", "CELL_TYPE", 63, 71], ["MARC145 cells", "CELL_LINE", 97, 110], ["PRCV", "SPECIES", 43, 47], ["PRRSV", "SPECIES", 76, 81], ["PRCV replication in ST cells", "TREATMENT", 43, 71], ["PRRSV replication in MARC145 cells", "TREATMENT", 76, 110], ["antiviral", "OBSERVATION", 14, 23], ["PRRSV replication", "OBSERVATION", 76, 93]]], ["The SNAP-treated, virus-infected and SNAP-untreated, virus-infected cells were infected with PRCV or PRRSV (10 5~6 TCID 50 /ml), with or without SNAP, respectively.", [["cells", "ANATOMY", 68, 73], ["SNAP", "CHEMICAL", 4, 8], ["SNAP", "CHEMICAL", 37, 41], ["SNAP", "CHEMICAL", 145, 149], ["SNAP", "SIMPLE_CHEMICAL", 4, 8], ["SNAP", "SIMPLE_CHEMICAL", 37, 41], ["cells", "CELL", 68, 73], ["PRRSV", "ORGANISM", 101, 106], ["SNAP", "SIMPLE_CHEMICAL", 145, 149], ["SNAP-untreated, virus-infected cells", "CELL_LINE", 37, 73], ["PRCV", "SPECIES", 93, 97], ["PRRSV", "SPECIES", 101, 106], ["The SNAP", "TEST", 0, 8], ["virus", "PROBLEM", 18, 23], ["infected", "PROBLEM", 24, 32], ["SNAP", "TEST", 37, 41], ["virus", "PROBLEM", 53, 58], ["infected cells", "PROBLEM", 59, 73], ["PRCV", "TREATMENT", 93, 97], ["PRRSV", "PROBLEM", 101, 106], ["infected cells", "OBSERVATION", 59, 73]]], ["At PTH 24 and 48, the cells were fixed in 95% ethanol and the TCID 50 /ml was titrated by immunofluorescent staining using virus-specific monoclonal antibodies (SDOW-17 for PRRSV and 25H7/14E3 for PRCV).", [["cells", "ANATOMY", 22, 27], ["ethanol", "CHEMICAL", 46, 53], ["ethanol", "CHEMICAL", 46, 53], ["cells", "CELL", 22, 27], ["ethanol", "SIMPLE_CHEMICAL", 46, 53], ["PRRSV", "ORGANISM", 173, 178], ["PRCV", "CANCER", 197, 201], ["monoclonal antibodies", "PROTEIN", 138, 159], ["SDOW", "PROTEIN", 161, 165], ["17", "PROTEIN", 166, 168], ["25H7", "PROTEIN", 183, 187], ["14E3", "PROTEIN", 188, 192], ["PRCV", "PROTEIN", 197, 201], ["PRRSV", "SPECIES", 173, 178], ["PRCV", "SPECIES", 197, 201], ["PTH", "TEST", 3, 6], ["the cells", "TEST", 18, 27], ["the TCID", "TREATMENT", 58, 66], ["immunofluorescent staining", "TEST", 90, 116], ["virus", "TEST", 123, 128], ["specific monoclonal antibodies", "TEST", 129, 159], ["SDOW", "TEST", 161, 165], ["PRRSV", "TEST", 173, 178], ["PRCV", "TREATMENT", 197, 201]]], ["The TCID 50 /ml was calculated according to the Reed and Muench method.", [["The TCID", "TREATMENT", 0, 8]]], ["All assays were performed independently three times.", [["All assays", "TEST", 0, 10]]], ["Asterisks (*, P<0.05; **, P<0.01) indicate statistically significant differences between SNAP-treated, virusinfected and SNAP-untreated, virus-infected cells by unpaired Student t-test.", [["cells", "ANATOMY", 152, 157], ["SNAP", "CHEMICAL", 89, 93], ["SNAP", "CHEMICAL", 121, 125], ["SNAP", "SIMPLE_CHEMICAL", 89, 93], ["SNAP", "SIMPLE_CHEMICAL", 121, 125], ["cells", "CELL", 152, 157], ["SNAP-treated, virusinfected and SNAP-untreated, virus-infected cells", "CELL_LINE", 89, 157], ["Asterisks", "TEST", 0, 9], ["P", "TEST", 14, 15], ["statistically significant differences between SNAP", "PROBLEM", 43, 93], ["SNAP", "TEST", 121, 125], ["virus", "PROBLEM", 137, 142], ["infected cells", "PROBLEM", 143, 157], ["infected cells", "OBSERVATION", 143, 157]]]], "904d886a8a305e2bc1125fccad82741d78690fef": [["INTRODUCTIONMycoplasma pneumoniae (MP) is one of the most common pathogens of community-acquired pneumonia in children and adolescents.", [["MP", "DISEASE", 35, 37], ["pneumonia", "DISEASE", 97, 106], ["INTRODUCTIONMycoplasma pneumoniae", "ORGANISM", 0, 33], ["MP", "CANCER", 35, 37], ["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["adolescents", "SPECIES", 123, 134], ["INTRODUCTIONMycoplasma pneumoniae", "SPECIES", 0, 33], ["INTRODUCTIONMycoplasma pneumoniae", "PROBLEM", 0, 33], ["community-acquired pneumonia", "PROBLEM", 78, 106], ["pneumoniae", "OBSERVATION", 23, 33], ["most common", "OBSERVATION_MODIFIER", 53, 64], ["pneumonia", "OBSERVATION", 97, 106]]], ["It can cause a variety of clinical manifestations, from mild respiratory symptoms to severe fatal pneumonia with extrapulmonary Given the increase of MRMP, some secondary treatment agents, such as corticosteroids, tetracyclines, and fluoroquinolones, have been considered for the treatment of MRMP pneumonia, although several studies have suggested that macrolides have clinical efficacy for the treatment of MRMP.", [["respiratory", "ANATOMY", 61, 72], ["respiratory symptoms", "DISEASE", 61, 81], ["pneumonia", "DISEASE", 98, 107], ["MRMP", "DISEASE", 150, 154], ["tetracyclines", "CHEMICAL", 214, 227], ["fluoroquinolones", "CHEMICAL", 233, 249], ["pneumonia", "DISEASE", 298, 307], ["macrolides", "CHEMICAL", 354, 364], ["MRMP", "DISEASE", 409, 413], ["corticosteroids", "CHEMICAL", 197, 212], ["tetracyclines", "CHEMICAL", 214, 227], ["fluoroquinolones", "CHEMICAL", 233, 249], ["macrolides", "CHEMICAL", 354, 364], ["tetracyclines", "SIMPLE_CHEMICAL", 214, 227], ["fluoroquinolones", "SIMPLE_CHEMICAL", 233, 249], ["macrolides", "SIMPLE_CHEMICAL", 354, 364], ["MRMP", "SIMPLE_CHEMICAL", 409, 413], ["clinical manifestations", "PROBLEM", 26, 49], ["mild respiratory symptoms", "PROBLEM", 56, 81], ["severe fatal pneumonia", "PROBLEM", 85, 107], ["MRMP", "TREATMENT", 150, 154], ["treatment agents", "TREATMENT", 171, 187], ["corticosteroids", "TREATMENT", 197, 212], ["tetracyclines", "TREATMENT", 214, 227], ["fluoroquinolones", "TREATMENT", 233, 249], ["MRMP pneumonia", "PROBLEM", 293, 307], ["several studies", "TEST", 318, 333], ["macrolides", "TREATMENT", 354, 364], ["MRMP", "PROBLEM", 409, 413], ["variety", "OBSERVATION_MODIFIER", 15, 22], ["mild", "OBSERVATION_MODIFIER", 56, 60], ["respiratory symptoms", "OBSERVATION", 61, 81], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["fatal", "OBSERVATION_MODIFIER", 92, 97], ["pneumonia", "OBSERVATION", 98, 107], ["extrapulmonary", "ANATOMY", 113, 127], ["increase", "OBSERVATION_MODIFIER", 138, 146], ["secondary treatment", "OBSERVATION", 161, 180], ["pneumonia", "OBSERVATION", 298, 307]]], ["[17] [18] [19] Tetracyclines, including minocycline and doxycycline, have been reported as alternative agents for children with MRMP.", [["[17] [18] [19] Tetracyclines", "CHEMICAL", 0, 28], ["minocycline", "CHEMICAL", 40, 51], ["doxycycline", "CHEMICAL", 56, 67], ["MRMP", "DISEASE", 128, 132], ["[17] [18] [19] Tetracyclines", "CHEMICAL", 0, 28], ["minocycline", "CHEMICAL", 40, 51], ["doxycycline", "CHEMICAL", 56, 67], ["[17] [18] [19] Tetracyclines", "SIMPLE_CHEMICAL", 0, 28], ["minocycline", "SIMPLE_CHEMICAL", 40, 51], ["doxycycline", "SIMPLE_CHEMICAL", 56, 67], ["children", "ORGANISM", 114, 122], ["children", "SPECIES", 114, 122], ["Tetracyclines", "TREATMENT", 15, 28], ["minocycline", "TREATMENT", 40, 51], ["doxycycline", "TREATMENT", 56, 67]]], ["20,21 However, they are not recommended for use in patients younger than 8 years of age, because tetracyclines can cause tooth discoloration in children during the periods of osteogenesis and odontogenesis.", [["tooth", "ANATOMY", 121, 126], ["tetracyclines", "CHEMICAL", 97, 110], ["tooth discoloration", "DISEASE", 121, 140], ["osteogenesis", "DISEASE", 175, 187], ["odontogenesis", "DISEASE", 192, 205], ["tetracyclines", "CHEMICAL", 97, 110], ["patients", "ORGANISM", 51, 59], ["tetracyclines", "SIMPLE_CHEMICAL", 97, 110], ["tooth", "ORGAN", 121, 126], ["children", "ORGANISM", 144, 152], ["patients", "SPECIES", 51, 59], ["children", "SPECIES", 144, 152], ["tetracyclines", "TREATMENT", 97, 110], ["tooth discoloration", "PROBLEM", 121, 140], ["osteogenesis", "PROBLEM", 175, 187], ["odontogenesis", "PROBLEM", 192, 205], ["discoloration", "OBSERVATION", 127, 140], ["osteogenesis", "OBSERVATION", 175, 187], ["odontogenesis", "OBSERVATION", 192, 205]]], ["22 In addition, fluoroquinolones have been associated with a risk of musculoskeletal toxicities, including tendinitis, arthritis, and growth impairment in children.", [["musculoskeletal", "ANATOMY", 69, 84], ["fluoroquinolones", "CHEMICAL", 16, 32], ["toxicities", "DISEASE", 85, 95], ["tendinitis", "DISEASE", 107, 117], ["arthritis", "DISEASE", 119, 128], ["growth impairment", "DISEASE", 134, 151], ["fluoroquinolones", "CHEMICAL", 16, 32], ["fluoroquinolones", "SIMPLE_CHEMICAL", 16, 32], ["children", "ORGANISM", 155, 163], ["children", "SPECIES", 155, 163], ["fluoroquinolones", "TREATMENT", 16, 32], ["musculoskeletal toxicities", "PROBLEM", 69, 95], ["tendinitis", "PROBLEM", 107, 117], ["arthritis", "PROBLEM", 119, 128], ["growth impairment in children", "PROBLEM", 134, 163], ["musculoskeletal", "ANATOMY", 69, 84], ["toxicities", "OBSERVATION", 85, 95], ["tendinitis", "OBSERVATION", 107, 117], ["arthritis", "OBSERVATION", 119, 128], ["growth", "OBSERVATION_MODIFIER", 134, 140]]], ["23 Although there is still lack of information on their safety in children, it was reported that there were no clinically detectable adverse events for up to 5 years after treatment with levofloxacin (LFX).", [["levofloxacin", "CHEMICAL", 187, 199], ["LFX", "CHEMICAL", 201, 204], ["levofloxacin", "CHEMICAL", 187, 199], ["LFX", "CHEMICAL", 201, 204], ["children", "ORGANISM", 66, 74], ["levofloxacin", "SIMPLE_CHEMICAL", 187, 199], ["LFX", "SIMPLE_CHEMICAL", 201, 204], ["children", "SPECIES", 66, 74], ["clinically detectable adverse events", "PROBLEM", 111, 147], ["treatment", "TREATMENT", 172, 181], ["levofloxacin", "TREATMENT", 187, 199], ["no", "UNCERTAINTY", 108, 110]]], ["24 Some studies have reported the clinical effectiveness of systemic corticosteroids (CST) in the treatment of refractory MP pneumonia, because hyper-reaction of the host immune system may contribute to its pathogenesis.", [["immune system", "ANATOMY", 171, 184], ["MP", "DISEASE", 122, 124], ["pneumonia", "DISEASE", 125, 134], ["corticosteroids", "CHEMICAL", 69, 84], ["CST", "SIMPLE_CHEMICAL", 86, 89], ["Some studies", "TEST", 3, 15], ["systemic corticosteroids", "TREATMENT", 60, 84], ["refractory MP pneumonia", "PROBLEM", 111, 134], ["hyper-reaction of the host immune system", "PROBLEM", 144, 184], ["its pathogenesis", "PROBLEM", 203, 219], ["refractory", "OBSERVATION_MODIFIER", 111, 121], ["MP", "OBSERVATION_MODIFIER", 122, 124], ["pneumonia", "OBSERVATION", 125, 134], ["host immune", "OBSERVATION", 166, 177]]], ["25, 26 However, CST can also cause several side effects, such as growth disorder, glucose intolerance, and the suppression of the immune system.", [["immune system", "ANATOMY", 130, 143], ["growth disorder", "DISEASE", 65, 80], ["glucose intolerance", "DISEASE", 82, 101], ["glucose", "CHEMICAL", 82, 89], ["CST", "SIMPLE_CHEMICAL", 16, 19], ["glucose", "SIMPLE_CHEMICAL", 82, 89], ["several side effects", "PROBLEM", 35, 55], ["growth disorder", "PROBLEM", 65, 80], ["glucose intolerance", "PROBLEM", 82, 101], ["the suppression of the immune system", "PROBLEM", 107, 143], ["glucose intolerance", "OBSERVATION", 82, 101]]], ["27 We aimed to compare the therapeutic efficacy of prolonged macrolides (PMCs), CST, doxycycline (DXC), and LFX against macrolide-unresponsive MP pneumonia in children, and to evaluate the safety of CST, DXC, and LFX.Subjects and study designWe retrospectively analyzed the medical records of patients with MP pneumonia aged \u2264 18 years old who were hospitalized at Gil Medical Center between January 2015 and April 2017.Subjects and study designThe diagnosis of MP pneumonia was confirmed if all the following conditions were satisfied: 1) signs and symptoms (fever, cough, dyspnea, productive sputum, chest pain, or abnormal breath sounds) of pneumonia; 2) abnormal chest X-ray findings compatible with pneumonia; and 3) identification of MP IgM antibody performed during the illness via enzyme-linked immunosorbent assay.Subjects and study designAmong these patients, macrolide-unresponsive MP pneumonia cases were clinically defined as persistent fever \u2265 38.0\u00b0C at \u2265 72 hours after macrolide treatment in this study.", [["PMCs", "ANATOMY", 73, 77], ["sputum", "ANATOMY", 594, 600], ["chest", "ANATOMY", 602, 607], ["macrolides", "CHEMICAL", 61, 71], ["PMCs", "CHEMICAL", 73, 77], ["doxycycline", "CHEMICAL", 85, 96], ["DXC", "CHEMICAL", 98, 101], ["LFX", "CHEMICAL", 108, 111], ["macrolide", "CHEMICAL", 120, 129], ["MP pneumonia", "DISEASE", 143, 155], ["DXC", "CHEMICAL", 204, 207], ["LFX", "CHEMICAL", 213, 216], ["MP pneumonia", "DISEASE", 307, 319], ["MP", "DISEASE", 462, 464], ["pneumonia", "DISEASE", 465, 474], ["fever", "DISEASE", 560, 565], ["cough", "DISEASE", 567, 572], ["dyspnea", "DISEASE", 574, 581], ["chest pain", "DISEASE", 602, 612], ["abnormal breath sounds", "DISEASE", 617, 639], ["pneumonia", "DISEASE", 644, 653], ["pneumonia", "DISEASE", 704, 713], ["macrolide", "CHEMICAL", 870, 879], ["MP", "DISEASE", 893, 895], ["pneumonia", "DISEASE", 896, 905], ["fever", "DISEASE", 950, 955], ["macrolide", "CHEMICAL", 985, 994], ["macrolides", "CHEMICAL", 61, 71], ["doxycycline", "CHEMICAL", 85, 96], ["DXC", "CHEMICAL", 98, 101], ["LFX", "CHEMICAL", 108, 111], ["macrolide", "CHEMICAL", 120, 129], ["macrolide", "CHEMICAL", 870, 879], ["macrolide", "CHEMICAL", 985, 994], ["macrolides", "SIMPLE_CHEMICAL", 61, 71], ["PMCs", "SIMPLE_CHEMICAL", 73, 77], ["CST", "SIMPLE_CHEMICAL", 80, 83], ["doxycycline", "SIMPLE_CHEMICAL", 85, 96], ["DXC", "SIMPLE_CHEMICAL", 98, 101], ["LFX", "SIMPLE_CHEMICAL", 108, 111], ["macrolide", "SIMPLE_CHEMICAL", 120, 129], ["MP", "ORGANISM", 143, 145], ["children", "ORGANISM", 159, 167], ["CST", "SIMPLE_CHEMICAL", 199, 202], ["DXC", "SIMPLE_CHEMICAL", 204, 207], ["LFX", "SIMPLE_CHEMICAL", 213, 216], ["patients", "ORGANISM", 293, 301], ["chest", "ORGANISM_SUBDIVISION", 602, 607], ["MP", "GENE_OR_GENE_PRODUCT", 740, 742], ["patients", "ORGANISM", 860, 868], ["macrolide", "SIMPLE_CHEMICAL", 870, 879], ["MP", "ORGANISM", 893, 895], ["macrolide", "SIMPLE_CHEMICAL", 985, 994], ["MP IgM antibody", "PROTEIN", 740, 755], ["children", "SPECIES", 159, 167], ["patients", "SPECIES", 293, 301], ["patients", "SPECIES", 860, 868], ["prolonged macrolides (PMCs", "TREATMENT", 51, 77], ["CST", "TREATMENT", 80, 83], ["doxycycline (DXC)", "TREATMENT", 85, 102], ["LFX", "TREATMENT", 108, 111], ["macrolide", "TREATMENT", 120, 129], ["unresponsive MP pneumonia", "PROBLEM", 130, 155], ["CST", "TEST", 199, 202], ["MP pneumonia", "PROBLEM", 307, 319], ["MP pneumonia", "PROBLEM", 462, 474], ["signs and symptoms", "PROBLEM", 540, 558], ["fever", "PROBLEM", 560, 565], ["cough", "PROBLEM", 567, 572], ["dyspnea", "PROBLEM", 574, 581], ["productive sputum", "PROBLEM", 583, 600], ["chest pain", "PROBLEM", 602, 612], ["abnormal breath sounds", "PROBLEM", 617, 639], ["pneumonia", "PROBLEM", 644, 653], ["abnormal chest X-ray findings", "PROBLEM", 658, 687], ["pneumonia", "PROBLEM", 704, 713], ["MP IgM antibody", "TEST", 740, 755], ["enzyme", "TEST", 789, 795], ["immunosorbent assay", "TEST", 803, 822], ["macrolide", "TREATMENT", 870, 879], ["unresponsive MP pneumonia cases", "PROBLEM", 880, 911], ["persistent fever", "PROBLEM", 939, 955], ["macrolide treatment", "TREATMENT", 985, 1004], ["this study", "TEST", 1008, 1018], ["pneumonia", "OBSERVATION", 146, 155], ["pneumonia", "OBSERVATION", 310, 319], ["pneumonia", "OBSERVATION", 465, 474], ["chest", "ANATOMY", 602, 607], ["pneumonia", "OBSERVATION", 644, 653], ["chest", "ANATOMY", 667, 672], ["compatible with", "UNCERTAINTY", 688, 703], ["pneumonia", "OBSERVATION", 704, 713], ["IgM antibody", "OBSERVATION", 743, 755], ["pneumonia", "OBSERVATION", 896, 905]]], ["The macrolide-unresponsive MP pneumonia cases were divided into four groups, PMC, CST, DXC, and LFX.", [["macrolide", "CHEMICAL", 4, 13], ["pneumonia", "DISEASE", 30, 39], ["macrolide", "CHEMICAL", 4, 13], ["macrolide", "SIMPLE_CHEMICAL", 4, 13], ["MP", "ORGANISM", 27, 29], ["The macrolide", "TREATMENT", 0, 13], ["unresponsive MP pneumonia cases", "PROBLEM", 14, 45], ["PMC", "TEST", 77, 80], ["CST", "TEST", 82, 85], ["DXC", "TEST", 87, 90], ["pneumonia", "OBSERVATION", 30, 39], ["LFX", "ANATOMY", 96, 99]]], ["The PMC group was defined as cases treated with PMC without a change of antibiotics.", [["PMC", "ANATOMY", 4, 7], ["PMC", "CANCER", 4, 7], ["PMC", "TREATMENT", 48, 51], ["a change of antibiotics", "TREATMENT", 60, 83]]], ["The CST, DXC, and LFX groups were defined as cases with treatment added on (CST) or changed to secondary treatment (DXC, LFX) because of persistent symptoms despite macrolide treatment.Subjects and study designPatients with any of the following were excluded: 1) patients for whom clinical symptoms and radiologic findings were not compatible with pneumonia, despite positive MP IgM; 2) patients with a history of MP infection within the past year; 3) patients whose fever had subsided within 72 hours after macrolide treatment; 4) patients who were prescribed oseltamivir because of proven influenza during hospitalization period; or 5) patients for which a secondary treatment was started \u2265 12 hours after the last time with a fever of \u2265 38.0\u00b0C.Subjects and study designThe mean duration of administration in the CST, DXC, and LFX groups was 5.9 \u00b1 3.1 days (oral prednisolone dosage of 1 mg/kg/day or intravenous methylprednisolone dosage of 1-2 mg/kg/day), 9.4 \u00b1 3.4 days (at a dosage of 4 mg/kg/day), and 8.2 \u00b1 2.4 days (at a dosage of 10 mg/kg/day).Data collection and analysisThe collected data included age, sex, hospitalization period, duration of fever (febrile days before macrolide treatment, febrile days during macrolide single treatment, time to defervescence [TTD] after initial macrolide treatment, and TTD after secondary treatment), chest X-ray findings, prescribed antibiotics, extrapulmonary symptoms (hepatitis, skin rash, arthritis, hematologic, and neurological symptoms), oxygen use, intensive care unit (ICU) hospitalization, percutaneous catheter drainage (PCD) insertion, re-hospitalization, and side effects associated with secondary treatments (CST, DXC, and LFX).", [["CST", "ANATOMY", 815, 818], ["oral", "ANATOMY", 860, 864], ["intravenous", "ANATOMY", 903, 914], ["skin", "ANATOMY", 1433, 1437], ["hematologic", "ANATOMY", 1455, 1466], ["neurological", "ANATOMY", 1472, 1484], ["percutaneous", "ANATOMY", 1551, 1563], ["macrolide", "CHEMICAL", 165, 174], ["pneumonia", "DISEASE", 348, 357], ["MP infection", "DISEASE", 414, 426], ["fever", "DISEASE", 467, 472], ["macrolide", "CHEMICAL", 508, 517], ["oseltamivir", "CHEMICAL", 561, 572], ["influenza", "DISEASE", 591, 600], ["fever", "DISEASE", 729, 734], ["prednisolone", "CHEMICAL", 865, 877], ["methylprednisolone", "CHEMICAL", 915, 933], ["fever", "DISEASE", 1156, 1161], ["febrile", "DISEASE", 1163, 1170], ["macrolide", "CHEMICAL", 1183, 1192], ["febrile", "DISEASE", 1204, 1211], ["macrolide", "CHEMICAL", 1224, 1233], ["TTD", "DISEASE", 1275, 1278], ["macrolide", "CHEMICAL", 1294, 1303], ["TTD", "DISEASE", 1319, 1322], ["extrapulmonary symptoms", "DISEASE", 1397, 1420], ["hepatitis", "DISEASE", 1422, 1431], ["skin rash", "DISEASE", 1433, 1442], ["arthritis", "DISEASE", 1444, 1453], ["hematologic, and neurological symptoms", "DISEASE", 1455, 1493], ["oxygen", "CHEMICAL", 1496, 1502], ["macrolide", "CHEMICAL", 165, 174], ["macrolide", "CHEMICAL", 508, 517], ["oseltamivir", "CHEMICAL", 561, 572], ["prednisolone", "CHEMICAL", 865, 877], ["methylprednisolone", "CHEMICAL", 915, 933], ["macrolide", "CHEMICAL", 1183, 1192], ["macrolide", "CHEMICAL", 1224, 1233], ["macrolide", "CHEMICAL", 1294, 1303], ["oxygen", "CHEMICAL", 1496, 1502], ["macrolide", "SIMPLE_CHEMICAL", 165, 174], ["patients", "ORGANISM", 263, 271], ["patients", "ORGANISM", 387, 395], ["patients", "ORGANISM", 452, 460], ["patients", "ORGANISM", 532, 540], ["patients", "ORGANISM", 638, 646], ["oral", "ORGANISM_SUBDIVISION", 860, 864], ["prednisolone", "SIMPLE_CHEMICAL", 865, 877], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 903, 914], ["methylprednisolone", "SIMPLE_CHEMICAL", 915, 933], ["skin", "ORGAN", 1433, 1437], ["oxygen", "SIMPLE_CHEMICAL", 1496, 1502], ["IgM", "PROTEIN", 379, 382], ["patients", "SPECIES", 263, 271], ["patients", "SPECIES", 387, 395], ["patients", "SPECIES", 452, 460], ["patients", "SPECIES", 532, 540], ["patients", "SPECIES", 638, 646], ["The CST", "TEST", 0, 7], ["DXC", "TEST", 9, 12], ["treatment", "TREATMENT", 56, 65], ["secondary treatment (DXC, LFX", "TREATMENT", 95, 124], ["persistent symptoms", "PROBLEM", 137, 156], ["macrolide treatment", "TREATMENT", 165, 184], ["clinical symptoms", "PROBLEM", 281, 298], ["radiologic findings", "TEST", 303, 322], ["pneumonia", "PROBLEM", 348, 357], ["positive MP IgM", "PROBLEM", 367, 382], ["MP infection", "PROBLEM", 414, 426], ["fever", "PROBLEM", 467, 472], ["macrolide treatment", "TREATMENT", 508, 527], ["oseltamivir", "TREATMENT", 561, 572], ["influenza", "PROBLEM", 591, 600], ["a secondary treatment", "TREATMENT", 657, 678], ["a fever", "PROBLEM", 727, 734], ["the CST", "TEST", 811, 818], ["DXC", "TEST", 820, 823], ["oral prednisolone dosage", "TREATMENT", 860, 884], ["intravenous methylprednisolone dosage", "TREATMENT", 903, 940], ["Data collection", "TEST", 1054, 1069], ["analysis", "TEST", 1074, 1082], ["fever", "PROBLEM", 1156, 1161], ["macrolide treatment", "TREATMENT", 1183, 1202], ["febrile", "PROBLEM", 1204, 1211], ["macrolide single treatment", "TREATMENT", 1224, 1250], ["initial macrolide treatment", "TREATMENT", 1286, 1313], ["secondary treatment", "TREATMENT", 1329, 1348], ["chest X-ray findings", "TEST", 1351, 1371], ["prescribed antibiotics", "TREATMENT", 1373, 1395], ["extrapulmonary symptoms", "PROBLEM", 1397, 1420], ["hepatitis", "PROBLEM", 1422, 1431], ["skin rash", "PROBLEM", 1433, 1442], ["arthritis", "PROBLEM", 1444, 1453], ["hematologic", "PROBLEM", 1455, 1466], ["neurological symptoms", "PROBLEM", 1472, 1493], ["hospitalization", "TREATMENT", 1534, 1549], ["percutaneous catheter drainage (PCD) insertion", "TREATMENT", 1551, 1597], ["re-hospitalization", "TREATMENT", 1599, 1617], ["side effects", "PROBLEM", 1623, 1635], ["secondary treatments", "TREATMENT", 1652, 1672], ["CST, DXC, and LFX)", "TREATMENT", 1674, 1692], ["not compatible with", "UNCERTAINTY", 328, 347], ["pneumonia", "OBSERVATION", 348, 357], ["infection", "OBSERVATION", 417, 426], ["chest", "ANATOMY", 1351, 1356], ["extrapulmonary", "ANATOMY", 1397, 1411], ["skin", "ANATOMY", 1433, 1437], ["rash", "OBSERVATION", 1438, 1442], ["arthritis", "OBSERVATION", 1444, 1453], ["catheter drainage", "OBSERVATION", 1564, 1581]]], ["The chest X-ray findings were from the records read by two radiologists and classified according to the presence of consolidation (lobar or patchy), reticular opacities, pneumonic infiltration, and parapneumonic effusion.", [["chest", "ANATOMY", 4, 9], ["lobar", "ANATOMY", 131, 136], ["reticular opacities", "ANATOMY", 149, 168], ["reticular opacities", "DISEASE", 149, 168], ["pneumonic infiltration", "DISEASE", 170, 192], ["parapneumonic effusion", "DISEASE", 198, 220], ["The chest X-ray", "TEST", 0, 15], ["consolidation (lobar or patchy)", "PROBLEM", 116, 147], ["reticular opacities", "PROBLEM", 149, 168], ["pneumonic infiltration", "PROBLEM", 170, 192], ["parapneumonic effusion", "PROBLEM", 198, 220], ["chest", "ANATOMY", 4, 9], ["consolidation", "OBSERVATION", 116, 129], ["lobar", "OBSERVATION_MODIFIER", 131, 136], ["patchy", "OBSERVATION_MODIFIER", 140, 146], ["reticular", "OBSERVATION_MODIFIER", 149, 158], ["opacities", "OBSERVATION", 159, 168], ["pneumonic", "OBSERVATION_MODIFIER", 170, 179], ["infiltration", "OBSERVATION", 180, 192], ["parapneumonic", "OBSERVATION_MODIFIER", 198, 211], ["effusion", "OBSERVATION", 212, 220]]], ["In addition, information about mixed infections with other respiratory pathogens identified through multiplexed reverse transcription-polymerase chain reaction (RT-PCR) for respiratory viruses from a nasopharyngeal swab was included.Data collection and analysisWe compared the TTD after secondary treatment, the use of combined antibiotics, other required treatments and outcomes among the CST, DXC and LFX groups.", [["nasopharyngeal swab", "ANATOMY", 200, 219], ["infections", "DISEASE", 37, 47], ["respiratory viruses", "DISEASE", 173, 192], ["TTD", "DISEASE", 277, 280], ["nasopharyngeal swab", "CANCER", 200, 219], ["mixed infections", "PROBLEM", 31, 47], ["other respiratory pathogens", "PROBLEM", 53, 80], ["multiplexed reverse transcription", "TEST", 100, 133], ["polymerase chain reaction", "PROBLEM", 134, 159], ["RT-PCR", "TEST", 161, 167], ["respiratory viruses", "PROBLEM", 173, 192], ["a nasopharyngeal swab", "TEST", 198, 219], ["Data collection", "TEST", 233, 248], ["analysisWe", "TREATMENT", 253, 263], ["secondary treatment", "TREATMENT", 287, 306], ["combined antibiotics", "TREATMENT", 319, 339], ["treatments", "TREATMENT", 356, 366], ["the CST", "TEST", 386, 393], ["DXC and LFX groups", "TREATMENT", 395, 413], ["respiratory", "ANATOMY", 173, 184], ["viruses", "OBSERVATION", 185, 192], ["nasopharyngeal", "ANATOMY", 200, 214]]], ["In addition, we compared the TTD after initial macrolide treatment and the length of hospital stay between PMC group vs. each CST, DXC, and LFX group.", [["TTD", "DISEASE", 29, 32], ["macrolide", "CHEMICAL", 47, 56], ["macrolide", "CHEMICAL", 47, 56], ["initial macrolide treatment", "TREATMENT", 39, 66], ["each CST", "TEST", 121, 129]]], ["To adjust some variables which could affect the fever duration, we performed propensity score (PS) matching analysis.Data collection and analysisSide effects such as Cushing appearance and peptic ulcer for CST, tooth discoloration for DXC, and tendinopathy, arthritis for LFX were evaluated for one month after medication.Statistical analysisAll analyses except PS matching were performed using IBM SPSS Statistics ver.", [["peptic ulcer", "ANATOMY", 189, 201], ["tooth", "ANATOMY", 211, 216], ["fever", "DISEASE", 48, 53], ["Cushing appearance", "DISEASE", 166, 184], ["ulcer", "DISEASE", 196, 201], ["tooth discoloration", "DISEASE", 211, 230], ["DXC", "DISEASE", 235, 238], ["tendinopathy", "DISEASE", 244, 256], ["arthritis", "DISEASE", 258, 267], ["LFX", "DISEASE", 272, 275], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 189, 201], ["tooth", "ORGAN", 211, 216], ["the fever duration", "PROBLEM", 44, 62], ["matching analysis", "TEST", 99, 116], ["Data collection", "TEST", 117, 132], ["analysis", "TEST", 137, 145], ["Side effects", "PROBLEM", 145, 157], ["Cushing appearance", "PROBLEM", 166, 184], ["peptic ulcer", "PROBLEM", 189, 201], ["CST", "PROBLEM", 206, 209], ["tooth discoloration", "PROBLEM", 211, 230], ["DXC", "PROBLEM", 235, 238], ["tendinopathy", "PROBLEM", 244, 256], ["arthritis", "PROBLEM", 258, 267], ["LFX", "PROBLEM", 272, 275], ["medication", "TREATMENT", 311, 321], ["Statistical analysis", "TEST", 322, 342], ["All analyses", "TEST", 342, 354], ["PS matching", "TREATMENT", 362, 373], ["peptic", "OBSERVATION_MODIFIER", 189, 195], ["ulcer", "OBSERVATION", 196, 201], ["tooth", "ANATOMY", 211, 216], ["tendinopathy", "OBSERVATION", 244, 256], ["arthritis", "OBSERVATION", 258, 267]]], ["The Kruskal-Wallis test or Mann-Whitney test was used for continuous variables such as age, hospitalization period, and duration of fever.", [["fever", "DISEASE", 132, 137], ["The Kruskal-Wallis test", "TEST", 0, 23], ["Whitney test", "TEST", 32, 44], ["fever", "PROBLEM", 132, 137]]], ["The \u03c7 2 or Fisher's exact tests were used for categorical variables such as sex, chest X-ray findings, antibiotics, extrapulmonary symptoms, oxygen use, ICU hospitalization, PCD insertion, and re-hospitalization.", [["extrapulmonary symptoms", "DISEASE", 116, 139], ["oxygen", "CHEMICAL", 141, 147], ["PCD", "DISEASE", 174, 177], ["oxygen", "CHEMICAL", 141, 147], ["oxygen", "SIMPLE_CHEMICAL", 141, 147], ["Fisher's exact tests", "TEST", 11, 31], ["categorical variables", "TEST", 46, 67], ["chest X-ray findings", "TEST", 81, 101], ["antibiotics", "TREATMENT", 103, 114], ["extrapulmonary symptoms", "PROBLEM", 116, 139], ["ICU hospitalization", "TREATMENT", 153, 172], ["PCD insertion", "TREATMENT", 174, 187], ["re-hospitalization", "TREATMENT", 193, 211], ["chest", "ANATOMY", 81, 86], ["extrapulmonary", "ANATOMY", 116, 130]]], ["If the variables were statistically significant when compared among more than two groups, they were further analyzed by Mann-Whitney test, \u03c7 2 test or Fisher's exact test for comparing two groups.Statistical analysisWe compared the TTD after initial macrolide treatment between PMC group and each secondary treatment group through PS matching to reduce selection bias and to control potential confounding factors.", [["TTD", "DISEASE", 232, 235], ["macrolide", "CHEMICAL", 250, 259], ["macrolide", "CHEMICAL", 250, 259], ["macrolide", "SIMPLE_CHEMICAL", 250, 259], ["Fisher's exact test", "TEST", 151, 170], ["the TTD", "TREATMENT", 228, 235], ["initial macrolide treatment", "TREATMENT", 242, 269], ["PMC group", "TREATMENT", 278, 287], ["secondary treatment group through PS matching", "TREATMENT", 297, 342], ["selection bias", "TREATMENT", 353, 367], ["potential confounding factors", "PROBLEM", 383, 412]]], ["The estimated PS for being assigned to each group was calculated for each patient using multiple logistic regression models with the following covariates: age, sex, radiographic findings, mixed infection with other pathogens.", [["infection", "DISEASE", 194, 203], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["The estimated PS", "TEST", 0, 16], ["multiple logistic regression models", "TREATMENT", 88, 123], ["radiographic findings", "TEST", 165, 186], ["mixed infection", "PROBLEM", 188, 203], ["other pathogens", "PROBLEM", 209, 224], ["mixed", "OBSERVATION_MODIFIER", 188, 193], ["infection", "OBSERVATION", 194, 203]]], ["Patients were matched at a ratio of PMC:CST = 2:1, PMC:DXC = 1:1, and PMC:LFX = 2:1, based on a greedy 8-1 digits matching algorithm.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["CST", "TEST", 40, 43], ["DXC", "TEST", 55, 58], ["LFX", "TEST", 74, 77]]], ["This algorithm attempted to match the PMC subjects and the secondary treatment subjects on the first 8 digits of the PS.", [["the PS", "TREATMENT", 113, 119]]], ["The PMC subjects that did not match were then matched to secondary treatment subjects on 7 digits of the PS.", [["the PS", "TREATMENT", 101, 107]]], ["We processed through the algorithm sequentially to the 1-digit match on the PS.", [["the PS", "TREATMENT", 72, 78]]], ["The patients with no corresponding match were excluded.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["PS matching was performed using SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA).", [["SAS", "TEST", 32, 35]]], ["P values of < 0.05 were considered to be statistically significant.Ethics statementThis study was approved by the Institutional Review Board (IRB) of Gachon University Gil Medical Center (IRB No.", [["P values", "TEST", 0, 8], ["This study", "TEST", 83, 93]]], ["GBIRB2017-361).Characteristics of subjectsThe total number of subjects who met the inclusion criteria for MP diagnosis within the study period was 1,165.", [["GBIRB2017-361", "CHEMICAL", 0, 13], ["MP", "DISEASE", 106, 108], ["GBIRB2017-361", "CHEMICAL", 0, 13], ["total", "OBSERVATION_MODIFIER", 46, 51]]], ["After exclusion by our study criteria, 190 cases (16.3%) of macrolideunresponsive MP pneumonia were enrolled.", [["MP", "DISEASE", 82, 84], ["pneumonia", "DISEASE", 85, 94], ["our study criteria", "TEST", 19, 37], ["cases", "TEST", 43, 48], ["macrolideunresponsive MP pneumonia", "PROBLEM", 60, 94], ["pneumonia", "OBSERVATION", 85, 94]]], ["Among those, 138 cases were continuously treated with macrolide approximately for 7-14 days, and 32 cases were treated with addon CST and continuous macrolide.", [["macrolide", "CHEMICAL", 54, 63], ["macrolide", "CHEMICAL", 149, 158], ["macrolide", "CHEMICAL", 54, 63], ["macrolide", "CHEMICAL", 149, 158], ["macrolide", "SIMPLE_CHEMICAL", 54, 63], ["addon CST", "SIMPLE_CHEMICAL", 124, 133], ["macrolide", "SIMPLE_CHEMICAL", 149, 158], ["macrolide", "TREATMENT", 54, 63], ["addon CST", "TREATMENT", 124, 133], ["continuous macrolide", "TREATMENT", 138, 158]]], ["Fourteen and 6 cases were treated with secondary antimicrobial therapy with DXC and LFX, respectively.", [["DXC", "CHEMICAL", 76, 79], ["DXC", "CHEMICAL", 76, 79], ["DXC", "SIMPLE_CHEMICAL", 76, 79], ["LFX", "SIMPLE_CHEMICAL", 84, 87], ["secondary antimicrobial therapy", "TREATMENT", 39, 70], ["DXC and LFX", "TREATMENT", 76, 87], ["antimicrobial therapy", "OBSERVATION", 49, 70]]], ["Two patients were excluded: one patient had improved when administered a combination therapy of corticosteroid and LFX after treatment failure of the add-on of corticosteroid alone; the other patient was treated with corticosteroid and LFX simultaneously.Characteristics of subjectsThe median age of patients in the PMC, CST, DXC, and LFX groups was 5.2 years old (range: 0.6-16.0), 4.9 years old (range: 1.2-14.8), 10.1 years old (range: 8.1-14.6), and 9.7 years old (range: 4.8-17.0), respectively (P < 0.001).", [["PMC", "ANATOMY", 316, 319], ["CST", "ANATOMY", 321, 324], ["LFX", "CHEMICAL", 115, 118], ["LFX", "CHEMICAL", 236, 239], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 32, 39], ["corticosteroid", "SIMPLE_CHEMICAL", 96, 110], ["LFX", "SIMPLE_CHEMICAL", 115, 118], ["corticosteroid", "SIMPLE_CHEMICAL", 160, 174], ["patient", "ORGANISM", 192, 199], ["corticosteroid", "SIMPLE_CHEMICAL", 217, 231], ["LFX", "SIMPLE_CHEMICAL", 236, 239], ["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 32, 39], ["patient", "SPECIES", 192, 199], ["patients", "SPECIES", 300, 308], ["a combination therapy", "TREATMENT", 71, 92], ["corticosteroid and LFX", "TREATMENT", 96, 118], ["treatment failure", "TREATMENT", 125, 142], ["corticosteroid alone", "TREATMENT", 160, 180], ["corticosteroid and LFX simultaneously", "TREATMENT", 217, 254], ["CST", "TEST", 321, 324], ["DXC", "TEST", 326, 329]]], ["Patients in the DXC group were significantly older than in the PMC and CST groups (P < 0.001 for both).", [["Patients", "ORGANISM", 0, 8], ["DXC", "CANCER", 16, 19], ["Patients", "SPECIES", 0, 8]]], ["The number of boys in each group was 59 (42.8%), 19 (59.4%), 4 (28.6%), and 3 (50.0%), respectively (P = 0.850).", [["boys", "SPECIES", 14, 18], ["P", "TEST", 101, 102]]], ["The median duration of hospitalization was 9.5 days (range: 5.0-22.0), 9.5 days (range: 6.0-17.0), 9.0 days (range: 4.0-16.0), and 9.5 days (range: 8.0-23.0), respectively (P = 0.726) ( Table 1) Table 2 ).Defervescence after the change of treatment among the CST, DXC, and LFX groupsAfter the change to the secondary treatment, the TTD was the shortest in the CST group (8.4 \u00b1 26.8 hours) , followed by the LFX (16.8 \u00b1 18 .0 hours) and DXC (27.4 \u00b1 33.", [["Defervescence", "DISEASE", 205, 218], ["TTD", "DISEASE", 332, 335], ["P", "TEST", 173, 174], ["Defervescence", "PROBLEM", 205, 218], ["treatment", "TREATMENT", 239, 248], ["the CST", "TEST", 255, 262], ["DXC, and LFX groups", "TREATMENT", 264, 283], ["the secondary treatment", "TREATMENT", 303, 326], ["the TTD", "TEST", 328, 335], ["the LFX", "TEST", 403, 410], ["DXC", "TEST", 436, 439]]], ["The numbers of patients who achieved defervescence within 48 hours in CST, DXC, and LFX groups were 31 (96.9%), 12 (85.7%), and 5 (83.3%), respectively (Defervescence after initial macrolide treatment among the PMC, CST, DXC, and LFX groupsThe TTDs after initial macrolide treatment were compared in the matched analysis between the PMC group and each secondary treatment group.", [["defervescence", "DISEASE", 37, 50], ["macrolide", "CHEMICAL", 181, 190], ["DXC", "CHEMICAL", 221, 224], ["macrolide", "CHEMICAL", 263, 272], ["macrolide", "CHEMICAL", 181, 190], ["macrolide", "CHEMICAL", 263, 272], ["patients", "ORGANISM", 15, 23], ["macrolide", "SIMPLE_CHEMICAL", 263, 272], ["PMC", "CANCER", 333, 336], ["patients", "SPECIES", 15, 23], ["CST", "TEST", 70, 73], ["DXC", "TEST", 75, 78], ["LFX groups", "TEST", 84, 94], ["initial macrolide treatment", "TREATMENT", 173, 200], ["the PMC", "TREATMENT", 207, 214], ["CST", "TEST", 216, 219], ["DXC", "TEST", 221, 224], ["The TTDs", "TREATMENT", 240, 248], ["initial macrolide treatment", "TREATMENT", 255, 282], ["the matched analysis", "TEST", 300, 320], ["the PMC group", "TREATMENT", 329, 342], ["secondary treatment group", "TREATMENT", 352, 377]]], ["The TTDs after initial macrolide treatment were not significantly different between PMC and CST groups ( Table 3) .", [["macrolide", "CHEMICAL", 23, 32], ["macrolide", "CHEMICAL", 23, 32], ["macrolide", "SIMPLE_CHEMICAL", 23, 32], ["The TTDs", "TREATMENT", 0, 8], ["initial macrolide treatment", "TREATMENT", 15, 42]]], ["There was no difference in the length of hospital stay between the PMC group and each secondary treatment group.Combined antibiotics, other required treatments, and outcomesThe number of patients who received combined treatment with third-generation cephalosporin was higher in the PMC than other groups.", [["PMC", "ANATOMY", 282, 285], ["cephalosporin", "CHEMICAL", 250, 263], ["cephalosporin", "CHEMICAL", 250, 263], ["patients", "ORGANISM", 187, 195], ["third-generation cephalosporin", "SIMPLE_CHEMICAL", 233, 263], ["PMC", "CANCER", 282, 285], ["patients", "SPECIES", 187, 195], ["the PMC group", "TREATMENT", 63, 76], ["secondary treatment group", "TREATMENT", 86, 111], ["Combined antibiotics", "TREATMENT", 112, 132], ["treatments", "TREATMENT", 149, 159], ["combined treatment", "TREATMENT", 209, 227], ["third-generation cephalosporin", "TREATMENT", 233, 263], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["Patients who received combined treatment with vancomycin or needed PCD insertion were identified only in the PMC group.", [["vancomycin", "CHEMICAL", 46, 56], ["vancomycin", "CHEMICAL", 46, 56], ["Patients", "ORGANISM", 0, 8], ["vancomycin", "SIMPLE_CHEMICAL", 46, 56], ["PMC", "CANCER", 109, 112], ["Patients", "SPECIES", 0, 8], ["combined treatment", "TREATMENT", 22, 40], ["vancomycin", "TREATMENT", 46, 56], ["PCD insertion", "TREATMENT", 67, 80]]], ["There was no patient who required ICU care and no difference in re-hospitalization rates was found among the groups ( Table 4 ).", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["ICU care", "TREATMENT", 34, 42], ["no", "UNCERTAINTY", 10, 12]]], ["There was no patient whose clinical symptoms were aggravated after secondary treatment.SafetyNo side effects associated with CST, DXC, and LFX were observed.", [["DXC", "CHEMICAL", 130, 133], ["LFX", "CHEMICAL", 139, 142], ["DXC", "CHEMICAL", 130, 133], ["patient", "ORGANISM", 13, 20], ["CST", "SIMPLE_CHEMICAL", 125, 128], ["DXC", "SIMPLE_CHEMICAL", 130, 133], ["LFX", "SIMPLE_CHEMICAL", 139, 142], ["patient", "SPECIES", 13, 20], ["patient whose clinical symptoms", "PROBLEM", 13, 44], ["secondary treatment", "TREATMENT", 67, 86], ["side effects", "PROBLEM", 96, 108], ["CST", "TEST", 125, 128], ["DXC", "TEST", 130, 133], ["no", "UNCERTAINTY", 10, 12]]], ["Combined use of 3rd generation cephalosporin was significantly different between PMC with corticosteroid or DXC groups (P < 0.001 for both).DISCUSSIONThe incidence of macrolide resistance of MP has recently increased and has been related to life-threatening or refractory MP pneumonia in children.", [["cephalosporin", "CHEMICAL", 31, 44], ["DXC", "CHEMICAL", 108, 111], ["macrolide", "CHEMICAL", 167, 176], ["MP", "DISEASE", 191, 193], ["MP", "DISEASE", 272, 274], ["pneumonia", "DISEASE", 275, 284], ["cephalosporin", "CHEMICAL", 31, 44], ["DXC", "CHEMICAL", 108, 111], ["macrolide", "CHEMICAL", 167, 176], ["cephalosporin", "SIMPLE_CHEMICAL", 31, 44], ["corticosteroid", "SIMPLE_CHEMICAL", 90, 104], ["DXC", "SIMPLE_CHEMICAL", 108, 111], ["macrolide", "SIMPLE_CHEMICAL", 167, 176], ["MP", "GENE_OR_GENE_PRODUCT", 191, 193], ["children", "ORGANISM", 288, 296], ["children", "SPECIES", 288, 296], ["3rd generation cephalosporin", "TREATMENT", 16, 44], ["corticosteroid or DXC groups", "TREATMENT", 90, 118], ["macrolide resistance of MP", "PROBLEM", 167, 193], ["refractory MP pneumonia", "PROBLEM", 261, 284], ["macrolide resistance", "OBSERVATION", 167, 187], ["increased", "OBSERVATION_MODIFIER", 207, 216], ["refractory", "OBSERVATION_MODIFIER", 261, 271], ["MP", "OBSERVATION_MODIFIER", 272, 274], ["pneumonia", "OBSERVATION", 275, 284]]], ["16 Several studies on macrolide and alternative treatments for MRMP have been reported.", [["macrolide", "CHEMICAL", 22, 31], ["MRMP", "CHEMICAL", 63, 67], ["macrolide", "CHEMICAL", 22, 31], ["macrolide", "SIMPLE_CHEMICAL", 22, 31], ["MRMP", "SIMPLE_CHEMICAL", 63, 67], ["Several studies", "TEST", 3, 18], ["macrolide", "TREATMENT", 22, 31], ["alternative treatments", "TREATMENT", 36, 58], ["MRMP", "TREATMENT", 63, 67]]], ["However, data on their therapeutic efficacy and safety in children are still limited.", [["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66]]], ["We compared the therapeutic efficacy of PMC, CST, DXC, and LFX against macrolide-unresponsive MP pneumonia and collected data about their safety in children.", [["PMC", "CHEMICAL", 40, 43], ["DXC", "CHEMICAL", 50, 53], ["LFX", "CHEMICAL", 59, 62], ["macrolide", "CHEMICAL", 71, 80], ["MP pneumonia", "DISEASE", 94, 106], ["macrolide", "CHEMICAL", 71, 80], ["PMC", "SIMPLE_CHEMICAL", 40, 43], ["CST", "SIMPLE_CHEMICAL", 45, 48], ["DXC", "SIMPLE_CHEMICAL", 50, 53], ["LFX", "SIMPLE_CHEMICAL", 59, 62], ["macrolide", "SIMPLE_CHEMICAL", 71, 80], ["children", "ORGANISM", 148, 156], ["children", "SPECIES", 148, 156], ["PMC", "PROBLEM", 40, 43], ["CST", "TEST", 45, 48], ["DXC", "TEST", 50, 53], ["LFX", "TREATMENT", 59, 62], ["macrolide", "TREATMENT", 71, 80], ["unresponsive MP pneumonia", "PROBLEM", 81, 106], ["pneumonia", "OBSERVATION", 97, 106]]], ["Most of the patient achieved defervescence within 48 hours after the secondary treatment and any side effect was not observed in the CST, DXC, and LFX groups.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19], ["the secondary treatment", "TREATMENT", 65, 88], ["any side effect", "PROBLEM", 93, 108]]], ["However, TTD after initial macrolide treatment did not differ significantly between the PMC, CST, DXC, and LFX groups.DISCUSSIONMacrolide resistance of MP is genetically determined by the 23S rRNA gene mutation.", [["TTD", "DISEASE", 9, 12], ["macrolide", "CHEMICAL", 27, 36], ["DISCUSSIONMacrolide", "CHEMICAL", 118, 137], ["MP", "DISEASE", 152, 154], ["macrolide", "CHEMICAL", 27, 36], ["macrolide", "SIMPLE_CHEMICAL", 27, 36], ["MP", "GENE_OR_GENE_PRODUCT", 152, 154], ["23S", "GENE_OR_GENE_PRODUCT", 188, 191], ["rRNA", "CELLULAR_COMPONENT", 192, 196], ["23S rRNA gene", "DNA", 188, 201], ["TTD", "PROBLEM", 9, 12], ["initial macrolide treatment", "TREATMENT", 19, 46], ["the PMC", "TEST", 84, 91], ["CST", "TEST", 93, 96], ["DXC", "TEST", 98, 101], ["the 23S rRNA gene mutation", "PROBLEM", 184, 210]]], ["As there was no difference in the clinical manifestation between macrolide-susceptible M. pneumoniae (MSMP) and MRMP, it is difficult to clinically distinguish MRMP from MSMP.", [["macrolide", "CHEMICAL", 65, 74], ["MSMP", "DISEASE", 170, 174], ["macrolide", "CHEMICAL", 65, 74], ["macrolide", "SIMPLE_CHEMICAL", 65, 74], ["M. pneumoniae", "ORGANISM", 87, 100], ["MRMP", "CANCER", 160, 164], ["MSMP", "CANCER", 170, 174], ["M. pneumoniae", "SPECIES", 87, 100], ["M. pneumoniae", "SPECIES", 87, 100], ["macrolide", "TREATMENT", 65, 74], ["susceptible M. pneumoniae", "PROBLEM", 75, 100], ["no", "UNCERTAINTY", 13, 15], ["difference", "OBSERVATION_MODIFIER", 16, 26], ["pneumoniae", "OBSERVATION", 90, 100]]], ["However, it has been reported that the duration of fever after the administration of macrolide was longer in MRMP than MSMP in childhood pneumonia and that persistent fever might suggest the possibility of infection with MRMP.", [["fever", "DISEASE", 51, 56], ["macrolide", "CHEMICAL", 85, 94], ["MSMP", "CHEMICAL", 119, 123], ["pneumonia", "DISEASE", 137, 146], ["fever", "DISEASE", 167, 172], ["infection", "DISEASE", 206, 215], ["MRMP", "CHEMICAL", 221, 225], ["macrolide", "CHEMICAL", 85, 94], ["macrolide", "SIMPLE_CHEMICAL", 85, 94], ["MRMP", "SIMPLE_CHEMICAL", 109, 113], ["MRMP", "SIMPLE_CHEMICAL", 221, 225], ["fever", "PROBLEM", 51, 56], ["macrolide", "TREATMENT", 85, 94], ["childhood pneumonia", "PROBLEM", 127, 146], ["persistent fever", "PROBLEM", 156, 172], ["infection", "PROBLEM", 206, 215], ["MRMP", "PROBLEM", 221, 225], ["pneumonia", "OBSERVATION", 137, 146], ["persistent", "OBSERVATION_MODIFIER", 156, 166], ["fever", "OBSERVATION", 167, 172], ["suggest the possibility of", "UNCERTAINTY", 179, 205], ["infection", "OBSERVATION", 206, 215]]], ["The patients with MSMP achieved defervescence within 48-72 hours in more than 80% of cases after treatment with macrolide.", [["MSMP", "DISEASE", 18, 22], ["macrolide", "CHEMICAL", 112, 121], ["macrolide", "CHEMICAL", 112, 121], ["patients", "ORGANISM", 4, 12], ["macrolide", "SIMPLE_CHEMICAL", 112, 121], ["patients", "SPECIES", 4, 12], ["treatment", "TREATMENT", 97, 106], ["macrolide", "TREATMENT", 112, 121]]], ["14,15,28 As mycoplasma takes a long time to isolate, antibiotic susceptibility testing is difficult to apply in practical clinical situations.", [["14,15,28", "CHEMICAL", 0, 8], ["mycoplasma", "PROBLEM", 12, 22], ["antibiotic susceptibility testing", "TEST", 53, 86]]], ["Molecular tests to confirm macrolide resistance are not currently available in Korean hospitals, except in some cases for research purposes.", [["macrolide", "CHEMICAL", 27, 36], ["macrolide", "CHEMICAL", 27, 36], ["macrolide", "SIMPLE_CHEMICAL", 27, 36], ["Molecular tests", "TEST", 0, 15], ["macrolide resistance", "PROBLEM", 27, 47], ["research purposes", "TEST", 122, 139], ["macrolide resistance", "OBSERVATION", 27, 47]]], ["Japanese societies have recommended a change of antibiotics to second-line agents when fever does not subside in 48-72 hours from macrolides administration.", [["fever", "DISEASE", 87, 92], ["macrolides", "CHEMICAL", 130, 140], ["macrolides", "CHEMICAL", 130, 140], ["macrolides", "SIMPLE_CHEMICAL", 130, 140], ["a change of antibiotics", "TREATMENT", 36, 59], ["second-line agents", "TREATMENT", 63, 81], ["fever", "PROBLEM", 87, 92], ["macrolides administration", "TREATMENT", 130, 155]]], ["28 In this study, macrolide-unresponsive MP pneumonia was defined as persistent fever of \u2265 38.0\u00b0C at \u2265 72 hours after macrolide treatment.DISCUSSIONIn this study, the prevalence of macrolide-unresponsive MP pneumonia was 16.3%, which was much lower than the prevalence of MRMP reported in Korea (87.2% in 2015) .", [["macrolide", "CHEMICAL", 18, 27], ["MP", "DISEASE", 41, 43], ["pneumonia", "DISEASE", 44, 53], ["fever", "DISEASE", 80, 85], ["macrolide", "CHEMICAL", 118, 127], ["macrolide", "CHEMICAL", 181, 190], ["MP", "DISEASE", 204, 206], ["pneumonia", "DISEASE", 207, 216], ["MRMP", "DISEASE", 272, 276], ["macrolide", "CHEMICAL", 18, 27], ["macrolide", "CHEMICAL", 118, 127], ["macrolide", "CHEMICAL", 181, 190], ["macrolide", "SIMPLE_CHEMICAL", 18, 27], ["MP", "ORGANISM", 41, 43], ["C", "GENE_OR_GENE_PRODUCT", 96, 97], ["macrolide", "SIMPLE_CHEMICAL", 118, 127], ["macrolide", "SIMPLE_CHEMICAL", 181, 190], ["this study", "TEST", 6, 16], ["macrolide", "TREATMENT", 18, 27], ["unresponsive MP pneumonia", "PROBLEM", 28, 53], ["persistent fever", "PROBLEM", 69, 85], ["macrolide treatment", "TREATMENT", 118, 137], ["this study", "TEST", 151, 161], ["macrolide", "TREATMENT", 181, 190], ["unresponsive MP pneumonia", "PROBLEM", 191, 216], ["pneumonia", "OBSERVATION", 44, 53], ["persistent", "OBSERVATION_MODIFIER", 69, 79], ["fever", "OBSERVATION", 80, 85], ["pneumonia", "OBSERVATION", 207, 216]]], ["14 This discrepancy between macrolide-resistance and macrolide-unresponsiveness indicated that most patients with MRMP pneumonia achieved defervescence within 72 hours after macrolide administration.", [["macrolide", "CHEMICAL", 28, 37], ["macrolide", "CHEMICAL", 53, 62], ["pneumonia", "DISEASE", 119, 128], ["defervescence", "DISEASE", 138, 151], ["macrolide", "CHEMICAL", 174, 183], ["macrolide", "CHEMICAL", 28, 37], ["macrolide", "CHEMICAL", 53, 62], ["macrolide", "CHEMICAL", 174, 183], ["macrolide", "SIMPLE_CHEMICAL", 28, 37], ["macrolide", "SIMPLE_CHEMICAL", 53, 62], ["patients", "ORGANISM", 100, 108], ["macrolide", "SIMPLE_CHEMICAL", 174, 183], ["patients", "SPECIES", 100, 108], ["macrolide-resistance", "TREATMENT", 28, 48], ["macrolide", "TREATMENT", 53, 62], ["unresponsiveness", "PROBLEM", 63, 79], ["MRMP pneumonia", "PROBLEM", 114, 128], ["macrolide administration", "TREATMENT", 174, 198], ["pneumonia", "OBSERVATION", 119, 128]]], ["Matsubara et al. 19 demonstrated that 22.7% of MRMP cases showed clinical improvement within 3 days after macrolide treatment.", [["macrolide", "CHEMICAL", 106, 115], ["macrolide", "CHEMICAL", 106, 115], ["MRMP", "CANCER", 47, 51], ["macrolide", "SIMPLE_CHEMICAL", 106, 115], ["Matsubara et al.", "TEST", 0, 16], ["MRMP cases", "TEST", 47, 57], ["macrolide treatment", "TREATMENT", 106, 125]]], ["In addition, Suzuki et al. 17 reported that fever resolved with the initially prescribed macrolide, without changing antibiotics, for the treatment of MRMP infection, and there was no apparent treatment failure or cases of serious illness.", [["fever", "DISEASE", 44, 49], ["macrolide", "CHEMICAL", 89, 98], ["infection", "DISEASE", 156, 165], ["macrolide", "CHEMICAL", 89, 98], ["macrolide", "SIMPLE_CHEMICAL", 89, 98], ["fever", "PROBLEM", 44, 49], ["macrolide", "TREATMENT", 89, 98], ["changing antibiotics", "TREATMENT", 108, 128], ["MRMP infection", "PROBLEM", 151, 165], ["apparent treatment failure", "PROBLEM", 184, 210], ["serious illness", "PROBLEM", 223, 238], ["infection", "OBSERVATION", 156, 165], ["no apparent", "UNCERTAINTY", 181, 192]]], ["It was suggested that macrolides have anti-inflammatory effects, as well as antimicrobial effects, through the inhibition of the production of cytokines such as IL-6 and IL-8 in human bronchial epithelial cells.", [["bronchial epithelial cells", "ANATOMY", 184, 210], ["macrolides", "CHEMICAL", 22, 32], ["macrolides", "CHEMICAL", 22, 32], ["macrolides", "SIMPLE_CHEMICAL", 22, 32], ["IL-6", "GENE_OR_GENE_PRODUCT", 161, 165], ["IL-8", "GENE_OR_GENE_PRODUCT", 170, 174], ["human", "ORGANISM", 178, 183], ["bronchial epithelial cells", "CELL", 184, 210], ["cytokines", "PROTEIN", 143, 152], ["IL-6", "PROTEIN", 161, 165], ["IL-8", "PROTEIN", 170, 174], ["human bronchial epithelial cells", "CELL_TYPE", 178, 210], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["macrolides", "TREATMENT", 22, 32], ["anti-inflammatory effects", "TREATMENT", 38, 63], ["antimicrobial effects", "TREATMENT", 76, 97], ["cytokines", "PROBLEM", 143, 152], ["IL", "TEST", 161, 163], ["IL", "TEST", 170, 172], ["bronchial epithelial", "ANATOMY", 184, 204], ["cells", "OBSERVATION", 205, 210]]], ["29, 30 In our data, there were no cases of treatment failure in the PMC group, except for two cases of re-hospitalization.", [["PMC", "CANCER", 68, 71], ["treatment failure", "PROBLEM", 43, 60]]], ["In these two cases, defervescence occurred within 24 hours without a change in antibiotics after rehospitalization.DISCUSSIONIn some previous reports, systemic CST induced clinical and radiological improvement in severe refractory MP pneumonia.", [["defervescence", "DISEASE", 20, 33], ["MP", "DISEASE", 231, 233], ["pneumonia", "DISEASE", 234, 243], ["defervescence", "PROBLEM", 20, 33], ["a change in antibiotics", "TREATMENT", 67, 90], ["rehospitalization", "TREATMENT", 97, 114], ["severe refractory MP pneumonia", "PROBLEM", 213, 243], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["refractory", "OBSERVATION_MODIFIER", 220, 230], ["MP", "OBSERVATION_MODIFIER", 231, 233], ["pneumonia", "OBSERVATION", 234, 243]]], ["25, 26, 31 Immune regulatory and anti-inflammatory effects of CST could result in the clinical improvement of severe refractory MP pneumonia.", [["MP", "DISEASE", 128, 130], ["pneumonia", "DISEASE", 131, 140], ["CST", "SIMPLE_CHEMICAL", 62, 65], ["CST", "TREATMENT", 62, 65], ["severe refractory MP pneumonia", "PROBLEM", 110, 140], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["refractory", "OBSERVATION_MODIFIER", 117, 127], ["MP", "OBSERVATION_MODIFIER", 128, 130], ["pneumonia", "OBSERVATION", 131, 140]]], ["32, 33 In this study, CST improved fever in the shortest time (8.4 \u00b1 26.8 hours) compared with other medications, which was similar to those reported in other studies.", [["fever", "DISEASE", 35, 40], ["CST", "SIMPLE_CHEMICAL", 22, 25], ["this study", "TEST", 10, 20], ["CST improved fever", "PROBLEM", 22, 40], ["other medications", "TREATMENT", 95, 112], ["other studies", "TEST", 153, 166], ["improved", "OBSERVATION_MODIFIER", 26, 34], ["fever", "OBSERVATION", 35, 40]]], ["Lee et al. 34 reported that 93% of patients with severe MP pneumonia achieved defervescence within 24 hours.", [["MP", "DISEASE", 56, 58], ["pneumonia", "DISEASE", 59, 68], ["defervescence", "DISEASE", 78, 91], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["severe MP pneumonia", "PROBLEM", 49, 68], ["pneumonia", "OBSERVATION", 59, 68]]], ["In another study, the TTD was approximately 8-48 hours in prednisolone-treated patients.", [["TTD", "DISEASE", 22, 25], ["prednisolone", "CHEMICAL", 58, 70], ["prednisolone", "CHEMICAL", 58, 70], ["prednisolone", "SIMPLE_CHEMICAL", 58, 70], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["another study", "TEST", 3, 16], ["the TTD", "TEST", 18, 25], ["prednisolone", "TREATMENT", 58, 70]]], ["25 Recently, several studies suggested that tetracycline and fluoroquinolone had a therapeutic effect on MRMP in children.", [["tetracycline", "CHEMICAL", 44, 56], ["fluoroquinolone", "CHEMICAL", 61, 76], ["tetracycline", "CHEMICAL", 44, 56], ["fluoroquinolone", "CHEMICAL", 61, 76], ["tetracycline", "SIMPLE_CHEMICAL", 44, 56], ["fluoroquinolone", "SIMPLE_CHEMICAL", 61, 76], ["MRMP", "SIMPLE_CHEMICAL", 105, 109], ["children", "ORGANISM", 113, 121], ["children", "SPECIES", 113, 121], ["several studies", "TEST", 13, 28], ["tetracycline", "TREATMENT", 44, 56], ["fluoroquinolone", "TREATMENT", 61, 76]]], ["Most patients administered DXC or minocycline achieved defervescence within 24 hours, with a significantly shorter TTD than macrolide in the MRMP group (13.5 \u00b1 4.1 vs. 123.3 \u00b1 59 .0 hours).", [["DXC", "CHEMICAL", 27, 30], ["minocycline", "CHEMICAL", 34, 45], ["defervescence", "DISEASE", 55, 68], ["TTD", "DISEASE", 115, 118], ["macrolide", "CHEMICAL", 124, 133], ["DXC", "CHEMICAL", 27, 30], ["minocycline", "CHEMICAL", 34, 45], ["macrolide", "CHEMICAL", 124, 133], ["patients", "ORGANISM", 5, 13], ["DXC", "SIMPLE_CHEMICAL", 27, 30], ["minocycline", "SIMPLE_CHEMICAL", 34, 45], ["macrolide", "SIMPLE_CHEMICAL", 124, 133], ["MRMP", "CANCER", 141, 145], ["patients", "SPECIES", 5, 13], ["DXC", "TREATMENT", 27, 30], ["minocycline", "TREATMENT", 34, 45], ["a significantly shorter TTD", "PROBLEM", 91, 118], ["macrolide", "TREATMENT", 124, 133]]], ["21, 35 Miyashita et al. 36 reported that 77% of patients with MRMP in the quinolone group achieved defervescence within 48 hours after the initiation of antibiotics and quinolone was more effective than macrolide for MRMP treatment (P = 0.036).", [["MRMP", "CHEMICAL", 62, 66], ["quinolone", "CHEMICAL", 74, 83], ["defervescence", "DISEASE", 99, 112], ["quinolone", "CHEMICAL", 169, 178], ["macrolide", "CHEMICAL", 203, 212], ["MRMP", "CHEMICAL", 217, 221], ["quinolone", "CHEMICAL", 74, 83], ["quinolone", "CHEMICAL", 169, 178], ["macrolide", "CHEMICAL", 203, 212], ["MRMP", "CHEMICAL", 217, 221], ["patients", "ORGANISM", 48, 56], ["MRMP", "CANCER", 62, 66], ["quinolone", "SIMPLE_CHEMICAL", 74, 83], ["quinolone", "SIMPLE_CHEMICAL", 169, 178], ["macrolide", "SIMPLE_CHEMICAL", 203, 212], ["MRMP", "SIMPLE_CHEMICAL", 217, 221], ["patients", "SPECIES", 48, 56], ["MRMP", "TREATMENT", 62, 66], ["the quinolone group", "TREATMENT", 70, 89], ["antibiotics", "TREATMENT", 153, 164], ["quinolone", "TREATMENT", 169, 178], ["macrolide", "TREATMENT", 203, 212], ["MRMP treatment", "TREATMENT", 217, 231]]], ["In this study, TTD after DXC and LFX treatment was 27.4 \u00b1 33.2 hours and 16.8 \u00b1 18 .0 hours, respectively.", [["TTD", "DISEASE", 15, 18], ["DXC", "CHEMICAL", 25, 28], ["LFX", "CHEMICAL", 33, 36], ["this study", "TEST", 3, 13], ["TTD", "TEST", 15, 18], ["DXC", "TEST", 25, 28], ["LFX treatment", "TREATMENT", 33, 46]]], ["In addition, 85.7% and 83.3% of patients achieved defervescence within 48 hours in the DXC and LFX groups, respectively ( Table 2) .", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["Direct comparison of TTD between the PMC group and the secondary treatment groups was not possible, because all patients were initially treated with macrolide and added on or switched to CST, DXC, and LFX.", [["TTD", "DISEASE", 21, 24], ["macrolide", "CHEMICAL", 149, 158], ["DXC", "CHEMICAL", 192, 195], ["LFX", "CHEMICAL", 201, 204], ["macrolide", "CHEMICAL", 149, 158], ["PMC", "CANCER", 37, 40], ["patients", "ORGANISM", 112, 120], ["macrolide", "SIMPLE_CHEMICAL", 149, 158], ["CST", "SIMPLE_CHEMICAL", 187, 190], ["DXC", "SIMPLE_CHEMICAL", 192, 195], ["LFX", "SIMPLE_CHEMICAL", 201, 204], ["patients", "SPECIES", 112, 120], ["TTD", "PROBLEM", 21, 24], ["the secondary treatment groups", "TREATMENT", 51, 81], ["macrolide", "TREATMENT", 149, 158], ["CST", "TEST", 187, 190], ["DXC", "TREATMENT", 192, 195]]], ["Therefore, we performed PS matching to adjust differences in baseline characteristics among the groups and compared TTD after initial macrolide treatment between groups.", [["TTD", "DISEASE", 116, 119], ["macrolide", "CHEMICAL", 134, 143], ["macrolide", "CHEMICAL", 134, 143], ["macrolide", "SIMPLE_CHEMICAL", 134, 143], ["PS matching", "TREATMENT", 24, 35], ["initial macrolide treatment", "TREATMENT", 126, 153]]], ["However, the TTDs after initial macrolide treatment of the CST, DXC, LFX groups did not differ from that of each matched PMC group (P = 0.085, P = 0.453, and P = 0.283, respectively).", [["PMC", "ANATOMY", 121, 124], ["TTDs", "DISEASE", 13, 17], ["macrolide", "CHEMICAL", 32, 41], ["macrolide", "CHEMICAL", 32, 41], ["macrolide", "SIMPLE_CHEMICAL", 32, 41], ["PMC", "CANCER", 121, 124], ["initial macrolide treatment", "TREATMENT", 24, 51], ["the CST", "TEST", 55, 62], ["P", "TEST", 132, 133], ["P", "TEST", 143, 144], ["P", "TEST", 158, 159]]], ["There was no difference in length of hospital stay between the PMC group and the secondary treatment groups ( Table 3) .DISCUSSIONWe investigated the frequency of the use of broad-spectrum antibiotics in the treatment of community-acquired pneumonia in children.", [["pneumonia", "DISEASE", 240, 249], ["children", "ORGANISM", 253, 261], ["children", "SPECIES", 253, 261], ["the secondary treatment groups", "TREATMENT", 77, 107], ["broad-spectrum antibiotics", "TREATMENT", 174, 200], ["the treatment", "TREATMENT", 204, 217], ["community-acquired pneumonia", "PROBLEM", 221, 249], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["length", "OBSERVATION_MODIFIER", 27, 33], ["pneumonia", "OBSERVATION", 240, 249]]], ["The number of patients treated with 3rd generation cephalosporin was higher in the PMC group than other groups.", [["PMC", "ANATOMY", 83, 86], ["cephalosporin", "CHEMICAL", 51, 64], ["cephalosporin", "CHEMICAL", 51, 64], ["patients", "ORGANISM", 14, 22], ["cephalosporin", "SIMPLE_CHEMICAL", 51, 64], ["PMC", "CANCER", 83, 86], ["patients", "SPECIES", 14, 22], ["3rd generation cephalosporin", "TREATMENT", 36, 64]]], ["In addition, the use of vancomycin was observed only in the PMC group ( Table 4 ).", [["PMC", "ANATOMY", 60, 63], ["vancomycin", "CHEMICAL", 24, 34], ["vancomycin", "CHEMICAL", 24, 34], ["vancomycin", "SIMPLE_CHEMICAL", 24, 34], ["PMC", "CANCER", 60, 63], ["vancomycin", "TREATMENT", 24, 34]]], ["These results suggested that the choice of appropriate second-line agents in the treatment of macrolide-unresponsive MP pneumonia reduced the use of unnecessary broad-spectrum antibiotics.DISCUSSIONIn the DXC and LFX groups, no side effects such as tooth discoloration or tendinopathy and arthritis were observed.", [["tooth", "ANATOMY", 249, 254], ["macrolide", "CHEMICAL", 94, 103], ["MP", "DISEASE", 117, 119], ["pneumonia", "DISEASE", 120, 129], ["tooth discoloration", "DISEASE", 249, 268], ["tendinopathy", "DISEASE", 272, 284], ["arthritis", "DISEASE", 289, 298], ["macrolide", "CHEMICAL", 94, 103], ["macrolide", "SIMPLE_CHEMICAL", 94, 103], ["tooth", "ORGAN", 249, 254], ["appropriate second-line agents", "TREATMENT", 43, 73], ["the treatment", "TREATMENT", 77, 90], ["macrolide", "TREATMENT", 94, 103], ["unresponsive MP pneumonia", "PROBLEM", 104, 129], ["unnecessary broad-spectrum antibiotics", "TREATMENT", 149, 187], ["the DXC and LFX groups", "TREATMENT", 201, 223], ["side effects", "PROBLEM", 228, 240], ["tooth discoloration", "PROBLEM", 249, 268], ["tendinopathy", "PROBLEM", 272, 284], ["arthritis", "PROBLEM", 289, 298], ["pneumonia", "OBSERVATION", 120, 129], ["tendinopathy", "OBSERVATION", 272, 284], ["arthritis", "OBSERVATION", 289, 298]]], ["It was reported that tooth staining or color change were not observed in children aged between 2 and 8 years old treated with DXC.", [["tooth", "ANATOMY", 21, 26], ["DXC", "CHEMICAL", 126, 129], ["DXC", "CHEMICAL", 126, 129], ["tooth", "ORGAN", 21, 26], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["tooth staining", "PROBLEM", 21, 35], ["color change", "PROBLEM", 39, 51], ["DXC", "TREATMENT", 126, 129], ["tooth", "ANATOMY", 21, 26], ["staining", "OBSERVATION", 27, 35]]], ["37 However, because DXC, approved by the U.S. Food and Drug Administration for children aged \u2265 8 years old, is still contraindicated for children younger than 12 years of age in Korea, the age indications for tetracycline-bound drugs, including DXC, should be reconsidered.", [["DXC", "CHEMICAL", 20, 23], ["tetracycline", "CHEMICAL", 209, 221], ["DXC", "CHEMICAL", 245, 248], ["DXC", "CHEMICAL", 20, 23], ["tetracycline", "CHEMICAL", 209, 221], ["DXC", "SIMPLE_CHEMICAL", 20, 23], ["children", "ORGANISM", 79, 87], ["children", "ORGANISM", 137, 145], ["tetracycline", "SIMPLE_CHEMICAL", 209, 221], ["DXC", "SIMPLE_CHEMICAL", 245, 248], ["children", "SPECIES", 79, 87], ["children", "SPECIES", 137, 145], ["tetracycline", "TREATMENT", 209, 221], ["bound drugs", "TREATMENT", 222, 233], ["DXC", "TREATMENT", 245, 248]]], ["In addition, the risk of cartilage injury with LFX was clinically undetectable in children over 5 years old, or was easily reversible.", [["cartilage", "ANATOMY", 25, 34], ["cartilage injury", "DISEASE", 25, 41], ["LFX", "CHEMICAL", 47, 50], ["cartilage", "TISSUE", 25, 34], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["cartilage injury", "PROBLEM", 25, 41], ["cartilage", "ANATOMY", 25, 34], ["injury", "OBSERVATION", 35, 41]]], ["24 Of the 1,340 subjects treated with LFX, only one case (0.07%) was 'possibly related' to drug therapy assessed at 5 years, and this was not different from the comparator group (1/893, 0.1%).", [["LFX", "TREATMENT", 38, 41], ["drug therapy", "TREATMENT", 91, 103]]], ["However, because concerns about the safety of tetracycline and fluoroquinolone in children still exist, it should be cautiously used with the consideration of both the risk and benefit in children with macrolide-unresponsive MP pneumonia.", [["tetracycline", "CHEMICAL", 46, 58], ["fluoroquinolone", "CHEMICAL", 63, 78], ["macrolide", "CHEMICAL", 202, 211], ["MP", "DISEASE", 225, 227], ["pneumonia", "DISEASE", 228, 237], ["tetracycline", "CHEMICAL", 46, 58], ["fluoroquinolone", "CHEMICAL", 63, 78], ["macrolide", "CHEMICAL", 202, 211], ["tetracycline", "SIMPLE_CHEMICAL", 46, 58], ["fluoroquinolone", "SIMPLE_CHEMICAL", 63, 78], ["children", "ORGANISM", 82, 90], ["children", "ORGANISM", 188, 196], ["macrolide", "SIMPLE_CHEMICAL", 202, 211], ["children", "SPECIES", 82, 90], ["children", "SPECIES", 188, 196], ["tetracycline", "TREATMENT", 46, 58], ["fluoroquinolone", "TREATMENT", 63, 78], ["macrolide", "TREATMENT", 202, 211], ["unresponsive MP pneumonia", "PROBLEM", 212, 237], ["pneumonia", "OBSERVATION", 228, 237]]], ["This study has some limitations.", [["This study", "TEST", 0, 10]]], ["Firstly, as this study was performed retrospectively, the clinical information might be uncertain, especially with regard to the use and duration of macrolide prescribed in other clinics.", [["macrolide", "CHEMICAL", 149, 158], ["macrolide", "CHEMICAL", 149, 158], ["macrolide", "SIMPLE_CHEMICAL", 149, 158], ["this study", "TEST", 12, 22], ["macrolide", "TREATMENT", 149, 158]]], ["Secondly, the numbers of patients in DXC and LFX groups were small.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["numbers", "OBSERVATION_MODIFIER", 14, 21], ["small", "OBSERVATION_MODIFIER", 61, 66]]], ["In the future, it is necessary to carry out prospective randomized studies or to conduct studies involving more subjects through multicenter studies.", [["prospective randomized studies", "TEST", 44, 74], ["conduct studies", "TEST", 81, 96], ["multicenter studies", "TEST", 129, 148]]], ["Lastly, the IgM antibody test was used to diagnose MP infection.", [["MP infection", "DISEASE", 51, 63], ["IgM", "GENE_OR_GENE_PRODUCT", 12, 15], ["MP", "GENE_OR_GENE_PRODUCT", 51, 53], ["IgM antibody", "PROTEIN", 12, 24], ["the IgM antibody test", "TEST", 8, 29], ["MP infection", "PROBLEM", 51, 63], ["infection", "OBSERVATION", 54, 63]]], ["Although the patients with a history of MP infection within past year were excluded, some subjects with false positive could be included due to prolonged existence of IgM for several months after past infection.", [["MP infection", "DISEASE", 40, 52], ["infection", "DISEASE", 201, 210], ["patients", "ORGANISM", 13, 21], ["MP", "GENE_OR_GENE_PRODUCT", 40, 42], ["IgM", "GENE_OR_GENE_PRODUCT", 167, 170], ["IgM", "PROTEIN", 167, 170], ["patients", "SPECIES", 13, 21], ["MP infection", "PROBLEM", 40, 52], ["false positive", "PROBLEM", 104, 118], ["IgM", "PROBLEM", 167, 170], ["past infection", "PROBLEM", 196, 210], ["infection", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 201, 210]]], ["In addition, false negatives could also exist due to a lack of IgM antibodies in early stages.", [["IgM antibodies", "GENE_OR_GENE_PRODUCT", 63, 77], ["IgM antibodies", "PROTEIN", 63, 77], ["false negatives", "PROBLEM", 13, 28], ["IgM antibodies", "PROBLEM", 63, 77], ["false negatives", "OBSERVATION", 13, 28]]], ["However, other alternative methods, such as isolation or the molecular detection of MP, cannot differentiate asymptomatic carriage of MP in the nasopharynx from infection or MP pneumonia.DISCUSSIONIn this study, the macrolide resistance of MP determined by molecular analysis or susceptibility test was not identified.", [["nasopharynx", "ANATOMY", 144, 155], ["MP", "DISEASE", 84, 86], ["MP", "DISEASE", 134, 136], ["infection", "DISEASE", 161, 170], ["MP", "DISEASE", 174, 176], ["pneumonia", "DISEASE", 177, 186], ["macrolide", "CHEMICAL", 216, 225], ["MP", "DISEASE", 240, 242], ["macrolide", "CHEMICAL", 216, 225], ["MP", "GENE_OR_GENE_PRODUCT", 84, 86], ["MP", "GENE_OR_GENE_PRODUCT", 134, 136], ["nasopharynx", "ORGAN", 144, 155], ["macrolide", "SIMPLE_CHEMICAL", 216, 225], ["MP", "GENE_OR_GENE_PRODUCT", 240, 242], ["asymptomatic carriage of MP in the nasopharynx", "PROBLEM", 109, 155], ["infection", "PROBLEM", 161, 170], ["MP pneumonia", "PROBLEM", 174, 186], ["this study", "TEST", 200, 210], ["the macrolide resistance of MP", "TEST", 212, 242], ["molecular analysis", "TEST", 257, 275], ["susceptibility test", "TEST", 279, 298], ["nasopharynx", "ANATOMY", 144, 155], ["infection", "OBSERVATION", 161, 170], ["MP", "OBSERVATION_MODIFIER", 174, 176], ["pneumonia", "OBSERVATION", 177, 186]]], ["But, this study was based on an actual treatment course for MP pneumonia in a clinical setting.", [["pneumonia", "DISEASE", 63, 72], ["this study", "TEST", 5, 15], ["an actual treatment course", "TREATMENT", 29, 55], ["MP pneumonia", "PROBLEM", 60, 72], ["pneumonia", "OBSERVATION", 63, 72]]], ["If fever persists despite the use of macrolide, it is necessary to consider a secondary treatment without the results of antimicrobial susceptibility.", [["fever", "DISEASE", 3, 8], ["macrolide", "CHEMICAL", 37, 46], ["macrolide", "CHEMICAL", 37, 46], ["macrolide", "SIMPLE_CHEMICAL", 37, 46], ["fever", "PROBLEM", 3, 8], ["macrolide", "TREATMENT", 37, 46], ["a secondary treatment", "TREATMENT", 76, 97], ["antimicrobial susceptibility", "PROBLEM", 121, 149], ["antimicrobial susceptibility", "OBSERVATION", 121, 149]]], ["We compared the therapeutic efficacy of the secondary treatments on clinically assessed macrolide-unresponsive MP pneumonia.DISCUSSIONMost of macrolide-unresponsive MP pneumonia patients achieved defervescence within 48 hours with CST add-on or treatment changes to DXC, and LFX, and any side effects were not observed in the secondary treatment groups.", [["macrolide", "CHEMICAL", 88, 97], ["MP", "DISEASE", 111, 113], ["pneumonia", "DISEASE", 114, 123], ["macrolide", "CHEMICAL", 142, 151], ["MP", "DISEASE", 165, 167], ["pneumonia", "DISEASE", 168, 177], ["DXC", "CHEMICAL", 266, 269], ["macrolide", "CHEMICAL", 88, 97], ["macrolide", "CHEMICAL", 142, 151], ["DXC", "CHEMICAL", 266, 269], ["macrolide", "SIMPLE_CHEMICAL", 88, 97], ["macrolide", "SIMPLE_CHEMICAL", 142, 151], ["MP", "ORGANISM", 165, 167], ["patients", "ORGANISM", 178, 186], ["DXC", "SIMPLE_CHEMICAL", 266, 269], ["LFX", "SIMPLE_CHEMICAL", 275, 278], ["patients", "SPECIES", 178, 186], ["the secondary treatments", "TREATMENT", 40, 64], ["macrolide", "TREATMENT", 88, 97], ["unresponsive MP pneumonia", "PROBLEM", 98, 123], ["macrolide", "TREATMENT", 142, 151], ["unresponsive MP pneumonia", "PROBLEM", 152, 177], ["treatment changes", "TREATMENT", 245, 262], ["DXC", "TEST", 266, 269], ["any side effects", "PROBLEM", 284, 300], ["pneumonia", "OBSERVATION", 114, 123], ["pneumonia", "OBSERVATION", 168, 177]]], ["However, the secondary treatments did not shorten the duration of fever or hospitalization compared to PMC treatment.", [["fever", "DISEASE", 66, 71], ["fever", "PROBLEM", 66, 71], ["PMC treatment", "TREATMENT", 103, 116]]], ["A large-scale prospective study is needed to guide appropriate treatment in children with mycoplasma pneumonia.", [["mycoplasma pneumonia", "DISEASE", 90, 110], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["A large-scale prospective study", "TEST", 0, 31], ["appropriate treatment", "TREATMENT", 51, 72], ["mycoplasma pneumonia", "PROBLEM", 90, 110], ["large", "OBSERVATION_MODIFIER", 2, 7], ["mycoplasma", "OBSERVATION_MODIFIER", 90, 100], ["pneumonia", "OBSERVATION", 101, 110]]]], "PMC7319614": [], "8dc43945368ca5eddbb6cb85b161422ba1fa03f9": [["The ongoing pandemic of COVID-19, caused by the novel coronavirus SARS-CoV-2, is a matter of global concern.", [["COVID-19", "CHEMICAL", 24, 32], ["COVID-19", "ORGANISM", 24, 32], ["coronavirus SARS-CoV-2", "ORGANISM", 54, 76], ["coronavirus SARS-CoV", "SPECIES", 54, 74], ["COVID-19", "SPECIES", 24, 32], ["COVID", "TEST", 24, 29], ["the novel coronavirus SARS", "PROBLEM", 44, 70]]], ["As of late July 2020, the total number of confirmed COVID-19 cases worldwide has surged past 14 million, causing more than 600,000 deaths [1] .", [["COVID", "DISEASE", 52, 57], ["deaths", "DISEASE", 131, 137], ["COVID", "TEST", 52, 57]]], ["To impede its rapid spread, much of the world have resorted to partial or complete lockdown, resulting in an enormous social and economic impact.", [["its rapid spread", "PROBLEM", 10, 26], ["rapid", "OBSERVATION_MODIFIER", 14, 19], ["spread", "OBSERVATION_MODIFIER", 20, 26], ["enormous", "OBSERVATION_MODIFIER", 109, 117], ["social", "OBSERVATION", 118, 124]]], ["In the absence of any functioning vaccine or treatment, rapid and accurate detection of COVID-19 infections is crucial for limiting the associated disease burden.", [["infections", "DISEASE", 97, 107], ["COVID-19", "ORGANISM", 88, 96], ["COVID-19", "SPECIES", 88, 96], ["any functioning vaccine", "TREATMENT", 18, 41], ["treatment", "TREATMENT", 45, 54], ["COVID-19 infections", "PROBLEM", 88, 107], ["the associated disease burden", "PROBLEM", 132, 161], ["infections", "OBSERVATION", 97, 107], ["disease", "OBSERVATION", 147, 154]]]], "21e25bdde453834963191d4194dc369dcb9213e9": [["IntroductionOptimizing the safety of obstetric patient care is a primary concern for many hospitals.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["IntroductionOptimizing", "TREATMENT", 0, 22]]], ["Identifying performance indicators that measure aspects of patient care processes related to preventable harms can present opportunities to improve health systems.IntroductionIn this paper, we present our protocol for a scoping review to identify performance indicators for obstetric safety.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["a scoping review", "TEST", 218, 234]]], ["We aim to identify a comprehensive list of obstetric safety indicators which may help reduce the number of preventable patient harms, to summarize the data and to synthesize the results.Methods and analysisWe will use the methodological framework described by Arksey and O' Malley and further expanded by Levac.", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126]]], ["We will search multiple electronic databases such as Medline, Embase, CINAHL and the Cochrane Library as well as websites from professional bodies and other organisations, using an iterative search strategy.", [["the Cochrane Library", "TREATMENT", 81, 101], ["an iterative search strategy", "TREATMENT", 178, 206]]], ["We will include indicators that relate to preventable harms in the process of obstetric care.Methods and analysisTwo reviewers will independently screen titles and abstracts of search results to determine eligibility for inclusion.", [["obstetric care", "TREATMENT", 78, 92]]], ["We will narratively describe quantitative data, such as the frequency with which indicators are identified, and conduct a thematic analysis of the qualitative data.", [["the qualitative data", "TEST", 143, 163]]], ["We will compile a comprehensive list of patient safety indicators identified during our scoping review and organise them according to concepts that best suit the data such as the Donabedian model or the Hospital Harm Framework.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["We will discuss the implications of the indicators for future research, clinical practice and policy making.Methods and analysisWe will report the conduct of the review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA ScR) Checklist.Ethics and DisseminationThe sources of information included in this scoping review will be available to the public.", [["Systematic Reviews", "TEST", 209, 227]]], ["Therefore, ethical review for this research is not warranted.", [["ethical review", "TEST", 11, 25]]], ["We will disseminate our research results using multiple modes of delivery such as a peer-reviewed publication, conference presentations and stakeholder communications.KeywordsObstetrics, patient safety, performance indicators, prevention, hospital harms, scoping review, protocol.KeywordsStrengths and limitations of this study 1.", [["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194], ["delivery", "TREATMENT", 65, 73], ["scoping review", "TEST", 255, 269], ["this study", "TEST", 317, 327]]], ["We will use systematic methods to conduct and report this scoping review based on established methods introduced by Arksey and O' Malley and further developed by Levac.", [["systematic methods", "TREATMENT", 12, 30]]], ["We will limit the focus of this review to patient safety indicators from English language resources aimed at health system processes in developed countries.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49]]], ["We will not assess the risk of bias or certainty of the evidence in the included records because this is a scoping review to identify potential obstetrical safety indicators.", [["a scoping review", "TEST", 105, 121], ["potential obstetrical safety indicators", "PROBLEM", 134, 173]]], ["After the scoping review, we will present the identified indicators to key informants in a consensus process to create a shortlist that may not be suitable for inclusion in a future obstetrical safety dashboard for BORN (Better Outcomes Registry and Network) Ontario.", [["the scoping review", "TEST", 6, 24]]], ["BORN collects and safeguards data, and shares information to improve the delivery of maternal, neonatal and child healthcare across the province.KeywordsIntroduction: An aim of healthcare delivery is to avoid preventable harm to patients.", [["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["healthcare delivery", "TREATMENT", 177, 196]]], ["However, human limitations and the complex nature of health care systems are contributing factors that make errors an expected phenomenon (1).", [["human", "ORGANISM", 9, 14], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14]]], ["Preventable harms that occur during hospital stays are also known as hospital harms, patient safety incidents, hospital adverse events or hospital errors.", [["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["hospital adverse events", "PROBLEM", 111, 134], ["harms", "OBSERVATION", 12, 17]]], ["The Canadian Institute for Health Information (CIHI ) defines hospital harms as the \"rate of acute care hospitalizations with at least one occurrence of unintended harm during a hospital stay that could have been potentially prevented by implementing known evidence-informed practices\" (3). caused by procedure-associated conditions.", [["associated conditions", "PROBLEM", 311, 332]]], ["They also reported that during the same period, 670 incidences of obstetric hemorrhage were caused by health care or medication associated conditions and 960 incidences were caused by procedure associated-conditions.", [["obstetric hemorrhage", "DISEASE", 66, 86], ["obstetric hemorrhage", "PROBLEM", 66, 86], ["medication associated conditions", "PROBLEM", 117, 149], ["hemorrhage", "OBSERVATION", 76, 86]]], ["In addition, 855 birth trauma incidences were caused by health care or medication-associated conditions and 1417 incidences were caused by procedure-associated conditions.KeywordsCertain harms require exploration of each patient case to assess whether the harm is potentially preventable, and others are more obviously preventable, such as fatal medication doses (8) or wrong-site surgeries.", [["birth trauma", "DISEASE", 17, 29], ["patient", "ORGANISM", 221, 228], ["patient", "SPECIES", 221, 228], ["birth trauma incidences", "PROBLEM", 17, 40], ["medication", "TREATMENT", 71, 81], ["exploration", "TEST", 201, 212], ["fatal medication doses", "TREATMENT", 340, 362], ["wrong-site surgeries", "TREATMENT", 370, 390]]], ["The Hospital Harm Framework classifies harms into 4 categories: health care/medication-associated conditions; health care associated infections; patient accidents; and procedure-associated conditions (9) .KeywordsSeveral studies have shown strategies that have successfully reduced preventable patient harm.", [["infections", "DISEASE", 133, 143], ["accidents", "DISEASE", 153, 162], ["patient", "ORGANISM", 145, 152], ["patient", "ORGANISM", 294, 301], ["patient", "SPECIES", 145, 152], ["patient", "SPECIES", 294, 301], ["procedure", "TREATMENT", 168, 177], ["Several studies", "TEST", 213, 228], ["reduced", "OBSERVATION_MODIFIER", 274, 281]]], ["Existing research has shown that making patient safety central to the delivery of care can lead to system-level improvements.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["the delivery of care", "TREATMENT", 66, 86]]], ["In the United States, Pettker and colleagues implemented a comprehensive obstetric patient safety program which led to reductions in adverse outcomes and litigation cases, and improvements in staff perceptions of safety and improvements in the safety climate, (10-12).", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["litigation cases", "TEST", 154, 170]]], ["Also in the United States, the California Maternal Quality Care Collaborative [CMQCC] California has identified a correlation between the work of perinatal quality collaboratives (PQCs) and a 50% reduction in maternal mortality rates in the state of California (13) .KeywordsAudit and feedback interventions may help to prevent patient harm.", [["patient", "ORGANISM", 328, 335], ["patient", "SPECIES", 328, 335], ["a 50% reduction", "TREATMENT", 190, 205], ["maternal mortality rates", "PROBLEM", 209, 233], ["feedback interventions", "TREATMENT", 285, 307], ["patient harm", "PROBLEM", 328, 340]]], ["In the UK, an ethnographic study of a maternity unit with an excellent record for patient safety found that staff partly attributed its success to a maternity dashboard which facilitated audit and feedback (15) .", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["an ethnographic study", "TEST", 11, 32]]], ["The Better Outcomes Registry & Network (BORN Ontario) developed a dashboard of six key clinical performance indicators to measure data relating to the quality of maternal and newborn patient care in Ontario, Canada (16) (17) (18) .", [["patient", "ORGANISM", 183, 190], ["patient", "SPECIES", 183, 190]]], ["In a pilot study, a quality improvement project focusing on one of the indicators identified by BORN, led to a welcome and significant reduction in the rate of elective repeat caesarean sections (ECRS) in low risk women at less than 39 weeks' gestation (19) .", [["sections", "ANATOMY", 186, 194], ["women", "ORGANISM", 214, 219], ["women", "SPECIES", 214, 219], ["a pilot study", "TEST", 3, 16], ["significant reduction", "PROBLEM", 123, 144], ["elective repeat caesarean sections", "TREATMENT", 160, 194], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["reduction", "OBSERVATION_MODIFIER", 135, 144], ["low risk", "OBSERVATION_MODIFIER", 205, 213]]], ["A systematic review by Ivers and colleagues (21) found that audit and feedback can lead to small improvements in the practice of care delivery by health care professionals.", [["care delivery", "TREATMENT", 129, 142], ["small", "OBSERVATION_MODIFIER", 91, 96], ["improvements", "OBSERVATION_MODIFIER", 97, 109]]], ["In a rapid review, Anthony and colleagues found that audit and feedback in combination with other obstetrical safety initiatives may reduce maternal and neonatal morbidity and mortality (22) .KeywordsIt is necessary to identify patient safety indicators to ensure the effectiveness of future audit and feedback strategies.", [["patient", "ORGANISM", 228, 235], ["patient", "SPECIES", 228, 235], ["audit and feedback", "TREATMENT", 53, 71], ["other obstetrical safety initiatives", "TREATMENT", 92, 128], ["maternal and neonatal morbidity", "PROBLEM", 140, 171], ["feedback strategies", "TREATMENT", 302, 321]]], ["In this scoping review, we want to contribute to the improvement of obstetric patient safety by identifying indicators as the starting point of an approach to harm reduction.KeywordsThe term indicator is generally understood to mean a measure that provides information on health service delivery across organisations which enables tracking and comparison of performance over time.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["an approach", "TREATMENT", 144, 155], ["harm reduction", "TREATMENT", 159, 173]]], ["In a paper first published in 1966, Donebedian identified three types of measures of quality which can be used to evaluate the process of care at the patient-healthcare provider level; outcome measures; process measures and structure measures (25) .", [["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 150, 157]]], ["A fourth type, balancing measures, relate to positive or negative phenomenon which happen as an unintended consequence of a change (14) .KeywordsMany desirable criteria for measuring the quality of care delivered by a health system have been proposed in the literature.", [["positive or negative phenomenon", "PROBLEM", 45, 76], ["fourth type", "OBSERVATION_MODIFIER", 2, 13], ["positive", "OBSERVATION_MODIFIER", 45, 53], ["negative phenomenon", "OBSERVATION", 57, 76]]], ["Kessner and colleagues (26) suggested using tracers which are a set of specific health conditions or activities.", [["tracers", "TREATMENT", 44, 51]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Keywordsis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/19012153 doi: medRxiv preprint adequate for statistical analysis, having a demonstrable potential to improve health conditions, relate to processes involving prevention, diagnosis, treatment or rehabilitation, and contextual influences should be understood.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 196, 216], ["this preprint", "TREATMENT", 221, 234], ["medRxiv", "TREATMENT", 275, 282], ["statistical analysis", "TEST", 305, 325], ["treatment", "TREATMENT", 442, 451], ["rehabilitation", "TREATMENT", 455, 469], ["med", "ANATOMY", 95, 98]]], ["Janakariaman and Ecker listed their ideal criteria for measures as: easily definable and observable; important to patients and health care professionals; identifies areas where improvements are needed and uses accessible data (27) .KeywordsA systematic review by Saturno-Hern\u00e1ndez and colleagues found that despite the existence of a large number of indicators for monitoring obstetric care, they were lacking in scientific rigor and many are not suitable for implementation (28) .", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["monitoring obstetric care", "TREATMENT", 365, 390]]], ["They used the following desirable criteria for indicators: presenting a full description, clearly based on explicit evidence, reliable, and feasible (confirmed by pilot testing).KeywordsAlthough it is likely that indicators have the potential to improve patient safety there are no consistent standards for measuring obstetric patient safety.", [["patient", "ORGANISM", 254, 261], ["patient", "ORGANISM", 327, 334], ["patient", "SPECIES", 254, 261], ["patient", "SPECIES", 327, 334], ["pilot testing", "TEST", 163, 176], ["is likely", "UNCERTAINTY", 198, 207]]], ["In order to use obstetric safety indicators as part of a harm reduction strategy they should resonate with health care professionals.KeywordsQuality and safety indicators are closely linked and sometimes used interchangeably.", [["obstetric safety indicators", "TREATMENT", 16, 43], ["a harm reduction strategy", "TREATMENT", 55, 80]]], ["For this review, we will use the definition of patient safety indicators used by Kristensen and colleagues i.e. measures that directly or indirectly monitor preventable hospital harms (29) .", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54]]], ["In the field of obstetric patient safety, there is a need to identify indicators which measure the aspects of care that relate to preventable harms caused by medical errors.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33]]], ["This can be challenging because it is not always clear which indicators should be used and there are variations in practice and outcomes across hospitals, regions etc.KeywordsIt is important to note that some safety indicators may be judged as avoidable depending on the patient case.", [["patient", "ORGANISM", 271, 278], ["patient", "SPECIES", 271, 278]]], ["Therefore, we will focus on obstetric safety indicators that relate to the prevention of harms that are at least partly potentially avoidable to patients.KeywordsThe aim of our review will be to scope the body of relevant literature (30) to identify a comprehensive list of potential obstetric safety indicators which can help reduce preventable patient harms.", [["patients", "ORGANISM", 145, 153], ["patient", "ORGANISM", 346, 353], ["patients", "SPECIES", 145, 153], ["patient", "SPECIES", 346, 353], ["harms", "PROBLEM", 89, 94]]], ["This scoping review is being undertaken to inform which indicators will be included in a patient safety dashboard from BORN Ontario.Methods and analysis:We will undertake a scoping review to systematically map the available literature on performance indicators relevant to the reduction of preventable harms within the purview of obstetric safety.", [["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["a scoping review", "TEST", 171, 187]]], ["We will use the PRISMA extension for scoping reviews PRISMA ScR Checklist (31) to guide the reporting of the scoping review.", [["the PRISMA extension", "TREATMENT", 12, 32], ["the scoping review", "TEST", 105, 123]]], ["We will use the scoping study framework introduced by Arksey and O' Malley (32) and the recommendations later developed by Levac (33) to guide our methods.", [["the scoping study", "TEST", 12, 29]]], ["We will follow all six suggested stages as described below.Methods and analysis:Stage 1: Identifying the research question Through consultation with the author team we defined the concepts, target population and type of indicators of interest, and iteratively developed the main research question for the scoping review.", [["the scoping review", "TEST", 301, 319]]], ["We ensured that it aligned with the purpose and scope of the review and the expected outcome (a comprehensive list of relevant indicators).This question is: According to the available literature, what are the obstetrical safety indicators related to processes of care for low risk births that aim to reduce preventable hospital harms?For the purposes of this review, we will use the Southern Ontario Obstetrical Network (SOON) definition of a lowrisk birth target population namely, nulliparous pregnant individuals, singleton gestation with cephalic presentation, who deliver at 37 weeks of gestation or more (34) .", [["individuals", "ORGANISM", 504, 515], ["cephalic", "ANATOMY", 542, 550]]], ["SOON has also specified exclusion criteria shown in the table in Appendix 2.", [["Appendix", "ANATOMY", 65, 73]]], ["The term 'fetal anomalies' featured in the SOON definition is an umbrella term for multiple anomalies.", [["fetal", "ANATOMY", 10, 15], ["fetal anomalies", "DISEASE", 10, 25], ["fetal", "ANATOMICAL_SYSTEM", 10, 15], ["The term 'fetal anomalies'", "PROBLEM", 0, 26], ["multiple anomalies", "PROBLEM", 83, 101], ["anomalies", "OBSERVATION", 16, 25], ["multiple", "OBSERVATION_MODIFIER", 83, 91], ["anomalies", "OBSERVATION", 92, 101]]], ["Therefore, we will use the list of major sentinel congenital anomalies (see Appendix 3) that was developed in 2017 by BORN Ontario and OCAC (Ontario Congenital Anomalies Committee) as an additional tool during screening.Stage 2: Identifying relevant studiesThe search strategy will be drafted by one of the authors who has trained as an information specialist (AC) and developed iteratively based on consultation with the author team and at least one other library and information professional.", [["congenital anomalies", "DISEASE", 50, 70], ["Congenital Anomalies", "DISEASE", 149, 169], ["major sentinel congenital anomalies", "PROBLEM", 35, 70], ["screening", "TEST", 210, 219], ["relevant studies", "TEST", 241, 257]]], ["We will also search relevant websites of professional bodies or organisations such as the Society of Obstetricians and Gynaecologists of Canada (SOGC)(36), Royal College of Obstetricians and Gynaecologists (RCOG)(37), Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) (38) and American College of Obstetricians and Gynecologists (ACOG) (39) etc. We will contact individuals or groups to source additional material if deemed appropriate.Stage 2: Identifying relevant studiesWe will use both thesauri terms (such as MeSH, Emtree and CINAHL headings) and free text terms as well as Boolean operators and field limiters (where appropriate), to build our search.", [["relevant studies", "TEST", 494, 510], ["MeSH", "TREATMENT", 551, 555]]], ["It will be tailored according to the functionality of each database or other resource we search.Stage 2: Identifying relevant studiesStage 3: Selecting studies Two reviewers will undertake a test of interrater reliability to increase the likelihood of reliable screening.", [["Selecting studies", "TEST", 142, 159], ["interrater reliability", "TEST", 199, 221], ["reliable screening", "TEST", 252, 270]]], ["We may revise the inclusion and exclusion criteria if indicated.", [["exclusion criteria", "TEST", 32, 50]]], ["When we have achieved a 0.80 or higher level of agreement between raters, we will independently conduct three phases of screening.", [["screening", "TEST", 120, 129]]], ["Firstly, we will screen the titles and abstracts of records that are not randomized trials to determine eligibility for inclusion against the agreed inclusion and exclusion criteria using screening software (Covidence).", [["screening software", "TEST", 188, 206]]], ["Thirdly, two reviewers will independently screen the full-text records for which it was not clear whether they met inclusion criteria in the previous screening phase.", [["the previous screening phase", "TEST", 137, 165]]], ["We will undertake interrater reliability testing after every 1,000 records screened.Stage 2: Identifying relevant studiesRecords will be selected using the following inclusion criteria:Stage 2: Identifying relevant studies\u2022 one or more indicator is proposed or in use to prevent harm and improve obstetric safety \u2022 specifies or includes a low risk birth population \u2022 in-hospital settings \u2022 care during the period from admission to discharge from hospital following birth \u2022 indicators that can be improved or are controllable \u2022 feature a level of measurability/auditabilityStage 2: Identifying relevant studiesWe will include any type of primary study and most other record types discussing indicators such as reports, guidance documents and discussion papers, with the exception of conference papers.", [["interrater reliability testing", "TEST", 18, 48], ["relevant studies", "TEST", 206, 222], ["auditability", "PROBLEM", 560, 572], ["relevant studies", "TEST", 593, 609], ["primary study", "TEST", 637, 650]]], ["We will not exclude sources based on the year they were made available or published, or on their publication status (published or unpublished).Stage 2: Identifying relevant studiesWe will only include English language records due to resource restrictions for translation services.", [["relevant studies", "TEST", 164, 180], ["translation services", "TREATMENT", 259, 279]]], ["We will exclude records focusing on indicators specifically designed for use within underdeveloped or developing world settings because our indicators should be applicable to a developed country (Canada) .Stage 2: Identifying relevant studiesWe will present an adapted PRISMA flow diagram (41) to document the number of records identified, screened, assessed for eligibility, and included or excluded.", [["relevant studies", "TEST", 226, 242], ["an adapted PRISMA flow diagram", "TEST", 258, 288]]], ["We will document the main reasons why records were excluded.Stage 2: Identifying relevant studiesStage 4: Charting the data We will identify variables that are relevant and develop a standardized data collection form (15) .", [["a standardized data collection", "TEST", 181, 211]]], ["Two reviewers will independently carry out data extraction for each included record.", [["data extraction", "TREATMENT", 43, 58]]], ["Initially, we will independently extract data from five randomly-selected, included records and compare the extracted data for consistency.", [["the extracted data", "TEST", 104, 122]]], ["The form may be iteratively developed throughout the charting process.", [["may be", "UNCERTAINTY", 9, 15]]], ["Data items will include:Stage 2: Identifying relevant studies\uf0b7 indicator source (bibliographic information) \uf0b7 study design and/or record format \uf0b7 country of origin \uf0b7 type of indicator (outcome/process/structure/balancing) \uf0b7 indicator name \uf0b7 indicator definition \uf0b7 numerator \uf0b7 denominator \uf0b7 measurement properties (tools, instruments etc.) \uf0b7 the population that is targeted by the indicator; maternal, fetal or infant following birth (or a combination) \uf0b7 the timeframe covered by the indicator; admission for birth including care during labour, during birth, during the postpartum period prior to discharge from hospital \uf0b7 category of hospital harm being addressed \uf0b7 whether indicator relates to a desirable or undesirable event \uf0b7 evidence-based indicator (yes/no/unclear) Stage 5: Collating, summarizing and reporting results As recommended by Levac, we will divide this final stage into three parts: analysis of data; reporting of results and discussion of the implications of the results for research, practice and policy (33).Stage 2: Identifying relevant studies1.", [["fetal", "ANATOMY", 401, 406], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 401, 406], ["infant", "SPECIES", 410, 416], ["analysis of data", "TEST", 901, 917]]], ["We will produce descriptive numerical summaries through analysis of the quantitative data, such as the frequency with which indicators are identified.", [["the quantitative data", "TEST", 68, 89]]], ["The qualitative data will be uploaded to NVivo software and thematic analysis will be conducted.", [["NVivo software", "TEST", 41, 55], ["thematic analysis", "TEST", 60, 77]]], ["We will report our results by compiling a comprehensive list of patient safety indicators identified during our scoping review and organizing them according to concepts that best suit the data such as the Donabedian model or categories within the Hospital Harm Framework.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["our scoping review", "TEST", 108, 126]]], ["This scoping review is the first in a multi-step approach to inform the development of a core set of indicators.", [["a multi-step approach", "TREATMENT", 36, 57]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Stage 6: Consultationis the (which was not peer-reviewed) The copyright holder for this preprint . monitor and report surveillance data entered by health care professionals, and aim to contribute to improvements in obstetric safety.Ethics and DisseminationThis scoping review will not require ethical approval because included sources are or can be made available to the public (42) .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 209, 229], ["this preprint", "TREATMENT", 234, 247], ["surveillance data", "TEST", 269, 286], ["ethical approval", "TREATMENT", 444, 460], ["med", "ANATOMY", 95, 98]]], ["This research will be disseminated with the intention of reaching a wide audience through the use of multiple modes of delivery such as stakeholder engagement, publication(s) in a peer-reviewed journal and conference paper(s).Authors' contributionsIn consultation with all authors, AC wrote the first draft which SID and JR reviewed.", [["delivery", "TREATMENT", 119, 127]]], ["All authors contributed to the planning and writing of this protocol and approved submission of the final manuscript to the publishing journal.", [["this protocol", "TREATMENT", 55, 68]]]], "e3e703765514feecf3f421345af0ec2b1dcd852a": [["IntroductionEmerging coronaviruses have caused serious global public health concerns in the past two decades and cause infections that lead to severe respiratory and occasionally systemic disease [1] .", [["respiratory", "ANATOMY", 150, 161], ["infections", "DISEASE", 119, 129], ["IntroductionEmerging coronaviruses", "PROBLEM", 0, 34], ["infections", "PROBLEM", 119, 129], ["severe respiratory and occasionally systemic disease", "PROBLEM", 143, 195], ["serious", "OBSERVATION_MODIFIER", 47, 54], ["infections", "OBSERVATION", 119, 129], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["respiratory", "ANATOMY", 150, 161]]], ["These include severe acute respiratory syndrome (SARS)-CoV as well as Middle East respiratory syndrome (MERS)-CoV, both of which resulted in high morbidity and mortality in infected humans [2, 3] .", [["acute respiratory syndrome (SARS)-CoV", "DISEASE", 21, 58], ["Middle East respiratory syndrome", "DISEASE", 70, 102], ["humans", "ORGANISM", 182, 188], ["humans", "SPECIES", 182, 188], ["severe acute respiratory syndrome (SARS)-CoV", "SPECIES", 14, 58], ["Middle East respiratory syndrome (MERS)-CoV", "SPECIES", 70, 113], ["humans", "SPECIES", 182, 188], ["severe acute respiratory syndrome", "PROBLEM", 14, 47], ["CoV", "PROBLEM", 55, 58], ["Middle East respiratory syndrome", "PROBLEM", 70, 102], ["CoV", "PROBLEM", 110, 113], ["high morbidity", "PROBLEM", 141, 155], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["respiratory syndrome", "OBSERVATION", 27, 47], ["Middle", "ANATOMY_MODIFIER", 70, 76], ["respiratory syndrome", "OBSERVATION", 82, 102], ["high", "OBSERVATION_MODIFIER", 141, 145], ["morbidity", "OBSERVATION", 146, 155], ["infected", "OBSERVATION", 173, 181]]], ["Similar to other emerging CoV, the novel SARS-CoV-2 likely arose from an ancestor in bats and amplified in a yet unknown animal reservoir before making its jump into the human population [4] .IntroductionSARS-CoV-2 has pushed global health systems to the brink of breakdown.", [["SARS", "DISEASE", 41, 45], ["CoV", "ORGANISM", 26, 29], ["SARS-CoV-2", "ORGANISM", 41, 51], ["human", "ORGANISM", 170, 175], ["SARS-CoV-2", "DNA", 41, 51], ["human", "SPECIES", 170, 175], ["SARS-CoV", "SPECIES", 41, 49], ["human", "SPECIES", 170, 175], ["IntroductionSARS", "TEST", 192, 208], ["breakdown", "PROBLEM", 264, 273], ["breakdown", "OBSERVATION", 264, 273]]], ["The remarkably fast and unexpected spread of SARS-CoV-2 can be attributed to efficient replication in the upper respiratory tract and robust human-to-human transmission.", [["upper respiratory tract", "ANATOMY", 106, 129], ["SARS", "DISEASE", 45, 49], ["SARS-CoV-2", "ORGANISM", 45, 55], ["upper respiratory", "ORGANISM_SUBDIVISION", 106, 123], ["tract", "ORGANISM_SUBDIVISION", 124, 129], ["human", "ORGANISM", 141, 146], ["human", "ORGANISM", 150, 155], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 150, 155], ["SARS-CoV", "SPECIES", 45, 53], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 150, 155], ["SARS", "PROBLEM", 45, 49], ["efficient replication in the upper respiratory tract", "PROBLEM", 77, 129], ["fast", "OBSERVATION_MODIFIER", 15, 19], ["spread", "OBSERVATION_MODIFIER", 35, 41], ["efficient", "OBSERVATION_MODIFIER", 77, 86], ["replication", "OBSERVATION", 87, 98], ["upper", "ANATOMY_MODIFIER", 106, 111], ["respiratory tract", "ANATOMY", 112, 129]]], ["While COVID-19 is primarily a respiratory syndrome, it can induce quite variable clinical signs including fatigue, headache, and gastrointestinal symptoms, which can in severe cases result in fatality [5] .", [["gastrointestinal", "ANATOMY", 129, 145], ["COVID-19", "CHEMICAL", 6, 14], ["respiratory syndrome", "DISEASE", 30, 50], ["fatigue", "DISEASE", 106, 113], ["headache", "DISEASE", 115, 123], ["gastrointestinal symptoms", "DISEASE", 129, 154], ["gastrointestinal", "ORGAN", 129, 145], ["COVID", "TEST", 6, 11], ["a respiratory syndrome", "PROBLEM", 28, 50], ["fatigue", "PROBLEM", 106, 113], ["headache", "PROBLEM", 115, 123], ["gastrointestinal symptoms", "PROBLEM", 129, 154], ["respiratory syndrome", "OBSERVATION", 30, 50], ["gastrointestinal", "ANATOMY", 129, 145]]], ["It has become evident that differences in the type and severity of SARS-CoV-2-induced disease and its sequelae seem to be strongly correlated with the age of patients and exacerbated by pre-existing medical conditions (e.g., chronic obstructive pulmonary disease, heart disease, diabetes, obesity) [1, [6] [7] [8] .IntroductionThe availability of reliable animal models is of critical importance for pathogenesis studies as well as the development and preclinical evaluation of vaccines and therapeutics [2, 9, 10] .", [["pulmonary", "ANATOMY", 245, 254], ["heart", "ANATOMY", 264, 269], ["SARS", "DISEASE", 67, 71], ["chronic obstructive pulmonary disease", "DISEASE", 225, 262], ["heart disease", "DISEASE", 264, 277], ["diabetes", "DISEASE", 279, 287], ["obesity", "DISEASE", 289, 296], ["SARS-CoV-2", "ORGANISM", 67, 77], ["patients", "ORGANISM", 158, 166], ["pulmonary", "ORGAN", 245, 254], ["heart", "ORGAN", 264, 269], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 302, 313], ["patients", "SPECIES", 158, 166], ["SARS-CoV", "SPECIES", 67, 75], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["induced disease", "PROBLEM", 78, 93], ["its sequelae", "PROBLEM", 98, 110], ["pre-existing medical conditions", "PROBLEM", 186, 217], ["chronic obstructive pulmonary disease", "PROBLEM", 225, 262], ["heart disease", "PROBLEM", 264, 277], ["diabetes", "PROBLEM", 279, 287], ["obesity)", "PROBLEM", 289, 297], ["pathogenesis studies", "TEST", 400, 420], ["preclinical evaluation", "TEST", 452, 474], ["vaccines", "TREATMENT", 478, 486], ["chronic", "OBSERVATION_MODIFIER", 225, 232], ["obstructive", "OBSERVATION_MODIFIER", 233, 244], ["pulmonary", "ANATOMY", 245, 254], ["disease", "OBSERVATION", 255, 262], ["heart", "ANATOMY", 264, 269], ["disease", "OBSERVATION", 270, 277]]], ["For SARS-CoV-2, the susceptibility of several animal species was predicted by in silico analysis based on comparisons of the entry receptor for SARS-CoV and SARS-CoV-2, angiotensin converting enzyme 2 (ACE2).", [["angiotensin", "CHEMICAL", 169, 180], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 144, 152], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 157, 167], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 169, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 202, 206], ["entry receptor", "PROTEIN", 125, 139], ["SARS-CoV and SARS-CoV-2, angiotensin converting enzyme 2", "PROTEIN", 144, 200], ["ACE2", "PROTEIN", 202, 206], ["SARS-CoV", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 157, 165], ["SARS", "PROBLEM", 4, 8], ["CoV", "TEST", 9, 12], ["several animal species", "PROBLEM", 38, 60], ["silico analysis", "TEST", 81, 96], ["the entry receptor", "TEST", 121, 139], ["SARS", "TEST", 144, 148], ["CoV", "TEST", 149, 152], ["SARS", "TEST", 157, 161], ["CoV", "TEST", 162, 165], ["angiotensin converting enzyme", "TEST", 169, 198]]], ["These predictions are of relevance because the ACE2 sequence is deemed an important factor governing susceptibility [11] .", [["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["ACE2", "PROTEIN", 47, 51], ["the ACE2 sequence", "TEST", 43, 60]]], ["More specifically, the interaction of the viral spike (S) glycoprotein receptor binding domain with its ACE2 counterpart was examined [12, 13] , and in some cases confirmed in vivo [9] .", [["viral spike (S) glycoprotein receptor", "GENE_OR_GENE_PRODUCT", 42, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["viral spike (S) glycoprotein receptor binding domain", "PROTEIN", 42, 94], ["ACE2", "PROTEIN", 104, 108], ["the viral spike (S) glycoprotein receptor binding domain", "TREATMENT", 38, 94], ["its ACE2 counterpart", "TEST", 100, 120]]], ["Productive SARS-CoV-2 infection was shown in non-human primates, which developed respiratory disease recapitulating moderate disease as observed in humans [14] [15] [16] [17] .", [["respiratory", "ANATOMY", 81, 92], ["SARS-CoV-2 infection", "DISEASE", 11, 31], ["respiratory disease", "DISEASE", 81, 100], ["SARS-CoV-2", "ORGANISM", 11, 21], ["non-human", "ORGANISM", 45, 54], ["primates", "ORGANISM", 55, 63], ["humans", "ORGANISM", 148, 154], ["[14] [15] [16] [17]", "SIMPLE_CHEMICAL", 155, 174], ["humans", "SPECIES", 148, 154], ["non-human primates", "SPECIES", 45, 63], ["humans", "SPECIES", 148, 154], ["Productive SARS-CoV-2 infection", "PROBLEM", 0, 31], ["respiratory disease recapitulating moderate disease", "PROBLEM", 81, 132], ["SARS", "OBSERVATION", 11, 15], ["infection", "OBSERVATION", 22, 31], ["respiratory disease", "OBSERVATION", 81, 100], ["moderate", "OBSERVATION_MODIFIER", 116, 124], ["disease", "OBSERVATION", 125, 132]]], ["Mice are not naturally susceptible to SARS-CoV-2, but mouse-adapted virus strains have been developed and used in BALB/c mice [18, 19] .", [["SARS", "DISEASE", 38, 42], ["Mice", "ORGANISM", 0, 4], ["SARS-CoV-2", "ORGANISM", 38, 48], ["mouse-adapted virus strains", "ORGANISM", 54, 81], ["BALB/c mice", "ORGANISM", 114, 125], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 54, 59], ["mice", "SPECIES", 121, 125], ["SARS-CoV", "SPECIES", 38, 46], ["mouse", "SPECIES", 54, 59], ["mice", "SPECIES", 121, 125], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["adapted virus strains", "PROBLEM", 60, 81]]], ["Moreover, transgenic mice expressing human ACE2 represent a lethal SARS-CoV-2 infection model resulting in significant weight loss and permitting robust virus replication in the respiratory tract including the lungs [20] .", [["respiratory tract", "ANATOMY", 178, 195], ["lungs", "ANATOMY", 210, 215], ["SARS", "DISEASE", 67, 71], ["infection", "DISEASE", 78, 87], ["weight loss", "DISEASE", 119, 130], ["mice", "ORGANISM", 21, 25], ["human", "ORGANISM", 37, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["SARS-CoV-2", "ORGANISM", 67, 77], ["respiratory tract", "ORGANISM_SUBDIVISION", 178, 195], ["lungs", "ORGAN", 210, 215], ["human ACE2", "PROTEIN", 37, 47], ["mice", "SPECIES", 21, 25], ["human", "SPECIES", 37, 42], ["mice", "SPECIES", 21, 25], ["human", "SPECIES", 37, 42], ["a lethal SARS", "PROBLEM", 58, 71], ["2 infection model", "PROBLEM", 76, 93], ["significant weight loss", "PROBLEM", 107, 130], ["permitting robust virus replication", "PROBLEM", 135, 170], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["weight loss", "OBSERVATION", 119, 130], ["robust", "OBSERVATION_MODIFIER", 146, 152], ["virus", "OBSERVATION", 153, 158], ["respiratory tract", "ANATOMY", 178, 195], ["lungs", "ANATOMY", 210, 215]]], ["Ferrets have provided valuable data in the case of SARS-CoV [21, 22] , and two studies describe the infection of ferrets with SARS-CoV-2 and successful transmission to in-contact animals without clinical signs [23, 24] .IntroductionFirst and preliminary studies also focused on the assessment of a Syrian hamster model that had previously been used successfully in SARS and MERS research [21, 22, 25, 26] .", [["SARS", "DISEASE", 51, 55], ["infection", "DISEASE", 100, 109], ["SARS", "DISEASE", 126, 130], ["SARS", "DISEASE", 365, 369], ["SARS-CoV", "ORGANISM", 51, 59], ["ferrets", "ORGANISM", 113, 120], ["CoV-2", "ORGANISM", 131, 136], ["Syrian hamster", "ORGANISM", 298, 312], ["ferrets", "SPECIES", 113, 120], ["SARS-CoV", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 126, 134], ["Syrian hamster", "SPECIES", 298, 312], ["SARS", "PROBLEM", 51, 55], ["the infection of ferrets", "PROBLEM", 96, 120], ["clinical signs", "TEST", 195, 209], ["preliminary studies", "TEST", 242, 261], ["the assessment", "TEST", 278, 292], ["a Syrian hamster model", "TREATMENT", 296, 318], ["infection", "OBSERVATION", 100, 109]]], ["It was suggested that hamsters are highly susceptible, although they were reported to show no or only moderate respiratory signs and body weight losses.", [["respiratory", "ANATOMY", 111, 122], ["body", "ANATOMY", 133, 137], ["weight losses", "DISEASE", 138, 151], ["hamsters", "ORGANISM", 22, 30], ["body", "ORGANISM_SUBDIVISION", 133, 137], ["hamsters", "SPECIES", 22, 30], ["hamsters", "SPECIES", 22, 30], ["moderate respiratory signs", "PROBLEM", 102, 128], ["body weight losses", "PROBLEM", 133, 151], ["moderate", "OBSERVATION_MODIFIER", 102, 110], ["respiratory signs", "OBSERVATION", 111, 128]]], ["However, it is important to note that only young male hamsters of 4 to 5 weeks of age were used in these studies [27, 28] .IntroductionWe sought to explore age-related differences in the course of SARS-CoV-2 infection in Syrian hamsters and to establish a small-animal model that resembles the more severe SARS-CoV-2-infection observed particularly in elderly patients.Ethics StatementWe conducted all animal work in compliance with relevant national and international guidelines for care and humane use of animals.", [["SARS", "DISEASE", 197, 201], ["infection", "DISEASE", 208, 217], ["SARS-CoV-2-infection", "DISEASE", 306, 326], ["hamsters", "ORGANISM", 54, 62], ["SARS-CoV-2", "ORGANISM", 197, 207], ["Syrian hamsters", "ORGANISM", 221, 236], ["SARS-CoV-2", "ORGANISM", 306, 316], ["patients", "ORGANISM", 360, 368], ["Syrian hamsters", "SPECIES", 221, 236], ["patients", "SPECIES", 360, 368], ["SARS-CoV-2", "SPECIES", 197, 207], ["Syrian hamsters", "SPECIES", 221, 236], ["SARS-CoV", "SPECIES", 306, 314], ["these studies", "TEST", 99, 112], ["SARS", "PROBLEM", 197, 201], ["CoV", "PROBLEM", 202, 205], ["2 infection", "PROBLEM", 206, 217], ["a small-animal model", "PROBLEM", 254, 274], ["the more severe SARS", "PROBLEM", 290, 310], ["infection", "PROBLEM", 317, 326], ["infection", "OBSERVATION", 208, 217], ["small", "OBSERVATION_MODIFIER", 256, 261], ["severe", "OBSERVATION_MODIFIER", 299, 305], ["SARS", "OBSERVATION", 306, 310], ["infection", "OBSERVATION", 317, 326]]], ["The animal use protocol for the experiments reported here was approved by the Landesamt f\u00fcr Gesundheit und Soziales in Berlin, Germany (approval number 0086/20; approved on 30.04.2020).Viruses and CellsVirus stocks were prepared from a previously published SARS-CoV-2 isolate (BetaCoV/Germany/BavPat1/2020) [29] , which was kindly provided by Drs. Daniela Niemeyer und Christian Drosten, Charit\u00e9 Berlin, Germany.", [["CellsVirus stocks", "CELL", 197, 214], ["SARS-CoV-2 isolate (BetaCoV/Germany/BavPat1/2020)", "SPECIES", 257, 306], ["Viruses", "PROBLEM", 185, 192], ["CellsVirus stocks", "TREATMENT", 197, 214], ["CoV", "TEST", 262, 265], ["BetaCoV/Germany/BavPat1/2020)", "TREATMENT", 277, 306]]], ["The isolate, referred to as SARS-CoV-2 M\u00fcnchen (SARS-CoV-2M) [30] , was handled under the appropriate safety precautions in a BSL-3 facility (Freie Universit\u00e4t Berlin, Institut f\u00fcr Virologie) and propagated on Vero E6 cells (ATCC CRL-1586) in minimal essential medium (MEM; PAN Biotech, Aidenbach, Germany) supplemented with 10% fetal bovine serum (PAN Biotech), 100 IU/mL penicillin G and 100 \u00b5g/mL streptomycin (Carl Roth, Karlsruhe, Germany).Animal HusbandryThirty-six 6-or 32-to-34-week-old female and male Syrian hamsters (Mesocricetus auratus; breed RjHan:AURA, Janvier Labs, Saint-Berthevin, France) were kept in individually ventilated cages (IVCs; Tecniplast, Buguggiate, Italy) in an approved BSL-3 facility.", [["Vero E6 cells", "ANATOMY", 210, 223], ["ATCC CRL-1586", "ANATOMY", 225, 238], ["fetal bovine serum", "ANATOMY", 329, 347], ["ATCC CRL-1586", "CHEMICAL", 225, 238], ["PAN", "CHEMICAL", 349, 352], ["penicillin", "CHEMICAL", 373, 383], ["streptomycin", "CHEMICAL", 400, 412], ["penicillin G", "CHEMICAL", 373, 385], ["streptomycin", "CHEMICAL", 400, 412], ["SARS-CoV-2M", "ORGANISM", 48, 59], ["Vero E6 cells", "CELL", 210, 223], ["ATCC CRL-1586", "CELL", 225, 238], ["bovine", "ORGANISM", 335, 341], ["serum", "ORGANISM_SUBSTANCE", 342, 347], ["penicillin G", "SIMPLE_CHEMICAL", 373, 385], ["streptomycin", "SIMPLE_CHEMICAL", 400, 412], ["female", "ORGANISM", 495, 501], ["Syrian hamsters", "ORGANISM", 511, 526], ["Mesocricetus auratus", "ORGANISM", 528, 548], ["Vero E6 cells", "CELL_LINE", 210, 223], ["bovine", "SPECIES", 335, 341], ["Syrian hamsters", "SPECIES", 511, 526], ["Mesocricetus auratus", "SPECIES", 528, 548], ["SARS-CoV-2 M\u00fcnchen (SARS-CoV-2M", "SPECIES", 28, 59], ["Vero E6", "SPECIES", 210, 217], ["ATCC CRL-1586", "SPECIES", 225, 238], ["bovine", "SPECIES", 335, 341], ["Syrian hamsters", "SPECIES", 511, 526], ["Mesocricetus auratus", "SPECIES", 528, 548], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["Vero E6 cells", "TREATMENT", 210, 223], ["ATCC CRL", "TEST", 225, 233], ["minimal essential medium (MEM", "TREATMENT", 243, 272], ["10% fetal bovine serum (PAN Biotech)", "TREATMENT", 325, 361], ["penicillin G", "TREATMENT", 373, 385], ["streptomycin", "TREATMENT", 400, 412], ["AURA", "PROBLEM", 562, 566], ["Janvier Labs", "TEST", 568, 580]]], ["IVCs were equipped with enrichment (Carfil, Oud-Turnhout, Belgium).", [["IVCs", "ANATOMY", 0, 4], ["IVCs", "SIMPLE_CHEMICAL", 0, 4], ["IVCs", "TREATMENT", 0, 4]]], ["All animals had unrestricted access to food and water and were allowed to acclimate to the conditions for seven days prior to infection.", [["infection", "DISEASE", 126, 135], ["infection", "PROBLEM", 126, 135], ["infection", "OBSERVATION", 126, 135]]], ["Cage temperatures and relative humidities were recorded daily and ranged from 22-24 \u2022 C and 40-55%, respectively.Animal ExperimentsThe 6-week-old hamsters were randomly distributed into two groups: mock (n = 12, 6-week-old) and young infected (n = 12, 6-week-old).", [["hamsters", "ORGANISM", 146, 154], ["hamsters", "SPECIES", 146, 154], ["Cage temperatures", "TEST", 0, 17], ["relative humidities", "TEST", 22, 41], ["young infected", "PROBLEM", 228, 242], ["infected", "OBSERVATION", 234, 242]]], ["The third group represents the aged infected hamsters (n = 12, 32-34-week-old).", [["hamsters", "ORGANISM", 45, 53], ["hamsters", "SPECIES", 45, 53]]], ["IPTT-300 transponders (BioMedic Data Systems, Seaford, DE, USA) were subcutaneously implanted into all hamsters 2 days prior to infection to allow the identification and monitoring of body temperatures.", [["body", "ANATOMY", 184, 188], ["IPTT-300", "CHEMICAL", 0, 8], ["infection", "DISEASE", 128, 137], ["hamsters", "ORGANISM", 103, 111], ["body", "ORGANISM_SUBDIVISION", 184, 188], ["IPTT", "TEST", 0, 4], ["infection", "PROBLEM", 128, 137], ["the identification", "TEST", 147, 165], ["monitoring of body temperatures", "TEST", 170, 201], ["infection", "OBSERVATION", 128, 137]]], ["Animals were mock-infected with 60 \u00b5L medium from uninfected Vero E6 cells or infected with 1 \u00d7 105 pfu SARS-CoV-2M in 60 \u00b5L by intranasal instillation.", [["cells", "ANATOMY", 69, 74], ["Animals", "ORGANISM", 0, 7], ["Vero E6 cells", "CELL", 61, 74], ["CoV", "ORGANISM", 109, 112], ["-2M", "GENE_OR_GENE_PRODUCT", 112, 115], ["uninfected Vero E6 cells", "CELL_LINE", 50, 74], ["Vero E6", "SPECIES", 61, 68], ["infected", "PROBLEM", 18, 26], ["uninfected Vero E6 cells", "PROBLEM", 50, 74], ["pfu SARS", "TEST", 100, 108], ["CoV", "TEST", 109, 112], ["intranasal instillation", "TREATMENT", 128, 151]]], ["For transponder implantation, hamsters were sedated with butorphanol (2.5 mg/kg; CP-Pharma, Burgdorf, Germany) and midazolam (2 mg/kg; Braun, Melsungen, Germany).", [["butorphanol", "CHEMICAL", 57, 68], ["midazolam", "CHEMICAL", 115, 124], ["butorphanol", "CHEMICAL", 57, 68], ["midazolam", "CHEMICAL", 115, 124], ["hamsters", "ORGANISM", 30, 38], ["butorphanol", "SIMPLE_CHEMICAL", 57, 68], ["midazolam", "SIMPLE_CHEMICAL", 115, 124], ["hamsters", "SPECIES", 30, 38], ["transponder implantation", "TREATMENT", 4, 28], ["butorphanol", "TREATMENT", 57, 68], ["CP", "PROBLEM", 81, 83], ["Pharma", "TREATMENT", 84, 90], ["Burgdorf", "TREATMENT", 92, 100], ["midazolam", "TREATMENT", 115, 124]]], ["For infections, hamsters were sedated with ketamine (25 mg/kg; Serumwerk Bernburg, Bernburg, Germany) and midazolam (2 mg/kg; Braun).", [["infections", "DISEASE", 4, 14], ["ketamine", "CHEMICAL", 43, 51], ["midazolam", "CHEMICAL", 106, 115], ["ketamine", "CHEMICAL", 43, 51], ["midazolam", "CHEMICAL", 106, 115], ["hamsters", "ORGANISM", 16, 24], ["ketamine", "SIMPLE_CHEMICAL", 43, 51], ["midazolam", "SIMPLE_CHEMICAL", 106, 115], ["hamsters", "SPECIES", 16, 24], ["hamsters", "SPECIES", 16, 24], ["infections", "PROBLEM", 4, 14], ["ketamine", "TREATMENT", 43, 51], ["Serumwerk Bernburg", "TREATMENT", 63, 81], ["midazolam", "TREATMENT", 106, 115], ["infections", "OBSERVATION", 4, 14]]], ["On 2, 3, and 5 days post-infection (dpi), three randomly assigned hamsters of each group were euthanized by exsanguination under medetomidine (0.15 mg/kg; Pharma-Partner, Hamburg, Germany), midazolam (2 mg/kg), and butorphanol (2.5 mg/kg) anesthesia [31] .", [["medetomidine", "CHEMICAL", 129, 141], ["midazolam", "CHEMICAL", 190, 199], ["butorphanol", "CHEMICAL", 215, 226], ["medetomidine", "CHEMICAL", 129, 141], ["midazolam", "CHEMICAL", 190, 199], ["butorphanol", "CHEMICAL", 215, 226], ["hamsters", "ORGANISM", 66, 74], ["medetomidine", "SIMPLE_CHEMICAL", 129, 141], ["midazolam", "SIMPLE_CHEMICAL", 190, 199], ["butorphanol", "SIMPLE_CHEMICAL", 215, 226], ["medetomidine", "TREATMENT", 129, 141], ["midazolam", "TREATMENT", 190, 199], ["butorphanol", "TREATMENT", 215, 226]]], ["Blood, nasal washes, bucco-laryngeal swabs, lungs (left and right), kidneys, spleens, duodenums, and blood sera were collected for (histo)pathological examinations and/or virus titrations, RT-qPCR, and serological examination.", [["Blood", "ANATOMY", 0, 5], ["nasal", "ANATOMY", 7, 12], ["bucco-laryngeal swabs", "ANATOMY", 21, 42], ["lungs", "ANATOMY", 44, 49], ["left", "ANATOMY", 51, 55], ["right", "ANATOMY", 60, 65], ["kidneys", "ANATOMY", 68, 75], ["spleens", "ANATOMY", 77, 84], ["duodenums", "ANATOMY", 86, 95], ["blood sera", "ANATOMY", 101, 111], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["nasal", "ORGANISM_SUBDIVISION", 7, 12], ["bucco-laryngeal swabs", "MULTI-TISSUE_STRUCTURE", 21, 42], ["lungs", "ORGAN", 44, 49], ["kidneys", "ORGAN", 68, 75], ["spleens", "ORGAN", 77, 84], ["duodenums", "CANCER", 86, 95], ["blood sera", "ORGANISM_SUBSTANCE", 101, 111], ["Blood", "TEST", 0, 5], ["nasal washes", "TEST", 7, 19], ["bucco-laryngeal swabs", "TEST", 21, 42], ["blood sera", "TEST", 101, 111], ["pathological examinations", "TEST", 138, 163], ["virus titrations", "TEST", 171, 187], ["RT-qPCR", "TEST", 189, 196], ["serological examination", "TEST", 202, 225], ["nasal", "ANATOMY", 7, 12], ["washes", "OBSERVATION", 13, 19], ["laryngeal swabs", "ANATOMY", 27, 42], ["lungs", "ANATOMY", 44, 49], ["left", "ANATOMY_MODIFIER", 51, 55], ["right", "ANATOMY_MODIFIER", 60, 65], ["kidneys", "ANATOMY", 68, 75], ["spleens", "ANATOMY", 77, 84], ["duodenums", "ANATOMY", 86, 95]]], ["During the 14-day experiment, body temperatures, body weights, and clinical signs of all animals were monitored twice daily.", [["body", "ANATOMY", 30, 34], ["body", "ANATOMY", 49, 53], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["body temperatures", "TEST", 30, 47], ["body weights", "TEST", 49, 61], ["clinical signs", "TEST", 67, 81]]], ["Animals that had a body weight loss of more than 10% weight over a 72 h period were euthanized in compliance with the animal use protocol.", [["body", "ANATOMY", 19, 23], ["weight loss", "DISEASE", 24, 35], ["Animals", "ORGANISM", 0, 7], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["a body weight loss", "PROBLEM", 17, 35], ["the animal use protocol", "TREATMENT", 114, 137]]], ["Such humane termination applies to the two hamsters euthanized 7 dpi.Histopathological ExaminationFor histopathology and in situ hybridization (ISH), the left lung lobe was carefully removed, immersion-fixed in formalin, pH 7.0, for 48 h, embedded in paraffin, and cut in 2 \u00b5m sections.", [["left lung lobe", "ANATOMY", 154, 168], ["sections", "ANATOMY", 277, 285], ["formalin", "CHEMICAL", 211, 219], ["paraffin", "CHEMICAL", 251, 259], ["hamsters", "ORGANISM", 43, 51], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 159, 168], ["formalin", "SIMPLE_CHEMICAL", 211, 219], ["Histopathological Examination", "TEST", 69, 98], ["histopathology", "TEST", 102, 116], ["the left lung lobe", "PROBLEM", 150, 168], ["immersion", "TEST", 192, 201], ["pH", "TEST", 221, 223], ["left", "ANATOMY_MODIFIER", 154, 158], ["lung", "ANATOMY", 159, 163], ["lobe", "ANATOMY_MODIFIER", 164, 168]]], ["For histopathology, slides were stained with hematoxylin and eosin (HE) after dewaxing in xylene and rehydration in decreasing ethanol concentrations.", [["hematoxylin and eosin", "CHEMICAL", 45, 66], ["xylene", "CHEMICAL", 90, 96], ["ethanol", "CHEMICAL", 127, 134], ["hematoxylin", "CHEMICAL", 45, 56], ["eosin", "CHEMICAL", 61, 66], ["xylene", "CHEMICAL", 90, 96], ["ethanol", "CHEMICAL", 127, 134], ["hematoxylin", "SIMPLE_CHEMICAL", 45, 56], ["eosin", "SIMPLE_CHEMICAL", 61, 66], ["xylene", "SIMPLE_CHEMICAL", 90, 96], ["ethanol", "SIMPLE_CHEMICAL", 127, 134], ["histopathology", "TEST", 4, 18], ["hematoxylin", "TREATMENT", 45, 56], ["eosin", "TREATMENT", 61, 66], ["dewaxing in xylene", "TREATMENT", 78, 96], ["rehydration", "TREATMENT", 101, 112], ["decreasing ethanol concentrations", "TREATMENT", 116, 149]]], ["Lung sections were microscopically evaluated in a blinded fashion by a board-certified veterinary pathologist to assess the character and severity of pathologic lesions using lung-specific inflammation scoring parameters as described for other lung infection models before [32] .", [["Lung sections", "ANATOMY", 0, 13], ["lesions", "ANATOMY", 161, 168], ["lung", "ANATOMY", 175, 179], ["lung", "ANATOMY", 244, 248], ["lung infection", "DISEASE", 244, 258], ["Lung sections", "CANCER", 0, 13], ["pathologic lesions", "PATHOLOGICAL_FORMATION", 150, 168], ["lung", "ORGAN", 175, 179], ["lung", "ORGAN", 244, 248], ["Lung sections", "TEST", 0, 13], ["pathologic lesions", "PROBLEM", 150, 168], ["specific inflammation scoring parameters", "PROBLEM", 180, 220], ["other lung infection models", "PROBLEM", 238, 265], ["pathologic", "OBSERVATION_MODIFIER", 150, 160], ["lesions", "OBSERVATION", 161, 168], ["lung", "ANATOMY", 175, 179], ["inflammation", "OBSERVATION", 189, 201], ["lung", "ANATOMY", 244, 248], ["infection", "OBSERVATION", 249, 258]]], ["Three different scores were used that included the following parameters: (1) lung inflammation score including severity of (i) interstitial pneumonia (ii) bronchitis, (iii) epithelial necrosis of bronchi and alveoli, and (iv) hyperplasia of type II-alveolar epithelial cells; (2) immune cell infiltration score taking into account the presence of (i) neutrophils, (ii) macrophages, and (iii) lymphocytes in the lungs as well as (iv) perivascular lymphocytic cuffing; and (3) edema score including (i) alveolar edema and (ii) perivascular edema.Histopathological ExaminationISH was performed as reported previously [33] using the ViewRNA\u2122 ISH Tissue Assay Kit (Invitrogen by Thermo Fisher Scientific, Darmstadt, Germany) following the manufacturer's instructions with minor adjustments.", [["lung", "ANATOMY", 77, 81], ["interstitial", "ANATOMY", 127, 139], ["epithelial", "ANATOMY", 173, 183], ["bronchi", "ANATOMY", 196, 203], ["alveoli", "ANATOMY", 208, 215], ["type II-alveolar epithelial cells", "ANATOMY", 241, 274], ["immune cell", "ANATOMY", 280, 291], ["neutrophils", "ANATOMY", 351, 362], ["macrophages", "ANATOMY", 369, 380], ["lymphocytes", "ANATOMY", 392, 403], ["lungs", "ANATOMY", 411, 416], ["perivascular lymphocytic", "ANATOMY", 433, 457], ["edema", "ANATOMY", 475, 480], ["alveolar edema", "ANATOMY", 501, 515], ["perivascular edema", "ANATOMY", 525, 543], ["inflammation", "DISEASE", 82, 94], ["interstitial pneumonia", "DISEASE", 127, 149], ["bronchitis", "DISEASE", 155, 165], ["necrosis", "DISEASE", 184, 192], ["edema", "DISEASE", 475, 480], ["alveolar edema", "DISEASE", 501, 515], ["edema", "DISEASE", 538, 543], ["lung", "ORGAN", 77, 81], ["epithelial", "TISSUE", 173, 183], ["bronchi", "MULTI-TISSUE_STRUCTURE", 196, 203], ["alveoli", "MULTI-TISSUE_STRUCTURE", 208, 215], ["alveolar epithelial cells", "CELL", 249, 274], ["immune cell", "CELL", 280, 291], ["neutrophils", "CELL", 351, 362], ["macrophages", "CELL", 369, 380], ["lymphocytes", "CELL", 392, 403], ["lungs", "ORGAN", 411, 416], ["edema", "PATHOLOGICAL_FORMATION", 475, 480], ["alveolar edema", "PATHOLOGICAL_FORMATION", 501, 515], ["perivascular edema", "PATHOLOGICAL_FORMATION", 525, 543], ["type II-alveolar epithelial cells", "CELL_TYPE", 241, 274], ["neutrophils", "CELL_TYPE", 351, 362], ["macrophages", "CELL_TYPE", 369, 380], ["lymphocytes", "CELL_TYPE", 392, 403], ["lung inflammation score", "PROBLEM", 77, 100], ["severity of (i) interstitial pneumonia (ii) bronchitis", "PROBLEM", 111, 165], ["epithelial necrosis of bronchi and alveoli", "PROBLEM", 173, 215], ["(iv) hyperplasia of type II-alveolar epithelial cells", "PROBLEM", 221, 274], ["immune cell infiltration score", "PROBLEM", 280, 310], ["neutrophils", "TEST", 351, 362], ["macrophages", "TEST", 369, 380], ["(iii) lymphocytes in the lungs", "PROBLEM", 386, 416], ["perivascular lymphocytic cuffing", "PROBLEM", 433, 465], ["edema score", "PROBLEM", 475, 486], ["(i) alveolar edema", "PROBLEM", 497, 515], ["(ii) perivascular edema", "PROBLEM", 520, 543], ["Histopathological ExaminationISH", "TEST", 544, 576], ["the ViewRNA", "TEST", 625, 636], ["minor adjustments", "TREATMENT", 767, 784], ["lung", "ANATOMY", 77, 81], ["inflammation", "OBSERVATION", 82, 94], ["interstitial", "ANATOMY_MODIFIER", 127, 139], ["pneumonia", "OBSERVATION", 140, 149], ["bronchitis", "OBSERVATION", 155, 165], ["epithelial", "ANATOMY_MODIFIER", 173, 183], ["necrosis", "OBSERVATION", 184, 192], ["bronchi", "ANATOMY", 196, 203], ["alveoli", "ANATOMY", 208, 215], ["hyperplasia", "OBSERVATION", 226, 237], ["type II", "OBSERVATION_MODIFIER", 241, 248], ["alveolar", "ANATOMY_MODIFIER", 249, 257], ["epithelial cells", "OBSERVATION", 258, 274], ["immune cell infiltration", "OBSERVATION", 280, 304], ["lungs", "ANATOMY", 411, 416], ["perivascular", "ANATOMY", 433, 445], ["lymphocytic cuffing", "OBSERVATION", 446, 465], ["edema", "OBSERVATION", 475, 480], ["alveolar", "ANATOMY", 501, 509], ["edema", "OBSERVATION", 510, 515], ["perivascular", "ANATOMY_MODIFIER", 525, 537], ["edema", "OBSERVATION", 538, 543]]], ["Probes for the detection of N gene RNA of SARS-CoV-2 (NCBI database NC_045512.2, nucleotides 28,274 to 9533, assay ID: VPNKRHM) and the mouse housekeeping gene eukaryotic translation elongation factor-1\u03b1 (EF1a; assay ID: VB1-14428-VT, Affymetrix, Inc., Santa Clara, CA, USA), which shares 95% sequence identity with the Syrian hamster orthologue, were designed.", [["Probes", "GENE_OR_GENE_PRODUCT", 0, 6], ["SARS-CoV-2", "ORGANISM", 42, 52], ["mouse", "ORGANISM", 136, 141], ["eukaryotic translation elongation factor-1\u03b1", "GENE_OR_GENE_PRODUCT", 160, 203], ["EF1a", "GENE_OR_GENE_PRODUCT", 205, 209], ["Syrian hamster", "ORGANISM", 320, 334], ["N gene RNA", "RNA", 28, 38], ["SARS-CoV-2", "DNA", 42, 52], ["nucleotides 28,274 to 9533", "DNA", 81, 107], ["mouse housekeeping gene", "DNA", 136, 159], ["eukaryotic translation elongation factor-1\u03b1", "PROTEIN", 160, 203], ["EF1a", "PROTEIN", 205, 209], ["VB1", "PROTEIN", 221, 224], ["mouse", "SPECIES", 136, 141], ["Syrian hamster", "SPECIES", 320, 334], ["SARS-CoV", "SPECIES", 42, 50], ["mouse", "SPECIES", 136, 141], ["Syrian hamster orthologue", "SPECIES", 320, 345], ["the detection", "TEST", 11, 24], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["NCBI database NC", "TEST", 54, 70], ["nucleotides", "TEST", 81, 92], ["elongation factor", "TEST", 183, 200], ["VB1", "TEST", 221, 224], ["VT", "PROBLEM", 231, 233], ["Affymetrix", "TEST", 235, 245]]], ["Lung sections (2 \u00b5m thickness) on adhesive glass slides were dewaxed in xylol and dehydrated in ethanol.", [["Lung sections", "ANATOMY", 0, 13], ["xylol", "CHEMICAL", 72, 77], ["ethanol", "CHEMICAL", 96, 103], ["xylol", "CHEMICAL", 72, 77], ["ethanol", "CHEMICAL", 96, 103], ["Lung sections", "MULTI-TISSUE_STRUCTURE", 0, 13], ["xylol", "SIMPLE_CHEMICAL", 72, 77], ["ethanol", "SIMPLE_CHEMICAL", 96, 103], ["Lung sections", "TEST", 0, 13], ["adhesive glass slides", "TREATMENT", 34, 55]]], ["Tissues were incubated at 95 \u2022 C for 10 min with subsequent protease digestion for 20 min.", [["Tissues", "ANATOMY", 0, 7], ["Tissues", "CANCER", 0, 7], ["protease", "PROTEIN", 60, 68], ["subsequent protease digestion", "TREATMENT", 49, 78]]], ["Sections were fixed with 4% paraformaldehyde in phosphate-buffered saline (Alfa Aesar, Thermo Fisher, Kandel, Germany) and hybridized with the probes.", [["phosphate", "CHEMICAL", 48, 57], ["paraformaldehyde", "CHEMICAL", 28, 44], ["phosphate", "CHEMICAL", 48, 57], ["paraformaldehyde", "SIMPLE_CHEMICAL", 28, 44], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 48, 73], ["4% paraformaldehyde in phosphate", "TREATMENT", 25, 57], ["buffered saline (Alfa Aesar", "TREATMENT", 58, 85], ["the probes", "TREATMENT", 139, 149]]], ["Amplifier and label probe hybridizations were performed according to the manufacturer's instructions using fast red as the chromogen, followed by counterstaining with hematoxylin for 45 s, washing in tap water for 5 min, and mounting with Roti \u00ae -Mount Fluor-Care DAPI (4, 6-diaminidino-2-phenylindole; Carl Roth).", [["4, 6-diaminidino-2-phenylindole", "CHEMICAL", 270, 301], ["hematoxylin", "CHEMICAL", 167, 178], ["DAPI", "CHEMICAL", 264, 268], ["4, 6-diaminidino-2-phenylindole", "CHEMICAL", 270, 301], ["chromogen", "SIMPLE_CHEMICAL", 123, 132], ["hematoxylin", "SIMPLE_CHEMICAL", 167, 178], ["DAPI", "SIMPLE_CHEMICAL", 264, 268], ["4, 6-diaminidino-2-phenylindole", "SIMPLE_CHEMICAL", 270, 301], ["Amplifier", "TREATMENT", 0, 9], ["label probe hybridizations", "TREATMENT", 14, 40], ["the chromogen", "TREATMENT", 119, 132], ["hematoxylin", "TREATMENT", 167, 178], ["Roti", "TEST", 239, 243], ["DAPI", "TEST", 264, 268], ["diaminidino", "TEST", 275, 286]]], ["For negative and morphologically intact controls, lungs from uninfected hamsters of each group (n = 4) were included.", [["lungs", "ANATOMY", 50, 55], ["lungs", "ORGAN", 50, 55], ["hamsters", "ORGANISM", 72, 80], ["morphologically", "OBSERVATION_MODIFIER", 17, 32], ["intact", "OBSERVATION", 33, 39], ["lungs", "ANATOMY", 50, 55]]], ["In addition, an irrelevant probe for the detection of pneumolysin was used as a negative control for unspecific reactions.", [["pneumolysin", "GENE_OR_GENE_PRODUCT", 54, 65], ["pneumolysin", "PROTEIN", 54, 65], ["an irrelevant probe", "TREATMENT", 13, 32], ["pneumolysin", "PROBLEM", 54, 65], ["unspecific reactions", "PROBLEM", 101, 121]]], ["HE-stained and ISH slides were analyzed and images were taken using an Olympus BX41 microscope with a DP80 Microscope Digital Camera and the cellSens\u2122 Imaging Software, version 1.18 (Olympus Corporation, M\u00fcnster, Germany).", [["ISH slides", "TEST", 15, 25], ["images", "TEST", 44, 50], ["version", "TEST", 169, 176]]], ["For the display of overviews of whole lung lobe sections, slides were automatically digitized using the Aperio CS2 slide scanner (Leica Biosystems Imaging Inc., Vista, CA, USA), and image files were generated using the Image Scope Software (Leica Biosystems Imaging Inc.).Histopathological ExaminationThe percentages of lung tissues affected by inflammation were determined histologically by an experienced board certified experimental veterinary pathologist (K.D.) as described previously [34] .", [["lung lobe sections", "ANATOMY", 38, 56], ["lung tissues", "ANATOMY", 320, 332], ["inflammation", "DISEASE", 345, 357], ["lung lobe sections", "MULTI-TISSUE_STRUCTURE", 38, 56], ["lung tissues", "TISSUE", 320, 332], ["whole lung lobe sections", "TEST", 32, 56], ["the Aperio CS2 slide scanner", "TEST", 100, 128], ["image files", "TEST", 182, 193], ["the Image Scope", "TEST", 215, 230], ["Histopathological Examination", "TEST", 272, 301], ["inflammation", "PROBLEM", 345, 357], ["lung", "ANATOMY", 38, 42], ["lobe", "ANATOMY_MODIFIER", 43, 47], ["lung tissues", "ANATOMY", 320, 332], ["inflammation", "OBSERVATION", 345, 357]]], ["Lung inflammation scores were determined as (0) absent, (1) minimal, (2) mild, (3) moderate, or (4) severe, and quantified as described previously [35] .", [["Lung", "ANATOMY", 0, 4], ["Lung inflammation", "DISEASE", 0, 17], ["Lung", "ORGAN", 0, 4], ["Lung inflammation scores", "PROBLEM", 0, 24], ["absent, (1) minimal, (2) mild, (3) moderate, or (4) severe, and quantified as", "PROBLEM", 48, 125], ["inflammation", "OBSERVATION", 5, 17], ["minimal", "OBSERVATION_MODIFIER", 60, 67], ["mild", "OBSERVATION_MODIFIER", 73, 77], ["moderate", "OBSERVATION_MODIFIER", 83, 91], ["severe", "OBSERVATION_MODIFIER", 100, 106]]], ["Immune cell influx scores and edema scores were rated from (0) absent to (1) sporadic, (2) mild, (3) moderate, or (4) severe.Histopathological ExaminationISH signals were digitally quantified on scanned whole slides of each animal using the Aperio positive pixel count algorithm (Leica Biosystems Imaging Inc.) with minor adjustments.", [["Immune cell", "ANATOMY", 0, 11], ["edema", "ANATOMY", 30, 35], ["edema", "DISEASE", 30, 35], ["Immune cell", "CELL", 0, 11], ["edema", "PATHOLOGICAL_FORMATION", 30, 35], ["Immune cell influx scores", "TEST", 0, 25], ["edema scores", "PROBLEM", 30, 42], ["sporadic, (2) mild, (3) moderate, or (4) severe", "PROBLEM", 77, 124], ["Histopathological ExaminationISH signals", "TEST", 125, 165], ["the Aperio", "TEST", 237, 247], ["Leica Biosystems Imaging", "TEST", 280, 304], ["minor adjustments", "TREATMENT", 316, 333], ["edema", "OBSERVATION", 30, 35], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["moderate", "OBSERVATION_MODIFIER", 101, 109], ["severe", "OBSERVATION_MODIFIER", 118, 124]]], ["Specifically, a positivity score encompassing the number of positive pixels in relation to the total number of pixels per tissue scan as well as the total intensity of positive pixels were determined ( Figure S3 ).Virus TitrationsFor an assessment of virus titers from 25 mg of lung tissue, tissue homogenates were serially diluted and plated on Vero E6 cells in 12-well cell culture plates (Sarstedt, N\u00fcmbrecht, Germany).", [["tissue", "ANATOMY", 122, 128], ["lung tissue", "ANATOMY", 278, 289], ["tissue homogenates", "ANATOMY", 291, 309], ["cells", "ANATOMY", 354, 359], ["cell", "ANATOMY", 371, 375], ["tissue", "TISSUE", 122, 128], ["Virus", "ORGANISM", 214, 219], ["lung tissue", "TISSUE", 278, 289], ["tissue homogenates", "ORGANISM_SUBSTANCE", 291, 309], ["Vero E6 cells", "CELL", 346, 359], ["cell", "CELL", 371, 375], ["Vero E6 cells", "CELL_LINE", 346, 359], ["Vero E6", "SPECIES", 346, 353], ["a positivity score", "PROBLEM", 14, 32], ["positive pixels", "PROBLEM", 60, 75], ["tissue scan", "TEST", 122, 133], ["positive pixels", "PROBLEM", 168, 183], ["Virus Titrations", "TREATMENT", 214, 230], ["an assessment", "TEST", 234, 247], ["virus titers", "TREATMENT", 251, 263], ["lung tissue", "PROBLEM", 278, 289], ["tissue homogenates", "TREATMENT", 291, 309], ["Vero E6 cells", "TREATMENT", 346, 359], ["positive pixels", "OBSERVATION", 60, 75], ["positive pixels", "OBSERVATION", 168, 183], ["lung", "ANATOMY", 278, 282]]], ["At 3 dpi, cells were fixed in 4% formalin, stained with 0.1% crystal violet (in 25% methanol), and plaques were counted.RNA Extractions and Quantitative RT-PCRRNA was extracted from nasal washes and tracheal swabs with the RTP DNA/RNA Virus Mini Kit (Stratec, Birkenfeld, Germany) according to the manufacturer's instructions.", [["cells", "ANATOMY", 10, 15], ["plaques", "ANATOMY", 99, 106], ["nasal", "ANATOMY", 182, 187], ["tracheal swabs", "ANATOMY", 199, 213], ["formalin", "CHEMICAL", 33, 41], ["crystal violet", "CHEMICAL", 61, 75], ["formalin", "CHEMICAL", 33, 41], ["methanol", "CHEMICAL", 84, 92], ["cells", "CELL", 10, 15], ["formalin", "SIMPLE_CHEMICAL", 33, 41], ["crystal violet", "SIMPLE_CHEMICAL", 61, 75], ["methanol", "SIMPLE_CHEMICAL", 84, 92], ["plaques", "PATHOLOGICAL_FORMATION", 99, 106], ["tracheal swabs", "MULTI-TISSUE_STRUCTURE", 199, 213], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["RTP DNA", "DNA", 223, 230], ["cells", "TEST", 10, 15], ["crystal violet", "TEST", 61, 75], ["plaques", "PROBLEM", 99, 106], ["RNA Extractions", "TREATMENT", 120, 135], ["Quantitative RT", "TEST", 140, 155], ["PCRRNA", "PROBLEM", 156, 162], ["nasal washes", "TREATMENT", 182, 194], ["tracheal swabs", "TEST", 199, 213], ["the RTP DNA", "TEST", 219, 230], ["plaques", "OBSERVATION", 99, 106], ["nasal", "ANATOMY", 182, 187], ["washes", "OBSERVATION", 188, 194], ["tracheal", "ANATOMY", 199, 207]]], ["The innuPREP Virus DNA/RNA Kit (Analytic Jena, Jena, Germany) was used for RNA extractions from tissue samples.", [["tissue samples", "ANATOMY", 96, 110], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["tissue samples", "CANCER", 96, 110], ["innuPREP Virus DNA", "DNA", 4, 22], ["The innuPREP Virus DNA", "TREATMENT", 0, 22], ["RNA extractions", "TREATMENT", 75, 90], ["tissue samples", "TEST", 96, 110]]], ["Viral RNA was quantified using a one-step RT qPCR reaction with the NEB Luna Universal Probe One-Step RT-qPCR (New England Biolabs, Ipswitch, MA, USA) and the 2019-nCoV RT-qPCR primers and probe (E_Sarbeco) [36] on a StepOnePlus RealTime PCR System (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions.", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["2019-nCoV RT-qPCR primers", "DNA", 159, 184], ["Viral RNA", "PROBLEM", 0, 9], ["a one-step RT qPCR reaction", "TREATMENT", 31, 58], ["the NEB", "TREATMENT", 64, 71], ["nCoV RT-qPCR primers", "TREATMENT", 164, 184]]], ["Viral RNA copies were then normalized to cellular RPL18 as previously described [37] .", [["cellular", "ANATOMY", 41, 49], ["cellular", "CELL", 41, 49], ["RPL18", "GENE_OR_GENE_PRODUCT", 50, 55], ["RPL18", "PROTEIN", 50, 55], ["Viral RNA copies", "TEST", 0, 16], ["cellular RPL18", "TEST", 41, 55]]], ["All primers and probes are listed in Table S2 .RNA Extractions and Quantitative RT-PCRStandard curves for absolute quantification were generated from serial dilutions of SARS-CoV-2 RNA obtained from a full-length virus genome cloned as a bacterial artificial chromosome and propagated in E. coli or from serial dilutions of the purified hamster RPL-18 PCR product.", [["chromosome", "ANATOMY", 259, 269], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 170, 180], ["chromosome", "CELLULAR_COMPONENT", 259, 269], ["E. coli", "ORGANISM", 288, 295], ["hamster", "ORGANISM", 337, 344], ["SARS-CoV-2 RNA", "RNA", 170, 184], ["full-length virus genome", "DNA", 201, 225], ["bacterial artificial chromosome", "DNA", 238, 269], ["purified hamster RPL-18 PCR product", "PROTEIN", 328, 363], ["E. coli", "SPECIES", 288, 295], ["hamster", "SPECIES", 337, 344], ["SARS-CoV", "SPECIES", 170, 178], ["E. coli", "SPECIES", 288, 295], ["hamster", "SPECIES", 337, 344], ["All primers", "TREATMENT", 0, 11], ["Extractions", "TEST", 51, 62], ["Quantitative RT-PCRStandard curves", "TEST", 67, 101], ["absolute quantification", "TEST", 106, 129], ["serial dilutions", "TEST", 150, 166], ["SARS", "PROBLEM", 170, 174], ["CoV", "TEST", 175, 178], ["a full-length virus genome", "TREATMENT", 199, 225], ["a bacterial artificial chromosome", "TREATMENT", 236, 269], ["E. coli", "PROBLEM", 288, 295], ["serial dilutions", "TEST", 304, 320], ["the purified hamster RPL", "TREATMENT", 324, 348], ["E. coli", "OBSERVATION", 288, 295]]], ["The latter was generated by PCR using RPL-18 qPCR-primers (Table S2 ) and a cDNA template obtained from hamster lung tissue.", [["hamster lung tissue", "ANATOMY", 104, 123], ["hamster", "ORGANISM", 104, 111], ["lung tissue", "TISSUE", 112, 123], ["RPL-18 qPCR-primers", "DNA", 38, 57], ["cDNA template", "DNA", 76, 89], ["hamster", "SPECIES", 104, 111], ["hamster", "SPECIES", 104, 111], ["PCR", "TEST", 28, 31], ["RPL", "TEST", 38, 41], ["a cDNA template", "TREATMENT", 74, 89], ["hamster lung tissue", "PROBLEM", 104, 123], ["lung", "ANATOMY", 112, 116], ["tissue", "OBSERVATION", 117, 123]]], ["In lung tissue, viral RNA copies were calculated per 1\u00d710 5 hamster RPL-18 transcripts.SerologyFor serum neutralization assays, 50 \u00b5L of medium containing 103.3 tissue culture infectious doses 50 (TCID 50 ) of SARS-CoV-2M were mixed with 50 \u00b5L of diluted serum.", [["lung tissue", "ANATOMY", 3, 14], ["serum", "ANATOMY", 99, 104], ["tissue", "ANATOMY", 161, 167], ["serum", "ANATOMY", 255, 260], ["lung tissue", "TISSUE", 3, 14], ["hamster", "ORGANISM", 60, 67], ["RPL-18", "GENE_OR_GENE_PRODUCT", 68, 74], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["serum", "ORGANISM_SUBSTANCE", 255, 260], ["viral RNA copies", "RNA", 16, 32], ["1\u00d710 5 hamster RPL-18 transcripts", "RNA", 53, 86], ["hamster", "SPECIES", 60, 67], ["SARS-CoV", "SPECIES", 210, 218], ["viral RNA copies", "TEST", 16, 32], ["5 hamster RPL", "TREATMENT", 58, 71], ["Serology", "TEST", 87, 95], ["serum neutralization assays", "TEST", 99, 126], ["tissue culture", "TEST", 161, 175], ["SARS", "TEST", 210, 214], ["lung", "ANATOMY", 3, 7], ["tissue", "ANATOMY_MODIFIER", 8, 14]]], ["Each sample was tested in triplicate.", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11]]], ["After 1 h incubation at 37 \u2022 C, the mixture was transferred to confluent Vero E6 cells in a 96-well plate (Sarstedt, N\u00fcmbrecht, Germany).", [["cells", "ANATOMY", 81, 86], ["Vero E6 cells", "CELL", 73, 86], ["confluent Vero E6 cells", "CELL_LINE", 63, 86], ["Vero E6", "SPECIES", 73, 80], ["confluent Vero E6 cells", "TREATMENT", 63, 86]]], ["Viral replication was assessed after 3 days by the detection of cytopathic effects.Statistical AnalysesStatistical analyses were performed using Graph-Pad Prism v8 (GraphPad Software Inc., San Diego, CA, USA).", [["Viral", "ORGANISM", 0, 5], ["Viral replication", "PROBLEM", 0, 17], ["cytopathic effects", "PROBLEM", 64, 82], ["Statistical AnalysesStatistical analyses", "TEST", 83, 123], ["Graph", "TEST", 145, 150], ["cytopathic", "OBSERVATION_MODIFIER", 64, 74]]], ["The statistical details of all analyzed experiments can be found in the respective figure legend.Results and DiscussionFor our experiments, we used a total of 36 female and male Syrian hamsters (Mesocricetus auratus), which were either 6 (n = 24) or 32 to 34 weeks old (n = 12).", [["Syrian hamsters", "ORGANISM", 178, 193], ["Mesocricetus auratus", "ORGANISM", 195, 215], ["Syrian hamsters", "SPECIES", 178, 193], ["Mesocricetus auratus", "SPECIES", 195, 215], ["Syrian hamsters", "SPECIES", 178, 193], ["Mesocricetus auratus", "SPECIES", 195, 215]]], ["Hamsters were kept in individually ventilated cages (IVCs) and randomly assigned to three groups: mock (n = 12, 6-week-old), young infected (n = 12, 6-week-old) and aged infected (n = 12, 32-to 34-week-old).", [["IVCs", "ANATOMY", 53, 57], ["Hamsters", "ORGANISM", 0, 8], ["Hamsters", "SPECIES", 0, 8], ["Hamsters", "SPECIES", 0, 8], ["young infected", "PROBLEM", 125, 139], ["infected", "OBSERVATION", 131, 139]]], ["Animals were mock-infected with supernatants of cell culture medium taken from uninfected Vero E6 cells or infected with 1 \u00d7 10 5 plaque-forming units of SARS-CoV-2 M\u00fcnchen (SARS-CoV-2M; BetaCoV/Germany/ BavPat1/2020) [30] .", [["supernatants", "ANATOMY", 32, 44], ["cell", "ANATOMY", 48, 52], ["cells", "ANATOMY", 98, 103], ["Animals", "ORGANISM", 0, 7], ["cell", "CELL", 48, 52], ["Vero E6 cells", "CELL", 90, 103], ["SARS-CoV-2M", "ORGANISM", 174, 185], ["BetaCoV", "ORGANISM", 187, 194], ["uninfected Vero E6 cells", "CELL_LINE", 79, 103], ["Vero E6", "SPECIES", 90, 97], ["SARS-CoV-2 M\u00fcnchen (SARS-CoV-2M; BetaCoV/Germany/ BavPat1/2020)", "SPECIES", 154, 217], ["cell culture medium", "TEST", 48, 67], ["uninfected Vero E6 cells", "PROBLEM", 79, 103], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["BetaCoV", "TREATMENT", 187, 194], ["Vero E6 cells", "OBSERVATION", 90, 103], ["infected", "OBSERVATION_MODIFIER", 107, 115]]], ["During the 14-day experiment, body temperatures, body weights, and clinical signs were recorded daily.", [["body", "ANATOMY", 30, 34], ["body", "ANATOMY", 49, 53], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["body temperatures", "TEST", 30, 47], ["body weights", "TEST", 49, 61], ["clinical signs", "TEST", 67, 81]]], ["Animals were euthanized and sampled at different time points after infection to assess virus titers in various organs and to examine pathological changes in the lungs (Figures 1 and 2) . each group (n = 3 for 2, 3, and 5 dpi, n = 1 for 7 dpi and n = 2 for 14 dpi; Bar = 0.5 cm) (B) Affected areas of inflammation were identified histologically for each lung and compared between the groups.", [["organs", "ANATOMY", 111, 117], ["lungs", "ANATOMY", 161, 166], ["lung", "ANATOMY", 353, 357], ["inflammation", "DISEASE", 300, 312], ["Animals", "ORGANISM", 0, 7], ["organs", "ORGAN", 111, 117], ["lungs", "ORGAN", 161, 166], ["lung", "ORGAN", 353, 357], ["infection", "PROBLEM", 67, 76], ["virus titers in various organs", "PROBLEM", 87, 117], ["pathological changes in the lungs", "PROBLEM", 133, 166], ["Affected areas of inflammation", "PROBLEM", 282, 312], ["lungs", "ANATOMY", 161, 166], ["inflammation", "OBSERVATION", 300, 312], ["lung", "ANATOMY", 353, 357]]], ["(C) Lung inflammation score taking into account (i) severity of pulmonary inflammation; (ii) bronchitis (iii) bronchial and alveolar necrosis; iv) hyperplasia of alveolar epithelial cells type II.", [["Lung", "ANATOMY", 4, 8], ["pulmonary", "ANATOMY", 64, 73], ["bronchial", "ANATOMY", 110, 119], ["alveolar", "ANATOMY", 124, 132], ["alveolar epithelial cells", "ANATOMY", 162, 187], ["Lung inflammation", "DISEASE", 4, 21], ["pulmonary inflammation", "DISEASE", 64, 86], ["bronchitis", "DISEASE", 93, 103], ["necrosis", "DISEASE", 133, 141], ["hyperplasia", "DISEASE", 147, 158], ["Lung", "ORGAN", 4, 8], ["pulmonary", "ORGAN", 64, 73], ["bronchial", "MULTI-TISSUE_STRUCTURE", 110, 119], ["alveolar epithelial cells type II", "CELL", 162, 195], ["alveolar epithelial cells", "CELL_TYPE", 162, 187], ["Lung inflammation score", "PROBLEM", 4, 27], ["pulmonary inflammation", "PROBLEM", 64, 86], ["bronchitis (iii) bronchial and alveolar necrosis", "PROBLEM", 93, 141], ["hyperplasia of alveolar epithelial cells type II", "PROBLEM", 147, 195], ["Lung", "ANATOMY", 4, 8], ["inflammation", "OBSERVATION", 9, 21], ["pulmonary", "ANATOMY", 64, 73], ["inflammation", "OBSERVATION", 74, 86], ["bronchitis", "OBSERVATION", 93, 103], ["bronchial", "ANATOMY", 110, 119], ["alveolar", "ANATOMY_MODIFIER", 124, 132], ["necrosis", "OBSERVATION", 133, 141], ["hyperplasia", "OBSERVATION", 147, 158], ["alveolar", "ANATOMY_MODIFIER", 162, 170], ["epithelial cells", "OBSERVATION", 171, 187]]], ["(D) Immune cell influx score taking into account the infiltration of lung tissue with (i) neutrophils; (ii) macrophages; (iii) lymphocytes; (iv) perivascular lymphocytic cuffing; and (E) edema score including (i) alveolar and (ii) perivascular edema.", [["Immune cell", "ANATOMY", 4, 15], ["lung tissue", "ANATOMY", 69, 80], ["neutrophils", "ANATOMY", 90, 101], ["macrophages", "ANATOMY", 108, 119], ["lymphocytes", "ANATOMY", 127, 138], ["perivascular lymphocytic", "ANATOMY", 145, 169], ["edema", "ANATOMY", 187, 192], ["alveolar", "ANATOMY", 213, 221], ["perivascular edema", "ANATOMY", 231, 249], ["edema", "DISEASE", 187, 192], ["edema", "DISEASE", 244, 249], ["Immune cell", "CELL", 4, 15], ["lung tissue", "TISSUE", 69, 80], ["neutrophils", "CELL", 90, 101], ["macrophages", "CELL", 108, 119], ["lymphocytes", "CELL", 127, 138], ["edema", "PATHOLOGICAL_FORMATION", 187, 192], ["alveolar", "MULTI-TISSUE_STRUCTURE", 213, 221], ["perivascular edema", "PATHOLOGICAL_FORMATION", 231, 249], ["neutrophils", "CELL_TYPE", 90, 101], ["macrophages", "CELL_TYPE", 108, 119], ["lymphocytes", "CELL_TYPE", 127, 138], ["Immune cell influx score", "PROBLEM", 4, 28], ["the infiltration of lung tissue", "PROBLEM", 49, 80], ["neutrophils", "TEST", 90, 101], ["macrophages", "TEST", 108, 119], ["lymphocytes", "TEST", 127, 138], ["perivascular lymphocytic cuffing", "PROBLEM", 145, 177], ["(E) edema score", "PROBLEM", 183, 198], ["alveolar and (ii) perivascular edema", "PROBLEM", 213, 249], ["infiltration", "OBSERVATION", 53, 65], ["lung tissue", "ANATOMY", 69, 80], ["macrophages", "ANATOMY", 108, 119], ["perivascular", "ANATOMY", 145, 157], ["lymphocytic cuffing", "OBSERVATION", 158, 177], ["edema", "OBSERVATION", 187, 192], ["alveolar", "ANATOMY", 213, 221], ["perivascular", "ANATOMY", 231, 243], ["edema", "OBSERVATION", 244, 249]]], ["Scores and parameters in C to E were graded as absent (0), minimal (1), mild (2), moderate (3), or severe (4) as described [35] .", [["Scores", "TEST", 0, 6], ["parameters in C to E", "TEST", 11, 31], ["minimal (1), mild (2), moderate (3), or severe (4)", "PROBLEM", 59, 109], ["minimal", "OBSERVATION_MODIFIER", 59, 66], ["mild", "OBSERVATION_MODIFIER", 72, 76], ["moderate", "OBSERVATION_MODIFIER", 82, 90], ["severe", "OBSERVATION_MODIFIER", 99, 105]]], ["(F) Time-dependent distribution of SARS-CoV-2 RNA signals in young and adult hamsters representative of each group as detected by in situ hybridization (group sizes as in A; for digital image analysis of the differences, see Figure S3 ; bar = 0.5 cm).Results and DiscussionFirst, we observed age-dependent SARS-CoV-2-induced body weight losses, with more pronounced weight reductions in aged compared to young hamsters ( Figure 1A-C) .", [["body", "ANATOMY", 325, 329], ["SARS", "DISEASE", 306, 310], ["weight losses", "DISEASE", 330, 343], ["weight reductions", "DISEASE", 366, 383], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 35, 45], ["hamsters", "ORGANISM", 77, 85], ["body", "ORGANISM_SUBDIVISION", 325, 329], ["hamsters", "ORGANISM", 410, 418], ["SARS-CoV-2 RNA", "RNA", 35, 49], ["hamsters", "SPECIES", 410, 418], ["SARS", "PROBLEM", 35, 39], ["digital image analysis", "TEST", 178, 200], ["dependent SARS", "PROBLEM", 296, 310], ["CoV", "TEST", 311, 314], ["induced body weight losses", "PROBLEM", 317, 343], ["more pronounced weight reductions", "PROBLEM", 350, 383]]], ["Mean body weight losses peaked at 6 to 7 days post-infection (dpi), with partial recovery until 14 dpi in both infected groups.", [["body", "ANATOMY", 5, 9], ["infection", "DISEASE", 51, 60], ["body", "ORGANISM_SUBDIVISION", 5, 9], ["Mean body weight losses", "PROBLEM", 0, 23], ["infection", "PROBLEM", 51, 60], ["infection", "OBSERVATION", 51, 60], ["infected", "OBSERVATION", 111, 119]]], ["There were no differences in body temperatures between the infected groups or between infected and mock-infected animals ( Figure 1D ).Results and DiscussionNext, we determined viral titers and SARS-CoV-2 RNA copy numbers in various tissues by RT-qPCR [36, 37] and performed virus titrations from lung homogenates using Vero E6 cells ( Figure 1E -H).", [["body", "ANATOMY", 29, 33], ["tissues", "ANATOMY", 233, 240], ["lung homogenates", "ANATOMY", 297, 313], ["Vero E6 cells", "ANATOMY", 320, 333], ["body", "ORGANISM_SUBDIVISION", 29, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 194, 204], ["tissues", "TISSUE", 233, 240], ["lung", "ORGAN", 297, 301], ["Vero E6 cells", "CELL", 320, 333], ["Figure 1E -H", "CELL", 336, 348], ["Vero E6 cells", "CELL_LINE", 320, 333], ["SARS-CoV", "SPECIES", 194, 202], ["Vero E6", "SPECIES", 320, 327], ["differences in body temperatures", "PROBLEM", 14, 46], ["viral titers", "TEST", 177, 189], ["SARS", "TEST", 194, 198], ["CoV", "TEST", 199, 202], ["qPCR", "TEST", 247, 251], ["virus titrations", "TEST", 275, 291], ["lung homogenates", "TEST", 297, 313], ["Vero E6 cells", "TREATMENT", 320, 333], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["infected", "OBSERVATION", 59, 67], ["infected", "OBSERVATION", 86, 94], ["lung", "ANATOMY", 297, 301]]], ["Results were similar between age groups and confirmed high viral loads in respiratory samples at early time points after infection, but a relatively rapid clearance of infection.", [["respiratory samples", "ANATOMY", 74, 93], ["infection", "DISEASE", 121, 130], ["infection", "DISEASE", 168, 177], ["high viral loads in respiratory samples", "PROBLEM", 54, 93], ["infection", "PROBLEM", 121, 130], ["infection", "PROBLEM", 168, 177], ["high viral loads", "OBSERVATION", 54, 70], ["respiratory samples", "OBSERVATION", 74, 93], ["infection", "OBSERVATION", 121, 130], ["infection", "OBSERVATION", 168, 177]]], ["While we did not identify any other sex-specific differences, it seems important to note that the RT-qPCR of blood samples revealed viremia in two male individuals from both age groups with viral RNA copy numbers of >10 5 at 5 and 7 dpi, respectively ( Figure 1I ).", [["blood samples", "ANATOMY", 109, 122], ["viremia", "DISEASE", 132, 139], ["blood samples", "ORGANISM_SUBSTANCE", 109, 122], ["the RT-qPCR", "TEST", 94, 105], ["blood samples", "TEST", 109, 122], ["viremia", "PROBLEM", 132, 139], ["viral RNA copy numbers", "TEST", 190, 212], ["viremia", "OBSERVATION", 132, 139], ["viral RNA", "OBSERVATION", 190, 199]]], ["In these individuals, we also detected relatively high levels of viral RNA in the spleen, kidneys, and duodenum, indicating a systemic spread of SARS-CoV-2 in some cases (Table S1 ).", [["spleen", "ANATOMY", 82, 88], ["kidneys", "ANATOMY", 90, 97], ["duodenum", "ANATOMY", 103, 111], ["SARS", "DISEASE", 145, 149], ["spleen", "ORGAN", 82, 88], ["kidneys", "ORGAN", 90, 97], ["duodenum", "ORGAN", 103, 111], ["viral RNA", "RNA", 65, 74], ["SARS-CoV", "SPECIES", 145, 153], ["viral RNA in the spleen, kidneys, and duodenum", "PROBLEM", 65, 111], ["a systemic spread of SARS", "PROBLEM", 124, 149], ["CoV", "TEST", 150, 153], ["high", "OBSERVATION_MODIFIER", 50, 54], ["viral RNA", "OBSERVATION", 65, 74], ["spleen", "ANATOMY", 82, 88], ["kidneys", "ANATOMY", 90, 97], ["duodenum", "ANATOMY", 103, 111], ["systemic", "OBSERVATION_MODIFIER", 126, 134], ["spread", "OBSERVATION_MODIFIER", 135, 141]]], ["To further investigate the potential dissemination of infection, we tested the aforementioned organs from all animals sacrificed at 5 dpi and found them to be either negative for SARS-CoV-2 RNA or to contain only low levels of viral RNA (Table S1 ).Results and DiscussionViral loads in bucco-laryngeal swabs and nasal washes appeared to be a reliable surrogate of the presence or absence of virus in the lungs in both age groups.", [["organs", "ANATOMY", 94, 100], ["bucco-laryngeal swabs", "ANATOMY", 286, 307], ["nasal", "ANATOMY", 312, 317], ["lungs", "ANATOMY", 404, 409], ["infection", "DISEASE", 54, 63], ["organs", "ORGAN", 94, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 179, 189], ["bucco-laryngeal swabs", "ORGANISM_SUBSTANCE", 286, 307], ["nasal", "ORGAN", 312, 317], ["lungs", "ORGAN", 404, 409], ["SARS-CoV-2 RNA", "RNA", 179, 193], ["viral RNA", "RNA", 227, 236], ["infection", "PROBLEM", 54, 63], ["SARS", "PROBLEM", 179, 183], ["CoV", "TEST", 184, 187], ["low levels of viral RNA", "PROBLEM", 213, 236], ["DiscussionViral loads", "TREATMENT", 261, 282], ["bucco-laryngeal swabs", "TREATMENT", 286, 307], ["nasal washes", "TREATMENT", 312, 324], ["virus in the lungs", "PROBLEM", 391, 409], ["infection", "OBSERVATION", 54, 63], ["low levels", "OBSERVATION_MODIFIER", 213, 223], ["viral RNA", "OBSERVATION", 227, 236], ["nasal", "ANATOMY", 312, 317], ["virus", "OBSERVATION", 391, 396], ["lungs", "ANATOMY", 404, 409]]], ["The average loads ranged between 10 4 and 10 7 copies, respectively, at early times after infection, indicating that these sampling techniques can be used to monitor SARS-CoV-2 replication in Syrian hamsters ( Figure 1G,H) .Results and DiscussionAt 14 dpi, hamsters had mounted a humoral immune response as evidenced by relatively high titers of neutralizing antibodies.", [["infection", "DISEASE", 90, 99], ["CoV-2", "ORGANISM", 171, 176], ["Syrian hamsters", "ORGANISM", 192, 207], ["hamsters", "ORGANISM", 257, 265], ["neutralizing antibodies", "PROTEIN", 346, 369], ["Syrian hamsters", "SPECIES", 192, 207], ["SARS-CoV", "SPECIES", 166, 174], ["Syrian hamsters", "SPECIES", 192, 207], ["hamsters", "SPECIES", 257, 265], ["The average loads", "TEST", 0, 17], ["infection", "PROBLEM", 90, 99], ["these sampling techniques", "TREATMENT", 117, 142], ["SARS", "TEST", 166, 170], ["CoV", "TEST", 171, 174], ["relatively high titers of neutralizing antibodies", "PROBLEM", 320, 369], ["average", "OBSERVATION_MODIFIER", 4, 11], ["loads", "OBSERVATION_MODIFIER", 12, 17], ["infection", "OBSERVATION", 90, 99], ["neutralizing antibodies", "OBSERVATION", 346, 369]]], ["It is worth noting that antibody titers appear to be higher in young when compared to aged hamsters in the animals tested (Table S1) .Results and DiscussionHistopathology revealed clear age-dependent differences, with young hamsters launching an earlier and stronger immune cell influx into the lungs associated with a faster recovery than their aged counterparts (Figure 2A-E) .", [["immune cell", "ANATOMY", 267, 278], ["lungs", "ANATOMY", 295, 300], ["hamsters", "ORGANISM", 91, 99], ["hamsters", "ORGANISM", 224, 232], ["immune cell", "CELL", 267, 278], ["lungs", "ORGAN", 295, 300], ["hamsters", "SPECIES", 91, 99], ["hamsters", "SPECIES", 224, 232], ["antibody titers", "PROBLEM", 24, 39], ["DiscussionHistopathology", "TEST", 146, 170], ["higher", "OBSERVATION_MODIFIER", 53, 59], ["dependent", "OBSERVATION_MODIFIER", 190, 199], ["immune cell influx", "OBSERVATION", 267, 285], ["lungs", "ANATOMY", 295, 300]]], ["At 2 dpi, young hamsters developed a marked necro-suppurative bronchointerstitial pneumonia with strong alveolar and interstitial influx of neutrophils and macrophages as well as perivascular lymphocytic cuffing, which was much milder or absent in the aged group ( Figure S1A, right panel) .", [["bronchointerstitial", "ANATOMY", 62, 81], ["alveolar", "ANATOMY", 104, 112], ["interstitial", "ANATOMY", 117, 129], ["neutrophils", "ANATOMY", 140, 151], ["macrophages", "ANATOMY", 156, 167], ["perivascular lymphocytic", "ANATOMY", 179, 203], ["pneumonia", "DISEASE", 82, 91], ["hamsters", "ORGANISM", 16, 24], ["alveolar", "MULTI-TISSUE_STRUCTURE", 104, 112], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 129], ["neutrophils", "CELL", 140, 151], ["macrophages", "CELL", 156, 167], ["neutrophils", "CELL_TYPE", 140, 151], ["macrophages", "CELL_TYPE", 156, 167], ["hamsters", "SPECIES", 16, 24], ["a marked necro-suppurative bronchointerstitial pneumonia", "PROBLEM", 35, 91], ["strong alveolar and interstitial influx of neutrophils", "PROBLEM", 97, 151], ["macrophages", "PROBLEM", 156, 167], ["perivascular lymphocytic cuffing", "PROBLEM", 179, 211], ["marked", "OBSERVATION_MODIFIER", 37, 43], ["necro-suppurative", "OBSERVATION_MODIFIER", 44, 61], ["bronchointerstitial", "OBSERVATION_MODIFIER", 62, 81], ["pneumonia", "OBSERVATION", 82, 91], ["strong", "OBSERVATION_MODIFIER", 97, 103], ["alveolar", "ANATOMY_MODIFIER", 104, 112], ["interstitial", "ANATOMY_MODIFIER", 117, 129], ["influx of neutrophils", "OBSERVATION", 130, 151], ["macrophages", "OBSERVATION", 156, 167], ["perivascular", "ANATOMY_MODIFIER", 179, 191], ["lymphocytic cuffing", "OBSERVATION", 192, 211], ["milder", "OBSERVATION_MODIFIER", 228, 234], ["absent", "OBSERVATION_MODIFIER", 238, 244], ["right", "ANATOMY_MODIFIER", 277, 282]]], ["In contrast, only aged animals developed pronounced alveolar and perivascular edema indicating vascular leakage at 3 dpi ( Figure 2E and Figure S2C) .", [["alveolar", "ANATOMY", 52, 60], ["perivascular edema", "ANATOMY", 65, 83], ["vascular", "ANATOMY", 95, 103], ["edema", "DISEASE", 78, 83], ["alveolar", "MULTI-TISSUE_STRUCTURE", 52, 60], ["perivascular edema", "PATHOLOGICAL_FORMATION", 65, 83], ["vascular", "MULTI-TISSUE_STRUCTURE", 95, 103], ["pronounced alveolar and perivascular edema", "PROBLEM", 41, 83], ["vascular leakage", "PROBLEM", 95, 111], ["pronounced", "OBSERVATION_MODIFIER", 41, 51], ["alveolar", "ANATOMY_MODIFIER", 52, 60], ["perivascular", "ANATOMY_MODIFIER", 65, 77], ["edema", "OBSERVATION", 78, 83], ["vascular", "ANATOMY", 95, 103], ["leakage", "OBSERVATION", 104, 111]]], ["A more diffuse, severe bronchointerstitial pneumonia was similarly present in both groups at 5 dpi with an onset of tissue regeneration, including hyperplasia of the bronchial epithelium ( Figure S1C , arrowhead) and type II alveolar epithelial cells.Results and DiscussionOnly at the 5 dpi time point was the arterial and venous endothelium of animals in both groups swollen and vacuolated, with necrotic endothelial cells separated from the underlying basement membrane by the presence of subendothelial lymphocytes and neutrophils ( Figure S2C, left) , which was consistent with what has been described as endothelialitis in human SARS-CoV-2 infection [38] .", [["bronchointerstitial", "ANATOMY", 23, 42], ["tissue", "ANATOMY", 116, 122], ["bronchial epithelium", "ANATOMY", 166, 186], ["alveolar epithelial cells", "ANATOMY", 225, 250], ["arterial", "ANATOMY", 310, 318], ["venous endothelium", "ANATOMY", 323, 341], ["necrotic endothelial cells", "ANATOMY", 397, 423], ["basement membrane", "ANATOMY", 454, 471], ["subendothelial lymphocytes", "ANATOMY", 491, 517], ["neutrophils", "ANATOMY", 522, 533], ["pneumonia", "DISEASE", 43, 52], ["necrotic", "DISEASE", 397, 405], ["endothelialitis", "DISEASE", 609, 624], ["SARS-CoV-2 infection", "DISEASE", 634, 654], ["tissue", "TISSUE", 116, 122], ["bronchial epithelium", "TISSUE", 166, 186], ["type II alveolar epithelial cells", "CELL", 217, 250], ["arterial", "MULTI-TISSUE_STRUCTURE", 310, 318], ["venous endothelium", "TISSUE", 323, 341], ["necrotic endothelial cells", "CELL", 397, 423], ["basement membrane", "CELLULAR_COMPONENT", 454, 471], ["subendothelial lymphocytes", "CELL", 491, 517], ["neutrophils", "CELL", 522, 533], ["Figure S2C", "GENE_OR_GENE_PRODUCT", 536, 546], ["human", "ORGANISM", 628, 633], ["SARS-CoV-2", "ORGANISM", 634, 644], ["type II alveolar epithelial cells", "CELL_TYPE", 217, 250], ["necrotic endothelial cells", "CELL_TYPE", 397, 423], ["subendothelial lymphocytes", "CELL_TYPE", 491, 517], ["neutrophils", "CELL_TYPE", 522, 533], ["human", "SPECIES", 628, 633], ["human SARS-CoV-2", "SPECIES", 628, 644], ["A more diffuse, severe bronchointerstitial pneumonia", "PROBLEM", 0, 52], ["tissue regeneration", "PROBLEM", 116, 135], ["hyperplasia of the bronchial epithelium", "PROBLEM", 147, 186], ["Figure S1C", "TEST", 189, 199], ["type II alveolar epithelial cells", "PROBLEM", 217, 250], ["necrotic endothelial cells", "PROBLEM", 397, 423], ["subendothelial lymphocytes", "TEST", 491, 517], ["neutrophils", "TEST", 522, 533], ["Figure S2C", "TEST", 536, 546], ["endothelialitis", "PROBLEM", 609, 624], ["human SARS", "PROBLEM", 628, 638], ["CoV-2 infection", "PROBLEM", 639, 654], ["more", "OBSERVATION_MODIFIER", 2, 6], ["diffuse", "OBSERVATION_MODIFIER", 7, 14], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["bronchointerstitial", "OBSERVATION_MODIFIER", 23, 42], ["pneumonia", "OBSERVATION", 43, 52], ["onset", "OBSERVATION_MODIFIER", 107, 112], ["tissue regeneration", "OBSERVATION", 116, 135], ["hyperplasia", "OBSERVATION", 147, 158], ["bronchial epithelium", "ANATOMY", 166, 186], ["type II", "OBSERVATION_MODIFIER", 217, 224], ["alveolar", "ANATOMY_MODIFIER", 225, 233], ["epithelial cells", "OBSERVATION", 234, 250], ["arterial", "ANATOMY", 310, 318], ["venous endothelium", "ANATOMY", 323, 341], ["necrotic endothelial cells", "OBSERVATION", 397, 423], ["subendothelial lymphocytes", "ANATOMY", 491, 517], ["neutrophils", "OBSERVATION_MODIFIER", 522, 533], ["left", "ANATOMY_MODIFIER", 548, 552], ["consistent with", "UNCERTAINTY", 566, 581]]], ["At 7 dpi, recovery as indicated by the marked hyperplasia of bronchial epithelial cells and type II alveolar epithelial cells were seen in both groups ( Figure S2A ).", [["bronchial epithelial cells", "ANATOMY", 61, 87], ["type II alveolar epithelial cells", "ANATOMY", 92, 125], ["hyperplasia", "DISEASE", 46, 57], ["bronchial epithelial cells", "CELL", 61, 87], ["type II alveolar epithelial cells", "CELL", 92, 125], ["bronchial epithelial cells", "CELL_TYPE", 61, 87], ["type II alveolar epithelial cells", "CELL_TYPE", 92, 125], ["the marked hyperplasia of bronchial epithelial cells", "PROBLEM", 35, 87], ["type II alveolar epithelial cells", "PROBLEM", 92, 125], ["marked", "OBSERVATION_MODIFIER", 39, 45], ["hyperplasia", "OBSERVATION", 46, 57], ["bronchial epithelial cells", "OBSERVATION", 61, 87], ["alveolar", "ANATOMY_MODIFIER", 100, 108], ["epithelial cells", "OBSERVATION", 109, 125]]], ["Interestingly, lung tissues had almost recovered in young hamsters at day 14, while the aged animals still had persistent tissue damage and active inflammation ( Figure S2B ).", [["lung tissues", "ANATOMY", 15, 27], ["tissue", "ANATOMY", 122, 128], ["tissue damage", "DISEASE", 122, 135], ["inflammation", "DISEASE", 147, 159], ["lung tissues", "TISSUE", 15, 27], ["hamsters", "ORGANISM", 58, 66], ["animals", "ORGANISM", 93, 100], ["tissue", "TISSUE", 122, 128], ["persistent tissue damage", "PROBLEM", 111, 135], ["active inflammation", "PROBLEM", 140, 159], ["lung", "ANATOMY", 15, 19], ["tissues", "OBSERVATION", 20, 27], ["almost", "OBSERVATION_MODIFIER", 32, 38], ["recovered", "OBSERVATION_MODIFIER", 39, 48], ["persistent tissue", "OBSERVATION_MODIFIER", 111, 128], ["damage", "OBSERVATION", 129, 135], ["active", "OBSERVATION_MODIFIER", 140, 146], ["inflammation", "OBSERVATION", 147, 159]]], ["From 2 dpi onwards, SARS-CoV-2 RNA was detected by in situ hybridization in bronchial epithelial cells, debris in the bronchial lumen, alveolar epithelial cells type I and type II, as well as macrophages in both groups, again with clear age-dependent differences over time ( Figure 2F , Figures S2D and S3) .", [["bronchial epithelial cells", "ANATOMY", 76, 102], ["debris", "ANATOMY", 104, 110], ["bronchial lumen", "ANATOMY", 118, 133], ["alveolar epithelial cells", "ANATOMY", 135, 160], ["macrophages", "ANATOMY", 192, 203], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["bronchial epithelial cells", "CELL", 76, 102], ["bronchial lumen", "MULTI-TISSUE_STRUCTURE", 118, 133], ["alveolar epithelial cells type I", "CELL", 135, 167], ["type II", "GENE_OR_GENE_PRODUCT", 172, 179], ["macrophages", "CELL", 192, 203], ["SARS-CoV-2 RNA", "RNA", 20, 34], ["bronchial epithelial cells", "CELL_TYPE", 76, 102], ["alveolar epithelial cells", "CELL_TYPE", 135, 160], ["macrophages", "CELL_TYPE", 192, 203], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["bronchial epithelial cells", "PROBLEM", 76, 102], ["debris in the bronchial lumen", "PROBLEM", 104, 133], ["alveolar epithelial cells type I", "PROBLEM", 135, 167], ["type II", "PROBLEM", 172, 179], ["bronchial", "ANATOMY", 76, 85], ["epithelial cells", "OBSERVATION", 86, 102], ["debris", "OBSERVATION", 104, 110], ["bronchial", "ANATOMY", 118, 127], ["lumen", "ANATOMY_MODIFIER", 128, 133], ["alveolar", "ANATOMY_MODIFIER", 135, 143], ["epithelial cells", "OBSERVATION", 144, 160], ["type II", "OBSERVATION_MODIFIER", 172, 179], ["macrophages", "OBSERVATION", 192, 203], ["dependent", "OBSERVATION_MODIFIER", 241, 250], ["differences", "OBSERVATION_MODIFIER", 251, 262], ["S3", "ANATOMY", 303, 305]]], ["Young animals had high amounts of viral RNA in numerous bronchial epithelial cells and within the bronchial lumen that was accompanied by marked spreading through the lung parenchyma on 2 and 3 dpi.", [["bronchial epithelial cells", "ANATOMY", 56, 82], ["bronchial lumen", "ANATOMY", 98, 113], ["lung parenchyma", "ANATOMY", 167, 182], ["animals", "ORGANISM", 6, 13], ["bronchial epithelial cells", "CELL", 56, 82], ["bronchial lumen", "MULTI-TISSUE_STRUCTURE", 98, 113], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 167, 182], ["viral RNA", "RNA", 34, 43], ["bronchial epithelial cells", "CELL_TYPE", 56, 82], ["viral RNA in numerous bronchial epithelial cells", "PROBLEM", 34, 82], ["high amounts", "OBSERVATION_MODIFIER", 18, 30], ["viral RNA", "OBSERVATION", 34, 43], ["numerous", "OBSERVATION_MODIFIER", 47, 55], ["bronchial epithelial cells", "OBSERVATION", 56, 82], ["bronchial", "ANATOMY", 98, 107], ["lumen", "ANATOMY_MODIFIER", 108, 113], ["marked", "OBSERVATION_MODIFIER", 138, 144], ["spreading", "OBSERVATION_MODIFIER", 145, 154], ["lung", "ANATOMY", 167, 171], ["parenchyma", "ANATOMY_MODIFIER", 172, 182]]], ["In contrast, aged animals had less virus RNA present in the bronchi.", [["bronchi", "ANATOMY", 60, 67], ["animals", "ORGANISM", 18, 25], ["bronchi", "MULTI-TISSUE_STRUCTURE", 60, 67], ["virus RNA", "RNA", 35, 44], ["less virus RNA", "PROBLEM", 30, 44], ["less", "OBSERVATION_MODIFIER", 30, 34], ["virus RNA", "OBSERVATION", 35, 44], ["bronchi", "ANATOMY", 60, 67]]], ["We detected only a scattered pattern of infected bronchial epithelial cells and sporadic areas of parenchymal infection at 2 and 3 dpi.", [["bronchial epithelial cells", "ANATOMY", 49, 75], ["parenchymal", "ANATOMY", 98, 109], ["parenchymal infection", "DISEASE", 98, 119], ["bronchial epithelial cells", "CELL", 49, 75], ["parenchymal", "TISSUE", 98, 109], ["infected bronchial epithelial cells", "CELL_TYPE", 40, 75], ["infected bronchial epithelial cells", "PROBLEM", 40, 75], ["parenchymal infection", "PROBLEM", 98, 119], ["scattered", "OBSERVATION_MODIFIER", 19, 28], ["pattern", "OBSERVATION_MODIFIER", 29, 36], ["infected", "OBSERVATION_MODIFIER", 40, 48], ["bronchial epithelial cells", "OBSERVATION", 49, 75], ["sporadic", "OBSERVATION_MODIFIER", 80, 88], ["areas", "OBSERVATION_MODIFIER", 89, 94], ["parenchymal", "ANATOMY_MODIFIER", 98, 109], ["infection", "OBSERVATION", 110, 119]]], ["At 5 dpi, viral RNA was undetectable in the bronchi of young hamsters, and only small infected areas containing low levels of RNA with a patchy distribution were detected.", [["bronchi", "ANATOMY", 44, 51], ["bronchi", "ORGAN", 44, 51], ["hamsters", "ORGANISM", 61, 69], ["viral RNA", "RNA", 10, 19], ["hamsters", "SPECIES", 61, 69], ["hamsters", "SPECIES", 61, 69], ["viral RNA", "TEST", 10, 19], ["small infected areas containing low levels of RNA", "PROBLEM", 80, 129], ["a patchy distribution", "PROBLEM", 135, 156], ["viral RNA", "OBSERVATION", 10, 19], ["bronchi", "ANATOMY", 44, 51], ["young hamsters", "OBSERVATION", 55, 69], ["small", "OBSERVATION_MODIFIER", 80, 85], ["infected", "OBSERVATION", 86, 94], ["low levels", "OBSERVATION_MODIFIER", 112, 122], ["RNA", "OBSERVATION_MODIFIER", 126, 129], ["patchy", "OBSERVATION_MODIFIER", 137, 143], ["distribution", "OBSERVATION_MODIFIER", 144, 156]]], ["It is noteworthy that aged animals, at the same time after infection, had increased numbers of infected areas with a similarly patchy distribution throughout the lungs as well as copious amounts of viral RNA associated with cellular debris in the bronchial lumen.", [["lungs", "ANATOMY", 162, 167], ["cellular", "ANATOMY", 224, 232], ["bronchial lumen", "ANATOMY", 247, 262], ["infection", "DISEASE", 59, 68], ["lungs", "ORGAN", 162, 167], ["cellular", "CELL", 224, 232], ["bronchial lumen", "MULTI-TISSUE_STRUCTURE", 247, 262], ["viral RNA", "RNA", 198, 207], ["infection", "PROBLEM", 59, 68], ["increased numbers of infected areas", "PROBLEM", 74, 109], ["a similarly patchy distribution throughout the lungs", "PROBLEM", 115, 167], ["copious amounts of viral RNA", "PROBLEM", 179, 207], ["cellular debris in the bronchial lumen", "PROBLEM", 224, 262], ["infection", "OBSERVATION", 59, 68], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["numbers", "OBSERVATION_MODIFIER", 84, 91], ["infected", "OBSERVATION", 95, 103], ["similarly", "OBSERVATION_MODIFIER", 117, 126], ["patchy", "OBSERVATION_MODIFIER", 127, 133], ["distribution", "OBSERVATION_MODIFIER", 134, 146], ["lungs", "ANATOMY", 162, 167], ["copious", "OBSERVATION_MODIFIER", 179, 186], ["amounts", "OBSERVATION_MODIFIER", 187, 194], ["viral RNA", "OBSERVATION", 198, 207], ["cellular", "OBSERVATION_MODIFIER", 224, 232], ["debris", "OBSERVATION", 233, 239], ["bronchial", "ANATOMY", 247, 256], ["lumen", "ANATOMY_MODIFIER", 257, 262]]], ["Using this technique, no viral RNA was detected at 14 dpi in either group.Results and DiscussionIn summary, our study examined the suitability of a small animal model to study SARS-CoV-2 infections and expands on determining the role that age might play in the differences with respect to disease progression.", [["SARS", "DISEASE", 176, 180], ["infections", "DISEASE", 187, 197], ["SARS-CoV-2", "ORGANISM", 176, 186], ["viral RNA", "RNA", 25, 34], ["SARS-CoV-2", "SPECIES", 176, 186], ["this technique", "TEST", 6, 20], ["viral RNA", "PROBLEM", 25, 34], ["our study", "TEST", 108, 117], ["study SARS", "TEST", 170, 180], ["CoV-2 infections", "PROBLEM", 181, 197], ["disease progression", "PROBLEM", 289, 308], ["no", "UNCERTAINTY", 22, 24], ["viral RNA", "OBSERVATION", 25, 34], ["infections", "OBSERVATION", 187, 197], ["disease", "OBSERVATION", 289, 296]]], ["Intranasal infection of Syrian hamsters resulted in weight loss and robust virus replication in the upper and lower respiratory tract.", [["upper", "ANATOMY", 100, 105], ["lower respiratory tract", "ANATOMY", 110, 133], ["infection", "DISEASE", 11, 20], ["weight loss", "DISEASE", 52, 63], ["Syrian hamsters", "ORGANISM", 24, 39], ["upper", "ORGANISM_SUBDIVISION", 100, 105], ["lower respiratory", "ORGANISM_SUBDIVISION", 110, 127], ["tract", "ORGANISM_SUBDIVISION", 128, 133], ["Syrian hamsters", "SPECIES", 24, 39], ["Syrian hamsters", "SPECIES", 24, 39], ["Intranasal infection of Syrian hamsters", "PROBLEM", 0, 39], ["weight loss", "PROBLEM", 52, 63], ["robust virus replication in the upper and lower respiratory tract", "PROBLEM", 68, 133], ["infection", "OBSERVATION", 11, 20], ["weight loss", "OBSERVATION", 52, 63], ["robust", "OBSERVATION_MODIFIER", 68, 74], ["virus replication", "OBSERVATION", 75, 92], ["upper", "ANATOMY_MODIFIER", 100, 105], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory tract", "ANATOMY", 116, 133]]], ["A limitation of this study is the lack of an age-matched mock group for the older hamsters, which we are unable to include for legal reasons as we are bound under German law to follow the 3R principle.", [["hamsters", "ORGANISM", 82, 90], ["this study", "TEST", 16, 26]]], ["We further demonstrate that aged 32-to 34-week-old hamsters experienced higher and more consistent weight loss after intranasal infection, while body temperatures and virus replication in upper airways and lungs were similar between both age groups.", [["body", "ANATOMY", 145, 149], ["upper airways", "ANATOMY", 188, 201], ["lungs", "ANATOMY", 206, 211], ["weight loss", "DISEASE", 99, 110], ["infection", "DISEASE", 128, 137], ["hamsters", "ORGANISM", 51, 59], ["body", "ORGANISM_SUBDIVISION", 145, 149], ["upper airways", "MULTI-TISSUE_STRUCTURE", 188, 201], ["lungs", "ORGAN", 206, 211], ["weight loss", "PROBLEM", 99, 110], ["intranasal infection", "PROBLEM", 117, 137], ["body temperatures", "TEST", 145, 162], ["virus replication in upper airways and lungs", "PROBLEM", 167, 211], ["weight loss", "OBSERVATION_MODIFIER", 99, 110], ["infection", "OBSERVATION", 128, 137], ["virus replication", "OBSERVATION", 167, 184], ["upper", "ANATOMY_MODIFIER", 188, 193], ["airways", "ANATOMY", 194, 201], ["lungs", "ANATOMY", 206, 211]]], ["Furthermore, we show that, using in situ hybridization, viral RNA was detectable in bronchial epithelial cells, type I and type II alveolar epithelial cells, and macrophages.", [["bronchial epithelial cells", "ANATOMY", 84, 110], ["alveolar epithelial cells", "ANATOMY", 131, 156], ["macrophages", "ANATOMY", 162, 173], ["bronchial epithelial cells", "CELL", 84, 110], ["type I", "CELL", 112, 118], ["type II alveolar epithelial cells", "CELL", 123, 156], ["macrophages", "CELL", 162, 173], ["viral RNA", "RNA", 56, 65], ["bronchial epithelial cells", "CELL_TYPE", 84, 110], ["type I and type II alveolar epithelial cells", "CELL_TYPE", 112, 156], ["macrophages", "CELL_TYPE", 162, 173], ["viral RNA", "TEST", 56, 65], ["bronchial epithelial cells", "PROBLEM", 84, 110], ["type I and type II alveolar epithelial cells", "PROBLEM", 112, 156], ["macrophages", "PROBLEM", 162, 173], ["viral RNA", "OBSERVATION", 56, 65], ["bronchial", "ANATOMY", 84, 93], ["epithelial cells", "OBSERVATION", 94, 110], ["alveolar", "ANATOMY_MODIFIER", 131, 139], ["epithelial cells", "OBSERVATION", 140, 156], ["macrophages", "ANATOMY", 162, 173]]], ["All these cell types are potential targets of SARS-CoV-2 in human lung tissue; hence, the infection of hamsters of different ages seems to closely reflect what has been reported for human patients [28, 39] .", [["cell", "ANATOMY", 10, 14], ["lung tissue", "ANATOMY", 66, 77], ["infection", "DISEASE", 90, 99], ["cell", "CELL", 10, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["human", "ORGANISM", 60, 65], ["lung tissue", "TISSUE", 66, 77], ["hamsters", "ORGANISM", 103, 111], ["human", "ORGANISM", 182, 187], ["patients", "ORGANISM", 188, 196], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 182, 187], ["patients", "SPECIES", 188, 196], ["SARS-CoV", "SPECIES", 46, 54], ["human", "SPECIES", 60, 65], ["hamsters", "SPECIES", 103, 111], ["human", "SPECIES", 182, 187], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54], ["the infection of hamsters", "PROBLEM", 86, 111], ["cell types", "OBSERVATION", 10, 20], ["lung tissue", "ANATOMY", 66, 77], ["infection", "OBSERVATION", 90, 99]]], ["In contrast to SARS-CoV-2 titers, histopathological changes differed markedly between young and aged Syrian hamsters over time: younger animals launched more severe reactions at early time points after infection, while lesions and inflammation in the lungs became more pronounced and widespread at later time points in the elderly.", [["lesions", "ANATOMY", 219, 226], ["lungs", "ANATOMY", 251, 256], ["SARS", "DISEASE", 15, 19], ["infection", "DISEASE", 202, 211], ["inflammation", "DISEASE", 231, 243], ["CoV-2", "GENE_OR_GENE_PRODUCT", 20, 25], ["Syrian hamsters", "ORGANISM", 101, 116], ["lesions", "PATHOLOGICAL_FORMATION", 219, 226], ["lungs", "ORGAN", 251, 256], ["Syrian hamsters", "SPECIES", 101, 116], ["SARS-CoV", "SPECIES", 15, 23], ["Syrian hamsters", "SPECIES", 101, 116], ["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["histopathological changes", "PROBLEM", 34, 59], ["severe reactions", "PROBLEM", 158, 174], ["infection", "PROBLEM", 202, 211], ["lesions", "PROBLEM", 219, 226], ["inflammation in the lungs", "PROBLEM", 231, 256], ["infection", "OBSERVATION", 202, 211], ["lesions", "OBSERVATION", 219, 226], ["inflammation", "OBSERVATION", 231, 243], ["lungs", "ANATOMY", 251, 256], ["more pronounced", "OBSERVATION_MODIFIER", 264, 279], ["widespread", "OBSERVATION_MODIFIER", 284, 294]]], ["Notably, age-related differences of SARS-Cov-2 infections have also been observed in non-human primates [17] , and while this manuscript was under revision, in hamsters [40] .", [["SARS", "DISEASE", 36, 40], ["infections", "DISEASE", 47, 57], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["hamsters", "ORGANISM", 160, 168], ["SARS", "PROBLEM", 36, 40], ["2 infections", "PROBLEM", 45, 57], ["revision", "OBSERVATION", 147, 155]]], ["The study by Imai et al. also describes infections of Syrian hamsters of different age groups, and they also observed more robust body weight losses in older hamsters [40] .Results and DiscussionBased on the data presented here, we propose that comparative preclinical assessments of SARS-CoV-2 vaccines and other treatment options in young versus aged hamsters may yield valuable and relevant results, as this small animal model appears to mimic age-dependent differences in humans.", [["body", "ANATOMY", 130, 134], ["infections", "DISEASE", 40, 50], ["weight losses", "DISEASE", 135, 148], ["SARS", "DISEASE", 284, 288], ["Syrian hamsters", "ORGANISM", 54, 69], ["body", "ORGANISM_SUBDIVISION", 130, 134], ["SARS-CoV-2", "ORGANISM", 284, 294], ["hamsters", "ORGANISM", 353, 361], ["humans", "ORGANISM", 476, 482], ["Syrian hamsters", "SPECIES", 54, 69], ["humans", "SPECIES", 476, 482], ["Syrian hamsters", "SPECIES", 54, 69], ["hamsters", "SPECIES", 353, 361], ["humans", "SPECIES", 476, 482], ["The study", "TEST", 0, 9], ["comparative preclinical assessments", "TEST", 245, 280], ["SARS", "PROBLEM", 284, 288], ["CoV-2 vaccines", "TREATMENT", 289, 303], ["other treatment options", "TREATMENT", 308, 331], ["infections", "OBSERVATION", 40, 50], ["dependent", "OBSERVATION_MODIFIER", 451, 460]]], ["The development of a humoral immune response emphasizes that hamsters are likely suitable for vaccination trials.", [["hamsters", "ORGANISM", 61, 69], ["hamsters", "SPECIES", 61, 69], ["hamsters", "SPECIES", 61, 69], ["a humoral immune response", "TREATMENT", 19, 44], ["vaccination trials", "TREATMENT", 94, 112], ["humoral immune response", "OBSERVATION", 21, 44]]], ["Our observations also confirm that body weight loss is a readily quantifiable parameter that has proven very useful to measure disease severity in SARS-CoV-2 infection of Syrian hamsters.", [["body", "ANATOMY", 35, 39], ["weight loss", "DISEASE", 40, 51], ["SARS-CoV-2 infection", "DISEASE", 147, 167], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["SARS-CoV-2", "ORGANISM", 147, 157], ["Syrian hamsters", "ORGANISM", 171, 186], ["Syrian hamsters", "SPECIES", 171, 186], ["SARS-CoV-2", "SPECIES", 147, 157], ["Syrian hamsters", "SPECIES", 171, 186], ["body weight loss", "PROBLEM", 35, 51], ["disease severity", "PROBLEM", 127, 143], ["SARS", "PROBLEM", 147, 151], ["CoV", "PROBLEM", 152, 155]]], ["This makes the difference in body weight loss between age groups with more consistent losses in aged hamsters only more important as it provides an objective way to judge clinical efficacy of antiviral therapy or vaccination.", [["body", "ANATOMY", 29, 33], ["weight loss", "DISEASE", 34, 45], ["body", "ORGANISM_SUBDIVISION", 29, 33], ["hamsters", "ORGANISM", 101, 109], ["body weight loss", "PROBLEM", 29, 45], ["antiviral therapy", "TREATMENT", 192, 209], ["vaccination", "TREATMENT", 213, 224]]]], "PMC7476752": [["IntroductionInfectious diseases are increasingly emerging as a cause of morbidity and mortality worldwide, mainly due to the fact that some diseases are caused by multi-resistant microorganisms to existing drugs (1,2).", [["IntroductionInfectious diseases", "DISEASE", 0, 31], ["IntroductionInfectious diseases", "PROBLEM", 0, 31], ["morbidity", "PROBLEM", 72, 81], ["some diseases", "PROBLEM", 135, 148], ["multi-resistant microorganisms", "PROBLEM", 163, 193], ["diseases", "OBSERVATION", 140, 148], ["multi-resistant", "OBSERVATION_MODIFIER", 163, 178], ["microorganisms", "OBSERVATION", 179, 193]]], ["Antimicrobial resistance occurs when microorganisms (such as bacteria, fungi, viruses and parasites) change when they are exposed to antimicrobial drugs (such as antibiotics, antifungals, antivirals, antimalarials, and anthelmintics).", [["Antimicrobial resistance", "PROBLEM", 0, 24], ["microorganisms", "PROBLEM", 37, 51], ["bacteria", "PROBLEM", 61, 69], ["fungi", "PROBLEM", 71, 76], ["viruses", "PROBLEM", 78, 85], ["parasites", "PROBLEM", 90, 99], ["antimicrobial drugs", "TREATMENT", 133, 152], ["antibiotics", "TREATMENT", 162, 173], ["antifungals", "TREATMENT", 175, 186], ["antivirals", "TREATMENT", 188, 198], ["antimalarials", "TREATMENT", 200, 213], ["anthelmintics", "TREATMENT", 219, 232]]], ["As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others.", [["body", "ANATOMY", 76, 80], ["infections", "DISEASE", 50, 60], ["body", "ORGANISM_SUBDIVISION", 76, 80], ["the medicines", "TREATMENT", 13, 26], ["infections", "PROBLEM", 50, 60], ["ineffective", "OBSERVATION_MODIFIER", 34, 45], ["infections", "OBSERVATION", 50, 60], ["body", "ANATOMY", 76, 80]]], ["Without effective antimicrobials for prevention and treatment of infections, medical procedures such as organ transplantation, cancer chemotherapy, diabetes management and major surgery (for example, caesarean sections or hip replacements) become very high risk.", [["organ", "ANATOMY", 104, 109], ["cancer", "ANATOMY", 127, 133], ["sections", "ANATOMY", 210, 218], ["hip", "ANATOMY", 222, 225], ["infections", "DISEASE", 65, 75], ["cancer", "DISEASE", 127, 133], ["diabetes", "DISEASE", 148, 156], ["organ", "ORGAN", 104, 109], ["cancer", "CANCER", 127, 133], ["hip", "ORGANISM_SUBDIVISION", 222, 225], ["effective antimicrobials", "TREATMENT", 8, 32], ["treatment", "TREATMENT", 52, 61], ["infections", "PROBLEM", 65, 75], ["medical procedures", "TREATMENT", 77, 95], ["organ transplantation", "TREATMENT", 104, 125], ["cancer chemotherapy", "TREATMENT", 127, 146], ["diabetes management", "TREATMENT", 148, 167], ["major surgery", "TREATMENT", 172, 185], ["caesarean sections", "TREATMENT", 200, 218], ["hip replacements", "TREATMENT", 222, 238], ["very high risk", "PROBLEM", 247, 261], ["infections", "OBSERVATION", 65, 75], ["cancer", "OBSERVATION", 127, 133], ["hip", "ANATOMY", 222, 225]]], ["Beyond that, antimicrobial resistance increases the cost of health care with lengthier stays in hospitals and more intensive care required, as stated by World Health Organization (WHO) (1,3).IntroductionConsidering the health concern, nanotechnology offers potential opportunities to design effective medicines and vaccines for diseases treatment (4\u20136).", [["design effective medicines", "TREATMENT", 284, 310], ["vaccines", "TREATMENT", 315, 323], ["diseases treatment", "TREATMENT", 328, 346], ["antimicrobial resistance", "OBSERVATION", 13, 37]]], ["Nanotechnology is a multidisciplinary science field that studies the fabrication and application of structures with one of its dimensions less than 100 nm (7,8).", [["the fabrication", "TREATMENT", 65, 80], ["application of structures", "TREATMENT", 85, 110]]], ["The use of nanostructures in health area are desirable due to the fact that their size are 100 to 10000 times smaller than eukaryotic cells and similar size to the most biological molecules and structures including DNA, proteins, cell membranes and pathogenic microorganisms (9,10).", [["cells", "ANATOMY", 134, 139], ["cell membranes", "ANATOMY", 230, 244], ["cells", "CELL", 134, 139], ["DNA", "CELLULAR_COMPONENT", 215, 218], ["cell membranes", "CELLULAR_COMPONENT", 230, 244], ["eukaryotic cells", "CELL_TYPE", 123, 139], ["nanostructures in health area", "PROBLEM", 11, 40], ["DNA, proteins, cell membranes", "TEST", 215, 244], ["pathogenic microorganisms", "PROBLEM", 249, 274], ["nanostructures", "OBSERVATION_MODIFIER", 11, 25], ["size", "OBSERVATION_MODIFIER", 82, 86], ["size", "OBSERVATION_MODIFIER", 152, 156], ["most biological", "OBSERVATION_MODIFIER", 164, 179], ["molecules", "OBSERVATION", 180, 189], ["cell membranes", "OBSERVATION", 230, 244], ["pathogenic", "OBSERVATION_MODIFIER", 249, 259], ["microorganisms", "OBSERVATION_MODIFIER", 260, 274]]], ["In addition, the nanometric size can potentialize nanomaterials action and efficacy comprising an emerging tools to develop therapeutic agents, diagnosis systems, medical devices and drug delivery platforms including medicines and vaccines for infectious diseases treatment (8,11\u201314).IntroductionThe use of nanomaterials as carriers for controlled drug release has increasingly been explored due to their small size, high surface area and ability to pass through epithelial and endothelial barriers increasing drugs permeability without change its pharmacological properties (15\u201318).", [["surface area", "ANATOMY", 422, 434], ["epithelial", "ANATOMY", 463, 473], ["endothelial", "ANATOMY", 478, 489], ["infectious diseases", "DISEASE", 244, 263], ["epithelial", "TISSUE", 463, 473], ["endothelial", "CELL", 478, 489], ["therapeutic agents", "TREATMENT", 124, 142], ["medical devices", "TREATMENT", 163, 178], ["drug delivery platforms", "TREATMENT", 183, 206], ["medicines", "TREATMENT", 217, 226], ["vaccines", "TREATMENT", 231, 239], ["infectious diseases treatment", "TREATMENT", 244, 273], ["nanomaterials", "TREATMENT", 307, 320], ["controlled drug release", "TREATMENT", 337, 360], ["their small size", "PROBLEM", 399, 415], ["high surface area", "PROBLEM", 417, 434], ["epithelial and endothelial barriers increasing drugs permeability", "TREATMENT", 463, 528], ["nanometric", "OBSERVATION_MODIFIER", 17, 27], ["size", "OBSERVATION_MODIFIER", 28, 32], ["small", "OBSERVATION_MODIFIER", 405, 410], ["size", "OBSERVATION_MODIFIER", 411, 415], ["high", "OBSERVATION_MODIFIER", 417, 421], ["surface", "OBSERVATION_MODIFIER", 422, 429], ["endothelial", "ANATOMY", 478, 489]]], ["These nanosystems can reach the action site with considerable drugs concentration increasing their specific retention time reducing side effects (8,15\u201319).", [["These nanosystems", "TREATMENT", 0, 17], ["considerable drugs concentration", "TREATMENT", 49, 81]]], ["Nanoparticles can be produced from various materials such as amphiphilic structures, lipids, biodegradable polymers and inorganic compounds (1,2,16,20).", [["inorganic compounds", "CHEMICAL", 120, 139], ["Nanoparticles", "SIMPLE_CHEMICAL", 0, 13], ["lipids", "SIMPLE_CHEMICAL", 85, 91], ["biodegradable polymers", "SIMPLE_CHEMICAL", 93, 115], ["inorganic compounds", "SIMPLE_CHEMICAL", 120, 139], ["1,2,16,20", "SIMPLE_CHEMICAL", 141, 150], ["Nanoparticles", "TREATMENT", 0, 13], ["lipids, biodegradable polymers", "TREATMENT", 85, 115], ["biodegradable polymers", "OBSERVATION", 93, 115], ["inorganic compounds", "OBSERVATION", 120, 139]]], ["Specifically, inorganic platforms as mesoporous silica nanoparticles (MSNs) comprise a potential nanosystem for healthcare applications due to interesting characteristics such as easy functionalization, large surface area, high chemical and physical stabilities and hydroxyl groups available in their surface/pores.", [["surface area", "ANATOMY", 209, 221], ["surface", "ANATOMY", 301, 308], ["mesoporous silica", "CHEMICAL", 37, 54], ["MSNs", "CHEMICAL", 70, 74], ["hydroxyl", "CHEMICAL", 266, 274], ["silica", "CHEMICAL", 48, 54], ["hydroxyl", "CHEMICAL", 266, 274], ["mesoporous silica nanoparticles", "SIMPLE_CHEMICAL", 37, 68], ["MSNs", "SIMPLE_CHEMICAL", 70, 74], ["hydroxyl", "SIMPLE_CHEMICAL", 266, 274], ["surface", "CELLULAR_COMPONENT", 301, 308], ["pores", "CELLULAR_COMPONENT", 309, 314], ["inorganic platforms as mesoporous silica nanoparticles", "TREATMENT", 14, 68], ["healthcare applications", "TREATMENT", 112, 135], ["interesting characteristics", "PROBLEM", 143, 170], ["easy functionalization", "TREATMENT", 179, 201], ["large surface area", "PROBLEM", 203, 221], ["high chemical and physical stabilities", "PROBLEM", 223, 261], ["hydroxyl groups", "TREATMENT", 266, 281], ["large", "OBSERVATION_MODIFIER", 203, 208], ["surface", "OBSERVATION_MODIFIER", 209, 216]]], ["In addition, MSNs tunable morphology, size, surface charges and pores make them carriers with good biocompatibility and biodegradability, low toxicity, good biodistribution and elimination (12,21\u201327).", [["surface", "ANATOMY", 44, 51], ["toxicity", "DISEASE", 142, 150], ["MSNs", "SIMPLE_CHEMICAL", 13, 17], ["low toxicity", "PROBLEM", 138, 150], ["MSNs tunable", "OBSERVATION", 13, 25], ["morphology", "OBSERVATION_MODIFIER", 26, 36], ["size", "OBSERVATION_MODIFIER", 38, 42], ["low toxicity", "OBSERVATION_MODIFIER", 138, 150]]], ["Drugs loaded into MSNs pores leading to pharmacological properties maintenance besides protection against degradation and immediate drug release (23,24,28,29).IntroductionTaking into account that infectious diseases are a serious global public health concern and MSNs present several interesting properties that make them widely desirable to design controlled drug delivery systems, this review reports a brief overview of MSNs properties and their influence in biological behavior as well as highlights the advances in MSNs applications as multifunctional controlled drug release nanoplatforms for infectious diseases treatment.Infectious DiseasesInfectious diseases are those caused by pathogenic microorganisms such as bacteria, fungi, viruses and parasites, which invade host's cells in order to reproduce and thereby damage tissues causing disease.", [["MSNs pores", "ANATOMY", 18, 28], ["cells", "ANATOMY", 782, 787], ["tissues", "ANATOMY", 829, 836], ["infectious diseases", "DISEASE", 196, 215], ["infectious diseases", "DISEASE", 599, 618], ["Infectious diseases", "DISEASE", 648, 667], ["Drugs", "SIMPLE_CHEMICAL", 0, 5], ["MSNs", "SIMPLE_CHEMICAL", 263, 267], ["cells", "CELL", 782, 787], ["tissues", "TISSUE", 829, 836], ["Drugs", "TREATMENT", 0, 5], ["MSNs pores", "TREATMENT", 18, 28], ["pharmacological properties maintenance", "TREATMENT", 40, 78], ["infectious diseases", "PROBLEM", 196, 215], ["design controlled drug delivery systems", "TREATMENT", 342, 381], ["MSNs applications", "TREATMENT", 520, 537], ["multifunctional controlled drug release nanoplatforms", "TREATMENT", 541, 594], ["infectious diseases treatment", "TREATMENT", 599, 628], ["pathogenic microorganisms", "PROBLEM", 688, 713], ["bacteria", "PROBLEM", 722, 730], ["fungi", "PROBLEM", 732, 737], ["viruses", "PROBLEM", 739, 746], ["parasites", "PROBLEM", 751, 760], ["thereby damage tissues", "PROBLEM", 814, 836], ["disease", "PROBLEM", 845, 852], ["infectious", "OBSERVATION", 196, 206], ["damage tissues", "OBSERVATION", 822, 836]]], ["These diseases are transmitted directly or indirectly from person to person (30\u201332).", [["person", "SPECIES", 59, 65], ["person", "SPECIES", 69, 75], ["diseases", "OBSERVATION", 6, 14]]], ["Currently, infectious diseases are emerging at a global level and a rate never seen before, representing a challenge for the 21st century regarding to the discovery and development of new formulations (31,33).Infectious DiseasesThe WHO brings cholera, Ebola virus, influenza, meningitis, COVID-19, poliomyelitis, yellow fever as public health emergencies.", [["infectious diseases", "DISEASE", 11, 30], ["Infectious Diseases", "DISEASE", 209, 228], ["cholera", "DISEASE", 243, 250], ["Ebola virus", "DISEASE", 252, 263], ["influenza", "DISEASE", 265, 274], ["meningitis", "DISEASE", 276, 286], ["poliomyelitis", "DISEASE", 298, 311], ["yellow fever", "DISEASE", 313, 325], ["Ebola virus", "ORGANISM", 252, 263], ["Ebola virus", "SPECIES", 252, 263], ["Ebola virus", "SPECIES", 252, 263], ["a rate", "TEST", 66, 72], ["cholera", "PROBLEM", 243, 250], ["Ebola virus", "PROBLEM", 252, 263], ["influenza", "PROBLEM", 265, 274], ["meningitis", "PROBLEM", 276, 286], ["COVID", "TEST", 288, 293], ["poliomyelitis", "PROBLEM", 298, 311], ["yellow fever", "PROBLEM", 313, 325], ["infectious", "OBSERVATION", 11, 21], ["new", "OBSERVATION_MODIFIER", 184, 187], ["meningitis", "OBSERVATION", 276, 286]]], ["Five of them are caused by virus and two by bacteria (considering that the main meningitis causing agent is bacteria) (34).", [["meningitis", "DISEASE", 80, 90], ["virus", "PROBLEM", 27, 32], ["bacteria", "PROBLEM", 44, 52], ["the main meningitis", "PROBLEM", 71, 90], ["bacteria", "PROBLEM", 108, 116], ["virus", "OBSERVATION", 27, 32], ["main", "OBSERVATION_MODIFIER", 75, 79], ["meningitis", "OBSERVATION", 80, 90]]], ["This may explain the data obtained in Fig. 1, where the association of the keywords \u201cinfectious diseases and virus and new formulations\u201d recovered the largest number of manuscripts published in the period from 2000 to 2020, corresponding to 41%, followed by the association of the keywords \u201cinfectious diseases and bacteria and new formulations\u201d which are assigned to 28%.Infectious DiseasesBecause virus cannot reproduce or shows metabolism outside a host cell, it is not considered an organism, but rather particles, which are coated with a protein or lipid capsid.", [["cell", "ANATOMY", 457, 461], ["infectious diseases", "DISEASE", 85, 104], ["infectious diseases", "DISEASE", 291, 310], ["host cell", "CELL", 452, 461], ["lipid capsid", "PROTEIN", 554, 566], ["infectious diseases", "PROBLEM", 85, 104], ["virus", "PROBLEM", 109, 114], ["new formulations", "TREATMENT", 119, 135], ["infectious diseases", "PROBLEM", 291, 310], ["bacteria", "PROBLEM", 315, 323], ["new formulations", "TREATMENT", 328, 344], ["virus", "PROBLEM", 399, 404], ["a host cell", "PROBLEM", 450, 461], ["an organism", "PROBLEM", 484, 495], ["a protein or lipid capsid", "PROBLEM", 541, 566], ["largest", "OBSERVATION_MODIFIER", 151, 158], ["number", "OBSERVATION_MODIFIER", 159, 165], ["manuscripts", "OBSERVATION", 169, 180], ["host cell", "OBSERVATION", 452, 461], ["not considered", "UNCERTAINTY", 469, 483], ["organism", "OBSERVATION", 487, 495], ["lipid capsid", "OBSERVATION", 554, 566]]], ["As for the genetic material, they are divided into double or single stranded DNA viruses, or RNA, single or double stranded viruses (30).", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["the genetic material", "PROBLEM", 7, 27], ["double or single stranded DNA viruses", "PROBLEM", 51, 88], ["RNA", "PROBLEM", 93, 96], ["single or double stranded viruses", "PROBLEM", 98, 131], ["viruses", "OBSERVATION", 124, 131]]], ["Viruses listed as a public health emergency by the WHO, Ebola virus, influenza, COVID-19, poliomyelitis and yellow fever, are all single stranded RNA viruses (35\u201341).Infectious DiseasesCoronavirus, which causes COVID-19, is the current major threat due to its ability to spread quickly (35,42).", [["Ebola virus", "DISEASE", 56, 67], ["influenza", "DISEASE", 69, 78], ["poliomyelitis", "DISEASE", 90, 103], ["yellow fever", "DISEASE", 108, 120], ["Infectious DiseasesCoronavirus", "DISEASE", 166, 196], ["Ebola virus", "ORGANISM", 56, 67], ["COVID-19", "ORGANISM", 80, 88], ["yellow fever", "ORGANISM", 108, 120], ["Ebola virus", "SPECIES", 56, 67], ["yellow fever", "SPECIES", 108, 120], ["Ebola virus", "SPECIES", 56, 67], ["COVID-19", "SPECIES", 80, 88], ["Ebola virus", "PROBLEM", 56, 67], ["influenza", "PROBLEM", 69, 78], ["COVID", "TEST", 80, 85], ["poliomyelitis", "PROBLEM", 90, 103], ["yellow fever", "PROBLEM", 108, 120], ["all single stranded RNA viruses", "PROBLEM", 126, 157], ["Infectious DiseasesCoronavirus", "PROBLEM", 166, 196], ["COVID", "TEST", 211, 216], ["yellow fever", "OBSERVATION", 108, 120], ["RNA viruses", "OBSERVATION", 146, 157]]], ["Until May 31, 2020 5,956,883 confirmed cases (being that the largest number of cases are concentrated in the Americas) and 366,409 deaths worldwide, which shows the seriousness of this pandemic started in December 2019.", [["deaths", "DISEASE", 131, 137]]], ["Generally, this virus causes infection in the upper respiratory tract, or, in some patients in the lower respiratory tract, presenting fever, cough and headache as main symptoms (6,34,35,42,43).Infectious DiseasesIn the period of 2014-2016, worldwide efforts were focused on combating the outbreak caused by Ebola virus in West Africa, a severe hemorrhagic fever, fatal in many cases, the average mortality rate in this period was 50%.", [["upper respiratory tract", "ANATOMY", 46, 69], ["lower respiratory tract", "ANATOMY", 99, 122], ["infection in the upper respiratory tract", "DISEASE", 29, 69], ["lower respiratory tract", "DISEASE", 99, 122], ["fever", "DISEASE", 135, 140], ["cough", "DISEASE", 142, 147], ["headache", "DISEASE", 152, 160], ["Infectious Diseases", "DISEASE", 194, 213], ["Ebola virus", "DISEASE", 308, 319], ["hemorrhagic fever", "DISEASE", 345, 362], ["upper respiratory", "ORGANISM_SUBDIVISION", 46, 63], ["tract", "ORGANISM_SUBDIVISION", 64, 69], ["patients", "ORGANISM", 83, 91], ["lower", "ORGANISM_SUBDIVISION", 99, 104], ["respiratory tract", "ORGANISM_SUBDIVISION", 105, 122], ["Ebola virus", "ORGANISM", 308, 319], ["patients", "SPECIES", 83, 91], ["Ebola virus", "SPECIES", 308, 319], ["Ebola virus", "SPECIES", 308, 319], ["this virus", "PROBLEM", 11, 21], ["infection in the upper respiratory tract", "PROBLEM", 29, 69], ["fever", "PROBLEM", 135, 140], ["cough", "PROBLEM", 142, 147], ["headache", "PROBLEM", 152, 160], ["main symptoms", "PROBLEM", 164, 177], ["Ebola virus", "PROBLEM", 308, 319], ["a severe hemorrhagic fever", "PROBLEM", 336, 362], ["infection", "OBSERVATION", 29, 38], ["upper", "ANATOMY_MODIFIER", 46, 51], ["respiratory tract", "ANATOMY", 52, 69], ["lower", "ANATOMY_MODIFIER", 99, 104], ["respiratory tract", "ANATOMY", 105, 122], ["fever", "OBSERVATION", 135, 140], ["Ebola virus", "OBSERVATION", 308, 319], ["severe", "OBSERVATION_MODIFIER", 338, 344], ["hemorrhagic", "OBSERVATION_MODIFIER", 345, 356], ["fever", "OBSERVATION", 357, 362], ["fatal", "OBSERVATION_MODIFIER", 364, 369]]], ["Although the outbreak period has passed, there is currently a great concern related to the persistence of this virus in the reproductive tract of male people who survived this disease (34,37,44).Infectious DiseasesThe yellow fever virus, transmitted by mosquitoes of the genera Haemagogus and Aedes, was the cause of severe epidemics that occurred in the 17th, 18th and 19th centuries.", [["Infectious Diseases", "DISEASE", 195, 214], ["yellow fever", "DISEASE", 218, 230], ["reproductive tract", "ORGANISM_SUBDIVISION", 124, 142], ["people", "ORGANISM", 151, 157], ["yellow fever virus", "ORGANISM", 218, 236], ["people", "SPECIES", 151, 157], ["yellow fever virus", "SPECIES", 218, 236], ["yellow fever virus", "SPECIES", 218, 236], ["this virus", "PROBLEM", 106, 116], ["this disease", "PROBLEM", 171, 183], ["Infectious Diseases", "PROBLEM", 195, 214], ["The yellow fever virus", "PROBLEM", 214, 236], ["severe epidemics", "PROBLEM", 317, 333], ["yellow", "OBSERVATION_MODIFIER", 218, 224], ["fever virus", "OBSERVATION", 225, 236], ["severe", "OBSERVATION_MODIFIER", 317, 323], ["epidemics", "OBSERVATION", 324, 333]]], ["In the 1930s, fundamental vaccines were developed to contain this disease, but it is not the same that is used nowadays due to the appearance of adverse reactions.", [["fundamental vaccines", "TREATMENT", 14, 34], ["this disease", "PROBLEM", 61, 73], ["adverse reactions", "PROBLEM", 145, 162]]], ["Even with the vaccine, this disease is still epidemic in many regions such as Africa and South America.", [["the vaccine", "TREATMENT", 10, 21], ["this disease", "PROBLEM", 23, 35], ["disease", "OBSERVATION", 28, 35], ["epidemic", "OBSERVATION_MODIFIER", 45, 53]]], ["It is a severe acute disease that presents as symptoms fever, epigastric pain, nausea, vomiting, renal failure, hepatitis accompanied by jaundice, hemorrhage, shock and death in 20-60% of cases (34,40,45,46).Infectious DiseasesIn the years 1918 and 1919, the influenza virus was the cause of a pandemic that caused about 20 to 50 million fatal victims worldwide (47).", [["epigastric", "ANATOMY", 62, 72], ["renal", "ANATOMY", 97, 102], ["fever", "DISEASE", 55, 60], ["epigastric pain", "DISEASE", 62, 77], ["nausea", "DISEASE", 79, 85], ["vomiting", "DISEASE", 87, 95], ["renal failure", "DISEASE", 97, 110], ["hepatitis", "DISEASE", 112, 121], ["jaundice", "DISEASE", 137, 145], ["hemorrhage", "DISEASE", 147, 157], ["shock", "DISEASE", 159, 164], ["death", "DISEASE", 169, 174], ["Infectious Diseases", "DISEASE", 208, 227], ["influenza virus", "DISEASE", 259, 274], ["epigastric", "ORGANISM_SUBDIVISION", 62, 72], ["renal", "ORGAN", 97, 102], ["influenza virus", "ORGANISM", 259, 274], ["influenza virus", "SPECIES", 259, 274], ["influenza virus", "SPECIES", 259, 274], ["a severe acute disease", "PROBLEM", 6, 28], ["symptoms", "PROBLEM", 46, 54], ["fever", "PROBLEM", 55, 60], ["epigastric pain", "PROBLEM", 62, 77], ["nausea", "PROBLEM", 79, 85], ["vomiting", "PROBLEM", 87, 95], ["renal failure", "PROBLEM", 97, 110], ["hepatitis", "PROBLEM", 112, 121], ["jaundice", "PROBLEM", 137, 145], ["hemorrhage", "PROBLEM", 147, 157], ["shock", "PROBLEM", 159, 164], ["death", "PROBLEM", 169, 174], ["the influenza virus", "PROBLEM", 255, 274], ["a pandemic", "PROBLEM", 292, 302], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["disease", "OBSERVATION", 21, 28], ["epigastric", "ANATOMY", 62, 72], ["pain", "OBSERVATION", 73, 77], ["nausea", "OBSERVATION", 79, 85], ["renal", "ANATOMY", 97, 102], ["failure", "OBSERVATION", 103, 110], ["hepatitis", "OBSERVATION", 112, 121], ["jaundice", "OBSERVATION", 137, 145], ["hemorrhage", "OBSERVATION", 147, 157], ["shock", "OBSERVATION_MODIFIER", 159, 164]]], ["This pandemic causing strain was the influenza virus type A, which has the subtypes H1N1, H3N2 and H5N1, although influenza virus type B and type C are also infectious in humans (41,48).", [["H3N2", "DISEASE", 90, 94], ["H5N1", "DISEASE", 99, 103], ["influenza virus type B", "DISEASE", 114, 136], ["influenza virus type A", "ORGANISM", 37, 59], ["H3N2", "ORGANISM", 90, 94], ["H5N1", "ORGANISM", 99, 103], ["influenza virus type B", "ORGANISM", 114, 136], ["type C", "ORGANISM", 141, 147], ["humans", "ORGANISM", 171, 177], ["influenza virus", "SPECIES", 37, 52], ["H3N2 and H5N1", "SPECIES", 90, 103], ["influenza virus", "SPECIES", 114, 129], ["humans", "SPECIES", 171, 177], ["influenza virus type A", "SPECIES", 37, 59], ["humans", "SPECIES", 171, 177], ["strain", "PROBLEM", 22, 28], ["the influenza virus type A", "PROBLEM", 33, 59], ["H1N1", "PROBLEM", 84, 88], ["H3N2", "PROBLEM", 90, 94], ["H5N1", "PROBLEM", 99, 103], ["influenza virus type B", "PROBLEM", 114, 136], ["type C", "PROBLEM", 141, 147], ["influenza virus", "OBSERVATION", 37, 52], ["H5N1", "OBSERVATION", 99, 103], ["influenza virus", "OBSERVATION", 114, 129], ["infectious", "OBSERVATION_MODIFIER", 157, 167]]], ["Nowadays, the major concern consists on prevents and controls this seasonal disease in order to avoid new influenza pandemics from happening (34).Infectious DiseasesPoliomyelitis is a disease that has been plaguing humanity for centuries, its first clinical description dates from 1789, being that only in 1955 the first vaccine was developed (49).", [["influenza", "DISEASE", 106, 115], ["Infectious DiseasesPoliomyelitis", "DISEASE", 146, 178], ["this seasonal disease", "PROBLEM", 62, 83], ["new influenza pandemics", "PROBLEM", 102, 125], ["Infectious DiseasesPoliomyelitis", "PROBLEM", 146, 178], ["a disease", "PROBLEM", 182, 191]]], ["Children are the most affected by this disease, which can affect the nervous system and cause paralysis.", [["nervous system", "ANATOMY", 69, 83], ["paralysis", "DISEASE", 94, 103], ["Children", "ORGANISM", 0, 8], ["nervous system", "ANATOMICAL_SYSTEM", 69, 83], ["Children", "SPECIES", 0, 8], ["this disease", "PROBLEM", 34, 46], ["paralysis", "PROBLEM", 94, 103], ["most affected", "OBSERVATION_MODIFIER", 17, 30], ["disease", "OBSERVATION", 39, 46], ["paralysis", "OBSERVATION", 94, 103]]], ["Nowadays, it is endemic in areas of Afghanistan and Pakistan, and in the period of 10 years, 200,000 new cases were observed, probably due to failures in strategic actions implementation, leading to a high transmission of this virus (34).Infectious DiseasesBacteria, another infectious disease causative agent, are prokaryotic single-cell microorganisms.", [["Infectious DiseasesBacteria", "DISEASE", 238, 265], ["single-cell", "CELL", 327, 338], ["failures in strategic actions implementation", "PROBLEM", 142, 186], ["a high transmission of this virus", "PROBLEM", 199, 232], ["Infectious DiseasesBacteria", "PROBLEM", 238, 265], ["another infectious disease causative agent", "PROBLEM", 267, 309], ["prokaryotic single-cell microorganisms", "PROBLEM", 315, 353], ["endemic", "OBSERVATION_MODIFIER", 16, 23], ["probably due to", "UNCERTAINTY", 126, 141], ["failures", "OBSERVATION", 142, 150], ["infectious", "OBSERVATION_MODIFIER", 275, 285], ["cell microorganisms", "OBSERVATION", 334, 353]]], ["They are classified according to their morphology and the Gram stain reaction (30).", [["the Gram stain reaction", "TEST", 54, 77]]], ["An example of a bacterial infectious disease would be cholera, caused by Vibrio cholerae, a gram-negative bacterium.", [["bacterial infectious disease", "DISEASE", 16, 44], ["cholera", "DISEASE", 54, 61], ["Vibrio cholerae", "DISEASE", 73, 88], ["Vibrio cholerae", "ORGANISM", 73, 88], ["Vibrio cholerae", "SPECIES", 73, 88], ["Vibrio cholerae", "SPECIES", 73, 88], ["a bacterial infectious disease", "PROBLEM", 14, 44], ["cholera", "PROBLEM", 54, 61], ["Vibrio cholerae", "PROBLEM", 73, 88], ["a gram", "TEST", 90, 96], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["infectious", "OBSERVATION", 26, 36], ["negative bacterium", "OBSERVATION", 97, 115]]], ["It is an old disease, which has been the cause of seven pandemics throughout human history, the first being dated in 1817 (50,51).Infectious DiseasesCholera is considered serious because it is the cause of acute watery diarrhea and severe dehydration.", [["Infectious DiseasesCholera", "DISEASE", 130, 156], ["diarrhea", "DISEASE", 219, 227], ["dehydration", "DISEASE", 239, 250], ["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["an old disease", "PROBLEM", 6, 20], ["acute watery diarrhea", "PROBLEM", 206, 227], ["severe dehydration", "PROBLEM", 232, 250], ["old", "OBSERVATION_MODIFIER", 9, 12], ["disease", "OBSERVATION", 13, 20], ["seven", "OBSERVATION_MODIFIER", 50, 55], ["pandemics", "OBSERVATION", 56, 65], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["watery", "OBSERVATION_MODIFIER", 212, 218], ["diarrhea", "OBSERVATION", 219, 227], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["dehydration", "OBSERVATION", 239, 250]]], ["Currently, cholera still is considered a serious public health problem by the WHO, being contracted by the ingestion of contaminated water or food and considered a social inequality indicator.", [["cholera", "DISEASE", 11, 18], ["serious", "OBSERVATION_MODIFIER", 41, 48]]], ["It is responsible for 21,000 to 143,000 deaths per year, in areas such as Asia, Africa and the Americas, where this disease only evolves (34,51).Infectious DiseasesMeningitis is another bacterial disease considered by WHO as an emergency, although also caused by fungi and viruses, the most frequent cause is bacterial.", [["deaths", "DISEASE", 40, 46], ["Meningitis", "DISEASE", 164, 174], ["bacterial disease", "DISEASE", 186, 203], ["this disease", "PROBLEM", 111, 123], ["Meningitis", "PROBLEM", 164, 174], ["another bacterial disease", "PROBLEM", 178, 203], ["fungi", "PROBLEM", 263, 268], ["viruses", "PROBLEM", 273, 280], ["bacterial", "PROBLEM", 309, 318], ["bacterial disease", "OBSERVATION", 186, 203], ["viruses", "OBSERVATION", 273, 280], ["bacterial", "OBSERVATION", 309, 318]]], ["Neisseria meningitidis and Streptococcus pneumoniae are the largely responsible for the threat to public health related to this disease.", [["Neisseria meningitidis", "DISEASE", 0, 22], ["Streptococcus pneumoniae", "DISEASE", 27, 51], ["Neisseria meningitidis", "ORGANISM", 0, 22], ["Streptococcus pneumoniae", "ORGANISM", 27, 51], ["Neisseria meningitidis", "SPECIES", 0, 22], ["Streptococcus pneumoniae", "SPECIES", 27, 51], ["Neisseria meningitidis", "SPECIES", 0, 22], ["Streptococcus pneumoniae", "SPECIES", 27, 51], ["Neisseria meningitidis", "PROBLEM", 0, 22], ["Streptococcus pneumoniae", "PROBLEM", 27, 51], ["this disease", "PROBLEM", 123, 135], ["meningitidis", "OBSERVATION", 10, 22], ["Streptococcus pneumoniae", "OBSERVATION", 27, 51]]], ["Meningitis has high morbidity due to the inflammatory response resulting from their passage through the blood-brain barrier causing inflammation in the meninges and brain edema, leading to neurological sequelae in this disease survivors (34,52,53).Infectious DiseasesAlthough fungal and parasitic diseases are not placed as a public health emergency by WHO, it is worth noting that fungi, single or multi-celled eukaryotic microorganisms, cause infections ranging from superficial and mucous membranes to systemic infections, which can lead the patient to death.", [["blood-brain barrier", "ANATOMY", 104, 123], ["meninges", "ANATOMY", 152, 160], ["brain", "ANATOMY", 165, 170], ["neurological", "ANATOMY", 189, 201], ["superficial", "ANATOMY", 469, 480], ["mucous membranes", "ANATOMY", 485, 501], ["Meningitis", "DISEASE", 0, 10], ["inflammation", "DISEASE", 132, 144], ["brain edema", "DISEASE", 165, 176], ["neurological sequelae", "DISEASE", 189, 210], ["Infectious Diseases", "DISEASE", 248, 267], ["fungal and parasitic diseases", "DISEASE", 276, 305], ["infections", "DISEASE", 445, 455], ["systemic infections", "DISEASE", 505, 524], ["death", "DISEASE", 556, 561], ["blood", "MULTI-TISSUE_STRUCTURE", 104, 109], ["brain barrier", "TISSUE", 110, 123], ["meninges", "ORGAN", 152, 160], ["brain", "ORGAN", 165, 170], ["edema", "PATHOLOGICAL_FORMATION", 171, 176], ["superficial", "TISSUE", 469, 480], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 485, 501], ["patient", "ORGANISM", 545, 552], ["patient", "SPECIES", 545, 552], ["Meningitis", "PROBLEM", 0, 10], ["high morbidity", "PROBLEM", 15, 29], ["the inflammatory response", "PROBLEM", 37, 62], ["the blood", "TEST", 100, 109], ["inflammation in the meninges", "PROBLEM", 132, 160], ["brain edema", "PROBLEM", 165, 176], ["neurological sequelae", "PROBLEM", 189, 210], ["this disease survivors", "PROBLEM", 214, 236], ["fungal", "PROBLEM", 276, 282], ["parasitic diseases", "PROBLEM", 287, 305], ["fungi", "PROBLEM", 382, 387], ["single or multi-celled eukaryotic microorganisms", "PROBLEM", 389, 437], ["infections", "PROBLEM", 445, 455], ["superficial and mucous membranes", "PROBLEM", 469, 501], ["systemic infections", "PROBLEM", 505, 524], ["death", "PROBLEM", 556, 561], ["high", "OBSERVATION_MODIFIER", 15, 19], ["morbidity", "OBSERVATION", 20, 29], ["inflammatory", "OBSERVATION", 41, 53], ["brain", "ANATOMY", 110, 115], ["inflammation", "OBSERVATION", 132, 144], ["meninges", "ANATOMY", 152, 160], ["brain", "ANATOMY", 165, 170], ["edema", "OBSERVATION", 171, 176], ["neurological", "OBSERVATION_MODIFIER", 189, 201], ["sequelae", "OBSERVATION_MODIFIER", 202, 210], ["fungal", "OBSERVATION_MODIFIER", 276, 282], ["parasitic diseases", "OBSERVATION", 287, 305], ["infections", "OBSERVATION", 445, 455], ["superficial", "OBSERVATION_MODIFIER", 469, 480], ["mucous membranes", "ANATOMY", 485, 501], ["systemic", "OBSERVATION_MODIFIER", 505, 513], ["infections", "OBSERVATION", 514, 524]]], ["Fungal diseases epidemiology is difficult to measure, as they are often underdiagnosed (7,30,54).Infectious DiseasesAs for parasitic diseases, they are caused by protozoa (single-celled eukaryotic cells) and helminths (invertebrate animals) (30,55).", [["cells", "ANATOMY", 197, 202], ["Fungal diseases", "DISEASE", 0, 15], ["parasitic diseases", "DISEASE", 123, 141], ["cells", "CELL", 197, 202], ["eukaryotic cells", "CELL_TYPE", 186, 202], ["Fungal diseases epidemiology", "PROBLEM", 0, 28], ["parasitic diseases", "PROBLEM", 123, 141], ["protozoa", "PROBLEM", 162, 170], ["diseases", "OBSERVATION", 7, 15], ["difficult to measure", "OBSERVATION_MODIFIER", 32, 52], ["parasitic diseases", "OBSERVATION", 123, 141]]], ["Parasitic diseases are a public health concern that affects humans throughout history, leading to the millions death of people annually (56,57).Infectious DiseasesFaced with the human being fragility in relation to the severity of some infectious diseases that prove to be a worldwide public health problem, the current scenario in which the planet finds itself sparing no effort in order to face a pandemic or even in the fight against resistant microorganisms, considering the new formulations development essential.", [["Parasitic diseases", "DISEASE", 0, 18], ["death", "DISEASE", 111, 116], ["Infectious Diseases", "DISEASE", 144, 163], ["infectious diseases", "DISEASE", 236, 255], ["humans", "ORGANISM", 60, 66], ["people", "ORGANISM", 120, 126], ["human", "ORGANISM", 178, 183], ["humans", "SPECIES", 60, 66], ["people", "SPECIES", 120, 126], ["human", "SPECIES", 178, 183], ["humans", "SPECIES", 60, 66], ["human", "SPECIES", 178, 183], ["Parasitic diseases", "PROBLEM", 0, 18], ["some infectious diseases", "PROBLEM", 231, 255], ["a pandemic", "PROBLEM", 397, 407], ["resistant microorganisms", "PROBLEM", 437, 461], ["diseases", "OBSERVATION", 10, 18], ["infectious", "OBSERVATION", 236, 246]]], ["In light of this, the drugs association with promising nanocarriers such as MSNs is fundamental to achieve new smart nanotherapeutics systems for all aforementioned diseases (12,20,58\u201360).Synthesis and Types of Mesoporous Silica Nanoparticles ::: Mesoporous Silica NanoparticlesNeed for materials with high thermal, chemical and mechanical properties have led to the development of MSNs.", [["MSNs", "CHEMICAL", 76, 80], ["Silica", "CHEMICAL", 222, 228], ["Silica", "CHEMICAL", 258, 264], ["MSNs", "SIMPLE_CHEMICAL", 76, 80], ["Mesoporous Silica Nanoparticles", "SIMPLE_CHEMICAL", 211, 242], ["Silica Nanoparticles", "SIMPLE_CHEMICAL", 258, 278], ["MSNs", "CELL", 382, 386], ["promising nanocarriers", "PROBLEM", 45, 67], ["all aforementioned diseases", "PROBLEM", 146, 173], ["Synthesis and Types of Mesoporous Silica Nanoparticles", "TREATMENT", 188, 242], ["Mesoporous Silica Nanoparticles", "TREATMENT", 247, 278], ["materials", "TREATMENT", 287, 296], ["chemical and mechanical properties", "TREATMENT", 316, 350], ["MSNs", "PROBLEM", 382, 386], ["Mesoporous Silica Nanoparticles", "OBSERVATION", 211, 242], ["Silica Nanoparticles", "OBSERVATION", 258, 278]]], ["As per IUPAC, mesoporous materials are define as the one having a pore size in the range of 2-50 nm and an ordered arrangement of pores giving an ordered structure to it (61,62).", [["pore", "ANATOMY", 66, 70], ["a pore size", "TEST", 64, 75], ["an ordered arrangement of pores", "TREATMENT", 104, 135], ["an ordered structure", "TREATMENT", 143, 163], ["pore", "OBSERVATION_MODIFIER", 66, 70], ["size", "OBSERVATION_MODIFIER", 71, 75]]], ["Mobil Research and Development Corporation was the first to synthesize mesoporous solids from aluminosilicate gels using liquid crystal template mechanism in the year 1992.", [["aluminosilicate", "CHEMICAL", 94, 109], ["aluminosilicate", "CHEMICAL", 94, 109], ["aluminosilicate", "SIMPLE_CHEMICAL", 94, 109], ["synthesize mesoporous solids from aluminosilicate gels", "TREATMENT", 60, 114], ["liquid crystal template mechanism", "TREATMENT", 121, 154]]], ["They designated it as (Mobil Crystalline Materials or Mobil Composition of Matter) MCM-41.", [["MCM-41", "CHEMICAL", 83, 89], ["Mobil Crystalline Materials", "TREATMENT", 23, 50], ["MCM", "TEST", 83, 86]]], ["The pore size of the mesoporous materials could be varied and tuned through the choice of surfactants used.", [["pore", "ANATOMY", 4, 8], ["the mesoporous materials", "TREATMENT", 17, 41], ["surfactants", "TREATMENT", 90, 101], ["pore", "OBSERVATION_MODIFIER", 4, 8], ["size", "OBSERVATION_MODIFIER", 9, 13], ["mesoporous materials", "OBSERVATION", 21, 41]]], ["MCM-41 is hexagonal with a pore diameter from 2.5 to 6 nm wherein cationic surfactants were used as templates.", [["pore", "ANATOMY", 27, 31], ["MCM-41", "CHEMICAL", 0, 6], ["MCM-41", "CHEMICAL", 0, 6], ["cationic surfactants", "SIMPLE_CHEMICAL", 66, 86], ["a pore diameter", "TREATMENT", 25, 40], ["6 nm wherein cationic surfactants", "TREATMENT", 53, 86], ["hexagonal", "OBSERVATION_MODIFIER", 10, 19], ["pore", "OBSERVATION_MODIFIER", 27, 31], ["diameter", "OBSERVATION_MODIFIER", 32, 40]]], ["Various other materials of mesoporous nature have also been synthesized by varying the starting precursors and reaction conditions.", [["reaction conditions", "PROBLEM", 111, 130]]], ["These mesoporous materials may vary in their structural arrangement or the pore size.", [["pore", "ANATOMY", 75, 79], ["These mesoporous materials", "TREATMENT", 0, 26], ["mesoporous materials", "OBSERVATION", 6, 26], ["structural", "OBSERVATION_MODIFIER", 45, 55], ["arrangement", "OBSERVATION_MODIFIER", 56, 67], ["pore", "OBSERVATION_MODIFIER", 75, 79], ["size", "OBSERVATION_MODIFIER", 80, 84]]], ["MCM-48 has a cubic arrangement whereas MCM-50 has a lamella-like arrangement (61,63).", [["MCM-48", "CHEMICAL", 0, 6], ["MCM-50", "CHEMICAL", 39, 45], ["MCM-48", "CHEMICAL", 0, 6], ["MCM-50", "CHEMICAL", 39, 45]]], ["Non-ionic triblock copolymers like alkyl poly(ethylene oxide) (PEO) oligomeric surfactants and poly(alkylene oxide) block copolymers have also been used by University of California, Santa Barbara for synthesized the named Santa Barbara Amorphous materials (SBA).", [["triblock copolymers", "CHEMICAL", 10, 29], ["alkyl poly(ethylene oxide", "CHEMICAL", 35, 60], ["PEO", "CHEMICAL", 63, 66], ["poly(alkylene oxide", "CHEMICAL", 95, 114], ["alkyl poly(ethylene oxide)", "CHEMICAL", 35, 61], ["PEO", "CHEMICAL", 63, 66], ["poly(alkylene oxide)", "CHEMICAL", 95, 115], ["Non-ionic triblock copolymers", "SIMPLE_CHEMICAL", 0, 29], ["alkyl poly(ethylene oxide) (PEO) oligomeric surfactants", "SIMPLE_CHEMICAL", 35, 90], ["poly(alkylene oxide) block copolymers", "SIMPLE_CHEMICAL", 95, 132], ["Non-ionic triblock copolymers", "TREATMENT", 0, 29], ["alkyl poly(ethylene oxide) (PEO) oligomeric surfactants", "TREATMENT", 35, 90], ["poly(alkylene oxide) block copolymers", "TREATMENT", 95, 132]]], ["The ratio of ethylene oxide to propylene oxide was varied to achieve the desired symmetry of mesoporous materials (SBA-11 (cubic), SBA-12 (3-d hexagonal), SBA-15 (hexagonal) and SBA-16 (cubic cage-structured) (61).", [["ethylene oxide", "CHEMICAL", 13, 27], ["propylene oxide", "CHEMICAL", 31, 46], ["SBA-11", "CHEMICAL", 115, 121], ["ethylene oxide", "CHEMICAL", 13, 27], ["propylene oxide", "CHEMICAL", 31, 46], ["SBA-11", "CHEMICAL", 115, 121], ["SBA-12", "CHEMICAL", 131, 137], ["SBA-15", "CHEMICAL", 155, 161], ["SBA-16", "CHEMICAL", 178, 184], ["ethylene oxide", "SIMPLE_CHEMICAL", 13, 27], ["propylene oxide", "SIMPLE_CHEMICAL", 31, 46], ["SBA-11", "SIMPLE_CHEMICAL", 115, 121], ["SBA-12", "SIMPLE_CHEMICAL", 131, 137], ["3-d hexagonal)", "SIMPLE_CHEMICAL", 139, 153], ["SBA-15", "SIMPLE_CHEMICAL", 155, 161], ["SBA-16", "SIMPLE_CHEMICAL", 178, 184], ["The ratio of ethylene oxide to propylene oxide", "TREATMENT", 0, 46], ["SBA", "TEST", 115, 118], ["SBA", "TEST", 131, 134], ["SBA", "TEST", 155, 158], ["SBA", "TEST", 178, 181], ["ethylene oxide", "OBSERVATION", 13, 27]]], ["This is different from MCM in that they possess larger pores of 4.6-30 nm and thicker silica walls.", [["MCM", "CHEMICAL", 23, 26], ["silica", "CHEMICAL", 86, 92], ["different", "OBSERVATION_MODIFIER", 8, 17], ["from MCM", "OBSERVATION_MODIFIER", 18, 26], ["larger", "OBSERVATION_MODIFIER", 48, 54], ["pores", "OBSERVATION_MODIFIER", 55, 60], ["4.6-30 nm", "OBSERVATION_MODIFIER", 64, 73], ["silica", "ANATOMY_MODIFIER", 86, 92], ["walls", "ANATOMY_MODIFIER", 93, 98]]], ["FSM-16, that is, folded sheets of mesoporous materials are another type of mesoporous materials, which are synthesized using quaternary ammonium surfactant as a template and layered polysilicate kanemite (64).", [["quaternary ammonium", "CHEMICAL", 125, 144], ["polysilicate kanemite", "CHEMICAL", 182, 203], ["FSM-16", "CHEMICAL", 0, 6], ["ammonium", "CHEMICAL", 136, 144], ["polysilicate kanemite", "CHEMICAL", 182, 203], ["quaternary ammonium surfactant", "SIMPLE_CHEMICAL", 125, 155], ["layered polysilicate kanemite", "SIMPLE_CHEMICAL", 174, 203], ["FSM", "TEST", 0, 3], ["mesoporous materials", "TREATMENT", 34, 54], ["mesoporous materials", "PROBLEM", 75, 95], ["quaternary ammonium surfactant", "TREATMENT", 125, 155], ["a template and layered polysilicate kanemite", "TREATMENT", 159, 203], ["mesoporous materials", "OBSERVATION", 34, 54], ["mesoporous materials", "OBSERVATION", 75, 95]]], ["Various other MSNs have been synthesized which vary in their pore symmetry and shape, TUD-1 (Technical Delft University), HMM-33 (Hiroshima Mesoporous Material-33), COK-12 (Centrum Voor Oppervlaktechemie en Katalyse/Centre for Research Chemistry and Catalysis) (65).", [["pore", "ANATOMY", 61, 65], ["MSNs", "CELL", 14, 18], ["MSNs", "DNA", 14, 18], ["TUD", "TEST", 86, 89], ["HMM", "TEST", 122, 125], ["Hiroshima Mesoporous Material", "TEST", 130, 159], ["COK", "TEST", 165, 168], ["Research Chemistry", "TEST", 227, 245], ["Catalysis", "TEST", 250, 259], ["MSNs", "OBSERVATION", 14, 18], ["vary", "OBSERVATION_MODIFIER", 47, 51], ["pore symmetry", "OBSERVATION_MODIFIER", 61, 74], ["shape", "OBSERVATION_MODIFIER", 79, 84]]], ["The schematic representation of several MSNs structures is shown in Fig. 2 as well as structural characteristics and applications of some mesoporous materials are listed in Table I.Synthesis and Types of Mesoporous Silica Nanoparticles ::: Mesoporous Silica NanoparticlesMSNs are characterized by high surface area and large pore volume, uniform and tunable pore size, facile surface functionalization and a stable and rigid framework (71).Synthesis and Types of Mesoporous Silica Nanoparticles ::: Mesoporous Silica NanoparticlesMSNs are commonly prepared by sol-gel \u201cchimie douce\u201d process in aqueous solution.", [["MSNs structures", "ANATOMY", 40, 55], ["surface", "ANATOMY", 302, 309], ["pore", "ANATOMY", 325, 329], ["pore", "ANATOMY", 358, 362], ["surface", "ANATOMY", 376, 383], ["Silica", "CHEMICAL", 251, 257], ["Silica", "CHEMICAL", 510, 516], ["Silica", "CHEMICAL", 215, 221], ["Silica", "CHEMICAL", 251, 257], ["Silica", "CHEMICAL", 474, 480], ["Silica", "CHEMICAL", 510, 516], ["Mesoporous Silica Nanoparticles", "SIMPLE_CHEMICAL", 204, 235], ["Silica NanoparticlesMSNs", "SIMPLE_CHEMICAL", 251, 275], ["Mesoporous Silica Nanoparticles", "SIMPLE_CHEMICAL", 463, 494], ["Silica NanoparticlesMSNs", "SIMPLE_CHEMICAL", 510, 534], ["chimie", "SIMPLE_CHEMICAL", 569, 575], ["douce", "SIMPLE_CHEMICAL", 576, 581], ["some mesoporous materials", "TREATMENT", 133, 158], ["Mesoporous Silica NanoparticlesMSNs", "TEST", 240, 275], ["high surface area", "PROBLEM", 297, 314], ["large pore volume", "PROBLEM", 319, 336], ["uniform and tunable pore size", "PROBLEM", 338, 367], ["facile surface functionalization", "TREATMENT", 369, 401], ["Mesoporous Silica NanoparticlesMSNs", "TREATMENT", 499, 534], ["several", "OBSERVATION_MODIFIER", 32, 39], ["MSNs structures", "OBSERVATION", 40, 55], ["Fig", "OBSERVATION_MODIFIER", 68, 71], ["Mesoporous", "OBSERVATION", 204, 214], ["Silica Nanoparticles", "OBSERVATION", 215, 235], ["Silica NanoparticlesMSNs", "OBSERVATION", 251, 275], ["high", "OBSERVATION_MODIFIER", 297, 301], ["surface", "OBSERVATION_MODIFIER", 302, 309], ["area", "OBSERVATION_MODIFIER", 310, 314], ["large", "OBSERVATION_MODIFIER", 319, 324], ["pore volume", "OBSERVATION", 325, 336], ["uniform", "OBSERVATION_MODIFIER", 338, 345], ["tunable", "OBSERVATION_MODIFIER", 350, 357], ["pore", "OBSERVATION_MODIFIER", 358, 362], ["size", "OBSERVATION_MODIFIER", 363, 367], ["facile", "OBSERVATION_MODIFIER", 369, 375], ["surface functionalization", "OBSERVATION", 376, 401], ["stable", "OBSERVATION_MODIFIER", 408, 414], ["Mesoporous Silica Nanoparticles", "OBSERVATION", 463, 494], ["Silica NanoparticlesMSNs", "OBSERVATION", 510, 534]]], ["This process involves the synthesis of an inorganic polymeric network at low temperature, being the gel formed from a colloidal suspension or by hydrolysis and subsequent condensation of an silica precursor (Si(OEt)4), generally the most used is a tetraethyl orthosilicate, TEOS, in solution.", [["silica", "CHEMICAL", 190, 196], ["Si(OEt)4", "CHEMICAL", 208, 216], ["tetraethyl orthosilicate", "CHEMICAL", 248, 272], ["TEOS", "CHEMICAL", 274, 278], ["silica", "CHEMICAL", 190, 196], ["Si(OEt)4", "CHEMICAL", 208, 216], ["tetraethyl orthosilicate", "CHEMICAL", 248, 272], ["TEOS", "CHEMICAL", 274, 278], ["silica precursor", "SIMPLE_CHEMICAL", 190, 206], ["Si(OEt)4", "SIMPLE_CHEMICAL", 208, 216], ["tetraethyl orthosilicate", "SIMPLE_CHEMICAL", 248, 272], ["TEOS", "SIMPLE_CHEMICAL", 274, 278], ["an inorganic polymeric network", "TREATMENT", 39, 69], ["low temperature", "PROBLEM", 73, 88], ["a colloidal suspension", "TREATMENT", 116, 138], ["hydrolysis", "PROBLEM", 145, 155], ["an silica precursor (Si(OEt)", "TREATMENT", 187, 215], ["a tetraethyl orthosilicate", "TREATMENT", 246, 272], ["TEOS", "TREATMENT", 274, 278], ["low temperature", "OBSERVATION_MODIFIER", 73, 88], ["silica precursor", "OBSERVATION", 190, 206]]], ["In hydrolysis reactions, the alkoxide group (OR) of the silica precursor is replaced by the silanol group (Si-OH), forming an alcohol in parallel, due to the nucleophilic attack of the oxygen atom of the water hydroxyl group (72,73).", [["alkoxide", "CHEMICAL", 29, 37], ["silica", "CHEMICAL", 56, 62], ["silanol", "CHEMICAL", 92, 99], ["Si-OH", "CHEMICAL", 107, 112], ["alcohol", "CHEMICAL", 126, 133], ["oxygen", "CHEMICAL", 185, 191], ["hydroxyl", "CHEMICAL", 210, 218], ["alkoxide", "CHEMICAL", 29, 37], ["silica", "CHEMICAL", 56, 62], ["silanol", "CHEMICAL", 92, 99], ["Si-OH", "CHEMICAL", 107, 112], ["alcohol", "CHEMICAL", 126, 133], ["oxygen", "CHEMICAL", 185, 191], ["hydroxyl", "CHEMICAL", 210, 218], ["alkoxide", "SIMPLE_CHEMICAL", 29, 37], ["silica precursor", "SIMPLE_CHEMICAL", 56, 72], ["silanol", "SIMPLE_CHEMICAL", 92, 99], ["Si-OH", "SIMPLE_CHEMICAL", 107, 112], ["alcohol", "SIMPLE_CHEMICAL", 126, 133], ["oxygen", "SIMPLE_CHEMICAL", 185, 191], ["water hydroxyl", "SIMPLE_CHEMICAL", 204, 218], ["hydrolysis reactions", "PROBLEM", 3, 23], ["the alkoxide group", "TREATMENT", 25, 43], ["the silica precursor", "TREATMENT", 52, 72], ["the oxygen atom", "TREATMENT", 181, 196], ["the water hydroxyl group", "TREATMENT", 200, 224], ["hydrolysis reactions", "OBSERVATION", 3, 23], ["alcohol", "OBSERVATION", 126, 133], ["nucleophilic attack", "OBSERVATION", 158, 177], ["oxygen atom", "OBSERVATION", 185, 196]]], ["In condensation reactions, dimers, linear trimers, cyclic and polymeric species with siloxane bonds (Si-O-Si) are formed (73).", [["siloxane", "CHEMICAL", 85, 93], ["Si-O-Si", "CHEMICAL", 101, 108], ["siloxane", "CHEMICAL", 85, 93], ["Si-O", "CHEMICAL", 101, 105], ["Si", "CHEMICAL", 106, 108], ["cyclic", "SIMPLE_CHEMICAL", 51, 57], ["polymeric species", "SIMPLE_CHEMICAL", 62, 79], ["siloxane bonds", "SIMPLE_CHEMICAL", 85, 99], ["Si-O-Si", "SIMPLE_CHEMICAL", 101, 108], ["condensation reactions", "PROBLEM", 3, 25], ["dimers", "PROBLEM", 27, 33], ["linear trimers", "PROBLEM", 35, 49], ["cyclic and polymeric species", "PROBLEM", 51, 79], ["siloxane bonds", "TREATMENT", 85, 99], ["condensation reactions", "OBSERVATION", 3, 25], ["linear trimers", "OBSERVATION_MODIFIER", 35, 49], ["polymeric species", "OBSERVATION", 62, 79]]], ["In order to obtain mesoporous nanomaterials, surfactants have been used, such as cetyltrimethylammonium bromide (also known as CTAB) (74).", [["cetyltrimethylammonium bromide", "CHEMICAL", 81, 111], ["cetyltrimethylammonium bromide", "CHEMICAL", 81, 111], ["CTAB", "CHEMICAL", 127, 131], ["surfactants", "SIMPLE_CHEMICAL", 45, 56], ["cetyltrimethylammonium bromide", "SIMPLE_CHEMICAL", 81, 111], ["mesoporous nanomaterials", "TREATMENT", 19, 43], ["surfactants", "TREATMENT", 45, 56], ["cetyltrimethylammonium bromide", "TREATMENT", 81, 111]]], ["Usually, the surfactant will self-aggregate into micelles at a concentration higher than the critical micelle concentration (CMC).", [["surfactant", "SIMPLE_CHEMICAL", 13, 23], ["micelles", "SIMPLE_CHEMICAL", 49, 57], ["the surfactant", "TREATMENT", 9, 23]]], ["Then, the silica precursors can condense at the micelles surface forming MSNs.", [["surface", "ANATOMY", 57, 64], ["silica", "CHEMICAL", 10, 16], ["silica", "CHEMICAL", 10, 16], ["silica precursors", "SIMPLE_CHEMICAL", 10, 27], ["MSNs", "SIMPLE_CHEMICAL", 73, 77], ["the silica precursors", "PROBLEM", 6, 27]]], ["Finally, the template surfactant can be removed either by calcination or by solvent extraction to generate pores (74,75), as depicted in Fig. 3.Synthesis and Types of Mesoporous Silica Nanoparticles ::: Mesoporous Silica NanoparticlesConsidering the abundant availability of various surfactants types and the deep understanding of sol\u2013gel chemistry, MSNs with different structures have been developed.", [["Silica", "CHEMICAL", 178, 184], ["Silica", "CHEMICAL", 214, 220], ["Mesoporous Silica Nanoparticles", "SIMPLE_CHEMICAL", 167, 198], ["Silica Nanoparticles", "SIMPLE_CHEMICAL", 214, 234], ["sol\u2013gel", "SIMPLE_CHEMICAL", 331, 338], ["MSNs", "SIMPLE_CHEMICAL", 350, 354], ["the template surfactant", "TREATMENT", 9, 32], ["solvent extraction", "TREATMENT", 76, 94], ["Synthesis and Types of Mesoporous Silica Nanoparticles", "TREATMENT", 144, 198], ["Mesoporous Silica Nanoparticles", "TREATMENT", 203, 234], ["various surfactants types", "TREATMENT", 275, 300], ["Mesoporous Silica Nanoparticles", "OBSERVATION", 167, 198], ["Silica Nanoparticles", "OBSERVATION", 214, 234]]], ["The size, morphology, pore size, and pore structure of MSNs can be rationally designed and the synthesis process can be freely controlled.Synthesis and Types of Mesoporous Silica Nanoparticles ::: Mesoporous Silica NanoparticlesThe resulting silica-based mesoporous matrices may offer the following unique structural: 1) ordered porous structure.", [["pore", "ANATOMY", 22, 26], ["pore", "ANATOMY", 37, 41], ["MSNs", "CHEMICAL", 55, 59], ["silica", "CHEMICAL", 242, 248], ["Silica", "CHEMICAL", 172, 178], ["Silica", "CHEMICAL", 208, 214], ["silica", "CHEMICAL", 242, 248], ["MSNs", "SIMPLE_CHEMICAL", 55, 59], ["Mesoporous Silica Nanoparticles", "SIMPLE_CHEMICAL", 161, 192], ["Silica Nanoparticles", "SIMPLE_CHEMICAL", 208, 228], ["silica", "SIMPLE_CHEMICAL", 242, 248], ["the synthesis process", "PROBLEM", 91, 112], ["Mesoporous Silica Nanoparticles", "TREATMENT", 197, 228], ["The resulting silica-based mesoporous matrices", "TREATMENT", 228, 274], ["size", "OBSERVATION_MODIFIER", 4, 8], ["morphology", "OBSERVATION_MODIFIER", 10, 20], ["pore", "OBSERVATION_MODIFIER", 22, 26], ["size", "OBSERVATION_MODIFIER", 27, 31], ["pore structure", "OBSERVATION", 37, 51], ["Mesoporous Silica Nanoparticles", "OBSERVATION", 161, 192], ["Silica Nanoparticles", "OBSERVATION", 208, 228]]], ["MSNs have along-range ordered porous structure without interconnection between individual porous channels, which allows fine control of the drug loading and release kinetics; 2) large pore volume and surface area.", [["pore", "ANATOMY", 184, 188], ["surface area", "ANATOMY", 200, 212], ["MSNs", "SIMPLE_CHEMICAL", 0, 4], ["interconnection between individual porous channels", "PROBLEM", 55, 105], ["the drug loading", "TREATMENT", 136, 152], ["large pore volume and surface area", "TREATMENT", 178, 212], ["large", "OBSERVATION_MODIFIER", 178, 183], ["pore volume", "OBSERVATION_MODIFIER", 184, 195], ["surface", "OBSERVATION_MODIFIER", 200, 207]]], ["The pore volume and surface area of MSNs are usually above 1cm3 g-1 and 700 m2 g-1, respectively, showing high potential for molecules loading and dissolution enhancement; 3) tunable particle size.", [["pore", "ANATOMY", 4, 8], ["surface area", "ANATOMY", 20, 32], ["MSNs", "SIMPLE_CHEMICAL", 36, 40], ["The pore volume", "TEST", 0, 15], ["MSNs", "TEST", 36, 40], ["molecules loading and dissolution enhancement", "PROBLEM", 125, 170], ["pore", "OBSERVATION_MODIFIER", 4, 8], ["volume", "OBSERVATION_MODIFIER", 9, 15], ["surface", "OBSERVATION_MODIFIER", 20, 27], ["area", "OBSERVATION_MODIFIER", 28, 32], ["MSNs", "ANATOMY", 36, 40], ["high potential", "OBSERVATION_MODIFIER", 106, 120], ["particle", "OBSERVATION_MODIFIER", 183, 191], ["size", "OBSERVATION_MODIFIER", 192, 196]]], ["The MSNs particle size can be controlled from 50 to 300 nm, which is suitable for facile endocytosis by living cells; 4) two functional surfaces, namely cylindrical pore surface and exterior particle surface.", [["cells", "ANATOMY", 111, 116], ["pore surface", "ANATOMY", 165, 177], ["cells", "CELL", 111, 116], ["pore surface", "CELLULAR_COMPONENT", 165, 177], ["particle surface", "CELLULAR_COMPONENT", 191, 207], ["facile endocytosis", "PROBLEM", 82, 100], ["MSNs particle", "OBSERVATION", 4, 17], ["size", "OBSERVATION_MODIFIER", 18, 22], ["cylindrical", "OBSERVATION_MODIFIER", 153, 164], ["pore", "OBSERVATION_MODIFIER", 165, 169], ["surface", "OBSERVATION_MODIFIER", 170, 177], ["exterior", "ANATOMY_MODIFIER", 182, 190], ["particle", "OBSERVATION_MODIFIER", 191, 199]]], ["These silanol-contained surfaces can be selectively functionalized to achieve better control over drug loading and release.", [["silanol", "CHEMICAL", 6, 13], ["silanol", "CHEMICAL", 6, 13], ["silanol", "SIMPLE_CHEMICAL", 6, 13], ["These silanol-contained surfaces", "TREATMENT", 0, 32], ["drug loading", "TREATMENT", 98, 110]]], ["Moreover, the external surface can be conjugated with targeting ligands for efficient cell-specific drug delivery (61,74\u201377).Properties Effect of MSNs in Drug Delivery Systems ::: Mesoporous Silica NanoparticlesStable suspension formation in solution, tunable pore size and structure, controlled particle size and shape, high pore volume and surface area, make the MSNs ideal for applications as nanocarriers (12,77).Properties Effect of MSNs in Drug Delivery Systems ::: Mesoporous Silica NanoparticlesThe pores size control influences on loading and release rates of molecules.", [["surface", "ANATOMY", 23, 30], ["cell", "ANATOMY", 86, 90], ["pore", "ANATOMY", 260, 264], ["pore", "ANATOMY", 326, 330], ["surface area", "ANATOMY", 342, 354], ["pores", "ANATOMY", 507, 512], ["Silica", "CHEMICAL", 191, 197], ["Silica", "CHEMICAL", 191, 197], ["Silica", "CHEMICAL", 483, 489], ["surface", "CELLULAR_COMPONENT", 23, 30], ["cell", "CELL", 86, 90], ["Silica", "SIMPLE_CHEMICAL", 191, 197], ["Silica Nanoparticles", "SIMPLE_CHEMICAL", 483, 503], ["the external surface", "TREATMENT", 10, 30], ["targeting ligands", "TREATMENT", 54, 71], ["Mesoporous Silica NanoparticlesStable suspension formation in solution", "TREATMENT", 180, 250], ["high pore volume and surface area", "TREATMENT", 321, 354], ["Mesoporous Silica Nanoparticles", "TREATMENT", 472, 503], ["The pores size control", "TREATMENT", 503, 525], ["Silica NanoparticlesStable", "OBSERVATION", 191, 217], ["suspension formation", "OBSERVATION", 218, 238], ["tunable", "OBSERVATION_MODIFIER", 252, 259], ["pore", "OBSERVATION_MODIFIER", 260, 264], ["size", "OBSERVATION_MODIFIER", 265, 269], ["structure", "OBSERVATION_MODIFIER", 274, 283], ["controlled", "OBSERVATION_MODIFIER", 285, 295], ["particle", "OBSERVATION_MODIFIER", 296, 304], ["size", "OBSERVATION_MODIFIER", 305, 309], ["shape", "OBSERVATION_MODIFIER", 314, 319], ["high pore", "OBSERVATION_MODIFIER", 321, 330], ["volume", "OBSERVATION_MODIFIER", 331, 337], ["surface", "OBSERVATION_MODIFIER", 342, 349], ["Silica Nanoparticles", "OBSERVATION", 483, 503], ["pores", "OBSERVATION_MODIFIER", 507, 512], ["size", "OBSERVATION_MODIFIER", 513, 517]]], ["Increasing pores size, more molecules can be loaded inside the pores and consequently, an increase of release rates can be observed (12,77,78).", [["pores", "ANATOMY", 11, 16], ["Increasing pores size", "PROBLEM", 0, 21], ["pores", "OBSERVATION_MODIFIER", 11, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["more molecules", "OBSERVATION_MODIFIER", 23, 37], ["pores", "OBSERVATION_MODIFIER", 63, 68], ["increase", "OBSERVATION_MODIFIER", 90, 98]]], ["Pores volume is an important factor on drug loading properties.", [["Pores volume", "PROBLEM", 0, 12], ["drug loading properties", "TREATMENT", 39, 62]]], ["High pores volume can avoid strong drug-drug interactions consequently facilitating drug-pores wall intermolecular interactions leading to large filling of the mesopores channels (12,77).", [["wall", "ANATOMY", 95, 99], ["High pores volume", "PROBLEM", 0, 17], ["drug interactions", "PROBLEM", 40, 57], ["pores wall intermolecular interactions", "PROBLEM", 89, 127], ["large filling of the mesopores channels", "PROBLEM", 139, 178], ["pores volume", "OBSERVATION", 5, 17], ["large", "OBSERVATION_MODIFIER", 139, 144], ["filling", "OBSERVATION", 145, 152], ["mesopores channels", "OBSERVATION", 160, 178]]], ["The type of pores arrangement can also influence on cargo loading and release rates.", [["The type of pores arrangement", "TREATMENT", 0, 29], ["cargo loading", "TREATMENT", 52, 65]]], ["Three distinct pore arrangement, TUD-1, MCM-41 and SBA-15 materials, were evaluated in processes on ibuprofen loading and release processes by Heikkil\u00e4 et al .", [["pore", "ANATOMY", 15, 19], ["ibuprofen", "CHEMICAL", 100, 109], ["MCM-41", "CHEMICAL", 40, 46], ["ibuprofen", "CHEMICAL", 100, 109], ["TUD-1", "SIMPLE_CHEMICAL", 33, 38], ["MCM-41", "SIMPLE_CHEMICAL", 40, 46], ["SBA-15", "SIMPLE_CHEMICAL", 51, 57], ["ibuprofen", "SIMPLE_CHEMICAL", 100, 109], ["TUD", "TEST", 33, 36], ["MCM", "TEST", 40, 43], ["SBA", "TEST", 51, 54], ["ibuprofen loading", "TREATMENT", 100, 117], ["distinct", "OBSERVATION_MODIFIER", 6, 14], ["pore", "OBSERVATION_MODIFIER", 15, 19], ["arrangement", "OBSERVATION_MODIFIER", 20, 31]]], ["TUD-1 (disordered mesoporous) materials that present 3D pores arrangement showed faster drug release than 2D hexagonal mesopores materials (SBA-15 and MCM-41).", [["MCM-41", "CHEMICAL", 151, 157], ["TUD-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["SBA-15", "SIMPLE_CHEMICAL", 140, 146], ["TUD", "TEST", 0, 3], ["disordered mesoporous) materials", "TREATMENT", 7, 39], ["faster drug release", "PROBLEM", 81, 100], ["2D hexagonal mesopores materials", "TREATMENT", 106, 138], ["SBA", "TEST", 140, 143], ["MCM", "TEST", 151, 154]]], ["(81) demonstrated that similar hexagonal mesostructured materials with interconnected (SBA-1) pores displayed faster release rate than unconnected (SBA-3) pores systems.", [["similar hexagonal mesostructured materials", "TREATMENT", 23, 65], ["interconnected (SBA", "TREATMENT", 71, 90], ["faster release rate", "PROBLEM", 110, 129], ["hexagonal", "OBSERVATION_MODIFIER", 31, 40], ["mesostructured materials", "OBSERVATION", 41, 65]]], ["For these systems, similar drug loading amounts were detected.Properties Effect of MSNs in Drug Delivery Systems ::: Mesoporous Silica NanoparticlesLarge surface area is also a crucial characteristic regarding to cargo diffusion process from MSNs.", [["Silica", "CHEMICAL", 128, 134], ["Silica", "CHEMICAL", 128, 134], ["MSNs", "SIMPLE_CHEMICAL", 242, 246], ["these systems", "TEST", 4, 17], ["similar drug loading amounts", "TREATMENT", 19, 47], ["Mesoporous Silica NanoparticlesLarge surface area", "PROBLEM", 117, 166], ["Silica NanoparticlesLarge", "OBSERVATION", 128, 153], ["surface", "OBSERVATION_MODIFIER", 154, 161], ["cargo diffusion", "OBSERVATION", 213, 228]]], ["Vallet-Reg\u00ed group (82\u201384) reported the 2-D hexagonal mesoporous silica as carriers showing higher drugs adsorption values for MCM-41 (Specific surface area (SBET) = 1157 m2 g\u22121) than for SBA-15 (SBET = 719 m2 g\u22121) systems.Properties Effect of MSNs in Drug Delivery Systems ::: Mesoporous Silica NanoparticlesParticles size and shape can also influence their blood circulation, cellular uptake and tumor penetration, being determinant parameters to achieve therapeutic effects.", [["blood", "ANATOMY", 358, 363], ["cellular", "ANATOMY", 377, 385], ["tumor", "ANATOMY", 397, 402], ["silica", "CHEMICAL", 64, 70], ["MCM-41", "CHEMICAL", 126, 132], ["Silica", "CHEMICAL", 288, 294], ["tumor", "DISEASE", 397, 402], ["silica", "CHEMICAL", 64, 70], ["MCM-41", "CHEMICAL", 126, 132], ["SBA-15", "CHEMICAL", 187, 193], ["Silica", "CHEMICAL", 288, 294], ["2-D hexagonal mesoporous silica", "SIMPLE_CHEMICAL", 39, 70], ["MCM-41", "SIMPLE_CHEMICAL", 126, 132], ["SBA-15", "SIMPLE_CHEMICAL", 187, 193], ["blood", "ORGANISM_SUBSTANCE", 358, 363], ["cellular", "CELL", 377, 385], ["tumor", "CANCER", 397, 402], ["Vallet", "TEST", 0, 6], ["the 2-D hexagonal mesoporous silica", "TREATMENT", 35, 70], ["MCM", "TEST", 126, 129], ["SBET", "TEST", 157, 161], ["SBA", "TEST", 187, 190], ["SBET", "TEST", 195, 199], ["Mesoporous Silica NanoparticlesParticles size", "TREATMENT", 277, 322], ["cellular uptake", "PROBLEM", 377, 392], ["tumor penetration", "PROBLEM", 397, 414], ["Silica NanoparticlesParticles", "OBSERVATION", 288, 317], ["size", "OBSERVATION_MODIFIER", 318, 322], ["shape", "OBSERVATION_MODIFIER", 327, 332], ["cellular", "OBSERVATION_MODIFIER", 377, 385], ["uptake", "OBSERVATION_MODIFIER", 386, 392], ["tumor penetration", "OBSERVATION", 397, 414]]], ["Regarding particles size, a diameter range from 50 to 300 nm can favor an optimal cellular uptake, long circulation time, high drug loading and high accumulation in tumors (12).", [["cellular", "ANATOMY", 82, 90], ["tumors", "ANATOMY", 165, 171], ["tumors", "DISEASE", 165, 171], ["cellular", "CELL", 82, 90], ["tumors", "CANCER", 165, 171], ["a diameter range", "TEST", 26, 42], ["an optimal cellular uptake", "PROBLEM", 71, 97], ["high drug loading", "PROBLEM", 122, 139], ["high accumulation in tumors", "PROBLEM", 144, 171], ["particles", "OBSERVATION_MODIFIER", 10, 19], ["size", "OBSERVATION_MODIFIER", 20, 24], ["diameter", "OBSERVATION_MODIFIER", 28, 36], ["optimal", "OBSERVATION_MODIFIER", 74, 81], ["cellular uptake", "OBSERVATION", 82, 97], ["high", "OBSERVATION_MODIFIER", 144, 148], ["accumulation", "OBSERVATION_MODIFIER", 149, 161], ["tumors", "OBSERVATION", 165, 171]]], ["(85,86) described the importance of particle shape design towards therapeutic application showing faster and higher internalization of rod-shaped MSNs on tumor cells than spherical MSNs.Biocompatibility and Biodistribution ::: Biological Behavior of MSNs: Biocompatibility, Biodistribution, Biodegradability and ClearanceDetermining the safety and biocompatibility of MSNs is crucial owing to its variable characteristics.", [["tumor cells", "ANATOMY", 154, 165], ["tumor", "DISEASE", 154, 159], ["MSNs", "CHEMICAL", 368, 372], ["MSNs", "CELL", 146, 150], ["tumor cells", "CELL", 154, 165], ["MSNs", "CELL", 181, 185], ["MSNs", "SIMPLE_CHEMICAL", 368, 372], ["tumor cells", "CELL_TYPE", 154, 165], ["therapeutic application", "TREATMENT", 66, 89], ["rod-shaped MSNs on tumor cells", "PROBLEM", 135, 165], ["Biodegradability", "TREATMENT", 291, 307], ["ClearanceDetermining", "TREATMENT", 312, 332], ["biocompatibility of MSNs", "TREATMENT", 348, 372], ["particle shape", "OBSERVATION_MODIFIER", 36, 50], ["tumor cells", "OBSERVATION", 154, 165], ["Biocompatibility", "OBSERVATION_MODIFIER", 256, 272]]], ["The data generated from literature suggest that careful control of particle size and shape is the determinant factor in the biodistribution and toxicity of MSNs.", [["toxicity", "DISEASE", 144, 152], ["MSNs", "SIMPLE_CHEMICAL", 156, 160], ["The data", "TEST", 0, 8], ["toxicity of MSNs", "PROBLEM", 144, 160], ["particle size", "OBSERVATION_MODIFIER", 67, 80]]], ["In addition, the safety and toxicity of MSNs also depend on the administered MSNs dosage.", [["toxicity", "DISEASE", 28, 36], ["MSNs", "CHEMICAL", 40, 44], ["MSNs", "SIMPLE_CHEMICAL", 40, 44], ["MSNs", "SIMPLE_CHEMICAL", 77, 81], ["toxicity of MSNs", "PROBLEM", 28, 44], ["the administered MSNs dosage", "TREATMENT", 60, 88]]], ["Surface MSNs properties also have a great impact on their biodistribution and biocompatibility (64,87\u201390).", [["great", "OBSERVATION_MODIFIER", 36, 41], ["impact", "OBSERVATION_MODIFIER", 42, 48], ["biocompatibility", "OBSERVATION_MODIFIER", 78, 94]]], ["The major toxicity pathway associated with silica is due to its surface chemistry (silanol groups) which can interact with the membrane components leading to the cells lysis and cellular components leaking (91,92).", [["surface", "ANATOMY", 64, 71], ["membrane components", "ANATOMY", 127, 146], ["cells", "ANATOMY", 162, 167], ["cellular", "ANATOMY", 178, 186], ["toxicity", "DISEASE", 10, 18], ["silica", "CHEMICAL", 43, 49], ["silanol", "CHEMICAL", 83, 90], ["silica", "CHEMICAL", 43, 49], ["silanol", "CHEMICAL", 83, 90], ["silica", "SIMPLE_CHEMICAL", 43, 49], ["silanol", "SIMPLE_CHEMICAL", 83, 90], ["membrane components", "CELLULAR_COMPONENT", 127, 146], ["cells", "CELL", 162, 167], ["cellular", "CELL", 178, 186], ["The major toxicity pathway", "PROBLEM", 0, 26], ["the membrane components", "TREATMENT", 123, 146], ["the cells lysis", "TREATMENT", 158, 173], ["cellular components", "PROBLEM", 178, 197], ["major", "OBSERVATION_MODIFIER", 4, 9], ["toxicity", "OBSERVATION", 10, 18], ["cells lysis", "OBSERVATION", 162, 173], ["cellular", "OBSERVATION_MODIFIER", 178, 186], ["components", "OBSERVATION_MODIFIER", 187, 197], ["leaking", "OBSERVATION_MODIFIER", 198, 205]]], ["Mesoporous silica exhibited lower hemolytic effect compared to non-porous silica (25).", [["silica", "CHEMICAL", 11, 17], ["hemolytic", "DISEASE", 34, 43], ["non-porous silica", "CHEMICAL", 63, 80], ["silica", "CHEMICAL", 11, 17], ["silica", "CHEMICAL", 74, 80], ["Mesoporous silica", "SIMPLE_CHEMICAL", 0, 17], ["Mesoporous silica", "PROBLEM", 0, 17], ["lower hemolytic effect", "PROBLEM", 28, 50], ["non-porous silica", "TEST", 63, 80], ["lower", "OBSERVATION_MODIFIER", 28, 33], ["hemolytic effect", "OBSERVATION", 34, 50], ["non-porous silica", "OBSERVATION_MODIFIER", 63, 80]]], ["This could be attributed to the lower density of silanol groups on the surface of mesoporous structures (93).", [["surface", "ANATOMY", 71, 78], ["silanol", "CHEMICAL", 49, 56], ["silanol", "CHEMICAL", 49, 56], ["silanol", "SIMPLE_CHEMICAL", 49, 56], ["surface", "CELLULAR_COMPONENT", 71, 78], ["the lower density of silanol groups", "PROBLEM", 28, 63], ["lower", "OBSERVATION_MODIFIER", 32, 37], ["density", "OBSERVATION", 38, 45], ["silanol groups", "OBSERVATION", 49, 63], ["surface", "OBSERVATION_MODIFIER", 71, 78]]], ["Authors (61,94) made an attempt to study the single and repeated dose MSNs toxicity following intravenous administration in mice.", [["intravenous", "ANATOMY", 94, 105], ["MSNs", "CHEMICAL", 70, 74], ["toxicity", "DISEASE", 75, 83], ["MSNs", "SIMPLE_CHEMICAL", 70, 74], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 105], ["mice", "ORGANISM", 124, 128], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["repeated dose MSNs toxicity", "TREATMENT", 56, 83], ["intravenous administration", "TREATMENT", 94, 120]]], ["LD50 of MSNs was found to be higher than 1000 mg kg-1.", [["MSNs", "CHEMICAL", 8, 12], ["MSNs", "SIMPLE_CHEMICAL", 8, 12], ["MSNs", "TEST", 8, 12]]], ["In single dose toxicity studies, mice were injected with MSNs at a low dose and high dose.", [["toxicity", "DISEASE", 15, 23], ["MSNs", "CHEMICAL", 57, 61], ["mice", "ORGANISM", 33, 37], ["MSNs", "SIMPLE_CHEMICAL", 57, 61], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["single dose toxicity studies", "TEST", 3, 31], ["MSNs", "TREATMENT", 57, 61]]], ["At the higher dose of 1280 mg kg-1, mice did not survive.", [["mice", "ORGANISM", 36, 40], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40]]], ["In contrast, the groups treated with low MSNs dose did not show any behavioral changes nor any hematology or pathological changes.", [["MSNs", "CHEMICAL", 41, 45], ["low MSNs dose", "TREATMENT", 37, 50], ["any behavioral changes", "PROBLEM", 64, 86], ["pathological changes", "PROBLEM", 109, 129]]], ["To carry out the detailed repeated dose toxicity studies, intravenous administration of hollow MSNs (HMSNs) were given to mice continuously for 14 days and observed for a month.", [["intravenous", "ANATOMY", 58, 69], ["toxicity", "DISEASE", 40, 48], ["HMSNs", "CHEMICAL", 101, 106], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 69], ["hollow MSNs", "SIMPLE_CHEMICAL", 88, 99], ["HMSNs", "SIMPLE_CHEMICAL", 101, 106], ["mice", "ORGANISM", 122, 126], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["intravenous administration of hollow MSNs (HMSNs)", "TREATMENT", 58, 107]]], ["During the one-month observation period, no mortality was observed.", [["mortality", "PROBLEM", 44, 53]]], ["Moreover, no remarkable changes in pathology or blood parameters were observed.", [["blood", "ANATOMY", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["remarkable changes in pathology", "PROBLEM", 13, 44], ["blood parameters", "TEST", 48, 64], ["no", "UNCERTAINTY", 10, 12], ["remarkable", "OBSERVATION_MODIFIER", 13, 23], ["changes", "OBSERVATION", 24, 31], ["pathology", "OBSERVATION", 35, 44]]], ["(95) tested MSNs with a particle size of 110 nm in ICR mice.", [["MSNs", "CELL", 12, 16], ["mice", "ORGANISM", 55, 59], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["a particle size", "TEST", 22, 37], ["110 nm", "OBSERVATION_MODIFIER", 41, 47]]], ["Following administration via hypodermic, intramuscular and intravenous injection as well as oral administration, the in vivo distribution of fluorescent-tagged MSNs was tracked.", [["intramuscular", "ANATOMY", 41, 54], ["intravenous", "ANATOMY", 59, 70], ["oral", "ANATOMY", 92, 96], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 70], ["oral", "ORGANISM_SUBDIVISION", 92, 96], ["MSNs", "CELL", 160, 164], ["MSNs", "PROTEIN", 160, 164], ["hypodermic", "TREATMENT", 29, 39], ["intramuscular and intravenous injection", "TREATMENT", 41, 80], ["oral administration", "TREATMENT", 92, 111], ["fluorescent-tagged MSNs", "TREATMENT", 141, 164]]], ["It was observed that of all the exposure routes, the oral route was found to be well tolerated even when the dose was increased to 5000 mg kg-1 and intravenous route seemed to have the least threshold.", [["oral", "ANATOMY", 53, 57], ["intravenous", "ANATOMY", 148, 159], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 148, 159], ["intravenous route", "TREATMENT", 148, 165]]], ["MSNs administered via intravenous route were found to preferentially accumulate in the liver and spleen at the end of 24 h and 7 days whereas those administered by other routes did not show any fluorescence in these organs.", [["intravenous", "ANATOMY", 22, 33], ["liver", "ANATOMY", 87, 92], ["spleen", "ANATOMY", 97, 103], ["organs", "ANATOMY", 216, 222], ["MSNs", "CHEMICAL", 0, 4], ["MSNs", "SIMPLE_CHEMICAL", 0, 4], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 33], ["liver", "ORGAN", 87, 92], ["spleen", "ORGAN", 97, 103], ["organs", "ORGAN", 216, 222], ["intravenous route", "TREATMENT", 22, 39], ["any fluorescence in these organs", "PROBLEM", 190, 222], ["liver", "ANATOMY", 87, 92], ["spleen", "ANATOMY", 97, 103], ["organs", "ANATOMY", 216, 222]]], ["It was observed that a portion of the MSNs administered via intramuscular and hypodermic routes could cross different biological barriers with a slow absorption rate.", [["intramuscular", "ANATOMY", 60, 73], ["MSNs", "CHEMICAL", 38, 42], ["MSNs", "SIMPLE_CHEMICAL", 38, 42], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["the MSNs", "TREATMENT", 34, 42], ["intramuscular and hypodermic routes", "TREATMENT", 60, 95], ["a slow absorption rate", "TREATMENT", 143, 165]]], ["The major excretion routes of MSNs were found to be via urine and feces with the highest values after oral administration as compared to other routes.", [["urine", "ANATOMY", 56, 61], ["feces", "ANATOMY", 66, 71], ["oral", "ANATOMY", 102, 106], ["MSNs", "CHEMICAL", 30, 34], ["MSNs", "SIMPLE_CHEMICAL", 30, 34], ["urine", "ORGANISM_SUBSTANCE", 56, 61], ["feces", "ORGANISM_SUBSTANCE", 66, 71], ["oral", "ORGANISM_SUBDIVISION", 102, 106], ["urine and feces", "TEST", 56, 71], ["oral administration", "TREATMENT", 102, 121], ["urine", "OBSERVATION", 56, 61], ["feces", "OBSERVATION", 66, 71]]], ["No histopathological changes were observed in liver, spleen, kidney and lung at the end of 24 h and 7 days by different exposure routes.", [["liver", "ANATOMY", 46, 51], ["spleen", "ANATOMY", 53, 59], ["kidney", "ANATOMY", 61, 67], ["lung", "ANATOMY", 72, 76], ["liver", "ORGAN", 46, 51], ["spleen", "ORGAN", 53, 59], ["kidney", "ORGAN", 61, 67], ["lung", "ORGAN", 72, 76], ["histopathological changes", "PROBLEM", 3, 28], ["histopathological", "OBSERVATION", 3, 20], ["liver", "ANATOMY", 46, 51], ["spleen", "ANATOMY", 53, 59], ["kidney", "ANATOMY", 61, 67], ["lung", "ANATOMY", 72, 76]]], ["The results suggested that MSNs were found to be safe and well tolerated when administered by oral and intravenous routes (87,95).Effect of Size ::: Biodegradability ::: Biological Behavior of MSNs: Biocompatibility, Biodistribution, Biodegradability and ClearanceChen et al .", [["oral", "ANATOMY", 94, 98], ["intravenous", "ANATOMY", 103, 114], ["MSNs", "CHEMICAL", 27, 31], ["MSNs", "SIMPLE_CHEMICAL", 27, 31], ["oral", "ORGANISM_SUBDIVISION", 94, 98], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 114], ["Size", "OBSERVATION_MODIFIER", 140, 144]]], ["(98) demonstrated that the degradation of MSNs is independent of their diameter with 390, 310, 200, and 150 nm nanoparticles in simulated body fluid (SBF) at 37 \u00b0C. During the first two days, the degradation rate was nearly 45% per day, which then slowed down to about 1% per day, and the degradation was completed in a week (88,98,99).", [["body fluid", "ANATOMY", 138, 148], ["MSNs", "SIMPLE_CHEMICAL", 42, 46], ["body", "ORGANISM_SUBDIVISION", 138, 142], ["fluid", "ORGANISM_SUBSTANCE", 143, 148], ["the degradation of MSNs", "PROBLEM", 23, 46], ["the degradation rate", "TEST", 192, 212]]], ["(100) investigated the role of the surface area on the degradation of mesoporous silica, comparing three samples of surface areas of 958, 829, and 282 m2 g-1 at fixed concentration of 0.1 mg mL-1 in SBF, which were sealed in polyethylene bottles at 37 \u00b0C and shaken at 150 rpm with a mechanical shaker.", [["surface area", "ANATOMY", 35, 47], ["surface", "ANATOMY", 116, 123], ["mesoporous silica", "CHEMICAL", 70, 87], ["silica", "CHEMICAL", 81, 87], ["polyethylene", "CHEMICAL", 225, 237], ["mesoporous silica", "SIMPLE_CHEMICAL", 70, 87], ["the degradation of mesoporous silica", "TREATMENT", 51, 87], ["surface", "OBSERVATION_MODIFIER", 35, 42], ["mesoporous silica", "OBSERVATION", 70, 87], ["surface", "OBSERVATION_MODIFIER", 116, 123], ["sealed", "OBSERVATION_MODIFIER", 215, 221], ["polyethylene bottles", "OBSERVATION", 225, 245], ["mechanical shaker", "OBSERVATION", 284, 301]]], ["This study indicated, on the one hand, that there was a burst degradation in the first 2 to 4 h, leading to 30, 70, and 90% of silica hydrolytic degradation as the surface increased, and, on the other hand, a complete degradation was obtained in 15 days.Effects of Morphology and Degradation Medium ::: Biodegradability ::: Biological Behavior of MSNs: Biocompatibility, Biodistribution, Biodegradability and ClearanceA remarkable study was reported by Li et al .", [["surface", "ANATOMY", 164, 171], ["silica", "CHEMICAL", 127, 133], ["Li", "CHEMICAL", 453, 455], ["silica", "CHEMICAL", 127, 133], ["silica", "SIMPLE_CHEMICAL", 127, 133], ["surface", "CELLULAR_COMPONENT", 164, 171], ["This study", "TEST", 0, 10], ["a burst degradation", "PROBLEM", 54, 73], ["silica hydrolytic degradation", "PROBLEM", 127, 156], ["burst", "OBSERVATION_MODIFIER", 56, 61], ["degradation", "OBSERVATION", 62, 73], ["silica", "OBSERVATION", 127, 133], ["hydrolytic degradation", "OBSERVATION", 134, 156], ["surface", "OBSERVATION_MODIFIER", 164, 171], ["increased", "OBSERVATION_MODIFIER", 172, 181]]], ["(101) regarding the degradation of MSNs with spherical and rod-shaped morphologies with aspect ratios (ARs) of 1.75 and 5.", [["MSNs", "SIMPLE_CHEMICAL", 35, 39], ["the degradation of MSNs", "PROBLEM", 16, 39], ["aspect ratios", "TEST", 88, 101], ["rod-shaped morphologies", "OBSERVATION_MODIFIER", 59, 82]]], ["Authors investigated these nanoparticles by TEM and sample weight measurements after degradation for 7 days by soaking in three different degradation media: simulated gastric fluid (SGF, pH 1.2), simulated intestinal fluid (SIF, pH 6.5), and SBF (pH 7).", [["gastric fluid", "ANATOMY", 167, 180], ["intestinal fluid", "ANATOMY", 206, 222], ["gastric fluid", "MULTI-TISSUE_STRUCTURE", 167, 180], ["intestinal", "ORGAN", 206, 216], ["sample weight measurements", "TEST", 52, 78], ["SGF", "TEST", 182, 185], ["pH", "TEST", 187, 189], ["simulated intestinal fluid", "TEST", 196, 222], ["pH", "TEST", 229, 231], ["SBF (pH", "TEST", 242, 249], ["gastric", "ANATOMY", 167, 174], ["fluid", "OBSERVATION", 175, 180], ["intestinal", "ANATOMY", 206, 216], ["fluid", "OBSERVATION", 217, 222]]], ["After a week in acidic gastric fluid, none of the three MSNs did displayed significant alteration, and their degradation was only about 10 wt% for all nanoparticles.", [["gastric fluid", "ANATOMY", 23, 36], ["gastric fluid", "MULTI-TISSUE_STRUCTURE", 23, 36], ["acidic gastric fluid", "PROBLEM", 16, 36], ["significant alteration", "PROBLEM", 75, 97], ["gastric", "ANATOMY", 23, 30], ["fluid", "OBSERVATION", 31, 36], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["alteration", "OBSERVATION", 87, 97]]], ["On the contrary, the degradation was much more pronounced and AR dependent in both simulated intestinal and body fluids.", [["intestinal", "ANATOMY", 93, 103], ["body fluids", "ANATOMY", 108, 119], ["AR", "GENE_OR_GENE_PRODUCT", 62, 64], ["intestinal", "MULTI-TISSUE_STRUCTURE", 93, 103], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["AR", "PROTEIN", 62, 64], ["AR dependent", "PROBLEM", 62, 74], ["more pronounced", "OBSERVATION_MODIFIER", 42, 57], ["intestinal", "ANATOMY", 93, 103]]], ["The same group also showed that spherical MSNs were more rapidly degraded than rod-like MSNs with ARs of 2 and 4, and the presence of FBS in the Dulbecco\u2019s modified Eagle medium (DMEM) accelerated the degradation process (88,102).Effect of Size ::: Clearance ::: Biological Behavior of MSNs: Biocompatibility, Biodistribution, Biodegradability and ClearanceHe et al .", [["FBS", "ANATOMY", 134, 137], ["DMEM", "CHEMICAL", 179, 183], ["MSNs", "SIMPLE_CHEMICAL", 42, 46], ["FBS", "ORGANISM_SUBSTANCE", 134, 137], ["ARs", "TEST", 98, 101], ["FBS", "TEST", 134, 137], ["the degradation process", "PROBLEM", 197, 220], ["spherical MSNs", "OBSERVATION", 32, 46], ["FBS", "OBSERVATION", 134, 137], ["Size", "OBSERVATION_MODIFIER", 240, 244], ["Biocompatibility", "OBSERVATION_MODIFIER", 292, 308]]], ["(104) reported an in-depth study of bare MSNs of various diameters (80, 120, 200, and 360 nm) and observed a significant nanoparticles excretion from 15 to 45% after the first 30 min with consistently higher excretion percentages for larger nanoparticles.", [["an in-depth study", "TEST", 15, 32], ["a significant nanoparticles excretion", "TEST", 107, 144], ["larger nanoparticles", "PROBLEM", 234, 254], ["diameters", "OBSERVATION_MODIFIER", 57, 66], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["nanoparticles excretion", "OBSERVATION", 121, 144], ["larger", "OBSERVATION_MODIFIER", 234, 240], ["nanoparticles", "OBSERVATION", 241, 254]]], ["(105) have shown that nonporous silica quantum dots (3-6 nm) can be effectively (\u2248 70%) cleared out of an animal body by renal excretion in 2 days, while Kumar et al .", [["body", "ANATOMY", 113, 117], ["renal", "ANATOMY", 121, 126], ["silica", "CHEMICAL", 32, 38], ["silica", "CHEMICAL", 32, 38], ["silica quantum dots", "SIMPLE_CHEMICAL", 32, 51], ["body", "ORGANISM_SUBDIVISION", 113, 117], ["renal", "ORGAN", 121, 126], ["nonporous silica quantum dots", "PROBLEM", 22, 51], ["nonporous", "OBSERVATION_MODIFIER", 22, 31], ["silica quantum", "OBSERVATION", 32, 46], ["renal", "ANATOMY", 121, 126], ["excretion", "OBSERVATION", 127, 136]]], ["(106) showed that larger silica nanoparticles (20-25 nm) preferred hepatobiliary excretion, with a complete clearance over a period of 15 days.", [["hepatobiliary", "ANATOMY", 67, 80], ["silica", "CHEMICAL", 25, 31], ["silica", "CHEMICAL", 25, 31], ["silica nanoparticles", "SIMPLE_CHEMICAL", 25, 45], ["hepatobiliary", "ORGAN", 67, 80], ["larger silica nanoparticles", "PROBLEM", 18, 45], ["hepatobiliary excretion", "TEST", 67, 90], ["larger", "OBSERVATION_MODIFIER", 18, 24], ["silica nanoparticles", "OBSERVATION", 25, 45], ["hepatobiliary", "ANATOMY", 67, 80], ["excretion", "OBSERVATION", 81, 90]]], ["(107) studied dye-labeled nonporous silica nanoparticles of 50, 100 and 200 nm and demonstrated their clearance in the urine and bile.", [["urine", "ANATOMY", 119, 124], ["bile", "ANATOMY", 129, 133], ["silica nanoparticles", "CHEMICAL", 36, 56], ["silica", "CHEMICAL", 36, 42], ["nonporous silica nanoparticles", "SIMPLE_CHEMICAL", 26, 56], ["urine", "ORGANISM_SUBSTANCE", 119, 124], ["bile", "MULTI-TISSUE_STRUCTURE", 129, 133], ["dye-labeled nonporous silica nanoparticles", "TEST", 14, 56], ["their clearance in the urine", "TEST", 96, 124], ["urine", "OBSERVATION", 119, 124], ["bile", "ANATOMY", 129, 133]]], ["The 50 nm nanoparticles cleared faster than 100 and 200 nm ones, and 200 nm nanoparticles were less excreted.Effect of Surface Functions ::: Clearance ::: Biological Behavior of MSNs: Biocompatibility, Biodistribution, Biodegradability and ClearanceSome authors (96,104,108) showed that PEG-modified 45 nm nonporous silica nanoparticles exhibit a much longer blood circulation time (t\u00bd = 180 \u00b1 40 min) than unmodified silica nanoparticles (t\u00bd = 80 \u00b1 30 min) and carboxylated silica nanoparticles (t\u00bd = 35 \u00b1 10 min), being partly excreted via renal clearance.", [["blood", "ANATOMY", 359, 364], ["renal", "ANATOMY", 542, 547], ["PEG", "CHEMICAL", 287, 290], ["silica", "CHEMICAL", 316, 322], ["silica nanoparticles", "CHEMICAL", 418, 438], ["carboxylated silica", "CHEMICAL", 462, 481], ["PEG", "CHEMICAL", 287, 290], ["silica", "CHEMICAL", 316, 322], ["silica", "CHEMICAL", 418, 424], ["silica", "CHEMICAL", 475, 481], ["PEG", "SIMPLE_CHEMICAL", 287, 290], ["nonporous silica nanoparticles", "SIMPLE_CHEMICAL", 306, 336], ["blood", "ORGANISM_SUBSTANCE", 359, 364], ["silica nanoparticles", "SIMPLE_CHEMICAL", 418, 438], ["carboxylated silica nanoparticles", "SIMPLE_CHEMICAL", 462, 495], ["renal", "ORGAN", 542, 547], ["The 50 nm nanoparticles", "TEST", 0, 23], ["PEG", "TREATMENT", 287, 290], ["modified 45 nm nonporous silica nanoparticles", "TREATMENT", 291, 336], ["unmodified silica nanoparticles", "TREATMENT", 407, 438], ["carboxylated silica nanoparticles", "TREATMENT", 462, 495], ["renal", "ANATOMY", 542, 547], ["clearance", "OBSERVATION", 548, 557]]], ["A stealth behavior is acquired by PEGylation, which reduces the RES uptake and increases the circulation half-life.", [["RES", "CHEMICAL", 64, 67], ["RES", "SIMPLE_CHEMICAL", 64, 67], ["A stealth behavior", "PROBLEM", 0, 18], ["PEGylation", "TREATMENT", 34, 44], ["the RES uptake", "PROBLEM", 60, 74], ["PEGylation", "OBSERVATION", 34, 44]]], ["As a result, PEGylated MSNs of various sizes (80, 120, 200, and 360 nm) were excreted slower than unfunctionalized ones due to the much slower particle capture by the liver and spleen.Effect of Charge ::: Clearance ::: Biological Behavior of MSNs: Biocompatibility, Biodistribution, Biodegradability and ClearanceThe particle charge-clearance dependence studies indicated that MSNs with a positive charge (+34 mV) at neutral pH are rapidly excreted from the liver into the gastrointestinal tract and then eliminated through the feces, while negatively charged (\u221218 mV) MSNs remained trapped in the liver (104,109).Effect of Morphology ::: Clearance ::: Biological Behavior of MSNs: Biocompatibility, Biodistribution, Biodegradability and ClearanceThe morphology influence on the clearance displayed that mesoporous silica nanorods of aspect ratio \u22481.5 (185 \u00b1 22 nm long) are more rapidly cleared than longer nanorods of aspect ratio around 5 (720 \u00b1 65 nm long).", [["liver", "ANATOMY", 167, 172], ["spleen", "ANATOMY", 177, 183], ["liver", "ANATOMY", 458, 463], ["gastrointestinal tract", "ANATOMY", 473, 495], ["feces", "ANATOMY", 528, 533], ["liver", "ANATOMY", 598, 603], ["MSNs", "CHEMICAL", 23, 27], ["MSNs", "CHEMICAL", 377, 381], ["silica nanorods", "CHEMICAL", 815, 830], ["silica", "CHEMICAL", 815, 821], ["PEGylated MSNs", "SIMPLE_CHEMICAL", 13, 27], ["liver", "ORGAN", 167, 172], ["spleen", "ORGAN", 177, 183], ["MSNs", "SIMPLE_CHEMICAL", 377, 381], ["liver", "ORGAN", 458, 463], ["gastrointestinal tract", "ORGAN", 473, 495], ["feces", "ORGANISM_SUBSTANCE", 528, 533], ["liver", "ORGAN", 598, 603], ["mesoporous silica nanorods", "SIMPLE_CHEMICAL", 804, 830], ["clearance dependence studies", "TEST", 333, 361], ["neutral pH", "TEST", 417, 427], ["the clearance", "TEST", 775, 788], ["mesoporous silica nanorods of", "TREATMENT", 804, 833], ["aspect ratio", "TEST", 834, 846], ["aspect ratio", "TEST", 920, 932], ["PEGylated MSNs", "OBSERVATION", 13, 27], ["sizes", "OBSERVATION_MODIFIER", 39, 44], ["particle capture", "OBSERVATION", 143, 159], ["liver", "ANATOMY", 167, 172], ["spleen", "ANATOMY", 177, 183], ["Biocompatibility", "OBSERVATION", 248, 264], ["liver", "ANATOMY", 458, 463], ["gastrointestinal tract", "ANATOMY", 473, 495], ["feces", "OBSERVATION", 528, 533], ["trapped", "OBSERVATION", 583, 590], ["liver", "ANATOMY", 598, 603], ["Biocompatibility", "OBSERVATION", 682, 698], ["mesoporous", "OBSERVATION", 804, 814], ["silica nanorods", "OBSERVATION", 815, 830], ["rapidly", "OBSERVATION_MODIFIER", 880, 887]]], ["Comparing spherical-shaped and rod-shaped MSNs, nanospheres were mostly excreted during the first few hours, while nanorods had slower clearance rates (88,99).", [["MSNs", "SIMPLE_CHEMICAL", 42, 46], ["slower clearance rates", "PROBLEM", 128, 150], ["spherical", "OBSERVATION_MODIFIER", 10, 19], ["shaped", "OBSERVATION_MODIFIER", 20, 26], ["rod-shaped", "OBSERVATION_MODIFIER", 31, 41], ["MSNs", "OBSERVATION_MODIFIER", 42, 46], ["nanospheres", "OBSERVATION_MODIFIER", 48, 59]]], ["Several research groups consistently found nearly intact MSNs in the mice urine.", [["urine", "ANATOMY", 74, 79], ["MSNs", "CELL", 57, 61], ["mice", "ORGANISM", 69, 73], ["urine", "ORGANISM_SUBSTANCE", 74, 79], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 69, 73], ["intact", "OBSERVATION_MODIFIER", 50, 56], ["MSNs", "OBSERVATION", 57, 61]]], ["Rod-shaped MSNs of various aspect ratios were also found in the urine and feces of mice (96).Bacterial Infections ::: MSNs for Infectious Diseases TreatmentThe great challenge concerning bacterial infections treatment comprises the development of antibiotic resistance in several bacteria species, leading to ineffective treatment.", [["urine", "ANATOMY", 64, 69], ["feces", "ANATOMY", 74, 79], ["Infectious Diseases", "DISEASE", 127, 146], ["bacterial infections", "DISEASE", 187, 207], ["MSNs", "CELL", 11, 15], ["urine", "ORGANISM_SUBSTANCE", 64, 69], ["feces", "ORGANISM_SUBSTANCE", 74, 79], ["mice", "ORGANISM", 83, 87], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["the urine", "TEST", 60, 69], ["Infectious Diseases Treatment", "TREATMENT", 127, 156], ["bacterial infections treatment", "TREATMENT", 187, 217], ["antibiotic resistance", "PROBLEM", 247, 268], ["several bacteria species", "PROBLEM", 272, 296], ["ineffective treatment", "TREATMENT", 309, 330], ["shaped", "OBSERVATION_MODIFIER", 4, 10], ["MSNs", "OBSERVATION_MODIFIER", 11, 15], ["Infections", "OBSERVATION", 103, 113], ["bacterial", "OBSERVATION_MODIFIER", 187, 196], ["infections", "OBSERVATION", 197, 207], ["antibiotic resistance", "OBSERVATION", 247, 268], ["bacteria species", "OBSERVATION", 280, 296], ["ineffective", "OBSERVATION_MODIFIER", 309, 320]]], ["One way to overcome this drawback consists on to use nanoparticles that can interact efficiently to the bacterial surface disrupting their cell wall leading to cell death.", [["surface", "ANATOMY", 114, 121], ["cell wall", "ANATOMY", 139, 148], ["cell", "ANATOMY", 160, 164], ["death", "DISEASE", 165, 170], ["bacterial surface", "CELLULAR_COMPONENT", 104, 121], ["cell wall", "CELLULAR_COMPONENT", 139, 148], ["cell", "CELL", 160, 164], ["nanoparticles", "TREATMENT", 53, 66], ["cell death", "PROBLEM", 160, 170], ["cell death", "OBSERVATION", 160, 170]]], ["Interestingly, multifunctional nanoparticles can also interact with cellular organelles and biomolecules present in the bacteria, making difficult the resistance development against them (1,151).Bacterial Infections ::: MSNs for Infectious Diseases TreatmentConsidering the abovementioned advantages, authors have reported the use of MSNs containing peptides with antibacterial properties, aiming to prevent their enzymatic degradation potentiating their antimicrobial activity (110).", [["cellular organelles", "ANATOMY", 68, 87], ["Infectious Diseases", "DISEASE", 229, 248], ["cellular organelles", "CELLULAR_COMPONENT", 68, 87], ["MSNs", "SIMPLE_CHEMICAL", 334, 338], ["the bacteria", "PROBLEM", 116, 128], ["Infectious Diseases Treatment", "TREATMENT", 229, 258], ["MSNs containing peptides", "TREATMENT", 334, 358], ["antibacterial properties", "TREATMENT", 364, 388], ["their enzymatic degradation", "PROBLEM", 408, 435], ["nanoparticles", "OBSERVATION", 31, 44], ["cellular organelles", "OBSERVATION", 68, 87], ["biomolecules", "OBSERVATION_MODIFIER", 92, 104], ["bacteria", "OBSERVATION_MODIFIER", 120, 128], ["Infections", "OBSERVATION", 205, 215]]], ["It can also guarantee the same effect for loading antimicrobial proteins (115).", [["antimicrobial proteins", "PROTEIN", 50, 72], ["loading antimicrobial proteins", "TREATMENT", 42, 72]]], ["Other studies reported the use of hydrophobic antimicrobials drugs-loaded MSNs to enhance their effect in biological media (112,113,118).", [["MSNs", "CHEMICAL", 74, 78], ["MSNs", "SIMPLE_CHEMICAL", 74, 78], ["Other studies", "TEST", 0, 13], ["hydrophobic antimicrobials drugs", "TREATMENT", 34, 66], ["loaded MSNs", "TREATMENT", 67, 78]]], ["On the other hand, for hydrophilic antimicrobial drugs which are very soluble in an aqueous/biological environments, MSNs can also promote a controlled drug release (116).Bacterial Infections ::: MSNs for Infectious Diseases TreatmentThe association of multifunctional MSNs with antimicrobial drugs allows besides controlled drug release, efficient internalization in the bacterial environment (111,152).", [["MSNs", "CHEMICAL", 117, 121], ["Infectious Diseases", "DISEASE", 205, 224], ["MSNs", "SIMPLE_CHEMICAL", 117, 121], ["MSNs", "SIMPLE_CHEMICAL", 269, 273], ["hydrophilic antimicrobial drugs", "TREATMENT", 23, 54], ["Infectious Diseases Treatment", "TREATMENT", 205, 234], ["multifunctional MSNs", "TREATMENT", 253, 273], ["antimicrobial drugs", "TREATMENT", 279, 298], ["controlled drug release", "TREATMENT", 314, 337], ["Infections", "OBSERVATION", 181, 191], ["bacterial environment", "OBSERVATION", 372, 393]]], ["Drug-loaded mesoporous silica carriers were reported to access bone infections since fluids circulation in this region is very low which reduce drugs bioavailability via conventional administration (114,117).", [["bone", "ANATOMY", 63, 67], ["mesoporous silica", "CHEMICAL", 12, 29], ["bone infections", "DISEASE", 63, 78], ["silica", "CHEMICAL", 23, 29], ["Drug", "SIMPLE_CHEMICAL", 0, 4], ["mesoporous silica carriers", "SIMPLE_CHEMICAL", 12, 38], ["bone", "TISSUE", 63, 67], ["Drug-loaded mesoporous silica carriers", "TREATMENT", 0, 38], ["bone infections", "PROBLEM", 63, 78], ["fluids circulation", "TREATMENT", 85, 103], ["very low", "PROBLEM", 122, 130], ["mesoporous silica carriers", "OBSERVATION", 12, 38], ["bone", "ANATOMY", 63, 67], ["infections", "OBSERVATION", 68, 78]]], ["In addition, the MSNs specificity can be achieved by easily functionalization improving nanoplatforms action in target sites and controlled drugs release minimizing side effects.", [["sites", "ANATOMY", 119, 124], ["MSNs", "SIMPLE_CHEMICAL", 17, 21], ["nanoplatforms action", "TREATMENT", 88, 108], ["controlled drugs", "TREATMENT", 129, 145], ["side effects", "PROBLEM", 165, 177]]], ["Table III summarized examples of MSNs for bacterial infections treatment as well as drugs type, MSNs-based carriers, microorganisms and drugs absorption and release mechanisms.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentBacterial conventional treatment possesses challenges mainly due to the poor antimicrobial compound\u2019s permeation into the infected cells.", [["cells", "ANATOMY", 370, 375], ["bacterial infections", "DISEASE", 42, 62], ["MSNs", "CHEMICAL", 96, 100], ["Infectious Diseases", "DISEASE", 210, 229], ["MSNs", "SIMPLE_CHEMICAL", 33, 37], ["MSNs", "SIMPLE_CHEMICAL", 96, 100], ["cells", "CELL", 370, 375], ["infected cells", "CELL_TYPE", 361, 375], ["bacterial infections treatment", "TREATMENT", 42, 72], ["microorganisms", "PROBLEM", 117, 131], ["drugs absorption", "PROBLEM", 136, 152], ["Infectious Diseases", "TREATMENT", 210, 229], ["Bacterial conventional treatment possesses challenges", "TREATMENT", 239, 292], ["the poor antimicrobial compound", "PROBLEM", 307, 338], ["the infected cells", "PROBLEM", 357, 375], ["infections", "OBSERVATION", 52, 62], ["Infections", "OBSERVATION", 186, 196], ["Infectious", "OBSERVATION_MODIFIER", 210, 220], ["infected cells", "OBSERVATION", 361, 375]]], ["(110) proposed to evaluate distinct size of MSNs containing rifampicin (RIF) aiming to improve the intracellular bacterial infection treatment.", [["intracellular", "ANATOMY", 99, 112], ["rifampicin", "CHEMICAL", 60, 70], ["RIF", "CHEMICAL", 72, 75], ["infection", "DISEASE", 123, 132], ["rifampicin", "CHEMICAL", 60, 70], ["RIF", "CHEMICAL", 72, 75], ["MSNs", "SIMPLE_CHEMICAL", 44, 48], ["rifampicin", "SIMPLE_CHEMICAL", 60, 70], ["RIF", "SIMPLE_CHEMICAL", 72, 75], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 112], ["MSNs containing rifampicin", "TREATMENT", 44, 70], ["the intracellular bacterial infection treatment", "TREATMENT", 95, 142], ["size", "OBSERVATION_MODIFIER", 36, 40], ["rifampicin", "OBSERVATION_MODIFIER", 60, 70], ["intracellular", "OBSERVATION_MODIFIER", 99, 112], ["bacterial", "OBSERVATION_MODIFIER", 113, 122], ["infection", "OBSERVATION", 123, 132]]], ["Spherical MSNs were fabricated with average size of 40 and 100 nm (labeled MSNs-40 and MSNs-100, respectively), zeta potential values of -20 and -16.9 mV, respectively and pores size ranging from 8 to 9 nm.", [["MSNs", "CELL", 10, 14], ["average size", "TEST", 36, 48], ["labeled MSNs", "TEST", 67, 79], ["MSNs", "TEST", 87, 91], ["zeta potential values", "TEST", 112, 133], ["mV", "TEST", 151, 153], ["pores size", "TEST", 172, 182], ["average", "OBSERVATION_MODIFIER", 36, 43], ["size", "OBSERVATION_MODIFIER", 44, 48], ["pores", "OBSERVATION_MODIFIER", 172, 177], ["size", "OBSERVATION_MODIFIER", 178, 182], ["8 to 9 nm", "OBSERVATION_MODIFIER", 196, 205]]], ["RIF was successfully encapsulated into MSNs-40 and MSNs-100 via passive diffusion method, showing encapsulation efficiency (EE) values of 26.8 and 22.5%, respectively.", [["RIF", "CHEMICAL", 0, 3], ["MSNs-40", "CHEMICAL", 39, 46], ["MSNs-100", "CHEMICAL", 51, 59], ["RIF", "SIMPLE_CHEMICAL", 0, 3], ["MSNs-40", "CELL", 39, 46], ["MSNs-100", "SIMPLE_CHEMICAL", 51, 59], ["RIF", "TEST", 0, 3], ["MSNs", "TEST", 39, 43], ["MSNs", "TEST", 51, 55], ["passive diffusion method", "TEST", 64, 88], ["encapsulation efficiency", "PROBLEM", 98, 122], ["encapsulation efficiency", "OBSERVATION", 98, 122]]], ["Cellular uptake assays performed in RAW 264.7 cells exhibited interesting MSNs-100 macrophage internalization achieving up to 80%, whereas MSNs-40 showed lower uptake values (up to 40%), assigned to the exocytosis process more pronounced for smaller nanoparticles.", [["Cellular", "ANATOMY", 0, 8], ["RAW 264.7 cells", "ANATOMY", 36, 51], ["macrophage", "ANATOMY", 83, 93], ["MSNs-40", "CHEMICAL", 139, 146], ["Cellular", "CELL", 0, 8], ["RAW 264.7 cells", "CELL", 36, 51], ["MSNs-100 macrophage", "CELL", 74, 93], ["MSNs-40", "SIMPLE_CHEMICAL", 139, 146], ["RAW 264.7 cells", "CELL_LINE", 36, 51], ["Cellular uptake assays", "TEST", 0, 22], ["cells", "TEST", 46, 51], ["interesting MSNs", "TEST", 62, 78], ["macrophage internalization", "TEST", 83, 109], ["MSNs", "TEST", 139, 143], ["lower uptake values", "PROBLEM", 154, 173], ["the exocytosis process", "PROBLEM", 199, 221], ["smaller nanoparticles", "PROBLEM", 242, 263], ["uptake assays", "OBSERVATION", 9, 22], ["100 macrophage", "OBSERVATION_MODIFIER", 79, 93], ["uptake values", "OBSERVATION", 160, 173], ["more pronounced", "OBSERVATION_MODIFIER", 222, 237]]], ["From in vitro release assays, both RIF-loaded MSNs displayed low release rates up to 10% (in PBS buffer solution at pH 7.4).", [["RIF", "CHEMICAL", 35, 38], ["MSNs", "CHEMICAL", 46, 50], ["RIF", "CHEMICAL", 35, 38], ["RIF", "SIMPLE_CHEMICAL", 35, 38], ["MSNs", "SIMPLE_CHEMICAL", 46, 50], ["both RIF-loaded MSNs", "TREATMENT", 30, 50], ["low release rates", "PROBLEM", 61, 78], ["PBS buffer solution", "TREATMENT", 93, 112], ["pH", "TEST", 116, 118]]], ["In contrast, at pH 5.0, no changes were detected in release profile for both nanosystems within 12 h, attributed to the low RIF solubility.", [["RIF", "CHEMICAL", 124, 127], ["RIF", "CHEMICAL", 124, 127], ["RIF", "SIMPLE_CHEMICAL", 124, 127], ["pH", "TEST", 16, 18], ["the low RIF solubility", "PROBLEM", 116, 138], ["low RIF", "OBSERVATION_MODIFIER", 120, 127]]], ["Intracellular infection model was established using small colony variants (SCV) of Staphylococcus aureus in macrophages.", [["Intracellular", "ANATOMY", 0, 13], ["colony", "ANATOMY", 58, 64], ["macrophages", "ANATOMY", 108, 119], ["infection", "DISEASE", 14, 23], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Staphylococcus aureus", "ORGANISM", 83, 104], ["macrophages", "CELL", 108, 119], ["macrophages", "CELL_TYPE", 108, 119], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Intracellular infection model", "PROBLEM", 0, 29], ["small colony variants", "PROBLEM", 52, 73], ["Staphylococcus aureus in macrophages", "PROBLEM", 83, 119], ["infection", "OBSERVATION", 14, 23], ["small", "OBSERVATION_MODIFIER", 52, 57], ["colony variants", "OBSERVATION", 58, 73], ["SCV", "ANATOMY", 75, 78], ["Staphylococcus aureus", "OBSERVATION", 83, 104], ["macrophages", "OBSERVATION_MODIFIER", 108, 119]]], ["Results exhibited high MSNs-RIF internalization and an antibacterial activity enhancement regarding free RIF solution.", [["RIF", "CHEMICAL", 28, 31], ["RIF", "CHEMICAL", 105, 108], ["RIF", "CHEMICAL", 105, 108], ["MSNs", "SIMPLE_CHEMICAL", 23, 27], ["RIF", "SIMPLE_CHEMICAL", 28, 31], ["RIF", "SIMPLE_CHEMICAL", 105, 108], ["high MSNs", "TREATMENT", 18, 27], ["RIF internalization", "TREATMENT", 28, 47], ["an antibacterial activity enhancement", "TREATMENT", 52, 89], ["free RIF solution", "TREATMENT", 100, 117], ["high MSNs", "OBSERVATION", 18, 27], ["antibacterial activity", "OBSERVATION", 55, 77]]], ["Authors concluded that despites low release rates achieved, high internalization and bacterial activity enable these nanoplatforms to treat bacterial biofilms.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentRegarding bacterial biofilms infections and resistance, Vallet-Reg\u00ed group (8,111) developed a smart nanocarrier based on antibiotic levofloxacin (LEVO)-loaded MSNs decorated with the lectin concanavalin A (ConA), as displayed in Fig. 4.", [["biofilms", "ANATOMY", 150, 158], ["Infectious Diseases", "DISEASE", 193, 212], ["bacterial biofilms infections", "DISEASE", 232, 261], ["levofloxacin", "CHEMICAL", 354, 366], ["LEVO", "CHEMICAL", 368, 372], ["concanavalin A", "CHEMICAL", 412, 426], ["levofloxacin", "CHEMICAL", 354, 366], ["LEVO", "CHEMICAL", 368, 372], ["levofloxacin", "SIMPLE_CHEMICAL", 354, 366], ["LEVO", "SIMPLE_CHEMICAL", 368, 372], ["MSNs", "SIMPLE_CHEMICAL", 381, 385], ["concanavalin A", "SIMPLE_CHEMICAL", 412, 426], ["ConA", "SIMPLE_CHEMICAL", 428, 432], ["lectin concanavalin A", "PROTEIN", 405, 426], ["ConA", "PROTEIN", 428, 432], ["low release rates", "TREATMENT", 32, 49], ["high internalization", "TREATMENT", 60, 80], ["bacterial activity", "TREATMENT", 85, 103], ["these nanoplatforms", "TREATMENT", 111, 130], ["bacterial biofilms", "PROBLEM", 140, 158], ["Infectious Diseases Treatment", "TREATMENT", 193, 222], ["bacterial biofilms infections", "PROBLEM", 232, 261], ["resistance", "PROBLEM", 266, 276], ["a smart nanocarrier", "TREATMENT", 314, 333], ["antibiotic levofloxacin", "TREATMENT", 343, 366], ["LEVO", "TREATMENT", 368, 372], ["the lectin concanavalin", "TREATMENT", 401, 424], ["Infections", "OBSERVATION", 169, 179]]], ["ConA was used to aggregate specificity to the nanosystem promoting better internalization into biofilm and then antimicrobial activity.", [["biofilm", "ANATOMY", 95, 102], ["ConA", "SIMPLE_CHEMICAL", 0, 4], ["antimicrobial activity", "TREATMENT", 112, 134]]], ["MCM-41-like MSNs with spherical shape of 150 nm in size and hexagonal pores channels structure were fabricated.", [["MCM-41", "CHEMICAL", 0, 6], ["MCM", "TEST", 0, 3], ["hexagonal pores channels structure", "TREATMENT", 60, 94], ["spherical", "OBSERVATION_MODIFIER", 22, 31], ["shape", "OBSERVATION_MODIFIER", 32, 37], ["150 nm", "OBSERVATION_MODIFIER", 41, 47], ["size", "OBSERVATION_MODIFIER", 51, 55], ["hexagonal", "OBSERVATION", 60, 69], ["pores channels", "OBSERVATION", 70, 84]]], ["In vitro release tests displayed that bare MSNs retained drug release achieving up to 30% after 48 h.", [["MSNs", "SIMPLE_CHEMICAL", 43, 47], ["vitro release tests", "TEST", 3, 22]]], ["This can be attributed to the hydrogen bonding interaction between MSNs Si-OH groups and LEVO zwitterionic form.", [["Si-OH", "CHEMICAL", 72, 77], ["hydrogen", "CHEMICAL", 30, 38], ["Si-OH", "CHEMICAL", 72, 77], ["LEVO", "CHEMICAL", 89, 93], ["MSNs", "SIMPLE_CHEMICAL", 67, 71], ["Si-OH", "SIMPLE_CHEMICAL", 72, 77], ["LEVO zwitterionic form", "SIMPLE_CHEMICAL", 89, 111], ["the hydrogen bonding interaction", "PROBLEM", 26, 58], ["MSNs Si-OH groups", "TREATMENT", 67, 84], ["LEVO zwitterionic form", "TREATMENT", 89, 111], ["hydrogen bonding", "OBSERVATION", 30, 46]]], ["On the other hand, MSNConA promoted total LEVO release up to 5 days, assigned to the interaction of ConA protein on MSNs surface with LEVO that leads to its fast release from the mesopores.", [["MSNs surface", "ANATOMY", 116, 128], ["MSNConA", "CHEMICAL", 19, 26], ["LEVO", "CHEMICAL", 134, 138], ["MSNConA", "CHEMICAL", 19, 26], ["MSNConA", "SIMPLE_CHEMICAL", 19, 26], ["LEVO", "SIMPLE_CHEMICAL", 42, 46], ["ConA", "GENE_OR_GENE_PRODUCT", 100, 104], ["LEVO", "SIMPLE_CHEMICAL", 134, 138], ["LEVO", "PROTEIN", 42, 46], ["ConA protein", "PROTEIN", 100, 112], ["MSNConA", "TREATMENT", 19, 26], ["total LEVO release", "TREATMENT", 36, 54], ["ConA protein on MSNs surface", "TREATMENT", 100, 128], ["LEVO", "TREATMENT", 134, 138]]], ["The nanoantibiotic (labeled MSNConA@LEVO) targeting effect was successfully evaluated in Escherichia coli biofim exhibiting a dose dependent internalization, that means the greater is the MSNConA@LEVO concentration, the higher is the nanosystem penetration.", [["nanoantibiotic", "CHEMICAL", 4, 18], ["MSNConA@LEVO", "CHEMICAL", 28, 40], ["MSNConA@LEVO", "CHEMICAL", 188, 200], ["MSNConA@LEVO", "CHEMICAL", 188, 200], ["nanoantibiotic", "SIMPLE_CHEMICAL", 4, 18], ["MSNConA@LEVO", "SIMPLE_CHEMICAL", 28, 40], ["Escherichia coli", "ORGANISM", 89, 105], ["biofim", "ORGANISM", 106, 112], ["MSNConA@LEVO", "SIMPLE_CHEMICAL", 188, 200], ["nanosystem", "SIMPLE_CHEMICAL", 234, 244], ["Escherichia coli", "SPECIES", 89, 105], ["Escherichia coli", "SPECIES", 89, 105], ["The nanoantibiotic (labeled MSNConA@LEVO)", "TREATMENT", 0, 41], ["Escherichia coli biofim", "TREATMENT", 89, 112], ["a dose dependent internalization", "TREATMENT", 124, 156], ["the MSNConA@LEVO concentration", "TREATMENT", 184, 214], ["the nanosystem penetration", "TREATMENT", 230, 256], ["Escherichia coli", "OBSERVATION", 89, 105], ["greater", "OBSERVATION_MODIFIER", 173, 180], ["higher", "OBSERVATION_MODIFIER", 220, 226], ["nanosystem penetration", "OBSERVATION", 234, 256]]], ["The nanoplatform with negatively charged surface (potential zeta of -25 mV) promoted high electrostatic affinity toward the biofilm polysaccharide.", [["surface", "CELLULAR_COMPONENT", 41, 48], ["biofilm polysaccharide", "SIMPLE_CHEMICAL", 124, 146], ["zeta", "TEST", 60, 64], ["high electrostatic affinity", "PROBLEM", 85, 112], ["the biofilm polysaccharide", "TREATMENT", 120, 146], ["electrostatic affinity", "OBSERVATION", 90, 112]]], ["Antimicrobial in vitro assays were performed in three distinct MSNConA@LEVO concentrations (5, 10 and 20 \u03bcg mL-1).", [["MSNConA@LEVO", "CHEMICAL", 63, 75], ["MSNConA@LEVO", "SIMPLE_CHEMICAL", 63, 75], ["Antimicrobial in vitro assays", "TEST", 0, 29]]], ["Results confirm high internalization process displaying high antimicrobial efficacy values from 97 to 100%.", [["high internalization process", "PROBLEM", 16, 44], ["high antimicrobial efficacy values", "PROBLEM", 56, 90], ["high internalization", "OBSERVATION", 16, 36], ["high", "OBSERVATION_MODIFIER", 56, 60], ["antimicrobial efficacy", "OBSERVATION", 61, 83]]], ["Beyond that, cytotoxicity assays showed MSNConA@LEVO were nontoxic up to 50 \u03bcg mL-1 enabling these smart nanocarriers for further clinical translations.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentDeaconu et al .", [["MSNConA@LEVO", "CHEMICAL", 40, 52], ["Infectious Diseases", "DISEASE", 186, 205], ["MSNConA@LEVO", "CHEMICAL", 40, 52], ["MSNConA@LEVO", "SIMPLE_CHEMICAL", 40, 52], ["cytotoxicity assays", "TEST", 13, 32], ["MSNConA@LEVO", "TEST", 40, 52], ["these smart nanocarriers", "TREATMENT", 93, 117], ["Infectious Diseases", "PROBLEM", 186, 205], ["Infections", "OBSERVATION", 162, 172], ["Infectious", "OBSERVATION_MODIFIER", 186, 196]]], ["(112) reported the fabrication of norfloxacin (NFX)-loaded modified and unmodified MCM-type MSNs to evaluate their action against E. coli.", [["norfloxacin", "CHEMICAL", 34, 45], ["NFX", "CHEMICAL", 47, 50], ["norfloxacin", "CHEMICAL", 34, 45], ["NFX", "CHEMICAL", 47, 50], ["norfloxacin", "SIMPLE_CHEMICAL", 34, 45], ["NFX", "SIMPLE_CHEMICAL", 47, 50], ["MCM-type MSNs", "SIMPLE_CHEMICAL", 83, 96], ["E. coli", "ORGANISM", 130, 137], ["E. coli", "SPECIES", 130, 137], ["E. coli", "SPECIES", 130, 137], ["norfloxacin (NFX)", "TREATMENT", 34, 51], ["E. coli", "PROBLEM", 130, 137], ["coli", "OBSERVATION", 133, 137]]], ["Authors synthesized five types of MSNs: MCM-41 with long mesopores channels, pristine MSNs without surfactant (MSN), surfactant non-extracted (MSN-E), modified with vinyl groups (MSN-vinyl) and MCM-48 nanosystems.", [["MSN", "CHEMICAL", 111, 114], ["MSN-E", "CHEMICAL", 143, 148], ["MSN-vinyl", "CHEMICAL", 179, 188], ["MCM-41", "CHEMICAL", 40, 46], ["vinyl", "CHEMICAL", 165, 170], ["vinyl", "CHEMICAL", 183, 188], ["MCM-48", "CHEMICAL", 194, 200], ["MSNs", "CELL", 34, 38], ["MCM-41", "SIMPLE_CHEMICAL", 40, 46], ["MSNs", "SIMPLE_CHEMICAL", 86, 90], ["surfactant", "SIMPLE_CHEMICAL", 99, 109], ["MSN", "SIMPLE_CHEMICAL", 111, 114], ["surfactant non-extracted", "SIMPLE_CHEMICAL", 117, 141], ["MSN-E", "SIMPLE_CHEMICAL", 143, 148], ["vinyl groups", "SIMPLE_CHEMICAL", 165, 177], ["MSN-vinyl", "SIMPLE_CHEMICAL", 179, 188], ["MCM-48 nanosystems", "SIMPLE_CHEMICAL", 194, 212], ["MCM", "TEST", 40, 43], ["long mesopores channels", "TREATMENT", 52, 75]]], ["All MCM-type carriers showed spherical nanosized morphologies up to 60 nm.", [["spherical nanosized morphologies", "PROBLEM", 29, 61], ["nanosized morphologies", "OBSERVATION", 39, 61], ["60 nm", "OBSERVATION_MODIFIER", 68, 73]]], ["High surface area (up to 1222 m2 g-1) and pores size ranging from 2.5 to 9 nm were detected for these nanocarriers.", [["surface area", "ANATOMY", 5, 17], ["pores", "ANATOMY", 42, 47], ["High surface area", "PROBLEM", 0, 17], ["pores size", "TEST", 42, 52], ["these nanocarriers", "TREATMENT", 96, 114], ["surface", "OBSERVATION_MODIFIER", 5, 12], ["pores", "OBSERVATION_MODIFIER", 42, 47], ["size", "OBSERVATION_MODIFIER", 48, 52], ["2.5 to 9 nm", "OBSERVATION_MODIFIER", 66, 77]]], ["MCM-41 types exhibited hexagonal mesopores arrays with average size of 2.5-3.1 nm whereas MCM-48 showed interconnected pores forming cubic arrays with sizes of 2.5-9 nm.", [["MCM-48", "CHEMICAL", 90, 96], ["MCM-41", "CHEMICAL", 0, 6], ["MCM-48", "CHEMICAL", 90, 96], ["MCM", "TEST", 0, 3], ["hexagonal mesopores arrays", "TREATMENT", 23, 49], ["average size", "TEST", 55, 67], ["MCM", "TEST", 90, 93], ["interconnected pores forming cubic arrays", "TREATMENT", 104, 145], ["sizes", "TEST", 151, 156], ["hexagonal mesopores", "OBSERVATION", 23, 42], ["size", "OBSERVATION_MODIFIER", 63, 67], ["interconnected pores", "OBSERVATION", 104, 124], ["cubic arrays", "OBSERVATION", 133, 145], ["sizes", "OBSERVATION_MODIFIER", 151, 156]]], ["The successfully nanoconfinement into mesopores by impregnation method confirmed NFX amorphization.", [["NFX", "CHEMICAL", 81, 84], ["NFX", "CHEMICAL", 81, 84], ["NFX", "SIMPLE_CHEMICAL", 81, 84]]], ["In vitro release studies demonstrated NFX-loaded MSNs carriers enhanced dissolution rates regarding free NFX in same conditions.", [["NFX", "CHEMICAL", 38, 41], ["MSNs", "CHEMICAL", 49, 53], ["NFX", "CHEMICAL", 105, 108], ["NFX", "CHEMICAL", 38, 41], ["NFX", "CHEMICAL", 105, 108], ["NFX", "SIMPLE_CHEMICAL", 38, 41], ["MSNs", "SIMPLE_CHEMICAL", 49, 53], ["NFX", "SIMPLE_CHEMICAL", 105, 108], ["NFX", "PROTEIN", 105, 108], ["vitro release studies", "TEST", 3, 24], ["NFX-loaded MSNs carriers enhanced dissolution rates", "TREATMENT", 38, 89]]], ["In addition, the association and dissociation NFX-nanocarriers processes were considered reversible with a first-order kinetics.", [["NFX", "SIMPLE_CHEMICAL", 46, 49], ["the association and dissociation NFX-nanocarriers processes", "PROBLEM", 13, 72]]], ["In addition, high initial release of the antibiotic, which is suitable for applications in severe infections.", [["infections", "DISEASE", 98, 108], ["the antibiotic", "TREATMENT", 37, 51], ["severe infections", "PROBLEM", 91, 108], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["infections", "OBSERVATION", 98, 108]]], ["Authors concluded that NFX-loaded MCM-based nanocarriers displayed good and similar antibacterial activity compared to free NFX.", [["NFX", "CHEMICAL", 23, 26], ["NFX", "CHEMICAL", 124, 127], ["NFX", "CHEMICAL", 23, 26], ["NFX", "CHEMICAL", 124, 127], ["NFX", "SIMPLE_CHEMICAL", 23, 26], ["MCM-based nanocarriers", "SIMPLE_CHEMICAL", 34, 56], ["NFX", "SIMPLE_CHEMICAL", 124, 127], ["NFX", "PROTEIN", 124, 127], ["NFX", "TEST", 23, 26], ["MCM", "TREATMENT", 34, 37], ["antibacterial activity", "OBSERVATION", 84, 106]]], ["These nanosystems could be applied to avoid the use of high free NFX concentration, maximizing antibacterial effect in any biological media.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentConventional antibiotic treatments are less effective to S. aureus because this microorganism can invade host cells like osteoblasts and macrophages and use them as reservoir to reduce antibiotic action leading to infection recurrence.", [["cells", "ANATOMY", 313, 318], ["osteoblasts", "ANATOMY", 324, 335], ["macrophages", "ANATOMY", 340, 351], ["NFX", "CHEMICAL", 65, 68], ["Infectious Diseases", "DISEASE", 174, 193], ["infection", "DISEASE", 417, 426], ["NFX", "CHEMICAL", 65, 68], ["NFX", "SIMPLE_CHEMICAL", 65, 68], ["S. aureus", "ORGANISM", 260, 269], ["host cells", "CELL", 308, 318], ["osteoblasts", "CELL", 324, 335], ["macrophages", "CELL", 340, 351], ["host cells", "CELL_TYPE", 308, 318], ["osteoblasts", "CELL_TYPE", 324, 335], ["macrophages", "CELL_TYPE", 340, 351], ["S. aureus", "SPECIES", 260, 269], ["S. aureus", "SPECIES", 260, 269], ["These nanosystems", "TREATMENT", 0, 17], ["high free NFX concentration", "TREATMENT", 55, 82], ["maximizing antibacterial effect", "TREATMENT", 84, 115], ["Bacterial Infections", "PROBLEM", 140, 160], ["Infectious Diseases", "TREATMENT", 174, 193], ["Conventional antibiotic treatments", "TREATMENT", 203, 237], ["S. aureus", "PROBLEM", 260, 269], ["this microorganism", "PROBLEM", 278, 296], ["osteoblasts", "PROBLEM", 324, 335], ["macrophages", "PROBLEM", 340, 351], ["reservoir", "TREATMENT", 368, 377], ["antibiotic action", "TREATMENT", 388, 405], ["infection recurrence", "PROBLEM", 417, 437], ["Infections", "OBSERVATION", 150, 160], ["Infectious", "OBSERVATION_MODIFIER", 174, 184], ["infection", "OBSERVATION", 417, 426]]], ["(113) proposed to design a gentamicin (GEN)-loaded MSNs modified with a lipid bilayer surface shell and an bacterial-targeting peptide ubiquicidin (UBI29-41) onto lipid bilayer (labeled LU).", [["lipid bilayer", "ANATOMY", 163, 176], ["gentamicin", "CHEMICAL", 27, 37], ["GEN", "CHEMICAL", 39, 42], ["MSNs", "CHEMICAL", 51, 55], ["ubiquicidin", "CHEMICAL", 135, 146], ["UBI29-41", "CHEMICAL", 148, 156], ["gentamicin", "CHEMICAL", 27, 37], ["GEN", "CHEMICAL", 39, 42], ["ubiquicidin", "CHEMICAL", 135, 146], ["UBI29-41", "CHEMICAL", 148, 156], ["gentamicin", "SIMPLE_CHEMICAL", 27, 37], ["GEN", "SIMPLE_CHEMICAL", 39, 42], ["MSNs", "SIMPLE_CHEMICAL", 51, 55], ["ubiquicidin", "SIMPLE_CHEMICAL", 135, 146], ["UBI29-41", "SIMPLE_CHEMICAL", 148, 156], ["lipid bilayer", "SIMPLE_CHEMICAL", 163, 176], ["a gentamicin (GEN)-loaded MSNs", "TREATMENT", 25, 55], ["a lipid bilayer surface shell", "TREATMENT", 70, 99], ["an bacterial", "TEST", 104, 116], ["targeting peptide ubiquicidin", "TREATMENT", 117, 146], ["UBI29", "TEST", 148, 153]]], ["Spherical MSNs with highly ordered mesoporous channels and average size of 80 nm were synthesized.", [["mesoporous channels", "OBSERVATION", 35, 54], ["average", "OBSERVATION_MODIFIER", 59, 66], ["size", "OBSERVATION_MODIFIER", 67, 71], ["80 nm", "OBSERVATION_MODIFIER", 75, 80]]], ["GEN EE of 25.6% was achieved.", [["GEN", "CHEMICAL", 0, 3], ["EE", "CHEMICAL", 4, 6], ["GEN", "SIMPLE_CHEMICAL", 0, 3], ["GEN EE", "TEST", 0, 6]]], ["MSNs surface modification was firstly performed with liposome layer aiming to prevent nonspecific nanoparticles uptake under physiological conditions whereas the conjugated UBI29-41 allows the nanosystems targeting to bacteria in infected tissues.", [["surface", "ANATOMY", 5, 12], ["tissues", "ANATOMY", 239, 246], ["UBI29-41", "CHEMICAL", 173, 181], ["UBI29-41", "CHEMICAL", 173, 181], ["MSNs", "SIMPLE_CHEMICAL", 0, 4], ["UBI29-41", "SIMPLE_CHEMICAL", 173, 181], ["tissues", "TISSUE", 239, 246], ["MSNs surface modification", "TREATMENT", 0, 25], ["liposome layer", "TREATMENT", 53, 67], ["nonspecific nanoparticles uptake under physiological conditions", "PROBLEM", 86, 149], ["the conjugated UBI29", "TEST", 158, 178], ["the nanosystems", "TREATMENT", 189, 204], ["bacteria in infected tissues", "PROBLEM", 218, 246], ["infected tissues", "OBSERVATION", 230, 246]]], ["In addition, the liposomal bilayer can act as a blocker avoiding GEN leakage.", [["GEN", "CHEMICAL", 65, 68], ["GEN", "CHEMICAL", 65, 68], ["liposomal bilayer", "SIMPLE_CHEMICAL", 17, 34], ["GEN", "SIMPLE_CHEMICAL", 65, 68], ["the liposomal bilayer", "TREATMENT", 13, 34], ["a blocker", "TREATMENT", 46, 55], ["GEN leakage", "PROBLEM", 65, 76], ["leakage", "OBSERVATION", 69, 76]]], ["When the nanocarrier reaches the infected cells, the liposome can be degraded by bacterial enzymes and toxins.", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47], ["liposome", "SIMPLE_CHEMICAL", 53, 61], ["infected cells", "CELL_TYPE", 33, 47], ["bacterial enzymes", "PROTEIN", 81, 98], ["the liposome", "TREATMENT", 49, 61], ["bacterial enzymes", "TEST", 81, 98], ["toxins", "PROBLEM", 103, 109], ["infected cells", "OBSERVATION", 33, 47]]], ["In vitro and in vivo assays were performed on planktonic and intracellular infection of S. aureus bacteria.", [["intracellular", "ANATOMY", 61, 74], ["infection", "DISEASE", 75, 84], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["S. aureus bacteria", "ORGANISM", 88, 106], ["S. aureus", "SPECIES", 88, 97], ["S. aureus", "SPECIES", 88, 97], ["vivo assays", "TEST", 16, 27], ["intracellular infection", "PROBLEM", 61, 84], ["S. aureus bacteria", "PROBLEM", 88, 106], ["infection", "OBSERVATION", 75, 84], ["aureus bacteria", "OBSERVATION", 91, 106]]], ["In vitro tests revealed that the S. aureus growth on agar plates showed higher microbial inhibition for Gen@MSNs-LU than the unmodified nanosystem (GEN@MSNs) and free drug besides a responsive-bacterial toxin release.", [["Gen@MSNs", "CHEMICAL", 104, 112], ["GEN@MSNs", "CHEMICAL", 148, 156], ["S. aureus", "ORGANISM", 33, 42], ["Gen@MSNs-LU", "SIMPLE_CHEMICAL", 104, 115], ["nanosystem", "SIMPLE_CHEMICAL", 136, 146], ["GEN@MSNs", "SIMPLE_CHEMICAL", 148, 156], ["S. aureus", "SPECIES", 33, 42], ["S. aureus", "SPECIES", 33, 42], ["vitro tests", "TEST", 3, 14], ["the S. aureus growth", "PROBLEM", 29, 49], ["agar plates", "TEST", 53, 64], ["Gen@MSNs", "TEST", 104, 112], ["free drug", "TREATMENT", 162, 171], ["a responsive-bacterial toxin release", "TREATMENT", 180, 216], ["aureus", "OBSERVATION", 36, 42]]], ["From in vivo assays, high specificity, bacterial reduction and no infection recurrence were detected by using GEN@MSNs-LU.", [["infection", "DISEASE", 66, 75], ["vivo assays", "TEST", 8, 19], ["bacterial reduction", "PROBLEM", 39, 58], ["infection recurrence", "PROBLEM", 66, 86], ["no", "UNCERTAINTY", 63, 65], ["infection", "OBSERVATION", 66, 75]]], ["In addition, physiopathology studies were performed and no histological changes were detected in major organs indicating no organ toxicity when submitted to GEN@MSNs-LU treatment.", [["organs", "ANATOMY", 103, 109], ["organ", "ANATOMY", 124, 129], ["toxicity", "DISEASE", 130, 138], ["GEN@MSNs-LU", "CHEMICAL", 157, 168], ["organs", "ORGAN", 103, 109], ["organ", "ORGAN", 124, 129], ["GEN@MSNs-LU", "SIMPLE_CHEMICAL", 157, 168], ["physiopathology studies", "TEST", 13, 36], ["histological changes", "PROBLEM", 59, 79], ["organ toxicity", "PROBLEM", 124, 138], ["LU treatment", "TREATMENT", 166, 178], ["no", "UNCERTAINTY", 121, 123], ["organ", "ANATOMY", 124, 129], ["toxicity", "OBSERVATION", 130, 138]]], ["All these results enable this bacterial-responsive nanosytem as a promising and adaptable tool to delivery other drugs targeting distinct bacteria and, consequently, treat diverse kind of infections.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentInfected bone defects often cause limited blood circulation in the infected sites resulting in poor ability to self-heal for restoring the structure and function of bone tissue.", [["bone", "ANATOMY", 271, 275], ["blood", "ANATOMY", 304, 309], ["sites", "ANATOMY", 338, 343], ["bone tissue", "ANATOMY", 427, 438], ["infections", "DISEASE", 188, 198], ["Infectious Diseases", "DISEASE", 233, 252], ["bone defects", "DISEASE", 271, 283], ["nanosytem", "CANCER", 51, 60], ["bone", "TISSUE", 271, 275], ["blood", "ORGANISM_SUBSTANCE", 304, 309], ["bone tissue", "TISSUE", 427, 438], ["this bacterial-responsive nanosytem", "PROBLEM", 25, 60], ["delivery other drugs", "TREATMENT", 98, 118], ["distinct bacteria", "PROBLEM", 129, 146], ["infections", "PROBLEM", 188, 198], ["Bacterial Infections", "PROBLEM", 199, 219], ["Infectious Diseases", "PROBLEM", 233, 252], ["Infected bone defects", "PROBLEM", 262, 283], ["limited blood circulation", "PROBLEM", 296, 321], ["the infected sites", "PROBLEM", 325, 343], ["bone tissue", "PROBLEM", 427, 438], ["infections", "OBSERVATION", 188, 198], ["Infections", "OBSERVATION", 209, 219], ["Infectious", "OBSERVATION_MODIFIER", 233, 243], ["infected", "OBSERVATION", 329, 337], ["bone tissue", "ANATOMY", 427, 438]]], ["Take this into account, the development of bone implants based on specific and antibiotic controlled delivery systems is essential for an effective bone infection treatment.", [["bone", "ANATOMY", 43, 47], ["bone", "ANATOMY", 148, 152], ["bone infection", "DISEASE", 148, 162], ["bone", "TISSUE", 43, 47], ["bone", "TISSUE", 148, 152], ["bone implants", "TREATMENT", 43, 56], ["antibiotic controlled delivery systems", "TREATMENT", 79, 117], ["an effective bone infection treatment", "TREATMENT", 135, 172], ["bone", "ANATOMY", 43, 47], ["implants", "OBSERVATION", 48, 56], ["effective", "OBSERVATION_MODIFIER", 138, 147], ["bone", "ANATOMY", 148, 152], ["infection", "OBSERVATION", 153, 162]]], ["(114) designed scaffolds based on MSNs containing vancomycin (VAN) into mesopores channels dispersed in gelatinous matrix.", [["gelatinous matrix", "ANATOMY", 104, 121], ["vancomycin", "CHEMICAL", 50, 60], ["VAN", "CHEMICAL", 62, 65], ["vancomycin", "CHEMICAL", 50, 60], ["VAN", "CHEMICAL", 62, 65], ["MSNs", "SIMPLE_CHEMICAL", 34, 38], ["vancomycin", "SIMPLE_CHEMICAL", 50, 60], ["VAN", "SIMPLE_CHEMICAL", 62, 65], ["gelatinous matrix", "CELLULAR_COMPONENT", 104, 121], ["designed scaffolds", "TREATMENT", 6, 24], ["MSNs", "TREATMENT", 34, 38], ["vancomycin (VAN) into mesopores channels", "TREATMENT", 50, 90], ["gelatinous matrix", "OBSERVATION", 104, 121]]], ["In addition to control drug release, MSNs incorporated into polymer scaffolds can increase their mechanical properties, enhancing cell adhesion, proliferation and osteogenic osteoblasts differentiation.", [["cell", "ANATOMY", 130, 134], ["osteogenic osteoblasts", "ANATOMY", 163, 185], ["MSNs", "CHEMICAL", 37, 41], ["MSNs", "SIMPLE_CHEMICAL", 37, 41], ["cell", "CELL", 130, 134], ["osteoblasts", "CELL", 174, 185], ["control drug release", "TREATMENT", 15, 35], ["MSNs incorporated into polymer scaffolds", "TREATMENT", 37, 77], ["enhancing cell adhesion", "PROBLEM", 120, 143], ["proliferation", "PROBLEM", 145, 158], ["osteogenic osteoblasts differentiation", "PROBLEM", 163, 201], ["mechanical properties", "OBSERVATION_MODIFIER", 97, 118], ["enhancing cell adhesion", "OBSERVATION", 120, 143], ["proliferation", "OBSERVATION_MODIFIER", 145, 158], ["osteogenic osteoblasts differentiation", "OBSERVATION", 163, 201]]], ["In this context, spherical MSNs were successfully prepared with average size and pores diameter of 210 and 2.4 nm, respectively.", [["MSNs", "SIMPLE_CHEMICAL", 27, 31], ["pores diameter", "TEST", 81, 95], ["spherical MSNs", "OBSERVATION", 17, 31], ["size", "OBSERVATION_MODIFIER", 72, 76], ["pores", "OBSERVATION_MODIFIER", 81, 86], ["diameter", "OBSERVATION_MODIFIER", 87, 95], ["2.4 nm", "OBSERVATION_MODIFIER", 107, 113]]], ["In vitro VAN release was investigated for VAN@gelatin and VAN@MSNs/gelatin.", [["VAN", "CHEMICAL", 9, 12], ["VAN@gelatin", "CHEMICAL", 42, 53], ["VAN@gelatin", "CHEMICAL", 42, 53], ["VAN", "SIMPLE_CHEMICAL", 9, 12], ["VAN@gelatin", "SIMPLE_CHEMICAL", 42, 53], ["VAN@MSNs", "SIMPLE_CHEMICAL", 58, 66], ["gelatin", "SIMPLE_CHEMICAL", 67, 74], ["vitro VAN release", "TREATMENT", 3, 20], ["VAN@gelatin", "TREATMENT", 42, 53], ["VAN@MSNs", "TREATMENT", 58, 66], ["gelatin", "TREATMENT", 67, 74]]], ["While VAN@gelatin displayed an initial burst release (up to 45% in the first day), VAN@MSNs/gelatin presented an initial release of 19% (first day) and about 78% over 28 days, suggesting a sustained VAN release.", [["VAN@gelatin", "CHEMICAL", 6, 17], ["gelatin", "CHEMICAL", 92, 99], ["VAN", "CHEMICAL", 199, 202], ["VAN@gelatin", "SIMPLE_CHEMICAL", 6, 17], ["VAN@MSNs", "SIMPLE_CHEMICAL", 83, 91], ["gelatin", "SIMPLE_CHEMICAL", 92, 99], ["VAN", "SIMPLE_CHEMICAL", 199, 202], ["VAN@MSNs/gelatin", "TREATMENT", 83, 99], ["a sustained VAN release", "PROBLEM", 187, 210], ["burst", "OBSERVATION_MODIFIER", 39, 44]]], ["From in vitro antibacterial (S. aureus) assays, both composite systems showed antibacterial activity dose-dependent with 95% of growth inhibition at 60 \u03bcg mL-1.", [["S. aureus", "ORGANISM", 29, 38], ["S. aureus", "SPECIES", 29, 38], ["S. aureus", "SPECIES", 29, 38], ["S. aureus) assays", "TEST", 29, 46], ["antibacterial activity dose", "PROBLEM", 78, 105], ["growth inhibition", "TEST", 128, 145], ["aureus", "OBSERVATION", 32, 38], ["antibacterial activity", "OBSERVATION", 78, 100]]], ["Additionally, cytocompatibility tests were carried out presenting good spreadability and proliferation of bone mesenchymal stem cells (BMSCs) in the evaluated scaffolds.", [["bone mesenchymal stem cells", "ANATOMY", 106, 133], ["BMSCs", "ANATOMY", 135, 140], ["bone mesenchymal stem cells", "CELL", 106, 133], ["BMSCs", "CELL", 135, 140], ["bone mesenchymal stem cells", "CELL_TYPE", 106, 133], ["BMSCs", "CELL_TYPE", 135, 140], ["cytocompatibility tests", "TEST", 14, 37], ["proliferation of bone mesenchymal stem cells", "PROBLEM", 89, 133], ["bone", "ANATOMY", 106, 110], ["mesenchymal stem cells", "OBSERVATION", 111, 133]]], ["Osteogenic differentiation tests suggested that the incorporation of MSNs facilitated the osteogenic differentiation of BMSCs and VAN-loaded into mesopores had no negative effects on its bioactivity.", [["BMSCs", "ANATOMY", 120, 125], ["MSNs", "CHEMICAL", 69, 73], ["VAN", "CHEMICAL", 130, 133], ["MSNs", "SIMPLE_CHEMICAL", 69, 73], ["BMSCs", "CELL", 120, 125], ["VAN", "SIMPLE_CHEMICAL", 130, 133], ["BMSCs", "CELL_TYPE", 120, 125], ["Osteogenic differentiation tests", "TEST", 0, 32], ["the incorporation of MSNs", "TREATMENT", 48, 73], ["the osteogenic differentiation of BMSCs", "TREATMENT", 86, 125], ["VAN-loaded into mesopores", "TREATMENT", 130, 155], ["no", "UNCERTAINTY", 160, 162], ["negative effects", "OBSERVATION_MODIFIER", 163, 179]]], ["In vivo tests were established by bone infection induced in rabbits and the implantation of gelatin and MSNs/gelation were evaluated.", [["bone", "ANATOMY", 34, 38], ["bone infection", "DISEASE", 34, 48], ["gelatin", "CHEMICAL", 92, 99], ["MSNs", "CHEMICAL", 104, 108], ["bone", "TISSUE", 34, 38], ["rabbits", "ORGANISM", 60, 67], ["gelatin", "SIMPLE_CHEMICAL", 92, 99], ["MSNs", "SIMPLE_CHEMICAL", 104, 108], ["rabbits", "SPECIES", 60, 67], ["rabbits", "SPECIES", 60, 67], ["vivo tests", "TEST", 3, 13], ["bone infection", "PROBLEM", 34, 48], ["the implantation of gelatin and MSNs/gelation", "TREATMENT", 72, 117], ["bone", "ANATOMY", 34, 38], ["infection", "OBSERVATION", 39, 48]]], ["High leukocytes levels were detected after 8 weeks of treatment for both samples.", [["leukocytes", "ANATOMY", 5, 15], ["samples", "ANATOMY", 73, 80], ["leukocytes", "CELL", 5, 15], ["leukocytes", "CELL_TYPE", 5, 15], ["High leukocytes levels", "PROBLEM", 0, 22], ["treatment", "TREATMENT", 54, 63], ["leukocytes", "OBSERVATION", 5, 15]]], ["On the other hand, the implantation of VAN@MSNs/gelatin depicted the leukocyte concentration decreased significantly and reached a normal level after 4 weeks of treatment.", [["leukocyte", "ANATOMY", 69, 78], ["VAN@MSNs", "SIMPLE_CHEMICAL", 39, 47], ["gelatin", "SIMPLE_CHEMICAL", 48, 55], ["leukocyte", "CELL", 69, 78], ["VAN@MSNs", "PROTEIN", 39, 47], ["the implantation of VAN@MSNs/gelatin", "TREATMENT", 19, 55], ["the leukocyte concentration", "TEST", 65, 92], ["treatment", "TREATMENT", 161, 170], ["implantation", "OBSERVATION", 23, 35]]], ["The excellent result indicates that MSNs promoted a controlled VAN release at the specific site.", [["VAN", "CHEMICAL", 63, 66], ["VAN", "CHEMICAL", 63, 66], ["MSNs", "SIMPLE_CHEMICAL", 36, 40], ["VAN", "SIMPLE_CHEMICAL", 63, 66], ["a controlled VAN release", "TREATMENT", 50, 74]]], ["Authors concluded that the composite scaffolds based on MSNs as nanocarriers leaded to slow and prolonged VAN release inhibiting local infection in vivo and, consequently, bone regeneration, constituting a promising tool for infected bone defects therapy.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentThe antibiotic ciprofloxacin (CIP) possesses wide antibacterial spectra and good permeation for bone tissues, however, low blood circulation in bone site, high drug concentration and several side effects makes its direct application inviable.", [["bone", "ANATOMY", 172, 176], ["bone", "ANATOMY", 234, 238], ["bone tissues", "ANATOMY", 414, 426], ["blood", "ANATOMY", 441, 446], ["bone site", "ANATOMY", 462, 471], ["VAN", "CHEMICAL", 106, 109], ["infection", "DISEASE", 135, 144], ["infected bone defects", "DISEASE", 225, 246], ["Infectious Diseases", "DISEASE", 289, 308], ["ciprofloxacin", "CHEMICAL", 333, 346], ["CIP", "CHEMICAL", 348, 351], ["ciprofloxacin", "CHEMICAL", 333, 346], ["CIP", "CHEMICAL", 348, 351], ["MSNs", "SIMPLE_CHEMICAL", 56, 60], ["VAN", "SIMPLE_CHEMICAL", 106, 109], ["bone", "TISSUE", 172, 176], ["bone", "TISSUE", 234, 238], ["ciprofloxacin", "SIMPLE_CHEMICAL", 333, 346], ["CIP", "SIMPLE_CHEMICAL", 348, 351], ["bone tissues", "TISSUE", 414, 426], ["blood", "ORGANISM_SUBSTANCE", 441, 446], ["bone", "TISSUE", 462, 466], ["the composite scaffolds", "TREATMENT", 23, 46], ["MSNs", "TREATMENT", 56, 60], ["nanocarriers", "TREATMENT", 64, 76], ["prolonged VAN release", "TREATMENT", 96, 117], ["local infection in vivo", "PROBLEM", 129, 152], ["bone regeneration", "PROBLEM", 172, 189], ["infected bone defects therapy", "TREATMENT", 225, 254], ["Bacterial Infections", "PROBLEM", 255, 275], ["Infectious Diseases", "TREATMENT", 289, 308], ["The antibiotic ciprofloxacin (CIP)", "TREATMENT", 318, 352], ["wide antibacterial spectra", "TREATMENT", 363, 389], ["bone tissues", "PROBLEM", 414, 426], ["low blood circulation in bone site", "PROBLEM", 437, 471], ["high drug concentration", "TREATMENT", 473, 496], ["several side effects", "PROBLEM", 501, 521], ["infection", "OBSERVATION", 135, 144], ["bone", "ANATOMY", 172, 176], ["bone", "ANATOMY", 234, 238], ["defects", "OBSERVATION", 239, 246], ["Infections", "OBSERVATION", 265, 275], ["bone tissues", "ANATOMY", 414, 426], ["bone", "ANATOMY", 462, 466]]], ["(117) fabricated ciprofloxacin (CIP)-loaded SBA-16-type MSNs and SBA-16/hydroxyapatite (HA) composites for bone infection treatment.", [["bone", "ANATOMY", 107, 111], ["ciprofloxacin", "CHEMICAL", 17, 30], ["CIP", "CHEMICAL", 32, 35], ["SBA-16-type MSNs", "CHEMICAL", 44, 60], ["SBA-16/hydroxyapatite", "CHEMICAL", 65, 86], ["HA", "CHEMICAL", 88, 90], ["bone infection", "DISEASE", 107, 121], ["ciprofloxacin", "CHEMICAL", 17, 30], ["CIP", "CHEMICAL", 32, 35], ["SBA-16", "CHEMICAL", 65, 71], ["hydroxyapatite", "CHEMICAL", 72, 86], ["ciprofloxacin", "SIMPLE_CHEMICAL", 17, 30], ["CIP", "SIMPLE_CHEMICAL", 32, 35], ["SBA-16-type MSNs", "SIMPLE_CHEMICAL", 44, 60], ["SBA-16", "SIMPLE_CHEMICAL", 65, 71], ["hydroxyapatite", "SIMPLE_CHEMICAL", 72, 86], ["HA", "SIMPLE_CHEMICAL", 88, 90], ["bone", "TISSUE", 107, 111], ["fabricated ciprofloxacin (CIP", "TREATMENT", 6, 35], ["SBA", "TEST", 44, 47], ["SBA", "TEST", 65, 68], ["hydroxyapatite (HA) composites", "TREATMENT", 72, 102], ["bone infection treatment", "TREATMENT", 107, 131], ["bone", "ANATOMY", 107, 111], ["infection", "OBSERVATION", 112, 121]]], ["Both nanoplatforms were modified with 3-aminopropyltriethoxysilane (APTES), anchored with diethylenetriaminepentaacetic acid (DTPA) for chelating technetium-99m.", [["3-aminopropyltriethoxysilane", "CHEMICAL", 38, 66], ["APTES", "CHEMICAL", 68, 73], ["diethylenetriaminepentaacetic acid", "CHEMICAL", 90, 124], ["DTPA", "CHEMICAL", 126, 130], ["technetium", "CHEMICAL", 146, 156], ["3-aminopropyltriethoxysilane", "CHEMICAL", 38, 66], ["APTES", "CHEMICAL", 68, 73], ["diethylenetriaminepentaacetic acid", "CHEMICAL", 90, 124], ["DTPA", "CHEMICAL", 126, 130], ["technetium", "CHEMICAL", 146, 156], ["3-aminopropyltriethoxysilane", "SIMPLE_CHEMICAL", 38, 66], ["APTES", "SIMPLE_CHEMICAL", 68, 73], ["diethylenetriaminepentaacetic acid", "SIMPLE_CHEMICAL", 90, 124], ["DTPA", "SIMPLE_CHEMICAL", 126, 130], ["technetium-99m", "SIMPLE_CHEMICAL", 146, 160], ["Both nanoplatforms", "TREATMENT", 0, 18], ["3-aminopropyltriethoxysilane (APTES", "TREATMENT", 38, 73], ["diethylenetriaminepentaacetic acid (DTPA", "TREATMENT", 90, 130], ["chelating technetium", "TEST", 136, 156]]], ["The SBA-16 and SBA-16/HA exhibited ordered cubic mesoporous structures with average pores size of 3.4 and 3.8 nm, respectively.", [["SBA-16", "CHEMICAL", 4, 10], ["SBA-16", "CHEMICAL", 15, 21], ["SBA-16", "CHEMICAL", 4, 10], ["SBA-16", "SIMPLE_CHEMICAL", 4, 10], ["SBA-16", "SIMPLE_CHEMICAL", 15, 21], ["HA", "SIMPLE_CHEMICAL", 22, 24], ["SBA-16 and SBA-16/HA", "DNA", 4, 24], ["The SBA", "TEST", 0, 7], ["SBA", "TEST", 15, 18], ["HA", "PROBLEM", 22, 24], ["average pores size", "TEST", 76, 94], ["average", "OBSERVATION_MODIFIER", 76, 83], ["pores", "OBSERVATION_MODIFIER", 84, 89], ["size", "OBSERVATION_MODIFIER", 90, 94], ["3.8 nm", "OBSERVATION_MODIFIER", 106, 112]]], ["CIP loading ranging from 28 to 31% were detected for modified and unmodified SBA-16 carriers.", [["CIP", "CHEMICAL", 0, 3], ["CIP", "SIMPLE_CHEMICAL", 0, 3], ["SBA-16", "SIMPLE_CHEMICAL", 77, 83], ["CIP loading", "TEST", 0, 11]]], ["In vitro CIP release studies (SBF pH 7.3) displayed that SBA-16-APTES and SBA-16/HA-APTES were similar with initial burst release of 42-43% in the first 9 h, achieving the maximum release (51-53%) in 76 h.", [["SBA-16-APTES", "CHEMICAL", 57, 69], ["SBA-16/HA-APTES", "CHEMICAL", 74, 89], ["SBA-16-APTES", "CHEMICAL", 57, 69], ["SBA-16", "CHEMICAL", 74, 80], ["CIP", "SIMPLE_CHEMICAL", 9, 12], ["SBA-16-APTES", "SIMPLE_CHEMICAL", 57, 69], ["SBA-16", "SIMPLE_CHEMICAL", 74, 80], ["HA-APTES", "SIMPLE_CHEMICAL", 81, 89], ["SBF pH", "TEST", 30, 36], ["SBA", "TEST", 57, 60], ["APTES", "TEST", 64, 69], ["SBA", "TEST", 74, 77], ["HA-APTES", "TEST", 81, 89], ["initial burst release", "TEST", 108, 129], ["the maximum release", "TEST", 168, 187], ["burst", "OBSERVATION_MODIFIER", 116, 121]]], ["These results suggested that at SBF solution with pH 7.3, the nitrogen of piperazinyl ring is protonated and classified as a zwitterionic species, which can lead to great CIP interaction with the amine groups modified onto SBA-16 surface.", [["nitrogen", "CHEMICAL", 62, 70], ["piperazinyl", "CHEMICAL", 74, 85], ["amine", "CHEMICAL", 196, 201], ["nitrogen", "CHEMICAL", 62, 70], ["piperazinyl", "CHEMICAL", 74, 85], ["amine", "CHEMICAL", 196, 201], ["SBA-16", "CHEMICAL", 223, 229], ["piperazinyl ring", "SIMPLE_CHEMICAL", 74, 90], ["CIP", "SIMPLE_CHEMICAL", 171, 174], ["amine", "SIMPLE_CHEMICAL", 196, 201], ["SBF solution", "TEST", 32, 44], ["pH", "TEST", 50, 52], ["the nitrogen of piperazinyl ring", "TREATMENT", 58, 90], ["a zwitterionic species", "PROBLEM", 123, 145], ["great CIP interaction", "PROBLEM", 165, 186], ["the amine groups", "TREATMENT", 192, 208]]], ["In vitro antimicrobial assays by using S. aureus, Pseudomonas aeruginosa, E. coli and Bacillus cereus were performed for CIP@SBA-16-APTES and CIP@SBA-16/HA-APTES.", [["CIP@SBA-16-APTES", "CHEMICAL", 121, 137], ["CIP@SBA-16/HA-APTES", "CHEMICAL", 142, 161], ["CIP@SBA-16-APTES", "CHEMICAL", 121, 137], ["CIP@SBA-16", "CHEMICAL", 142, 152], ["S. aureus", "ORGANISM", 39, 48], ["Pseudomonas aeruginosa", "ORGANISM", 50, 72], ["E. coli", "ORGANISM", 74, 81], ["Bacillus cereus", "ORGANISM", 86, 101], ["CIP@SBA-16-APTES", "SIMPLE_CHEMICAL", 121, 137], ["CIP@SBA-16", "SIMPLE_CHEMICAL", 142, 152], ["HA-APTES", "SIMPLE_CHEMICAL", 153, 161], ["S. aureus", "SPECIES", 39, 48], ["Pseudomonas aeruginosa", "SPECIES", 50, 72], ["E. coli", "SPECIES", 74, 81], ["Bacillus cereus", "SPECIES", 86, 101], ["S. aureus", "SPECIES", 39, 48], ["Pseudomonas aeruginosa", "SPECIES", 50, 72], ["E. coli", "SPECIES", 74, 81], ["Bacillus cereus", "SPECIES", 86, 101], ["vitro antimicrobial assays", "TEST", 3, 29], ["S. aureus", "PROBLEM", 39, 48], ["Pseudomonas aeruginosa", "PROBLEM", 50, 72], ["E. coli", "PROBLEM", 74, 81], ["Bacillus cereus", "PROBLEM", 86, 101], ["CIP@SBA", "TEST", 121, 128], ["APTES", "TEST", 132, 137], ["CIP@SBA", "TEST", 142, 149], ["Bacillus cereus", "OBSERVATION", 86, 101]]], ["Both aminated platforms presented high antibacterial activity against all microorganisms especially relating to free CIP.", [["CIP", "CHEMICAL", 117, 120], ["CIP", "SIMPLE_CHEMICAL", 117, 120], ["high antibacterial activity", "PROBLEM", 34, 61], ["all microorganisms", "PROBLEM", 70, 88], ["free CIP", "PROBLEM", 112, 120], ["high", "OBSERVATION_MODIFIER", 34, 38], ["antibacterial activity", "OBSERVATION", 39, 61], ["free CIP", "OBSERVATION", 112, 120]]], ["It is worth emphasizing that the tested free CIP amount was approximately three times greater than CIP-loaded SBA-16 carriers.", [["SBA-16", "CHEMICAL", 110, 116], ["CIP", "CHEMICAL", 99, 102], ["SBA-16", "CHEMICAL", 110, 116], ["CIP", "SIMPLE_CHEMICAL", 45, 48], ["CIP", "SIMPLE_CHEMICAL", 99, 102], ["SBA-16", "SIMPLE_CHEMICAL", 110, 116], ["the tested free CIP amount", "PROBLEM", 29, 55]]], ["99mTc-DTPA-SBA-16-APTES and 99mTc-DTPA-SBA-16/HA-APTES were prepared as radiotracer platforms aiming to evaluate their in vivo biodistribution.", [["99mTc-DTPA", "CHEMICAL", 0, 10], ["SBA-16-APTES", "CHEMICAL", 11, 23], ["99mTc-DTPA", "CHEMICAL", 28, 38], ["SBA-16/HA-APTES", "CHEMICAL", 39, 54], ["99mTc", "CHEMICAL", 0, 5], ["DTPA", "CHEMICAL", 6, 10], ["SBA-16-APTES", "CHEMICAL", 11, 23], ["99mTc", "CHEMICAL", 28, 33], ["DTPA", "CHEMICAL", 34, 38], ["SBA-16/HA-APTES", "CHEMICAL", 39, 54], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 0, 10], ["SBA-16-APTES", "SIMPLE_CHEMICAL", 11, 23], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 28, 38], ["SBA-16/HA-APTES", "SIMPLE_CHEMICAL", 39, 54], ["99mTc-DTPA-SBA-16-APTES and 99mTc-DTPA-SBA-16/HA-APTES", "DNA", 0, 54], ["99mTc", "TEST", 0, 5], ["DTPA", "TEST", 6, 10], ["SBA", "TEST", 11, 14], ["APTES", "TEST", 18, 23], ["99mTc", "TEST", 28, 33], ["DTPA", "TEST", 34, 38], ["SBA", "TEST", 39, 42], ["radiotracer platforms", "TEST", 72, 93]]], ["Both nanosystems were mostly uptaken by liver and spleen, reaching the highest radioactivity level at 4 h post-injection.", [["liver", "ANATOMY", 40, 45], ["spleen", "ANATOMY", 50, 56], ["liver", "ORGAN", 40, 45], ["spleen", "ORGAN", 50, 56], ["nanosystems", "OBSERVATION", 5, 16], ["liver", "ANATOMY", 40, 45], ["spleen", "ANATOMY", 50, 56], ["highest", "OBSERVATION_MODIFIER", 71, 78], ["radioactivity", "OBSERVATION_MODIFIER", 79, 92]]], ["Considering bone uptake, a higher uptake for 99mTc-DTPA-SBA-16/HA-APTES was detected relating to 99mTc-DTPA-SBA-16-APTES, at 1 and 4 h post-injection.", [["bone", "ANATOMY", 12, 16], ["99mTc-DTPA-SBA-16/HA-APTES", "CHEMICAL", 45, 71], ["99mTc-DTPA-SBA-16-APTES", "CHEMICAL", 97, 120], ["99mTc", "CHEMICAL", 45, 50], ["DTPA", "CHEMICAL", 51, 55], ["SBA-16", "CHEMICAL", 56, 62], ["99mTc", "CHEMICAL", 97, 102], ["DTPA", "CHEMICAL", 103, 107], ["SBA-16-APTES", "CHEMICAL", 108, 120], ["bone", "TISSUE", 12, 16], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 45, 55], ["SBA-16", "SIMPLE_CHEMICAL", 56, 62], ["HA-APTES", "SIMPLE_CHEMICAL", 63, 71], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 97, 107], ["SBA-16-APTES", "SIMPLE_CHEMICAL", 108, 120], ["bone uptake", "TEST", 12, 23], ["a higher uptake", "TEST", 25, 40], ["99mTc", "TEST", 45, 50], ["DTPA", "TEST", 51, 55], ["SBA", "TEST", 56, 59], ["HA-APTES", "TEST", 63, 71], ["99mTc", "TEST", 97, 102], ["DTPA", "TEST", 103, 107], ["SBA", "TEST", 108, 111], ["APTES", "TEST", 115, 120], ["bone", "ANATOMY", 12, 16]]], ["These results suggested 99mTc-DTPA-SBA-16/HA-APTES was more specific for bone tissue than 99mTc-DTPA-SBA-16-APTES, which can be attributed to the presence of hydroxyapatite in the nanosystem that possesses high affinity for bone matrix.", [["bone tissue", "ANATOMY", 73, 84], ["bone matrix", "ANATOMY", 224, 235], ["99mTc-DTPA", "CHEMICAL", 24, 34], ["SBA-16/HA-APTES", "CHEMICAL", 35, 50], ["99mTc-DTPA-SBA-16-APTES", "CHEMICAL", 90, 113], ["hydroxyapatite", "CHEMICAL", 158, 172], ["99mTc", "CHEMICAL", 24, 29], ["DTPA", "CHEMICAL", 30, 34], ["SBA-16", "CHEMICAL", 35, 41], ["99mTc", "CHEMICAL", 90, 95], ["DTPA", "CHEMICAL", 96, 100], ["SBA-16-APTES", "CHEMICAL", 101, 113], ["hydroxyapatite", "CHEMICAL", 158, 172], ["99mTc-DTPA", "SIMPLE_CHEMICAL", 24, 34], ["SBA-16/HA-APTES", "SIMPLE_CHEMICAL", 35, 50], ["bone tissue", "TISSUE", 73, 84], ["99mTc-DTPA-SBA-16-APTES", "SIMPLE_CHEMICAL", 90, 113], ["hydroxyapatite", "SIMPLE_CHEMICAL", 158, 172], ["bone matrix", "CELLULAR_COMPONENT", 224, 235], ["99mTc", "TEST", 24, 29], ["DTPA", "TEST", 30, 34], ["SBA", "TEST", 35, 38], ["/HA", "TEST", 41, 44], ["APTES", "TEST", 45, 50], ["bone tissue", "TEST", 73, 84], ["99mTc", "TEST", 90, 95], ["DTPA", "TEST", 96, 100], ["SBA", "TEST", 101, 104], ["hydroxyapatite in the nanosystem", "TREATMENT", 158, 190], ["bone matrix", "PROBLEM", 224, 235], ["hydroxyapatite", "OBSERVATION", 158, 172]]], ["Authors pointed out that the fabrication of these nanocarriers are relevant showing low cost and easy preparation and effective CIP release, which make them promising nanoplatforms to treat bone infections.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentBacterial biofilm comprises up to 70% of infection and inflammation in clinic being usually resistant to the most conventional antibiotic treatment.", [["bone", "ANATOMY", 190, 194], ["bone infections", "DISEASE", 190, 205], ["Infectious Diseases", "DISEASE", 240, 259], ["Bacterial biofilm", "DISEASE", 269, 286], ["infection", "DISEASE", 310, 319], ["inflammation", "DISEASE", 324, 336], ["CIP", "SIMPLE_CHEMICAL", 128, 131], ["bone", "TISSUE", 190, 194], ["these nanocarriers", "TREATMENT", 44, 62], ["low cost", "PROBLEM", 84, 92], ["easy preparation", "TREATMENT", 97, 113], ["effective CIP release", "TREATMENT", 118, 139], ["bone infections", "PROBLEM", 190, 205], ["Bacterial Infections", "PROBLEM", 206, 226], ["Infectious Diseases", "PROBLEM", 240, 259], ["Bacterial biofilm", "PROBLEM", 269, 286], ["infection", "PROBLEM", 310, 319], ["inflammation", "PROBLEM", 324, 336], ["the most conventional antibiotic treatment", "TREATMENT", 374, 416], ["bone", "ANATOMY", 190, 194], ["infections", "OBSERVATION", 195, 205], ["Infections", "OBSERVATION", 216, 226], ["infection", "OBSERVATION", 310, 319], ["inflammation", "OBSERVATION", 324, 336]]], ["(115) prepared rod shaped hollow MSNs (HMSNs) with large and small cone shaped pores (HMSN-LP and HMSN-SP, respectively) via oil-water system containing lysozyme (LYZ) to treat E. coli biofilms.", [["biofilms", "ANATOMY", 185, 193], ["HMSN-LP", "CHEMICAL", 86, 93], ["HMSN-SP", "CHEMICAL", 98, 105], ["LYZ", "CHEMICAL", 163, 166], ["hollow MSNs", "SIMPLE_CHEMICAL", 26, 37], ["HMSNs", "SIMPLE_CHEMICAL", 39, 44], ["HMSN-LP", "SIMPLE_CHEMICAL", 86, 93], ["HMSN-SP", "SIMPLE_CHEMICAL", 98, 105], ["lysozyme", "SIMPLE_CHEMICAL", 153, 161], ["LYZ", "SIMPLE_CHEMICAL", 163, 166], ["E. coli", "ORGANISM", 177, 184], ["SP", "PROTEIN", 103, 105], ["lysozyme", "PROTEIN", 153, 161], ["E. coli", "SPECIES", 177, 184], ["E. coli", "SPECIES", 177, 184], ["large and small cone shaped pores", "PROBLEM", 51, 84], ["HMSN", "TEST", 86, 90], ["LP", "TEST", 91, 93], ["HMSN", "TEST", 98, 102], ["lysozyme (LYZ", "TREATMENT", 153, 166], ["E. coli biofilms", "PROBLEM", 177, 193], ["hollow MSNs", "OBSERVATION", 26, 37], ["large", "OBSERVATION_MODIFIER", 51, 56], ["small", "OBSERVATION_MODIFIER", 61, 66], ["cone shaped", "OBSERVATION_MODIFIER", 67, 78], ["coli biofilms", "OBSERVATION", 180, 193]]], ["The synthetized nanosystems presented averages particle length and width of 400 and 200 nm, respectively.", [["The synthetized nanosystems", "TREATMENT", 0, 27], ["width", "TEST", 67, 72], ["particle", "OBSERVATION_MODIFIER", 47, 55], ["length", "OBSERVATION_MODIFIER", 56, 62]]], ["Average pores size of 40 and 3 nm were found for HMSN-LP and HMSN-SP, respectively.", [["pores", "ANATOMY", 8, 13], ["HMSN-LP", "SIMPLE_CHEMICAL", 49, 56], ["HMSN-SP", "SIMPLE_CHEMICAL", 61, 68], ["HMSN", "PROTEIN", 49, 53], ["HMSN", "PROTEIN", 61, 65], ["SP", "PROTEIN", 66, 68], ["Average pores size", "TEST", 0, 18], ["HMSN", "TEST", 49, 53], ["LP", "TEST", 54, 56], ["HMSN", "TEST", 61, 65], ["pores", "OBSERVATION_MODIFIER", 8, 13], ["size", "OBSERVATION_MODIFIER", 14, 18]]], ["HMSN-LP exhibited loading capacity 7 times higher than HMSN-SP, ascribed to the pores size difference.", [["HMSN", "CHEMICAL", 0, 4], ["HMSN", "SIMPLE_CHEMICAL", 0, 4], ["HMSN-SP", "SIMPLE_CHEMICAL", 55, 62], ["HMSN", "PROTEIN", 55, 59], ["SP", "PROTEIN", 60, 62], ["HMSN", "TEST", 0, 4], ["LP", "TEST", 5, 7], ["loading capacity", "TEST", 18, 34], ["SP", "PROBLEM", 60, 62], ["loading capacity", "OBSERVATION", 18, 34], ["size", "OBSERVATION_MODIFIER", 86, 90]]], ["In vitro release tests (PBS pH 7.4) revealed that slower drug release was achieved by HMSN-LP than HMSN-SP, with up to 80% of LYZ release over 48 h.", [["HMSN-LP", "CHEMICAL", 86, 93], ["HMSN-SP", "CHEMICAL", 99, 106], ["LYZ", "CHEMICAL", 126, 129], ["LYZ", "CHEMICAL", 126, 129], ["HMSN-LP", "SIMPLE_CHEMICAL", 86, 93], ["HMSN-SP", "SIMPLE_CHEMICAL", 99, 106], ["LYZ", "SIMPLE_CHEMICAL", 126, 129], ["vitro release tests", "TEST", 3, 22], ["PBS pH", "TEST", 24, 30], ["slower drug release", "PROBLEM", 50, 69], ["HMSN", "TEST", 86, 90], ["HMSN", "TEST", 99, 103]]], ["Corroborating the aforementioned results, antimicrobial assays using E. coli biofilms model confirmed the highest antimicrobial action of HMSN-LP-LYZ compared to HMSN-SP-LYZ and free LYZ.", [["HMSN-LP-LYZ", "CHEMICAL", 138, 149], ["HMSN-SP-LYZ", "CHEMICAL", 162, 173], ["LYZ", "CHEMICAL", 183, 186], ["HMSN-LP-LYZ", "CHEMICAL", 138, 149], ["HMSN-SP-LYZ", "CHEMICAL", 162, 173], ["LYZ", "CHEMICAL", 183, 186], ["E. coli", "ORGANISM", 69, 76], ["HMSN-LP-LYZ", "SIMPLE_CHEMICAL", 138, 149], ["HMSN-SP-LYZ", "SIMPLE_CHEMICAL", 162, 173], ["LYZ", "SIMPLE_CHEMICAL", 183, 186], ["SP", "PROTEIN", 167, 169], ["E. coli", "SPECIES", 69, 76], ["E. coli", "SPECIES", 69, 76], ["antimicrobial assays", "TEST", 42, 62], ["E. coli biofilms model", "TEST", 69, 91], ["HMSN", "TEST", 138, 142], ["LP", "TEST", 143, 145], ["LYZ", "TEST", 146, 149], ["HMSN", "TEST", 162, 166]]], ["Additionally, the HMSN-LP was marked with fluorescent dye and its penetration ability into biofilms after 24 and 48 h of incubation was confirmed by confocal laser scanning microscope (CLSM) analysis.", [["biofilms", "ANATOMY", 91, 99], ["HMSN", "CHEMICAL", 18, 22], ["HMSN", "SIMPLE_CHEMICAL", 18, 22], ["fluorescent dye", "SIMPLE_CHEMICAL", 42, 57], ["HMSN", "PROTEIN", 18, 22], ["the HMSN", "TEST", 14, 22], ["LP", "TEST", 23, 25], ["fluorescent dye", "PROBLEM", 42, 57], ["confocal laser scanning microscope", "TEST", 149, 183], ["CLSM) analysis", "TEST", 185, 199]]], ["All results demonstrated the high therapeutic activity of HMSN-LP towards E. coli biofilms, which enable the design of novel and multi-responsive nanosystems against infectious pathogens.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentDoxycycline (DOXY) is an antibiotic very hydrophilic and soluble in biological fluid showing a high bioavailability at short time being the most part quickly eliminated by the kidneys.", [["biofilms", "ANATOMY", 82, 90], ["kidneys", "ANATOMY", 426, 433], ["HMSN-LP", "CHEMICAL", 58, 65], ["infectious pathogens", "DISEASE", 166, 186], ["Infectious Diseases", "DISEASE", 221, 240], ["Doxycycline", "CHEMICAL", 250, 261], ["DOXY", "CHEMICAL", 263, 267], ["Doxycycline", "CHEMICAL", 250, 261], ["DOXY", "CHEMICAL", 263, 267], ["HMSN-LP", "SIMPLE_CHEMICAL", 58, 65], ["E. coli", "ORGANISM", 74, 81], ["Doxycycline", "SIMPLE_CHEMICAL", 250, 261], ["DOXY", "SIMPLE_CHEMICAL", 263, 267], ["kidneys", "ORGAN", 426, 433], ["E. coli", "SPECIES", 74, 81], ["E. coli", "SPECIES", 74, 81], ["E. coli biofilms", "TREATMENT", 74, 90], ["multi-responsive nanosystems", "TREATMENT", 129, 157], ["infectious pathogens", "PROBLEM", 166, 186], ["Bacterial Infections", "PROBLEM", 187, 207], ["Infectious Diseases", "TREATMENT", 221, 240], ["TreatmentDoxycycline (DOXY)", "TREATMENT", 241, 268], ["an antibiotic very hydrophilic", "TREATMENT", 272, 302], ["soluble in biological fluid", "TREATMENT", 307, 334], ["coli biofilms", "OBSERVATION", 77, 90], ["Infections", "OBSERVATION", 197, 207], ["Infectious", "OBSERVATION_MODIFIER", 221, 231], ["kidneys", "ANATOMY", 426, 433]]], ["Aiming to overcome the aforementioned drawback and considering the development of bacterial resistance, Deaconu et al .", [["bacterial resistance", "PROBLEM", 82, 102], ["bacterial resistance", "OBSERVATION", 82, 102]]], ["(116) proposed to ally antibiotic properties and MSNs matrix by preparing DOXY-loaded MCM-41-type MSNs and modified MSNs to treat Klebsiella pneumoniae strains.", [["MSNs matrix", "ANATOMY", 49, 60], ["DOXY", "CHEMICAL", 74, 78], ["MCM-41-type MSNs", "CHEMICAL", 86, 102], ["Klebsiella pneumoniae", "DISEASE", 130, 151], ["DOXY", "CHEMICAL", 74, 78], ["MCM-41", "CHEMICAL", 86, 92], ["MSNs matrix", "SIMPLE_CHEMICAL", 49, 60], ["DOXY", "SIMPLE_CHEMICAL", 74, 78], ["MCM-41-type MSNs", "SIMPLE_CHEMICAL", 86, 102], ["MSNs", "SIMPLE_CHEMICAL", 116, 120], ["Klebsiella pneumoniae", "ORGANISM", 130, 151], ["Klebsiella pneumoniae", "SPECIES", 130, 151], ["Klebsiella pneumoniae", "SPECIES", 130, 151], ["ally antibiotic properties", "TREATMENT", 18, 44], ["MSNs matrix", "TREATMENT", 49, 60], ["DOXY-loaded MCM", "TREATMENT", 74, 89], ["type MSNs", "TREATMENT", 93, 102], ["modified MSNs", "TREATMENT", 107, 120], ["Klebsiella pneumoniae strains", "PROBLEM", 130, 159], ["Klebsiella pneumoniae", "OBSERVATION", 130, 151]]], ["MCM-41 (using hexadecyltrimethylammonium bromide (C16TAB) and TMOS as surfactant and inorganic precursor, respectively) platforms were prepared and then modified with phenyl, mercaptopropyl, propylsulfonic and magnesium labeled (MCM-C6H5, MCM-SH, MCM-SO3H and MCM-Mg, respectively).", [["MCM-41", "CHEMICAL", 0, 6], ["hexadecyltrimethylammonium bromide", "CHEMICAL", 14, 48], ["C16TAB", "CHEMICAL", 50, 56], ["TMOS", "CHEMICAL", 62, 66], ["phenyl", "CHEMICAL", 167, 173], ["mercaptopropyl", "CHEMICAL", 175, 189], ["propylsulfonic", "CHEMICAL", 191, 205], ["magnesium", "CHEMICAL", 210, 219], ["MCM-41", "CHEMICAL", 0, 6], ["hexadecyltrimethylammonium bromide", "CHEMICAL", 14, 48], ["C16TAB", "CHEMICAL", 50, 56], ["TMOS", "CHEMICAL", 62, 66], ["phenyl", "CHEMICAL", 167, 173], ["mercaptopropyl", "CHEMICAL", 175, 189], ["propylsulfonic", "CHEMICAL", 191, 205], ["magnesium", "CHEMICAL", 210, 219], ["MCM-C6H5", "CHEMICAL", 229, 237], ["MCM-SH", "CHEMICAL", 239, 245], ["MCM-SO3H", "CHEMICAL", 247, 255], ["MCM-Mg", "CHEMICAL", 260, 266], ["MCM-41", "SIMPLE_CHEMICAL", 0, 6], ["hexadecyltrimethylammonium bromide", "SIMPLE_CHEMICAL", 14, 48], ["C16TAB", "SIMPLE_CHEMICAL", 50, 56], ["TMOS", "SIMPLE_CHEMICAL", 62, 66], ["surfactant", "SIMPLE_CHEMICAL", 70, 80], ["phenyl", "SIMPLE_CHEMICAL", 167, 173], ["mercaptopropyl", "SIMPLE_CHEMICAL", 175, 189], ["propylsulfonic", "SIMPLE_CHEMICAL", 191, 205], ["magnesium", "SIMPLE_CHEMICAL", 210, 219], ["MCM-C6H5", "SIMPLE_CHEMICAL", 229, 237], ["MCM-SH", "SIMPLE_CHEMICAL", 239, 245], ["MCM-SO3H", "SIMPLE_CHEMICAL", 247, 255], ["MCM-Mg", "SIMPLE_CHEMICAL", 260, 266], ["MCM", "TEST", 0, 3], ["hexadecyltrimethylammonium bromide (C16TAB)", "TREATMENT", 14, 57], ["TMOS", "TREATMENT", 62, 66], ["surfactant", "TREATMENT", 70, 80], ["phenyl", "TREATMENT", 167, 173], ["mercaptopropyl", "TREATMENT", 175, 189], ["propylsulfonic", "TREATMENT", 191, 205], ["magnesium", "TREATMENT", 210, 219]]], ["MCM-C14 was also synthetized by using reduced chain surfactant (C14TAB) and TEOS as inorganic precursor.", [["MCM-C14", "CHEMICAL", 0, 7], ["C14TAB", "CHEMICAL", 64, 70], ["TEOS", "CHEMICAL", 76, 80], ["MCM-C14", "CHEMICAL", 0, 7], ["C14TAB", "CHEMICAL", 64, 70], ["TEOS", "CHEMICAL", 76, 80], ["MCM-C14", "SIMPLE_CHEMICAL", 0, 7], ["reduced chain surfactant", "SIMPLE_CHEMICAL", 38, 62], ["C14TAB", "SIMPLE_CHEMICAL", 64, 70], ["TEOS", "SIMPLE_CHEMICAL", 76, 80], ["inorganic precursor", "SIMPLE_CHEMICAL", 84, 103], ["reduced chain surfactant (C14TAB)", "TREATMENT", 38, 71], ["TEOS", "TREATMENT", 76, 80], ["C14", "ANATOMY", 4, 7]]], ["All MCM-41 nanoplatforms exhibited spherical shape ranging from 200-400 nm with ordered hexagonal mesopores channels arrays with mean pores size from 1.75 to 2.98 nm.", [["MCM-41", "CHEMICAL", 4, 10], ["All MCM", "TEST", 0, 7], ["spherical shape", "TEST", 35, 50], ["ordered hexagonal mesopores channels arrays", "TREATMENT", 80, 123], ["mean pores size", "TEST", 129, 144], ["spherical", "OBSERVATION_MODIFIER", 35, 44], ["shape", "OBSERVATION_MODIFIER", 45, 50], ["mean pores", "OBSERVATION_MODIFIER", 129, 139], ["size", "OBSERVATION_MODIFIER", 140, 144]]], ["DOXY incorporation was performed for all nanocarriers by wetness impregnation method.", [["DOXY", "CHEMICAL", 0, 4], ["DOXY", "CHEMICAL", 0, 4], ["DOXY", "SIMPLE_CHEMICAL", 0, 4], ["DOXY incorporation", "TREATMENT", 0, 18], ["all nanocarriers", "TREATMENT", 37, 53]]], ["From drug release studies (PBS pH 5.2) was detected that DOXY delivery profiles depend on the modification and distinct type of mesoporous silica matrix.", [["DOXY", "CHEMICAL", 57, 61], ["silica", "CHEMICAL", 139, 145], ["DOXY", "SIMPLE_CHEMICAL", 57, 61], ["drug release studies", "TEST", 5, 25], ["PBS pH", "TEST", 27, 33], ["DOXY delivery profiles", "PROBLEM", 57, 79], ["the modification", "TREATMENT", 90, 106], ["mesoporous silica matrix", "PROBLEM", 128, 152], ["mesoporous silica matrix", "OBSERVATION", 128, 152]]], ["The MCM-Mg showed lower DOXY release kinetic, which can be assigned to the enhanced basicity of the magnesium oxide particles formed on the silica surface.", [["Mg", "CHEMICAL", 8, 10], ["DOXY", "CHEMICAL", 24, 28], ["magnesium oxide", "CHEMICAL", 100, 115], ["MCM-Mg", "CHEMICAL", 4, 10], ["DOXY", "CHEMICAL", 24, 28], ["magnesium oxide", "CHEMICAL", 100, 115], ["silica", "CHEMICAL", 140, 146], ["MCM-Mg", "SIMPLE_CHEMICAL", 4, 10], ["DOXY", "SIMPLE_CHEMICAL", 24, 28], ["magnesium oxide particles", "SIMPLE_CHEMICAL", 100, 125], ["DOXY", "PROTEIN", 24, 28], ["The MCM", "TEST", 0, 7], ["lower DOXY release kinetic", "PROBLEM", 18, 44], ["the magnesium oxide particles", "TREATMENT", 96, 125], ["magnesium oxide particles", "OBSERVATION", 100, 125], ["silica", "ANATOMY", 140, 146], ["surface", "ANATOMY_MODIFIER", 147, 154]]], ["Despite distinct DOXY release kinetics obtained, effective and similar antibacterial activity was detected for all nanoplatforms.", [["DOXY", "CHEMICAL", 17, 21], ["DOXY", "SIMPLE_CHEMICAL", 17, 21], ["distinct DOXY release kinetics", "TREATMENT", 8, 38], ["similar antibacterial activity", "PROBLEM", 63, 93], ["all nanoplatforms", "TREATMENT", 111, 128], ["antibacterial activity", "OBSERVATION", 71, 93]]], ["In addition, these results were similar to free DOXY expected that controlled and prolonged release can be achieved only by using the nanocarriers.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentThe use of MSNs to transport and deliver poorly soluble drugs to the target diseases sites comprises an attractive and useful method to improve drug\u2019s efficacy.", [["DOXY", "CHEMICAL", 48, 52], ["Infectious Diseases", "DISEASE", 181, 200], ["DOXY", "SIMPLE_CHEMICAL", 48, 52], ["MSNs", "SIMPLE_CHEMICAL", 221, 225], ["free DOXY", "TREATMENT", 43, 52], ["the nanocarriers", "TREATMENT", 130, 146], ["MSNs to transport", "TREATMENT", 221, 238], ["poorly soluble drugs", "TREATMENT", 251, 271], ["the target diseases sites", "PROBLEM", 275, 300], ["Infections", "OBSERVATION", 157, 167]]], ["Notwithstanding, high loading and also total release drugs amount is a great challenge due to the nanoconfinement and possible interaction with the matrix.", [["matrix", "CELLULAR_COMPONENT", 148, 154], ["total release drugs amount", "TREATMENT", 39, 65], ["high loading", "OBSERVATION_MODIFIER", 17, 29]]], ["(118) demonstrated the use of acetophenone (AP), an FDA-approved food additive as co-solvent (known as chaperone) to promotes efficient clofazimine (CFZ) entrapment and release from MSNs channels to aqueous environment.", [["acetophenone", "CHEMICAL", 30, 42], ["AP", "CHEMICAL", 44, 46], ["clofazimine", "CHEMICAL", 136, 147], ["CFZ", "CHEMICAL", 149, 152], ["acetophenone", "CHEMICAL", 30, 42], ["clofazimine", "CHEMICAL", 136, 147], ["CFZ", "CHEMICAL", 149, 152], ["acetophenone", "SIMPLE_CHEMICAL", 30, 42], ["AP", "SIMPLE_CHEMICAL", 44, 46], ["clofazimine", "SIMPLE_CHEMICAL", 136, 147], ["CFZ", "SIMPLE_CHEMICAL", 149, 152], ["MSNs", "SIMPLE_CHEMICAL", 182, 186], ["chaperone", "PROTEIN", 103, 112], ["acetophenone", "TREATMENT", 30, 42], ["an FDA", "TREATMENT", 49, 55], ["efficient clofazimine (CFZ) entrapment", "TREATMENT", 126, 164]]], ["CFZ is a water-insoluble antibiotic used to treat leprosy and multidrug-resistant tuberculosis.", [["CFZ", "CHEMICAL", 0, 3], ["leprosy", "DISEASE", 50, 57], ["tuberculosis", "DISEASE", 82, 94], ["CFZ", "CHEMICAL", 0, 3], ["CFZ", "SIMPLE_CHEMICAL", 0, 3], ["CFZ", "TREATMENT", 0, 3], ["a water-insoluble antibiotic", "TREATMENT", 7, 35], ["leprosy", "PROBLEM", 50, 57], ["multidrug-resistant tuberculosis", "PROBLEM", 62, 94], ["leprosy", "OBSERVATION", 50, 57], ["resistant", "OBSERVATION_MODIFIER", 72, 81], ["tuberculosis", "OBSERVATION", 82, 94]]], ["Spherical and monodisperse MSNs with highly ordered hexagonal mesopores arrays and average size of 100 nm were obtained as well as high surface area (1060 m2 g-1), negatively charged (zeta potential of -21.2 mV) with average pore size of 2.8 nm.", [["surface area", "ANATOMY", 136, 148], ["pore", "ANATOMY", 225, 229], ["MSNs", "SIMPLE_CHEMICAL", 27, 31], ["highly ordered hexagonal mesopores arrays", "TREATMENT", 37, 78], ["zeta potential", "TEST", 184, 198], ["average pore size", "TEST", 217, 234], ["monodisperse MSNs", "OBSERVATION", 14, 31], ["hexagonal mesopores", "OBSERVATION", 52, 71], ["size", "OBSERVATION_MODIFIER", 91, 95], ["size", "OBSERVATION_MODIFIER", 230, 234], ["2.8 nm", "OBSERVATION_MODIFIER", 238, 244]]], ["All these results favor MSNs loading with CFZ and AP.", [["CFZ", "CHEMICAL", 42, 45], ["CFZ", "CHEMICAL", 42, 45], ["MSNs", "SIMPLE_CHEMICAL", 24, 28], ["CFZ", "SIMPLE_CHEMICAL", 42, 45], ["AP", "SIMPLE_CHEMICAL", 50, 52], ["CFZ", "PROTEIN", 42, 45], ["AP", "PROTEIN", 50, 52], ["CFZ", "TREATMENT", 42, 45], ["AP", "TEST", 50, 52], ["MSNs loading", "OBSERVATION", 24, 36]]], ["CFZ loading and release assays were carried out in DMSO and AP solvents.", [["CFZ", "CHEMICAL", 0, 3], ["DMSO", "CHEMICAL", 51, 55], ["CFZ", "CHEMICAL", 0, 3], ["DMSO", "CHEMICAL", 51, 55], ["CFZ", "SIMPLE_CHEMICAL", 0, 3], ["DMSO", "SIMPLE_CHEMICAL", 51, 55], ["AP solvents", "SIMPLE_CHEMICAL", 60, 71], ["CFZ loading", "TREATMENT", 0, 11], ["release assays", "TEST", 16, 30], ["AP solvents", "TREATMENT", 60, 71]]], ["The loading CFZ capacity by using AP increased as a function of CFZ concentration, showing 26.8% at 50 mM whereas by using DMSO the loading capacity was 5.9% at the same concentration.", [["CFZ", "CHEMICAL", 64, 67], ["DMSO", "CHEMICAL", 123, 127], ["CFZ", "CHEMICAL", 64, 67], ["DMSO", "CHEMICAL", 123, 127], ["AP", "SIMPLE_CHEMICAL", 34, 36], ["CFZ", "SIMPLE_CHEMICAL", 64, 67], ["DMSO", "SIMPLE_CHEMICAL", 123, 127], ["The loading CFZ capacity", "TEST", 0, 24], ["CFZ concentration", "TEST", 64, 81], ["DMSO the loading capacity", "TEST", 123, 148], ["loading CFZ", "OBSERVATION", 4, 15], ["capacity", "OBSERVATION_MODIFIER", 16, 24]]], ["By using AP strategy, the CFZ release efficiency was 47.2% whereas by using DMSO was only 0.02%.", [["DMSO", "CHEMICAL", 76, 80], ["DMSO", "CHEMICAL", 76, 80], ["CFZ", "SIMPLE_CHEMICAL", 26, 29], ["DMSO", "SIMPLE_CHEMICAL", 76, 80], ["the CFZ release efficiency", "TEST", 22, 48], ["DMSO", "TREATMENT", 76, 80]]], ["The novel strategy showed release efficiency 2300 times higher than the conventional method with DMSO (0.02%).", [["DMSO", "CHEMICAL", 97, 101], ["DMSO", "CHEMICAL", 97, 101], ["DMSO", "SIMPLE_CHEMICAL", 97, 101], ["release efficiency", "PROBLEM", 26, 44], ["DMSO", "TREATMENT", 97, 101]]], ["The high increase in CFZ release can be assigned to the release of AP from the MSNs pores carrying CFZ molecules together into the aqueous solution.", [["CFZ", "CHEMICAL", 21, 24], ["CFZ", "CHEMICAL", 99, 102], ["CFZ", "CHEMICAL", 21, 24], ["CFZ", "CHEMICAL", 99, 102], ["CFZ", "SIMPLE_CHEMICAL", 21, 24], ["AP", "SIMPLE_CHEMICAL", 67, 69], ["CFZ molecules", "SIMPLE_CHEMICAL", 99, 112], ["CFZ", "PROTEIN", 21, 24], ["CFZ molecules", "PROTEIN", 99, 112], ["The high increase in CFZ release", "TREATMENT", 0, 32], ["the MSNs pores carrying CFZ molecules", "TREATMENT", 75, 112], ["high", "OBSERVATION_MODIFIER", 4, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["The chaperon-based MSNs were evaluated in a macrophage model of Mycobacterium tuberculosis infection.", [["macrophage", "ANATOMY", 44, 54], ["Mycobacterium tuberculosis infection", "DISEASE", 64, 100], ["chaperon", "SIMPLE_CHEMICAL", 4, 12], ["MSNs", "CELL", 19, 23], ["macrophage", "CELL", 44, 54], ["Mycobacterium tuberculosis", "ORGANISM", 64, 90], ["chaperon-based MSNs", "DNA", 4, 23], ["Mycobacterium tuberculosis", "SPECIES", 64, 90], ["Mycobacterium tuberculosis", "SPECIES", 64, 90], ["The chaperon-based MSNs", "TREATMENT", 0, 23], ["Mycobacterium tuberculosis infection", "PROBLEM", 64, 100], ["Mycobacterium tuberculosis", "OBSERVATION", 64, 90], ["infection", "OBSERVATION", 91, 100]]], ["The optimized CFZ-AP(10mM CFZ in AP) exhibited high antimicrobial efficacy (dose-dependent) reducing the bacteria number by 1 log CFU (90% of bacteria were killed).", [["CFZ-AP", "CHEMICAL", 14, 20], ["CFZ", "CHEMICAL", 26, 29], ["AP", "CHEMICAL", 33, 35], ["CFZ", "CHEMICAL", 26, 29], ["CFZ-AP", "SIMPLE_CHEMICAL", 14, 20], ["CFZ", "SIMPLE_CHEMICAL", 26, 29], ["AP", "SIMPLE_CHEMICAL", 33, 35], ["The optimized CFZ", "TEST", 0, 17], ["mM CFZ in AP)", "TEST", 23, 36], ["high antimicrobial efficacy", "PROBLEM", 47, 74], ["the bacteria", "PROBLEM", 101, 113], ["bacteria", "PROBLEM", 142, 150], ["optimized", "OBSERVATION_MODIFIER", 4, 13], ["CFZ", "OBSERVATION", 14, 17], ["high", "OBSERVATION_MODIFIER", 47, 51], ["antimicrobial efficacy", "OBSERVATION", 52, 74]]], ["In addition, no changes on the macrophages morphological appearance were detected for the applied nanosystems.", [["macrophages", "ANATOMY", 31, 42], ["macrophages", "CELL", 31, 42], ["macrophages", "CELL_TYPE", 31, 42], ["changes on the macrophages morphological appearance", "PROBLEM", 16, 67], ["the applied nanosystems", "TREATMENT", 86, 109], ["no", "UNCERTAINTY", 13, 15], ["changes", "OBSERVATION_MODIFIER", 16, 23], ["macrophages", "OBSERVATION", 31, 42]]], ["This loading/delivery \u201cchaperone-assisted\u201d strategy can be used for other hydrophobic drugs with their suitable solvents (chaperone), opening up opportunities to design novel drug delivery MSNs-based nanosystems for biomedical applications.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentDespites the challenges cause by microbial biofilms formation and antibiotic resistance generation, Gram-negative bacteria possess outer membranes as a highly impermeable barrier as well as additional defense mechanisms no detect in Gram-positive bacteria (153).", [["biofilms", "ANATOMY", 346, 354], ["outer membranes", "ANATOMY", 434, 449], ["Infectious Diseases TreatmentDespites", "DISEASE", 274, 311], ["MSNs", "SIMPLE_CHEMICAL", 189, 193], ["outer membranes", "CELLULAR_COMPONENT", 434, 449], ["This loading/delivery", "TREATMENT", 0, 21], ["chaperone-assisted\u201d strategy", "TREATMENT", 23, 51], ["other hydrophobic drugs", "TREATMENT", 68, 91], ["their suitable solvents (chaperone", "TREATMENT", 97, 131], ["design novel drug delivery MSNs", "TREATMENT", 162, 193], ["biomedical applications", "TREATMENT", 216, 239], ["Infectious Diseases TreatmentDespites", "TREATMENT", 274, 311], ["microbial biofilms formation", "TREATMENT", 336, 364], ["antibiotic resistance generation", "TREATMENT", 369, 401], ["Gram", "TEST", 403, 407], ["negative bacteria possess outer membranes", "PROBLEM", 408, 449], ["a highly impermeable barrier", "TREATMENT", 453, 481], ["Gram-positive bacteria", "PROBLEM", 536, 558], ["Infections", "OBSERVATION", 250, 260], ["microbial biofilms", "OBSERVATION", 336, 354], ["negative bacteria", "OBSERVATION_MODIFIER", 408, 425], ["outer membranes", "OBSERVATION_MODIFIER", 434, 449]]], ["Considering these drawbacks, Gonz\u00e1lez et al .", [["these drawbacks", "TREATMENT", 12, 27], ["Gonz\u00e1lez et al", "TREATMENT", 29, 43]]], ["(119) developed nanoantibiotics based on levofloxacin (LEVO)-loaded MSNs covalently modified with third-generation poly(propyleneimine) dendrimer (G3), which has high affinity to negatively charged bacteria cell walls.", [["cell walls", "ANATOMY", 207, 217], ["levofloxacin", "CHEMICAL", 41, 53], ["LEVO", "CHEMICAL", 55, 59], ["poly(propyleneimine) dendrimer", "CHEMICAL", 115, 145], ["levofloxacin", "CHEMICAL", 41, 53], ["LEVO", "CHEMICAL", 55, 59], ["poly(propyleneimine)", "CHEMICAL", 115, 135], ["levofloxacin", "SIMPLE_CHEMICAL", 41, 53], ["LEVO", "SIMPLE_CHEMICAL", 55, 59], ["MSNs", "SIMPLE_CHEMICAL", 68, 72], ["poly(propyleneimine) dendrimer", "SIMPLE_CHEMICAL", 115, 145], ["G3", "SIMPLE_CHEMICAL", 147, 149], ["cell", "CELL", 207, 211], ["nanoantibiotics", "TREATMENT", 16, 31], ["levofloxacin", "TREATMENT", 41, 53], ["LEVO", "TREATMENT", 55, 59], ["third-generation poly(propyleneimine) dendrimer", "TREATMENT", 98, 145], ["high affinity", "PROBLEM", 162, 175], ["bacteria cell walls", "OBSERVATION", 198, 217]]], ["Beyond that, LEVO-loaded [3-(2-aminoethylamino) propyl]trimethoxysilane (labeled DAMO)-modified MSNs (noted LEVO@MSNs-DAMO) were also fabricated to evaluate antimicrobial action against Gram-negative bacteria.", [["LEVO", "CHEMICAL", 13, 17], ["[3-(2-aminoethylamino) propyl]trimethoxysilane", "CHEMICAL", 25, 71], ["DAMO", "CHEMICAL", 81, 85], ["LEVO@MSNs-DAMO", "CHEMICAL", 108, 122], ["LEVO", "CHEMICAL", 13, 17], ["[3-(2-aminoethylamino) propyl]trimethoxysilane", "CHEMICAL", 25, 71], ["DAMO", "CHEMICAL", 81, 85], ["DAMO", "CHEMICAL", 118, 122], ["LEVO", "SIMPLE_CHEMICAL", 13, 17], ["[3-(2-aminoethylamino) propyl]trimethoxysilane", "SIMPLE_CHEMICAL", 25, 71], ["DAMO", "SIMPLE_CHEMICAL", 81, 85], ["MSNs", "SIMPLE_CHEMICAL", 96, 100], ["LEVO@MSNs-DAMO", "SIMPLE_CHEMICAL", 108, 122], ["Gram", "SIMPLE_CHEMICAL", 186, 190], ["LEVO", "TREATMENT", 13, 17], ["aminoethylamino) propyl]trimethoxysilane (labeled DAMO", "TREATMENT", 31, 85], ["modified MSNs", "TREATMENT", 87, 100], ["LEVO@MSNs", "TREATMENT", 108, 117], ["antimicrobial action", "TEST", 157, 177], ["Gram-negative bacteria", "PROBLEM", 186, 208], ["negative bacteria", "OBSERVATION", 191, 208]]], ["Spherical-shaped MSNs with 2D hexagonal mesoporous arrangement were prepared, showing average diameter and pores size of 150 and 2.4 nm, respectively.", [["MSNs", "CELL", 17, 21], ["2D hexagonal mesoporous arrangement", "TREATMENT", 27, 62], ["shaped", "OBSERVATION_MODIFIER", 10, 16], ["MSNs", "OBSERVATION_MODIFIER", 17, 21], ["hexagonal", "OBSERVATION_MODIFIER", 30, 39], ["mesoporous arrangement", "OBSERVATION", 40, 62], ["average", "OBSERVATION_MODIFIER", 86, 93], ["diameter", "OBSERVATION_MODIFIER", 94, 102], ["pores", "OBSERVATION_MODIFIER", 107, 112], ["size", "OBSERVATION_MODIFIER", 113, 117]]], ["LEVO loading amount up to 7.8% were detected for the nanovehicles.", [["LEVO loading amount", "TREATMENT", 0, 19]]], ["LEVO release performance (PBS pH 7.4) were evaluated exhibiting a first-order kinetics for all nanosystems (LEVO@MSNs, LEVO@MSNs-DAMO and LEVO@MSNs-G3), with 100% of LEVO release over 72 h for LEVO@MSNs-G3.", [["LEVO@MSNs-DAMO", "CHEMICAL", 119, 133], ["LEVO", "CHEMICAL", 166, 170], ["LEVO@MSNs-G3", "CHEMICAL", 193, 205], ["LEVO", "SIMPLE_CHEMICAL", 0, 4], ["LEVO@MSNs", "SIMPLE_CHEMICAL", 108, 117], ["LEVO@MSNs-DAMO", "SIMPLE_CHEMICAL", 119, 133], ["LEVO@MSNs-G3", "SIMPLE_CHEMICAL", 138, 150], ["LEVO", "SIMPLE_CHEMICAL", 166, 170], ["LEVO@MSNs-G3", "SIMPLE_CHEMICAL", 193, 205], ["LEVO release performance", "TEST", 0, 24], ["PBS pH", "TEST", 26, 32], ["all nanosystems", "TREATMENT", 91, 106], ["LEVO@MSNs", "TREATMENT", 108, 117], ["LEVO@MSNs", "TREATMENT", 119, 128], ["DAMO", "TREATMENT", 129, 133], ["LEVO@MSNs", "TREATMENT", 138, 147], ["LEVO release", "TREATMENT", 166, 178]]], ["LEVO@MSNs showed lower release values indicating strong interaction via hydrogen bonding between LEVO zwitterionic form (at pH 7.4) and Si-OH groups from MSNs.", [["hydrogen", "CHEMICAL", 72, 80], ["LEVO", "CHEMICAL", 97, 101], ["Si-OH", "CHEMICAL", 136, 141], ["LEVO@MSNs", "SIMPLE_CHEMICAL", 0, 9], ["hydrogen", "SIMPLE_CHEMICAL", 72, 80], ["LEVO zwitterionic form", "SIMPLE_CHEMICAL", 97, 119], ["Si-OH", "SIMPLE_CHEMICAL", 136, 141], ["MSNs", "SIMPLE_CHEMICAL", 154, 158], ["LEVO@MSNs", "TEST", 0, 9], ["lower release values", "PROBLEM", 17, 37], ["strong interaction via hydrogen bonding", "PROBLEM", 49, 88], ["LEVO zwitterionic form", "TREATMENT", 97, 119], ["pH", "TEST", 124, 126], ["Si-OH groups from MSNs", "PROBLEM", 136, 158], ["hydrogen bonding", "OBSERVATION", 72, 88]]], ["E. coli internalization assays confirmed good MSNs-DAMO and MSNs-G3 internalization due to their positive charge density making electrostatic interactions with E. coli cells walls possible.", [["cells", "ANATOMY", 168, 173], ["MSNs", "CHEMICAL", 60, 64], ["E. coli", "ORGANISM", 0, 7], ["MSNs-DAMO", "SIMPLE_CHEMICAL", 46, 55], ["MSNs-G3", "SIMPLE_CHEMICAL", 60, 67], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 160, 167], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 160, 167], ["E. coli internalization assays", "TEST", 0, 30], ["G3 internalization", "TREATMENT", 65, 83], ["their positive charge density", "PROBLEM", 91, 120], ["electrostatic interactions", "PROBLEM", 128, 154], ["E. coli cells walls", "PROBLEM", 160, 179], ["coli", "OBSERVATION", 3, 7], ["good MSNs", "OBSERVATION", 41, 50], ["charge density", "OBSERVATION", 106, 120], ["electrostatic interactions", "OBSERVATION", 128, 154], ["coli cells", "OBSERVATION", 163, 173]]], ["Additionally, MSNs-G3 displayed higher internalization than MSNs-DAMO, ascribed to the MSNs-G3 high surface flexibility and high interaction points with negatively charged E. coli phospholipid membranes regarding MSNs-DAMO.", [["surface", "ANATOMY", 100, 107], ["phospholipid membranes", "ANATOMY", 180, 202], ["MSNs", "CHEMICAL", 14, 18], ["MSNs-DAMO", "CHEMICAL", 60, 69], ["MSNs-DAMO", "CHEMICAL", 213, 222], ["DAMO", "CHEMICAL", 65, 69], ["MSNs-G3", "SIMPLE_CHEMICAL", 14, 21], ["MSNs-DAMO", "SIMPLE_CHEMICAL", 60, 69], ["MSNs-DAMO", "SIMPLE_CHEMICAL", 213, 222], ["E. coli", "SPECIES", 172, 179], ["E. coli", "SPECIES", 172, 179], ["G3 high surface flexibility", "PROBLEM", 92, 119], ["high interaction points", "PROBLEM", 124, 147], ["negatively charged E. coli phospholipid membranes", "PROBLEM", 153, 202], ["coli phospholipid membranes", "OBSERVATION", 175, 202]]], ["These results corroborated antimicrobial assays against E. coli biofilms showing the MSNs-G3 with higher and remarkable antimicrobial efficacy relating to the other nanosystems.", [["MSNs", "CHEMICAL", 85, 89], ["E. coli", "ORGANISM", 56, 63], ["E. coli", "SPECIES", 56, 63], ["E. coli", "SPECIES", 56, 63], ["antimicrobial assays", "TEST", 27, 47], ["E. coli biofilms", "PROBLEM", 56, 72], ["remarkable antimicrobial efficacy", "PROBLEM", 109, 142], ["remarkable", "OBSERVATION_MODIFIER", 109, 119], ["antimicrobial efficacy", "OBSERVATION", 120, 142]]], ["These findings demonstrated that the synergistic combination of bacterial internalization and antimicrobial agents into MSNs-based nanovehicles lead to interesting and efficient antibiotics for infections treatment.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentRegarding the high mortality and morbility caused by bacterial resistance, Cao et al .", [["MSNs", "CHEMICAL", 120, 124], ["infections", "DISEASE", 194, 204], ["Infectious Diseases", "DISEASE", 249, 268], ["morbility", "DISEASE", 311, 320], ["MSNs", "SIMPLE_CHEMICAL", 120, 124], ["bacterial internalization", "TREATMENT", 64, 89], ["antimicrobial agents", "TREATMENT", 94, 114], ["MSNs-based nanovehicles", "TREATMENT", 120, 143], ["efficient antibiotics", "TREATMENT", 168, 189], ["infections treatment", "TREATMENT", 194, 214], ["Infectious Diseases Treatment", "TREATMENT", 249, 278], ["bacterial resistance", "PROBLEM", 331, 351], ["bacterial internalization", "OBSERVATION", 64, 89], ["Infections", "OBSERVATION", 225, 235], ["bacterial resistance", "OBSERVATION", 331, 351]]], ["(120) proposed to ally the amazing properties of MSNs with metallic nanoparticles such as silver (Ag) and bismuth (Bi).", [["silver (Ag", "CHEMICAL", 90, 100], ["bismuth", "CHEMICAL", 106, 113], ["Bi", "CHEMICAL", 115, 117], ["silver", "CHEMICAL", 90, 96], ["Ag", "CHEMICAL", 98, 100], ["bismuth", "CHEMICAL", 106, 113], ["Bi", "CHEMICAL", 115, 117], ["MSNs", "SIMPLE_CHEMICAL", 49, 53], ["metallic nanoparticles", "SIMPLE_CHEMICAL", 59, 81], ["silver (Ag)", "SIMPLE_CHEMICAL", 90, 101], ["bismuth (Bi)", "SIMPLE_CHEMICAL", 106, 118], ["metallic nanoparticles", "TREATMENT", 59, 81], ["silver (Ag) and bismuth (Bi)", "TREATMENT", 90, 118]]], ["Authors designed a multifunctional MSNs-suported Ag-Bi nanoparticles (NPs) associating hyperthermia generated by Bi nanoparticles with Ag release for synergistic antibacterial therapy as shown in Fig. 5.", [["Ag-Bi", "CHEMICAL", 49, 54], ["NPs", "CHEMICAL", 70, 73], ["hyperthermia", "DISEASE", 87, 99], ["Bi nanoparticles", "CHEMICAL", 113, 129], ["Ag", "CHEMICAL", 135, 137], ["Ag", "CHEMICAL", 49, 51], ["Bi", "CHEMICAL", 52, 54], ["Bi", "CHEMICAL", 113, 115], ["Ag", "CHEMICAL", 135, 137], ["MSNs", "SIMPLE_CHEMICAL", 35, 39], ["Ag-Bi nanoparticles", "SIMPLE_CHEMICAL", 49, 68], ["NPs", "SIMPLE_CHEMICAL", 70, 73], ["Bi nanoparticles", "SIMPLE_CHEMICAL", 113, 129], ["Ag", "SIMPLE_CHEMICAL", 135, 137], ["Ag", "PROTEIN", 49, 51], ["Ag", "PROTEIN", 135, 137], ["a multifunctional MSNs", "TREATMENT", 17, 39], ["suported Ag-Bi nanoparticles (NPs)", "TREATMENT", 40, 74], ["hyperthermia", "PROBLEM", 87, 99], ["Bi nanoparticles", "TREATMENT", 113, 129], ["Ag release", "TREATMENT", 135, 145], ["synergistic antibacterial therapy", "TREATMENT", 150, 183], ["hyperthermia", "OBSERVATION", 87, 99], ["antibacterial therapy", "OBSERVATION", 162, 183]]], ["Ag-Bi nanoparticles were fabricated via in situ growth onto MSNs pores structure aiming to avoid their aggregation and oxidation under physiological environment.", [["Ag", "CHEMICAL", 0, 2], ["Ag", "CHEMICAL", 0, 2], ["Bi", "CHEMICAL", 3, 5], ["Ag-Bi nanoparticles", "SIMPLE_CHEMICAL", 0, 19], ["Ag", "PROTEIN", 0, 2], ["Ag-Bi nanoparticles", "TREATMENT", 0, 19], ["MSNs pores structure", "TREATMENT", 60, 80], ["their aggregation", "PROBLEM", 97, 114]]], ["Under the NIR laser irradiation (808 nm laser irradiation, 1 W cm-2, 15 min), hyperthermia can be generated by Bi NPs destroying bacterial cell membrane and biofilm promoting and increasing Ag+ release from the nanocarrier, resulting in photothermal-enhanced antibacterial activity.", [["cell membrane", "ANATOMY", 139, 152], ["biofilm", "ANATOMY", 157, 164], ["hyperthermia", "DISEASE", 78, 90], ["Bi", "CHEMICAL", 111, 113], ["Ag", "CHEMICAL", 190, 192], ["Bi", "CHEMICAL", 111, 113], ["Ag+", "CHEMICAL", 190, 193], ["Bi NPs", "SIMPLE_CHEMICAL", 111, 117], ["cell membrane", "CELLULAR_COMPONENT", 139, 152], ["Ag+", "SIMPLE_CHEMICAL", 190, 193], ["Ag", "PROTEIN", 190, 192], ["the NIR laser irradiation", "TREATMENT", 6, 31], ["nm laser irradiation", "TREATMENT", 37, 57], ["hyperthermia", "PROBLEM", 78, 90], ["Bi NPs destroying bacterial cell membrane", "TREATMENT", 111, 152], ["biofilm promoting", "TREATMENT", 157, 174], ["increasing Ag+ release", "PROBLEM", 179, 201], ["the nanocarrier", "TREATMENT", 207, 222], ["photothermal-enhanced antibacterial activity", "TREATMENT", 237, 281], ["bacterial cell membrane", "OBSERVATION", 129, 152], ["antibacterial activity", "OBSERVATION", 259, 281]]], ["Spherical nanosystems with average size and pores of 200-240 nm and 3.4-4.8 nm, respectively were successfully fabricated.", [["nanosystems", "OBSERVATION", 10, 21], ["average", "OBSERVATION_MODIFIER", 27, 34], ["size", "OBSERVATION_MODIFIER", 35, 39], ["pores", "OBSERVATION_MODIFIER", 44, 49]]], ["In addition, Ag NPs showed average size of ~15 nm.", [["Ag", "CHEMICAL", 13, 15], ["Ag", "CHEMICAL", 13, 15], ["Ag NPs", "SIMPLE_CHEMICAL", 13, 19], ["Ag NPs", "TEST", 13, 19], ["average", "OBSERVATION_MODIFIER", 27, 34], ["size", "OBSERVATION_MODIFIER", 35, 39], ["15 nm", "OBSERVATION_MODIFIER", 44, 49]]], ["Photothermal therapy (PTT) ability of Ag-Bi@MSNs was evaluated exhibiting high stability and laser power irradiation and concentration dependence.", [["Ag-Bi@MSNs", "CHEMICAL", 38, 48], ["Ag", "CHEMICAL", 38, 40], ["Ag-Bi@MSNs", "SIMPLE_CHEMICAL", 38, 48], ["Ag", "PROTEIN", 38, 40], ["Photothermal therapy", "TREATMENT", 0, 20], ["PTT", "TEST", 22, 25], ["Ag", "TEST", 38, 40], ["Bi@MSNs", "TEST", 41, 48], ["high stability", "PROBLEM", 74, 88], ["laser power irradiation", "TREATMENT", 93, 116], ["concentration dependence", "PROBLEM", 121, 145], ["high stability", "OBSERVATION_MODIFIER", 74, 88], ["power irradiation", "OBSERVATION", 99, 116], ["concentration dependence", "OBSERVATION", 121, 145]]], ["As higher is laser power density and Ag-Bi@MSNs concentration, higher is the achieved temperature confirming great PTT performance.", [["Ag-Bi@MSNs", "CHEMICAL", 37, 47], ["Ag", "CHEMICAL", 37, 39], ["Bi@MSNs", "CHEMICAL", 40, 47], ["Ag-Bi@MSNs", "SIMPLE_CHEMICAL", 37, 47], ["Ag", "PROTEIN", 37, 39], ["great PTT performance", "PROBLEM", 109, 130], ["laser", "OBSERVATION_MODIFIER", 13, 18], ["power density", "OBSERVATION_MODIFIER", 19, 32]]], ["In vitro antibacterial activity was evaluated against MRSA cells by adding Ag-Bi@MSNs with or without laser irradiation.", [["MRSA cells", "ANATOMY", 54, 64], ["Ag-Bi@MSNs", "CHEMICAL", 75, 85], ["Ag", "CHEMICAL", 75, 77], ["Bi@MSNs", "CHEMICAL", 78, 85], ["MRSA cells", "CELL", 54, 64], ["Ag-Bi@MSNs", "SIMPLE_CHEMICAL", 75, 85], ["MRSA cells", "CELL_LINE", 54, 64], ["Ag", "PROTEIN", 75, 77], ["MRSA", "SPECIES", 54, 58], ["MRSA", "SPECIES", 54, 58], ["vitro antibacterial activity", "TREATMENT", 3, 31], ["MRSA cells", "PROBLEM", 54, 64], ["Ag", "TEST", 75, 77], ["laser irradiation", "TREATMENT", 102, 119], ["antibacterial activity", "OBSERVATION", 9, 31]]], ["At same concentration (128 \u03bcg mL-1), 22 and 76% of cells death were achieved without and with laser irradiation, respectively.", [["cells", "ANATOMY", 51, 56], ["death", "DISEASE", 57, 62], ["cells", "CELL", 51, 56], ["cells death", "TEST", 51, 62], ["laser irradiation", "TREATMENT", 94, 111]]], ["Additionally, release studies were performed for 75 min with and without laser irradiation (at the same concentration, 200 \u03bcg mL-1).", [["release studies", "TEST", 14, 29], ["laser irradiation", "TREATMENT", 73, 90]]], ["Results corroborate antibacterial assays displaying a NIR-responsive Ag+ release, with 11.3 and 37.3% of release without and with laser irradiation, respectively.", [["Ag", "CHEMICAL", 69, 71], ["Ag+", "CHEMICAL", 69, 72], ["Ag+", "SIMPLE_CHEMICAL", 69, 72], ["Ag", "PROTEIN", 69, 71], ["antibacterial assays", "TEST", 20, 40], ["a NIR", "TEST", 52, 57], ["laser irradiation", "TREATMENT", 130, 147]]], ["Aiming to prove the synergic antibacterial effect, MRSA-infected mice were investigated with five groups: PBS, Bi@MSNs, Ag-Bi@MSNs, Bi@MSNs + NIR and Ag-Bi@MSNs + NIR groups.", [["MRSA", "CHEMICAL", 51, 55], ["Bi@MSNs", "CHEMICAL", 111, 118], ["Ag-Bi@MSNs", "CHEMICAL", 120, 130], ["Bi@MSNs", "CHEMICAL", 132, 139], ["Ag-Bi@MSNs", "CHEMICAL", 150, 160], ["Ag", "CHEMICAL", 120, 122], ["Bi@MSNs", "CHEMICAL", 132, 139], ["Ag", "CHEMICAL", 150, 152], ["Bi@MSNs", "CHEMICAL", 153, 160], ["MRSA", "SIMPLE_CHEMICAL", 51, 55], ["mice", "ORGANISM", 65, 69], ["Bi@MSNs", "SIMPLE_CHEMICAL", 111, 118], ["Ag-Bi@MSNs", "SIMPLE_CHEMICAL", 120, 130], ["Bi@MSNs + NIR", "SIMPLE_CHEMICAL", 132, 145], ["Ag-Bi@MSNs + NIR", "SIMPLE_CHEMICAL", 150, 166], ["Ag", "PROTEIN", 120, 122], ["Ag", "PROTEIN", 150, 152], ["MRSA", "SPECIES", 51, 55], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["the synergic antibacterial effect", "TREATMENT", 16, 49], ["MRSA", "PROBLEM", 51, 55], ["PBS", "TEST", 106, 109], ["Bi@MSNs", "TEST", 111, 118], ["Ag", "TEST", 120, 122], ["Bi@MSNs", "TEST", 123, 130], ["Bi@MSNs", "TEST", 132, 139], ["NIR", "TEST", 142, 145], ["Ag", "TEST", 150, 152], ["Bi@MSNs", "TEST", 153, 160], ["MRSA", "OBSERVATION", 51, 55]]], ["Regarding to the control group (PBS), the number of colonies were reduced to 90.3, 74.6, 35.1 and 5.9% for Bi@MSNs, Bi@MSNs + NIR, Ag-Bi@MSNs and Ag-Bi@MSNs + NIR, respectively, indicating that multimodal synergistic therapy based on Ag-Bi@MSNs could effectively treat MRSA skin infection.", [["colonies", "ANATOMY", 52, 60], ["skin", "ANATOMY", 274, 278], ["Bi@MSNs", "CHEMICAL", 107, 114], ["Bi@MSNs", "CHEMICAL", 116, 123], ["Ag-Bi@MSNs", "CHEMICAL", 131, 141], ["Ag", "CHEMICAL", 146, 148], ["Ag-Bi@MSNs", "CHEMICAL", 234, 244], ["MRSA skin infection", "DISEASE", 269, 288], ["Ag", "CHEMICAL", 131, 133], ["Bi@MSNs", "CHEMICAL", 134, 141], ["Ag", "CHEMICAL", 146, 148], ["Ag", "CHEMICAL", 234, 236], ["Bi@MSNs", "SIMPLE_CHEMICAL", 107, 114], ["Bi@MSNs + NIR", "SIMPLE_CHEMICAL", 116, 129], ["Ag-Bi@MSNs", "SIMPLE_CHEMICAL", 131, 141], ["Ag-Bi@MSNs + NIR", "SIMPLE_CHEMICAL", 146, 162], ["Ag-Bi@MSNs", "SIMPLE_CHEMICAL", 234, 244], ["skin", "ORGAN", 274, 278], ["Bi@MSNs", "PROTEIN", 116, 123], ["Ag", "PROTEIN", 131, 133], ["Bi@MSNs", "PROTEIN", 134, 141], ["Ag", "PROTEIN", 146, 148], ["Bi@MSNs", "PROTEIN", 149, 156], ["Ag", "PROTEIN", 234, 236], ["MRSA", "SPECIES", 269, 273], ["MRSA", "SPECIES", 269, 273], ["colonies", "TEST", 52, 60], ["Bi@MSNs", "TEST", 107, 114], ["Bi@MSNs", "TEST", 116, 123], ["NIR", "TEST", 126, 129], ["Ag", "TEST", 131, 133], ["Bi@MSNs", "TEST", 134, 141], ["Ag", "TEST", 146, 148], ["Bi@MSNs", "TEST", 149, 156], ["multimodal synergistic therapy", "TREATMENT", 194, 224], ["Ag", "TEST", 234, 236], ["Bi@MSNs", "TREATMENT", 237, 244], ["MRSA skin infection", "PROBLEM", 269, 288], ["skin", "ANATOMY", 274, 278], ["infection", "OBSERVATION", 279, 288]]], ["The therapeutic effect was confirmed by histological analysis.", [["histological analysis", "TEST", 40, 61]]], ["Beyond that, the animals evaluated showed no obvious changes in their body weight suggesting no biotoxicity.", [["body", "ANATOMY", 70, 74], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["obvious changes in their body weight", "PROBLEM", 45, 81], ["biotoxicity", "PROBLEM", 96, 107], ["no obvious", "UNCERTAINTY", 42, 52], ["no", "UNCERTAINTY", 93, 95], ["biotoxicity", "OBSERVATION", 96, 107]]], ["These findings made Ag-Bi@MSNs a promising multimodal nanoplatform against bacterial infections and for further clinical translations.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentFast and accurate bacteria detection and their effectively killing in the bloodstream in low doses are crucial and act as key roles in medicine and microbiology studies.", [["bloodstream", "ANATOMY", 271, 282], ["Ag-Bi@MSNs", "CHEMICAL", 20, 30], ["bacterial infections", "DISEASE", 75, 95], ["Infectious Diseases", "DISEASE", 168, 187], ["Ag", "CHEMICAL", 20, 22], ["Ag-Bi@MSNs", "SIMPLE_CHEMICAL", 20, 30], ["Ag", "PROTEIN", 20, 22], ["Ag", "TEST", 20, 22], ["bacterial infections", "PROBLEM", 75, 95], ["Infectious Diseases", "PROBLEM", 168, 187], ["accurate bacteria detection", "TEST", 206, 233], ["microbiology studies", "TEST", 345, 365], ["infections", "OBSERVATION", 85, 95], ["Infections", "OBSERVATION", 144, 154], ["bloodstream", "ANATOMY", 271, 282], ["low doses", "OBSERVATION_MODIFIER", 286, 295]]], ["Integrating diagnosis and treatment to achieve accurate diagnosis and efficient treatment of diseases has always been an important goal of modern medicine.", [["treatment", "TREATMENT", 26, 35], ["diseases", "PROBLEM", 93, 101], ["modern medicine", "TREATMENT", 139, 154]]], ["(122) developed a smart and theranostic nanoplatform based on vancomycin (VAN)-loaded magnetic (Fe3O4 NPs) MSNs (MMSNs) modified with sufonated-hyaluronic acid (S-HA) and S. aureus antibody (Ab) grafting via amidation reaction (labeled Ab@S-HA) for S. aureus detection and treatment in bloodstreams.", [["bloodstreams", "ANATOMY", 286, 298], ["vancomycin", "CHEMICAL", 62, 72], ["VAN", "CHEMICAL", 74, 77], ["Fe3O4 NPs", "CHEMICAL", 96, 105], ["MSNs", "CHEMICAL", 107, 111], ["MMSNs", "CHEMICAL", 113, 118], ["sufonated-hyaluronic acid", "CHEMICAL", 134, 159], ["S-HA", "CHEMICAL", 161, 165], ["Ab@S-HA", "CHEMICAL", 236, 243], ["vancomycin", "CHEMICAL", 62, 72], ["VAN", "CHEMICAL", 74, 77], ["Fe3O4", "CHEMICAL", 96, 101], ["vancomycin", "SIMPLE_CHEMICAL", 62, 72], ["VAN", "SIMPLE_CHEMICAL", 74, 77], ["Fe3O4 NPs) MSNs", "SIMPLE_CHEMICAL", 96, 111], ["MMSNs", "SIMPLE_CHEMICAL", 113, 118], ["sufonated-hyaluronic acid", "SIMPLE_CHEMICAL", 134, 159], ["S-HA", "SIMPLE_CHEMICAL", 161, 165], ["S. aureus", "ORGANISM", 171, 180], ["antibody", "SIMPLE_CHEMICAL", 181, 189], ["Ab@S-HA", "SIMPLE_CHEMICAL", 236, 243], ["S. aureus", "ORGANISM", 249, 258], ["Ab", "PROTEIN", 191, 193], ["S. aureus", "SPECIES", 171, 180], ["S. aureus", "SPECIES", 249, 258], ["S. aureus", "SPECIES", 171, 180], ["S. aureus", "SPECIES", 249, 258], ["a smart and theranostic nanoplatform", "TREATMENT", 16, 52], ["vancomycin (VAN)-loaded magnetic (Fe3O4 NPs)", "TREATMENT", 62, 106], ["sufonated", "TEST", 134, 143], ["hyaluronic acid", "TEST", 144, 159], ["HA", "PROBLEM", 163, 165], ["S. aureus antibody", "PROBLEM", 171, 189], ["Ab) grafting", "TREATMENT", 191, 203], ["amidation reaction", "PROBLEM", 208, 226], ["labeled Ab@S", "TEST", 228, 240], ["HA", "PROBLEM", 241, 243], ["S. aureus detection", "PROBLEM", 249, 268], ["treatment in bloodstreams", "TREATMENT", 273, 298], ["aureus", "OBSERVATION", 174, 180], ["aureus", "OBSERVATION", 252, 258]]], ["S-HA was selected due to its capping and targeting function, biocompatibility, biodegradability besides promotes drug sustained release and anti-adhesion effects.", [["S-HA", "CHEMICAL", 0, 4], ["S-HA", "GENE_OR_GENE_PRODUCT", 0, 4], ["HA", "PROBLEM", 2, 4], ["its capping", "PROBLEM", 25, 36], ["anti-adhesion effects", "TREATMENT", 140, 161]]], ["Fe3O4 NPs displayed average size of 180 nm whereas spherical MMSNs achieved average size and pores diameter of 240 and 3 nm, respectively.", [["Fe3O4", "CHEMICAL", 0, 5], ["Fe3O4", "CHEMICAL", 0, 5], ["Fe3O4 NPs", "SIMPLE_CHEMICAL", 0, 9], ["MMSNs", "SIMPLE_CHEMICAL", 61, 66], ["Fe3O4 NPs", "TEST", 0, 9], ["spherical MMSNs", "TEST", 51, 66], ["pores diameter", "TEST", 93, 107], ["average", "OBSERVATION_MODIFIER", 20, 27], ["size", "OBSERVATION_MODIFIER", 28, 32], ["180 nm", "OBSERVATION_MODIFIER", 36, 42], ["size", "OBSERVATION_MODIFIER", 84, 88], ["pores", "OBSERVATION_MODIFIER", 93, 98], ["diameter", "OBSERVATION_MODIFIER", 99, 107]]], ["In addition, Ab@S-HA exhibited 180 nm core uniformly wrapped with 30 nm shell, with zeta potential of -5.32 mV.", [["Ab@S-HA", "CHEMICAL", 13, 20], ["Ab@S-HA", "SIMPLE_CHEMICAL", 13, 20], ["Ab@S", "PROTEIN", 13, 17], ["Ab@S", "TEST", 13, 17], ["HA", "PROBLEM", 18, 20], ["zeta potential", "TEST", 84, 98]]], ["Van loading efficacy of 10.7 wt% was achieved and antibacterial assays were carried out since S. aureus can secrete hyaluronidase (Hyal), enzyme that degrades S-HA promoting controlled VAN release.", [["S-HA", "CHEMICAL", 159, 163], ["VAN", "CHEMICAL", 185, 188], ["S. aureus", "ORGANISM", 94, 103], ["hyaluronidase", "GENE_OR_GENE_PRODUCT", 116, 129], ["Hyal", "SIMPLE_CHEMICAL", 131, 135], ["S-HA", "SIMPLE_CHEMICAL", 159, 163], ["VAN", "SIMPLE_CHEMICAL", 185, 188], ["hyaluronidase", "PROTEIN", 116, 129], ["Hyal", "PROTEIN", 131, 135], ["S. aureus", "SPECIES", 94, 103], ["S. aureus", "SPECIES", 94, 103], ["Van loading efficacy", "TREATMENT", 0, 20], ["antibacterial assays", "TEST", 50, 70], ["S. aureus", "PROBLEM", 94, 103]]], ["Results exhibited 98% of bacterial reduction suggesting high antibacterial efficacy and Hyal-responsive controlled VAN release.", [["Hyal", "CHEMICAL", 88, 92], ["VAN", "CHEMICAL", 115, 118], ["Hyal", "SIMPLE_CHEMICAL", 88, 92], ["VAN", "SIMPLE_CHEMICAL", 115, 118], ["bacterial reduction", "TREATMENT", 25, 44], ["high antibacterial efficacy", "PROBLEM", 56, 83], ["Hyal-responsive controlled VAN release", "TREATMENT", 88, 126], ["high", "OBSERVATION_MODIFIER", 56, 60], ["antibacterial efficacy", "OBSERVATION", 61, 83]]], ["In vitro release tests were conducted showing that no significant VAN was release without Hyal presence whereas after Hyal addition (up to 500 U mL-1), up to 83% of VAN corroborating the Hyal role in the \u201con-demand\u201d drug release.", [["VAN", "CHEMICAL", 66, 69], ["Hyal", "CHEMICAL", 118, 122], ["VAN", "CHEMICAL", 165, 168], ["Hyal", "CHEMICAL", 118, 122], ["VAN", "SIMPLE_CHEMICAL", 66, 69], ["Hyal", "SIMPLE_CHEMICAL", 90, 94], ["Hyal", "SIMPLE_CHEMICAL", 118, 122], ["VAN", "SIMPLE_CHEMICAL", 165, 168], ["vitro release tests", "TEST", 3, 22]]], ["The Ab@S-HA magnetization behavior was evaluated and despites magnetization values reduction after all modification, the nanosystem presented good magnetic responsivity and can be utilized to modify the surface of magnetic glassy carbon electrode (MGCE) (noted Ab@S-HA) by magnetic interaction.", [["surface", "ANATOMY", 203, 210], ["glassy carbon", "CHEMICAL", 223, 236], ["MGCE", "CHEMICAL", 248, 252], ["Ab@S-HA", "CHEMICAL", 261, 268], ["glassy carbon", "CHEMICAL", 223, 236], ["Ab@S-HA", "SIMPLE_CHEMICAL", 4, 11], ["glassy carbon electrode", "SIMPLE_CHEMICAL", 223, 246], ["MGCE", "SIMPLE_CHEMICAL", 248, 252], ["Ab@S-HA", "SIMPLE_CHEMICAL", 261, 268], ["The Ab@S", "TEST", 0, 8], ["HA magnetization behavior", "PROBLEM", 9, 34], ["magnetization values reduction", "TREATMENT", 62, 92], ["all modification", "TREATMENT", 99, 115], ["magnetic glassy carbon electrode", "TREATMENT", 214, 246], ["HA", "PROBLEM", 266, 268]]], ["From electrochemical and analytical studies, the fabricated immunosensor exhibited an excellent electrochemical response towards S. aureus in the range of 1x101\u20131x1010 CFU mL-1 with high selectivity, stability and reproducibility.", [["S. aureus", "ORGANISM", 129, 138], ["S. aureus", "SPECIES", 129, 138], ["S. aureus", "SPECIES", 129, 138], ["analytical studies", "TEST", 25, 43], ["the fabricated immunosensor", "TEST", 45, 72], ["S. aureus", "PROBLEM", 129, 138], ["excellent", "OBSERVATION_MODIFIER", 86, 95], ["electrochemical response", "OBSERVATION", 96, 120], ["aureus", "OBSERVATION", 132, 138], ["high selectivity", "OBSERVATION_MODIFIER", 182, 198], ["stability", "OBSERVATION_MODIFIER", 200, 209], ["reproducibility", "OBSERVATION_MODIFIER", 214, 229]]], ["The detection limit with linear range was up to 3 CFU mL-1, and this responsiveness was also well demonstrated in the blood environment.", [["blood", "ANATOMY", 118, 123], ["blood", "ORGANISM_SUBSTANCE", 118, 123]]], ["Beyond that S-HA-modified MMSNs possess anticoagulant property, the Ab@S-HA displayed antiadhesion property, ensuring that it can be directly applied to detect S. aureus in whole blood.", [["whole blood", "ANATOMY", 173, 184], ["S-HA", "CHEMICAL", 12, 16], ["Ab@S-HA", "CHEMICAL", 68, 75], ["S-HA", "SIMPLE_CHEMICAL", 12, 16], ["MMSNs", "SIMPLE_CHEMICAL", 26, 31], ["Ab@S-HA", "SIMPLE_CHEMICAL", 68, 75], ["S. aureus", "ORGANISM", 160, 169], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["S-HA-modified MMSNs", "CELL_LINE", 12, 31], ["S. aureus", "SPECIES", 160, 169], ["S. aureus", "SPECIES", 160, 169], ["anticoagulant property", "TREATMENT", 40, 62], ["HA", "PROBLEM", 73, 75], ["S. aureus in whole blood", "PROBLEM", 160, 184], ["aureus", "OBSERVATION", 163, 169]]], ["Additionally, increasing S. aureus amount of arriving at Ab@S-HA, the capping Ab@S-HA were degraded by Hyal secreted by S. aureus and \u201con demand\u201d VAN released was achieved.", [["Ab@S-HA", "CHEMICAL", 57, 64], ["Ab@S-HA", "CHEMICAL", 78, 85], ["Hyal", "CHEMICAL", 103, 107], ["VAN", "CHEMICAL", 146, 149], ["S. aureus", "ORGANISM", 25, 34], ["Ab@S-HA", "SIMPLE_CHEMICAL", 57, 64], ["Ab@S-HA", "SIMPLE_CHEMICAL", 78, 85], ["Hyal", "SIMPLE_CHEMICAL", 103, 107], ["S. aureus", "ORGANISM", 120, 129], ["VAN", "SIMPLE_CHEMICAL", 146, 149], ["S. aureus", "SPECIES", 25, 34], ["S. aureus", "SPECIES", 120, 129], ["S. aureus", "SPECIES", 25, 34], ["S. aureus", "SPECIES", 120, 129], ["increasing S. aureus amount", "PROBLEM", 14, 41], ["HA", "PROBLEM", 62, 64], ["the capping Ab@S", "TEST", 66, 82], ["HA", "PROBLEM", 83, 85], ["S. aureus", "PROBLEM", 120, 129], ["demand\u201d VAN", "TREATMENT", 138, 149], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["aureus", "OBSERVATION_MODIFIER", 28, 34], ["amount", "OBSERVATION_MODIFIER", 35, 41], ["aureus", "OBSERVATION", 123, 129]]], ["All results suggest this multifunctional theranostic nanoplatform for accurate diagnosis and efficient treatment of S. aureus bloodstream infection.Bacterial Infections ::: MSNs for Infectious Diseases TreatmentZink group (23,118,125,132\u2013135) have designed stimuli-responsive controlled drug delivery MSNs-based nanoplatforms to treat infectious diseases such as caused by Francisella tularensis (125,130,134,135) and M. tuberculosis (118,132,133).", [["bloodstream", "ANATOMY", 126, 137], ["S. aureus bloodstream infection", "DISEASE", 116, 147], ["Infectious Diseases TreatmentZink", "DISEASE", 182, 215], ["MSNs", "CHEMICAL", 301, 305], ["infectious diseases", "DISEASE", 335, 354], ["tuberculosis", "DISEASE", 421, 433], ["S. aureus bloodstream", "ORGANISM", 116, 137], ["MSNs", "SIMPLE_CHEMICAL", 301, 305], ["Francisella tularensis", "ORGANISM", 373, 395], ["M. tuberculosis", "ORGANISM", 418, 433], ["S. aureus", "SPECIES", 116, 125], ["Francisella tularensis", "SPECIES", 373, 395], ["M. tuberculosis", "SPECIES", 418, 433], ["S. aureus", "SPECIES", 116, 125], ["Francisella tularensis", "SPECIES", 373, 395], ["M. tuberculosis", "SPECIES", 418, 433], ["this multifunctional theranostic nanoplatform", "TREATMENT", 20, 65], ["S. aureus bloodstream infection", "PROBLEM", 116, 147], ["stimuli-responsive controlled drug delivery MSNs", "TREATMENT", 257, 305], ["based nanoplatforms", "TREATMENT", 306, 325], ["infectious diseases", "PROBLEM", 335, 354], ["Francisella tularensis", "PROBLEM", 373, 395], ["M. tuberculosis", "PROBLEM", 418, 433], ["aureus", "OBSERVATION_MODIFIER", 119, 125], ["bloodstream", "OBSERVATION_MODIFIER", 126, 137], ["infection", "OBSERVATION", 138, 147], ["Infections", "OBSERVATION", 158, 168], ["infectious", "OBSERVATION", 335, 345], ["tuberculosis", "OBSERVATION", 421, 433]]], ["From one of these works (135), authors developed a pathogen-specific detection and drug delivery nanoplatform based on MSNs modified with silane groups attached with lipopolisaccharide chain of F. tularensis live vaccine strain (Ft-LVS-LPS) as stalks (modified antigen) that interact with FB11 anti-O-antigen antibody (FB11) nanovalve as a capping agent to block the mesopores avoiding drug diffusion without specific stimulus.", [["stalks", "ANATOMY", 244, 250], ["silane", "CHEMICAL", 138, 144], ["silane", "CHEMICAL", 138, 144], ["lipopolisaccharide", "CHEMICAL", 166, 184], ["MSNs", "SIMPLE_CHEMICAL", 119, 123], ["F. tularensis", "ORGANISM", 194, 207], ["LPS", "SIMPLE_CHEMICAL", 236, 239], ["FB11 anti-O-antigen", "GENE_OR_GENE_PRODUCT", 289, 308], ["FB11", "SIMPLE_CHEMICAL", 319, 323], ["modified antigen", "PROTEIN", 252, 268], ["FB11", "PROTEIN", 289, 293], ["anti-O-antigen antibody", "PROTEIN", 294, 317], ["FB11", "PROTEIN", 319, 323], ["F. tularensis", "SPECIES", 194, 207], ["F. tularensis", "SPECIES", 194, 207], ["a pathogen", "PROBLEM", 49, 59], ["specific detection", "TEST", 60, 78], ["drug delivery nanoplatform", "TREATMENT", 83, 109], ["MSNs modified with silane groups", "TREATMENT", 119, 151], ["lipopolisaccharide chain", "TREATMENT", 166, 190], ["nanovalve", "TREATMENT", 325, 334], ["a capping agent", "TREATMENT", 338, 353], ["drug diffusion", "PROBLEM", 386, 400]]], ["By manipulation of the non-covalently interaction MSNs modified antigen (Ft-LVS-LPS)-antibody (FB11), the antigen produced by the target bacteria can compete effectively for binding to the gatekeeper antibody, reducing stalk-nanovalve interaction, leading to displacement of the antibody, pore uncapping and finally cargo release.", [["nanovalve", "ANATOMY", 225, 234], ["pore", "ANATOMY", 289, 293], ["Ft-LVS-LPS", "GENE_OR_GENE_PRODUCT", 73, 83], ["FB11", "SIMPLE_CHEMICAL", 95, 99], ["non-covalently interaction MSNs modified antigen (Ft-LVS-LPS)-antibody", "PROTEIN", 23, 93], ["FB11", "PROTEIN", 95, 99], ["gatekeeper antibody", "PROTEIN", 189, 208], ["Ft", "TEST", 73, 75], ["LVS", "TEST", 76, 79], ["LPS", "TEST", 80, 83], ["antibody", "TEST", 85, 93], ["FB11", "TEST", 95, 99], ["the antigen", "TEST", 102, 113], ["the target bacteria", "PROBLEM", 126, 145], ["nanovalve interaction", "PROBLEM", 225, 246], ["displacement of the antibody", "PROBLEM", 259, 287]]], ["Model drugs such as fluorescein or Hoechst 33342 were used to evaluate the nanoplatform specificity and action.", [["fluorescein", "CHEMICAL", 20, 31], ["Hoechst 33342", "CHEMICAL", 35, 48], ["fluorescein", "CHEMICAL", 20, 31], ["Hoechst 33342", "CHEMICAL", 35, 48], ["fluorescein", "SIMPLE_CHEMICAL", 20, 31], ["Hoechst 33342", "SIMPLE_CHEMICAL", 35, 48], ["Model drugs", "TREATMENT", 0, 11], ["fluorescein", "TREATMENT", 20, 31], ["Hoechst 33342", "TREATMENT", 35, 48], ["the nanoplatform specificity", "TEST", 71, 99]]], ["Spherical MSNs with high surface area (840 m2 g-1), surface charge of +36 mV and average diameter and pores size of 117 and 3.8 nm, respectively, were prepared as nanoplatform.", [["surface", "ANATOMY", 25, 32], ["surface", "ANATOMY", 52, 59], ["MSNs", "SIMPLE_CHEMICAL", 10, 14], ["high surface area", "PROBLEM", 20, 37], ["surface charge", "TEST", 52, 66], ["pores size", "TEST", 102, 112], ["MSNs", "OBSERVATION", 10, 14], ["high", "OBSERVATION_MODIFIER", 20, 24], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["840 m2", "OBSERVATION_MODIFIER", 39, 45], ["+36 mV", "OBSERVATION_MODIFIER", 70, 76], ["average", "OBSERVATION_MODIFIER", 81, 88], ["diameter", "OBSERVATION_MODIFIER", 89, 97], ["pores", "OBSERVATION_MODIFIER", 102, 107], ["size", "OBSERVATION_MODIFIER", 108, 112], ["3.8 nm", "OBSERVATION_MODIFIER", 124, 130]]], ["The specific antigen-antibody modification was successfully confirmed by immunostaining assay showing no nonspecific binding of the FB11 antibody to the unfunctionalized MSN surface and also no nonspecific binding of the fluorescent secondary goat-antimouse (GAM) immunostaining antibody to the unfunctionalized MSN surface or the Ft-LVS-LPS.", [["MSN surface", "ANATOMY", 170, 181], ["MSN surface", "ANATOMY", 312, 323], ["LPS", "CHEMICAL", 338, 341], ["FB11 antibody", "GENE_OR_GENE_PRODUCT", 132, 145], ["MSN surface", "CELLULAR_COMPONENT", 170, 181], ["GAM", "GENE_OR_GENE_PRODUCT", 259, 262], ["LPS", "SIMPLE_CHEMICAL", 338, 341], ["FB11 antibody", "PROTEIN", 132, 145], ["fluorescent secondary goat-antimouse (GAM) immunostaining antibody", "PROTEIN", 221, 287], ["goat", "SPECIES", 243, 247], ["The specific antigen-antibody modification", "TEST", 0, 42], ["immunostaining assay", "TEST", 73, 93], ["the FB11 antibody", "TEST", 128, 145], ["the fluorescent secondary goat", "PROBLEM", 217, 247], ["immunostaining antibody", "TEST", 264, 287], ["LPS", "PROBLEM", 338, 341], ["no", "UNCERTAINTY", 191, 193], ["nonspecific", "OBSERVATION_MODIFIER", 194, 205]]], ["Authors also evaluated whether a competitive FB11 antibodies displacement could be achieved in the presence of Ft-LVS-LPS.", [["LPS", "CHEMICAL", 118, 121], ["FB11", "GENE_OR_GENE_PRODUCT", 45, 49], ["Ft", "SIMPLE_CHEMICAL", 111, 113], ["LPS", "SIMPLE_CHEMICAL", 118, 121], ["FB11 antibodies", "PROTEIN", 45, 60], ["a competitive FB11 antibodies displacement", "PROBLEM", 31, 73], ["Ft", "TEST", 111, 113], ["LPS", "PROBLEM", 118, 121]]], ["From immunostaining assays, by using both types of silane groups (APTES and ICPTES) as stalks to interact with the modified antigen, successful displacement of FB11 antibodies from the MSN surface in the presence of Ft-LVS bacteria can be confirmed in vitro indicating that the operation of the nanovalve is feasible at high bacterial concentration.", [["stalks", "ANATOMY", 87, 93], ["MSN surface", "ANATOMY", 185, 196], ["silane", "CHEMICAL", 51, 57], ["APTES", "CHEMICAL", 66, 71], ["silane", "CHEMICAL", 51, 57], ["ICPTES", "CHEMICAL", 76, 82], ["silane groups", "SIMPLE_CHEMICAL", 51, 64], ["APTES", "SIMPLE_CHEMICAL", 66, 71], ["ICPTES", "SIMPLE_CHEMICAL", 76, 82], ["FB11 antibodies", "GENE_OR_GENE_PRODUCT", 160, 175], ["MSN surface", "CELLULAR_COMPONENT", 185, 196], ["Ft", "SIMPLE_CHEMICAL", 216, 218], ["FB11 antibodies", "PROTEIN", 160, 175], ["immunostaining assays", "TEST", 5, 26], ["silane groups (APTES and ICPTES)", "TREATMENT", 51, 83], ["successful displacement of FB11 antibodies", "TREATMENT", 133, 175], ["LVS bacteria", "PROBLEM", 219, 231], ["the operation", "TREATMENT", 274, 287], ["the nanovalve", "TREATMENT", 291, 304], ["high bacterial concentration", "PROBLEM", 320, 348]]], ["In addition, the reduction of the FB11 antibody affinity to the LPS-modified MSNs surface was achieved by acetylation of LPS-modified MSNs reducing the OH groups available for hydrogen-bonding with FB11, requiring lower Ft bacterial concentrations to displace FB11 antibody from the nanoplatform.", [["MSNs surface", "ANATOMY", 77, 89], ["LPS", "CHEMICAL", 64, 67], ["LPS", "CHEMICAL", 121, 124], ["OH", "CHEMICAL", 152, 154], ["FB11", "CHEMICAL", 198, 202], ["OH", "CHEMICAL", 152, 154], ["hydrogen", "CHEMICAL", 176, 184], ["FB11", "CHEMICAL", 198, 202], ["FB11", "CHEMICAL", 260, 264], ["FB11", "GENE_OR_GENE_PRODUCT", 34, 38], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["LPS", "SIMPLE_CHEMICAL", 121, 124], ["MSNs", "SIMPLE_CHEMICAL", 134, 138], ["OH", "SIMPLE_CHEMICAL", 152, 154], ["hydrogen", "SIMPLE_CHEMICAL", 176, 184], ["FB11", "SIMPLE_CHEMICAL", 198, 202], ["Ft", "SIMPLE_CHEMICAL", 220, 222], ["FB11 antibody", "GENE_OR_GENE_PRODUCT", 260, 273], ["FB11 antibody", "PROTEIN", 34, 47], ["FB11 antibody", "PROTEIN", 260, 273], ["the FB11 antibody affinity", "TREATMENT", 30, 56], ["the LPS", "TEST", 60, 67], ["LPS", "TREATMENT", 121, 124], ["modified MSNs", "TREATMENT", 125, 138], ["the OH groups", "TREATMENT", 148, 161], ["FB11", "TREATMENT", 198, 202], ["lower Ft bacterial concentrations", "TREATMENT", 214, 247], ["FB11 antibody", "TREATMENT", 260, 273], ["the nanoplatform", "TREATMENT", 279, 295]]], ["From cargo release studies, authors reported that the use of LPS from a Ft wzy deletion mutant can promote better mesopores capping avoiding any cargo leakage before reach the target site.", [["LPS", "CHEMICAL", 61, 64], ["LPS", "SIMPLE_CHEMICAL", 61, 64], ["Ft", "GENE_OR_GENE_PRODUCT", 72, 74], ["Ft wzy deletion mutant", "DNA", 72, 94], ["LPS", "TREATMENT", 61, 64], ["a Ft wzy deletion mutant", "TREATMENT", 70, 94], ["any cargo leakage", "PROBLEM", 141, 158], ["cargo leakage", "OBSERVATION", 145, 158]]], ["Beyond that, from this highly specific nature of the antibody-antigen interaction, a significant cargo release was detected only in Ft-LVS-LPS presence.", [["LPS", "CHEMICAL", 139, 142], ["antibody-antigen", "GENE_OR_GENE_PRODUCT", 53, 69], ["Ft", "SIMPLE_CHEMICAL", 132, 134], ["LPS", "SIMPLE_CHEMICAL", 139, 142]]], ["These results suggested that the pathogen-sensitive controlled cargo release nanoplatforms can be also applied to other gram-negative bacteria as novel theranostic smart MSNs-based nanosystem for infectious diseases treatment.Parasitic Infections ::: MSNs for Infectious Diseases TreatmentMSNs have received great attention towards vaccines production due to the large amount of silanol groups on its surface that facilitates the functionalization and drugs incorporation.", [["surface", "ANATOMY", 401, 408], ["infectious diseases", "DISEASE", 196, 215], ["Parasitic Infections", "DISEASE", 226, 246], ["Infectious Diseases", "DISEASE", 260, 279], ["MSNs", "CHEMICAL", 289, 293], ["silanol", "CHEMICAL", 379, 386], ["silanol", "CHEMICAL", 379, 386], ["MSNs", "SIMPLE_CHEMICAL", 170, 174], ["silanol", "SIMPLE_CHEMICAL", 379, 386], ["surface", "CELLULAR_COMPONENT", 401, 408], ["the pathogen", "PROBLEM", 29, 41], ["cargo release nanoplatforms", "TREATMENT", 63, 90], ["other gram", "TEST", 114, 124], ["negative bacteria", "PROBLEM", 125, 142], ["novel theranostic smart MSNs", "TREATMENT", 146, 174], ["infectious diseases treatment", "TREATMENT", 196, 225], ["Parasitic Infections", "PROBLEM", 226, 246], ["Infectious Diseases TreatmentMSNs", "TREATMENT", 260, 293], ["vaccines production", "TREATMENT", 332, 351], ["the functionalization", "TREATMENT", 426, 447], ["drugs incorporation", "TREATMENT", 452, 471], ["Infections", "OBSERVATION", 236, 246], ["large", "OBSERVATION_MODIFIER", 363, 368], ["amount", "OBSERVATION_MODIFIER", 369, 375], ["silanol groups", "OBSERVATION", 379, 393]]], ["The surface functionalization with several molecules allows improving cells target and uptake besides favor drugs transport and release from the mesopores, leading to interesting immune and cellular responses, which makes MSNs attractive and potential nanoplatforms for vaccines fabrication against any infectious diseases (154).Parasitic Infections ::: MSNs for Infectious Diseases TreatmentFew studies have been reported in the literature applying MSNs for parasitic diseases treatment (as shown in Table III).", [["surface", "ANATOMY", 4, 11], ["cells", "ANATOMY", 70, 75], ["cellular", "ANATOMY", 190, 198], ["infectious diseases", "DISEASE", 303, 322], ["Parasitic Infections", "DISEASE", 329, 349], ["Infectious Diseases", "DISEASE", 363, 382], ["parasitic diseases", "DISEASE", 459, 477], ["cells", "CELL", 70, 75], ["cellular", "CELL", 190, 198], ["MSNs", "SIMPLE_CHEMICAL", 222, 226], ["The surface functionalization", "TREATMENT", 0, 29], ["drugs transport", "TREATMENT", 108, 123], ["the mesopores", "PROBLEM", 141, 154], ["potential nanoplatforms", "TREATMENT", 242, 265], ["vaccines fabrication", "TREATMENT", 270, 290], ["any infectious diseases", "PROBLEM", 299, 322], ["Parasitic Infections", "PROBLEM", 329, 349], ["Infectious Diseases", "PROBLEM", 363, 382], ["Few studies", "TEST", 392, 403], ["parasitic diseases treatment", "TREATMENT", 459, 487], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["functionalization", "OBSERVATION", 12, 29], ["Infections", "OBSERVATION", 339, 349]]], ["For instance, Oliveira et al .", [["Oliveira et al", "TREATMENT", 14, 28]]], ["(136) described that vaccine and prophylactic protection development against Schistosoma mansoni are essential to reduce the infection cases.", [["Schistosoma mansoni", "DISEASE", 77, 96], ["infection", "DISEASE", 125, 134], ["Schistosoma mansoni", "ORGANISM", 77, 96], ["Schistosoma mansoni", "SPECIES", 77, 96], ["Schistosoma mansoni", "SPECIES", 77, 96], ["vaccine", "TREATMENT", 21, 28], ["prophylactic protection development", "TREATMENT", 33, 68], ["Schistosoma mansoni", "PROBLEM", 77, 96], ["the infection cases", "PROBLEM", 121, 140], ["infection", "OBSERVATION", 125, 134]]], ["In this way, authors reported the use of MSNs containing SWAP (Antigenic Preparation of Soluble Worm) as new strategy to treat S. mansoni infection.", [["MSNs", "CHEMICAL", 41, 45], ["S. mansoni infection", "DISEASE", 127, 147], ["MSNs", "SIMPLE_CHEMICAL", 41, 45], ["S. mansoni", "ORGANISM", 127, 137], ["S. mansoni", "SPECIES", 127, 137], ["S. mansoni", "SPECIES", 127, 137], ["MSNs", "TREATMENT", 41, 45], ["SWAP (Antigenic Preparation of Soluble Worm)", "TREATMENT", 57, 101], ["new strategy", "TREATMENT", 105, 117], ["S. mansoni infection", "PROBLEM", 127, 147], ["mansoni", "OBSERVATION_MODIFIER", 130, 137], ["infection", "OBSERVATION", 138, 147]]], ["MSNs were characterized according to their size (38.8 nm), polydispersity index (0.24), zeta potential (-32.9 mV), surface area (871.19 m2 g-1) and porosity with pores volume and diameter of 0.243 cm3 g-1 and 6.91 nm, respectively.", [["surface", "ANATOMY", 115, 122], ["MSNs", "CELL", 0, 4], ["polydispersity index", "TEST", 59, 79], ["zeta potential", "TEST", 88, 102], ["surface area", "TEST", 115, 127], ["g", "TEST", 139, 140], ["porosity", "TEST", 148, 156], ["pores volume", "TEST", 162, 174], ["diameter", "TEST", 179, 187], ["pores volume", "OBSERVATION", 162, 174], ["diameter", "OBSERVATION_MODIFIER", 179, 187]]], ["SWAP was successfully incorporated into MSNs showing EE up to 35.35%.", [["EE", "CHEMICAL", 53, 55], ["SWAP", "PROTEIN", 0, 4], ["EE", "TEST", 53, 55]]], ["Immunological tests indicated that MSNs were able to stimulate a high immune response compared to conventional adjuvants (SWAP-associated aluminum salt).", [["aluminum salt", "CHEMICAL", 138, 151], ["aluminum salt", "CHEMICAL", 138, 151], ["MSNs", "SIMPLE_CHEMICAL", 35, 39], ["aluminum salt", "SIMPLE_CHEMICAL", 138, 151], ["Immunological tests", "TEST", 0, 19], ["a high immune response", "PROBLEM", 63, 85], ["conventional adjuvants", "TREATMENT", 98, 120], ["SWAP-associated aluminum salt)", "TREATMENT", 122, 152]]], ["Authors also reported that higher immunization performance observed for MSNs may be related to some unique characteristics presented by the nanosystem, such as high surface area, spherical morphology, high pores volume, stability, biocompatibility and non-toxicity which make SWAP-loaded MSNs a promising strategy to improve immune response against S. mansoni and enabling vaccines production.Parasitic Infections ::: MSNs for Infectious Diseases TreatmentIn another study, Nhavene et al .", [["surface area", "ANATOMY", 165, 177], ["S. mansoni", "DISEASE", 349, 359], ["Parasitic Infections", "DISEASE", 393, 413], ["Infectious Diseases", "DISEASE", 427, 446], ["MSNs", "SIMPLE_CHEMICAL", 72, 76], ["MSNs", "SIMPLE_CHEMICAL", 288, 292], ["S. mansoni", "ORGANISM", 349, 359], ["S. mansoni", "SPECIES", 349, 359], ["S. mansoni", "SPECIES", 349, 359], ["higher immunization performance", "PROBLEM", 27, 58], ["MSNs", "PROBLEM", 72, 76], ["high pores volume", "PROBLEM", 201, 218], ["biocompatibility", "PROBLEM", 231, 247], ["non-toxicity", "PROBLEM", 252, 264], ["SWAP-loaded MSNs", "TREATMENT", 276, 292], ["S. mansoni", "PROBLEM", 349, 359], ["enabling vaccines production", "PROBLEM", 364, 392], ["Infectious Diseases Treatment", "TREATMENT", 427, 456], ["another study", "TEST", 459, 472], ["spherical morphology", "OBSERVATION", 179, 199], ["high", "OBSERVATION_MODIFIER", 201, 205], ["pores volume", "OBSERVATION", 206, 218], ["stability", "OBSERVATION_MODIFIER", 220, 229], ["Infections", "OBSERVATION", 403, 413]]], ["(137) designed multifunctional MSNs based on MCM-41 functionalized with (3-glycidoxypropy) trimethoxysilane (GPTMS) and chitosan succinate (CS) containing benznidazole (BZ) onto modified MSNs surface aiming to evaluate their action against the parasite Trypanosoma cruzi responsible for Chagas disease.", [["MSNs surface", "ANATOMY", 187, 199], ["MCM-41", "CHEMICAL", 45, 51], ["3-glycidoxypropy) trimethoxysilane", "CHEMICAL", 73, 107], ["GPTMS", "CHEMICAL", 109, 114], ["chitosan succinate", "CHEMICAL", 120, 138], ["CS", "CHEMICAL", 140, 142], ["benznidazole", "CHEMICAL", 155, 167], ["BZ", "CHEMICAL", 169, 171], ["Trypanosoma cruzi", "DISEASE", 253, 270], ["Chagas disease", "DISEASE", 287, 301], ["MCM-41", "CHEMICAL", 45, 51], ["(3-glycidoxypropy) trimethoxysilane", "CHEMICAL", 72, 107], ["GPTMS", "CHEMICAL", 109, 114], ["succinate", "CHEMICAL", 129, 138], ["benznidazole", "CHEMICAL", 155, 167], ["MSNs", "SIMPLE_CHEMICAL", 31, 35], ["MCM-41", "SIMPLE_CHEMICAL", 45, 51], ["(3-glycidoxypropy) trimethoxysilane", "SIMPLE_CHEMICAL", 72, 107], ["GPTMS", "SIMPLE_CHEMICAL", 109, 114], ["chitosan succinate", "SIMPLE_CHEMICAL", 120, 138], ["CS", "SIMPLE_CHEMICAL", 140, 142], ["benznidazole", "SIMPLE_CHEMICAL", 155, 167], ["BZ", "SIMPLE_CHEMICAL", 169, 171], ["parasite", "ORGANISM", 244, 252], ["Trypanosoma cruzi", "ORGANISM", 253, 270], ["Trypanosoma cruzi", "SPECIES", 253, 270], ["Trypanosoma cruzi", "SPECIES", 253, 270], ["multifunctional MSNs", "TEST", 15, 35], ["MCM", "TEST", 45, 48], ["trimethoxysilane (GPTMS)", "TREATMENT", 91, 115], ["chitosan succinate (CS)", "TREATMENT", 120, 143], ["benznidazole (BZ)", "TREATMENT", 155, 172], ["modified MSNs surface", "TREATMENT", 178, 199], ["the parasite Trypanosoma cruzi", "PROBLEM", 240, 270], ["Chagas disease", "PROBLEM", 287, 301]]], ["The MSNs-like MCM-41 were successfully prepared with well-defined hexagonal arrays of uniform mesopores network, spherical shape and pores size of 3.3 nm.", [["MCM-41", "CHEMICAL", 14, 20], ["MSNs", "SIMPLE_CHEMICAL", 4, 8], ["MSNs", "DNA", 4, 8], ["MCM", "TEST", 14, 17], ["pores size", "TEST", 133, 143], ["uniform", "OBSERVATION_MODIFIER", 86, 93], ["mesopores network", "OBSERVATION", 94, 111], ["spherical", "OBSERVATION_MODIFIER", 113, 122], ["shape", "OBSERVATION_MODIFIER", 123, 128], ["pores", "OBSERVATION_MODIFIER", 133, 138], ["size", "OBSERVATION_MODIFIER", 139, 143], ["3.3 nm", "OBSERVATION_MODIFIER", 147, 153]]], ["The MSNs functionalization with GPTMS and CS was confirmed by spectroscopic analysis.", [["GPTMS", "CHEMICAL", 32, 37], ["CS", "CHEMICAL", 42, 44], ["GPTMS", "CHEMICAL", 32, 37], ["MSNs", "SIMPLE_CHEMICAL", 4, 8], ["GPTMS", "SIMPLE_CHEMICAL", 32, 37], ["CS", "SIMPLE_CHEMICAL", 42, 44], ["CS", "TEST", 42, 44], ["spectroscopic analysis", "TEST", 62, 84], ["MSNs functionalization", "OBSERVATION", 4, 26]]], ["BZ anchored onto CS-modified MSNs surface via hydrogen bond interactions was confirmed by spectroscopic and density functional theory (DFT) analysis.", [["MSNs surface", "ANATOMY", 29, 41], ["BZ", "CHEMICAL", 0, 2], ["CS", "CHEMICAL", 17, 19], ["hydrogen", "CHEMICAL", 46, 54], ["BZ", "SIMPLE_CHEMICAL", 0, 2], ["CS", "SIMPLE_CHEMICAL", 17, 19], ["hydrogen bond", "OBSERVATION", 46, 59]]], ["In vitro assays showed that the nanosystem can effectively performed BZ delivery being thirty times more active against epimastiogotes T. cruzi CL-Brener than free BZ, revealing its potential and effectiveness as nanocarrier for BZ delivery.", [["BZ", "CHEMICAL", 69, 71], ["BZ", "CHEMICAL", 164, 166], ["BZ", "CHEMICAL", 229, 231], ["BZ", "SIMPLE_CHEMICAL", 69, 71], ["T. cruzi", "ORGANISM", 135, 143], ["CL-Brener", "ORGANISM", 144, 153], ["BZ", "SIMPLE_CHEMICAL", 164, 166], ["BZ", "SIMPLE_CHEMICAL", 229, 231], ["T. cruzi", "SPECIES", 135, 143], ["T. cruzi", "SPECIES", 135, 143], ["vitro assays", "TEST", 3, 15], ["BZ delivery", "TREATMENT", 69, 80], ["T. cruzi CL", "TEST", 135, 146], ["nanocarrier", "TREATMENT", 213, 224], ["BZ delivery", "TREATMENT", 229, 240]]], ["Authors also concluded that all results demonstrated MSNs-GPTMS-CS as a potential and promising nanoplatform for drugs and genes delivery to treat neglected diseases such as Chagas disease or American trypanosomiasis.Parasitic Infections ::: MSNs for Infectious Diseases TreatmentTawfeek et al .", [["MSNs-GPTMS", "CHEMICAL", 53, 63], ["Chagas disease", "DISEASE", 174, 188], ["trypanosomiasis", "DISEASE", 201, 216], ["Parasitic Infections", "DISEASE", 217, 237], ["Infectious Diseases", "DISEASE", 251, 270], ["MSNs-GPTMS-CS", "SIMPLE_CHEMICAL", 53, 66], ["American trypanosomiasis", "SPECIES", 192, 216], ["drugs", "TREATMENT", 113, 118], ["genes delivery", "TREATMENT", 123, 137], ["neglected diseases", "PROBLEM", 147, 165], ["Chagas disease", "PROBLEM", 174, 188], ["American trypanosomiasis", "PROBLEM", 192, 216], ["Parasitic Infections", "PROBLEM", 217, 237], ["Infectious Diseases", "PROBLEM", 251, 270], ["Infections", "OBSERVATION", 227, 237]]], ["(138) fabricated praziquantel (PZQ)-loaded MSNs in order to evaluate its therapeutic effect against murine S. mansoni.", [["praziquantel", "CHEMICAL", 17, 29], ["PZQ", "CHEMICAL", 31, 34], ["murine S. mansoni", "DISEASE", 100, 117], ["praziquantel", "CHEMICAL", 17, 29], ["PZQ", "CHEMICAL", 31, 34], ["praziquantel", "SIMPLE_CHEMICAL", 17, 29], ["PZQ", "SIMPLE_CHEMICAL", 31, 34], ["MSNs", "SIMPLE_CHEMICAL", 43, 47], ["murine", "ORGANISM", 100, 106], ["S. mansoni", "ORGANISM", 107, 117], ["murine", "SPECIES", 100, 106], ["S. mansoni", "SPECIES", 107, 117], ["S. mansoni", "SPECIES", 107, 117], ["fabricated praziquantel (PZQ)", "TREATMENT", 6, 35], ["MSNs", "TREATMENT", 43, 47], ["murine S. mansoni", "PROBLEM", 100, 117], ["mansoni", "OBSERVATION", 110, 117]]], ["MSNs@PZQ showed spherical shape, average size ranging from 100 to 105 nm, zeta potential from +31.9 to +30 mV and EE of 83%.", [["MSNs@PZQ", "CHEMICAL", 0, 8], ["MSNs@PZQ", "SIMPLE_CHEMICAL", 0, 8], ["MSNs@PZQ", "PROTEIN", 0, 8], ["spherical shape", "PROBLEM", 16, 31], ["average size", "TEST", 33, 45], ["zeta potential", "TEST", 74, 88], ["mV", "TEST", 107, 109], ["EE", "TEST", 114, 116], ["spherical", "OBSERVATION_MODIFIER", 16, 25], ["shape", "OBSERVATION_MODIFIER", 26, 31], ["average", "OBSERVATION_MODIFIER", 33, 40], ["size", "OBSERVATION_MODIFIER", 41, 45], ["ranging", "OBSERVATION_MODIFIER", 46, 53]]], ["Mice were infected with S. mansoni and treated 6 weeks after infection with similar doses of MSNs@PQZ and free PZQ evaluating several concentrations, orally and intraperitoneally (IP).", [["S. mansoni", "DISEASE", 24, 34], ["infection", "DISEASE", 61, 70], ["MSNs@PQZ", "CHEMICAL", 93, 101], ["PZQ", "CHEMICAL", 111, 114], ["PZQ", "CHEMICAL", 111, 114], ["Mice", "ORGANISM", 0, 4], ["S. mansoni", "ORGANISM", 24, 34], ["MSNs@PQZ", "SIMPLE_CHEMICAL", 93, 101], ["PZQ", "SIMPLE_CHEMICAL", 111, 114], ["Mice", "SPECIES", 0, 4], ["S. mansoni", "SPECIES", 24, 34], ["Mice", "SPECIES", 0, 4], ["S. mansoni", "SPECIES", 24, 34], ["S. mansoni", "PROBLEM", 24, 34], ["infection", "PROBLEM", 61, 70], ["MSNs@PQZ", "TREATMENT", 93, 101], ["free PZQ", "TREATMENT", 106, 114]]], ["A maximum anti-schistosomal effect was achieved using MSNs@PZQ administered orally.", [["MSNs@PZQ", "CHEMICAL", 54, 62], ["MSNs@PZQ", "CHEMICAL", 54, 62], ["MSNs@PZQ", "SIMPLE_CHEMICAL", 54, 62], ["A maximum anti-schistosomal effect", "TREATMENT", 0, 34], ["MSNs@PZQ", "TREATMENT", 54, 62], ["maximum", "OBSERVATION_MODIFIER", 2, 9]]], ["The biomarkers related to liver oxidative stress status and immunomodulatory effect (serum TNF-\u03b1 and IL-10) were significantly improved showing IP route was less effective for PQZ delivery.", [["liver", "ANATOMY", 26, 31], ["serum", "ANATOMY", 85, 90], ["PQZ", "CHEMICAL", 176, 179], ["PQZ", "CHEMICAL", 176, 179], ["liver", "ORGAN", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 91, 96], ["IL-10", "GENE_OR_GENE_PRODUCT", 101, 106], ["IP", "SIMPLE_CHEMICAL", 144, 146], ["PQZ", "SIMPLE_CHEMICAL", 176, 179], ["TNF", "PROTEIN", 91, 94], ["IL", "PROTEIN", 101, 103], ["The biomarkers", "TEST", 0, 14], ["liver oxidative stress status", "PROBLEM", 26, 55], ["immunomodulatory effect", "PROBLEM", 60, 83], ["serum TNF", "TEST", 85, 94], ["IL", "TEST", 101, 103], ["IP route", "TREATMENT", 144, 152], ["PQZ delivery", "TREATMENT", 176, 188], ["liver", "ANATOMY", 26, 31], ["oxidative stress", "OBSERVATION", 32, 48]]], ["Authors also reported that the MSNs@PQZ administration allows the reduction of the effective therapeutic dose, indicating MSNs as a safe nanoplatform that enhances anti-schistosomal, antioxidant, immunomodulatory and anti-inflammatory PQZ actions in animal model infected by S. mansoni.Parasitic Infections ::: MSNs for Infectious Diseases TreatmentYunessnia lehi et al .", [["MSNs@PQZ", "CHEMICAL", 31, 39], ["PQZ", "CHEMICAL", 235, 238], ["S. mansoni", "DISEASE", 275, 285], ["Parasitic Infections", "DISEASE", 286, 306], ["Infectious Diseases", "DISEASE", 320, 339], ["MSNs@PQZ", "CHEMICAL", 31, 39], ["MSNs@PQZ", "SIMPLE_CHEMICAL", 31, 39], ["MSNs", "SIMPLE_CHEMICAL", 122, 126], ["PQZ", "SIMPLE_CHEMICAL", 235, 238], ["S. mansoni", "ORGANISM", 275, 285], ["S. mansoni", "SPECIES", 275, 285], ["S. mansoni", "SPECIES", 275, 285], ["the MSNs@PQZ administration", "TREATMENT", 27, 54], ["MSNs", "TREATMENT", 122, 126], ["a safe nanoplatform", "TREATMENT", 130, 149], ["antioxidant", "TREATMENT", 183, 194], ["immunomodulatory", "TREATMENT", 196, 212], ["anti-inflammatory PQZ actions", "TREATMENT", 217, 246], ["Parasitic Infections", "PROBLEM", 286, 306], ["Infectious Diseases", "PROBLEM", 320, 339], ["anti-inflammatory PQZ", "OBSERVATION", 217, 238], ["infected", "OBSERVATION_MODIFIER", 263, 271], ["mansoni", "OBSERVATION", 278, 285], ["Infections", "OBSERVATION", 296, 306], ["Infectious", "OBSERVATION_MODIFIER", 320, 330]]], ["(139) synthesized whisker-formed SBA-15 nanoparticles as a pH-sensitive metronidazole (MNZ)-trapped nanocarrier.", [["SBA-15 nanoparticles", "CHEMICAL", 33, 53], ["metronidazole", "CHEMICAL", 72, 85], ["MNZ", "CHEMICAL", 87, 90], ["SBA-15", "CHEMICAL", 33, 39], ["metronidazole", "CHEMICAL", 72, 85], ["MNZ", "CHEMICAL", 87, 90], ["SBA-15 nanoparticles", "SIMPLE_CHEMICAL", 33, 53], ["metronidazole", "SIMPLE_CHEMICAL", 72, 85], ["MNZ", "SIMPLE_CHEMICAL", 87, 90], ["synthesized whisker", "TEST", 6, 25], ["SBA", "TEST", 33, 36], ["a pH", "TEST", 57, 61], ["metronidazole", "TREATMENT", 72, 85]]], ["This nanosystem was modified with tannic acid (TA) aiming to block the mesopores and control drug release process.", [["tannic acid", "CHEMICAL", 34, 45], ["TA", "CHEMICAL", 47, 49], ["tannic acid", "CHEMICAL", 34, 45], ["tannic acid", "SIMPLE_CHEMICAL", 34, 45], ["TA", "SIMPLE_CHEMICAL", 47, 49], ["This nanosystem", "TREATMENT", 0, 15], ["tannic acid (TA)", "TREATMENT", 34, 50], ["block the mesopores", "TREATMENT", 61, 80]]], ["The SBA-15 nanowhiskers had small fibrous structures 0.5-1.5 \u03bcm in length and up to 50 nm in diameter.", [["fibrous structures", "ANATOMY", 34, 52], ["SBA-15", "CHEMICAL", 4, 10], ["fibrous structures", "PATHOLOGICAL_FORMATION", 34, 52], ["SBA-15 nanowhiskers", "DNA", 4, 23], ["The SBA", "TEST", 0, 7], ["small fibrous structures", "PROBLEM", 28, 52], ["length", "TEST", 67, 73], ["small", "OBSERVATION_MODIFIER", 28, 33], ["fibrous", "OBSERVATION", 34, 41], ["0.5-1.5 \u03bcm", "OBSERVATION_MODIFIER", 53, 63], ["length", "OBSERVATION_MODIFIER", 67, 73], ["50 nm", "OBSERVATION_MODIFIER", 84, 89], ["diameter", "OBSERVATION_MODIFIER", 93, 101]]], ["Through characterization analysis, 2D ordered hexagonal mesostructures were detected, with surface area of 491.38 m2 and pores volume and diameter of 0.593 cm3 g-1 and 6.06 nm, respectively.", [["surface", "ANATOMY", 91, 98], ["characterization analysis", "TEST", 8, 33], ["2D ordered hexagonal mesostructures", "TEST", 35, 70], ["surface area", "TEST", 91, 103], ["pores volume", "TEST", 121, 133], ["diameter", "TEST", 138, 146], ["hexagonal mesostructures", "OBSERVATION", 46, 70], ["pores", "OBSERVATION_MODIFIER", 121, 126], ["volume", "OBSERVATION_MODIFIER", 127, 133], ["diameter", "OBSERVATION_MODIFIER", 138, 146]]], ["In addition, the modification with TA increased MNZ EE from 62.6 to 71.4%.", [["TA", "CHEMICAL", 35, 37], ["EE", "CHEMICAL", 52, 54], ["TA", "SIMPLE_CHEMICAL", 35, 37], ["TA increased MNZ EE", "TEST", 35, 54]]], ["In vitro release assays exhibited fast MNZ release from unmodified SBA-15 nanowhiskers whereas TA-SBA-15 nanocarriers controlled MNZ release for an extended time.", [["MNZ", "CHEMICAL", 39, 42], ["SBA-15 nanowhiskers", "CHEMICAL", 67, 86], ["TA-SBA-15 nanocarriers", "CHEMICAL", 95, 117], ["MNZ", "CHEMICAL", 129, 132], ["SBA-15", "CHEMICAL", 67, 73], ["MNZ", "SIMPLE_CHEMICAL", 39, 42], ["SBA-15 nanowhiskers", "SIMPLE_CHEMICAL", 67, 86], ["TA-SBA-15 nanocarriers", "SIMPLE_CHEMICAL", 95, 117], ["MNZ", "SIMPLE_CHEMICAL", 129, 132], ["MNZ", "PROTEIN", 129, 132], ["vitro release assays", "TEST", 3, 23], ["SBA", "TEST", 67, 70], ["TA", "TEST", 95, 97], ["SBA", "TEST", 98, 101]]], ["Interestingly, the modified nanosystems displayed a pH-sensitive behavior, showing MNZ release up to 85% at pH 5.8.", [["MNZ", "CHEMICAL", 83, 86], ["MNZ", "CHEMICAL", 83, 86], ["MNZ", "SIMPLE_CHEMICAL", 83, 86], ["a pH", "TEST", 50, 54], ["MNZ release", "TEST", 83, 94], ["pH", "TEST", 108, 110]]], ["The minimal lethal concentration (0.5 mg mL-1) of TA-modified SBA-15@MNZ showed 100% protozoal growth inhibition for 180 min regarding to parasite control and free MNZ solution.", [["TA", "CHEMICAL", 50, 52], ["SBA-15@MNZ", "CHEMICAL", 62, 72], ["MNZ", "CHEMICAL", 164, 167], ["SBA-15@MNZ", "CHEMICAL", 62, 72], ["MNZ", "CHEMICAL", 164, 167], ["TA", "SIMPLE_CHEMICAL", 50, 52], ["SBA-15@MNZ", "SIMPLE_CHEMICAL", 62, 72], ["MNZ", "SIMPLE_CHEMICAL", 164, 167], ["The minimal lethal concentration", "TREATMENT", 0, 32], ["TA", "TEST", 50, 52], ["SBA", "TEST", 62, 65], ["parasite control", "TREATMENT", 138, 154], ["free MNZ solution", "TREATMENT", 159, 176], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["lethal", "OBSERVATION_MODIFIER", 12, 18], ["concentration", "OBSERVATION_MODIFIER", 19, 32]]], ["These studies suggest this multifunctional nanoplatform as promising and efficient MNZ delivery system for parasitic diseases treatment.Fungal Infections ::: MSNs for Infectious Diseases TreatmentThe development of new formulations against Candida albicans is essential to overcome drawbacks as multiple resistance mechanisms developed by biofilms formation, which makes this pathogen resistant to drugs such as fluconazole and amphotericin B, and, consequently, making difficult to treat effectively these infections, contributing to high morbidity and mortality rates in immunocompromised patients (141,155).", [["biofilms", "ANATOMY", 339, 347], ["parasitic diseases", "DISEASE", 107, 125], ["Fungal Infections", "DISEASE", 136, 153], ["Infectious Diseases", "DISEASE", 167, 186], ["Candida albicans", "DISEASE", 240, 256], ["fluconazole", "CHEMICAL", 412, 423], ["amphotericin B", "CHEMICAL", 428, 442], ["infections", "DISEASE", 507, 517], ["fluconazole", "CHEMICAL", 412, 423], ["amphotericin B", "CHEMICAL", 428, 442], ["MNZ", "SIMPLE_CHEMICAL", 83, 86], ["Candida albicans", "ORGANISM", 240, 256], ["fluconazole", "SIMPLE_CHEMICAL", 412, 423], ["amphotericin B", "SIMPLE_CHEMICAL", 428, 442], ["patients", "ORGANISM", 591, 599], ["Candida albicans", "SPECIES", 240, 256], ["patients", "SPECIES", 591, 599], ["Candida albicans", "SPECIES", 240, 256], ["These studies", "TEST", 0, 13], ["this multifunctional nanoplatform", "TREATMENT", 22, 55], ["efficient MNZ delivery system", "TREATMENT", 73, 102], ["parasitic diseases treatment", "TREATMENT", 107, 135], ["Fungal Infections", "PROBLEM", 136, 153], ["Infectious Diseases Treatment", "TREATMENT", 167, 196], ["new formulations", "TREATMENT", 215, 231], ["Candida albicans", "PROBLEM", 240, 256], ["multiple resistance mechanisms", "PROBLEM", 295, 325], ["biofilms formation", "PROBLEM", 339, 357], ["this pathogen", "PROBLEM", 371, 384], ["drugs", "TREATMENT", 398, 403], ["fluconazole", "TREATMENT", 412, 423], ["amphotericin B", "TREATMENT", 428, 442], ["these infections", "PROBLEM", 501, 517], ["high morbidity", "PROBLEM", 535, 549], ["mortality rates", "TEST", 554, 569], ["parasitic diseases", "OBSERVATION", 107, 125], ["Infections", "OBSERVATION", 143, 153]]], ["(141) reported a nanosystem based on MSNs modified with Rose Bengal (RB) as photodynamic therapy (PDT) as antimicrobial alternative to treat C. albicans biofilms.", [["biofilms", "ANATOMY", 153, 161], ["Rose Bengal", "CHEMICAL", 56, 67], ["MSNs", "SIMPLE_CHEMICAL", 37, 41], ["Rose Bengal", "SIMPLE_CHEMICAL", 56, 67], ["RB", "SIMPLE_CHEMICAL", 69, 71], ["C. albicans", "ORGANISM", 141, 152], ["C. albicans", "SPECIES", 141, 152], ["C. albicans", "SPECIES", 141, 152], ["a nanosystem", "TREATMENT", 15, 27], ["photodynamic therapy (PDT)", "TREATMENT", 76, 102], ["antimicrobial alternative", "TREATMENT", 106, 131], ["C. albicans biofilms", "PROBLEM", 141, 161]]], ["MSNs with average pores size and diameter of 2 and 500 nm, respectively, were amino functionalized aiming to increase the conjugation capacity of RB.", [["amino functionalized", "CHEMICAL", 78, 98], ["amino", "CHEMICAL", 78, 83], ["MSNs", "SIMPLE_CHEMICAL", 0, 4], ["RB", "SIMPLE_CHEMICAL", 146, 148], ["RB", "PROTEIN", 146, 148], ["average pores size", "TEST", 10, 28], ["diameter", "TEST", 33, 41], ["amino functionalized", "TREATMENT", 78, 98], ["average", "OBSERVATION_MODIFIER", 10, 17], ["pores", "OBSERVATION_MODIFIER", 18, 23], ["size", "OBSERVATION_MODIFIER", 24, 28], ["diameter", "OBSERVATION_MODIFIER", 33, 41]]], ["RB is a photosensitizer, an organic compound that absorbs light of a suitable wavelength generating singlet oxygen and reactive oxygen species (ROS), which can kill microbial systems.", [["RB", "CHEMICAL", 0, 2], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 128, 134], ["ROS", "CHEMICAL", 144, 147], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 128, 134], ["RB", "SIMPLE_CHEMICAL", 0, 2], ["singlet oxygen", "SIMPLE_CHEMICAL", 100, 114], ["reactive oxygen species", "SIMPLE_CHEMICAL", 119, 142], ["ROS", "SIMPLE_CHEMICAL", 144, 147], ["RB", "PROTEIN", 0, 2], ["a photosensitizer", "TREATMENT", 6, 23], ["singlet oxygen", "TREATMENT", 100, 114], ["reactive oxygen species", "PROBLEM", 119, 142], ["singlet oxygen", "OBSERVATION", 100, 114], ["reactive", "OBSERVATION_MODIFIER", 119, 127], ["oxygen species", "OBSERVATION", 128, 142]]], ["High values of RB EE (58.54%) was achieved by amino-modified MSNs due to the good electrostatic interaction of the positively charged MSNs surface with anionic dye RB.", [["EE", "CHEMICAL", 18, 20], ["MSNs", "SIMPLE_CHEMICAL", 61, 65], ["MSNs surface", "CELLULAR_COMPONENT", 134, 146], ["anionic dye RB", "SIMPLE_CHEMICAL", 152, 166], ["RB", "PROTEIN", 164, 166], ["anionic dye RB", "PROBLEM", 152, 166], ["dye RB", "OBSERVATION", 160, 166]]], ["Taking the aforementioned into account, in vitro release tests showed a slow and controlled RB release with a maximum of 66.38% after 3 h.", [["RB", "SIMPLE_CHEMICAL", 92, 94], ["RB", "PROTEIN", 92, 94], ["vitro release tests", "TEST", 43, 62], ["a slow and controlled RB release", "PROBLEM", 70, 102]]], ["Additionally, cellular uptake studies exhibited high MSNs-RB uptake (up to 47%) compared to the free RB (up to 10%) after 3 h.", [["cellular", "ANATOMY", 14, 22], ["cellular", "CELL", 14, 22], ["MSNs-RB", "SIMPLE_CHEMICAL", 53, 60], ["RB", "PROTEIN", 58, 60], ["RB", "PROTEIN", 101, 103], ["cellular uptake studies", "TEST", 14, 37], ["RB uptake", "TEST", 58, 67], ["the free RB", "TEST", 92, 103], ["high MSNs", "OBSERVATION", 48, 57], ["RB uptake", "OBSERVATION", 58, 67]]], ["Through in vitro release results, amine groups modified onto MSNs enabled a slow and controlled release, by electrostatic attraction with the RB, which is desirable and allow a good PDT action after a single administration.", [["amine", "CHEMICAL", 34, 39], ["amine", "CHEMICAL", 34, 39], ["amine", "SIMPLE_CHEMICAL", 34, 39], ["MSNs", "SIMPLE_CHEMICAL", 61, 65], ["RB", "SIMPLE_CHEMICAL", 142, 144], ["RB", "PROTEIN", 142, 144], ["a single administration", "TREATMENT", 199, 222]]], ["When associated with PDT, high values of MSNs-RB antimicrobial action were achieved for both C. albicans planktonic cells (up to 88.7%) and biofilms (up to 79.7%) regarding pristine MSNs and free RB.", [["cells", "ANATOMY", 116, 121], ["MSNs", "CHEMICAL", 41, 45], ["MSNs-RB", "SIMPLE_CHEMICAL", 41, 48], ["C. albicans planktonic cells", "CELL", 93, 121], ["MSNs", "SIMPLE_CHEMICAL", 182, 186], ["RB", "PROTEIN", 196, 198], ["C. albicans", "SPECIES", 93, 104], ["C. albicans", "SPECIES", 93, 104], ["PDT", "TREATMENT", 21, 24], ["high values of MSNs", "PROBLEM", 26, 45], ["RB antimicrobial action", "TREATMENT", 46, 69], ["C. albicans planktonic cells", "TEST", 93, 121], ["biofilms", "TEST", 140, 148], ["free RB", "OBSERVATION", 191, 198]]], ["Beyond that, after light irradiation, MSNs-RB exhibited high ROS production, proteins leakage (from cytoplasm C. albicans cells), DNA damage and lipid peroxidation.", [["cytoplasm", "ANATOMY", 100, 109], ["cells", "ANATOMY", 122, 127], ["MSNs", "CHEMICAL", 38, 42], ["ROS", "CHEMICAL", 61, 64], ["MSNs-RB", "SIMPLE_CHEMICAL", 38, 45], ["ROS", "SIMPLE_CHEMICAL", 61, 64], ["cytoplasm", "ORGANISM_SUBSTANCE", 100, 109], ["C. albicans cells", "CELL", 110, 127], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["lipid", "SIMPLE_CHEMICAL", 145, 150], ["RB", "PROTEIN", 43, 45], ["C. albicans", "SPECIES", 110, 121], ["C. albicans", "SPECIES", 110, 121], ["light irradiation", "TREATMENT", 19, 36], ["RB", "PROBLEM", 43, 45], ["high ROS production", "PROBLEM", 56, 75], ["proteins leakage", "PROBLEM", 77, 93], ["cytoplasm C. albicans cells", "TEST", 100, 127], ["DNA damage", "PROBLEM", 130, 140], ["lipid peroxidation", "PROBLEM", 145, 163], ["high ROS", "OBSERVATION", 56, 64], ["leakage", "OBSERVATION_MODIFIER", 86, 93], ["albicans cells", "OBSERVATION", 113, 127], ["lipid peroxidation", "OBSERVATION", 145, 163]]], ["These results confirmed the MSNs-RB as an efficient nanosystem as antimicrobial PDT against infections caused by antifungal drug resistant and biofilm forming strains, being its application extended to enhance C. albicans eradication on medical devices such as implants and catheters.Fungal Infections ::: MSNs for Infectious Diseases TreatmentEconazole (ECO), an antifungal widely used for topical infections treatment has limited bioavailability due to its low aqueous solubility (156).", [["MSNs", "CHEMICAL", 28, 32], ["PDT", "CHEMICAL", 80, 83], ["infections", "DISEASE", 92, 102], ["Fungal Infections", "DISEASE", 284, 301], ["Infectious Diseases", "DISEASE", 315, 334], ["Econazole", "CHEMICAL", 344, 353], ["ECO", "CHEMICAL", 355, 358], ["infections", "DISEASE", 399, 409], ["Econazole", "CHEMICAL", 344, 353], ["MSNs", "SIMPLE_CHEMICAL", 28, 32], ["C. albicans", "ORGANISM", 210, 221], ["Econazole", "SIMPLE_CHEMICAL", 344, 353], ["ECO", "SIMPLE_CHEMICAL", 355, 358], ["RB", "PROTEIN", 33, 35], ["C. albicans", "SPECIES", 210, 221], ["C. albicans", "SPECIES", 210, 221], ["antimicrobial PDT", "TREATMENT", 66, 83], ["infections", "PROBLEM", 92, 102], ["antifungal drug resistant and biofilm forming strains", "PROBLEM", 113, 166], ["C. albicans eradication", "TREATMENT", 210, 233], ["medical devices", "TREATMENT", 237, 252], ["implants and catheters", "TREATMENT", 261, 283], ["Fungal Infections", "PROBLEM", 284, 301], ["Infectious Diseases", "TREATMENT", 315, 334], ["TreatmentEconazole (ECO)", "TREATMENT", 335, 359], ["an antifungal", "TREATMENT", 361, 374], ["topical infections treatment", "TREATMENT", 391, 419], ["its low aqueous solubility", "PROBLEM", 455, 481], ["antifungal drug resistant", "OBSERVATION", 113, 138], ["implants", "OBSERVATION", 261, 269], ["catheters", "OBSERVATION", 274, 283], ["Infections", "OBSERVATION", 291, 301]]], ["Aiming to overcome ECO solubility drawbacks, Montazeri et al .", [["ECO", "SIMPLE_CHEMICAL", 19, 22], ["ECO solubility drawbacks", "TREATMENT", 19, 43], ["Montazeri et al", "TREATMENT", 45, 60]]], ["(140) developed ECO-loaded MSNs modified with aminopropyl groups.", [["ECO", "CHEMICAL", 16, 19], ["aminopropyl", "CHEMICAL", 46, 57], ["aminopropyl", "CHEMICAL", 46, 57], ["ECO", "SIMPLE_CHEMICAL", 16, 19], ["MSNs", "SIMPLE_CHEMICAL", 27, 31], ["aminopropyl", "SIMPLE_CHEMICAL", 46, 57], ["ECO-loaded MSNs", "TREATMENT", 16, 31], ["aminopropyl groups", "TREATMENT", 46, 64]]], ["Spherical shape and hexagonal mesopores arrays were detected for MSNs.", [["MSNs", "DNA", 65, 69], ["Spherical shape and hexagonal mesopores arrays", "PROBLEM", 0, 46], ["shape", "OBSERVATION_MODIFIER", 10, 15], ["hexagonal", "OBSERVATION_MODIFIER", 20, 29], ["mesopores arrays", "OBSERVATION", 30, 46]]], ["Pristine MSNs, modified MSNs and ECO-loaded MSNs displayed average size ranging from 39 to 91 nm while the nanosystems presented average pores size up to 2.54 nm.", [["ECO", "CHEMICAL", 33, 36], ["Pristine", "SIMPLE_CHEMICAL", 0, 8], ["MSNs", "SIMPLE_CHEMICAL", 9, 13], ["MSNs", "CELL", 24, 28], ["ECO", "SIMPLE_CHEMICAL", 33, 36], ["MSNs", "CELL", 44, 48], ["ECO", "TEST", 33, 36], ["average size", "TEST", 59, 71], ["the nanosystems", "TEST", 103, 118], ["size", "OBSERVATION_MODIFIER", 67, 71], ["size", "OBSERVATION_MODIFIER", 143, 147], ["2.54 nm", "OBSERVATION_MODIFIER", 154, 161]]], ["In addition, MSNs was negatively charged (MSNs and MSNs-ECO showed -12.14 and -17.51 mV, respectively) whereas after amino modification the nanosystem showed positive surface charge (MSNs-NH2 and MSNs-ECO-NH2 exhibited +32.52 and +33.63 mV, respectively).", [["surface", "ANATOMY", 167, 174], ["amino", "CHEMICAL", 117, 122], ["NH2", "CHEMICAL", 188, 191], ["NH2", "CHEMICAL", 205, 208], ["MSNs", "SIMPLE_CHEMICAL", 13, 17], ["MSNs", "SIMPLE_CHEMICAL", 42, 46], ["MSNs-NH2", "SIMPLE_CHEMICAL", 183, 191], ["NH2", "PROTEIN", 188, 191], ["MSNs", "PROTEIN", 196, 200], ["ECO", "PROTEIN", 201, 204], ["NH2", "PROTEIN", 205, 208], ["MSNs", "TEST", 51, 55], ["ECO", "TEST", 56, 59], ["amino modification the nanosystem", "TEST", 117, 150], ["positive surface charge", "PROBLEM", 158, 181], ["MSNs", "TEST", 183, 187], ["MSNs", "TEST", 196, 200], ["ECO", "TEST", 201, 204], ["mV", "TEST", 237, 239]]], ["MSNs and MSNs-NH2 exhibited ECO EE of up to 42 and 63% and release rate of 29.57 and 38.65, respectively.", [["MSNs", "CHEMICAL", 9, 13], ["EE", "CHEMICAL", 32, 34], ["NH2", "CHEMICAL", 14, 17], ["MSNs", "SIMPLE_CHEMICAL", 0, 4], ["MSNs-NH2", "SIMPLE_CHEMICAL", 9, 17], ["NH2", "PROTEIN", 14, 17], ["ECO EE", "TEST", 28, 34], ["release rate", "TEST", 59, 71]]], ["Both MSNs and modified MSNs containing ECO were non-toxic to human dermal fibroblast strains cells.", [["dermal fibroblast strains cells", "ANATOMY", 67, 98], ["ECO", "CHEMICAL", 39, 42], ["MSNs", "SIMPLE_CHEMICAL", 5, 9], ["MSNs", "CELL", 23, 27], ["ECO", "SIMPLE_CHEMICAL", 39, 42], ["human", "ORGANISM", 61, 66], ["dermal fibroblast strains cells", "CELL", 67, 98], ["human dermal fibroblast strains cells", "CELL_LINE", 61, 98], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["modified MSNs containing ECO", "TREATMENT", 14, 42], ["human dermal fibroblast strains cells", "PROBLEM", 61, 98], ["fibroblast strains cells", "OBSERVATION", 74, 98]]], ["Distinct ECO/MSNs and modified MSNs ratios were evaluated being that the antifungal activity (C. albicans) for all nanosystems increased as drug amount loading increased.", [["ECO", "CELL", 9, 12], ["MSNs", "CELL", 13, 17], ["MSNs", "SIMPLE_CHEMICAL", 31, 35], ["C. albicans", "ORGANISM", 94, 105], ["MSNs", "DNA", 13, 17], ["C. albicans", "SPECIES", 94, 105], ["C. albicans", "SPECIES", 94, 105], ["Distinct ECO/MSNs", "TEST", 0, 17], ["modified MSNs ratios", "TEST", 22, 42], ["the antifungal activity (C. albicans", "TREATMENT", 69, 105], ["all nanosystems", "TREATMENT", 111, 126], ["drug amount loading", "TREATMENT", 140, 159], ["MSNs", "ANATOMY", 13, 17]]], ["Greater antifungal activity was observed for modified nanosystems compared to the non-modified ones showing inhibition zone of up to 19.5 and 16.0 mm, respectively (at 1.2 mg mL-1 of ECO).", [["Greater antifungal activity", "TREATMENT", 0, 27], ["modified nanosystems", "PROBLEM", 45, 65], ["inhibition zone", "TEST", 108, 123], ["antifungal activity", "OBSERVATION", 8, 27]]], ["ECO-loaded MSNs displayed greater antifungal activity regarding to the econazole cream, confirming the nanosystem efficiency for the infectious treatment caused by fungus such as C. albicans.", [["ECO", "CHEMICAL", 0, 3], ["MSNs", "CHEMICAL", 11, 15], ["econazole cream", "CHEMICAL", 71, 86], ["econazole", "CHEMICAL", 71, 80], ["ECO", "SIMPLE_CHEMICAL", 0, 3], ["MSNs", "SIMPLE_CHEMICAL", 11, 15], ["econazole", "SIMPLE_CHEMICAL", 71, 80], ["C. albicans", "ORGANISM", 179, 190], ["C. albicans", "SPECIES", 179, 190], ["C. albicans", "SPECIES", 179, 190], ["ECO", "TEST", 0, 3], ["MSNs", "TREATMENT", 11, 15], ["greater antifungal activity", "TREATMENT", 26, 53], ["the econazole cream", "TREATMENT", 67, 86], ["the nanosystem efficiency", "PROBLEM", 99, 124], ["the infectious treatment", "TREATMENT", 129, 153], ["fungus", "PROBLEM", 164, 170], ["C. albicans", "PROBLEM", 179, 190], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["antifungal activity", "OBSERVATION", 34, 53], ["nanosystem efficiency", "OBSERVATION", 103, 124], ["infectious", "OBSERVATION", 133, 143]]], ["Additionally, the developed nanosystem exhibited non induced skin irritation on rabbits, being cutaneous reaction negligible after 72 h.", [["skin", "ANATOMY", 61, 65], ["cutaneous", "ANATOMY", 95, 104], ["skin irritation", "DISEASE", 61, 76], ["skin", "ORGAN", 61, 65], ["rabbits", "ORGANISM", 80, 87], ["rabbits", "SPECIES", 80, 87], ["rabbits", "SPECIES", 80, 87], ["non induced skin irritation", "PROBLEM", 49, 76], ["cutaneous reaction", "PROBLEM", 95, 113], ["non induced", "OBSERVATION_MODIFIER", 49, 60], ["skin", "ANATOMY", 61, 65], ["irritation", "OBSERVATION", 66, 76], ["cutaneous", "ANATOMY", 95, 104]]], ["It is worth mentioning that the designed nanoplatform could reduce the treatment duration by increasing patient compliance, making this nanosystem desirable for fungal therapy purposes.Fungal Infections ::: MSNs for Infectious Diseases TreatmentIn another study, authors (142) fabricated pH-responsive gated MSNs-based nanosystem aiming to treat fungal infections such as vaginal candidiasis.", [["vaginal", "ANATOMY", 372, 379], ["Fungal Infections", "DISEASE", 185, 202], ["Infectious Diseases TreatmentIn", "DISEASE", 216, 247], ["fungal infections", "DISEASE", 346, 363], ["vaginal candidiasis", "DISEASE", 372, 391], ["patient", "ORGANISM", 104, 111], ["MSNs", "SIMPLE_CHEMICAL", 308, 312], ["vaginal candidiasis", "PATHOLOGICAL_FORMATION", 372, 391], ["patient", "SPECIES", 104, 111], ["the designed nanoplatform", "TREATMENT", 28, 53], ["this nanosystem", "TREATMENT", 131, 146], ["fungal therapy purposes", "TREATMENT", 161, 184], ["another study", "TEST", 248, 261], ["fabricated pH", "TEST", 277, 290], ["responsive gated MSNs", "TREATMENT", 291, 312], ["based nanosystem", "TREATMENT", 313, 329], ["fungal infections", "PROBLEM", 346, 363], ["vaginal candidiasis", "PROBLEM", 372, 391], ["Infections", "OBSERVATION", 192, 202], ["vaginal", "ANATOMY", 372, 379], ["candidiasis", "OBSERVATION", 380, 391]]], ["The sensitive MSNs like MCM-41 nanoplatforms were loaded with tebuconazole (TEB) and modified with silane groups as 3-[2-(2-aminoethylamino)ethylamino]propyltrimethoxysilane (N3) used as gatekeepers that can avoid TEB leakage from the mesopores before the nanosystem reach the target site.", [["MCM-41", "CHEMICAL", 24, 30], ["tebuconazole", "CHEMICAL", 62, 74], ["TEB", "CHEMICAL", 76, 79], ["silane", "CHEMICAL", 99, 105], ["3-[2-(2-aminoethylamino)ethylamino]propyltrimethoxysilane", "CHEMICAL", 116, 173], ["N3", "CHEMICAL", 175, 177], ["MCM-41", "CHEMICAL", 24, 30], ["tebuconazole", "CHEMICAL", 62, 74], ["TEB", "CHEMICAL", 76, 79], ["silane", "CHEMICAL", 99, 105], ["3-[2-(2-aminoethylamino)ethylamino]propyltrimethoxysilane", "CHEMICAL", 116, 173], ["N3", "CHEMICAL", 175, 177], ["TEB", "CHEMICAL", 214, 217], ["MSNs", "CELL", 14, 18], ["MCM-41 nanoplatforms", "SIMPLE_CHEMICAL", 24, 44], ["tebuconazole", "SIMPLE_CHEMICAL", 62, 74], ["TEB", "SIMPLE_CHEMICAL", 76, 79], ["3-[2-(2-aminoethylamino)ethylamino]propyltrimethoxysilane", "SIMPLE_CHEMICAL", 116, 173], ["N3", "SIMPLE_CHEMICAL", 175, 177], ["TEB", "SIMPLE_CHEMICAL", 214, 217], ["MCM", "TEST", 24, 27], ["nanoplatforms", "TREATMENT", 31, 44], ["tebuconazole (TEB", "TREATMENT", 62, 79], ["modified with silane groups", "TREATMENT", 85, 112], ["2-aminoethylamino)ethylamino]propyltrimethoxysilane (N3)", "TREATMENT", 122, 178], ["TEB leakage", "PROBLEM", 214, 225], ["the mesopores", "TREATMENT", 231, 244], ["the nanosystem", "TREATMENT", 252, 266]]], ["Spherical-shaped silica nanoplatform with average size of 100 nm and hexagonal pores arrays with mean diameter of 2.45 nm were successfully prepared as well as the TEB loading (0.064 mmol g-1 of MSNs) into mesopores and subsequently capping with N3 groups (2.43 mmol g-1 of MSNs).", [["TEB", "CHEMICAL", 164, 167], ["N3", "CHEMICAL", 246, 248], ["silica", "CHEMICAL", 17, 23], ["TEB", "CHEMICAL", 164, 167], ["N3", "CHEMICAL", 246, 248], ["silica nanoplatform", "SIMPLE_CHEMICAL", 17, 36], ["TEB", "SIMPLE_CHEMICAL", 164, 167], ["Spherical-shaped silica nanoplatform", "TREATMENT", 0, 36], ["hexagonal pores arrays", "TREATMENT", 69, 91], ["mean diameter", "TEST", 97, 110], ["the TEB loading", "TREATMENT", 160, 175], ["N3 groups", "TREATMENT", 246, 255], ["shaped", "OBSERVATION_MODIFIER", 10, 16], ["silica nanoplatform", "OBSERVATION", 17, 36], ["average", "OBSERVATION_MODIFIER", 42, 49], ["size", "OBSERVATION_MODIFIER", 50, 54], ["100 nm", "OBSERVATION_MODIFIER", 58, 64], ["mean diameter", "OBSERVATION_MODIFIER", 97, 110], ["2.45 nm", "OBSERVATION_MODIFIER", 114, 121]]], ["For cellular uptake assays, fluorescein (FL, green dye) were loaded into MSNs and modified with the N3 gatekeeper.", [["cellular", "ANATOMY", 4, 12], ["fluorescein", "CHEMICAL", 28, 39], ["FL, green dye", "CHEMICAL", 41, 54], ["fluorescein", "CHEMICAL", 28, 39], ["N3", "CHEMICAL", 100, 102], ["cellular", "CELL", 4, 12], ["fluorescein", "SIMPLE_CHEMICAL", 28, 39], ["FL", "SIMPLE_CHEMICAL", 41, 43], ["green dye", "SIMPLE_CHEMICAL", 45, 54], ["MSNs", "SIMPLE_CHEMICAL", 73, 77], ["cellular uptake assays", "TEST", 4, 26], ["fluorescein (FL, green dye", "TREATMENT", 28, 54], ["the N3 gatekeeper", "TREATMENT", 96, 113], ["uptake assays", "OBSERVATION", 13, 26]]], ["The simulated nanosystem exhibited good cellular internalization (Saccharomyces cerevisiae cells, incubated at pH 3.7) detected by fluorescence microscopy.", [["cellular", "ANATOMY", 40, 48], ["cells", "ANATOMY", 91, 96], ["cellular", "CELL", 40, 48], ["Saccharomyces cerevisiae cells", "CELL", 66, 96], ["Saccharomyces cerevisiae cells", "CELL_LINE", 66, 96], ["Saccharomyces cerevisiae", "SPECIES", 66, 90], ["Saccharomyces cerevisiae", "SPECIES", 66, 90], ["Saccharomyces cerevisiae cells", "TEST", 66, 96], ["pH", "TEST", 111, 113], ["fluorescence microscopy", "TEST", 131, 154], ["good", "OBSERVATION_MODIFIER", 35, 39], ["cellular internalization", "OBSERVATION", 40, 64], ["cerevisiae cells", "OBSERVATION", 80, 96]]], ["In addition, in vitro release FL tests were performed at pHs 3.7 and 5.5.", [["vitro release FL tests", "TEST", 16, 38], ["pHs", "TEST", 57, 60]]], ["Results showed that more than 95% of FL was released after 12 h whereas almost no release was detected at pH 3.7, confirming the design of pH-responsive nanosystem.", [["FL", "CHEMICAL", 37, 39], ["FL", "GENE_OR_GENE_PRODUCT", 37, 39], ["FL", "TEST", 37, 39], ["pH", "TEST", 106, 108], ["pH-responsive nanosystem", "PROBLEM", 139, 163], ["responsive nanosystem", "OBSERVATION", 142, 163]]], ["At pH 3.7, the polyamines of N3 capping was more protonated than at pH 5.5, which allowed high rigid chain conformation and high interactions with anions (as SO42-), that favor the mesopores blockage.", [["N3", "CHEMICAL", 29, 31], ["polyamines", "CHEMICAL", 15, 25], ["N3", "CHEMICAL", 29, 31], ["SO42", "CHEMICAL", 158, 162], ["polyamines", "SIMPLE_CHEMICAL", 15, 25], ["N3", "SIMPLE_CHEMICAL", 29, 31], ["anions", "SIMPLE_CHEMICAL", 147, 153], ["SO42", "SIMPLE_CHEMICAL", 158, 162], ["pH", "TEST", 3, 5], ["the polyamines of N3 capping", "TREATMENT", 11, 39], ["pH", "TEST", 68, 70], ["high rigid chain conformation", "PROBLEM", 90, 119], ["the mesopores blockage", "PROBLEM", 177, 199], ["N3 capping", "OBSERVATION", 29, 39], ["high rigid", "OBSERVATION_MODIFIER", 90, 100], ["mesopores blockage", "OBSERVATION", 181, 199]]], ["At pH 5.5, the polyamine chains is more flexible allowing pores opening and FL release.", [["polyamine", "CHEMICAL", 15, 24], ["FL", "CHEMICAL", 76, 78], ["polyamine", "CHEMICAL", 15, 24], ["polyamine chains", "SIMPLE_CHEMICAL", 15, 31], ["FL", "GENE_OR_GENE_PRODUCT", 76, 78], ["pH", "TEST", 3, 5], ["the polyamine chains", "TREATMENT", 11, 31], ["polyamine chains", "OBSERVATION", 15, 31], ["pores opening", "OBSERVATION", 58, 71]]], ["After successful cellular uptake and FL release tests, in vitro antifungal assays (C. albicans cells) were performed with the MSNs-TEB-N3 and free TEB.", [["cellular", "ANATOMY", 17, 25], ["cells", "ANATOMY", 95, 100], ["FL", "CHEMICAL", 37, 39], ["TEB-N3", "CHEMICAL", 131, 137], ["TEB", "CHEMICAL", 147, 150], ["cellular", "CELL", 17, 25], ["C. albicans cells", "CELL", 83, 100], ["TEB-N3", "CELL", 131, 137], ["TEB", "SIMPLE_CHEMICAL", 147, 150], ["C. albicans", "SPECIES", 83, 94], ["C. albicans", "SPECIES", 83, 94], ["FL release tests", "TEST", 37, 53], ["vitro antifungal assays", "TREATMENT", 58, 81], ["C. albicans cells", "TEST", 83, 100], ["the MSNs", "TEST", 122, 130], ["TEB", "TEST", 131, 134], ["free TEB", "TREATMENT", 142, 150], ["cellular uptake", "OBSERVATION", 17, 32]]], ["Results exhibited high antifungal activity promoting 90% of cells death by using MSNs-TEB-N3 while free TB showed only 10% of action.", [["cells", "ANATOMY", 60, 65], ["death", "DISEASE", 66, 71], ["MSNs-TEB-N3", "CHEMICAL", 81, 92], ["cells", "CELL", 60, 65], ["MSNs", "SIMPLE_CHEMICAL", 81, 85], ["TEB-N3", "SIMPLE_CHEMICAL", 86, 92], ["high antifungal activity", "TREATMENT", 18, 42], ["cells death", "PROBLEM", 60, 71], ["MSNs", "TEST", 81, 85], ["TEB", "TEST", 86, 89], ["free TB", "TEST", 99, 106], ["high", "OBSERVATION_MODIFIER", 18, 22], ["antifungal activity", "OBSERVATION", 23, 42]]], ["In this way, the designed smart nanoplatform improved TEB efficacy comprising an interesting tool to overcome side effects associated with topical therapies for vulvovaginal infection and improve its cost-effectiveness.", [["vulvovaginal", "ANATOMY", 161, 173], ["vulvovaginal infection", "DISEASE", 161, 183], ["TEB", "SIMPLE_CHEMICAL", 54, 57], ["vulvovaginal", "ORGANISM_SUBDIVISION", 161, 173], ["side effects", "PROBLEM", 110, 122], ["topical therapies", "TREATMENT", 139, 156], ["vulvovaginal infection", "PROBLEM", 161, 183], ["vulvovaginal", "ANATOMY", 161, 173], ["infection", "OBSERVATION", 174, 183]]], ["A schematic pH-responsive nanosystem action is displayed in Fig. 6.Fungal Infections ::: MSNs for Infectious Diseases TreatmentIn order to facilitate metallic nanoparticles (MNPs) applications as multifunctional drug delivery systems, authors (143,144,157) have proposed their association with MSNs aiming to increase biocompatibility avoiding MNPs aggregation and action lost.", [["Fungal Infections", "DISEASE", 67, 84], ["Infectious Diseases", "DISEASE", 98, 117], ["MNPs", "CHEMICAL", 174, 178], ["MNPs", "CHEMICAL", 344, 348], ["metallic nanoparticles", "SIMPLE_CHEMICAL", 150, 172], ["MNPs", "SIMPLE_CHEMICAL", 174, 178], ["MSNs", "SIMPLE_CHEMICAL", 294, 298], ["MNPs", "SIMPLE_CHEMICAL", 344, 348], ["A schematic pH", "TEST", 0, 14], ["responsive nanosystem action", "TREATMENT", 15, 43], ["Fungal Infections", "PROBLEM", 67, 84], ["Infectious Diseases TreatmentIn", "TREATMENT", 98, 129], ["metallic nanoparticles (MNPs)", "TREATMENT", 150, 179], ["multifunctional drug delivery systems", "TREATMENT", 196, 233], ["MSNs", "TREATMENT", 294, 298], ["increase biocompatibility", "TREATMENT", 309, 334], ["MNPs aggregation", "PROBLEM", 344, 360], ["Infections", "OBSERVATION", 74, 84]]], ["(143) incorporated zinc oxide nanoparticles (ZNPs) into MSNs (noted ZnO@MSNs) in order to evaluate the antifungal efficiency against two strains of Aspergillus niger (MTCC 10180 and MTCC 2196) and two strains of Fusarium oxysporum (NCIM 1043 and NCIM 1072).", [["zinc oxide", "CHEMICAL", 19, 29], ["ZNPs", "CHEMICAL", 45, 49], ["MTCC 10180 and MTCC 2196", "CHEMICAL", 167, 191], ["Fusarium oxysporum", "DISEASE", 212, 230], ["NCIM 1043", "CHEMICAL", 232, 241], ["NCIM 1072", "CHEMICAL", 246, 255], ["zinc oxide", "CHEMICAL", 19, 29], ["(143)", "SIMPLE_CHEMICAL", 0, 5], ["zinc oxide nanoparticles", "SIMPLE_CHEMICAL", 19, 43], ["ZNPs", "SIMPLE_CHEMICAL", 45, 49], ["MSNs", "SIMPLE_CHEMICAL", 56, 60], ["ZnO@MSNs", "SIMPLE_CHEMICAL", 68, 76], ["Aspergillus niger", "ORGANISM", 148, 165], ["MTCC 10180", "CELL", 167, 177], ["MTCC 2196", "CELL", 182, 191], ["Fusarium oxysporum", "ORGANISM", 212, 230], ["Aspergillus niger", "SPECIES", 148, 165], ["Fusarium oxysporum", "SPECIES", 212, 230], ["Aspergillus niger", "SPECIES", 148, 165], ["MTCC 10180", "SPECIES", 167, 177], ["MTCC 2196", "SPECIES", 182, 191], ["Fusarium oxysporum (NCIM 1043 and NCIM 1072", "SPECIES", 212, 255], ["zinc oxide nanoparticles (ZNPs)", "TREATMENT", 19, 50], ["the antifungal efficiency", "PROBLEM", 99, 124], ["Aspergillus niger", "PROBLEM", 148, 165], ["Fusarium oxysporum", "PROBLEM", 212, 230]]], ["The MSNs and ZnO@MSNs nanosystems displayed spherical shape with a size ranging from 20 to 40 nm with average pore size ranging from 2.5 to 3.1 nm, respectively.", [["pore", "ANATOMY", 110, 114], ["ZnO@MSNs", "CHEMICAL", 13, 21], ["ZnO@MSNs", "CHEMICAL", 13, 21], ["MSNs", "CELL", 4, 8], ["ZnO@MSNs", "SIMPLE_CHEMICAL", 13, 21], ["The MSNs and ZnO@MSNs nanosystems", "TEST", 0, 33], ["average pore size", "TEST", 102, 119], ["MSNs", "ANATOMY", 4, 8], ["spherical shape", "OBSERVATION", 44, 59], ["size", "OBSERVATION_MODIFIER", 67, 71], ["ranging", "OBSERVATION_MODIFIER", 72, 79], ["20 to 40 nm", "OBSERVATION_MODIFIER", 85, 96], ["average", "OBSERVATION_MODIFIER", 102, 109], ["pore", "OBSERVATION_MODIFIER", 110, 114], ["size", "OBSERVATION_MODIFIER", 115, 119], ["ranging", "OBSERVATION_MODIFIER", 120, 127], ["2.5 to 3.1 nm", "OBSERVATION_MODIFIER", 133, 146]]], ["The authors observed that ZnO@MSNs activity was dose dependent, requiring high doses to achieve antifungal response.", [["ZnO@MSNs", "CHEMICAL", 26, 34], ["ZnO@MSNs", "SIMPLE_CHEMICAL", 26, 34], ["dose dependent", "PROBLEM", 48, 62], ["antifungal response", "TREATMENT", 96, 115]]], ["The enzymatic tests showed that ZnO@MSNs activity occurred through the generation of oxidative stress through ROS generation.", [["ZnO@MSNs", "CHEMICAL", 32, 40], ["ROS", "CHEMICAL", 110, 113], ["ZnO@MSNs", "SIMPLE_CHEMICAL", 32, 40], ["ROS", "SIMPLE_CHEMICAL", 110, 113], ["The enzymatic tests", "TEST", 0, 19], ["ZnO@MSNs activity", "PROBLEM", 32, 49], ["oxidative stress", "PROBLEM", 85, 101]]], ["The generated oxidative stress caused morphological changes in the fungi.", [["The generated oxidative stress", "PROBLEM", 0, 30], ["morphological changes in the fungi", "PROBLEM", 38, 72], ["oxidative stress", "OBSERVATION", 14, 30], ["fungi", "OBSERVATION", 67, 72]]], ["Both in vitro and in vivo tests indicated good biocompatibility of the developed nanosystem, with sustained release exerted by MSNs preventing the ZnO direct exposure reducing toxic effects, which makes the developed MSNs-based nanoplatform enable to desirable antimicrobial applications.Fungal Infections ::: MSNs for Infectious Diseases TreatmentIn another study, silver nanoparticles (AgNPs), synthesized by green synthesis using Azadirachta indica leaf extract as a reducing agent, were loaded into MSNs (noted MSNs-AgNPs) aiming to evaluate antifungal activity against C. albicans 077 strains.", [["MSNs", "CHEMICAL", 127, 131], ["ZnO", "CHEMICAL", 147, 150], ["Fungal Infections", "DISEASE", 288, 305], ["Infectious Diseases TreatmentIn", "DISEASE", 319, 350], ["silver nanoparticles", "CHEMICAL", 366, 386], ["AgNPs", "CHEMICAL", 388, 393], ["Azadirachta indica leaf extract", "CHEMICAL", 433, 464], ["MSNs-AgNPs", "CHEMICAL", 515, 525], ["ZnO", "CHEMICAL", 147, 150], ["silver", "CHEMICAL", 366, 372], ["MSNs", "SIMPLE_CHEMICAL", 127, 131], ["ZnO", "SIMPLE_CHEMICAL", 147, 150], ["MSNs", "SIMPLE_CHEMICAL", 217, 221], ["silver nanoparticles", "SIMPLE_CHEMICAL", 366, 386], ["AgNPs", "SIMPLE_CHEMICAL", 388, 393], ["green", "SIMPLE_CHEMICAL", 411, 416], ["Azadirachta indica", "ORGANISM", 433, 451], ["MSNs", "SIMPLE_CHEMICAL", 503, 507], ["MSNs-AgNPs", "SIMPLE_CHEMICAL", 515, 525], ["C. albicans 077", "ORGANISM", 574, 589], ["Azadirachta indica", "SPECIES", 433, 451], ["C. albicans", "SPECIES", 574, 585], ["Azadirachta indica", "SPECIES", 433, 451], ["C. albicans 077", "SPECIES", 574, 589], ["vivo tests", "TEST", 21, 31], ["MSNs", "TREATMENT", 127, 131], ["the ZnO direct exposure", "TREATMENT", 143, 166], ["based nanoplatform", "TREATMENT", 222, 240], ["desirable antimicrobial applications", "TREATMENT", 251, 287], ["Infectious Diseases", "PROBLEM", 319, 338], ["another study", "TEST", 351, 364], ["silver nanoparticles (AgNPs)", "TREATMENT", 366, 394], ["Azadirachta indica leaf extract", "TREATMENT", 433, 464], ["a reducing agent", "TREATMENT", 468, 484], ["antifungal activity", "TREATMENT", 546, 565], ["C. albicans", "PROBLEM", 574, 585], ["strains", "PROBLEM", 590, 597], ["Infections", "OBSERVATION", 295, 305]]], ["The fabricated MSNs presented spherical shape with size of around 400 nm and hexagonal pores structures with average size of ~7.6 nm.", [["MSNs", "SIMPLE_CHEMICAL", 15, 19], ["average size", "TEST", 109, 121], ["spherical", "OBSERVATION_MODIFIER", 30, 39], ["shape", "OBSERVATION_MODIFIER", 40, 45], ["size", "OBSERVATION_MODIFIER", 51, 55], ["400 nm", "OBSERVATION_MODIFIER", 66, 72], ["hexagonal", "ANATOMY_MODIFIER", 77, 86], ["pores", "ANATOMY_MODIFIER", 87, 92], ["average", "OBSERVATION_MODIFIER", 109, 116], ["size", "OBSERVATION_MODIFIER", 117, 121], ["7.6 nm", "OBSERVATION_MODIFIER", 126, 132]]], ["The impregnated AgNPs were detected onto MSNs pores/surface showing spherical shape with average size ranging from 5 to 50 nm.", [["surface", "ANATOMY", 52, 59], ["AgNPs", "CHEMICAL", 16, 21], ["AgNPs", "SIMPLE_CHEMICAL", 16, 21], ["surface", "CELLULAR_COMPONENT", 52, 59], ["The impregnated AgNPs", "PROBLEM", 0, 21], ["impregnated", "OBSERVATION_MODIFIER", 4, 15], ["AgNPs", "OBSERVATION", 16, 21], ["spherical shape", "OBSERVATION", 68, 83], ["average", "OBSERVATION_MODIFIER", 89, 96], ["size", "OBSERVATION_MODIFIER", 97, 101], ["ranging", "OBSERVATION_MODIFIER", 102, 109]]], ["From antifungal activity assays, MSNs-AgNPs proved to be efficient in inhibiting the fungus growth in a dose-dependent manner, both in the disc diffusion and in vitro killing assays, being a promising alternative approach to infections treatment caused by C. albicans.", [["fungus", "ANATOMY", 85, 91], ["MSNs", "CHEMICAL", 33, 37], ["AgNPs", "CHEMICAL", 38, 43], ["infections", "DISEASE", 225, 235], ["MSNs-AgNPs", "SIMPLE_CHEMICAL", 33, 43], ["C. albicans", "ORGANISM", 256, 267], ["C. albicans", "SPECIES", 256, 267], ["C. albicans", "SPECIES", 256, 267], ["antifungal activity assays", "TEST", 5, 31], ["the fungus growth", "PROBLEM", 81, 98], ["the disc diffusion", "TEST", 135, 153], ["infections treatment", "TREATMENT", 225, 245], ["C. albicans", "PROBLEM", 256, 267], ["antifungal activity", "OBSERVATION", 5, 24], ["disc", "ANATOMY", 139, 143], ["infections", "OBSERVATION", 225, 235]]], ["However, more preclinical studies are already essential to better understand the real potential of the MSNs-AgNPs for future clinical translations (144).Viral Infections ::: MSNs for Infectious Diseases TreatmentViral infections and spreadability can be establish only by their interaction with host cells.", [["cells", "ANATOMY", 300, 305], ["AgNPs", "CHEMICAL", 108, 113], ["Viral Infections", "DISEASE", 153, 169], ["Infectious Diseases", "DISEASE", 183, 202], ["Viral infections", "DISEASE", 212, 228], ["MSNs-AgNPs", "SIMPLE_CHEMICAL", 103, 113], ["host cells", "CELL", 295, 305], ["host cells", "CELL_TYPE", 295, 305], ["preclinical studies", "TEST", 14, 33], ["Viral Infections", "PROBLEM", 153, 169], ["Infectious Diseases", "PROBLEM", 183, 202], ["Viral infections", "PROBLEM", 212, 228], ["spreadability", "PROBLEM", 233, 246], ["Infections", "OBSERVATION", 159, 169], ["Infectious", "OBSERVATION_MODIFIER", 183, 193]]], ["The key and great challenge to develop viral infections treatment consist on understand and elucidate the interaction virus-host cells at molecular level.", [["cells", "ANATOMY", 129, 134], ["viral infections", "DISEASE", 39, 55], ["host cells", "CELL", 124, 134], ["host cells", "CELL_TYPE", 124, 134], ["viral infections treatment", "TREATMENT", 39, 65], ["the interaction virus", "PROBLEM", 102, 123], ["infections", "OBSERVATION", 45, 55]]], ["In addition, virus can evolve by genetic mutation and become drug resistant making urgeous and essential the design of new drugs.", [["virus", "PROBLEM", 13, 18], ["genetic mutation", "PROBLEM", 33, 49], ["new drugs", "TREATMENT", 119, 128], ["virus", "OBSERVATION", 13, 18]]], ["In current medical scenario, the lack of antiviral broad-spectrum drugs, the fast and wide spreadability and the long time demanded to elucidate virus mechanism action to design a safety and efficient vaccines or treatment making viral infections such as SARS-CoV-2 a great threat to human global health (6,146,147,158,159).Viral Infections ::: MSNs for Infectious Diseases TreatmentTaking the aforementioned into account, the design of new antiviral MSNs can be an effective approach to control viral infections inhibiting virus mechanism action by interaction with virus, targeted drug delivery, interaction with host cells receptors inducing cellular immune response (6,146,147,158,159).Viral Infections ::: MSNs for Infectious Diseases TreatmentVenezuelan equine encephalitis virus (VEEV) comprises a great public health concern due to its possibility amenability for use as a bioterrorism agent and its severe health consequences in humans.", [["cells", "ANATOMY", 620, 625], ["cellular", "ANATOMY", 645, 653], ["viral infections", "DISEASE", 230, 246], ["SARS", "DISEASE", 255, 259], ["Viral Infections", "DISEASE", 324, 340], ["Infectious Diseases", "DISEASE", 354, 373], ["MSNs", "CHEMICAL", 451, 455], ["viral infections", "DISEASE", 496, 512], ["Viral Infections", "DISEASE", 690, 706], ["Infectious Diseases", "DISEASE", 720, 739], ["Venezuelan equine encephalitis", "DISEASE", 749, 779], ["VEEV", "DISEASE", 787, 791], ["SARS-CoV-2", "ORGANISM", 255, 265], ["human", "ORGANISM", 284, 289], ["MSNs", "SIMPLE_CHEMICAL", 451, 455], ["host cells", "CELL", 615, 625], ["cellular", "CELL", 645, 653], ["Venezuelan equine encephalitis virus", "ORGANISM", 749, 785], ["humans", "ORGANISM", 938, 944], ["host cells receptors", "PROTEIN", 615, 635], ["human", "SPECIES", 284, 289], ["Venezuelan equine encephalitis virus", "SPECIES", 749, 785], ["humans", "SPECIES", 938, 944], ["SARS-CoV", "SPECIES", 255, 263], ["human", "SPECIES", 284, 289], ["Venezuelan equine encephalitis virus", "SPECIES", 749, 785], ["VEEV", "SPECIES", 787, 791], ["humans", "SPECIES", 938, 944], ["antiviral broad-spectrum drugs", "TREATMENT", 41, 71], ["the fast and wide spreadability", "PROBLEM", 73, 104], ["virus mechanism action", "TREATMENT", 145, 167], ["a safety and efficient vaccines", "TREATMENT", 178, 209], ["treatment", "TREATMENT", 213, 222], ["viral infections", "PROBLEM", 230, 246], ["SARS", "PROBLEM", 255, 259], ["CoV", "TEST", 260, 263], ["Infectious Diseases Treatment", "TREATMENT", 354, 383], ["new antiviral MSNs", "TREATMENT", 437, 455], ["an effective approach", "TREATMENT", 463, 484], ["viral infections inhibiting virus mechanism action", "PROBLEM", 496, 546], ["targeted drug delivery", "TREATMENT", 574, 596], ["host cells receptors", "TREATMENT", 615, 635], ["Infectious Diseases", "PROBLEM", 720, 739], ["TreatmentVenezuelan equine encephalitis virus", "TREATMENT", 740, 785], ["a bioterrorism agent", "TREATMENT", 879, 899], ["Infections", "OBSERVATION", 330, 340], ["cellular immune response", "OBSERVATION", 645, 669], ["Infections", "OBSERVATION", 696, 706], ["severe", "OBSERVATION_MODIFIER", 908, 914]]], ["In addition, natural VEEV outbreaks resulted in equine and human infections, provoking high death rates in equines (85%) and chronic neurological complications in humans.", [["neurological", "ANATOMY", 133, 145], ["VEEV outbreaks", "DISEASE", 21, 35], ["infections", "DISEASE", 65, 75], ["death", "DISEASE", 92, 97], ["neurological complications", "DISEASE", 133, 159], ["VEEV", "ORGANISM", 21, 25], ["equine", "ORGANISM", 48, 54], ["human", "ORGANISM", 59, 64], ["humans", "ORGANISM", 163, 169], ["equine", "SPECIES", 48, 54], ["human", "SPECIES", 59, 64], ["humans", "SPECIES", 163, 169], ["VEEV", "SPECIES", 21, 25], ["equine", "SPECIES", 48, 54], ["human", "SPECIES", 59, 64], ["humans", "SPECIES", 163, 169], ["natural VEEV outbreaks", "PROBLEM", 13, 35], ["human infections", "PROBLEM", 59, 75], ["high death rates in equines", "PROBLEM", 87, 114], ["chronic neurological complications in humans", "PROBLEM", 125, 169], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["neurological complications", "OBSERVATION", 133, 159]]], ["A chemical VEEV inhibitor known as ML336 was developed and its effectiveness in VEEV infection was confirmed in preclinical assays.", [["ML336", "CHEMICAL", 35, 40], ["VEEV infection", "DISEASE", 80, 94], ["ML336", "CHEMICAL", 35, 40], ["ML336", "SIMPLE_CHEMICAL", 35, 40], ["VEEV", "ORGANISM", 80, 84], ["VEEV", "SPECIES", 11, 15], ["VEEV", "SPECIES", 80, 84], ["A chemical VEEV inhibitor", "TREATMENT", 0, 25], ["VEEV infection", "PROBLEM", 80, 94], ["preclinical assays", "TEST", 112, 130], ["VEEV", "OBSERVATION_MODIFIER", 80, 84], ["infection", "OBSERVATION", 85, 94]]], ["However, the great limitation for ML336 clinical translation consists on its poor solubility and stability in biological media.", [["ML336", "CHEMICAL", 34, 39], ["great", "OBSERVATION_MODIFIER", 13, 18], ["poor solubility", "OBSERVATION_MODIFIER", 77, 92], ["stability", "OBSERVATION_MODIFIER", 97, 106]]], ["(145) designed lipid-coated MSNs (LC-MSNs) as smart nanocarriers for ML336 delivery, as depicted in Fig. 7.", [["ML336", "CHEMICAL", 69, 74], ["lipid-coated MSNs", "SIMPLE_CHEMICAL", 15, 32], ["LC-MSNs", "SIMPLE_CHEMICAL", 34, 41], ["ML336", "SIMPLE_CHEMICAL", 69, 74], ["lipid-coated MSNs (LC-MSNs", "TREATMENT", 15, 41], ["smart nanocarriers", "TREATMENT", 46, 64], ["ML336 delivery", "TREATMENT", 69, 83]]], ["This nanovehicle was proposed to improve ML336 stability, promoting its controlled release for VEEV treatment.", [["ML336", "SIMPLE_CHEMICAL", 41, 46], ["VEEV", "ORGANISM", 95, 99], ["VEEV", "SPECIES", 95, 99], ["VEEV treatment", "TREATMENT", 95, 109]]], ["Narrow size distribution (~75 nm) and hexagonal pores structures (average pore size of 2.65 nm) were achieved for MSNs.", [["pore", "ANATOMY", 74, 78], ["hexagonal pores structures", "PROBLEM", 38, 64], ["average pore size", "TEST", 66, 83], ["MSNs", "PROBLEM", 114, 118], ["size", "OBSERVATION_MODIFIER", 7, 11], ["distribution", "OBSERVATION_MODIFIER", 12, 24], ["75 nm", "OBSERVATION_MODIFIER", 27, 32], ["hexagonal", "ANATOMY_MODIFIER", 38, 47], ["pores", "ANATOMY_MODIFIER", 48, 53], ["average", "OBSERVATION_MODIFIER", 66, 73], ["pore", "OBSERVATION_MODIFIER", 74, 78], ["size", "OBSERVATION_MODIFIER", 79, 83], ["2.65 nm", "OBSERVATION_MODIFIER", 87, 94]]], ["The lipidic shell consists of a liposome structure composed by 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC):Cholestrol:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000)), which can enhance colloidal stability, circulation time besides reduce protein adsorption to the nanosystem surface.", [["nanosystem surface", "ANATOMY", 325, 343], ["1,2-distearoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 63, 105], ["DSPC", "CHEMICAL", 107, 111], ["Cholestrol:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000", "CHEMICAL", 113, 208], ["DSPE-PEG", "CHEMICAL", 211, 219], ["1,2-distearoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 63, 105], ["DSPC", "CHEMICAL", 107, 111], ["Cholestrol", "CHEMICAL", 113, 123], ["1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000", "CHEMICAL", 124, 208], ["DSPE", "CHEMICAL", 211, 215], ["PEG", "CHEMICAL", 216, 219], ["liposome", "SIMPLE_CHEMICAL", 32, 40], ["1,2-distearoyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 63, 105], ["DSPC", "SIMPLE_CHEMICAL", 107, 111], ["Cholestrol:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]", "SIMPLE_CHEMICAL", 113, 209], ["DSPE-PEG(2000)", "SIMPLE_CHEMICAL", 211, 225], ["surface", "CELLULAR_COMPONENT", 336, 343], ["a liposome structure", "TREATMENT", 30, 50], ["distearoyl", "TEST", 67, 77], ["glycero", "TEST", 81, 88], ["Cholestrol", "TEST", 113, 123], ["distearoyl", "TREATMENT", 128, 138], ["glycero", "TREATMENT", 142, 149], ["phosphoethanolamine-N-[methoxy(polyethylene glycol)", "TREATMENT", 152, 203], ["DSPE-PEG", "TREATMENT", 211, 219], ["lipidic shell", "OBSERVATION", 4, 17]]], ["From electron microscopy analysis, LC-MSNs@ML336 showed a lipid bilayer thickness of 6 nm besides zeta potential of -1.76 mV.", [["lipid bilayer", "ANATOMY", 58, 71], ["LC-MSNs@ML336", "SIMPLE_CHEMICAL", 35, 48], ["electron microscopy analysis", "TEST", 5, 33], ["LC", "TEST", 35, 37], ["a lipid bilayer thickness", "TEST", 56, 81], ["zeta potential", "TEST", 98, 112]]], ["20 \u03bcg ML336/mg LC-MSNs were loaded into the nanocarrier showing a ML336 release of 34% over 24 h.", [["ML336", "CHEMICAL", 66, 71], ["ML336", "CHEMICAL", 66, 71], ["LC-MSNs", "SIMPLE_CHEMICAL", 15, 22], ["ML336", "SIMPLE_CHEMICAL", 66, 71]]], ["TC-83 VEEV infected HeLa cells were treated with LC-MSNs@ML336.", [["HeLa cells", "ANATOMY", 20, 30], ["TC-83 VEEV", "CELL", 0, 10], ["HeLa cells", "CELL", 20, 30], ["LC-MSNs@ML336", "SIMPLE_CHEMICAL", 49, 62], ["TC-83 VEEV infected HeLa cells", "CELL_LINE", 0, 30], ["VEEV", "SPECIES", 6, 10], ["TC", "TEST", 0, 2], ["VEEV infected HeLa cells", "PROBLEM", 6, 30], ["HeLa cells", "OBSERVATION", 20, 30]]], ["Results displayed virus inhibition in a dose-dependent manner, with significantly decreased viral load by 4 orders of magnitude after 24 h and 6 orders of magnitude after 48 and 72 h.", [["virus inhibition", "PROBLEM", 18, 34], ["significantly decreased viral load", "PROBLEM", 68, 102], ["virus inhibition", "OBSERVATION", 18, 34], ["viral load", "OBSERVATION", 92, 102]]], ["From in vivo assays, LC-MSNs were considered nontoxic at 0.11 g LC-MSNs/kg mouse dose administered per day during four days.", [["LC-MSNs", "CELL", 21, 28], ["mouse", "ORGANISM", 75, 80], ["mouse", "SPECIES", 75, 80], ["mouse", "SPECIES", 75, 80], ["vivo assays", "TEST", 8, 19], ["LC", "TEST", 21, 23], ["nontoxic", "PROBLEM", 45, 53], ["LC", "TEST", 64, 66]]], ["In addition, LC-MSNs@ML336 exhibited significant reduction (about 10-fold) of brain viral titer in VEEV infected mice compared to PBS and other controls.", [["brain", "ANATOMY", 78, 83], ["MSNs@ML336", "CHEMICAL", 16, 26], ["VEEV infected", "DISEASE", 99, 112], ["LC-MSNs@ML336", "SIMPLE_CHEMICAL", 13, 26], ["brain", "ORGAN", 78, 83], ["VEEV", "ORGANISM", 99, 103], ["mice", "ORGANISM", 113, 117], ["mice", "SPECIES", 113, 117], ["VEEV", "SPECIES", 99, 103], ["mice", "SPECIES", 113, 117], ["LC", "TEST", 13, 15], ["significant reduction", "PROBLEM", 37, 58], ["brain viral titer", "PROBLEM", 78, 95], ["LC", "ANATOMY", 13, 15], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["reduction", "OBSERVATION_MODIFIER", 49, 58], ["brain", "ANATOMY", 78, 83], ["viral titer", "OBSERVATION", 84, 95]]], ["These results highlighted the LC-MSNs@ML336 potential to treat VEEV infections and LC-MSNs as smart nanovehicles for antiviral applications.Viral Infections ::: MSNs for Infectious Diseases TreatmentHerpes simplex virus (HSV) provokes several infectious diseases such as orolabial and genital herpes being currently treated by guanine analogues such as acyclovir, valaciclovir and others, which inhibit viral DNA replication.", [["orolabial", "ANATOMY", 271, 280], ["VEEV infections", "DISEASE", 63, 78], ["Viral Infections", "DISEASE", 140, 156], ["Infectious Diseases", "DISEASE", 170, 189], ["Herpes simplex virus (HSV)", "DISEASE", 199, 225], ["infectious diseases", "DISEASE", 243, 262], ["orolabial and genital herpes", "DISEASE", 271, 299], ["guanine", "CHEMICAL", 327, 334], ["acyclovir", "CHEMICAL", 353, 362], ["valaciclovir", "CHEMICAL", 364, 376], ["guanine", "CHEMICAL", 327, 334], ["acyclovir", "CHEMICAL", 353, 362], ["valaciclovir", "CHEMICAL", 364, 376], ["VEEV", "ORGANISM", 63, 67], ["LC-MSNs", "SIMPLE_CHEMICAL", 83, 90], ["Infectious Diseases Treatment", "ORGANISM", 170, 199], ["Herpes simplex virus", "ORGANISM", 199, 219], ["HSV", "ORGANISM", 221, 224], ["genital herpes", "ORGANISM", 285, 299], ["guanine analogues", "SIMPLE_CHEMICAL", 327, 344], ["acyclovir", "SIMPLE_CHEMICAL", 353, 362], ["valaciclovir", "SIMPLE_CHEMICAL", 364, 376], ["DNA", "CELLULAR_COMPONENT", 409, 412], ["Herpes simplex virus", "SPECIES", 199, 219], ["VEEV", "SPECIES", 63, 67], ["Herpes simplex virus", "SPECIES", 199, 219], ["HSV", "SPECIES", 221, 224], ["VEEV infections", "PROBLEM", 63, 78], ["LC-MSNs", "TREATMENT", 83, 90], ["antiviral applications", "TREATMENT", 117, 139], ["Viral Infections", "PROBLEM", 140, 156], ["Infectious Diseases", "PROBLEM", 170, 189], ["Herpes simplex virus", "PROBLEM", 199, 219], ["HSV", "PROBLEM", 221, 224], ["several infectious diseases", "PROBLEM", 235, 262], ["orolabial and genital herpes", "PROBLEM", 271, 299], ["guanine analogues", "TREATMENT", 327, 344], ["acyclovir", "TREATMENT", 353, 362], ["valaciclovir", "TREATMENT", 364, 376], ["viral DNA replication", "TREATMENT", 403, 424], ["Infections", "OBSERVATION", 146, 156], ["Infectious", "OBSERVATION_MODIFIER", 170, 180], ["several", "OBSERVATION_MODIFIER", 235, 242], ["infectious", "OBSERVATION", 243, 253], ["genital", "ANATOMY", 285, 292], ["herpes", "OBSERVATION", 293, 299]]], ["However, these compounds suffer from antiviral drug resistance especially in immunocompromised individuals besides show poor bioavailability being necessary several and high doses administration (146,147).", [["antiviral drug resistance", "TREATMENT", 37, 62], ["immunocompromised individuals", "PROBLEM", 77, 106], ["poor bioavailability", "PROBLEM", 120, 140], ["high doses administration", "TREATMENT", 169, 194], ["antiviral drug resistance", "OBSERVATION", 37, 62]]], ["The HSV cells infection can start by electrostatic and hydrophobic interactions between viral glycoprotein (gB or gC) and cell glycosaminoglycans (GAGs, heparan sulfate) composed of negatively charged sulfonate groups linked by hydrophobic moieties.", [["HSV cells", "ANATOMY", 4, 13], ["cell", "ANATOMY", 122, 126], ["infection", "DISEASE", 14, 23], ["heparan sulfate", "CHEMICAL", 153, 168], ["sulfonate", "CHEMICAL", 201, 210], ["sulfonate", "CHEMICAL", 201, 210], ["HSV cells", "CELL", 4, 13], ["gB", "GENE_OR_GENE_PRODUCT", 108, 110], ["gC", "GENE_OR_GENE_PRODUCT", 114, 116], ["cell glycosaminoglycans", "CELLULAR_COMPONENT", 122, 145], ["GAGs", "GENE_OR_GENE_PRODUCT", 147, 151], ["heparan sulfate", "SIMPLE_CHEMICAL", 153, 168], ["negatively charged sulfonate groups", "SIMPLE_CHEMICAL", 182, 217], ["hydrophobic moieties", "SIMPLE_CHEMICAL", 228, 248], ["viral glycoprotein", "PROTEIN", 88, 106], ["gB", "PROTEIN", 108, 110], ["gC", "PROTEIN", 114, 116], ["cell glycosaminoglycans", "PROTEIN", 122, 145], ["HSV", "SPECIES", 4, 7], ["The HSV cells infection", "PROBLEM", 0, 23], ["viral glycoprotein (gB or gC)", "TREATMENT", 88, 117], ["cell glycosaminoglycans (GAGs, heparan sulfate)", "TREATMENT", 122, 169], ["negatively charged sulfonate groups", "TREATMENT", 182, 217], ["HSV cells infection", "OBSERVATION", 4, 23], ["hydrophobic moieties", "OBSERVATION", 228, 248]]], ["Molecules that mimic GAGs can interact with virus avoiding their interaction and penetration into susceptible cells (146,147).", [["cells", "ANATOMY", 110, 115], ["GAGs", "GENE_OR_GENE_PRODUCT", 21, 25], ["cells", "CELL", 110, 115], ["susceptible cells", "CELL_TYPE", 98, 115], ["virus", "TREATMENT", 44, 49], ["penetration into susceptible cells", "PROBLEM", 81, 115]]], ["(146,147) have designed GAG mimetic-functionalized MSNs to treat HSV-1 and HSV-2 infections.", [["HSV-2 infections", "DISEASE", 75, 91], ["GAG", "SIMPLE_CHEMICAL", 24, 27], ["MSNs", "SIMPLE_CHEMICAL", 51, 55], ["HSV-1", "ORGANISM", 65, 70], ["HSV-2", "ORGANISM", 75, 80], ["HSV-1", "SPECIES", 65, 70], ["HSV-1", "SPECIES", 65, 70], ["HSV-2", "SPECIES", 75, 80], ["GAG mimetic-functionalized MSNs", "TREATMENT", 24, 55], ["HSV", "TEST", 65, 68], ["HSV", "PROBLEM", 75, 78], ["2 infections", "PROBLEM", 79, 91], ["infections", "OBSERVATION", 81, 91]]], ["In a first work (146), aryl sulfonate GAG mimetic-modified MSNs exhibited low toxicity besides inhibited HSV-1 and HSV-2 penetration into health cells while controls were inactive.", [["cells", "ANATOMY", 145, 150], ["aryl sulfonate", "CHEMICAL", 23, 37], ["MSNs", "CHEMICAL", 59, 63], ["toxicity", "DISEASE", 78, 86], ["aryl sulfonate", "CHEMICAL", 23, 37], ["aryl sulfonate GAG mimetic-modified MSNs", "SIMPLE_CHEMICAL", 23, 63], ["HSV-1", "ORGANISM", 105, 110], ["HSV-2", "ORGANISM", 115, 120], ["health cells", "CELL", 138, 150], ["health cells", "CELL_TYPE", 138, 150], ["HSV-1", "SPECIES", 105, 110], ["HSV-1", "SPECIES", 105, 110], ["HSV-2", "SPECIES", 115, 120], ["aryl sulfonate GAG mimetic", "TREATMENT", 23, 49], ["low toxicity", "PROBLEM", 74, 86], ["HSV", "TEST", 105, 108], ["HSV", "PROBLEM", 115, 118], ["low toxicity", "OBSERVATION_MODIFIER", 74, 86]]], ["(147) explored distinct functional groups related to GAG structure attached to MSNs and investigated their activity against HSV-1 and HSV-2.", [["GAG", "SIMPLE_CHEMICAL", 53, 56], ["MSNs", "SIMPLE_CHEMICAL", 79, 83], ["HSV-1", "ORGANISM", 124, 129], ["HSV-2", "ORGANISM", 134, 139], ["HSV-1", "SPECIES", 124, 129], ["HSV-1", "SPECIES", 124, 129], ["HSV-2", "SPECIES", 134, 139], ["distinct functional groups", "PROBLEM", 15, 41], ["HSV", "TEST", 124, 127], ["HSV", "TEST", 134, 137]]], ["In addition, authors evaluated GAG mimetic-functionalized MSNs as smart nanocarriers for acyclovir (ACV) delivery aiming simultaneously inhibition of viral penetration and DNA replication.", [["acyclovir", "CHEMICAL", 89, 98], ["ACV", "CHEMICAL", 100, 103], ["acyclovir", "CHEMICAL", 89, 98], ["ACV", "CHEMICAL", 100, 103], ["GAG", "SIMPLE_CHEMICAL", 31, 34], ["MSNs", "SIMPLE_CHEMICAL", 58, 62], ["acyclovir", "SIMPLE_CHEMICAL", 89, 98], ["ACV", "SIMPLE_CHEMICAL", 100, 103], ["DNA", "CELLULAR_COMPONENT", 172, 175], ["GAG mimetic-functionalized MSNs", "TREATMENT", 31, 62], ["smart nanocarriers", "TREATMENT", 66, 84], ["acyclovir (ACV) delivery", "TREATMENT", 89, 113], ["viral penetration", "TREATMENT", 150, 167], ["DNA replication", "TREATMENT", 172, 187], ["viral penetration", "OBSERVATION", 150, 167]]], ["Five modified MSNs were prepared: benzene sulfonate-modified MSNs, propyl thiol-modified MSNs, propyl sulfonate-modified MSNs, zwitterionic sulfonate-modified MSNs and phenyl-modified MSNs ((MSNs-Phenyl-SO3, MSNs-Propyl-Thiol, MSNs-Propyl-SO3, MSNs-Zw-SO3 and MSNs-Phenyl, respectively).", [["benzene sulfonate", "CHEMICAL", 34, 51], ["propyl thiol", "CHEMICAL", 67, 79], ["propyl sulfonate", "CHEMICAL", 95, 111], ["zwitterionic sulfonate", "CHEMICAL", 127, 149], ["MSNs", "CHEMICAL", 159, 163], ["phenyl", "CHEMICAL", 168, 174], ["MSNs-Phenyl-SO3", "CHEMICAL", 191, 206], ["MSNs-Propyl-Thiol, MSNs-Propyl-SO3, MSNs-Zw-SO3", "CHEMICAL", 208, 255], ["MSNs", "CHEMICAL", 260, 264], ["benzene sulfonate", "CHEMICAL", 34, 51], ["propyl thiol", "CHEMICAL", 67, 79], ["propyl sulfonate", "CHEMICAL", 95, 111], ["sulfonate", "CHEMICAL", 140, 149], ["phenyl", "CHEMICAL", 168, 174], ["Phenyl", "CHEMICAL", 196, 202], ["SO3", "CHEMICAL", 203, 206], ["Propyl-Thiol", "CHEMICAL", 213, 225], ["Propyl-SO3", "CHEMICAL", 232, 242], ["Zw-SO3", "CHEMICAL", 249, 255], ["Phenyl", "CHEMICAL", 265, 271], ["MSNs", "SIMPLE_CHEMICAL", 14, 18], ["benzene sulfonate-modified MSNs", "SIMPLE_CHEMICAL", 34, 65], ["propyl thiol-modified MSNs", "SIMPLE_CHEMICAL", 67, 93], ["propyl sulfonate-modified MSNs", "SIMPLE_CHEMICAL", 95, 125], ["zwitterionic sulfonate-modified MSNs", "SIMPLE_CHEMICAL", 127, 163], ["phenyl-modified MSNs", "SIMPLE_CHEMICAL", 168, 188], ["MSNs-Phenyl-SO3", "SIMPLE_CHEMICAL", 191, 206], ["MSNs-Propyl-Thiol", "SIMPLE_CHEMICAL", 208, 225], ["MSNs-Propyl-SO3", "SIMPLE_CHEMICAL", 227, 242], ["MSNs-Zw-SO3", "SIMPLE_CHEMICAL", 244, 255], ["MSNs-Phenyl", "SIMPLE_CHEMICAL", 260, 271], ["Five modified MSNs", "TREATMENT", 0, 18], ["benzene sulfonate", "TREATMENT", 34, 51], ["modified MSNs", "TREATMENT", 52, 65], ["propyl thiol", "TREATMENT", 67, 79], ["modified MSNs", "TREATMENT", 80, 93], ["propyl sulfonate", "TREATMENT", 95, 111], ["modified MSNs", "TREATMENT", 112, 125], ["zwitterionic sulfonate", "TREATMENT", 127, 149], ["modified MSNs", "TREATMENT", 150, 163], ["phenyl-modified MSNs", "TREATMENT", 168, 188], ["MSNs", "TEST", 191, 195], ["Phenyl-SO3", "TREATMENT", 196, 206], ["MSNs", "TREATMENT", 208, 212], ["Propyl", "TREATMENT", 213, 219], ["Thiol", "TREATMENT", 220, 225], ["MSNs", "TREATMENT", 227, 231], ["Propyl", "TREATMENT", 232, 238], ["MSNs", "TREATMENT", 244, 248], ["Phenyl", "TREATMENT", 265, 271]]], ["All nanoplatforms were characterized showing average size from 100-150 nm and negative surface charge (~ -40 mV), conferring good colloidal stability by interparticle repulsion.", [["surface", "ANATOMY", 87, 94], ["All nanoplatforms", "TEST", 0, 17], ["surface charge", "TEST", 87, 101], ["average", "OBSERVATION_MODIFIER", 45, 52], ["size", "OBSERVATION_MODIFIER", 53, 57], ["good", "OBSERVATION_MODIFIER", 125, 129], ["colloidal stability", "OBSERVATION", 130, 149], ["interparticle repulsion", "OBSERVATION", 153, 176]]], ["Antiviral in vitro assays toward HSV-1 and HSV-2 were carried out displaying that sulfonate group presence was as a prerequisite for antiviral activity, with the benzene group (from benzene sulfonate-modified MSNs) enhancing the antiviral response regarding to an alkyl group (propyl sulfonate-modified MSNs).", [["sulfonate", "CHEMICAL", 82, 91], ["benzene", "CHEMICAL", 162, 169], ["benzene sulfonate", "CHEMICAL", 182, 199], ["MSNs", "CHEMICAL", 209, 213], ["alkyl", "CHEMICAL", 264, 269], ["propyl sulfonate", "CHEMICAL", 277, 293], ["sulfonate", "CHEMICAL", 82, 91], ["benzene", "CHEMICAL", 162, 169], ["benzene sulfonate", "CHEMICAL", 182, 199], ["propyl sulfonate", "CHEMICAL", 277, 293], ["HSV-1", "ORGANISM", 33, 38], ["HSV-2", "ORGANISM", 43, 48], ["sulfonate", "SIMPLE_CHEMICAL", 82, 91], ["benzene", "SIMPLE_CHEMICAL", 162, 169], ["benzene sulfonate", "SIMPLE_CHEMICAL", 182, 199], ["MSNs", "SIMPLE_CHEMICAL", 209, 213], ["alkyl", "SIMPLE_CHEMICAL", 264, 269], ["propyl sulfonate", "SIMPLE_CHEMICAL", 277, 293], ["MSNs", "SIMPLE_CHEMICAL", 303, 307], ["HSV-1", "SPECIES", 33, 38], ["HSV-1", "SPECIES", 33, 38], ["HSV-2", "SPECIES", 43, 48], ["Antiviral in vitro assays", "TEST", 0, 25], ["HSV", "TEST", 33, 36], ["HSV", "TEST", 43, 46], ["antiviral activity", "TREATMENT", 133, 151], ["benzene sulfonate-modified MSNs)", "TREATMENT", 182, 214], ["an alkyl group (propyl sulfonate-modified MSNs", "TREATMENT", 261, 307], ["antiviral response", "OBSERVATION", 229, 247]]], ["Phenyl-modified MSNs showed a relatively weak antiviral activity, reinforcing the sulfonate group importance.", [["Phenyl", "CHEMICAL", 0, 6], ["sulfonate", "CHEMICAL", 82, 91], ["Phenyl", "CHEMICAL", 0, 6], ["sulfonate", "CHEMICAL", 82, 91], ["Phenyl", "SIMPLE_CHEMICAL", 0, 6], ["MSNs", "SIMPLE_CHEMICAL", 16, 20], ["sulfonate", "SIMPLE_CHEMICAL", 82, 91], ["Phenyl-modified MSNs", "TREATMENT", 0, 20]]], ["From second study concerning ACV-loaded benzene sulfonate-modified MSNs (labeled ACV@MSNs-phenyl-SO3), high drug loading (34% w/w) and controlled and prolonged ACV release (70% (w/w) up to 24 h) were detected.", [["ACV", "CHEMICAL", 29, 32], ["benzene sulfonate", "CHEMICAL", 40, 57], ["MSNs", "CHEMICAL", 67, 71], ["ACV@MSNs-phenyl-SO3", "CHEMICAL", 81, 100], ["ACV", "CHEMICAL", 160, 163], ["ACV", "CHEMICAL", 29, 32], ["benzene sulfonate", "CHEMICAL", 40, 57], ["ACV@MSNs-phenyl-SO3", "CHEMICAL", 81, 100], ["ACV", "CHEMICAL", 160, 163], ["ACV", "SIMPLE_CHEMICAL", 29, 32], ["benzene sulfonate", "SIMPLE_CHEMICAL", 40, 57], ["MSNs", "SIMPLE_CHEMICAL", 67, 71], ["ACV@MSNs-phenyl-SO3", "SIMPLE_CHEMICAL", 81, 100], ["ACV", "SIMPLE_CHEMICAL", 160, 163], ["second study", "TEST", 5, 17], ["ACV-loaded benzene sulfonate", "TREATMENT", 29, 57], ["modified MSNs (labeled ACV@MSNs", "TREATMENT", 58, 89], ["phenyl-SO3", "TREATMENT", 90, 100], ["high drug loading", "TREATMENT", 103, 120], ["prolonged ACV release", "TREATMENT", 150, 171]]], ["This release profile can be assigned to the mesopores functionalization with hydrophobic groups which can act as blockers controlling drug release.", [["the mesopores functionalization with hydrophobic groups", "TREATMENT", 40, 95]]], ["To evaluate post viral penetration into cells, Vero cells were infected with HSV-1 and then, treated with the nanoplatforms.", [["cells", "ANATOMY", 40, 45], ["Vero cells", "ANATOMY", 47, 57], ["cells", "CELL", 40, 45], ["Vero cells", "CELL", 47, 57], ["HSV-1", "ORGANISM", 77, 82], ["Vero cells", "CELL_LINE", 47, 57], ["HSV-1", "SPECIES", 77, 82], ["post viral penetration into cells", "PROBLEM", 12, 45], ["Vero cells", "PROBLEM", 47, 57], ["HSV", "TEST", 77, 80], ["the nanoplatforms", "TREATMENT", 106, 123], ["viral penetration", "OBSERVATION", 17, 34]]], ["Results exhibited higher antiviral activity for ACV@MSNs-phenyl-SO3 than ACV@MSNs and free ACV.", [["ACV@MSNs-phenyl-SO3", "CHEMICAL", 48, 67], ["ACV@MSNs", "CHEMICAL", 73, 81], ["ACV", "CHEMICAL", 91, 94], ["ACV@MSNs-phenyl-SO3", "CHEMICAL", 48, 67], ["ACV@MSNs", "CHEMICAL", 73, 81], ["ACV", "CHEMICAL", 91, 94], ["ACV@MSNs-phenyl-SO3", "SIMPLE_CHEMICAL", 48, 67], ["ACV@MSNs", "SIMPLE_CHEMICAL", 73, 81], ["ACV", "SIMPLE_CHEMICAL", 91, 94], ["ACV@MSNs", "TEST", 48, 56], ["phenyl-SO3", "TREATMENT", 57, 67], ["ACV@MSNs", "TREATMENT", 73, 81], ["free ACV", "TREATMENT", 86, 94], ["higher", "OBSERVATION_MODIFIER", 18, 24], ["antiviral activity", "OBSERVATION", 25, 43]]], ["The targeting effect of GAG mimetic from ACV@MSNs-phenyl-SO3 against HSV-1 was investigated achieving 100% antiviral activity whereas both no interaction with HSV-1 were detected for ACV@MSNs and free ACV.", [["GAG", "CHEMICAL", 24, 27], ["ACV@MSNs-phenyl-SO3", "CHEMICAL", 41, 60], ["ACV", "CHEMICAL", 201, 204], ["ACV@MSNs-phenyl-SO3", "CHEMICAL", 41, 60], ["ACV", "CHEMICAL", 201, 204], ["GAG", "SIMPLE_CHEMICAL", 24, 27], ["ACV@MSNs-phenyl-SO3", "SIMPLE_CHEMICAL", 41, 60], ["HSV-1", "ORGANISM", 69, 74], ["HSV-1", "ORGANISM", 159, 164], ["ACV@MSNs", "SIMPLE_CHEMICAL", 183, 191], ["ACV", "SIMPLE_CHEMICAL", 201, 204], ["HSV-1", "SPECIES", 69, 74], ["HSV-1", "SPECIES", 69, 74], ["HSV-1", "SPECIES", 159, 164], ["GAG mimetic", "PROBLEM", 24, 35], ["ACV@MSNs", "TEST", 41, 49], ["phenyl-SO3", "TREATMENT", 50, 60], ["HSV", "PROBLEM", 69, 72], ["HSV", "TEST", 159, 162], ["ACV@MSNs", "TEST", 183, 191], ["free ACV", "TREATMENT", 196, 204], ["GAG mimetic", "OBSERVATION", 24, 35]]], ["These results confirmed that the GAG mimetic-functionalized MSNs performed dual action mechanism against HSV-1 and HSV-2 opening up new possibilities for virus infections treatment.Viral Infections ::: MSNs for Infectious Diseases TreatmentAs aforementioned, viruses comprise a harmful pathogen to the humans responsible for millions of people death every year.", [["GAG", "CHEMICAL", 33, 36], ["infections", "DISEASE", 160, 170], ["Viral Infections", "DISEASE", 181, 197], ["Infectious Diseases", "DISEASE", 211, 230], ["death", "DISEASE", 344, 349], ["GAG", "SIMPLE_CHEMICAL", 33, 36], ["MSNs", "SIMPLE_CHEMICAL", 60, 64], ["HSV-1", "ORGANISM", 105, 110], ["HSV-2", "ORGANISM", 115, 120], ["humans", "ORGANISM", 302, 308], ["people", "ORGANISM", 337, 343], ["HSV-1", "SPECIES", 105, 110], ["humans", "SPECIES", 302, 308], ["people", "SPECIES", 337, 343], ["HSV-1", "SPECIES", 105, 110], ["HSV-2", "SPECIES", 115, 120], ["humans", "SPECIES", 302, 308], ["the GAG mimetic", "TREATMENT", 29, 44], ["HSV", "TEST", 105, 108], ["HSV", "TEST", 115, 118], ["virus infections treatment", "TREATMENT", 154, 180], ["Infectious Diseases Treatment", "TREATMENT", 211, 240], ["viruses", "PROBLEM", 259, 266], ["Infections", "OBSERVATION", 187, 197]]], ["Despites some therapies such as highly active anti-retroviral therapy (HAART) available to treat human immunodeficiency virus (HIV), the demand for new therapies and vaccines are essential to fight against new viruses.", [["human immunodeficiency virus (HIV)", "DISEASE", 97, 131], ["human immunodeficiency virus", "ORGANISM", 97, 125], ["human", "SPECIES", 97, 102], ["immunodeficiency virus (HIV", "SPECIES", 103, 130], ["human immunodeficiency virus", "SPECIES", 97, 125], ["HIV", "SPECIES", 127, 130], ["some therapies", "TREATMENT", 9, 23], ["highly active anti-retroviral therapy", "TREATMENT", 32, 69], ["HAART)", "TREATMENT", 71, 77], ["human immunodeficiency virus", "PROBLEM", 97, 125], ["HIV", "PROBLEM", 127, 130], ["new therapies", "TREATMENT", 148, 161], ["vaccines", "TREATMENT", 166, 174], ["new viruses", "PROBLEM", 206, 217]]], ["To better understand the mechanism of antiviral MSNs action, Silva et al .", [["antiviral MSNs action", "TREATMENT", 38, 59]]], ["(54) developed modified MSNs to evaluate their biocompatibility and their ability to inhibit the virus transduction of target cells.", [["cells", "ANATOMY", 126, 131], ["MSNs", "CELL", 24, 28], ["cells", "CELL", 126, 131], ["target cells", "CELL_TYPE", 119, 131], ["the virus transduction", "TREATMENT", 93, 115], ["target cells", "OBSERVATION", 119, 131]]], ["(3-aminopropyl)triethoxysilane (APTES), (3-glycidyloxypropyl)trimethoxysilane (GPTMS) and trimethoxy-(2-phenylethyl)silane (TMPES) groups were used to modified MSNs surface and noted as MSNs-APTES, MSNs-GPTMS and MSNs-TMPES.", [["MSNs surface", "ANATOMY", 160, 172], ["3-aminopropyl)triethoxysilane", "CHEMICAL", 1, 30], ["APTES", "CHEMICAL", 32, 37], ["3-glycidyloxypropyl)trimethoxysilane", "CHEMICAL", 41, 77], ["GPTMS", "CHEMICAL", 79, 84], ["trimethoxy-(2-phenylethyl)silane", "CHEMICAL", 90, 122], ["TMPES", "CHEMICAL", 124, 129], ["MSNs", "CHEMICAL", 198, 202], ["MSNs", "CHEMICAL", 213, 217], ["(3-aminopropyl)triethoxysilane", "CHEMICAL", 0, 30], ["APTES", "CHEMICAL", 32, 37], ["(3-glycidyloxypropyl)trimethoxysilane", "CHEMICAL", 40, 77], ["GPTMS", "CHEMICAL", 79, 84], ["trimethoxy-(2-phenylethyl)silane", "CHEMICAL", 90, 122], ["TMPES", "CHEMICAL", 124, 129], ["(3-aminopropyl)triethoxysilane", "SIMPLE_CHEMICAL", 0, 30], ["APTES", "SIMPLE_CHEMICAL", 32, 37], ["(3-glycidyloxypropyl)trimethoxysilane", "SIMPLE_CHEMICAL", 40, 77], ["GPTMS", "SIMPLE_CHEMICAL", 79, 84], ["trimethoxy-(2-phenylethyl)silane", "SIMPLE_CHEMICAL", 90, 122], ["TMPES", "SIMPLE_CHEMICAL", 124, 129], ["MSNs-APTES", "SIMPLE_CHEMICAL", 186, 196], ["MSNs-GPTMS", "SIMPLE_CHEMICAL", 198, 208], ["MSNs-TMPES", "SIMPLE_CHEMICAL", 213, 223], ["3-aminopropyl)triethoxysilane (APTES)", "TREATMENT", 1, 38], ["trimethoxysilane (GPTMS)", "TREATMENT", 61, 85], ["trimethoxy-(2-phenylethyl)silane (TMPES) groups", "TREATMENT", 90, 137], ["GPTMS", "PROBLEM", 203, 208], ["MSNs", "PROBLEM", 213, 217], ["TMPES", "PROBLEM", 218, 223]]], ["Spherical-shaped modified MSNs with average size from 354-571 nm and negative surface charge (from -11.2 to -22.8 mV) were fabricated.", [["surface", "ANATOMY", 78, 85], ["MSNs", "CELL", 26, 30], ["surface charge", "TEST", 78, 92], ["shaped", "OBSERVATION_MODIFIER", 10, 16], ["MSNs", "OBSERVATION_MODIFIER", 26, 30], ["average", "OBSERVATION_MODIFIER", 36, 43], ["size", "OBSERVATION_MODIFIER", 44, 48]]], ["Cytotoxicity assays were performed for the nanosystems exhibiting cells metabolic activity similar to the control at lower particle concentration (10-5 g mL-1) and cells nuclei morphology preserved after interaction.", [["nanosystems", "ANATOMY", 43, 54], ["cells", "ANATOMY", 66, 71], ["cells nuclei", "ANATOMY", 164, 176], ["cells", "CELL", 66, 71], ["cells nuclei", "CELL", 164, 176], ["Cytotoxicity assays", "TEST", 0, 19], ["the nanosystems", "TEST", 39, 54], ["cells metabolic activity", "PROBLEM", 66, 90], ["metabolic activity", "OBSERVATION", 72, 90]]], ["The inhibitory potential of the nanosystems to prevent virus transduction was evaluated by using a truncated version of the HIV-gp120 glycoprotein that can interact with cells containing CD4 receptor and VSV-G envelope that can bind on different cell surfaces.", [["cells", "ANATOMY", 170, 175], ["cell surfaces", "ANATOMY", 246, 259], ["HIV-gp120", "ORGANISM", 124, 133], ["cells", "CELL", 170, 175], ["CD4 receptor", "GENE_OR_GENE_PRODUCT", 187, 199], ["VSV-G envelope", "GENE_OR_GENE_PRODUCT", 204, 218], ["cell", "CELL", 246, 250], ["HIV-gp120 glycoprotein", "PROTEIN", 124, 146], ["CD4 receptor", "PROTEIN", 187, 199], ["HIV", "SPECIES", 124, 127], ["HIV", "SPECIES", 124, 127], ["the nanosystems", "TREATMENT", 28, 43], ["virus transduction", "TREATMENT", 55, 73], ["the HIV-gp120 glycoprotein", "TREATMENT", 120, 146], ["CD4 receptor", "TREATMENT", 187, 199], ["VSV-G envelope", "TREATMENT", 204, 218], ["different cell surfaces", "OBSERVATION", 236, 259]]], ["When target cell was transduced by virus, GFP is expressed by the infected cell, that means, whether transduction occurs GFP can be detected.", [["cell", "ANATOMY", 12, 16], ["cell", "ANATOMY", 75, 79], ["cell", "CELL", 12, 16], ["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["cell", "CELL", 75, 79], ["GFP", "GENE_OR_GENE_PRODUCT", 121, 124], ["GFP", "PROTEIN", 42, 45], ["GFP", "PROTEIN", 121, 124], ["virus", "PROBLEM", 35, 40], ["GFP", "TEST", 42, 45], ["the infected cell", "PROBLEM", 62, 79], ["transduction occurs GFP", "PROBLEM", 101, 124], ["infected cell", "OBSERVATION", 66, 79]]], ["In this way, the pseudotyped preparation was treated with the nanosystems.", [["pseudotyped", "ORGANISM", 17, 28], ["the pseudotyped preparation", "TREATMENT", 13, 40], ["the nanosystems", "TREATMENT", 58, 73], ["pseudotyped", "OBSERVATION", 17, 28]]], ["At low concentration, all nanosystems reduced transduction for both recombinant lentivirus with VSV-G and HIV-gp120 envelopes.", [["lentivirus", "ORGANISM", 80, 90], ["VSV-G", "ORGANISM", 96, 101], ["HIV-gp120", "ORGANISM", 106, 115], ["HIV", "SPECIES", 106, 109], ["VSV", "SPECIES", 96, 99], ["HIV", "SPECIES", 106, 109], ["all nanosystems reduced transduction", "TREATMENT", 22, 58], ["both recombinant lentivirus", "TREATMENT", 63, 90], ["VSV", "TEST", 96, 99], ["HIV", "PROBLEM", 106, 109], ["low concentration", "OBSERVATION_MODIFIER", 3, 20]]], ["MSNs-APTES and MSNs-TMPES showed higher transduction reduction for VSV-G (~50%) and HIV-gp120 (~20%) envelopes, respectively.", [["MSNs", "CHEMICAL", 0, 4], ["MSNs", "CHEMICAL", 15, 19], ["TMPES", "CHEMICAL", 20, 25], ["MSNs", "SIMPLE_CHEMICAL", 0, 4], ["MSNs-TMPES", "SIMPLE_CHEMICAL", 15, 25], ["VSV-G", "GENE_OR_GENE_PRODUCT", 67, 72], ["APTES", "DNA", 5, 10], ["MSNs", "DNA", 15, 19], ["TMPES", "DNA", 20, 25], ["gp120", "PROTEIN", 88, 93], ["higher transduction reduction", "TREATMENT", 33, 62], ["VSV", "TEST", 67, 70], ["G", "TEST", 71, 72], ["HIV", "TEST", 84, 87], ["gp120", "TEST", 88, 93]]], ["Theoretical studies suggested that higher hydrophobicity could favor interaction with HIV-gp120 whereas hydrophilicity could lead to better interaction with VSV-G, explain the distinct responses.", [["HIV-gp120", "ORGANISM", 86, 95], ["VSV-G", "GENE_OR_GENE_PRODUCT", 157, 162], ["gp120", "PROTEIN", 90, 95], ["HIV", "SPECIES", 86, 89], ["Theoretical studies", "TEST", 0, 19], ["higher hydrophobicity", "PROBLEM", 35, 56], ["HIV-gp120", "PROBLEM", 86, 95], ["hydrophilicity", "PROBLEM", 104, 118], ["higher hydrophobicity", "OBSERVATION_MODIFIER", 35, 56]]], ["These results provide new insights towards the design of specific MSNs-based nanocarriers as new strategies for viral control and anti-HIV therapy.Viral Infections ::: MSNs for Infectious Diseases TreatmentPorcine circovirus type 2 (PCV2) is a primary etiological agent of post-weaning multi-systemic wasting syndrome (PMWS).", [["Viral Infections", "DISEASE", 147, 163], ["Infectious Diseases TreatmentPorcine circovirus type 2 (PCV2)", "DISEASE", 177, 238], ["multi-systemic wasting syndrome", "DISEASE", 286, 317], ["PMWS", "DISEASE", 319, 323], ["MSNs", "SIMPLE_CHEMICAL", 66, 70], ["anti-HIV", "CANCER", 130, 138], ["Infectious Diseases TreatmentPorcine circovirus type 2", "ORGANISM", 177, 231], ["PCV2", "ORGANISM", 233, 237], ["TreatmentPorcine circovirus type", "SPECIES", 197, 229], ["TreatmentPorcine circovirus type 2", "SPECIES", 197, 231], ["PCV2", "SPECIES", 233, 237], ["specific MSNs-based nanocarriers", "TREATMENT", 57, 89], ["new strategies", "TREATMENT", 93, 107], ["viral control", "TREATMENT", 112, 125], ["anti-HIV therapy", "TREATMENT", 130, 146], ["Viral Infections", "PROBLEM", 147, 163], ["Infectious Diseases", "PROBLEM", 177, 196], ["TreatmentPorcine circovirus type 2 (PCV2", "TREATMENT", 197, 237], ["post-weaning multi-systemic wasting syndrome", "PROBLEM", 273, 317], ["anti-HIV therapy", "OBSERVATION", 130, 146], ["Infections", "OBSERVATION", 153, 163]]], ["PMWS are severe in acute outbreaks, causing death of up to 80% of affected animals.", [["PMWS", "DISEASE", 0, 4], ["death", "DISEASE", 44, 49], ["PMWS", "PROBLEM", 0, 4], ["acute outbreaks", "PROBLEM", 19, 34], ["death", "PROBLEM", 44, 49], ["affected animals", "PROBLEM", 66, 82], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["outbreaks", "OBSERVATION", 25, 34]]], ["To develop new therapies for PCV2 infections is essential for pig industries.", [["PCV2 infections", "DISEASE", 29, 44], ["PCV2", "ORGANISM", 29, 33], ["pig", "ORGANISM", 62, 65], ["pig", "SPECIES", 62, 65], ["PCV2", "SPECIES", 29, 33], ["pig", "SPECIES", 62, 65], ["new therapies", "TREATMENT", 11, 24], ["PCV2 infections", "PROBLEM", 29, 44], ["pig industries", "TREATMENT", 62, 76], ["new", "OBSERVATION_MODIFIER", 11, 14], ["PCV2 infections", "OBSERVATION", 29, 44]]], ["(148) reported the preparation of PCV2 GST-ORF2-E protein-loaded HMSNs as nanovaccines aiming to induce persistent immune responses of PCV2.", [["HMSNs", "CHEMICAL", 65, 70], ["PCV2", "ORGANISM", 34, 38], ["GST", "GENE_OR_GENE_PRODUCT", 39, 42], ["HMSNs", "SIMPLE_CHEMICAL", 65, 70], ["PCV2", "ORGANISM", 135, 139], ["PCV2 GST-ORF2-E protein", "PROTEIN", 34, 57], ["PCV2", "SPECIES", 135, 139], ["PCV2 GST", "TEST", 34, 42], ["ORF2-E protein", "TREATMENT", 43, 57], ["HMSNs", "TREATMENT", 65, 70], ["nanovaccines", "TREATMENT", 74, 86], ["PCV2", "PROBLEM", 135, 139], ["PCV2", "OBSERVATION", 135, 139]]], ["The nanosystem was characterized exhibiting spherical shape with average size of 200 nm.", [["spherical", "OBSERVATION_MODIFIER", 44, 53], ["shape", "OBSERVATION_MODIFIER", 54, 59], ["average", "OBSERVATION_MODIFIER", 65, 72], ["size", "OBSERVATION_MODIFIER", 73, 77], ["200 nm", "OBSERVATION_MODIFIER", 81, 87]]], ["Maximum protein loading amount of 15% (w/w) were achieved.", [["Maximum protein loading amount", "TREATMENT", 0, 30]]], ["Protein release profile (PBS at pH 7) was time-dependent showing rapid release (~50%) up to 12 h and slow release up to the sixth day.", [["Protein release profile", "TEST", 0, 23], ["PBS at pH", "TEST", 25, 34], ["rapid release", "PROBLEM", 65, 78]]], ["To evaluate the specificity of mice antibodies immunized by GST-ORF2-E, mouse sera were used in immunofluorescence experiments to determine the specificity of antibodies by PCV2-infected PK15 cells.", [["sera", "ANATOMY", 78, 82], ["PK15 cells", "ANATOMY", 187, 197], ["mice", "ORGANISM", 31, 35], ["GST", "GENE_OR_GENE_PRODUCT", 60, 63], ["mouse", "ORGANISM", 72, 77], ["sera", "ORGANISM_SUBSTANCE", 78, 82], ["PCV2", "ORGANISM", 173, 177], ["PK15 cells", "CELL", 187, 197], ["mice antibodies", "PROTEIN", 31, 46], ["GST", "PROTEIN", 60, 63], ["ORF2", "DNA", 64, 68], ["antibodies", "PROTEIN", 159, 169], ["PK15 cells", "CELL_LINE", 187, 197], ["mice", "SPECIES", 31, 35], ["mouse", "SPECIES", 72, 77], ["mice", "SPECIES", 31, 35], ["mouse", "SPECIES", 72, 77], ["mice antibodies", "TEST", 31, 46], ["ORF2", "TEST", 64, 68], ["mouse sera", "TREATMENT", 72, 82], ["immunofluorescence experiments", "TEST", 96, 126], ["antibodies", "TEST", 159, 169], ["PCV2", "TEST", 173, 177], ["infected PK15 cells", "PROBLEM", 178, 197], ["PK15 cells", "OBSERVATION", 187, 197]]], ["Results displayed that no significant staining was detected suggesting specificity of the mouse antibody against PCV2.", [["mouse", "ORGANISM", 90, 95], ["PCV2", "ORGANISM", 113, 117], ["mouse antibody", "PROTEIN", 90, 104], ["mouse", "SPECIES", 90, 95], ["mouse", "SPECIES", 90, 95], ["PCV2", "SPECIES", 113, 117], ["significant staining", "PROBLEM", 26, 46], ["the mouse antibody", "TEST", 86, 104], ["PCV2", "PROBLEM", 113, 117], ["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["staining", "OBSERVATION", 38, 46]]], ["Indirect ELISA assays displayed that the antibody titers of mice immunized with PCV2 GST-ORF2-E@HMSNs were higher than those of mice immunized with the GST-ORF2-E protein, especially at the third- and fourth-weeks post-vaccination.", [["mice", "ORGANISM", 60, 64], ["PCV2", "ORGANISM", 80, 84], ["GST", "GENE_OR_GENE_PRODUCT", 85, 88], ["mice", "ORGANISM", 128, 132], ["GST", "GENE_OR_GENE_PRODUCT", 152, 155], ["ORF2-E", "GENE_OR_GENE_PRODUCT", 156, 162], ["PCV2 GST-ORF2-E@HMSNs", "DNA", 80, 101], ["GST", "PROTEIN", 152, 155], ["ORF2", "DNA", 156, 160], ["E protein", "PROTEIN", 161, 170], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 60, 64], ["PCV2", "SPECIES", 80, 84], ["mice", "SPECIES", 128, 132], ["Indirect ELISA assays", "TEST", 0, 21], ["the antibody titers", "TEST", 37, 56], ["PCV2 GST", "TEST", 80, 88], ["ORF2", "TEST", 89, 93], ["E@HMSNs", "TEST", 94, 101], ["the GST", "TEST", 148, 155], ["ORF2-E protein", "TEST", 156, 170]]], ["Furthermore, the T-lymphocyte proliferation response in mice induced by the PCV2 GST-ORF2-E@HMSNs remained at levels higher than those in mice immunized with the GST-ORF2-E protein, demonstrating that the proteins loaded into the HMSNs not only stimulate humoral and cellular immune responses but also induce persistent immune responses because of the release kinetics from HMSNs.", [["T-lymphocyte", "ANATOMY", 17, 29], ["HMSNs", "ANATOMY", 230, 235], ["cellular", "ANATOMY", 267, 275], ["T-lymphocyte", "CELL", 17, 29], ["mice", "ORGANISM", 56, 60], ["PCV2", "ORGANISM", 76, 80], ["GST", "GENE_OR_GENE_PRODUCT", 81, 84], ["ORF2", "GENE_OR_GENE_PRODUCT", 85, 89], ["mice", "ORGANISM", 138, 142], ["GST", "GENE_OR_GENE_PRODUCT", 162, 165], ["ORF2-E", "GENE_OR_GENE_PRODUCT", 166, 172], ["HMSNs", "GENE_OR_GENE_PRODUCT", 230, 235], ["cellular", "CELL", 267, 275], ["HMSNs", "SIMPLE_CHEMICAL", 374, 379], ["GST", "PROTEIN", 81, 84], ["ORF2", "DNA", 85, 89], ["E@HMSNs", "DNA", 90, 97], ["GST", "PROTEIN", 162, 165], ["ORF2", "DNA", 166, 170], ["E protein", "PROTEIN", 171, 180], ["HMSNs", "CELL_TYPE", 374, 379], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 56, 60], ["PCV2", "SPECIES", 76, 80], ["mice", "SPECIES", 138, 142], ["the PCV2 GST", "TEST", 72, 84], ["ORF2", "TEST", 85, 89], ["E@HMSNs", "TEST", 90, 97], ["the GST", "TEST", 158, 165], ["ORF2-E protein", "TEST", 166, 180], ["the proteins", "TEST", 201, 213], ["persistent immune responses", "PROBLEM", 309, 336], ["lymphocyte proliferation", "OBSERVATION", 19, 43], ["cellular immune", "OBSERVATION", 267, 282]]], ["Results confirmed HMSNs as an interesting an efficient vaccine nanovehicle for PCV2 treatment and further studies regarding virus therapy.Clinical Translation, Challenges and Future OutlookThe challenges of any designed nanostructure for therapeutic purposes consists on achieve good biocompatibility, biodegradability, complete and short clearance time as already stated by US FDA.", [["HMSNs", "SIMPLE_CHEMICAL", 18, 23], ["PCV2", "ORGANISM", 79, 83], ["PCV2", "SPECIES", 79, 83], ["an efficient vaccine nanovehicle", "TREATMENT", 42, 74], ["PCV2 treatment", "TREATMENT", 79, 93], ["further studies", "TEST", 98, 113], ["virus therapy", "TREATMENT", 124, 137], ["therapeutic purposes", "TEST", 238, 258]]], ["Considering the aforementioned, MSNs are very attractive as nanocarriers/nanotherapeutics because their interesting properties such as chemical and physical stabilities, size, morphology, surface and pores structures can be easily modulated to achieve good biological behavior and also effective drug loading and delivery at the desired site, comprising efficient nanoplatforms in most of pre-clinical assays.", [["surface", "ANATOMY", 188, 195], ["MSNs", "SIMPLE_CHEMICAL", 32, 36], ["surface", "CELLULAR_COMPONENT", 188, 195], ["nanocarriers/nanotherapeutics", "TREATMENT", 60, 89], ["effective drug loading", "TREATMENT", 286, 308], ["delivery", "TREATMENT", 313, 321], ["pre-clinical assays", "TEST", 389, 408], ["size", "OBSERVATION_MODIFIER", 170, 174]]], ["Internal, external or multi stimuli-responsive MSNs controlled drug delivery systems have been designed as smart nanoarchitectures that control pharmacokinetics parameters and emphasize the amazing properties of MSNs, stimulating researches towards their application in clinical trials (12,160,161).Clinical Translation, Challenges and Future OutlookWiesner group (162,163) described the fabrication of \u201cCornell dots or C dots\u201d (labeled 124IcRGDY\u2013PEG\u2013C dots) as the first nanosilica approved by the FDA for clinical assays.", [["124IcRGDY\u2013PEG\u2013C dots", "CHEMICAL", 437, 457], ["nanosilica", "CHEMICAL", 472, 482], ["PEG\u2013C dots", "CHEMICAL", 447, 457], ["nanosilica", "CHEMICAL", 472, 482], ["MSNs", "SIMPLE_CHEMICAL", 47, 51], ["MSNs", "SIMPLE_CHEMICAL", 212, 216], ["C dots\u201d", "SIMPLE_CHEMICAL", 420, 427], ["PEG\u2013C dots", "SIMPLE_CHEMICAL", 447, 457], ["Internal, external or multi stimuli-responsive MSNs controlled drug delivery systems", "TREATMENT", 0, 84], ["smart nanoarchitectures", "TREATMENT", 107, 130], ["pharmacokinetics parameters", "TEST", 144, 171], ["the amazing properties of MSNs", "TREATMENT", 186, 216], ["stimulating researches", "TREATMENT", 218, 240], ["\u201cCornell dots", "TREATMENT", 403, 416], ["C dots\u201d (labeled 124IcRGDY\u2013PEG\u2013C dots", "TREATMENT", 420, 457], ["clinical assays", "TEST", 507, 522]]], ["A smart core-shell nanosilica containing Cy5 dye and 124I radiolabels for optical-PET (positron emission tomography) dual imaging was fabricated and modified with PEG and cRGDY peptides as target agent for molecular expression in human melanoma xenografts (162,163).", [["melanoma xenografts", "ANATOMY", 236, 255], ["Cy5 dye", "CHEMICAL", 41, 48], ["PEG", "CHEMICAL", 163, 166], ["melanoma", "DISEASE", 236, 244], ["PEG", "CHEMICAL", 163, 166], ["shell nanosilica", "SIMPLE_CHEMICAL", 13, 29], ["Cy5 dye", "SIMPLE_CHEMICAL", 41, 48], ["124I radiolabels", "SIMPLE_CHEMICAL", 53, 69], ["PEG", "SIMPLE_CHEMICAL", 163, 166], ["cRGDY peptides", "SIMPLE_CHEMICAL", 171, 185], ["human", "ORGANISM", 230, 235], ["melanoma xenografts", "CANCER", 236, 255], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 230, 235], ["optical-PET", "TEST", 74, 85], ["positron emission tomography", "TEST", 87, 115], ["dual imaging", "TEST", 117, 129], ["PEG", "TREATMENT", 163, 166], ["cRGDY peptides", "TREATMENT", 171, 185], ["molecular expression in human melanoma xenografts", "TREATMENT", 206, 255], ["shell nanosilica", "OBSERVATION", 13, 29], ["melanoma xenografts", "OBSERVATION", 236, 255]]], ["Biological behavior was evaluated showing fast Cornell dots (C dots) excretion via the kidneys (~ 90%) and hepatobiliary route (~ 10%) with excretion times from 13 to 21 h (163).", [["kidneys", "ANATOMY", 87, 94], ["hepatobiliary", "ANATOMY", 107, 120], ["C dots", "SIMPLE_CHEMICAL", 61, 67], ["kidneys", "ORGAN", 87, 94], ["fast Cornell dots (C dots) excretion via the kidneys", "PROBLEM", 42, 94], ["hepatobiliary route", "TEST", 107, 126], ["excretion times", "TEST", 140, 155], ["kidneys", "ANATOMY", 87, 94], ["hepatobiliary", "ANATOMY", 107, 120]]], ["These smart silica-based nanostructures were successfully applied as nanoprobes for tumors detection and monitoring in clinical assays (163\u2013165).Clinical Translation, Challenges and Future OutlookChen et al .", [["tumors", "ANATOMY", 84, 90], ["silica", "CHEMICAL", 12, 18], ["tumors", "DISEASE", 84, 90], ["silica", "CHEMICAL", 12, 18], ["tumors", "CANCER", 84, 90], ["These smart silica-based nanostructures", "TREATMENT", 0, 39], ["tumors detection", "TEST", 84, 100], ["monitoring in clinical assays", "TEST", 105, 134], ["silica", "OBSERVATION_MODIFIER", 12, 18], ["based nanostructures", "OBSERVATION", 19, 39]]], ["(166) described the fabrication of C dots conjugated with the radiometal Zirconium-89 (89Zr, t1/2 = 78.4 h) using two different strategies: chelator-free and chelator-based radiolabeling.", [["Zirconium-89", "CHEMICAL", 73, 85], ["chelator", "CHEMICAL", 140, 148], ["chelator", "CHEMICAL", 158, 166], ["Zirconium-89", "CHEMICAL", 73, 85], ["C dots", "SIMPLE_CHEMICAL", 35, 41], ["radiometal Zirconium-89", "SIMPLE_CHEMICAL", 62, 85], ["chelator", "SIMPLE_CHEMICAL", 140, 148], ["chelator", "SIMPLE_CHEMICAL", 158, 166], ["the fabrication of C dots", "TREATMENT", 16, 41], ["the radiometal Zirconium", "TREATMENT", 58, 82], ["chelator", "TREATMENT", 140, 148], ["chelator-based radiolabeling", "TREATMENT", 158, 186]]], ["The best nanosystem (labeled 89Zr-DFO-cRGDY-PEG-C\u2032 dots) fabricated by chelator-based radiolabeling exhibited higher in vivo radiostability with good renal clearance, low reticuloendothelial system (RES) accumulation, high tumor uptake and target-to-background ratios relative to biological controls for human melanoma xenograft models.", [["renal", "ANATOMY", 150, 155], ["reticuloendothelial system", "ANATOMY", 171, 197], ["tumor", "ANATOMY", 223, 228], ["melanoma xenograft", "ANATOMY", 310, 328], ["89Zr-DFO-cRGDY-PEG-C\u2032 dots", "CHEMICAL", 29, 55], ["chelator", "CHEMICAL", 71, 79], ["tumor", "DISEASE", 223, 228], ["melanoma", "DISEASE", 310, 318], ["89Zr-DFO-cRGDY-PEG-C\u2032 dots", "CHEMICAL", 29, 55], ["89Zr-DFO", "SIMPLE_CHEMICAL", 29, 37], ["cRGDY-PEG-C\u2032 dots", "SIMPLE_CHEMICAL", 38, 55], ["chelator", "SIMPLE_CHEMICAL", 71, 79], ["renal", "ORGAN", 150, 155], ["reticuloendothelial system", "MULTI-TISSUE_STRUCTURE", 171, 197], ["RES", "SIMPLE_CHEMICAL", 199, 202], ["tumor", "CANCER", 223, 228], ["human", "ORGANISM", 304, 309], ["melanoma xenograft", "CANCER", 310, 328], ["cRGDY", "PROTEIN", 38, 43], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 304, 309], ["DFO", "TREATMENT", 34, 37], ["cRGDY", "TREATMENT", 38, 43], ["PEG-C\u2032 dots", "TREATMENT", 44, 55], ["chelator-based radiolabeling", "TREATMENT", 71, 99], ["low reticuloendothelial system (RES) accumulation", "PROBLEM", 167, 216], ["high tumor uptake", "PROBLEM", 218, 235], ["background ratios", "PROBLEM", 250, 267], ["human melanoma xenograft models", "TREATMENT", 304, 335], ["renal", "ANATOMY", 150, 155], ["clearance", "OBSERVATION", 156, 165], ["low", "OBSERVATION_MODIFIER", 167, 170], ["reticuloendothelial system", "ANATOMY", 171, 197], ["high", "OBSERVATION_MODIFIER", 218, 222], ["tumor uptake", "OBSERVATION", 223, 235], ["melanoma xenograft", "OBSERVATION", 310, 328]]], ["The first clinical trial using 89Zr-DFO-cRGDY-PEG-C\u2032 dots has been carried out for bioimaging of malignant brain tumors (NCT03465618).Clinical Translation, Challenges and Future OutlookKharlamov et al .", [["malignant brain tumors", "ANATOMY", 97, 119], ["89Zr-DFO-cRGDY-PEG-C\u2032 dots", "CHEMICAL", 31, 57], ["malignant brain tumors", "DISEASE", 97, 119], ["89Zr-DFO-cRGDY-PEG-C\u2032", "CHEMICAL", 31, 52], ["89Zr-DFO-cRGDY-PEG-C\u2032 dots", "SIMPLE_CHEMICAL", 31, 57], ["malignant brain tumors", "CANCER", 97, 119], ["89Zr-DFO-cRGDY-PEG-C\u2032 dots", "DNA", 31, 57], ["89Zr", "TREATMENT", 31, 35], ["DFO-cRGDY", "TREATMENT", 36, 45], ["PEG", "TREATMENT", 46, 49], ["C\u2032 dots", "TREATMENT", 50, 57], ["malignant brain tumors", "PROBLEM", 97, 119], ["Clinical Translation", "TREATMENT", 134, 154], ["Future OutlookKharlamov et al", "TREATMENT", 171, 200], ["malignant", "OBSERVATION_MODIFIER", 97, 106], ["brain", "ANATOMY", 107, 112], ["tumors", "OBSERVATION", 113, 119]]], ["(167) described the application of plasmonic photothermal therapy (PPTT) by using near-infrared (NIR) laser irradiation onto silica-gold nanoparticles (AuNPs) for Angioplasty and artery remodeling.", [["artery", "ANATOMY", 179, 185], ["silica-gold nanoparticles", "CHEMICAL", 125, 150], ["AuNPs", "CHEMICAL", 152, 157], ["silica", "CHEMICAL", 125, 131], ["silica-gold nanoparticles", "SIMPLE_CHEMICAL", 125, 150], ["AuNPs", "SIMPLE_CHEMICAL", 152, 157], ["artery", "MULTI-TISSUE_STRUCTURE", 179, 185], ["plasmonic photothermal therapy", "TREATMENT", 35, 65], ["PPTT", "TREATMENT", 67, 71], ["laser irradiation onto silica-gold nanoparticles (AuNPs)", "TREATMENT", 102, 158], ["Angioplasty and artery remodeling", "TREATMENT", 163, 196], ["Angioplasty", "OBSERVATION", 163, 174], ["artery", "ANATOMY", 179, 185]]], ["Interesting safety level and significant treatment efficacy with plaque burden reduction (79.4 mm3) was successfully achieved.", [["plaque", "ANATOMY", 65, 71], ["plaque", "DISEASE", 65, 71], ["plaque", "PATHOLOGICAL_FORMATION", 65, 71], ["significant treatment efficacy", "TREATMENT", 29, 59], ["plaque burden reduction", "TREATMENT", 65, 88], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["In this regard, authors (168) conducted a first-in-man trial (labeled NANOM-FIM, NCT01270139) by using multifunctional silica-AuNPs-dispersed on-artery patch associated with PPTT for atherosclerosis treatment.", [["artery", "ANATOMY", 145, 151], ["silica-AuNPs", "CHEMICAL", 119, 131], ["PPTT", "CHEMICAL", 174, 178], ["atherosclerosis", "DISEASE", 183, 198], ["silica", "CHEMICAL", 119, 125], ["silica-AuNPs", "SIMPLE_CHEMICAL", 119, 131], ["-artery", "MULTI-TISSUE_STRUCTURE", 144, 151], ["PPTT", "SIMPLE_CHEMICAL", 174, 178], ["man", "SPECIES", 51, 54], ["multifunctional silica-AuNPs", "TREATMENT", 103, 131], ["artery patch", "TREATMENT", 145, 157], ["PPTT", "TREATMENT", 174, 178], ["atherosclerosis treatment", "TREATMENT", 183, 208], ["artery", "ANATOMY", 145, 151], ["atherosclerosis", "OBSERVATION", 183, 198]]], ["Results exhibited significant regression of coronary atherosclerosis with good biocompatibility and no significant toxicity besides lower risk of cardiovascular death in humans.", [["coronary", "ANATOMY", 44, 52], ["cardiovascular", "ANATOMY", 146, 160], ["atherosclerosis", "DISEASE", 53, 68], ["toxicity", "DISEASE", 115, 123], ["cardiovascular death", "DISEASE", 146, 166], ["coronary", "MULTI-TISSUE_STRUCTURE", 44, 52], ["cardiovascular", "ANATOMICAL_SYSTEM", 146, 160], ["humans", "ORGANISM", 170, 176], ["humans", "SPECIES", 170, 176], ["humans", "SPECIES", 170, 176], ["coronary atherosclerosis", "PROBLEM", 44, 68], ["significant toxicity", "PROBLEM", 103, 123], ["cardiovascular death in humans", "PROBLEM", 146, 176], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["regression", "OBSERVATION_MODIFIER", 30, 40], ["coronary", "ANATOMY", 44, 52], ["atherosclerosis", "OBSERVATION", 53, 68], ["good", "OBSERVATION_MODIFIER", 74, 78], ["biocompatibility", "OBSERVATION", 79, 95], ["no", "UNCERTAINTY", 100, 102], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["toxicity", "OBSERVATION", 115, 123], ["cardiovascular death", "OBSERVATION", 146, 166]]], ["This bioengineered nanostructure offers great potential for further atherosclerosis theranostic purposes.Clinical Translation, Challenges and Future OutlookThe clinical applications of aforementioned silica-based nanostructures encourage researchers focuses on MSNs clinical translation and further commercialization.", [["atherosclerosis", "DISEASE", 68, 83], ["silica", "CHEMICAL", 200, 206], ["silica", "CHEMICAL", 200, 206], ["silica", "SIMPLE_CHEMICAL", 200, 206], ["This bioengineered nanostructure", "TREATMENT", 0, 32], ["further atherosclerosis theranostic purposes", "PROBLEM", 60, 104], ["aforementioned silica-based nanostructures", "TREATMENT", 185, 227], ["further commercialization", "TREATMENT", 291, 316], ["atherosclerosis", "OBSERVATION", 68, 83]]], ["Although several researches have been performed in the last two decades towards the biological behavior and preclinical evaluation of smart and engineered stimuli-responsive MSNs for monitoring and/or therapeutic purposes (12,88,89,96,161,169\u2013171), achieve their clinical translation is still a great challenge requiring long-term stability, scale-up of these nanostructures (from bench to industrial scale-up) and overcome obstacles in animal trials and regulating authorities evaluation (160,161,171).", [["MSNs", "CELL", 174, 178], ["preclinical evaluation", "TEST", 108, 130], ["monitoring", "TEST", 183, 193], ["therapeutic purposes", "TEST", 201, 221], ["long-term stability", "TREATMENT", 321, 340], ["regulating authorities evaluation", "TEST", 455, 488], ["long-term stability", "OBSERVATION_MODIFIER", 321, 340]]], ["Despites the numerously reports concerning multifunctional MSNs fabrication, their scale-up is rarely described.", [["multifunctional MSNs fabrication", "TREATMENT", 43, 75], ["MSNs fabrication", "OBSERVATION", 59, 75]]], ["Some authors (172,173) reported large-scale synthesis of dense and hollow mesoporous silica micro/nanoparticles (173) and monodisperse small MSNs with a fine size distribution at room temperature (27 \u00b0C) (172), both methods using CTAB as template.", [["CTAB", "CHEMICAL", 230, 234], ["silica", "CHEMICAL", 85, 91], ["CTAB", "CHEMICAL", 230, 234], ["CTAB", "SIMPLE_CHEMICAL", 230, 234], ["large-scale synthesis of dense", "PROBLEM", 32, 62], ["hollow mesoporous silica micro/nanoparticles", "TEST", 67, 111], ["monodisperse small MSNs", "PROBLEM", 122, 145], ["large", "OBSERVATION_MODIFIER", 32, 37], ["dense", "OBSERVATION_MODIFIER", 57, 62], ["hollow", "ANATOMY_MODIFIER", 67, 73], ["mesoporous silica", "OBSERVATION", 74, 91], ["monodisperse", "OBSERVATION_MODIFIER", 122, 134], ["small", "OBSERVATION_MODIFIER", 135, 140], ["MSNs", "OBSERVATION", 141, 145], ["fine", "OBSERVATION_MODIFIER", 153, 157], ["size", "OBSERVATION_MODIFIER", 158, 162], ["distribution", "OBSERVATION_MODIFIER", 163, 175]]], ["The structural stability of nanoparticles is usually determined by interaction with the biological environment and between themselves.", [["structural", "OBSERVATION_MODIFIER", 4, 14], ["stability", "OBSERVATION_MODIFIER", 15, 24], ["nanoparticles", "OBSERVATION", 28, 41]]], ["Poor colloidal and thermal stabilities can result in drawbacks with long-term storage and nanosystems administration.", [["nanosystems", "SIMPLE_CHEMICAL", 90, 101], ["Poor colloidal and thermal stabilities", "PROBLEM", 0, 38], ["long-term storage", "TREATMENT", 68, 85], ["nanosystems administration", "TREATMENT", 90, 116], ["colloidal", "OBSERVATION_MODIFIER", 5, 14], ["thermal stabilities", "OBSERVATION_MODIFIER", 19, 38]]], ["In this sense, MSNs present robust silica framework and exceptional electronic architecture easily optimized, making them amazing nanoarchitectures with interesting structural stability for biomedical applications (174).", [["silica", "CHEMICAL", 35, 41], ["MSNs", "SIMPLE_CHEMICAL", 15, 19], ["silica framework", "OBSERVATION", 35, 51]]], ["Additionally, authors reported that the association of MSNs with metals such as iron, Pt, Al and others, can improve the nanoplatforms thermal and physical stabilities considering a critical ratio of metal to silica content (174).Clinical Translation, Challenges and Future OutlookUp to now, preclinical assays related to MSNs were successfully performed whereas no MSNs have been described in clinical trials.", [["MSNs", "CHEMICAL", 55, 59], ["metals", "CHEMICAL", 65, 71], ["iron", "CHEMICAL", 80, 84], ["Pt", "CHEMICAL", 86, 88], ["Al", "CHEMICAL", 90, 92], ["silica", "CHEMICAL", 209, 215], ["iron", "CHEMICAL", 80, 84], ["Pt", "CHEMICAL", 86, 88], ["Al", "CHEMICAL", 90, 92], ["silica", "CHEMICAL", 209, 215], ["MSNs", "SIMPLE_CHEMICAL", 55, 59], ["metals", "SIMPLE_CHEMICAL", 65, 71], ["iron", "SIMPLE_CHEMICAL", 80, 84], ["Pt", "SIMPLE_CHEMICAL", 86, 88], ["Al", "SIMPLE_CHEMICAL", 90, 92], ["silica", "SIMPLE_CHEMICAL", 209, 215], ["MSNs", "CELL", 322, 326], ["MSNs", "CELL", 366, 370], ["MSNs", "DNA", 322, 326], ["MSNs", "DNA", 366, 370], ["iron", "TREATMENT", 80, 84], ["the nanoplatforms thermal and physical stabilities", "PROBLEM", 117, 167], ["preclinical assays", "TEST", 292, 310], ["MSNs", "TREATMENT", 322, 326], ["MSNs", "PROBLEM", 366, 370], ["silica content", "OBSERVATION", 209, 223]]], ["Authors (160) suggested that the clinical translation has failed due to the large physiological distinction between small animals and humans, indicating that animal models are not the better indication for further nanostructures success in humans.", [["humans", "ORGANISM", 134, 140], ["humans", "ORGANISM", 240, 246], ["humans", "SPECIES", 134, 140], ["humans", "SPECIES", 240, 246], ["humans", "SPECIES", 134, 140], ["humans", "SPECIES", 240, 246], ["the clinical translation", "PROBLEM", 29, 53], ["the large physiological distinction between small animals and humans", "PROBLEM", 72, 140], ["large", "OBSERVATION_MODIFIER", 76, 81], ["physiological distinction", "OBSERVATION", 82, 107], ["small", "OBSERVATION_MODIFIER", 116, 121], ["animals", "OBSERVATION", 122, 129]]], ["In addition, authors suggest that rather than prolonged xenografting experiments (in cancer treatment), positive animal toxicological results could allow to start phase 1 of clinical trials.Clinical Translation, Challenges and Future OutlookAnother concern related to MSNs or any nanostructures for clinical translation relies on regulatory agencies (as US FDA) evaluation.", [["cancer", "ANATOMY", 85, 91], ["cancer", "DISEASE", 85, 91], ["cancer", "CANCER", 85, 91], ["MSNs", "CELL", 268, 272], ["MSNs", "DNA", 268, 272], ["prolonged xenografting experiments", "TREATMENT", 46, 80], ["cancer treatment", "TREATMENT", 85, 101], ["clinical trials", "TREATMENT", 174, 189], ["MSNs", "PROBLEM", 268, 272], ["any nanostructures", "PROBLEM", 276, 294], ["evaluation", "TEST", 362, 372]]], ["Currently, nanostructured materials are evaluated as small-molecule drugs, being that some nanosystems can act only as nanoprobes or without loaded drugs.", [["nanosystems", "SIMPLE_CHEMICAL", 91, 102], ["small-molecule drugs", "TREATMENT", 53, 73], ["loaded drugs", "TREATMENT", 141, 153]]], ["In this sense, the actual evaluation processes by agencies comprise a bottleneck that allow only a few percentages of nanostructures can be approved for commercial purposes.", [["the actual evaluation", "TEST", 15, 36]]], ["Authors suggested that regulatory agencies could create specific evaluation category for nanomedicines aiming to streamline their translation (160,161,171).Clinical Translation, Challenges and Future OutlookFinally, taking into account all abovementioned challenges, the tunable properties of MSNs and recent advances regarding smart and multi stimuli-responsive MSNs for diagnosis, therapy or theranostic applications, we can expect in the next years MSNs-based nanoplatforms and other silica-based nanosystems will become approved by FDA, impacting the treatment way and global human health.ACKNOWLEDGMENTS AND DISCLOSURES ::: ConclusionsThis study was financed in part by the Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de Ensino Superior \u2013 Brasil (CAPES) \u2013 Finance code \u2013 001.", [["silica", "CHEMICAL", 487, 493], ["silica", "CHEMICAL", 487, 493], ["MSNs", "CELL", 293, 297], ["MSNs", "CELL", 363, 367], ["MSNs", "SIMPLE_CHEMICAL", 452, 456], ["silica", "SIMPLE_CHEMICAL", 487, 493], ["human", "ORGANISM", 580, 585], ["human", "SPECIES", 580, 585], ["human", "SPECIES", 580, 585], ["specific evaluation", "TEST", 56, 75], ["nanomedicines", "TREATMENT", 89, 102], ["smart and multi stimuli-responsive MSNs", "TREATMENT", 328, 367], ["therapy", "TREATMENT", 383, 390], ["theranostic applications", "TREATMENT", 394, 418], ["nanoplatforms", "TREATMENT", 463, 476], ["other silica-based nanosystems", "TREATMENT", 481, 511], ["This study", "TEST", 640, 650]]], ["The authors also are grateful to the S\u00e3o Paulo Research Foundation (FAPESP, Brazil, Grant #2018/25377-3) for research fellowship and financial support.", [["financial support", "TREATMENT", 133, 150]]], ["This study is part of the National Institute of Science and Technology in Pharmaceutical Nanotechnology: a transdisciplinary approach INCT-NANOFARMA, which is supported by S\u00e3o Paulo Research Foundation (FAPESP, Brazil) Grant #2014/50928-2, and by \"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico\" (CNPq, Brazil) Grant # 465687/2014-8.", [["This study", "TEST", 0, 10]]]], "0c0dbf4bc137fb862c9d69c3a771a26e4a28d01d": [["IntroductionHLH/MAS is thought to be a multisystem inflammatory disorder resulting from a pro-inflammatory \"cytokine storm\" from excessively activated lymphocytes and macrophages [1] .", [["lymphocytes", "ANATOMY", 151, 162], ["macrophages", "ANATOMY", 167, 178], ["inflammatory disorder", "DISEASE", 51, 72], ["lymphocytes", "CELL", 151, 162], ["macrophages", "CELL", 167, 178], ["cytokine", "PROTEIN", 108, 116], ["activated lymphocytes", "CELL_TYPE", 141, 162], ["macrophages", "CELL_TYPE", 167, 178], ["MAS", "PROBLEM", 16, 19], ["a multisystem inflammatory disorder", "PROBLEM", 37, 72], ["a pro-inflammatory \"cytokine storm", "PROBLEM", 88, 122], ["excessively activated lymphocytes and macrophages", "PROBLEM", 129, 178], ["thought to be", "UNCERTAINTY", 23, 36], ["multisystem", "OBSERVATION_MODIFIER", 39, 50], ["inflammatory", "OBSERVATION", 51, 63], ["pro-inflammatory", "OBSERVATION_MODIFIER", 90, 106]]], ["Hemophagocytic syndromes are divided into primary and secondary forms.", [["Hemophagocytic syndromes", "DISEASE", 0, 24], ["Hemophagocytic syndromes", "PROBLEM", 0, 24], ["secondary forms", "OBSERVATION", 54, 69]]], ["Primary cases are rare (1 in 50,000 live births), commonly present in the first year of life, and are often triggered by infection [2] .", [["infection", "DISEASE", 121, 130], ["infection", "OBSERVATION", 121, 130]]], ["They include familial, or primary, forms of hemophagocytic lymphohistiocytosis (fHLH) that have specific genetic homozygous or compound heterozygous loss-of-function mutations in perforin-mediated cytolytic pathway proteins (e.g., PRF1, STX11, UNC13D, UNC18-2) employed by CD8 T cells and natural killer (NK) cells [3] [4] [5] [6] .", [["CD8 T cells", "ANATOMY", 273, 284], ["natural killer (NK) cells", "ANATOMY", 289, 314], ["familial", "DISEASE", 13, 21], ["hemophagocytic lymphohistiocytosis", "DISEASE", 44, 78], ["fHLH", "DISEASE", 80, 84], ["hemophagocytic lymphohistiocytosis", "CANCER", 44, 78], ["fHLH", "CANCER", 80, 84], ["perforin", "GENE_OR_GENE_PRODUCT", 179, 187], ["PRF1", "GENE_OR_GENE_PRODUCT", 231, 235], ["STX11", "GENE_OR_GENE_PRODUCT", 237, 242], ["UNC13D", "GENE_OR_GENE_PRODUCT", 244, 250], ["UNC18-2", "GENE_OR_GENE_PRODUCT", 252, 259], ["CD8 T cells", "CELL", 273, 284], ["natural killer (NK) cells", "CELL", 289, 314], ["perforin", "PROTEIN", 179, 187], ["cytolytic pathway proteins", "PROTEIN", 197, 223], ["PRF1", "PROTEIN", 231, 235], ["STX11", "PROTEIN", 237, 242], ["UNC13D", "PROTEIN", 244, 250], ["UNC18", "PROTEIN", 252, 257], ["CD8 T cells", "CELL_TYPE", 273, 284], ["natural killer (NK) cells", "CELL_TYPE", 289, 314], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 44, 78], ["compound heterozygous loss", "PROBLEM", 127, 153], ["function mutations", "PROBLEM", 157, 175], ["perforin", "TEST", 179, 187], ["proteins", "TEST", 215, 223], ["PRF1", "TEST", 231, 235], ["STX11", "TEST", 237, 242], ["UNC13D", "TEST", 244, 250], ["UNC18", "TEST", 252, 257], ["cells", "TEST", 309, 314], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 44, 78], ["heterozygous loss", "OBSERVATION", 136, 153]]], ["Children with certain immunodeficiency syndromes, such as Ch\u00e9diak-Higashi syndrome, type II Hermansky-Pudlak syndrome, and type II Griscelli syndrome [7] , have associated genetic defects in cytolysis and are also at risk for developing fHLH.", [["immunodeficiency syndromes", "DISEASE", 22, 48], ["Ch\u00e9diak-Higashi syndrome", "DISEASE", 58, 82], ["Hermansky-Pudlak syndrome", "DISEASE", 92, 117], ["type II Griscelli syndrome", "DISEASE", 123, 149], ["defects in cytolysis", "DISEASE", 180, 200], ["fHLH", "DISEASE", 237, 241], ["Children", "ORGANISM", 0, 8], ["fHLH", "CANCER", 237, 241], ["Children", "SPECIES", 0, 8], ["certain immunodeficiency syndromes", "PROBLEM", 14, 48], ["Ch\u00e9diak-Higashi syndrome", "PROBLEM", 58, 82], ["type II Hermansky", "PROBLEM", 84, 101], ["Pudlak syndrome", "PROBLEM", 102, 117], ["type II Griscelli syndrome", "PROBLEM", 123, 149], ["genetic defects in cytolysis", "PROBLEM", 172, 200], ["developing fHLH", "PROBLEM", 226, 241], ["Pudlak syndrome", "OBSERVATION", 102, 117], ["defects", "OBSERVATION", 180, 187], ["cytolysis", "OBSERVATION", 191, 200]]], ["Specific X-linked immunodeficiencies (signaling-lymphocytic-activationmolecule-associated protein (SAP) and X-linked inhibitor of apoptosis (XIAP) deficiencies) are also associated with Epstein-Barr virus (EBV) triggered HLH [8] [9] [10] .", [["immunodeficiencies", "DISEASE", 18, 36], ["HLH", "DISEASE", 221, 224], ["signaling-lymphocytic-activationmolecule-associated protein", "GENE_OR_GENE_PRODUCT", 38, 97], ["SAP", "GENE_OR_GENE_PRODUCT", 99, 102], ["X-linked inhibitor of apoptosis", "GENE_OR_GENE_PRODUCT", 108, 139], ["XIAP", "GENE_OR_GENE_PRODUCT", 141, 145], ["Epstein-Barr virus", "ORGANISM", 186, 204], ["EBV", "ORGANISM", 206, 209], ["signaling-lymphocytic-activationmolecule-associated protein", "PROTEIN", 38, 97], ["SAP", "PROTEIN", 99, 102], ["XIAP", "PROTEIN", 141, 145], ["Epstein-Barr virus", "SPECIES", 186, 204], ["EBV", "SPECIES", 206, 209], ["Specific X-linked immunodeficiencies", "PROBLEM", 0, 36], ["lymphocytic-activationmolecule-associated protein (SAP)", "PROBLEM", 48, 103], ["X-linked inhibitor of apoptosis (XIAP) deficiencies", "PROBLEM", 108, 159], ["Epstein-Barr virus", "PROBLEM", 186, 204], ["HLH", "PROBLEM", 221, 224], ["immunodeficiencies", "OBSERVATION", 18, 36], ["lymphocytic", "OBSERVATION_MODIFIER", 48, 59], ["Barr virus", "OBSERVATION", 194, 204]]], ["Acquired or secondary forms of HLH (sHLH) are usually associated with conditions that cause chronic immune dysregulation, such as rheumatologic diseases [e.g., systemic juvenile idiopathic arthritis (sJIA), systemic lupus erythematosus (SLE)] and certain malignancies (e.g., leukemias, lymphomas).", [["malignancies", "ANATOMY", 255, 267], ["leukemias", "ANATOMY", 275, 284], ["lymphomas", "ANATOMY", 286, 295], ["HLH", "DISEASE", 31, 34], ["sHLH", "DISEASE", 36, 40], ["rheumatologic diseases", "DISEASE", 130, 152], ["juvenile idiopathic arthritis", "DISEASE", 169, 198], ["JIA", "DISEASE", 201, 204], ["systemic lupus erythematosus", "DISEASE", 207, 235], ["SLE", "DISEASE", 237, 240], ["malignancies", "DISEASE", 255, 267], ["leukemias", "DISEASE", 275, 284], ["lymphomas", "DISEASE", 286, 295], ["sHLH", "CANCER", 36, 40], ["malignancies", "CANCER", 255, 267], ["leukemias", "CANCER", 275, 284], ["lymphomas", "CANCER", 286, 295], ["HLH (sHLH)", "PROBLEM", 31, 41], ["chronic immune dysregulation", "PROBLEM", 92, 120], ["rheumatologic diseases", "PROBLEM", 130, 152], ["systemic juvenile idiopathic arthritis", "PROBLEM", 160, 198], ["sJIA)", "PROBLEM", 200, 205], ["systemic lupus erythematosus (SLE)", "PROBLEM", 207, 241], ["certain malignancies", "PROBLEM", 247, 267], ["leukemias", "PROBLEM", 275, 284], ["lymphomas", "PROBLEM", 286, 295], ["HLH", "OBSERVATION", 31, 34], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["immune dysregulation", "OBSERVATION", 100, 120], ["systemic", "OBSERVATION_MODIFIER", 160, 168], ["juvenile", "OBSERVATION_MODIFIER", 169, 177], ["idiopathic", "OBSERVATION_MODIFIER", 178, 188], ["arthritis", "OBSERVATION", 189, 198], ["systemic", "ANATOMY", 207, 215], ["lupus erythematosus", "OBSERVATION", 216, 235], ["malignancies", "OBSERVATION", 255, 267]]], ["Infectious agents, particularly EBV and other herpesvirus family members, may be the sHLH trigger, although identifiable infections are not always present [7] .", [["infections", "DISEASE", 121, 131], ["EBV", "ORGANISM", 32, 35], ["herpesvirus", "ORGANISM", 46, 57], ["EBV", "SPECIES", 32, 35], ["Infectious agents", "TREATMENT", 0, 17], ["identifiable infections", "PROBLEM", 108, 131], ["infections", "OBSERVATION", 121, 131]]], ["In addition, up to 40% of sHLH and macrophage activation syndrome (MAS) patients have been found to possess heterozygous (some dominant negative) mutations in known fHLH genes.", [["sHLH", "ANATOMY", 26, 30], ["macrophage", "ANATOMY", 35, 45], ["MAS", "DISEASE", 67, 70], ["sHLH", "GENE_OR_GENE_PRODUCT", 26, 30], ["macrophage", "CELL", 35, 45], ["patients", "ORGANISM", 72, 80], ["fHLH", "GENE_OR_GENE_PRODUCT", 165, 169], ["fHLH genes", "DNA", 165, 175], ["patients", "SPECIES", 72, 80], ["sHLH", "PROBLEM", 26, 30], ["macrophage activation syndrome", "PROBLEM", 35, 65], ["heterozygous (some dominant negative) mutations in known fHLH genes", "PROBLEM", 108, 175]]], ["Thus, some investigators consider MAS, sHLH, and fHLH to lie on a spectrum of disease [11] .IntroductionIn the clinical setting, the distinction between primary and secondary forms of HLH is less clear and even considered artificial by some.", [["HLH", "DISEASE", 184, 187], ["MAS", "PROBLEM", 34, 37], ["disease", "PROBLEM", 78, 85], ["HLH", "PROBLEM", 184, 187], ["disease", "OBSERVATION", 78, 85], ["HLH", "OBSERVATION", 184, 187]]], ["Furthermore, in some studies, only 40% of primary HLH cases are found to have recognized genetic mutations.", [["HLH", "DISEASE", 50, 53], ["HLH", "CANCER", 50, 53], ["some studies", "TEST", 16, 28], ["primary HLH cases", "TEST", 42, 59], ["genetic mutations", "PROBLEM", 89, 106], ["genetic mutations", "OBSERVATION", 89, 106]]], ["Moreover, both primary and secondary HLH are known to be precipitated by infections [14, 15] .", [["HLH", "DISEASE", 37, 40], ["infections", "DISEASE", 73, 83], ["secondary HLH", "PROBLEM", 27, 40], ["infections", "PROBLEM", 73, 83], ["secondary HLH", "OBSERVATION", 27, 40], ["infections", "OBSERVATION", 73, 83]]], ["Finally, as mentioned previously, many patients with sHLH have heterozygous mutations in known fHLHassociated genes, thus blurring the distinction between fHLH and sHLH.", [["sHLH", "DISEASE", 53, 57], ["fHLH", "DISEASE", 155, 159], ["sHLH", "DISEASE", 164, 168], ["patients", "ORGANISM", 39, 47], ["sHLH", "CANCER", 53, 57], ["fHLHassociated", "GENE_OR_GENE_PRODUCT", 95, 109], ["fHLH", "CANCER", 155, 159], ["sHLH", "CANCER", 164, 168], ["fHLHassociated genes", "DNA", 95, 115], ["patients", "SPECIES", 39, 47], ["heterozygous mutations", "PROBLEM", 63, 85], ["known fHLHassociated genes", "PROBLEM", 89, 115], ["blurring the distinction between fHLH and sHLH", "PROBLEM", 122, 168], ["fHLHassociated genes", "OBSERVATION", 95, 115]]], ["Regardless of terminology, the individual patient needs to be treated appropriately.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49]]], ["At present, most clinicians would agree that clear-cut infantile cases of fHLH will need bone marrow transplantation, typically preceded by an aggressive chemotherapeutic regimen which includes etoposide and corticosteroids.", [["bone marrow", "ANATOMY", 89, 100], ["fHLH", "DISEASE", 74, 78], ["etoposide", "CHEMICAL", 194, 203], ["etoposide", "CHEMICAL", 194, 203], ["corticosteroids", "CHEMICAL", 208, 223], ["fHLH", "CANCER", 74, 78], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 89, 100], ["etoposide", "SIMPLE_CHEMICAL", 194, 203], ["corticosteroids", "SIMPLE_CHEMICAL", 208, 223], ["fHLH", "PROBLEM", 74, 78], ["bone marrow transplantation", "TREATMENT", 89, 116], ["an aggressive chemotherapeutic regimen", "TREATMENT", 140, 178], ["etoposide", "TREATMENT", 194, 203], ["corticosteroids", "TREATMENT", 208, 223], ["bone marrow", "ANATOMY", 89, 100]]], ["In addition, identified infectious triggers should also be treated appropriately.", [["infectious triggers", "PROBLEM", 24, 43], ["infectious", "OBSERVATION", 24, 34]]], ["For all other children and adults with HLH, the most appropriate treatment remains unclear.", [["HLH", "DISEASE", 39, 42], ["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22], ["HLH", "PROBLEM", 39, 42]]], ["Etoposide is quite toxic, often leading to pancytopenia itself and increasing the risk of secondary sepsis as well as increased risk of secondary malignancies [14, 16] .", [["malignancies", "ANATOMY", 146, 158], ["Etoposide", "CHEMICAL", 0, 9], ["pancytopenia", "DISEASE", 43, 55], ["sepsis", "DISEASE", 100, 106], ["malignancies", "DISEASE", 146, 158], ["Etoposide", "CHEMICAL", 0, 9], ["Etoposide", "SIMPLE_CHEMICAL", 0, 9], ["malignancies", "CANCER", 146, 158], ["Etoposide", "TREATMENT", 0, 9], ["quite toxic", "PROBLEM", 13, 24], ["pancytopenia itself", "PROBLEM", 43, 62], ["secondary sepsis", "PROBLEM", 90, 106], ["secondary malignancies", "PROBLEM", 136, 158], ["toxic", "OBSERVATION_MODIFIER", 19, 24], ["pancytopenia", "OBSERVATION", 43, 55], ["secondary", "OBSERVATION_MODIFIER", 90, 99], ["sepsis", "OBSERVATION", 100, 106], ["secondary", "OBSERVATION_MODIFIER", 136, 145], ["malignancies", "OBSERVATION", 146, 158]]], ["Novel approaches have been anecdotally reported to dampen the overly exuberant immune response and control the cytokine storm and associated multiorgan dysfunction.", [["multiorgan", "ANATOMY", 141, 151], ["multiorgan dysfunction", "DISEASE", 141, 163], ["multiorgan", "ORGAN", 141, 151], ["cytokine", "PROTEIN", 111, 119], ["the cytokine storm", "PROBLEM", 107, 125], ["multiorgan dysfunction", "PROBLEM", 141, 163], ["exuberant", "OBSERVATION_MODIFIER", 69, 78], ["immune response", "OBSERVATION", 79, 94], ["cytokine storm", "OBSERVATION", 111, 125], ["multiorgan dysfunction", "OBSERVATION", 141, 163]]], ["Most notably, targeting of specific pro-inflammatory cytokines [e.g., interleukin-1 (IL-1) and interferon-gamma (IFN-\u03b3)] seems promising and lacks the toxicity associated with traditional chemotherapeutic approaches [17, 18] .IntroductionDespite advances in the current treatment protocols, the cure rate for HLH is low.", [["toxicity", "DISEASE", 151, 159], ["HLH", "DISEASE", 309, 312], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 70, 83], ["IL-1", "GENE_OR_GENE_PRODUCT", 85, 89], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 95, 111], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 113, 118], ["pro-inflammatory cytokines", "PROTEIN", 36, 62], ["interleukin-1 (IL-1", "PROTEIN", 70, 89], ["interferon-gamma", "PROTEIN", 95, 111], ["IFN", "PROTEIN", 113, 116], ["specific pro-inflammatory cytokines", "TEST", 27, 62], ["interleukin", "TEST", 70, 81], ["IL", "TEST", 85, 87], ["interferon", "TREATMENT", 95, 105], ["the toxicity", "PROBLEM", 147, 159], ["traditional chemotherapeutic approaches", "TREATMENT", 176, 215], ["the current treatment protocols", "TREATMENT", 258, 289], ["the cure rate", "TEST", 291, 304], ["HLH", "PROBLEM", 309, 312], ["gamma", "ANATOMY", 106, 111]]], ["Untreated cases of fHLH have a median survival of less than 2-6 months after diagnosis [19] .", [["fHLH", "DISEASE", 19, 23], ["fHLH", "CANCER", 19, 23], ["Untreated cases of fHLH", "PROBLEM", 0, 23]]], ["In a nationwide registry of pediatric patients with HLH in Korea, the 5-year overall survival rate was 68% (38% in the familial group and 81% in the presumed secondary group) [20] .", [["HLH", "DISEASE", 52, 55], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["HLH", "PROBLEM", 52, 55], ["survival rate", "TEST", 85, 98], ["HLH", "OBSERVATION", 52, 55]]], ["The prognosis for cases of sHLH varies depending on the underlying etiology, for example, the mortality rate is reported to be lower in cases associated with rheumatic diseases (8-22%) and greater when it is associated with malignancy.", [["sHLH", "DISEASE", 27, 31], ["rheumatic diseases", "DISEASE", 158, 176], ["malignancy", "DISEASE", 224, 234], ["sHLH", "CANCER", 27, 31], ["cases of sHLH varies", "PROBLEM", 18, 38], ["the mortality rate", "TEST", 90, 108], ["rheumatic diseases", "PROBLEM", 158, 176], ["malignancy", "PROBLEM", 224, 234], ["rheumatic", "OBSERVATION_MODIFIER", 158, 167], ["associated with", "UNCERTAINTY", 208, 223], ["malignancy", "OBSERVATION", 224, 234]]], ["The median overall survival is about 36-67% [21] [22] [23] .Pathophysiology and Cytokine StormMAS/HLH develops as a \"cytokine storm\" which is often triggered by infectious, rheumatologic, and oncologic diseases [24] .", [["HLH", "DISEASE", 98, 101], ["infectious, rheumatologic, and oncologic diseases", "DISEASE", 161, 210], ["Cytokine", "GENE_OR_GENE_PRODUCT", 80, 88], ["Cytokine", "PROTEIN", 80, 88], ["HLH", "PROTEIN", 98, 101], ["cytokine", "PROTEIN", 117, 125], ["Pathophysiology", "PROBLEM", 60, 75], ["Cytokine StormMAS", "PROBLEM", 80, 97], ["HLH", "PROBLEM", 98, 101], ["a \"cytokine storm", "PROBLEM", 114, 131], ["oncologic diseases", "PROBLEM", 192, 210], ["Cytokine StormMAS", "OBSERVATION", 80, 97], ["HLH", "OBSERVATION", 98, 101], ["infectious", "OBSERVATION_MODIFIER", 161, 171]]], ["Although not well defined, the pro-inflammatory cytokines associated with MAS/HLH likely include IL-1, IL-6, IL-12, IL-18, IFN-\u03b3, and tumor necrosis factor (TNF) [25, 26] (Table 14 .1).", [["HLH", "DISEASE", 78, 81], ["tumor necrosis", "DISEASE", 134, 148], ["IL-1", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["IL-12", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-18", "GENE_OR_GENE_PRODUCT", 116, 121], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 123, 128], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 134, 155], ["TNF", "GENE_OR_GENE_PRODUCT", 157, 160], ["pro-inflammatory cytokines", "PROTEIN", 31, 57], ["IL-18", "PROTEIN", 116, 121], ["IFN", "PROTEIN", 123, 126], ["\u03b3", "PROTEIN", 127, 128], ["tumor necrosis factor", "PROTEIN", 134, 155], ["TNF", "PROTEIN", 157, 160], ["the pro-inflammatory cytokines", "PROBLEM", 27, 57], ["MAS/HLH", "PROBLEM", 74, 81], ["IL", "TEST", 97, 99], ["IL", "TEST", 103, 105], ["IL", "TEST", 109, 111], ["IL", "TEST", 116, 118], ["IFN", "TEST", 123, 126], ["tumor necrosis factor", "PROBLEM", 134, 155], ["TNF", "TEST", 157, 160], ["not", "UNCERTAINTY", 9, 12], ["well defined", "OBSERVATION_MODIFIER", 13, 25], ["pro-inflammatory cytokines", "OBSERVATION", 31, 57], ["HLH", "OBSERVATION", 78, 81], ["tumor", "OBSERVATION_MODIFIER", 134, 139], ["necrosis", "OBSERVATION", 140, 148]]], ["Also IL-27, macrophage colony-stimulating factor (M-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) may be increased [27] [28] [29] .", [["IL-27", "GENE_OR_GENE_PRODUCT", 5, 10], ["macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 12, 48], ["M-CSF", "GENE_OR_GENE_PRODUCT", 50, 55], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 62, 110], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 112, 118], ["IL-27", "PROTEIN", 5, 10], ["macrophage colony-stimulating factor", "PROTEIN", 12, 48], ["CSF", "PROTEIN", 52, 55], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 62, 110], ["GM", "PROTEIN", 112, 114], ["CSF", "PROTEIN", 115, 118], ["IL", "TEST", 5, 7], ["macrophage colony", "TEST", 12, 29], ["stimulating factor", "TEST", 30, 48], ["granulocyte", "TEST", 62, 73], ["macrophage colony", "TEST", 74, 91], ["stimulating factor", "TEST", 92, 110], ["GM-CSF", "TEST", 112, 118], ["granulocyte", "ANATOMY", 62, 73], ["macrophage colony", "OBSERVATION", 74, 91]]], ["Furthermore, chemokines, such as IL-8/CXCL8, MIG/CXCL9, IP10/CXCL10, I-TAC/CXCL11, MCP-1/CCL2, MIP-1\u03b1/CCL3, and MIP-1\u03b2/ CCL4, have been reported to be increased [26, [30] [31] [32] .", [["IL-8", "GENE_OR_GENE_PRODUCT", 33, 37], ["CXCL8", "GENE_OR_GENE_PRODUCT", 38, 43], ["MIG", "GENE_OR_GENE_PRODUCT", 45, 48], ["CXCL9", "GENE_OR_GENE_PRODUCT", 49, 54], ["IP10", "GENE_OR_GENE_PRODUCT", 56, 60], ["CXCL10", "GENE_OR_GENE_PRODUCT", 61, 67], ["I-TAC", "GENE_OR_GENE_PRODUCT", 69, 74], ["CXCL11", "GENE_OR_GENE_PRODUCT", 75, 81], ["MCP-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["CCL2", "GENE_OR_GENE_PRODUCT", 89, 93], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 95, 101], ["CCL3", "GENE_OR_GENE_PRODUCT", 102, 106], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 112, 118], ["CCL4", "GENE_OR_GENE_PRODUCT", 120, 124], ["chemokines", "PROTEIN", 13, 23], ["IL-8", "PROTEIN", 33, 37], ["CXCL8", "PROTEIN", 38, 43], ["MIG", "PROTEIN", 45, 48], ["CXCL9", "PROTEIN", 49, 54], ["IP10", "PROTEIN", 56, 60], ["CXCL10", "PROTEIN", 61, 67], ["I", "PROTEIN", 69, 70], ["TAC", "PROTEIN", 71, 74], ["CXCL11", "PROTEIN", 75, 81], ["MCP", "PROTEIN", 83, 86], ["CCL2", "PROTEIN", 89, 93], ["MIP", "PROTEIN", 95, 98], ["1\u03b1", "PROTEIN", 99, 101], ["CCL3", "PROTEIN", 102, 106], ["MIP", "PROTEIN", 112, 115], ["\u03b2", "PROTEIN", 117, 118], ["CCL4", "PROTEIN", 120, 124], ["chemokines", "TEST", 13, 23], ["IL", "TEST", 33, 35], ["CXCL8", "TEST", 38, 43], ["MIG", "TEST", 45, 48], ["CXCL9", "TEST", 49, 54], ["IP10", "TEST", 56, 60], ["CXCL10", "TEST", 61, 67], ["I", "TEST", 69, 70], ["CXCL11", "TEST", 75, 81], ["MCP", "TEST", 83, 86], ["CCL2", "TEST", 89, 93], ["MIP", "TEST", 95, 98], ["CCL3", "TEST", 102, 106], ["MIP", "TEST", 112, 115]]], ["Both cytokines and chemokines activate the immune system, perpetuating the ongoing cytokine storm.", [["immune system", "ANATOMY", 43, 56], ["cytokines", "PROTEIN", 5, 14], ["chemokines", "PROTEIN", 19, 29], ["cytokine", "PROTEIN", 83, 91], ["Both cytokines", "TREATMENT", 0, 14], ["chemokines", "TREATMENT", 19, 29], ["cytokines", "OBSERVATION", 5, 14], ["cytokine storm", "OBSERVATION", 83, 97]]], ["On the other arm, levels of antiinflammatory cytokines, such as IL-10 and IL-18-binding protein (IL-18BP), are also increased but might not be sufficient to terminate the ongoing inflammation [33, 34] .", [["inflammation", "DISEASE", 179, 191], ["IL-10", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-18-binding protein", "GENE_OR_GENE_PRODUCT", 74, 95], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 97, 104], ["antiinflammatory cytokines", "PROTEIN", 28, 54], ["IL-18-binding protein", "PROTEIN", 74, 95], ["IL", "PROTEIN", 97, 99], ["18BP", "PROTEIN", 100, 104], ["antiinflammatory cytokines", "TREATMENT", 28, 54], ["IL", "TEST", 64, 66], ["IL", "TEST", 74, 76], ["the ongoing inflammation", "PROBLEM", 167, 191], ["arm", "ANATOMY", 13, 16], ["antiinflammatory cytokines", "OBSERVATION", 28, 54], ["inflammation", "OBSERVATION", 179, 191]]], ["Mazodier et al. described a discrepancy between the increase in IL-18 and its antagonist IL-18BP that lead to abnormally high levels of free IL-18 [33] .", [["IL-18", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 89, 96], ["IL-18", "GENE_OR_GENE_PRODUCT", 141, 146], ["IL-18", "PROTEIN", 64, 69], ["IL-18BP", "PROTEIN", 89, 96], ["IL", "PROTEIN", 141, 143], ["a discrepancy", "PROBLEM", 26, 39], ["the increase in IL", "TREATMENT", 48, 66], ["its antagonist IL", "TREATMENT", 74, 91], ["abnormally high levels of free IL", "PROBLEM", 110, 143], ["discrepancy", "OBSERVATION", 28, 39], ["increase", "OBSERVATION_MODIFIER", 52, 60]]], ["Similarly, the natural antagonist to IL-1, IL-1 receptor antagonist (IL-1Ra), has been noted to be elevated during MAS/HLH, and a recombinant form of IL-1Ra has been reported by several groups to be an effective therapy for MAS/HLH/ cytokine storm syndrome [35] [36] [37] .Pathophysiology and Cytokine StormThe etiology of the cytokine storm is not entirely clear.", [["HLH", "DISEASE", 119, 122], ["HLH", "DISEASE", 228, 231], ["IL-1", "GENE_OR_GENE_PRODUCT", 37, 41], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 43, 67], ["IL-1Ra", "GENE_OR_GENE_PRODUCT", 69, 75], ["IL-1Ra", "GENE_OR_GENE_PRODUCT", 150, 156], ["Cytokine", "GENE_OR_GENE_PRODUCT", 293, 301], ["IL", "PROTEIN", 37, 39], ["IL-1Ra", "PROTEIN", 150, 156], ["cytokine", "PROTEIN", 233, 241], ["Cytokine", "PROTEIN", 293, 301], ["cytokine", "PROTEIN", 327, 335], ["the natural antagonist to IL", "TREATMENT", 11, 39], ["IL-1 receptor antagonist", "TREATMENT", 43, 67], ["HLH", "PROBLEM", 119, 122], ["IL-1Ra", "TREATMENT", 150, 156], ["an effective therapy", "TREATMENT", 199, 219], ["MAS", "PROBLEM", 224, 227], ["HLH", "PROBLEM", 228, 231], ["cytokine storm syndrome", "PROBLEM", 233, 256], ["Pathophysiology", "PROBLEM", 273, 288], ["the cytokine storm", "PROBLEM", 323, 341], ["elevated", "OBSERVATION", 99, 107], ["Cytokine Storm", "OBSERVATION", 293, 307], ["cytokine storm", "OBSERVATION", 327, 341], ["not entirely", "UNCERTAINTY", 345, 357], ["clear", "OBSERVATION", 358, 363]]], ["Since fHLH is associated with biallelic defects in gene products involved in the perforin-mediated cytolytic pathway used by NK cells and CD8 T lymphocytes [48, 49] , the inability to clear the antigenic stimulus and thus turn off the inflammatory response has been hypothesized to result in hypercytokinemia [50] .", [["NK cells", "ANATOMY", 125, 133], ["CD8 T lymphocytes", "ANATOMY", 138, 155], ["fHLH", "DISEASE", 6, 10], ["hypercytokinemia", "DISEASE", 292, 308], ["fHLH", "GENE_OR_GENE_PRODUCT", 6, 10], ["perforin", "GENE_OR_GENE_PRODUCT", 81, 89], ["NK cells", "CELL", 125, 133], ["CD8 T lymphocytes", "CELL", 138, 155], ["perforin", "PROTEIN", 81, 89], ["NK cells", "CELL_TYPE", 125, 133], ["CD8 T lymphocytes", "CELL_TYPE", 138, 155], ["biallelic defects in gene products", "PROBLEM", 30, 64], ["CD8 T lymphocytes", "TEST", 138, 155], ["the inflammatory response", "PROBLEM", 231, 256], ["hypercytokinemia", "PROBLEM", 292, 308], ["associated with", "UNCERTAINTY", 14, 29], ["biallelic defects", "OBSERVATION", 30, 47], ["gene products", "OBSERVATION", 51, 64], ["antigenic stimulus", "OBSERVATION", 194, 212]]], ["Recently, the inability of CD8 T cells and NK cells to lyse antigen-presenting cells (APCs) via the perforinmediated cytolytic pathway was shown to prolong (by fivefold) the engagement time between the lytic lymphocyte and the APC.", [["CD8 T cells", "ANATOMY", 27, 38], ["NK cells", "ANATOMY", 43, 51], ["antigen-presenting cells", "ANATOMY", 60, 84], ["APCs", "ANATOMY", 86, 90], ["lytic lymphocyte", "ANATOMY", 202, 218], ["CD8", "GENE_OR_GENE_PRODUCT", 27, 30], ["NK cells", "CELL", 43, 51], ["antigen-presenting cells", "CELL", 60, 84], ["APCs", "CELL", 86, 90], ["lymphocyte", "CELL", 208, 218], ["APC", "GENE_OR_GENE_PRODUCT", 227, 230], ["CD8 T cells", "CELL_TYPE", 27, 38], ["NK cells", "CELL_TYPE", 43, 51], ["antigen-presenting cells", "CELL_TYPE", 60, 84], ["APCs", "CELL_TYPE", 86, 90], ["lytic lymphocyte", "CELL_TYPE", 202, 218], ["APC", "CELL_TYPE", 227, 230], ["NK cells", "PROBLEM", 43, 51], ["lyse antigen", "TEST", 55, 67], ["APCs", "TEST", 86, 90], ["the perforinmediated cytolytic pathway", "TEST", 96, 134], ["the lytic lymphocyte", "TEST", 198, 218], ["NK cells", "OBSERVATION", 43, 51], ["lytic lymphocyte", "OBSERVATION", 202, 218]]], ["This prolonged interaction resulted in increased levels of proinflammatory cytokines.", [["proinflammatory cytokines", "PROTEIN", 59, 84], ["This prolonged interaction", "PROBLEM", 0, 26], ["increased levels of proinflammatory cytokines", "PROBLEM", 39, 84], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["proinflammatory cytokines", "OBSERVATION", 59, 84]]], ["For up to 40% of sHLH cases, single-copy mutations in these same perforin pathway genes have been reported.", [["sHLH", "DISEASE", 17, 21], ["sHLH", "CANCER", 17, 21], ["perforin", "GENE_OR_GENE_PRODUCT", 65, 73], ["perforin pathway genes", "DNA", 65, 87], ["single-copy mutations", "PROBLEM", 29, 50]]], ["Some of the mutants have been demonstrated to act as complete or partial dominant-negative mutants [51] [52] [53] , resulting in sHLH in older children and adults [53, 54] , the oldest reported case being a 62-year-old patient [55] .", [["sHLH", "CANCER", 129, 133], ["children", "ORGANISM", 143, 151], ["patient", "ORGANISM", 219, 226], ["children", "SPECIES", 143, 151], ["patient", "SPECIES", 219, 226]]], ["One heterozygous mutation in RAB27A identified in two unrelated sHLH patients was shown to act in a partial dominantnegative fashion and delayed cytolytic granule polarization to the immunologic synapse between NK cells and their target cells.", [["granule", "ANATOMY", 155, 162], ["NK cells", "ANATOMY", 211, 219], ["cells", "ANATOMY", 237, 242], ["sHLH", "DISEASE", 64, 68], ["RAB27A", "GENE_OR_GENE_PRODUCT", 29, 35], ["sHLH", "CANCER", 64, 68], ["patients", "ORGANISM", 69, 77], ["NK cells", "CELL", 211, 219], ["cells", "CELL", 237, 242], ["RAB27A", "DNA", 29, 35], ["NK cells", "CELL_TYPE", 211, 219], ["target cells", "CELL_TYPE", 230, 242], ["patients", "SPECIES", 69, 77], ["One heterozygous mutation", "PROBLEM", 0, 25], ["delayed cytolytic granule polarization", "PROBLEM", 137, 175], ["heterozygous mutation", "OBSERVATION", 4, 25], ["cytolytic granule polarization", "OBSERVATION", 145, 175], ["immunologic synapse", "OBSERVATION", 183, 202], ["NK cells", "OBSERVATION", 211, 219], ["target cells", "OBSERVATION", 230, 242]]], ["This was also associated with an increase in IFN-\u03b3 production, mimicking the situation described for homozygous defects in perforin or granzyme B. Moreover, increased IL-6 production has been shown to decrease cytolytic activity of NK cells, further exacerbating the lytic defect and resultant production of pro-inflammatory cytokines.", [["NK cells", "ANATOMY", 232, 240], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 45, 50], ["perforin", "GENE_OR_GENE_PRODUCT", 123, 131], ["granzyme B.", "GENE_OR_GENE_PRODUCT", 135, 146], ["IL-6", "GENE_OR_GENE_PRODUCT", 167, 171], ["NK cells", "CELL", 232, 240], ["IFN", "PROTEIN", 45, 48], ["\u03b3", "PROTEIN", 49, 50], ["perforin", "PROTEIN", 123, 131], ["IL-6", "PROTEIN", 167, 171], ["NK cells", "CELL_TYPE", 232, 240], ["pro-inflammatory cytokines", "PROTEIN", 308, 334], ["an increase in IFN-\u03b3 production", "PROBLEM", 30, 61], ["homozygous defects", "PROBLEM", 101, 119], ["NK cells", "PROBLEM", 232, 240], ["the lytic defect", "PROBLEM", 263, 279], ["pro-inflammatory cytokines", "PROBLEM", 308, 334], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["IFN", "OBSERVATION_MODIFIER", 45, 48], ["NK cells", "OBSERVATION", 232, 240], ["lytic", "OBSERVATION_MODIFIER", 267, 272], ["defect", "OBSERVATION", 273, 279], ["resultant", "OBSERVATION_MODIFIER", 284, 293], ["production", "OBSERVATION_MODIFIER", 294, 304], ["pro-inflammatory cytokines", "OBSERVATION", 308, 334]]], ["In a healthy individual, exposure of most cells to many intracellular pathogens will normally initiate an inflammatory cascade, frequently leading to release of Th1 cytokines (IFN-\u03b3, TNF) that will activate macrophages, NK cells, and cytolytic T cells.", [["cells", "ANATOMY", 42, 47], ["intracellular", "ANATOMY", 56, 69], ["macrophages", "ANATOMY", 207, 218], ["NK cells", "ANATOMY", 220, 228], ["cytolytic T cells", "ANATOMY", 234, 251], ["cells", "CELL", 42, 47], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 176, 181], ["TNF", "GENE_OR_GENE_PRODUCT", 183, 186], ["macrophages", "CELL", 207, 218], ["NK cells", "CELL", 220, 228], ["cytolytic T cells", "CELL", 234, 251], ["Th1 cytokines", "PROTEIN", 161, 174], ["IFN", "PROTEIN", 176, 179], ["\u03b3", "PROTEIN", 180, 181], ["TNF", "PROTEIN", 183, 186], ["macrophages", "CELL_TYPE", 207, 218], ["NK cells", "CELL_TYPE", 220, 228], ["cytolytic T cells", "CELL_TYPE", 234, 251], ["most cells", "PROBLEM", 37, 47], ["many intracellular pathogens", "PROBLEM", 51, 79], ["an inflammatory cascade", "PROBLEM", 103, 126], ["Th1 cytokines", "TEST", 161, 174], ["IFN", "TEST", 176, 179], ["TNF", "PROBLEM", 183, 186], ["NK cells", "TEST", 220, 228], ["cytolytic T cells", "PROBLEM", 234, 251], ["most cells", "OBSERVATION_MODIFIER", 37, 47], ["pathogens", "OBSERVATION", 70, 79], ["inflammatory", "OBSERVATION", 106, 118], ["NK cells", "OBSERVATION", 220, 228], ["cytolytic T cells", "OBSERVATION", 234, 251]]], ["NK and cytolytic T cells release granules that contain perforin and granzymes [49] .", [["NK", "ANATOMY", 0, 2], ["T cells", "ANATOMY", 17, 24], ["granules", "ANATOMY", 33, 41], ["NK", "CELL", 0, 2], ["cytolytic T cells", "CELL", 7, 24], ["granules", "ORGANISM_SUBSTANCE", 33, 41], ["perforin", "GENE_OR_GENE_PRODUCT", 55, 63], ["granzymes", "GENE_OR_GENE_PRODUCT", 68, 77], ["NK and cytolytic T cells", "CELL_TYPE", 0, 24], ["perforin", "PROTEIN", 55, 63], ["granzymes", "PROTEIN", 68, 77], ["NK and cytolytic T cells release granules", "TREATMENT", 0, 41]]], ["Perforin is a key cytolytic protein that causes osmotic lysis of the target cell [56] and is also necessary for the uptake of granzymes by the target cell that will then catalyze cleavage of multiple protein substrates, including caspases which then trigger cell apoptosis.", [["cell", "ANATOMY", 76, 80], ["cell", "ANATOMY", 150, 154], ["cell", "ANATOMY", 258, 262], ["Perforin", "CHEMICAL", 0, 8], ["Perforin", "GENE_OR_GENE_PRODUCT", 0, 8], ["cell", "CELL", 76, 80], ["granzymes", "GENE_OR_GENE_PRODUCT", 126, 135], ["cell", "CELL", 150, 154], ["caspases", "GENE_OR_GENE_PRODUCT", 230, 238], ["cell", "CELL", 258, 262], ["Perforin", "PROTEIN", 0, 8], ["cytolytic protein", "PROTEIN", 18, 35], ["granzymes", "PROTEIN", 126, 135], ["target cell", "CELL_TYPE", 143, 154], ["protein substrates", "PROTEIN", 200, 218], ["caspases", "PROTEIN", 230, 238], ["osmotic lysis", "TREATMENT", 48, 61], ["the uptake of granzymes", "PROBLEM", 112, 135], ["multiple protein substrates", "TREATMENT", 191, 218], ["caspases", "TREATMENT", 230, 238], ["cell apoptosis", "PROBLEM", 258, 272], ["osmotic lysis", "OBSERVATION", 48, 61], ["cell apoptosis", "OBSERVATION", 258, 272]]], ["All the genetic defects described in fHLH involve either inadequate levels of perforin itself or improper granule exocytosis leading to impaired apoptosis of the target cell, improper removal of the stimulating antigen, and ultimately ongoing inflammation.Pathophysiology and Cytokine StormHowever, other pathways lacking cytolytic pathway gene defects can lead to the final endpoint of HLH or MAS.", [["granule", "ANATOMY", 106, 113], ["cell", "ANATOMY", 169, 173], ["fHLH", "DISEASE", 37, 41], ["inflammation", "DISEASE", 243, 255], ["HLH", "DISEASE", 387, 390], ["MAS", "DISEASE", 394, 397], ["fHLH", "CANCER", 37, 41], ["perforin", "GENE_OR_GENE_PRODUCT", 78, 86], ["granule exocytosis", "CELLULAR_COMPONENT", 106, 124], ["cell", "CELL", 169, 173], ["Cytokine", "GENE_OR_GENE_PRODUCT", 276, 284], ["perforin", "PROTEIN", 78, 86], ["target cell", "CELL_TYPE", 162, 173], ["stimulating antigen", "PROTEIN", 199, 218], ["Cytokine", "PROTEIN", 276, 284], ["All the genetic defects", "PROBLEM", 0, 23], ["perforin itself", "PROBLEM", 78, 93], ["improper granule exocytosis", "PROBLEM", 97, 124], ["impaired apoptosis of the target cell", "PROBLEM", 136, 173], ["improper removal", "TREATMENT", 175, 191], ["the stimulating antigen", "TEST", 195, 218], ["ongoing inflammation", "PROBLEM", 235, 255], ["Pathophysiology", "PROBLEM", 256, 271], ["Cytokine StormHowever", "TEST", 276, 297], ["lacking cytolytic pathway gene defects", "PROBLEM", 314, 352], ["HLH", "PROBLEM", 387, 390], ["MAS", "PROBLEM", 394, 397], ["genetic defects", "OBSERVATION", 8, 23], ["granule exocytosis", "OBSERVATION", 106, 124], ["impaired", "OBSERVATION_MODIFIER", 136, 144], ["apoptosis", "OBSERVATION_MODIFIER", 145, 154], ["target cell", "OBSERVATION", 162, 173], ["removal", "OBSERVATION_MODIFIER", 184, 191], ["ongoing", "OBSERVATION_MODIFIER", 235, 242], ["inflammation", "OBSERVATION", 243, 255], ["HLH", "OBSERVATION", 387, 390]]], ["In a murine model of MAS, it was shown that repeated stimulation of toll-like receptor 9 (TLR9) produced MAS on a normal genetic background, without exogenous antigen.", [["murine", "ORGANISM", 5, 11], ["toll-like receptor 9", "GENE_OR_GENE_PRODUCT", 68, 88], ["TLR9", "GENE_OR_GENE_PRODUCT", 90, 94], ["toll-like receptor 9", "PROTEIN", 68, 88], ["TLR9", "PROTEIN", 90, 94], ["exogenous antigen", "PROTEIN", 149, 166], ["murine", "SPECIES", 5, 11], ["MAS", "PROBLEM", 105, 108], ["exogenous antigen", "PROBLEM", 149, 166], ["without", "UNCERTAINTY", 141, 148]]], ["Interestingly, the TLR9-induced MAS model was IFN-\u03b3 dependent in some aspects of disease; however, lymphocytes were not required for the pathogenesis [57] .", [["lymphocytes", "ANATOMY", 99, 110], ["TLR9", "GENE_OR_GENE_PRODUCT", 19, 23], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 46, 51], ["lymphocytes", "CELL", 99, 110], ["TLR9", "PROTEIN", 19, 23], ["IFN", "PROTEIN", 46, 49], ["lymphocytes", "CELL_TYPE", 99, 110], ["IFN", "PROBLEM", 46, 49], ["disease", "PROBLEM", 81, 88], ["lymphocytes", "TEST", 99, 110], ["the pathogenesis", "PROBLEM", 133, 149], ["disease", "OBSERVATION", 81, 88]]], ["On the other hand, a state of inflammation may also reduce the lytic capacity of NK cells and CD8 T cells [58] [59] [60] , resulting in cytokine storm due to frustrated phagocytosis.", [["NK cells", "ANATOMY", 81, 89], ["CD8 T cells", "ANATOMY", 94, 105], ["inflammation", "DISEASE", 30, 42], ["NK cells", "CELL", 81, 89], ["CD8 T", "GENE_OR_GENE_PRODUCT", 94, 99], ["NK cells", "CELL_TYPE", 81, 89], ["CD8 T cells", "CELL_TYPE", 94, 105], ["cytokine", "PROTEIN", 136, 144], ["inflammation", "PROBLEM", 30, 42], ["the lytic capacity of NK cells", "PROBLEM", 59, 89], ["CD8 T cells", "TEST", 94, 105], ["frustrated phagocytosis", "PROBLEM", 158, 181], ["inflammation", "OBSERVATION", 30, 42], ["lytic", "OBSERVATION_MODIFIER", 63, 68], ["NK cells", "OBSERVATION", 81, 89], ["frustrated phagocytosis", "OBSERVATION", 158, 181]]], ["This was illustrated in a study where T-cell-directed immunotherapy for refractory leukemia resulted in cytokine storm and an MAS-like presentation [61] .", [["T-cell", "ANATOMY", 38, 44], ["leukemia", "ANATOMY", 83, 91], ["leukemia", "DISEASE", 83, 91], ["T-cell", "CELL", 38, 44], ["leukemia", "CANCER", 83, 91], ["cytokine", "PROTEIN", 104, 112], ["a study", "TEST", 24, 31], ["T-cell-directed immunotherapy", "TREATMENT", 38, 67], ["refractory leukemia", "PROBLEM", 72, 91], ["cytokine storm", "PROBLEM", 104, 118], ["an MAS", "TEST", 123, 129], ["refractory leukemia", "OBSERVATION", 72, 91], ["cytokine storm", "OBSERVATION", 104, 118]]], ["All the aforementioned pathways have led to the proposal that MAS is due to a combination of genetic predisposition and a hyperinflammatory state reducing cytolytic function, put into action by a trigger (e.g., infection, cancer, immunodeficiency, autoimmunity, and autoinflammation) [19, 53, [62] [63] [64] .", [["cancer", "ANATOMY", 222, 228], ["MAS", "DISEASE", 62, 65], ["infection", "DISEASE", 211, 220], ["cancer", "DISEASE", 222, 228], ["immunodeficiency", "DISEASE", 230, 246], ["autoimmunity", "DISEASE", 248, 260], ["autoinflammation", "DISEASE", 266, 282], ["cancer", "CANCER", 222, 228], ["genetic predisposition", "PROBLEM", 93, 115], ["a hyperinflammatory state reducing cytolytic function", "PROBLEM", 120, 173], ["infection", "PROBLEM", 211, 220], ["cancer", "PROBLEM", 222, 228], ["immunodeficiency", "PROBLEM", 230, 246], ["autoimmunity", "PROBLEM", 248, 260], ["autoinflammation", "TEST", 266, 282]]], ["At some point a threshold level of hypercytokinemia is reached at which the body is incapable of balancing the cytokine storm with anti-inflammatory products, such as IL-10, IL-1Ra, IL-18BP, and others.", [["body", "ANATOMY", 76, 80], ["hypercytokinemia", "DISEASE", 35, 51], ["body", "ORGANISM_SUBDIVISION", 76, 80], ["IL-10", "GENE_OR_GENE_PRODUCT", 167, 172], ["IL-1Ra", "GENE_OR_GENE_PRODUCT", 174, 180], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 182, 189], ["cytokine", "PROTEIN", 111, 119], ["anti-inflammatory products", "PROTEIN", 131, 157], ["IL", "PROTEIN", 182, 184], ["18BP", "PROTEIN", 185, 189], ["a threshold level of hypercytokinemia", "PROBLEM", 14, 51], ["anti-inflammatory products", "TREATMENT", 131, 157], ["IL", "TEST", 167, 169], ["hypercytokinemia", "OBSERVATION", 35, 51], ["cytokine storm", "OBSERVATION", 111, 125]]], ["This is then believed to trigger the multiorgan dysfunction resulting in clinical HLH.Clinical PictureInitial symptoms of HLH/MAS are usually nonspecific.", [["multiorgan", "ANATOMY", 37, 47], ["multiorgan dysfunction", "DISEASE", 37, 59], ["HLH", "DISEASE", 82, 85], ["HLH", "DISEASE", 122, 125], ["MAS", "DISEASE", 126, 129], ["the multiorgan dysfunction", "PROBLEM", 33, 59], ["clinical HLH", "PROBLEM", 73, 85], ["Clinical PictureInitial symptoms", "PROBLEM", 86, 118], ["HLH", "PROBLEM", 122, 125], ["MAS", "PROBLEM", 126, 129], ["multiorgan dysfunction", "OBSERVATION", 37, 59], ["HLH", "OBSERVATION", 82, 85], ["HLH", "OBSERVATION", 122, 125], ["MAS", "OBSERVATION", 126, 129], ["nonspecific", "OBSERVATION_MODIFIER", 142, 153]]], ["The cardinal feature is unremitting high fever.", [["fever", "DISEASE", 41, 46], ["unremitting high fever", "PROBLEM", 24, 46], ["unremitting", "OBSERVATION_MODIFIER", 24, 35], ["high", "OBSERVATION_MODIFIER", 36, 40], ["fever", "OBSERVATION", 41, 46]]], ["However, therapeutic targeting of pro-inflammatory cytokines (e.g., IL-1, IL-6) to treat underlying rheumatic diseases that often result in MAS (e.g., sJIA) makes fever not an absolute finding in all cases.", [["rheumatic diseases", "DISEASE", 100, 118], ["MAS", "DISEASE", 140, 143], ["fever", "DISEASE", 163, 168], ["IL-1", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL-6", "GENE_OR_GENE_PRODUCT", 74, 78], ["pro-inflammatory cytokines", "PROTEIN", 34, 60], ["IL-1, IL-6", "PROTEIN", 68, 78], ["pro-inflammatory cytokines", "TEST", 34, 60], ["IL", "TEST", 68, 70], ["underlying rheumatic diseases", "PROBLEM", 89, 118], ["MAS (e.g., sJIA)", "PROBLEM", 140, 156], ["fever", "PROBLEM", 163, 168], ["rheumatic", "OBSERVATION", 100, 109]]], ["This is attributed to the powerful antipyretic effect of biologics such as inhibitors of IL-1, IL-6, and TNF.", [["IL-1", "GENE_OR_GENE_PRODUCT", 89, 93], ["IL-6", "GENE_OR_GENE_PRODUCT", 95, 99], ["TNF", "GENE_OR_GENE_PRODUCT", 105, 108], ["IL-1, IL-6", "PROTEIN", 89, 99], ["TNF", "PROTEIN", 105, 108], ["biologics", "TREATMENT", 57, 66], ["inhibitors of IL", "TREATMENT", 75, 91], ["TNF", "TREATMENT", 105, 108]]], ["On examination, many patients have hepatomegaly, splenomegaly, or both, and up to 50% of MAS/HLH patients have central nervous system involvement ranging from mild confusion to seizures or frank coma [65] .", [["central nervous system", "ANATOMY", 111, 133], ["hepatomegaly", "DISEASE", 35, 47], ["splenomegaly", "DISEASE", 49, 61], ["MAS", "DISEASE", 89, 92], ["HLH", "DISEASE", 93, 96], ["confusion", "DISEASE", 164, 173], ["seizures", "DISEASE", 177, 185], ["coma", "DISEASE", 195, 199], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 97, 105], ["central nervous system", "ANATOMICAL_SYSTEM", 111, 133], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 97, 105], ["examination", "TEST", 3, 14], ["hepatomegaly", "PROBLEM", 35, 47], ["splenomegaly", "PROBLEM", 49, 61], ["MAS/HLH", "PROBLEM", 89, 96], ["central nervous system involvement", "PROBLEM", 111, 145], ["mild confusion", "PROBLEM", 159, 173], ["seizures", "PROBLEM", 177, 185], ["frank coma", "PROBLEM", 189, 199], ["hepatomegaly", "OBSERVATION", 35, 47], ["splenomegaly", "OBSERVATION", 49, 61], ["HLH", "OBSERVATION", 93, 96], ["central", "ANATOMY_MODIFIER", 111, 118], ["nervous system", "ANATOMY", 119, 133], ["mild", "OBSERVATION_MODIFIER", 159, 163]]], ["Different forms of rash can occur, often erythematous or purpuric.", [["rash", "DISEASE", 19, 23], ["purpuric", "DISEASE", 57, 65], ["rash", "PROBLEM", 19, 23], ["erythematous", "PROBLEM", 41, 53], ["purpuric", "PROBLEM", 57, 65], ["rash", "OBSERVATION", 19, 23], ["purpuric", "OBSERVATION", 57, 65]]], ["Patients can have progressive hepatic dysfunction and ultimately multiorgan failure.", [["hepatic", "ANATOMY", 30, 37], ["multiorgan", "ANATOMY", 65, 75], ["hepatic dysfunction", "DISEASE", 30, 49], ["multiorgan failure", "DISEASE", 65, 83], ["Patients", "ORGANISM", 0, 8], ["hepatic", "ORGAN", 30, 37], ["multiorgan", "ORGAN", 65, 75], ["Patients", "SPECIES", 0, 8], ["progressive hepatic dysfunction", "PROBLEM", 18, 49], ["multiorgan failure", "PROBLEM", 65, 83], ["progressive", "OBSERVATION_MODIFIER", 18, 29], ["hepatic", "ANATOMY", 30, 37], ["dysfunction", "OBSERVATION", 38, 49], ["multiorgan failure", "OBSERVATION", 65, 83]]], ["DIC-like features are often present and are partly explained by liver dysfunction, fibrinogen consumption, and thrombocytopenia [66] .", [["liver", "ANATOMY", 64, 69], ["DIC", "DISEASE", 0, 3], ["liver dysfunction", "DISEASE", 64, 81], ["thrombocytopenia", "DISEASE", 111, 127], ["liver", "ORGAN", 64, 69], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 83, 93], ["fibrinogen", "PROTEIN", 83, 93], ["DIC-like features", "PROBLEM", 0, 17], ["liver dysfunction", "PROBLEM", 64, 81], ["fibrinogen consumption", "PROBLEM", 83, 105], ["thrombocytopenia", "PROBLEM", 111, 127], ["partly explained", "UNCERTAINTY", 44, 60], ["liver", "ANATOMY", 64, 69], ["dysfunction", "OBSERVATION", 70, 81], ["thrombocytopenia", "OBSERVATION", 111, 127]]], ["This highlights the challenges in distinguishing microbial sepsisinduced DIC from HLH in the intensive care unit (ICU).", [["DIC", "DISEASE", 73, 76], ["HLH", "DISEASE", 82, 85], ["microbial sepsisinduced DIC", "PROBLEM", 49, 76], ["HLH", "PROBLEM", 82, 85], ["HLH", "OBSERVATION", 82, 85]]], ["Despite the similarities these two conditions share in clinical presentations, they are frequently treated differently: broad spectrum antibiotics (sepsis) versus immunosuppression (HLH), respectively [67] .", [["sepsis", "DISEASE", 148, 154], ["HLH", "DISEASE", 182, 185], ["broad spectrum antibiotics", "TREATMENT", 120, 146], ["sepsis", "PROBLEM", 148, 154], ["immunosuppression", "TREATMENT", 163, 180]]], ["As HLH is not a diagnosis of exclusion, and infections are common triggers of HLH, it is important to treat both infection and, if present, the associated cytokine storm of HLH.Classification CriteriaMAS/HLH can be difficult to diagnose, especially in the early stages where it can be easily misdiagnosed as shock or multiorgan dysfunction due to sepsis.", [["multiorgan", "ANATOMY", 317, 327], ["HLH", "DISEASE", 3, 6], ["infections", "DISEASE", 44, 54], ["HLH", "DISEASE", 78, 81], ["infection", "DISEASE", 113, 122], ["HLH", "DISEASE", 173, 176], ["HLH", "DISEASE", 204, 207], ["shock", "DISEASE", 308, 313], ["multiorgan dysfunction", "DISEASE", 317, 339], ["sepsis", "DISEASE", 347, 353], ["multiorgan", "ORGAN", 317, 327], ["cytokine", "PROTEIN", 155, 163], ["exclusion", "PROBLEM", 29, 38], ["infections", "PROBLEM", 44, 54], ["HLH", "PROBLEM", 78, 81], ["both infection", "PROBLEM", 108, 122], ["HLH", "PROBLEM", 173, 176], ["HLH", "PROBLEM", 204, 207], ["shock", "PROBLEM", 308, 313], ["multiorgan dysfunction", "PROBLEM", 317, 339], ["sepsis", "PROBLEM", 347, 353], ["exclusion", "OBSERVATION", 29, 38], ["infections", "OBSERVATION", 44, 54], ["HLH", "OBSERVATION", 78, 81], ["infection", "OBSERVATION", 113, 122], ["HLH", "OBSERVATION", 173, 176], ["HLH", "OBSERVATION", 204, 207], ["multiorgan dysfunction", "OBSERVATION", 317, 339], ["sepsis", "OBSERVATION", 347, 353]]], ["In addition, MAS may be confused with an underlying disease flare, as in the case of sJIA.", [["sJIA", "DISEASE", 85, 89], ["sJIA", "CANCER", 85, 89], ["confused", "PROBLEM", 24, 32], ["an underlying disease flare", "PROBLEM", 38, 65], ["sJIA", "PROBLEM", 85, 89], ["disease", "OBSERVATION", 52, 59], ["sJIA", "OBSERVATION", 85, 89]]], ["Because MAS can have a high mortality rate in children with sJIA (\u223c8-22%) [68] [69] [70] , sensitive diagnostic criteria are needed to assist with early detection, allowing for appropriate and timely therapy.", [["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["a high mortality rate", "PROBLEM", 21, 42], ["sJIA", "TEST", 60, 64], ["early detection", "TEST", 147, 162], ["appropriate and timely therapy", "TREATMENT", 177, 207]]], ["Because of the different diseases associated with MAS/HLH, different diagnostic and classification criteria have been proposed over the years, such as HLH-04, SLE-MAS criteria, the HScore, and the novel 2016 criteria for MAS complicating sJIA (Table 14.", [["MAS", "DISEASE", 50, 53], ["HLH", "DISEASE", 54, 57], ["HLH", "DISEASE", 151, 154], ["SLE", "DISEASE", 159, 162], ["MAS", "DISEASE", 221, 224], ["sJIA", "DISEASE", 238, 242], ["the different diseases", "PROBLEM", 11, 33], ["MAS", "PROBLEM", 50, 53], ["HLH", "PROBLEM", 54, 57], ["HLH", "TEST", 151, 154], ["MAS complicating sJIA", "PROBLEM", 221, 242], ["different", "OBSERVATION_MODIFIER", 15, 24], ["diseases", "OBSERVATION", 25, 33], ["HLH", "OBSERVATION", 54, 57]]], ["Some of these criteria are disease specific (e.g., sJIA, SLE) and can be both sensitive and specific, whereas others encompass all potential HLH-associated diagnoses, but tend to have lower sensitivities overall.", [["SLE", "DISEASE", 57, 60], ["HLH", "DISEASE", 141, 144], ["disease specific (e.g., sJIA, SLE)", "PROBLEM", 27, 61], ["lower sensitivities overall", "PROBLEM", 184, 211], ["HLH", "OBSERVATION", 141, 144]]], ["Clinically, and outside of clinical trials,HLH-2004 Diagnostic GuidelinesDue to the fact that MAS resembles fHLH in its clinical presentation, HLH-2004 diagnostic guidelines were initially used to diagnose MAS.", [["HLH", "DISEASE", 43, 46], ["fHLH", "DISEASE", 108, 112], ["HLH", "DISEASE", 143, 146], ["MAS", "DISEASE", 206, 209], ["fHLH", "CANCER", 108, 112], ["MAS resembles fHLH", "PROBLEM", 94, 112]]], ["Those guidelines were developed to diagnose genetic homozygous/compound heterozygous cases of fHLH [11] .", [["fHLH", "DISEASE", 94, 98], ["genetic homozygous/compound heterozygous cases of fHLH", "PROBLEM", 44, 98]]], ["The main deficiencies regarding the HLH-2004 criteria for diagnosing MAS in patients with sJIA are due to the underlying inflammatory nature of sJIA versus fHLH.", [["HLH", "DISEASE", 36, 39], ["MAS", "DISEASE", 69, 72], ["sJIA", "DISEASE", 90, 94], ["fHLH", "DISEASE", 156, 160], ["patients", "ORGANISM", 76, 84], ["sJIA", "CANCER", 90, 94], ["sJIA", "CANCER", 144, 148], ["fHLH", "CANCER", 156, 160], ["patients", "SPECIES", 76, 84], ["The main deficiencies", "PROBLEM", 0, 21], ["diagnosing MAS", "PROBLEM", 58, 72], ["sJIA", "PROBLEM", 90, 94], ["sJIA", "PROBLEM", 144, 148], ["fHLH", "PROBLEM", 156, 160], ["main", "OBSERVATION_MODIFIER", 4, 8], ["deficiencies", "OBSERVATION", 9, 21], ["HLH", "OBSERVATION", 36, 39], ["inflammatory", "OBSERVATION", 121, 133], ["sJIA", "OBSERVATION", 144, 148]]], ["In active sJIA, one would expect elevated levels of white blood cell counts, platelets, and fibrinogen as part of the inflammatory process.", [["white blood cell", "ANATOMY", 52, 68], ["platelets", "ANATOMY", 77, 86], ["sJIA", "CANCER", 10, 14], ["white blood cell", "CELL", 52, 68], ["platelets", "CELL", 77, 86], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 92, 102], ["platelets", "CELL_TYPE", 77, 86], ["fibrinogen", "PROTEIN", 92, 102], ["elevated levels", "PROBLEM", 33, 48], ["white blood cell counts", "TEST", 52, 75], ["platelets", "TEST", 77, 86], ["fibrinogen", "TEST", 92, 102], ["the inflammatory process", "PROBLEM", 114, 138], ["active", "OBSERVATION_MODIFIER", 3, 9], ["sJIA", "OBSERVATION", 10, 14], ["inflammatory", "OBSERVATION", 118, 130]]], ["Accordingly, a drop in their levels, which could still be in the normal limits as regards to the HLH-2004 criteria, should raise the suspicion of MAS.", [["HLH", "DISEASE", 97, 100], ["MAS", "DISEASE", 146, 149], ["a drop in their levels", "PROBLEM", 13, 35], ["MAS", "PROBLEM", 146, 149], ["drop", "OBSERVATION_MODIFIER", 15, 19], ["could still be", "UNCERTAINTY", 43, 57], ["normal limits", "OBSERVATION_MODIFIER", 65, 78]]], ["Also the underlying inflammatory process leads to elevated levels of ferritin [74] ; therefore, the cutoff of ferritin >500 ng/ml in the HLH-2004 guidelines makes it difficult to distinguish MAS complicating sJIA from an sJIA flare.", [["HLH", "DISEASE", 137, 140], ["MAS", "DISEASE", 191, 194], ["sJIA", "DISEASE", 208, 212], ["ferritin", "GENE_OR_GENE_PRODUCT", 69, 77], ["ferritin", "GENE_OR_GENE_PRODUCT", 110, 118], ["ferritin", "PROTEIN", 69, 77], ["ferritin", "PROTEIN", 110, 118], ["the underlying inflammatory process", "PROBLEM", 5, 40], ["elevated levels of ferritin", "PROBLEM", 50, 77], ["ferritin", "TEST", 110, 118], ["MAS", "PROBLEM", 191, 194], ["sJIA", "PROBLEM", 208, 212], ["an sJIA flare", "PROBLEM", 218, 231], ["inflammatory", "OBSERVATION", 20, 32], ["elevated", "OBSERVATION_MODIFIER", 50, 58], ["HLH", "ANATOMY", 137, 140], ["sJIA flare", "OBSERVATION", 221, 231]]], ["Adding to the shortcomings of HLH-2004 guidelines overall are the lack of availability and timely results of certain criteria, such as NK cell activity or sCD25 levels in many centers [25, 75, 76] .Preliminary Diagnostic Criteria for MAS Complicating sJIAEventually, preliminary diagnostic criteria were introduced for sJIA-MAS comparing it to sJIA flare [71] , which yielded better results in identifying MAS among sJIA patients when compared to HLH-2004 diagnostic guidelines [77] .", [["NK cell", "ANATOMY", 135, 142], ["HLH", "DISEASE", 30, 33], ["MAS", "DISEASE", 406, 409], ["sJIA", "DISEASE", 416, 420], ["HLH", "DISEASE", 447, 450], ["NK cell", "CELL", 135, 142], ["sCD25", "GENE_OR_GENE_PRODUCT", 155, 160], ["patients", "ORGANISM", 421, 429], ["sCD25", "PROTEIN", 155, 160], ["patients", "SPECIES", 421, 429], ["sCD25 levels", "PROBLEM", 155, 167], ["MAS", "PROBLEM", 234, 237], ["sJIA", "PROBLEM", 319, 323], ["sJIA flare", "PROBLEM", 344, 354], ["HLH", "TEST", 447, 450]]], ["However, these new criteria had their own shortcomings.", [["new", "OBSERVATION_MODIFIER", 15, 18]]], ["The study that led to the criteria development was lacking in some important laboratory parameters, including some of the important MAS markers such as ferritin, lactate dehydrogenase, and triglycerides [25, 75, 76] .", [["lactate", "CHEMICAL", 162, 169], ["lactate", "CHEMICAL", 162, 169], ["triglycerides", "CHEMICAL", 189, 202], ["ferritin", "GENE_OR_GENE_PRODUCT", 152, 160], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 162, 183], ["triglycerides", "SIMPLE_CHEMICAL", 189, 202], ["ferritin", "PROTEIN", 152, 160], ["lactate dehydrogenase", "PROTEIN", 162, 183], ["The study", "TEST", 0, 9], ["ferritin", "TEST", 152, 160], ["lactate dehydrogenase", "TEST", 162, 183], ["triglycerides", "TEST", 189, 202]]], ["Moreover, they were based on a relatively small sampling of patients, and they were not validated.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["small", "OBSERVATION_MODIFIER", 42, 47]]], ["These shortcomings were an impetus to develop new sJIA-specific MAS criteria.Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic ArthritisThe deficiencies in the previous guidelines have pushed for the development of more accurate criteria for sJIA-MAS.", [["Macrophage", "ANATOMY", 105, 115], ["Juvenile Idiopathic Arthritis", "DISEASE", 158, 187], ["Macrophage Activation Syndrome", "PROBLEM", 105, 135], ["Systemic Juvenile", "PROBLEM", 149, 166], ["Idiopathic Arthritis", "PROBLEM", 167, 187], ["The deficiencies", "PROBLEM", 187, 203], ["sJIA-MAS", "PROBLEM", 293, 301], ["new", "OBSERVATION_MODIFIER", 46, 49], ["sJIA", "OBSERVATION", 50, 54], ["Macrophage Activation", "OBSERVATION", 105, 126], ["Juvenile", "OBSERVATION_MODIFIER", 158, 166], ["Idiopathic", "OBSERVATION_MODIFIER", 167, 177], ["Arthritis", "OBSERVATION", 178, 187], ["deficiencies", "OBSERVATION", 191, 203]]], ["These were the result of an international collaborative effort combining expert consensus, evidence compiled from the medical literature, and analysis of real patients.", [["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167]]], ["The development of the 2016 criteria was conducted under the auspices of the European League Against Rheumatism, the American College of Rheumatology, and the Paediatric Rheumatology International Trials Organization [73] .", [["Rheumatism", "DISEASE", 101, 111]]], ["Based on the common consensus that clinical criteria of MAS are often delayed and/or difficult to distinguish from an underlying disease flare, the 2016 sJIA-MAS criteria are based primarily on laboratory parameters with fever as the only clinical criterion [76] .", [["MAS", "DISEASE", 56, 59], ["fever", "DISEASE", 221, 226], ["MAS", "PROBLEM", 56, 59], ["an underlying disease flare", "PROBLEM", 115, 142], ["laboratory parameters", "TEST", 194, 215], ["fever", "PROBLEM", 221, 226], ["disease", "OBSERVATION", 129, 136]]], ["However, the criteria are not ideal in the setting of children with sJIA who are being actively treated with IL-1 or IL-6 blockade.", [["children", "ORGANISM", 54, 62], ["sJIA", "CANCER", 68, 72], ["IL-1", "GENE_OR_GENE_PRODUCT", 109, 113], ["IL-6", "GENE_OR_GENE_PRODUCT", 117, 121], ["IL", "PROTEIN", 109, 111], ["children", "SPECIES", 54, 62], ["IL", "TREATMENT", 109, 111], ["IL", "TREATMENT", 117, 119]]], ["Ultimately, simple criteria that are not necessarily disease specific but maintain high sensitivity and specificity for establishing an MAS/HLH diagnosis are needed.MAS as Part of Systemic Lupus Erythematosus (SLE-MAS)Childhood SLE (cSLE) cases complicated by MAS have been reported with increasing frequency in the recent years.", [["HLH", "DISEASE", 140, 143], ["Systemic Lupus Erythematosus", "DISEASE", 180, 208], ["SLE-MAS", "DISEASE", 210, 217], ["SLE", "DISEASE", 228, 231], ["cSLE", "DISEASE", 233, 237], ["MAS", "DISEASE", 260, 263], ["high sensitivity", "PROBLEM", 83, 99], ["an MAS/HLH diagnosis", "PROBLEM", 133, 153], ["MAS", "PROBLEM", 165, 168], ["Systemic Lupus Erythematosus", "PROBLEM", 180, 208], ["SLE", "PROBLEM", 210, 213], ["MAS)", "PROBLEM", 214, 218], ["Childhood SLE (cSLE) cases", "PROBLEM", 218, 244], ["MAS", "PROBLEM", 260, 263], ["not necessarily", "UNCERTAINTY", 37, 52], ["Systemic", "OBSERVATION_MODIFIER", 180, 188], ["Lupus Erythematosus", "OBSERVATION", 189, 208], ["increasing", "OBSERVATION_MODIFIER", 288, 298]]], ["As an SLE disease flare itself often results in pancytopenia, diagnostic criteria for MAS in the setting of SLE are complicated.", [["SLE", "DISEASE", 6, 9], ["pancytopenia", "DISEASE", 48, 60], ["MAS", "DISEASE", 86, 89], ["SLE", "DISEASE", 108, 111], ["SLE", "CANCER", 108, 111], ["an SLE disease flare", "PROBLEM", 3, 23], ["pancytopenia", "PROBLEM", 48, 60], ["diagnostic criteria", "TEST", 62, 81], ["MAS", "PROBLEM", 86, 89], ["SLE", "PROBLEM", 108, 111], ["SLE", "OBSERVATION", 6, 9], ["pancytopenia", "OBSERVATION", 48, 60], ["SLE", "OBSERVATION", 108, 111]]], ["Accordingly, it has been suggested that cSLE-MAS may be under-recognized [78] .", [["cSLE-MAS", "GENE_OR_GENE_PRODUCT", 40, 48]]], ["Preliminary guidelines for SLE-MAS were proposed in 2009.", [["SLE", "DISEASE", 27, 30]]], ["A study was conducted based on a multinational survey and data analyzing 38 patients with cSLE-MAS [72] .", [["cSLE", "DISEASE", 90, 94], ["MAS", "DISEASE", 95, 98], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["A study", "TEST", 0, 7], ["a multinational survey", "TEST", 31, 53], ["data analyzing", "TEST", 58, 72]]], ["Patients who had evidence of macrophage hemophagocytosis on bone marrow aspiration were considered to have definite MAS, and those who did not were considered to have probable MAS.", [["macrophage", "ANATOMY", 29, 39], ["bone marrow", "ANATOMY", 60, 71], ["hemophagocytosis", "DISEASE", 40, 56], ["MAS", "DISEASE", 116, 119], ["MAS", "DISEASE", 176, 179], ["Patients", "ORGANISM", 0, 8], ["macrophage", "CELL", 29, 39], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 60, 71], ["Patients", "SPECIES", 0, 8], ["macrophage hemophagocytosis", "PROBLEM", 29, 56], ["bone marrow aspiration", "PROBLEM", 60, 82], ["MAS", "PROBLEM", 176, 179], ["evidence of", "UNCERTAINTY", 17, 28], ["macrophage hemophagocytosis", "OBSERVATION", 29, 56], ["bone", "ANATOMY", 60, 64], ["marrow aspiration", "OBSERVATION", 65, 82]]], ["The sensitivity, specificity, and the area under the receiver operating characteristic curve of various clinical and laboratory parameters were compared in SLE patients with MAS versus patients with active juvenile SLE without MAS.", [["SLE", "DISEASE", 156, 159], ["MAS", "DISEASE", 174, 177], ["juvenile SLE", "DISEASE", 206, 218], ["MAS", "DISEASE", 227, 230], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 185, 193], ["The sensitivity", "TEST", 0, 15], ["laboratory parameters", "TEST", 117, 138], ["active juvenile SLE", "PROBLEM", 199, 218], ["MAS", "PROBLEM", 227, 230]]], ["The best diagnostic performance was obtained using the simultaneous presence of any one or more clinical criteria and any two or more laboratory criteria, which had a sensitivity of 92.1% and a specificity of 90.9% (Table 14.", [["a sensitivity", "TEST", 165, 178], ["a specificity", "TEST", 192, 205]]], ["The demonstration of macrophage hemophagocytosis in the bone marrow aspirate was considered necessary for confirmation of doubtful cases only.", [["macrophage", "ANATOMY", 21, 31], ["bone marrow aspirate", "ANATOMY", 56, 76], ["hemophagocytosis", "DISEASE", 32, 48], ["macrophage", "CELL", 21, 31], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 56, 67], ["macrophage hemophagocytosis", "PROBLEM", 21, 48], ["the bone marrow aspirate", "TEST", 52, 76], ["macrophage hemophagocytosis", "OBSERVATION", 21, 48], ["bone", "ANATOMY", 56, 60]]], ["Those results have led to the practical recommendation that in the clinical setting, MAS should be suspected in a patient with cSLE presenting with unexplained fever and cytopenia associated with hyperferritinemia.", [["cSLE", "DISEASE", 127, 131], ["fever", "DISEASE", 160, 165], ["cytopenia", "DISEASE", 170, 179], ["hyperferritinemia", "DISEASE", 196, 213], ["patient", "ORGANISM", 114, 121], ["cSLE", "CANCER", 127, 131], ["patient", "SPECIES", 114, 121], ["unexplained fever", "PROBLEM", 148, 165], ["cytopenia", "PROBLEM", 170, 179], ["hyperferritinemia", "PROBLEM", 196, 213], ["fever", "OBSERVATION", 160, 165], ["cytopenia", "OBSERVATION", 170, 179], ["hyperferritinemia", "OBSERVATION", 196, 213]]], ["Both HLH-2004 criteria and preliminary diagnostic guidelines for sJIA-MAS were tested in the study but were found to be inaccurate for detecting cSLE-MAS.", [["HLH", "DISEASE", 5, 8], ["MAS", "DISEASE", 150, 153], ["sJIA", "PROBLEM", 65, 69], ["MAS", "PROBLEM", 70, 73], ["the study", "TEST", 89, 98], ["HLH", "OBSERVATION", 5, 8]]], ["Interestingly, about twothirds of the patients with cSLE-MAS developed it within 1 month of SLE diagnosis.", [["cSLE", "DISEASE", 52, 56], ["MAS", "DISEASE", 57, 60], ["SLE", "DISEASE", 92, 95], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["The frequency of ICU admission was 43.7%, and the mortality rate was 11.4%.Generic MAS Criteria/HScoreIn 2014, Fardet et al. developed and partially validated a diagnostic score for the broader category of reactive hemophagocytic syndrome (HS), called the HScore [79] , which can be used to estimate an individual's risk of having reactive hemophagocytic syndrome, or HLH.", [["hemophagocytic syndrome", "DISEASE", 215, 238], ["reactive hemophagocytic syndrome", "DISEASE", 331, 363], ["HLH", "DISEASE", 368, 371], ["the mortality rate", "TEST", 46, 64], ["reactive hemophagocytic syndrome", "PROBLEM", 206, 238], ["reactive hemophagocytic syndrome", "PROBLEM", 331, 363], ["HLH", "PROBLEM", 368, 371], ["reactive", "OBSERVATION_MODIFIER", 206, 214], ["hemophagocytic syndrome", "OBSERVATION", 215, 238], ["reactive", "OBSERVATION_MODIFIER", 331, 339], ["hemophagocytic syndrome", "OBSERVATION", 340, 363]]], ["This score was created and tested using a multicenter retrospective cohort of 312 patients scrutinizing 10 explanatory variables that were issued from a previous Delphi survey involving 24 HLH experts from 13 countries [80] .", [["HLH", "DISEASE", 189, 192], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["This score", "TEST", 0, 10]]], ["After showing positive associations of each variable with an HLH diagnosis, multivariate logistic regression was used to assess their independent contributions to the outcome.", [["HLH", "DISEASE", 61, 64], ["an HLH diagnosis", "TEST", 58, 74], ["multivariate logistic regression", "PROBLEM", 76, 108]]], ["Following calculating each variable's threshold value, the coefficients resulting from multiple logistic regression analysis were used to assign score points to each one.", [["calculating each variable's threshold value", "TEST", 10, 53], ["multiple logistic regression analysis", "PROBLEM", 87, 124]]], ["The performance of the score was assessed using developmental and validation data sets.", [["the score", "TEST", 19, 28], ["developmental and validation data sets", "TEST", 48, 86]]], ["The HScore revealed excellent diagnostic performance and discriminative ability in both developmental and validation data sets.", [["The HScore", "TEST", 0, 10], ["excellent", "OBSERVATION_MODIFIER", 20, 29]]], ["The probability of having HLH ranged from <1% with an HScore of \u226490 to >99% with an HScore of \u2265250.", [["HLH", "DISEASE", 26, 29], ["HLH", "TEST", 26, 29], ["an HScore", "TEST", 51, 60], ["an HScore", "TEST", 81, 90], ["HLH", "OBSERVATION", 26, 29]]], ["The HScore has some limitations including the heterogeneity of the underlying diseases (a high proportion had cancer-associated HLH), the retrospective manner of the data collection, and the small sample size (only 10% of the entire study population) of the validation data set.", [["cancer", "ANATOMY", 110, 116], ["cancer", "DISEASE", 110, 116], ["HLH", "DISEASE", 128, 131], ["cancer", "CANCER", 110, 116], ["the underlying diseases", "PROBLEM", 63, 86], ["cancer", "PROBLEM", 110, 116], ["HLH", "PROBLEM", 128, 131], ["the data collection", "TEST", 162, 181], ["the small sample size", "PROBLEM", 187, 208], ["the entire study population", "TEST", 222, 249], ["the validation data", "TEST", 254, 273], ["heterogeneity", "OBSERVATION_MODIFIER", 46, 59], ["underlying", "OBSERVATION_MODIFIER", 67, 77], ["diseases", "OBSERVATION", 78, 86], ["cancer", "OBSERVATION", 110, 116], ["small", "OBSERVATION_MODIFIER", 191, 196], ["sample", "OBSERVATION_MODIFIER", 197, 203], ["size", "OBSERVATION_MODIFIER", 204, 208]]], ["As the study included only adults with reactive HLH, the applicability in children, particularly those with sJIA-MAS, is questionable.", [["HLH", "DISEASE", 48, 51], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["the study", "TEST", 3, 12], ["reactive HLH", "PROBLEM", 39, 51], ["reactive", "OBSERVATION_MODIFIER", 39, 47], ["HLH", "OBSERVATION", 48, 51]]], ["Adding to its limitations in pediatric cases, some of the criteria in the HScore might not be practically applicable in children.", [["children", "ORGANISM", 120, 128], ["children", "SPECIES", 120, 128]]], ["For example, the definition of the item, \"Known underlying immunosuppression,\" lists some medications that are used infrequently in children with sJIA, such as cyclosporine A and azathioprine, and at the same time it does not mention the newer more widely used cytokine antagonists that have been associated with the occurrence of MAS [25, 81, 82] .", [["sJIA", "DISEASE", 146, 150], ["cyclosporine A", "CHEMICAL", 160, 174], ["azathioprine", "CHEMICAL", 179, 191], ["MAS", "DISEASE", 331, 334], ["cyclosporine A", "CHEMICAL", 160, 174], ["azathioprine", "CHEMICAL", 179, 191], ["children", "ORGANISM", 132, 140], ["cyclosporine A", "SIMPLE_CHEMICAL", 160, 174], ["azathioprine", "SIMPLE_CHEMICAL", 179, 191], ["cytokine", "PROTEIN", 261, 269], ["children", "SPECIES", 132, 140], ["some medications", "TREATMENT", 85, 101], ["sJIA", "TREATMENT", 146, 150], ["cyclosporine A", "TREATMENT", 160, 174], ["azathioprine", "TREATMENT", 179, 191], ["cytokine antagonists", "TREATMENT", 261, 281], ["immunosuppression", "OBSERVATION", 59, 76]]], ["Moreover, bone marrow aspirates in a search for hemophagocytosis are not frequently performed in children with sJIA-MAS, as it is not considered mandatory in either the HLH-2004 guidelines [11] or the preliminary MAS guidelines [71] .", [["bone marrow aspirates", "ANATOMY", 10, 31], ["hemophagocytosis", "DISEASE", 48, 64], ["HLH", "DISEASE", 169, 172], ["bone marrow aspirates", "MULTI-TISSUE_STRUCTURE", 10, 31], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["bone marrow aspirates", "TEST", 10, 31], ["hemophagocytosis", "PROBLEM", 48, 64], ["bone", "ANATOMY", 10, 14], ["marrow", "ANATOMY", 15, 21], ["aspirates", "OBSERVATION", 22, 31]]], ["In fact, absence of hemophagocytosis does not rule out MAS, and the procedure should not delay appropriate therapy.", [["hemophagocytosis", "DISEASE", 20, 36], ["MAS", "DISEASE", 55, 58], ["hemophagocytosis", "PROBLEM", 20, 36], ["MAS", "PROBLEM", 55, 58], ["the procedure", "TREATMENT", 64, 77], ["appropriate therapy", "TREATMENT", 95, 114], ["hemophagocytosis", "OBSERVATION", 20, 36]]], ["Furthermore, the underlying inflammatory nature of sJIA that is associated with marked thrombocytosis makes the threshold level for the platelet count (110,000/mm 3 ) too low for identifying MAS in the setting of sJIA.", [["platelet", "ANATOMY", 136, 144], ["sJIA", "DISEASE", 51, 55], ["thrombocytosis", "DISEASE", 87, 101], ["MAS", "DISEASE", 191, 194], ["sJIA", "DISEASE", 213, 217], ["sJIA", "CANCER", 51, 55], ["platelet", "CELL", 136, 144], ["sJIA", "CANCER", 213, 217], ["sJIA", "PROBLEM", 51, 55], ["marked thrombocytosis", "PROBLEM", 80, 101], ["the platelet count", "TEST", 132, 150], ["MAS", "PROBLEM", 191, 194], ["sJIA", "PROBLEM", 213, 217], ["inflammatory", "OBSERVATION_MODIFIER", 28, 40], ["sJIA", "OBSERVATION", 51, 55], ["marked", "OBSERVATION_MODIFIER", 80, 86], ["thrombocytosis", "OBSERVATION", 87, 101], ["sJIA", "OBSERVATION", 213, 217]]], ["It is the relative drop in platelets count, rather than an absolute decrease below a certain threshold, that is more useful to make an early diagnosis [77] .", [["platelets", "ANATOMY", 27, 36], ["platelets", "CELL", 27, 36], ["platelets", "CELL_TYPE", 27, 36], ["the relative drop in platelets count", "PROBLEM", 6, 42], ["an absolute decrease", "PROBLEM", 56, 76], ["relative", "OBSERVATION_MODIFIER", 10, 18], ["drop", "OBSERVATION_MODIFIER", 19, 23], ["platelets count", "OBSERVATION", 27, 42]]], ["Thus, the HScore is likely more valuable in diagnosing adults with HLH, particularly those with associated leukemias and lymphomas.New BiomarkersA new promising laboratory marker of MAS is soluble CD163 (sCD163).", [["leukemias", "ANATOMY", 107, 116], ["lymphomas", "ANATOMY", 121, 130], ["HLH", "DISEASE", 67, 70], ["leukemias", "DISEASE", 107, 116], ["lymphomas", "DISEASE", 121, 130], ["leukemias", "CANCER", 107, 116], ["lymphomas", "CANCER", 121, 130], ["CD163", "GENE_OR_GENE_PRODUCT", 197, 202], ["CD163", "GENE_OR_GENE_PRODUCT", 205, 210], ["CD163", "PROTEIN", 197, 202], ["CD163", "PROTEIN", 205, 210], ["HLH", "PROBLEM", 67, 70], ["associated leukemias", "PROBLEM", 96, 116], ["lymphomas", "PROBLEM", 121, 130], ["soluble CD163", "TEST", 189, 202], ["HLH", "OBSERVATION", 67, 70], ["leukemias", "OBSERVATION", 107, 116], ["lymphomas", "OBSERVATION", 121, 130], ["new", "OBSERVATION_MODIFIER", 147, 150], ["promising", "OBSERVATION_MODIFIER", 151, 160]]], ["Its expression is restricted to the macrophage/monocyte lineage only, unlike ferritin and soluble CD25 (IL-2 receptor \u03b1-chain), which are produced by a number of tissues and cell types, including the liver, spleen, heart, kidney, and T cells under a variety of nonspecific inflammatory conditions. sCD163 has been mainly evaluated in MAS, where combination testing of sCD25 and sCD163 identified patients with subclinical MAS [83] .", [["macrophage", "ANATOMY", 36, 46], ["monocyte lineage", "ANATOMY", 47, 63], ["tissues", "ANATOMY", 162, 169], ["cell", "ANATOMY", 174, 178], ["liver", "ANATOMY", 200, 205], ["spleen", "ANATOMY", 207, 213], ["heart", "ANATOMY", 215, 220], ["kidney", "ANATOMY", 222, 228], ["T cells", "ANATOMY", 234, 241], ["sCD163", "CHEMICAL", 298, 304], ["macrophage", "CELL", 36, 46], ["monocyte lineage", "CELL", 47, 63], ["ferritin", "GENE_OR_GENE_PRODUCT", 77, 85], ["CD25", "GENE_OR_GENE_PRODUCT", 98, 102], ["IL-2 receptor \u03b1-chain", "GENE_OR_GENE_PRODUCT", 104, 125], ["tissues", "TISSUE", 162, 169], ["cell types", "CELL", 174, 184], ["liver", "ORGAN", 200, 205], ["spleen", "ORGAN", 207, 213], ["heart", "ORGAN", 215, 220], ["kidney", "ORGAN", 222, 228], ["T cells", "CELL", 234, 241], ["sCD163", "GENE_OR_GENE_PRODUCT", 298, 304], ["sCD25", "GENE_OR_GENE_PRODUCT", 368, 373], ["sCD163", "GENE_OR_GENE_PRODUCT", 378, 384], ["patients", "ORGANISM", 396, 404], ["macrophage", "CELL_TYPE", 36, 46], ["monocyte lineage", "CELL_TYPE", 47, 63], ["ferritin", "PROTEIN", 77, 85], ["soluble CD25 (IL-2 receptor \u03b1-chain", "PROTEIN", 90, 125], ["T cells", "CELL_TYPE", 234, 241], ["sCD163", "PROTEIN", 298, 304], ["sCD25", "PROTEIN", 368, 373], ["sCD163", "PROTEIN", 378, 384], ["patients", "SPECIES", 396, 404], ["the macrophage/monocyte lineage", "TEST", 32, 63], ["ferritin", "TEST", 77, 85], ["soluble CD25", "TEST", 90, 102], ["nonspecific inflammatory conditions", "PROBLEM", 261, 296], ["sCD163", "TEST", 298, 304], ["combination testing", "TEST", 345, 364], ["sCD25", "PROBLEM", 368, 373], ["sCD163", "TEST", 378, 384], ["subclinical MAS", "PROBLEM", 410, 425], ["monocyte lineage", "OBSERVATION", 47, 63], ["cell types", "OBSERVATION", 174, 184], ["liver", "ANATOMY", 200, 205], ["spleen", "ANATOMY", 207, 213], ["heart", "ANATOMY", 215, 220], ["kidney", "ANATOMY", 222, 228], ["nonspecific", "OBSERVATION_MODIFIER", 261, 272], ["inflammatory conditions", "OBSERVATION", 273, 296]]], ["Further studies to evaluate its role in HLH not associated with autoimmune diseases are required.", [["HLH", "DISEASE", 40, 43], ["autoimmune diseases", "DISEASE", 64, 83], ["Further studies", "TEST", 0, 15], ["HLH", "PROBLEM", 40, 43], ["autoimmune diseases", "PROBLEM", 64, 83], ["HLH", "OBSERVATION", 40, 43], ["not associated with", "UNCERTAINTY", 44, 63], ["autoimmune", "OBSERVATION", 64, 74]]], ["Moreover, like sCD25, the testing is not currently available in a timely fashion in most centers around the world.New BiomarkersAnother novel biomarker, follistatin-related protein 1 (FSTL-1) was reported by Gorelik et al. to be elevated in active sJIA with higher levels during MAS.", [["sCD25", "GENE_OR_GENE_PRODUCT", 15, 20], ["follistatin-related protein 1", "GENE_OR_GENE_PRODUCT", 153, 182], ["FSTL-1", "GENE_OR_GENE_PRODUCT", 184, 190], ["sJIA", "CANCER", 248, 252], ["sCD25", "PROTEIN", 15, 20], ["follistatin-related protein 1", "PROTEIN", 153, 182], ["FSTL", "PROTEIN", 184, 188], ["the testing", "TEST", 22, 33], ["New Biomarkers", "TEST", 114, 128], ["Another novel biomarker", "TEST", 128, 151], ["follistatin", "TEST", 153, 164], ["protein", "TEST", 173, 180], ["FSTL", "TEST", 184, 188], ["elevated in active sJIA", "PROBLEM", 229, 252], ["elevated", "OBSERVATION", 229, 237], ["active", "OBSERVATION_MODIFIER", 241, 247], ["sJIA", "OBSERVATION", 248, 252]]], ["FSTL-1 levels correlated with sCD25 and ferritin levels, and FSTL-1 normalized after treatment.", [["FSTL-1", "GENE_OR_GENE_PRODUCT", 0, 6], ["sCD25", "GENE_OR_GENE_PRODUCT", 30, 35], ["ferritin", "GENE_OR_GENE_PRODUCT", 40, 48], ["FSTL-1", "GENE_OR_GENE_PRODUCT", 61, 67], ["FSTL", "PROTEIN", 0, 4], ["sCD25", "PROTEIN", 30, 35], ["ferritin", "PROTEIN", 40, 48], ["FSTL", "PROTEIN", 61, 65], ["FSTL", "TEST", 0, 4], ["sCD25", "TEST", 30, 35], ["ferritin levels", "TEST", 40, 55], ["FSTL", "TEST", 61, 65], ["treatment", "TREATMENT", 85, 94]]], ["Perhaps more importantly, Gorelik et al. also reported that in their small cohort (28 sJIA patients) a ferritin to ESR ratio > 80 had the highest sensitivity and specificity (100% and 100%, respectively) in distinguishing between MAS and new-onset sJIA disease flare [84] .", [["MAS", "DISEASE", 230, 233], ["patients", "ORGANISM", 91, 99], ["ferritin", "GENE_OR_GENE_PRODUCT", 103, 111], ["ferritin", "PROTEIN", 103, 111], ["ESR", "PROTEIN", 115, 118], ["patients", "SPECIES", 91, 99], ["a ferritin", "TEST", 101, 111], ["ESR ratio", "TEST", 115, 124], ["specificity", "TEST", 162, 173], ["MAS", "PROBLEM", 230, 233], ["new-onset sJIA disease flare", "PROBLEM", 238, 266], ["small", "OBSERVATION_MODIFIER", 69, 74], ["new", "OBSERVATION_MODIFIER", 238, 241], ["onset", "OBSERVATION_MODIFIER", 242, 247], ["sJIA disease", "OBSERVATION", 248, 260]]], ["As ferritin rises due to inflammation in MAS/HLH, and the ESR tends to drop as fibrinogen (an important driver of high ESRs) is consumed during coagulopathy, a simple ratio of ferritin to ESR may prove to be a simple and valuable tool in getting clinicians to consider a diagnosis of MAS/HLH in their febrile hospitalized patients.New BiomarkersAlthough the serum IL-18 level is also not routinely available clinically, it may also serve as a distinguishing biomarker for sJIA patients who develop MAS.", [["serum", "ANATOMY", 358, 363], ["inflammation", "DISEASE", 25, 37], ["HLH", "DISEASE", 45, 48], ["coagulopathy", "DISEASE", 144, 156], ["MAS", "DISEASE", 284, 287], ["HLH", "DISEASE", 288, 291], ["febrile", "DISEASE", 301, 308], ["MAS", "DISEASE", 498, 501], ["ferritin", "GENE_OR_GENE_PRODUCT", 3, 11], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 79, 89], ["ferritin", "GENE_OR_GENE_PRODUCT", 176, 184], ["patients", "ORGANISM", 322, 330], ["serum", "ORGANISM_SUBSTANCE", 358, 363], ["IL-18", "GENE_OR_GENE_PRODUCT", 364, 369], ["patients", "ORGANISM", 477, 485], ["ferritin", "PROTEIN", 3, 11], ["fibrinogen", "PROTEIN", 79, 89], ["ferritin", "PROTEIN", 176, 184], ["serum IL-18", "PROTEIN", 358, 369], ["patients", "SPECIES", 322, 330], ["patients", "SPECIES", 477, 485], ["ferritin rises", "PROBLEM", 3, 17], ["inflammation", "PROBLEM", 25, 37], ["MAS", "PROBLEM", 41, 44], ["HLH", "PROBLEM", 45, 48], ["the ESR", "TEST", 54, 61], ["fibrinogen", "TEST", 79, 89], ["high ESRs)", "PROBLEM", 114, 124], ["coagulopathy", "PROBLEM", 144, 156], ["a simple ratio of ferritin", "PROBLEM", 158, 184], ["ESR", "TEST", 188, 191], ["MAS", "PROBLEM", 284, 287], ["HLH", "PROBLEM", 288, 291], ["New Biomarkers", "TEST", 331, 345], ["the serum IL", "TEST", 354, 366], ["MAS", "PROBLEM", 498, 501], ["inflammation", "OBSERVATION", 25, 37], ["HLH", "OBSERVATION", 45, 48], ["HLH", "OBSERVATION", 288, 291]]], ["Comparing cytokine patterns between sJIA-MAS patients, EBV-HLH, Kawasaki disease, and healthy age-matched controls, Shimizu et al. reported that IL-18 concentrations during sJIA-MAS were significantly higher compared to the others, and they correlated with measures of disease activity (CRP, ferritin, LDH, and other cytokines).", [["EBV-HLH", "DISEASE", 55, 62], ["Kawasaki disease", "DISEASE", 64, 80], ["patients", "ORGANISM", 45, 53], ["EBV", "ORGANISM", 55, 58], ["IL-18", "GENE_OR_GENE_PRODUCT", 145, 150], ["sJIA", "SIMPLE_CHEMICAL", 173, 177], ["CRP", "GENE_OR_GENE_PRODUCT", 287, 290], ["ferritin", "GENE_OR_GENE_PRODUCT", 292, 300], ["LDH", "GENE_OR_GENE_PRODUCT", 302, 305], ["cytokine", "PROTEIN", 10, 18], ["IL-18", "PROTEIN", 145, 150], ["CRP", "PROTEIN", 287, 290], ["ferritin", "PROTEIN", 292, 300], ["LDH", "PROTEIN", 302, 305], ["cytokines", "PROTEIN", 317, 326], ["patients", "SPECIES", 45, 53], ["cytokine patterns", "TEST", 10, 27], ["EBV", "PROBLEM", 55, 58], ["HLH", "PROBLEM", 59, 62], ["Kawasaki disease", "PROBLEM", 64, 80], ["IL", "TEST", 145, 147], ["sJIA", "PROBLEM", 173, 177], ["MAS", "PROBLEM", 178, 181], ["disease activity", "PROBLEM", 269, 285], ["CRP", "TEST", 287, 290], ["ferritin", "TEST", 292, 300], ["LDH", "TEST", 302, 305], ["other cytokines", "TEST", 311, 326], ["HLH", "ANATOMY", 59, 62], ["Kawasaki disease", "OBSERVATION", 64, 80], ["LDH", "ANATOMY", 302, 305]]], ["In addition, serum neopterin and sTNF-RII levels were significantly higher during MAS compared to sJIA flares [85] .", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["neopterin", "GENE_OR_GENE_PRODUCT", 19, 28], ["sTNF-RII", "GENE_OR_GENE_PRODUCT", 33, 41], ["serum neopterin", "PROTEIN", 13, 28], ["sTNF", "PROTEIN", 33, 37], ["RII", "PROTEIN", 38, 41], ["serum neopterin", "TEST", 13, 28], ["sTNF-RII levels", "TEST", 33, 48], ["sJIA flares", "PROBLEM", 98, 109]]], ["Other reports also showed that IL-18 levels were significantly elevated in sJIA [86, 87] and the patients with high levels were more likely to develop MAS [88] .", [["MAS", "DISEASE", 151, 154], ["IL-18", "GENE_OR_GENE_PRODUCT", 31, 36], ["sJIA", "CANCER", 75, 79], ["patients", "ORGANISM", 97, 105], ["IL", "PROTEIN", 31, 33], ["patients", "SPECIES", 97, 105], ["IL", "TEST", 31, 33], ["significantly elevated", "PROBLEM", 49, 71], ["sJIA", "TEST", 75, 79], ["high levels", "PROBLEM", 111, 122], ["MAS", "TEST", 151, 154], ["elevated", "OBSERVATION_MODIFIER", 63, 71]]], ["Furthermore, sphingomyelinase was found to be elevated in HLH cases [89] .", [["HLH", "DISEASE", 58, 61], ["sphingomyelinase", "GENE_OR_GENE_PRODUCT", 13, 29], ["sphingomyelinase", "PROTEIN", 13, 29], ["sphingomyelinase", "TEST", 13, 29], ["elevated in HLH cases", "PROBLEM", 46, 67], ["elevated", "OBSERVATION_MODIFIER", 46, 54]]], ["Thus, a variety of new biomarkers may help identify MAS among sJIA patients.Genetic AssociationsGenetic HLH has been commonly classified into two groups: fHLH which are a group of autosomal recessive disorders, and immunodeficiency syndromes related HLH.", [["sJIA", "DISEASE", 62, 66], ["Genetic HLH", "DISEASE", 96, 107], ["fHLH", "DISEASE", 154, 158], ["autosomal recessive disorders", "DISEASE", 180, 209], ["immunodeficiency syndromes", "DISEASE", 215, 241], ["HLH", "DISEASE", 250, 253], ["patients", "ORGANISM", 67, 75], ["fHLH", "CANCER", 154, 158], ["patients", "SPECIES", 67, 75], ["new biomarkers", "TEST", 19, 33], ["autosomal recessive disorders", "PROBLEM", 180, 209], ["immunodeficiency syndromes", "PROBLEM", 215, 241], ["HLH", "PROBLEM", 250, 253], ["HLH", "OBSERVATION", 104, 107]]], ["Of the immunodeficiency syndromes, Chediak-Higashi, Griscelli, and Hermansky-Pudlak are associated with a variable degree of albinism/hypopigmentation of the skin or hair and platelet dysfunction which can assist in identifying potential cases of HLH (Table 14.", [["skin", "ANATOMY", 158, 162], ["hair", "ANATOMY", 166, 170], ["platelet", "ANATOMY", 175, 183], ["immunodeficiency syndromes", "DISEASE", 7, 33], ["albinism", "DISEASE", 125, 133], ["hypopigmentation", "DISEASE", 134, 150], ["platelet dysfunction", "DISEASE", 175, 195], ["HLH", "DISEASE", 247, 250], ["skin", "ORGAN", 158, 162], ["hair", "MULTI-TISSUE_STRUCTURE", 166, 170], ["platelet", "CELL", 175, 183], ["the immunodeficiency syndromes", "PROBLEM", 3, 33], ["Chediak", "TEST", 35, 42], ["Griscelli", "PROBLEM", 52, 61], ["Pudlak", "PROBLEM", 77, 83], ["albinism/hypopigmentation of the skin", "PROBLEM", 125, 162], ["hair and platelet dysfunction", "PROBLEM", 166, 195], ["HLH", "PROBLEM", 247, 250], ["immunodeficiency syndromes", "OBSERVATION", 7, 33], ["variable degree", "OBSERVATION_MODIFIER", 106, 121], ["albinism", "OBSERVATION", 125, 133], ["hypopigmentation", "OBSERVATION", 134, 150], ["skin", "ANATOMY", 158, 162], ["hair", "ANATOMY", 166, 170], ["platelet dysfunction", "OBSERVATION", 175, 195], ["HLH", "OBSERVATION", 247, 250]]], ["3) [2, [90] [91] [92] .", [["[2, [90] [91] [92]", "SIMPLE_CHEMICAL", 3, 21]]], ["Interestingly, up to 40% of sHLH cases possess heterozygous mutations in these same fHLH-associated gene products.", [["sHLH", "CANCER", 28, 32], ["fHLH", "GENE_OR_GENE_PRODUCT", 84, 88], ["fHLH-associated gene products", "PROTEIN", 84, 113], ["heterozygous mutations", "PROBLEM", 47, 69], ["heterozygous mutations", "OBSERVATION", 47, 69]]], ["Thus, the overall underlying genetic risk for sHLH may be rather striking.Genetic AssociationsIn addition to underlying inflammatory states (e.g., sJIA, leukemia) and genetic predispositions (e.g., perforin deficiency), infections (some from the commensal human microbiome) are frequently significant contributing factors in lowering the threshold required to develop a cytokine storm syndrome capable of resulting in HLH/ MAS (Table 14 .4).", [["leukemia", "ANATOMY", 153, 161], ["sHLH", "DISEASE", 46, 50], ["leukemia", "DISEASE", 153, 161], ["genetic predispositions", "DISEASE", 167, 190], ["perforin deficiency", "DISEASE", 198, 217], ["infections", "DISEASE", 220, 230], ["HLH", "DISEASE", 418, 421], ["sHLH", "CANCER", 46, 50], ["leukemia", "CANCER", 153, 161], ["perforin", "GENE_OR_GENE_PRODUCT", 198, 206], ["human", "ORGANISM", 256, 261], ["perforin", "PROTEIN", 198, 206], ["cytokine", "PROTEIN", 370, 378], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["sHLH", "PROBLEM", 46, 50], ["underlying inflammatory states", "PROBLEM", 109, 139], ["sJIA", "PROBLEM", 147, 151], ["leukemia", "PROBLEM", 153, 161], ["genetic predispositions", "PROBLEM", 167, 190], ["perforin deficiency)", "PROBLEM", 198, 218], ["infections", "PROBLEM", 220, 230], ["a cytokine storm syndrome", "PROBLEM", 368, 393], ["HLH/ MAS", "PROBLEM", 418, 426], ["inflammatory", "OBSERVATION", 120, 132], ["leukemia", "OBSERVATION", 153, 161], ["infections", "OBSERVATION", 220, 230]]], ["HLH has been associated with a vast variety of infections, with EBV as the most commonly reported trigger.", [["HLH", "DISEASE", 0, 3], ["infections", "DISEASE", 47, 57], ["EBV", "ORGANISM", 64, 67], ["EBV", "SPECIES", 64, 67], ["HLH", "PROBLEM", 0, 3], ["infections", "PROBLEM", 47, 57], ["EBV", "PROBLEM", 64, 67], ["infections", "OBSERVATION", 47, 57]]], ["Both familial (fHLH) and sporadic or secondary (sHLH) cases of HLH are often precipitated by acute infections.", [["familial", "DISEASE", 5, 13], ["fHLH", "DISEASE", 15, 19], ["sHLH", "DISEASE", 48, 52], ["HLH", "DISEASE", 63, 66], ["infections", "DISEASE", 99, 109], ["Both familial (fHLH)", "PROBLEM", 0, 20], ["secondary (sHLH) cases of HLH", "PROBLEM", 37, 66], ["acute infections", "PROBLEM", 93, 109], ["HLH", "OBSERVATION", 63, 66], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["infections", "OBSERVATION", 99, 109]]], ["It is also important to note that an underlying precipitating infection for HLH can be masked, as the HLH clinical picture can mimic an infectious process or Mycoplasma pneumoniae [146, 147] , Salmonella typhi [148] , Staphylococcus aureus [149, 150] , Klebsiella pneumoniae [151] , Aeromonas hydrophila [151] , Fusobacterium sp.", [["infection", "DISEASE", 62, 71], ["HLH", "DISEASE", 76, 79], ["HLH", "DISEASE", 102, 105], ["Mycoplasma pneumoniae", "DISEASE", 158, 179], ["Staphylococcus aureus", "DISEASE", 218, 239], ["Klebsiella pneumoniae", "DISEASE", 253, 274], ["Aeromonas hydrophila", "DISEASE", 283, 303], ["Mycoplasma pneumoniae", "ORGANISM", 158, 179], ["Salmonella typhi [148]", "ORGANISM", 193, 215], ["Staphylococcus aureus", "ORGANISM", 218, 239], ["Klebsiella pneumoniae", "ORGANISM", 253, 274], ["Aeromonas hydrophila", "ORGANISM", 283, 303], ["Fusobacterium sp", "ORGANISM", 312, 328], ["Mycoplasma pneumoniae", "SPECIES", 158, 179], ["Salmonella typhi", "SPECIES", 193, 209], ["Staphylococcus aureus", "SPECIES", 218, 239], ["Klebsiella pneumoniae", "SPECIES", 253, 274], ["Aeromonas hydrophila", "SPECIES", 283, 303], ["Mycoplasma pneumoniae", "SPECIES", 158, 179], ["Salmonella typhi", "SPECIES", 193, 209], ["Staphylococcus aureus", "SPECIES", 218, 239], ["Klebsiella pneumoniae", "SPECIES", 253, 274], ["Aeromonas hydrophila", "SPECIES", 283, 303], ["an underlying precipitating infection", "PROBLEM", 34, 71], ["HLH", "PROBLEM", 76, 79], ["the HLH clinical picture", "TEST", 98, 122], ["an infectious process", "PROBLEM", 133, 154], ["Mycoplasma pneumoniae", "PROBLEM", 158, 179], ["Salmonella typhi", "TEST", 193, 209], ["Staphylococcus aureus", "PROBLEM", 218, 239], ["Klebsiella pneumoniae", "PROBLEM", 253, 274], ["Aeromonas hydrophila", "TEST", 283, 303], ["Fusobacterium sp", "PROBLEM", 312, 328], ["infection", "OBSERVATION", 62, 71], ["infectious", "OBSERVATION", 136, 146]]], ["[152] , Chlamydia pneumoniae [153] , Legionella pneumophila [152] , Mycobacterium tuberculosis [154, 155] , Mycobacterium bovis-weakened form (bacillus Calmette-Gu\u00e9rin) [156, 157] , intravesical BCG [158] , Acinetobacter baumannii [159] , Escherichia coli [160] , M. leprae [161] , Abiotrophia defectiva in endocarditis patient [162]Zoonotic bacteriaAnaplasma phagocytophilum [163] , Bartonella henselae [164] , Borrelia burgdorferi (Lyme disease) [165] , Brucella sp.", [["Chlamydia pneumoniae", "DISEASE", 8, 28], ["Legionella pneumophila", "DISEASE", 37, 59], ["Mycobacterium tuberculosis", "DISEASE", 68, 94], ["Abiotrophia defectiva", "DISEASE", 282, 303], ["endocarditis", "DISEASE", 307, 319], ["Bartonella henselae", "DISEASE", 384, 403], ["Borrelia burgdorferi", "DISEASE", 412, 432], ["Lyme disease", "DISEASE", 434, 446], ["Chlamydia pneumoniae", "ORGANISM", 8, 28], ["Legionella pneumophila", "ORGANISM", 37, 59], ["Mycobacterium tuberculosis", "ORGANISM", 68, 94], ["Mycobacterium bovis", "ORGANISM", 108, 127], ["bacillus Calmette-Gu\u00e9rin", "ORGANISM", 143, 167], ["Acinetobacter baumannii", "ORGANISM", 207, 230], ["Escherichia coli", "ORGANISM", 239, 255], ["M. leprae", "ORGANISM", 264, 273], ["Abiotrophia defectiva", "ORGANISM", 282, 303], ["patient", "ORGANISM", 320, 327], ["Zoonotic bacteriaAnaplasma phagocytophilum", "ORGANISM", 333, 375], ["Bartonella henselae", "ORGANISM", 384, 403], ["Borrelia burgdorferi", "ORGANISM", 412, 432], ["Lyme disease", "ORGANISM", 434, 446], ["Brucella sp", "ORGANISM", 456, 467], ["Chlamydia pneumoniae", "SPECIES", 8, 28], ["Legionella pneumophila", "SPECIES", 37, 59], ["Mycobacterium tuberculosis", "SPECIES", 68, 94], ["Mycobacterium bovis", "SPECIES", 108, 127], ["Acinetobacter baumannii", "SPECIES", 207, 230], ["Escherichia coli", "SPECIES", 239, 255], ["M. leprae", "SPECIES", 264, 273], ["Abiotrophia defectiva", "SPECIES", 282, 303], ["patient", "SPECIES", 320, 327], ["Zoonotic bacteriaAnaplasma phagocytophilum", "SPECIES", 333, 375], ["Bartonella henselae", "SPECIES", 384, 403], ["Borrelia burgdorferi", "SPECIES", 412, 432], ["Chlamydia pneumoniae", "SPECIES", 8, 28], ["Legionella pneumophila", "SPECIES", 37, 59], ["Mycobacterium tuberculosis", "SPECIES", 68, 94], ["Mycobacterium bovis", "SPECIES", 108, 127], ["bacillus Calmette-Gu\u00e9rin", "SPECIES", 143, 167], ["Acinetobacter baumannii", "SPECIES", 207, 230], ["Escherichia coli", "SPECIES", 239, 255], ["M. leprae", "SPECIES", 264, 273], ["Abiotrophia defectiva", "SPECIES", 282, 303], ["Zoonotic bacteriaAnaplasma phagocytophilum", "SPECIES", 333, 375], ["Bartonella henselae", "SPECIES", 384, 403], ["Borrelia burgdorferi", "SPECIES", 412, 432], ["Chlamydia pneumoniae", "PROBLEM", 8, 28], ["Legionella pneumophila", "TEST", 37, 59], ["Mycobacterium tuberculosis", "PROBLEM", 68, 94], ["Mycobacterium bovis", "TEST", 108, 127], ["weakened form", "PROBLEM", 128, 141], ["bacillus Calmette", "TEST", 143, 160], ["intravesical BCG", "TEST", 182, 198], ["Acinetobacter baumannii", "TEST", 207, 230], ["Escherichia coli", "TEST", 239, 255], ["M. leprae", "TEST", 264, 273], ["Abiotrophia defectiva in endocarditis", "PROBLEM", 282, 319], ["Zoonotic bacteriaAnaplasma phagocytophilum", "TEST", 333, 375], ["Bartonella henselae", "PROBLEM", 384, 403], ["Borrelia burgdorferi (Lyme disease)", "PROBLEM", 412, 447], ["Brucella sp", "TREATMENT", 456, 467], ["Mycobacterium tuberculosis", "OBSERVATION", 68, 94], ["Mycobacterium bovis", "OBSERVATION", 108, 127], ["endocarditis", "OBSERVATION", 307, 319]]], ["[166] [167] [168] , Campylobacter sp.", [["Campylobacter sp", "ORGANISM", 20, 36], ["Campylobacter sp", "PROBLEM", 20, 36]]], ["[169] , Capnocytophaga sp.", [["Capnocytophaga sp", "PROBLEM", 8, 25]]], ["[170] , Clostridium sp.", [["Clostridium sp", "ORGANISM", 8, 22], ["Clostridium sp", "PROBLEM", 8, 22]]], ["[171, 172] ,Coxiella burnetii [173, 174] , Ehrlichia chaffeensis and Ehrlichia ewingii [175] [176] [177] , Leptospira sp.", [["Ehrlichia chaffeensis", "DISEASE", 43, 64], ["Coxiella burnetii", "ORGANISM", 12, 29], ["Ehrlichia", "ORGANISM", 43, 52], ["chaffeensis", "ORGANISM", 53, 64], ["Ehrlichia ewingii", "ORGANISM", 69, 86], ["Leptospira sp", "ORGANISM", 107, 120], ["Coxiella burnetii", "SPECIES", 12, 29], ["Ehrlichia chaffeensis", "SPECIES", 43, 64], ["Ehrlichia ewingii", "SPECIES", 69, 86], ["Leptospira", "SPECIES", 107, 117], ["Coxiella burnetii", "SPECIES", 12, 29], ["Ehrlichia chaffeensis", "SPECIES", 43, 64], ["Ehrlichia ewingii", "SPECIES", 69, 86], ["Coxiella burnetii", "TEST", 12, 29], ["Ehrlichia chaffeensis", "TEST", 43, 64], ["Ehrlichia ewingii", "TEST", 69, 86], ["Leptospira sp", "TEST", 107, 120]]], ["[178, 179] , Listeria monocytogenes [180] , Mycobacterium avium complex [181, 182] , Orientia tsutsugamushi [183] , Rickettsia spp.", [["Listeria monocytogenes", "ORGANISM", 13, 35], ["Mycobacterium avium", "ORGANISM", 44, 63], ["complex", "ORGANISM", 64, 71], ["Orientia tsutsugamushi", "ORGANISM", 85, 107], ["Rickettsia spp.", "ORGANISM", 116, 131], ["Listeria monocytogenes", "SPECIES", 13, 35], ["Mycobacterium avium", "SPECIES", 44, 63], ["Orientia tsutsugamushi", "SPECIES", 85, 107], ["Rickettsia spp.", "SPECIES", 116, 131], ["Listeria monocytogenes", "SPECIES", 13, 35], ["Mycobacterium avium", "SPECIES", 44, 63], ["Orientia tsutsugamushi", "SPECIES", 85, 107], ["Rickettsia spp.", "SPECIES", 116, 131], ["Listeria monocytogenes", "TEST", 13, 35], ["Mycobacterium avium complex", "TEST", 44, 71], ["Orientia tsutsugamushi", "TEST", 85, 107], ["Rickettsia spp.", "TEST", 116, 131]]], ["[184] , Salmonella sp. (excluding S. typhi) [185] Protozoal/zoonotic protozoa Leishmania sp.", [["Salmonella sp", "ORGANISM", 8, 21], ["S. typhi", "ORGANISM", 34, 42], ["Leishmania sp", "ORGANISM", 78, 91], ["S. typhi", "SPECIES", 34, 42], ["S. typhi", "SPECIES", 34, 42], ["Salmonella sp", "PROBLEM", 8, 21], ["Protozoal/zoonotic protozoa Leishmania sp", "PROBLEM", 50, 91], ["zoonotic", "OBSERVATION_MODIFIER", 60, 68], ["protozoa Leishmania", "OBSERVATION", 69, 88]]], ["[186] [187] [188] , Toxoplasma gondii [189, 190] , Babesia sp.", [["Toxoplasma gondii", "DISEASE", 20, 37], ["Toxoplasma gondii", "ORGANISM", 20, 37], ["Babesia sp", "ORGANISM", 51, 61], ["Toxoplasma gondii", "SPECIES", 20, 37], ["Toxoplasma gondii", "SPECIES", 20, 37], ["Toxoplasma gondii", "TEST", 20, 37], ["Babesia sp", "PROBLEM", 51, 61]]], ["[191] , Plasmodium falciparum [192] , Plasmodium vivax [193, 194] , Strongyloides stercoralis [152] FungalZoonotic bacteriaPneumocystis jiroveci [62] , Candida sp.", [["Plasmodium falciparum", "DISEASE", 8, 29], ["Plasmodium vivax", "DISEASE", 38, 54], ["Strongyloides stercoralis", "DISEASE", 68, 93], ["bacteriaPneumocystis jiroveci", "DISEASE", 115, 144], ["Plasmodium falciparum", "ORGANISM", 8, 29], ["Plasmodium vivax", "ORGANISM", 38, 54], ["Strongyloides stercoralis", "ORGANISM", 68, 93], ["FungalZoonotic bacteriaPneumocystis jiroveci", "ORGANISM", 100, 144], ["Candida sp", "ORGANISM", 152, 162], ["Plasmodium falciparum", "SPECIES", 8, 29], ["Plasmodium vivax", "SPECIES", 38, 54], ["Strongyloides stercoralis", "SPECIES", 68, 93], ["FungalZoonotic bacteriaPneumocystis jiroveci", "SPECIES", 100, 144], ["Plasmodium falciparum", "SPECIES", 8, 29], ["Plasmodium vivax", "SPECIES", 38, 54], ["Strongyloides stercoralis", "SPECIES", 68, 93], ["FungalZoonotic bacteriaPneumocystis jiroveci", "SPECIES", 100, 144], ["Plasmodium falciparum", "PROBLEM", 8, 29], ["Plasmodium vivax", "TEST", 38, 54], ["Strongyloides stercoralis", "PROBLEM", 68, 93], ["FungalZoonotic bacteriaPneumocystis jiroveci", "TREATMENT", 100, 144], ["Candida sp", "PROBLEM", 152, 162]]], ["[195] , Aspergillus sp.", [["Aspergillus sp", "ORGANISM", 8, 22], ["Aspergillus sp", "PROBLEM", 8, 22]]], ["[62] , Fusarium verticillioides [62]Zoonotic fungiCryptococcus neoformans [196] , Histoplasma capsulatum [197] [198] [199] , Penicillium marneffei [23, 200, 201] an overwhelming septicemia.", [["Fusarium verticillioides", "DISEASE", 7, 31], ["Histoplasma capsulatum", "DISEASE", 82, 104], ["Penicillium marneffei", "DISEASE", 125, 146], ["septicemia", "DISEASE", 178, 188], ["Fusarium verticillioides", "ORGANISM", 7, 31], ["Zoonotic fungiCryptococcus neoformans", "ORGANISM", 36, 73], ["Histoplasma capsulatum", "ORGANISM", 82, 104], ["Fusarium verticillioides", "SPECIES", 7, 31], ["fungiCryptococcus neoformans", "SPECIES", 45, 73], ["Histoplasma capsulatum", "SPECIES", 82, 104], ["Penicillium marneffei", "SPECIES", 125, 146], ["Fusarium verticillioides", "SPECIES", 7, 31], ["fungiCryptococcus neoformans", "SPECIES", 45, 73], ["Histoplasma capsulatum", "SPECIES", 82, 104], ["Penicillium marneffei", "SPECIES", 125, 146], ["Fusarium verticillioides", "TEST", 7, 31], ["Zoonotic fungiCryptococcus neoformans", "TEST", 36, 73], ["Histoplasma capsulatum", "TEST", 82, 104], ["Penicillium marneffei", "TEST", 125, 146], ["an overwhelming septicemia", "PROBLEM", 162, 188], ["overwhelming", "OBSERVATION_MODIFIER", 165, 177], ["septicemia", "OBSERVATION", 178, 188]]], ["It is important nonetheless to detect and remedy any underlying treatable infection in the setting of HLH.Virus-Associated Hemophagocytic Syndrome EBVEpidemiology As previously mentioned, EBV is the most commonly reported trigger of HLH [93] , with the highest incidence in East Asia [202] .", [["infection", "DISEASE", 74, 83], ["HLH", "DISEASE", 102, 105], ["HLH", "DISEASE", 233, 236], ["Virus", "ORGANISM", 106, 111], ["EBV", "ORGANISM", 188, 191], ["any underlying treatable infection", "PROBLEM", 49, 83], ["HLH", "PROBLEM", 102, 105], ["Virus", "PROBLEM", 106, 111], ["Hemophagocytic Syndrome", "PROBLEM", 123, 146], ["EBV", "PROBLEM", 188, 191], ["HLH", "PROBLEM", 233, 236], ["treatable", "OBSERVATION_MODIFIER", 64, 73], ["infection", "OBSERVATION", 74, 83], ["HLH", "OBSERVATION", 102, 105], ["Hemophagocytic Syndrome", "OBSERVATION", 123, 146], ["HLH", "OBSERVATION", 233, 236]]], ["This could be explained by the more pathogenic strains of EBV in this part of the world [203] and also by the higher prevalence of EBV and EBV-infected T cells in Asians [204] .", [["T cells", "ANATOMY", 152, 159], ["EBV", "ORGANISM", 58, 61], ["EBV", "ORGANISM", 131, 134], ["EBV", "ORGANISM", 139, 142], ["T cells", "CELL", 152, 159], ["T cells", "CELL_TYPE", 152, 159], ["EBV", "SPECIES", 58, 61], ["EBV", "SPECIES", 131, 134], ["the more pathogenic strains of EBV", "PROBLEM", 27, 61], ["EBV", "PROBLEM", 131, 134], ["EBV", "TEST", 139, 142]]], ["EBV-associated HLH (EBV-HLH) cases have also been described in the USA and Europe [205] .", [["HLH", "DISEASE", 15, 18], ["EBV-HLH", "DISEASE", 20, 27], ["EBV", "ORGANISM", 0, 3], ["EBV", "ORGANISM", 20, 23], ["EBV", "TEST", 0, 3], ["HLH", "PROBLEM", 15, 18], ["HLH", "OBSERVATION", 15, 18]]], ["Most EBV-HLH cases occur in apparently immunocompetent children and adolescents [206] ; however, it can also occur in the setting of primary/genetic forms (fHLH) [207] , immunodeficiency disorders (e.g., XLP) [208] , and secondary forms, including acute infections (e.g., infectious mononucleosis) [209] and lymphoproliferative disorders (e.g., NK cell and T-cell leukemias and lymphomas) [210] .Pathophysiology The mechanism by which EBV induces HLH has not been fully explained.", [["NK cell", "ANATOMY", 345, 352], ["T-cell leukemias", "ANATOMY", 357, 373], ["lymphomas", "ANATOMY", 378, 387], ["EBV-HLH", "DISEASE", 5, 12], ["fHLH", "DISEASE", 156, 160], ["immunodeficiency disorders", "DISEASE", 170, 196], ["acute infections", "DISEASE", 248, 264], ["infectious mononucleosis", "DISEASE", 272, 296], ["lymphoproliferative disorders", "DISEASE", 308, 337], ["T-cell leukemias and lymphomas", "DISEASE", 357, 387], ["HLH", "DISEASE", 447, 450], ["EBV", "ORGANISM", 5, 8], ["children", "ORGANISM", 55, 63], ["NK cell", "CANCER", 345, 352], ["T-cell leukemias", "CANCER", 357, 373], ["lymphomas", "CANCER", 378, 387], ["EBV", "ORGANISM", 435, 438], ["HLH", "PROTEIN", 447, 450], ["children", "SPECIES", 55, 63], ["adolescents", "SPECIES", 68, 79], ["primary/genetic forms (fHLH)", "PROBLEM", 133, 161], ["immunodeficiency disorders", "PROBLEM", 170, 196], ["secondary forms", "PROBLEM", 221, 236], ["acute infections", "PROBLEM", 248, 264], ["infectious mononucleosis)", "PROBLEM", 272, 297], ["lymphoproliferative disorders", "PROBLEM", 308, 337], ["NK cell", "PROBLEM", 345, 352], ["T-cell leukemias", "PROBLEM", 357, 373], ["lymphomas", "PROBLEM", 378, 387], ["HLH", "PROBLEM", 447, 450], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["infections", "OBSERVATION", 254, 264], ["lymphoproliferative disorders", "OBSERVATION", 308, 337], ["NK cell", "OBSERVATION", 345, 352], ["cell leukemias", "OBSERVATION", 359, 373]]], ["During primary infection, EBV typically infects and replicates in B cells, whereas a function of EBVspecific cytotoxic T cells is the regulation of the infected B cells and the production of memory cells.", [["B cells", "ANATOMY", 66, 73], ["EBVspecific cytotoxic T cells", "ANATOMY", 97, 126], ["B cells", "ANATOMY", 161, 168], ["memory cells", "ANATOMY", 191, 203], ["primary infection", "DISEASE", 7, 24], ["EBV", "ORGANISM", 26, 29], ["B cells", "CELL", 66, 73], ["EBVspecific cytotoxic T cells", "CELL", 97, 126], ["B cells", "CELL", 161, 168], ["memory cells", "CELL", 191, 203], ["B cells", "CELL_TYPE", 66, 73], ["EBVspecific cytotoxic T cells", "CELL_TYPE", 97, 126], ["infected B cells", "CELL_TYPE", 152, 168], ["memory cells", "CELL_TYPE", 191, 203], ["EBV", "SPECIES", 26, 29], ["primary infection", "PROBLEM", 7, 24], ["EBV", "PROBLEM", 26, 29], ["EBVspecific cytotoxic T cells", "PROBLEM", 97, 126], ["the infected B cells", "PROBLEM", 148, 168], ["infection", "OBSERVATION", 15, 24], ["B cells", "OBSERVATION_MODIFIER", 66, 73], ["cytotoxic T cells", "OBSERVATION", 109, 126], ["infected B cells", "OBSERVATION", 152, 168], ["memory cells", "OBSERVATION", 191, 203]]], ["On rare occasions, EBV may infect T cells and NK cells via CD21.", [["T cells", "ANATOMY", 34, 41], ["NK cells", "ANATOMY", 46, 54], ["EBV", "ORGANISM", 19, 22], ["T cells", "CELL", 34, 41], ["NK cells", "CELL", 46, 54], ["CD21", "GENE_OR_GENE_PRODUCT", 59, 63], ["T cells", "CELL_TYPE", 34, 41], ["NK cells", "CELL_TYPE", 46, 54], ["CD21", "PROTEIN", 59, 63], ["EBV", "SPECIES", 19, 22], ["EBV", "PROBLEM", 19, 22], ["CD21", "TEST", 59, 63], ["NK cells", "OBSERVATION", 46, 54]]], ["CD21 is expressed on the surface of these cells and induces persistent EBV infection, with monoclonal or oligoclonal proliferation resulting in chronic active EBV infection, lymphoproliferative disorders, and fulminantEBV-HLH [211] [212] [213] .", [["surface", "ANATOMY", 25, 32], ["cells", "ANATOMY", 42, 47], ["EBV infection", "DISEASE", 71, 84], ["chronic active EBV infection", "DISEASE", 144, 172], ["lymphoproliferative disorders", "DISEASE", 174, 203], ["HLH", "DISEASE", 222, 225], ["CD21", "GENE_OR_GENE_PRODUCT", 0, 4], ["surface", "CELLULAR_COMPONENT", 25, 32], ["cells", "CELL", 42, 47], ["EBV", "ORGANISM", 71, 74], ["EBV", "ORGANISM", 159, 162], ["CD21", "PROTEIN", 0, 4], ["EBV", "SPECIES", 71, 74], ["EBV", "SPECIES", 159, 162], ["CD21", "TEST", 0, 4], ["persistent EBV infection", "PROBLEM", 60, 84], ["monoclonal or oligoclonal proliferation", "PROBLEM", 91, 130], ["chronic active EBV infection", "PROBLEM", 144, 172], ["lymphoproliferative disorders", "PROBLEM", 174, 203], ["fulminantEBV-HLH", "PROBLEM", 209, 225], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["EBV infection", "OBSERVATION", 71, 84], ["monoclonal", "OBSERVATION_MODIFIER", 91, 101], ["oligoclonal proliferation", "OBSERVATION", 105, 130], ["chronic", "OBSERVATION_MODIFIER", 144, 151], ["active", "OBSERVATION_MODIFIER", 152, 158], ["EBV infection", "OBSERVATION", 159, 172], ["lymphoproliferative disorders", "OBSERVATION", 174, 203]]], ["Infection of CD8 T cells with EBV results in a cytokine storm with the release of pro-inflammatory and Th1-type cytokines [214] , including TNF and IFN-\u03b3, leading to widespread lymphohistiocytic activation [215] .", [["CD8 T cells", "ANATOMY", 13, 24], ["lymphohistiocytic", "ANATOMY", 177, 194], ["CD8 T cells", "CELL", 13, 24], ["EBV", "ORGANISM", 30, 33], ["TNF", "GENE_OR_GENE_PRODUCT", 140, 143], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 148, 153], ["CD8 T cells", "CELL_TYPE", 13, 24], ["cytokine", "PROTEIN", 47, 55], ["pro-inflammatory and Th1-type cytokines", "PROTEIN", 82, 121], ["TNF", "PROTEIN", 140, 143], ["IFN-\u03b3", "PROTEIN", 148, 153], ["Infection of CD8 T cells", "PROBLEM", 0, 24], ["EBV results", "TEST", 30, 41], ["pro-inflammatory", "TEST", 82, 98], ["TNF", "TEST", 140, 143], ["IFN", "TEST", 148, 151], ["widespread lymphohistiocytic activation", "PROBLEM", 166, 205], ["pro-inflammatory", "OBSERVATION_MODIFIER", 82, 98], ["widespread", "OBSERVATION_MODIFIER", 166, 176], ["lymphohistiocytic activation", "OBSERVATION", 177, 205]]], ["The resultant cytokine storm tends to be more prominent than those observed in non-EBV-HLH [216] .", [["HLH", "DISEASE", 87, 90], ["cytokine", "PROTEIN", 14, 22], ["The resultant cytokine storm", "PROBLEM", 0, 28], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["cytokine storm", "OBSERVATION", 14, 28], ["more prominent", "OBSERVATION_MODIFIER", 41, 55], ["HLH", "ANATOMY", 87, 90]]], ["In addition, impaired function of T cells or NK cells is thought to provide a phenotypic presentation of HLH resulting from EBV via any genetic mutation involved in the T-cell and/or NK cell activation pathways [217, 218] .Pathophysiology The mechanism by which EBV induces HLH has not been fully explained.", [["T cells", "ANATOMY", 34, 41], ["NK cells", "ANATOMY", 45, 53], ["T-cell", "ANATOMY", 169, 175], ["NK cell", "ANATOMY", 183, 190], ["HLH", "DISEASE", 105, 108], ["HLH", "DISEASE", 274, 277], ["T cells", "CELL", 34, 41], ["NK cells", "CELL", 45, 53], ["HLH", "CANCER", 105, 108], ["EBV", "ORGANISM", 124, 127], ["T-cell", "CELL", 169, 175], ["NK cell", "CELL", 183, 190], ["EBV", "ORGANISM", 262, 265], ["T cells", "CELL_TYPE", 34, 41], ["NK cells", "CELL_TYPE", 45, 53], ["HLH", "PROTEIN", 274, 277], ["EBV", "SPECIES", 124, 127], ["impaired function of T cells", "PROBLEM", 13, 41], ["NK cells", "PROBLEM", 45, 53], ["HLH", "PROBLEM", 105, 108], ["EBV", "PROBLEM", 124, 127], ["any genetic mutation", "PROBLEM", 132, 152], ["HLH", "PROBLEM", 274, 277]]], ["During primary infection, EBV typically infects and replicates in B cells, whereas a function of EBVspecific cytotoxic T cells is the regulation of the infected B cells and the production of memory cells.", [["B cells", "ANATOMY", 66, 73], ["EBVspecific cytotoxic T cells", "ANATOMY", 97, 126], ["B cells", "ANATOMY", 161, 168], ["memory cells", "ANATOMY", 191, 203], ["primary infection", "DISEASE", 7, 24], ["EBV", "ORGANISM", 26, 29], ["B cells", "CELL", 66, 73], ["EBVspecific cytotoxic T cells", "CELL", 97, 126], ["B cells", "CELL", 161, 168], ["memory cells", "CELL", 191, 203], ["B cells", "CELL_TYPE", 66, 73], ["EBVspecific cytotoxic T cells", "CELL_TYPE", 97, 126], ["infected B cells", "CELL_TYPE", 152, 168], ["memory cells", "CELL_TYPE", 191, 203], ["EBV", "SPECIES", 26, 29], ["primary infection", "PROBLEM", 7, 24], ["EBV", "PROBLEM", 26, 29], ["EBVspecific cytotoxic T cells", "PROBLEM", 97, 126], ["the infected B cells", "PROBLEM", 148, 168], ["infection", "OBSERVATION", 15, 24], ["B cells", "OBSERVATION_MODIFIER", 66, 73], ["cytotoxic T cells", "OBSERVATION", 109, 126], ["infected B cells", "OBSERVATION", 152, 168], ["memory cells", "OBSERVATION", 191, 203]]], ["On rare occasions, EBV may infect T cells and NK cells via CD21.", [["T cells", "ANATOMY", 34, 41], ["NK cells", "ANATOMY", 46, 54], ["EBV", "ORGANISM", 19, 22], ["T cells", "CELL", 34, 41], ["NK cells", "CELL", 46, 54], ["CD21", "GENE_OR_GENE_PRODUCT", 59, 63], ["T cells", "CELL_TYPE", 34, 41], ["NK cells", "CELL_TYPE", 46, 54], ["CD21", "PROTEIN", 59, 63], ["EBV", "SPECIES", 19, 22], ["EBV", "PROBLEM", 19, 22], ["CD21", "TEST", 59, 63], ["NK cells", "OBSERVATION", 46, 54]]], ["CD21 is expressed on the surface of these cells and induces persistent EBV infection, with monoclonal or oligoclonal proliferation resulting in chronic active EBV infection, lymphoproliferative disorders, and fulminantDiagnosis Serologic testing can help differentiate primary EBV infection from a reactivation process, although they have limitations such as delay in positivity and difficulty in result interpretation.", [["surface", "ANATOMY", 25, 32], ["cells", "ANATOMY", 42, 47], ["EBV infection", "DISEASE", 71, 84], ["chronic active EBV infection", "DISEASE", 144, 172], ["lymphoproliferative disorders", "DISEASE", 174, 203], ["EBV infection", "DISEASE", 277, 290], ["CD21", "GENE_OR_GENE_PRODUCT", 0, 4], ["surface", "CELLULAR_COMPONENT", 25, 32], ["cells", "CELL", 42, 47], ["EBV", "ORGANISM", 71, 74], ["EBV", "ORGANISM", 159, 162], ["EBV", "ORGANISM", 277, 280], ["CD21", "PROTEIN", 0, 4], ["EBV", "SPECIES", 71, 74], ["EBV", "SPECIES", 159, 162], ["EBV", "SPECIES", 277, 280], ["CD21", "TEST", 0, 4], ["persistent EBV infection", "PROBLEM", 60, 84], ["monoclonal or oligoclonal proliferation", "PROBLEM", 91, 130], ["chronic active EBV infection", "PROBLEM", 144, 172], ["lymphoproliferative disorders", "PROBLEM", 174, 203], ["fulminant", "PROBLEM", 209, 218], ["Serologic testing", "TEST", 228, 245], ["primary EBV infection", "PROBLEM", 269, 290], ["a reactivation process", "PROBLEM", 296, 318], ["delay in positivity", "PROBLEM", 359, 378], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["EBV infection", "OBSERVATION", 71, 84], ["monoclonal", "OBSERVATION_MODIFIER", 91, 101], ["oligoclonal proliferation", "OBSERVATION", 105, 130], ["chronic", "OBSERVATION_MODIFIER", 144, 151], ["active", "OBSERVATION_MODIFIER", 152, 158], ["EBV infection", "OBSERVATION", 159, 172], ["lymphoproliferative disorders", "OBSERVATION", 174, 203], ["fulminant", "OBSERVATION_MODIFIER", 209, 218], ["infection", "OBSERVATION", 281, 290]]], ["Real-time PCR is used to measure the EBV viral load which can help predict prognosis and response to treatment [219] .", [["EBV", "ORGANISM", 37, 40], ["EBV", "SPECIES", 37, 40], ["Real-time PCR", "TEST", 0, 13], ["the EBV viral load", "TEST", 33, 51], ["treatment", "TREATMENT", 101, 110]]], ["EBV PCR levels are usually higher than those seen in uncomplicated cases of EBV infectious mononucleosis [220] .", [["EBV infectious mononucleosis", "DISEASE", 76, 104], ["EBV", "ORGANISM", 0, 3], ["EBV", "ORGANISM", 76, 79], ["EBV", "SPECIES", 0, 3], ["EBV PCR levels", "TEST", 0, 14], ["EBV infectious mononucleosis", "PROBLEM", 76, 104], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["EBV", "OBSERVATION_MODIFIER", 76, 79], ["infectious", "OBSERVATION", 80, 90]]], ["Other techniques are available to determine the involvement of T cells or NK cells in helping to confirm the diagnosis.", [["T cells", "ANATOMY", 63, 70], ["NK cells", "ANATOMY", 74, 82], ["T cells", "CELL", 63, 70], ["NK cells", "CELL", 74, 82], ["T cells", "CELL_TYPE", 63, 70], ["NK cells", "CELL_TYPE", 74, 82], ["NK cells", "PROBLEM", 74, 82]]], ["T-cell receptor (TCR) gene rearrangement is detectable in half of the patients with EBV-HLH using Southern blotting and/or PCR analyses.", [["HLH", "DISEASE", 88, 91], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 0, 15], ["TCR", "GENE_OR_GENE_PRODUCT", 17, 20], ["patients", "ORGANISM", 70, 78], ["EBV", "ORGANISM", 84, 87], ["T-cell receptor (TCR) gene", "DNA", 0, 26], ["patients", "SPECIES", 70, 78], ["EBV", "TEST", 84, 87], ["HLH", "PROBLEM", 88, 91], ["Southern blotting", "TEST", 98, 115], ["PCR analyses", "TEST", 123, 135]]], ["It is hypothesized that the presence and change of TCR gene clonality probably plays a prognostic role for EBV-HLH [90] .", [["TCR", "CHEMICAL", 51, 54], ["HLH", "DISEASE", 111, 114], ["TCR", "GENE_OR_GENE_PRODUCT", 51, 54], ["EBV", "ORGANISM", 107, 110], ["TCR gene", "DNA", 51, 59], ["TCR gene clonality", "PROBLEM", 51, 69], ["EBV", "PROBLEM", 107, 110], ["HLH", "PROBLEM", 111, 114]]], ["Sandberg et al. [221] recently reported that Southern blot analysis could be replaced by BIOMED-2 multiplex PCR in routine testing of T-cell clonality.", [["T-cell", "ANATOMY", 134, 140], ["T-cell", "CELL", 134, 140], ["Southern blot analysis", "TEST", 45, 67], ["multiplex PCR", "TEST", 98, 111], ["routine testing", "TEST", 115, 130], ["cell clonality", "OBSERVATION", 136, 150]]], ["The EuroClonality (BIOMED-2) consortium developed a uniform reporting system for the description of the results and conclusions of Ig/TCR clonality assays to help improve the general performance level of clonality assessment and interpretation in cases with suspected lymphoproliferations [222] .", [["lymphoproliferations", "DISEASE", 268, 288], ["Ig", "GENE_OR_GENE_PRODUCT", 131, 133], ["TCR", "GENE_OR_GENE_PRODUCT", 134, 137], ["Ig", "PROTEIN", 131, 133], ["TCR", "PROTEIN", 134, 137], ["Ig/TCR clonality assays", "TEST", 131, 154], ["clonality assessment", "TEST", 204, 224]]], ["It was reported that TCR gene clonality with BIOMED-2 multiplex PCR [223] is highly sensitive for detecting T-cell clonality and is useful in predicting response to treatment in EBV-HLH cases [223] .", [["T-cell", "ANATOMY", 108, 114], ["EBV-HLH", "DISEASE", 178, 185], ["TCR", "GENE_OR_GENE_PRODUCT", 21, 24], ["BIOMED-2", "GENE_OR_GENE_PRODUCT", 45, 53], ["T-cell", "CELL", 108, 114], ["EBV", "ORGANISM", 178, 181], ["TCR gene", "DNA", 21, 29], ["multiplex PCR", "TEST", 54, 67], ["T-cell clonality", "PROBLEM", 108, 124], ["treatment", "TREATMENT", 165, 174], ["EBV", "TEST", 178, 181], ["cell clonality", "OBSERVATION", 110, 124]]], ["Interestingly, it was found that male patients with EBV-HLH may have mutations in the SH2D1A gene which is classically associated with X-linked lymphoproliferative syndrome (XLPS).", [["EBV-HLH", "DISEASE", 52, 59], ["X-linked lymphoproliferative syndrome", "DISEASE", 135, 172], ["XLPS", "DISEASE", 174, 178], ["patients", "ORGANISM", 38, 46], ["EBV", "ORGANISM", 52, 55], ["SH2D1A", "GENE_OR_GENE_PRODUCT", 86, 92], ["SH2D1A gene", "DNA", 86, 97], ["patients", "SPECIES", 38, 46], ["EBV", "PROBLEM", 52, 55], ["HLH", "PROBLEM", 56, 59], ["mutations in the SH2D1A gene", "PROBLEM", 69, 97], ["X-linked lymphoproliferative syndrome", "PROBLEM", 135, 172], ["HLH", "OBSERVATION", 56, 59], ["classically associated with", "UNCERTAINTY", 107, 134], ["X-linked", "OBSERVATION_MODIFIER", 135, 143], ["lymphoproliferative syndrome", "OBSERVATION", 144, 172]]], ["XLPS is a syndrome of immunodeficiency to EBV virus.", [["XLPS", "DISEASE", 0, 4], ["syndrome of immunodeficiency to EBV virus", "DISEASE", 10, 51], ["immunodeficiency", "ORGANISM", 22, 38], ["EBV", "ORGANISM", 42, 45], ["EBV virus", "SPECIES", 42, 51], ["a syndrome", "PROBLEM", 8, 18], ["immunodeficiency to EBV virus", "PROBLEM", 22, 51], ["syndrome", "OBSERVATION", 10, 18], ["immunodeficiency", "OBSERVATION", 22, 38], ["EBV virus", "OBSERVATION", 42, 51]]], ["Therefore, it is recommended to test for XLPS in male patients with EBV-HLH [224] .", [["EBV-HLH", "DISEASE", 68, 75], ["patients", "ORGANISM", 54, 62], ["EBV", "ORGANISM", 68, 71], ["patients", "SPECIES", 54, 62]]], ["It is also recommended to test for other genetic conditions such as fHLH, especially in male patients under 1 year of age, and in those with HLH in a sibling or with consanguineous parents, or when HLH is recurrent or unresponsive to treatment.Pathophysiology The mechanism by which EBV induces HLH has not been fully explained.", [["fHLH", "DISEASE", 68, 72], ["HLH", "DISEASE", 141, 144], ["HLH", "DISEASE", 198, 201], ["HLH", "DISEASE", 295, 298], ["patients", "ORGANISM", 93, 101], ["EBV", "ORGANISM", 283, 286], ["HLH", "PROTEIN", 295, 298], ["patients", "SPECIES", 93, 101], ["HLH", "PROBLEM", 141, 144], ["HLH", "PROBLEM", 198, 201], ["treatment", "TREATMENT", 234, 243], ["HLH", "PROBLEM", 295, 298]]], ["During primary infection, EBV typically infects and replicates in B cells, whereas a function of EBVspecific cytotoxic T cells is the regulation of the infected B cells and the production of memory cells.", [["B cells", "ANATOMY", 66, 73], ["EBVspecific cytotoxic T cells", "ANATOMY", 97, 126], ["B cells", "ANATOMY", 161, 168], ["memory cells", "ANATOMY", 191, 203], ["primary infection", "DISEASE", 7, 24], ["EBV", "ORGANISM", 26, 29], ["B cells", "CELL", 66, 73], ["EBVspecific cytotoxic T cells", "CELL", 97, 126], ["B cells", "CELL", 161, 168], ["memory cells", "CELL", 191, 203], ["B cells", "CELL_TYPE", 66, 73], ["EBVspecific cytotoxic T cells", "CELL_TYPE", 97, 126], ["infected B cells", "CELL_TYPE", 152, 168], ["memory cells", "CELL_TYPE", 191, 203], ["EBV", "SPECIES", 26, 29], ["primary infection", "PROBLEM", 7, 24], ["EBV", "PROBLEM", 26, 29], ["EBVspecific cytotoxic T cells", "PROBLEM", 97, 126], ["the infected B cells", "PROBLEM", 148, 168], ["infection", "OBSERVATION", 15, 24], ["B cells", "OBSERVATION_MODIFIER", 66, 73], ["cytotoxic T cells", "OBSERVATION", 109, 126], ["infected B cells", "OBSERVATION", 152, 168], ["memory cells", "OBSERVATION", 191, 203]]], ["On rare occasions, EBV may infect T cells and NK cells via CD21.", [["T cells", "ANATOMY", 34, 41], ["NK cells", "ANATOMY", 46, 54], ["EBV", "ORGANISM", 19, 22], ["T cells", "CELL", 34, 41], ["NK cells", "CELL", 46, 54], ["CD21", "GENE_OR_GENE_PRODUCT", 59, 63], ["T cells", "CELL_TYPE", 34, 41], ["NK cells", "CELL_TYPE", 46, 54], ["CD21", "PROTEIN", 59, 63], ["EBV", "SPECIES", 19, 22], ["EBV", "PROBLEM", 19, 22], ["CD21", "TEST", 59, 63], ["NK cells", "OBSERVATION", 46, 54]]], ["CD21 is expressed on the surface of these cells and induces persistent EBV infection, with monoclonal or oligoclonal proliferation resulting in chronic active EBV infection, lymphoproliferative disorders, and fulminantPrognosis Of all the viruses associated with HLH, EBV-HLH carries one of the worst prognoses.", [["surface", "ANATOMY", 25, 32], ["cells", "ANATOMY", 42, 47], ["EBV infection", "DISEASE", 71, 84], ["chronic active EBV infection", "DISEASE", 144, 172], ["lymphoproliferative disorders", "DISEASE", 174, 203], ["HLH", "DISEASE", 263, 266], ["HLH", "DISEASE", 272, 275], ["CD21", "GENE_OR_GENE_PRODUCT", 0, 4], ["surface", "CELLULAR_COMPONENT", 25, 32], ["cells", "CELL", 42, 47], ["EBV", "ORGANISM", 71, 74], ["EBV", "ORGANISM", 159, 162], ["EBV", "ORGANISM", 268, 271], ["CD21", "PROTEIN", 0, 4], ["EBV", "SPECIES", 71, 74], ["EBV", "SPECIES", 159, 162], ["CD21", "TEST", 0, 4], ["persistent EBV infection", "PROBLEM", 60, 84], ["monoclonal or oligoclonal proliferation", "PROBLEM", 91, 130], ["chronic active EBV infection", "PROBLEM", 144, 172], ["lymphoproliferative disorders", "PROBLEM", 174, 203], ["fulminant", "PROBLEM", 209, 218], ["HLH", "PROBLEM", 263, 266], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["EBV infection", "OBSERVATION", 71, 84], ["monoclonal", "OBSERVATION_MODIFIER", 91, 101], ["oligoclonal proliferation", "OBSERVATION", 105, 130], ["chronic", "OBSERVATION_MODIFIER", 144, 151], ["active", "OBSERVATION_MODIFIER", 152, 158], ["EBV infection", "OBSERVATION", 159, 172], ["lymphoproliferative disorders", "OBSERVATION", 174, 203], ["fulminant", "OBSERVATION_MODIFIER", 209, 218], ["viruses", "OBSERVATION", 239, 246], ["HLH", "OBSERVATION", 272, 275]]], ["In a nationwide survey in Japan to identify prognostic factors in children with EBV-HLH, Kogawa et al. [225] found that most of the clinical and laboratory parameters including EBV load, NK cell activity against EBV-infected cells, and the presence of clonality at the onset of disease were not associated with a poor outcome.", [["NK cell", "ANATOMY", 187, 194], ["cells", "ANATOMY", 225, 230], ["EBV-HLH", "DISEASE", 80, 87], ["children", "ORGANISM", 66, 74], ["EBV", "ORGANISM", 80, 83], ["EBV", "ORGANISM", 177, 180], ["NK cell", "CELL", 187, 194], ["EBV", "ORGANISM", 212, 215], ["cells", "CELL", 225, 230], ["EBV-infected cells", "CELL_TYPE", 212, 230], ["children", "SPECIES", 66, 74], ["EBV", "SPECIES", 177, 180], ["EBV", "SPECIES", 212, 215], ["EBV", "PROBLEM", 80, 83], ["HLH", "PROBLEM", 84, 87], ["laboratory parameters", "TEST", 145, 166], ["EBV load", "TEST", 177, 185], ["NK cell activity", "TEST", 187, 203], ["EBV", "PROBLEM", 212, 215], ["infected cells", "PROBLEM", 216, 230], ["clonality", "PROBLEM", 252, 261], ["disease", "PROBLEM", 278, 285], ["NK cell activity", "OBSERVATION", 187, 203], ["infected cells", "OBSERVATION", 216, 230], ["disease", "OBSERVATION", 278, 285]]], ["Nevertheless, Matsuda et al. showed that change of clonality can be a good marker of disease activity in childhood EBV-HLH [223] .", [["EBV-HLH", "DISEASE", 115, 122], ["EBV", "ORGANISM", 115, 118], ["change of clonality", "PROBLEM", 41, 60], ["disease activity", "PROBLEM", 85, 101], ["HLH", "PROBLEM", 119, 122]]], ["It is also reported that hyperbilirubinemia and hyperferritinemia at the time of diagnosis were significantly associated with a poor outcome.", [["hyperbilirubinemia", "DISEASE", 25, 43], ["hyperferritinemia", "DISEASE", 48, 65], ["hyperbilirubinemia", "PROBLEM", 25, 43], ["hyperferritinemia", "PROBLEM", 48, 65], ["hyperbilirubinemia", "OBSERVATION", 25, 43], ["hyperferritinemia", "OBSERVATION", 48, 65]]], ["Henter et al. also reported that hyperbilirubinemia and hyperferritinemia at diagnosis, and thrombocytopenia and hyperferritinemia 2 weeks after the initiation of treatment, adversely affect the outcome of HLH [226] .", [["hyperbilirubinemia", "DISEASE", 33, 51], ["hyperferritinemia", "DISEASE", 56, 73], ["thrombocytopenia", "DISEASE", 92, 108], ["hyperferritinemia", "DISEASE", 113, 130], ["HLH", "DISEASE", 206, 209], ["hyperbilirubinemia", "PROBLEM", 33, 51], ["hyperferritinemia", "PROBLEM", 56, 73], ["thrombocytopenia", "PROBLEM", 92, 108], ["hyperferritinemia", "PROBLEM", 113, 130], ["treatment", "TREATMENT", 163, 172], ["HLH", "PROBLEM", 206, 209], ["hyperbilirubinemia", "OBSERVATION", 33, 51], ["hyperferritinemia", "OBSERVATION", 56, 73], ["thrombocytopenia", "OBSERVATION", 92, 108], ["hyperferritinemia", "OBSERVATION", 113, 130]]], ["Better outcome is speculated to be associated with going into remission within 8 weeks of treatment initiation [225] .", [["treatment initiation", "TREATMENT", 90, 110]]], ["Huang et al. reported that hypoalbuminemia is an independent predictor for HLH in childhood EBV-associated disease [227] .Pathophysiology The mechanism by which EBV induces HLH has not been fully explained.", [["hypoalbuminemia", "DISEASE", 27, 42], ["HLH", "DISEASE", 75, 78], ["EBV-associated disease", "DISEASE", 92, 114], ["HLH", "DISEASE", 173, 176], ["EBV", "ORGANISM", 92, 95], ["EBV", "ORGANISM", 161, 164], ["HLH", "PROTEIN", 173, 176], ["hypoalbuminemia", "PROBLEM", 27, 42], ["HLH", "PROBLEM", 75, 78], ["associated disease", "PROBLEM", 96, 114], ["HLH", "PROBLEM", 173, 176], ["hypoalbuminemia", "OBSERVATION", 27, 42]]], ["During primary infection, EBV typically infects and replicates in B cells, whereas a function of EBVspecific cytotoxic T cells is the regulation of the infected B cells and the production of memory cells.", [["B cells", "ANATOMY", 66, 73], ["EBVspecific cytotoxic T cells", "ANATOMY", 97, 126], ["B cells", "ANATOMY", 161, 168], ["memory cells", "ANATOMY", 191, 203], ["primary infection", "DISEASE", 7, 24], ["EBV", "ORGANISM", 26, 29], ["B cells", "CELL", 66, 73], ["EBVspecific cytotoxic T cells", "CELL", 97, 126], ["B cells", "CELL", 161, 168], ["memory cells", "CELL", 191, 203], ["B cells", "CELL_TYPE", 66, 73], ["EBVspecific cytotoxic T cells", "CELL_TYPE", 97, 126], ["infected B cells", "CELL_TYPE", 152, 168], ["memory cells", "CELL_TYPE", 191, 203], ["EBV", "SPECIES", 26, 29], ["primary infection", "PROBLEM", 7, 24], ["EBV", "PROBLEM", 26, 29], ["EBVspecific cytotoxic T cells", "PROBLEM", 97, 126], ["the infected B cells", "PROBLEM", 148, 168], ["infection", "OBSERVATION", 15, 24], ["B cells", "OBSERVATION_MODIFIER", 66, 73], ["cytotoxic T cells", "OBSERVATION", 109, 126], ["infected B cells", "OBSERVATION", 152, 168], ["memory cells", "OBSERVATION", 191, 203]]], ["On rare occasions, EBV may infect T cells and NK cells via CD21.", [["T cells", "ANATOMY", 34, 41], ["NK cells", "ANATOMY", 46, 54], ["EBV", "ORGANISM", 19, 22], ["T cells", "CELL", 34, 41], ["NK cells", "CELL", 46, 54], ["CD21", "GENE_OR_GENE_PRODUCT", 59, 63], ["T cells", "CELL_TYPE", 34, 41], ["NK cells", "CELL_TYPE", 46, 54], ["CD21", "PROTEIN", 59, 63], ["EBV", "SPECIES", 19, 22], ["EBV", "PROBLEM", 19, 22], ["CD21", "TEST", 59, 63], ["NK cells", "OBSERVATION", 46, 54]]], ["CD21 is expressed on the surface of these cells and induces persistent EBV infection, with monoclonal or oligoclonal proliferation resulting in chronic active EBV infection, lymphoproliferative disorders, and fulminantTreatment Antiviral therapy with acyclovir, ganciclovir, or cidofovir is generally ineffective as monotherapy in infectious mononucleosis and EBV-HLH [228] .", [["surface", "ANATOMY", 25, 32], ["cells", "ANATOMY", 42, 47], ["EBV infection", "DISEASE", 71, 84], ["chronic active EBV infection", "DISEASE", 144, 172], ["lymphoproliferative disorders", "DISEASE", 174, 203], ["acyclovir", "CHEMICAL", 251, 260], ["ganciclovir", "CHEMICAL", 262, 273], ["cidofovir", "CHEMICAL", 278, 287], ["infectious mononucleosis", "DISEASE", 331, 355], ["HLH", "DISEASE", 364, 367], ["acyclovir", "CHEMICAL", 251, 260], ["ganciclovir", "CHEMICAL", 262, 273], ["cidofovir", "CHEMICAL", 278, 287], ["CD21", "GENE_OR_GENE_PRODUCT", 0, 4], ["surface", "CELLULAR_COMPONENT", 25, 32], ["cells", "CELL", 42, 47], ["EBV", "ORGANISM", 71, 74], ["EBV", "ORGANISM", 159, 162], ["acyclovir", "SIMPLE_CHEMICAL", 251, 260], ["ganciclovir", "SIMPLE_CHEMICAL", 262, 273], ["cidofovir", "SIMPLE_CHEMICAL", 278, 287], ["EBV", "ORGANISM", 360, 363], ["CD21", "PROTEIN", 0, 4], ["EBV", "SPECIES", 71, 74], ["EBV", "SPECIES", 159, 162], ["CD21", "TEST", 0, 4], ["persistent EBV infection", "PROBLEM", 60, 84], ["monoclonal or oligoclonal proliferation", "PROBLEM", 91, 130], ["chronic active EBV infection", "PROBLEM", 144, 172], ["lymphoproliferative disorders", "PROBLEM", 174, 203], ["fulminant", "PROBLEM", 209, 218], ["Treatment Antiviral therapy", "TREATMENT", 218, 245], ["acyclovir", "TREATMENT", 251, 260], ["ganciclovir", "TREATMENT", 262, 273], ["cidofovir", "TREATMENT", 278, 287], ["monotherapy", "TREATMENT", 316, 327], ["infectious mononucleosis", "PROBLEM", 331, 355], ["EBV", "TEST", 360, 363], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["EBV infection", "OBSERVATION", 71, 84], ["monoclonal", "OBSERVATION_MODIFIER", 91, 101], ["oligoclonal proliferation", "OBSERVATION", 105, 130], ["chronic", "OBSERVATION_MODIFIER", 144, 151], ["active", "OBSERVATION_MODIFIER", 152, 158], ["EBV infection", "OBSERVATION", 159, 172], ["lymphoproliferative disorders", "OBSERVATION", 174, 203], ["fulminant", "OBSERVATION_MODIFIER", 209, 218]]], ["However, aggressive therapy including immunochemotherapy and allogenic stem cell transplantation has radically improved the prognosis.", [["stem cell", "ANATOMY", 71, 80], ["allogenic stem cell", "CELL", 61, 80], ["aggressive therapy", "TREATMENT", 9, 27], ["immunochemotherapy", "TREATMENT", 38, 56], ["allogenic stem cell transplantation", "TREATMENT", 61, 96], ["allogenic stem cell transplantation", "OBSERVATION", 61, 96]]], ["The optimal treatment strategy [229] for EBV-HLH consists of immunosuppressive medications that inhibit overactive T-cell and NK cell responses [i.e., corticosteroids, cyclosporine A, intravenous immunoglobulin (IVIg), antithymocyte globulins, etoposide, and plasma or blood exchange transfusions] [229, 230] .", [["overactive T-cell", "ANATOMY", 104, 121], ["NK cell", "ANATOMY", 126, 133], ["intravenous", "ANATOMY", 184, 195], ["plasma", "ANATOMY", 259, 265], ["blood", "ANATOMY", 269, 274], ["HLH", "DISEASE", 45, 48], ["cyclosporine A", "CHEMICAL", 168, 182], ["IVIg", "CHEMICAL", 212, 216], ["antithymocyte globulins", "CHEMICAL", 219, 242], ["etoposide", "CHEMICAL", 244, 253], ["corticosteroids", "CHEMICAL", 151, 166], ["cyclosporine A", "CHEMICAL", 168, 182], ["etoposide", "CHEMICAL", 244, 253], ["EBV", "ORGANISM", 41, 44], ["overactive T-cell", "CELL", 104, 121], ["NK cell", "CELL", 126, 133], ["corticosteroids", "SIMPLE_CHEMICAL", 151, 166], ["cyclosporine A", "SIMPLE_CHEMICAL", 168, 182], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 184, 210], ["IVIg", "SIMPLE_CHEMICAL", 212, 216], ["antithymocyte globulins", "SIMPLE_CHEMICAL", 219, 242], ["etoposide", "SIMPLE_CHEMICAL", 244, 253], ["plasma", "ORGANISM_SUBSTANCE", 259, 265], ["blood", "ORGANISM_SUBSTANCE", 269, 274], ["intravenous immunoglobulin", "PROTEIN", 184, 210], ["The optimal treatment strategy", "TREATMENT", 0, 30], ["EBV", "TEST", 41, 44], ["HLH", "PROBLEM", 45, 48], ["immunosuppressive medications", "TREATMENT", 61, 90], ["overactive T-cell", "TREATMENT", 104, 121], ["NK cell responses", "TREATMENT", 126, 143], ["corticosteroids", "TREATMENT", 151, 166], ["cyclosporine", "TREATMENT", 168, 180], ["intravenous immunoglobulin (IVIg", "TREATMENT", 184, 216], ["antithymocyte globulins", "TREATMENT", 219, 242], ["etoposide", "TREATMENT", 244, 253], ["plasma", "TREATMENT", 259, 265], ["blood exchange transfusions", "TREATMENT", 269, 296], ["NK cell", "OBSERVATION", 126, 133]]], ["Hematopoietic stem cell transplantation (HSCT) is the last treatment resort for refractory forms of EBV-HLH, and in the case of EBV infection occurring in genetic forms of HLH [231] .", [["Hematopoietic stem cell", "ANATOMY", 0, 23], ["EBV-HLH", "DISEASE", 100, 107], ["EBV infection", "DISEASE", 128, 141], ["HLH", "DISEASE", 172, 175], ["Hematopoietic stem cell", "CELL", 0, 23], ["EBV", "ORGANISM", 100, 103], ["EBV", "ORGANISM", 128, 131], ["EBV", "SPECIES", 128, 131], ["Hematopoietic stem cell transplantation", "TREATMENT", 0, 39], ["the last treatment resort", "TREATMENT", 50, 75], ["EBV", "PROBLEM", 100, 103], ["HLH", "PROBLEM", 104, 107], ["EBV infection", "PROBLEM", 128, 141], ["HLH", "PROBLEM", 172, 175], ["stem cell transplantation", "OBSERVATION", 14, 39], ["HLH", "OBSERVATION", 104, 107], ["EBV", "OBSERVATION_MODIFIER", 128, 131], ["infection", "OBSERVATION", 132, 141]]], ["Despite the fact that reports have shown that HSCT is effective in treating patients with refractory EBV-HLH [232] , it should be compared to immunochemotherapy in a randomized study to provide evidence for which approach is superior and/or safer [233] .Pathophysiology The mechanism by which EBV induces HLH has not been fully explained.", [["EBV-HLH", "DISEASE", 101, 108], ["HLH", "DISEASE", 305, 308], ["patients", "ORGANISM", 76, 84], ["EBV", "ORGANISM", 101, 104], ["EBV", "ORGANISM", 293, 296], ["HLH", "PROTEIN", 305, 308], ["patients", "SPECIES", 76, 84], ["refractory EBV", "PROBLEM", 90, 104], ["HLH", "PROBLEM", 105, 108], ["immunochemotherapy", "TREATMENT", 142, 160], ["a randomized study", "TEST", 164, 182], ["HLH", "PROBLEM", 305, 308]]], ["During primary infection, EBV typically infects and replicates in B cells, whereas a function of EBVspecific cytotoxic T cells is the regulation of the infected B cells and the production of memory cells.", [["B cells", "ANATOMY", 66, 73], ["EBVspecific cytotoxic T cells", "ANATOMY", 97, 126], ["B cells", "ANATOMY", 161, 168], ["memory cells", "ANATOMY", 191, 203], ["primary infection", "DISEASE", 7, 24], ["EBV", "ORGANISM", 26, 29], ["B cells", "CELL", 66, 73], ["EBVspecific cytotoxic T cells", "CELL", 97, 126], ["B cells", "CELL", 161, 168], ["memory cells", "CELL", 191, 203], ["B cells", "CELL_TYPE", 66, 73], ["EBVspecific cytotoxic T cells", "CELL_TYPE", 97, 126], ["infected B cells", "CELL_TYPE", 152, 168], ["memory cells", "CELL_TYPE", 191, 203], ["EBV", "SPECIES", 26, 29], ["primary infection", "PROBLEM", 7, 24], ["EBV", "PROBLEM", 26, 29], ["EBVspecific cytotoxic T cells", "PROBLEM", 97, 126], ["the infected B cells", "PROBLEM", 148, 168], ["infection", "OBSERVATION", 15, 24], ["B cells", "OBSERVATION_MODIFIER", 66, 73], ["cytotoxic T cells", "OBSERVATION", 109, 126], ["infected B cells", "OBSERVATION", 152, 168], ["memory cells", "OBSERVATION", 191, 203]]], ["On rare occasions, EBV may infect T cells and NK cells via CD21.", [["T cells", "ANATOMY", 34, 41], ["NK cells", "ANATOMY", 46, 54], ["EBV", "ORGANISM", 19, 22], ["T cells", "CELL", 34, 41], ["NK cells", "CELL", 46, 54], ["CD21", "GENE_OR_GENE_PRODUCT", 59, 63], ["T cells", "CELL_TYPE", 34, 41], ["NK cells", "CELL_TYPE", 46, 54], ["CD21", "PROTEIN", 59, 63], ["EBV", "SPECIES", 19, 22], ["EBV", "PROBLEM", 19, 22], ["CD21", "TEST", 59, 63], ["NK cells", "OBSERVATION", 46, 54]]], ["CD21 is expressed on the surface of these cells and induces persistent EBV infection, with monoclonal or oligoclonal proliferation resulting in chronic active EBV infection, lymphoproliferative disorders, and fulminantIn 2007, Balamuth et al. [230] reported that adding rituximab to the HLH-2004 treatment protocol improves its efficacy.", [["surface", "ANATOMY", 25, 32], ["cells", "ANATOMY", 42, 47], ["EBV infection", "DISEASE", 71, 84], ["chronic active EBV infection", "DISEASE", 144, 172], ["lymphoproliferative disorders", "DISEASE", 174, 203], ["rituximab", "CHEMICAL", 270, 279], ["HLH", "DISEASE", 287, 290], ["CD21", "GENE_OR_GENE_PRODUCT", 0, 4], ["surface", "CELLULAR_COMPONENT", 25, 32], ["cells", "CELL", 42, 47], ["EBV", "ORGANISM", 71, 74], ["EBV", "ORGANISM", 159, 162], ["rituximab", "SIMPLE_CHEMICAL", 270, 279], ["CD21", "PROTEIN", 0, 4], ["EBV", "SPECIES", 71, 74], ["EBV", "SPECIES", 159, 162], ["CD21", "TEST", 0, 4], ["persistent EBV infection", "PROBLEM", 60, 84], ["monoclonal or oligoclonal proliferation", "PROBLEM", 91, 130], ["chronic active EBV infection", "PROBLEM", 144, 172], ["lymphoproliferative disorders", "PROBLEM", 174, 203], ["rituximab", "TREATMENT", 270, 279], ["the HLH", "PROBLEM", 283, 290], ["treatment protocol", "TREATMENT", 296, 314], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["EBV infection", "OBSERVATION", 71, 84], ["monoclonal", "OBSERVATION_MODIFIER", 91, 101], ["oligoclonal proliferation", "OBSERVATION", 105, 130], ["chronic", "OBSERVATION_MODIFIER", 144, 151], ["active", "OBSERVATION_MODIFIER", 152, 158], ["EBV infection", "OBSERVATION", 159, 172], ["lymphoproliferative disorders", "OBSERVATION", 174, 203], ["HLH", "ANATOMY", 287, 290]]], ["Rituximab is a monoclonal antibody against CD20 on the surface of B cells.", [["surface", "ANATOMY", 55, 62], ["B cells", "ANATOMY", 66, 73], ["Rituximab", "CHEMICAL", 0, 9], ["Rituximab", "SIMPLE_CHEMICAL", 0, 9], ["CD20", "GENE_OR_GENE_PRODUCT", 43, 47], ["surface", "CELLULAR_COMPONENT", 55, 62], ["B cells", "CELL", 66, 73], ["monoclonal antibody", "PROTEIN", 15, 34], ["CD20", "PROTEIN", 43, 47], ["B cells", "CELL_TYPE", 66, 73], ["Rituximab", "TREATMENT", 0, 9], ["a monoclonal antibody", "TEST", 13, 34], ["CD20", "PROBLEM", 43, 47], ["B cells", "OBSERVATION", 66, 73]]], ["Because EBV targets B cells in the initial phase of the disease, rituximab's elimination of B cells is thought to inhibit the extent of the infection.", [["B cells", "ANATOMY", 20, 27], ["B cells", "ANATOMY", 92, 99], ["rituximab", "CHEMICAL", 65, 74], ["infection", "DISEASE", 140, 149], ["EBV", "ORGANISM", 8, 11], ["B cells", "CELL", 20, 27], ["rituximab", "SIMPLE_CHEMICAL", 65, 74], ["B cells", "CELL", 92, 99], ["B cells", "CELL_TYPE", 20, 27], ["B cells", "CELL_TYPE", 92, 99], ["EBV", "SPECIES", 8, 11], ["EBV targets B cells", "PROBLEM", 8, 27], ["the disease", "PROBLEM", 52, 63], ["rituximab", "TREATMENT", 65, 74], ["B cells", "PROBLEM", 92, 99], ["the infection", "PROBLEM", 136, 149], ["B cells", "OBSERVATION", 20, 27], ["disease", "OBSERVATION", 56, 63], ["infection", "OBSERVATION", 140, 149]]], ["In addition, B cells may be a target in EBV-HLH, and rituximab may reduce morbidity and mortality by reducing the circulating B-cell population and the EBV load [234] .", [["B cells", "ANATOMY", 13, 20], ["B-cell", "ANATOMY", 126, 132], ["HLH", "DISEASE", 44, 47], ["rituximab", "CHEMICAL", 53, 62], ["B cells", "CELL", 13, 20], ["EBV", "ORGANISM", 40, 43], ["rituximab", "SIMPLE_CHEMICAL", 53, 62], ["B-cell", "CELL", 126, 132], ["EBV", "ORGANISM", 152, 155], ["B cells", "CELL_TYPE", 13, 20], ["circulating B-cell population", "CELL_TYPE", 114, 143], ["B cells", "PROBLEM", 13, 20], ["EBV", "TEST", 40, 43], ["HLH", "PROBLEM", 44, 47], ["rituximab", "TREATMENT", 53, 62], ["morbidity", "PROBLEM", 74, 83], ["the circulating B-cell population", "PROBLEM", 110, 143], ["the EBV load", "TEST", 148, 160]]], ["Rituximab seems to be most effective in the setting of XLPS patients infected with EBV but is likely less effective when EBV is capable of infecting the T-cell pool.", [["T-cell", "ANATOMY", 153, 159], ["Rituximab", "CHEMICAL", 0, 9], ["XLPS", "DISEASE", 55, 59], ["Rituximab", "SIMPLE_CHEMICAL", 0, 9], ["patients", "ORGANISM", 60, 68], ["EBV", "ORGANISM", 83, 86], ["EBV", "ORGANISM", 121, 124], ["T-cell", "CELL", 153, 159], ["patients", "SPECIES", 60, 68], ["EBV", "SPECIES", 83, 86], ["EBV", "SPECIES", 121, 124], ["Rituximab", "TREATMENT", 0, 9], ["XLPS", "PROBLEM", 55, 59], ["EBV", "PROBLEM", 83, 86], ["likely", "UNCERTAINTY", 94, 100], ["less effective", "OBSERVATION_MODIFIER", 101, 115]]], ["Nonetheless, the addition of rituximab to the treatment repertoire of EBV-HLH provides an opportunity to tailor therapy specific to the patient (personalized medicine approach).Other Herpes VirusesFollowing EBV, cytomegalovirus (CMV) and human herpes virus (HHV) 8 are the next most common of the herpesviruses to be associated with HLH.", [["rituximab", "CHEMICAL", 29, 38], ["HLH", "DISEASE", 74, 77], ["Herpes VirusesFollowing EBV, cytomegalovirus (CMV) and human herpes virus", "DISEASE", 183, 256], ["HLH", "DISEASE", 333, 336], ["rituximab", "SIMPLE_CHEMICAL", 29, 38], ["EBV", "ORGANISM", 70, 73], ["patient", "ORGANISM", 136, 143], ["Herpes VirusesFollowing EBV", "ORGANISM", 183, 210], ["cytomegalovirus", "ORGANISM", 212, 227], ["CMV", "ORGANISM", 229, 232], ["human herpes virus (HHV) 8", "ORGANISM", 238, 264], ["herpesviruses", "ORGANISM", 297, 310], ["patient", "SPECIES", 136, 143], ["human", "SPECIES", 238, 243], ["herpes virus", "SPECIES", 244, 256], ["CMV", "SPECIES", 229, 232], ["human herpes virus", "SPECIES", 238, 256], ["HHV", "SPECIES", 258, 261], ["rituximab", "TREATMENT", 29, 38], ["HLH", "PROBLEM", 74, 77], ["tailor therapy", "TREATMENT", 105, 119], ["personalized medicine approach", "TREATMENT", 145, 175], ["Other Herpes VirusesFollowing EBV", "PROBLEM", 177, 210], ["cytomegalovirus", "PROBLEM", 212, 227], ["CMV", "PROBLEM", 229, 232], ["human herpes virus", "PROBLEM", 238, 256], ["HLH", "PROBLEM", 333, 336], ["herpesviruses", "OBSERVATION", 297, 310], ["HLH", "OBSERVATION", 333, 336]]], ["CMV infection has been associated with HLH in otherwise healthy patients [96, 235] , premature infants [97] , patients with inflammatory bowel disease [236, 237] , rheumatological diseases [238, 239] , cancer [240] , and in transplant recipients [241, 242] .", [["bowel", "ANATOMY", 137, 142], ["cancer", "ANATOMY", 202, 208], ["CMV infection", "DISEASE", 0, 13], ["HLH", "DISEASE", 39, 42], ["inflammatory bowel disease", "DISEASE", 124, 150], ["rheumatological diseases", "DISEASE", 164, 188], ["cancer", "DISEASE", 202, 208], ["CMV", "ORGANISM", 0, 3], ["patients", "ORGANISM", 64, 72], ["infants", "ORGANISM", 95, 102], ["patients", "ORGANISM", 110, 118], ["bowel", "ORGAN", 137, 142], ["cancer", "CANCER", 202, 208], ["patients", "SPECIES", 64, 72], ["infants", "SPECIES", 95, 102], ["patients", "SPECIES", 110, 118], ["CMV", "SPECIES", 0, 3], ["CMV infection", "PROBLEM", 0, 13], ["HLH", "PROBLEM", 39, 42], ["premature infants", "PROBLEM", 85, 102], ["inflammatory bowel disease", "PROBLEM", 124, 150], ["rheumatological diseases", "PROBLEM", 164, 188], ["cancer", "PROBLEM", 202, 208], ["infection", "OBSERVATION", 4, 13], ["inflammatory", "OBSERVATION_MODIFIER", 124, 136], ["bowel", "ANATOMY", 137, 142], ["disease", "OBSERVATION", 143, 150]]], ["In a series of 171 patients undergoing HSCT, HLH was observed in 7 (4%) of them and was triggered by CMV in 3 cases [243] .", [["HLH", "DISEASE", 45, 48], ["patients", "ORGANISM", 19, 27], ["CMV", "ORGANISM", 101, 104], ["patients", "SPECIES", 19, 27], ["HSCT", "TEST", 39, 43], ["HLH", "PROBLEM", 45, 48], ["CMV", "TEST", 101, 104]]], ["In a Japanese registry with CMV-HLH diagnosed at less than a year of age (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) , four of the five infants died, suggesting that younger age may be associated with a worse prognosis [244] .", [["CMV-HLH", "DISEASE", 28, 35], ["CMV", "ORGANISM", 28, 31], ["infants", "ORGANISM", 211, 218], ["infants", "SPECIES", 211, 218], ["CMV", "PROBLEM", 28, 31], ["HLH", "PROBLEM", 32, 35], ["CMV", "OBSERVATION", 28, 31], ["HLH", "OBSERVATION", 32, 35]]], ["The use of specific anti-CMV therapy, such as CMV hyperimmune globulin, foscarnet, or ganciclovir, has been associated with recovery in selected cases [96, [236] [237] [238] 242] .Human Herpes Virus 8HHV-8 has been associated with HLH, mostly in the setting of Kaposi sarcoma [245] , multicentric Castleman disease [246] , or lymphoproliferative disorder [247] , as well as in immunocompromised hosts (HIV) [99] , transplant recipients [248] , and, rarely, in immunocompetent hosts [100, 101] .", [["Kaposi sarcoma", "ANATOMY", 261, 275], ["foscarnet", "CHEMICAL", 72, 81], ["ganciclovir", "CHEMICAL", 86, 97], ["HLH", "DISEASE", 231, 234], ["Kaposi sarcoma", "DISEASE", 261, 275], ["Castleman disease", "DISEASE", 297, 314], ["lymphoproliferative disorder", "DISEASE", 326, 354], ["foscarnet", "CHEMICAL", 72, 81], ["ganciclovir", "CHEMICAL", 86, 97], ["anti-CMV", "ORGANISM", 20, 28], ["CMV", "ORGANISM", 46, 49], ["hyperimmune globulin", "ORGANISM", 50, 70], ["foscarnet", "SIMPLE_CHEMICAL", 72, 81], ["ganciclovir", "SIMPLE_CHEMICAL", 86, 97], ["Human", "ORGANISM", 180, 185], ["Herpes Virus 8HHV-8", "ORGANISM", 186, 205], ["Kaposi sarcoma", "CANCER", 261, 275], ["multicentric Castleman disease", "CANCER", 284, 314], ["HIV", "ORGANISM", 402, 405], ["recipients", "ORGANISM", 425, 435], ["Human", "SPECIES", 180, 185], ["Herpes Virus 8HHV", "SPECIES", 186, 203], ["CMV", "SPECIES", 46, 49], ["Human Herpes Virus 8HHV-8", "SPECIES", 180, 205], ["HIV", "SPECIES", 402, 405], ["specific anti-CMV therapy", "TREATMENT", 11, 36], ["CMV hyperimmune globulin", "TREATMENT", 46, 70], ["foscarnet", "TREATMENT", 72, 81], ["ganciclovir", "TREATMENT", 86, 97], ["Human Herpes Virus 8HHV", "PROBLEM", 180, 203], ["HLH", "PROBLEM", 231, 234], ["Kaposi sarcoma", "PROBLEM", 261, 275], ["multicentric Castleman disease", "PROBLEM", 284, 314], ["lymphoproliferative disorder", "PROBLEM", 326, 354], ["HLH", "OBSERVATION", 231, 234], ["Kaposi sarcoma", "OBSERVATION", 261, 275], ["multicentric", "OBSERVATION_MODIFIER", 284, 296], ["Castleman", "OBSERVATION", 297, 306]]], ["In a prospective cohort of 44 patients with Castleman disease and human immunodeficiency virus (HIV), 4 (9%) had HLH [246] .", [["Castleman disease", "DISEASE", 44, 61], ["human immunodeficiency virus (HIV)", "DISEASE", 66, 100], ["HLH", "DISEASE", 113, 116], ["patients", "ORGANISM", 30, 38], ["human immunodeficiency virus", "ORGANISM", 66, 94], ["patients", "SPECIES", 30, 38], ["human", "SPECIES", 66, 71], ["immunodeficiency virus", "SPECIES", 72, 94], ["human immunodeficiency virus", "SPECIES", 66, 94], ["HIV", "SPECIES", 96, 99], ["Castleman disease", "PROBLEM", 44, 61], ["human immunodeficiency virus", "PROBLEM", 66, 94], ["HLH", "PROBLEM", 113, 116], ["Castleman", "OBSERVATION", 44, 53]]], ["Intriguingly, in this series, the levels of IL-8 and IFN-\u03b3 were increased, though the cytokine levels of many known inflammatory markers were not.", [["IL-8", "GENE_OR_GENE_PRODUCT", 44, 48], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-8", "PROTEIN", 44, 48], ["IFN-\u03b3", "PROTEIN", 53, 58], ["cytokine", "PROTEIN", 86, 94], ["inflammatory markers", "PROTEIN", 116, 136], ["the levels of IL", "TEST", 30, 46], ["IFN", "TEST", 53, 56], ["the cytokine levels", "TEST", 82, 101], ["many known inflammatory markers", "PROBLEM", 105, 136], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["inflammatory markers", "OBSERVATION", 116, 136]]], ["In this study, all patients recovered after treatment with splenectomy, etoposide, and rituximab [249] .", [["etoposide", "CHEMICAL", 72, 81], ["rituximab", "CHEMICAL", 87, 96], ["etoposide", "CHEMICAL", 72, 81], ["rituximab", "CHEMICAL", 87, 96], ["patients", "ORGANISM", 19, 27], ["etoposide", "SIMPLE_CHEMICAL", 72, 81], ["rituximab", "SIMPLE_CHEMICAL", 87, 96], ["patients", "SPECIES", 19, 27], ["this study", "TEST", 3, 13], ["treatment", "TREATMENT", 44, 53], ["splenectomy", "TREATMENT", 59, 70], ["etoposide", "TREATMENT", 72, 81], ["rituximab", "TREATMENT", 87, 96], ["splenectomy", "OBSERVATION", 59, 70]]], ["Ganciclovir and foscarnet have also been associated with recovery in some HHV8-HPS cases.", [["Ganciclovir", "CHEMICAL", 0, 11], ["foscarnet", "CHEMICAL", 16, 25], ["HPS", "DISEASE", 79, 82], ["Ganciclovir", "CHEMICAL", 0, 11], ["foscarnet", "CHEMICAL", 16, 25], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["foscarnet", "SIMPLE_CHEMICAL", 16, 25], ["HHV8", "ORGANISM", 74, 78], ["Ganciclovir", "TREATMENT", 0, 11], ["foscarnet", "TREATMENT", 16, 25]]], ["Finally, all other herpes viruses [102] [103] [104] 250] with the exception of HHV-7 have been associated with HLH.Neonatal Infection-Associated HLHDue to the lack of disease awareness among many physicians, HLH presenting within the first 4 weeks of life is rarely recognized.", [["herpes viruses", "DISEASE", 19, 33], ["HLH", "DISEASE", 111, 114], ["HLH", "DISEASE", 208, 211], ["herpes viruses", "ORGANISM", 19, 33], ["HHV-7", "ORGANISM", 79, 84], ["HHV-7", "SPECIES", 79, 84], ["all other herpes viruses", "TEST", 9, 33], ["HHV", "TEST", 79, 82], ["HLH", "PROBLEM", 111, 114], ["Neonatal Infection", "PROBLEM", 115, 133], ["HLH", "PROBLEM", 208, 211], ["HLH", "OBSERVATION", 111, 114], ["Infection", "OBSERVATION", 124, 133]]], ["Neonatal HLH differs from HLH in older children in etiology, manifestations, and laboratory findings.", [["HLH", "DISEASE", 9, 12], ["HLH", "DISEASE", 26, 29], ["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["Neonatal HLH", "PROBLEM", 0, 12], ["HLH", "PROBLEM", 26, 29], ["HLH", "OBSERVATION", 9, 12]]], ["In a nationwide survey in Japan published in 2009, 20 neonates were diagnosed with HLH within 4 weeks after birth; 6 (30%) of them were diagnosed with fHLH, and 6 (30%) were diagnosed with herpes simplex virus-associated HLH (HSV-HLH) [251] .", [["HLH", "DISEASE", 83, 86], ["fHLH", "DISEASE", 151, 155], ["herpes simplex virus", "DISEASE", 189, 209], ["HLH", "DISEASE", 221, 224], ["HSV-HLH", "DISEASE", 226, 233], ["neonates", "ORGANISM", 54, 62], ["herpes simplex virus", "ORGANISM", 189, 209], ["HSV", "ORGANISM", 226, 229], ["herpes simplex virus", "SPECIES", 189, 209], ["herpes simplex virus", "SPECIES", 189, 209], ["HLH", "PROBLEM", 83, 86], ["fHLH", "TEST", 151, 155], ["herpes simplex virus", "PROBLEM", 189, 209], ["HLH", "PROBLEM", 221, 224], ["HSV", "TEST", 226, 229]]], ["The overall survival rate of these 20 patients was 28.6% for fHLH and severe combined immunodeficiency (SCID)-HLH, and 33.3% for HSV-HLH, despite acyclovir treatment.", [["fHLH", "DISEASE", 61, 65], ["immunodeficiency", "DISEASE", 86, 102], ["SCID", "DISEASE", 104, 108], ["HLH", "DISEASE", 110, 113], ["HSV-HLH", "DISEASE", 129, 136], ["acyclovir", "CHEMICAL", 146, 155], ["acyclovir", "CHEMICAL", 146, 155], ["patients", "ORGANISM", 38, 46], ["HSV", "ORGANISM", 129, 132], ["acyclovir", "SIMPLE_CHEMICAL", 146, 155], ["patients", "SPECIES", 38, 46], ["The overall survival rate", "TEST", 0, 25], ["fHLH", "PROBLEM", 61, 65], ["severe combined immunodeficiency (SCID)", "PROBLEM", 70, 109], ["HLH", "PROBLEM", 110, 113], ["HSV", "PROBLEM", 129, 132], ["HLH", "PROBLEM", 133, 136], ["acyclovir treatment", "TREATMENT", 146, 165], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["immunodeficiency", "OBSERVATION", 86, 102], ["HLH", "OBSERVATION", 133, 136]]], ["Although uncommon in HLH of older children, enterovirus (echovirus and coxsackievirus) and HSV have been associated with fatal or fulminant neonatal HLH [252, 253] .", [["HLH", "DISEASE", 21, 24], ["enterovirus (echovirus and coxsackievirus)", "DISEASE", 44, 86], ["HLH", "DISEASE", 149, 152], ["children", "ORGANISM", 34, 42], ["enterovirus", "ORGANISM", 44, 55], ["coxsackievirus", "ORGANISM", 71, 85], ["HSV", "ORGANISM", 91, 94], ["children", "SPECIES", 34, 42], ["HSV", "SPECIES", 91, 94], ["enterovirus", "PROBLEM", 44, 55], ["echovirus", "PROBLEM", 57, 66], ["coxsackievirus", "PROBLEM", 71, 85], ["HSV", "PROBLEM", 91, 94], ["fulminant neonatal HLH", "PROBLEM", 130, 152], ["fulminant", "OBSERVATION_MODIFIER", 130, 139]]], ["This mandates early treatment with high-dose acyclovir in suspected cases without awaiting viral studies results.HIVHLH can be associated with HIV [117] infection [the etiology of acquired immunodeficiency syndrome (AIDS)] in different settings.", [["acyclovir", "CHEMICAL", 45, 54], ["HIVHLH", "CHEMICAL", 113, 119], ["HIV [117] infection", "DISEASE", 143, 162], ["acquired immunodeficiency syndrome", "DISEASE", 180, 214], ["AIDS", "DISEASE", 216, 220], ["acyclovir", "CHEMICAL", 45, 54], ["acyclovir", "SIMPLE_CHEMICAL", 45, 54], ["HIV [117]", "ORGANISM", 143, 152], ["HIV", "SPECIES", 143, 146], ["HIV", "SPECIES", 143, 146], ["early treatment", "TREATMENT", 14, 29], ["high-dose acyclovir", "TREATMENT", 35, 54], ["viral studies", "TEST", 91, 104], ["HIV [117] infection", "PROBLEM", 143, 162], ["acquired immunodeficiency syndrome", "PROBLEM", 180, 214], ["immunodeficiency syndrome", "OBSERVATION", 189, 214]]], ["HLH can occur either with HIV alone or with a variety of underlying associated disorders.", [["HLH", "DISEASE", 0, 3], ["HIV", "SPECIES", 26, 29], ["HIV", "SPECIES", 26, 29], ["HLH", "PROBLEM", 0, 3], ["HIV", "PROBLEM", 26, 29], ["underlying associated disorders", "PROBLEM", 57, 88]]], ["HLH has been reported in acute or late stages of HIV infection, in the setting of immune reconstitution inflammatory syndromes (IRIS), and in association with HIV-associated malignancies or infections (both opportunistic and non-opportunistic) [254] .", [["malignancies", "ANATOMY", 174, 186], ["HLH", "DISEASE", 0, 3], ["HIV infection", "DISEASE", 49, 62], ["immune reconstitution inflammatory syndromes", "DISEASE", 82, 126], ["IRIS", "DISEASE", 128, 132], ["HIV-associated malignancies", "DISEASE", 159, 186], ["infections", "DISEASE", 190, 200], ["HIV", "ORGANISM", 49, 52], ["malignancies", "CANCER", 174, 186], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 159, 162], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 159, 162], ["HLH", "PROBLEM", 0, 3], ["HIV infection", "PROBLEM", 49, 62], ["immune reconstitution inflammatory syndromes", "PROBLEM", 82, 126], ["HIV", "PROBLEM", 159, 162], ["associated malignancies", "PROBLEM", 163, 186], ["infections", "PROBLEM", 190, 200], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["late stages", "OBSERVATION_MODIFIER", 34, 45], ["HIV", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 53, 62], ["immune reconstitution", "OBSERVATION", 82, 103], ["inflammatory syndromes", "OBSERVATION", 104, 126], ["malignancies", "OBSERVATION", 174, 186], ["infections", "OBSERVATION", 190, 200]]], ["HLH has even been reported as the initial presentation of HIV infection [118] , which suggests a direct role for HIV in triggering HLH [195] .HIVDue to the fact that both HIV and HLH share many similar clinical and biological findings, it is likely that this association is also underdiagnosed.", [["HLH", "DISEASE", 0, 3], ["HIV infection", "DISEASE", 58, 71], ["HLH", "DISEASE", 131, 134], ["HIV and HLH", "DISEASE", 171, 182], ["HIV", "ORGANISM", 58, 61], ["HIV", "ORGANISM", 113, 116], ["HIV", "ORGANISM", 171, 174], ["HLH", "PROTEIN", 0, 3], ["HIV", "SPECIES", 171, 174], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 113, 116], ["HIV", "SPECIES", 171, 174], ["HLH", "PROBLEM", 0, 3], ["HIV infection", "PROBLEM", 58, 71], ["HIV", "PROBLEM", 113, 116]]], ["In one study, hemophagocytosis was observed in 20% of 56 autopsy cases of HIVpositive patients [255] .", [["hemophagocytosis", "DISEASE", 14, 30], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["one study", "TEST", 3, 12], ["hemophagocytosis", "PROBLEM", 14, 30], ["HIVpositive patients", "PROBLEM", 74, 94], ["hemophagocytosis", "OBSERVATION", 14, 30]]], ["Around 10% of bone marrow biopsies in HIV patients before highly active antiretroviral therapy (HAART) initiation revealed hemophagocytosis [256] .", [["bone marrow", "ANATOMY", 14, 25], ["hemophagocytosis", "DISEASE", 123, 139], ["bone marrow biopsies", "MULTI-TISSUE_STRUCTURE", 14, 34], ["HIV", "ORGANISM", 38, 41], ["patients", "ORGANISM", 42, 50], ["HIV", "SPECIES", 38, 41], ["patients", "SPECIES", 42, 50], ["HIV", "SPECIES", 38, 41], ["bone marrow biopsies", "TEST", 14, 34], ["highly active antiretroviral therapy", "TREATMENT", 58, 94], ["HAART", "TREATMENT", 96, 101], ["hemophagocytosis", "PROBLEM", 123, 139], ["bone marrow", "ANATOMY", 14, 25], ["hemophagocytosis", "OBSERVATION", 123, 139]]], ["In adult cases with acute HIV infection, HLH was associated with low CD4 T-cell counts (<200 cells/\u03bcL) in almost two-thirds of the cases.", [["CD4 T-cell", "ANATOMY", 69, 79], ["cells", "ANATOMY", 93, 98], ["acute HIV infection", "DISEASE", 20, 39], ["HLH", "DISEASE", 41, 44], ["HIV", "ORGANISM", 26, 29], ["CD4", "PROTEIN", 69, 72], ["HIV", "SPECIES", 26, 29], ["HIV", "SPECIES", 26, 29], ["acute HIV infection", "PROBLEM", 20, 39], ["HLH", "PROBLEM", 41, 44], ["low CD4 T-cell counts", "PROBLEM", 65, 86], ["cells/\u03bcL", "TEST", 93, 101], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["HIV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39]]], ["In addition, a lower CD4 T-cell count was associated with a worse prognosis [257] .InfluenzaThe association of HLH with influenza has been described with seasonal [122, [258] [259] [260] [261] [262] , avian [263, 264] , and swine (non-pandemic) influenza [265] .", [["CD4 T-cell", "ANATOMY", 21, 31], ["Influenza", "DISEASE", 83, 92], ["HLH", "DISEASE", 111, 114], ["influenza", "DISEASE", 120, 129], ["influenza", "DISEASE", 245, 254], ["avian", "ORGANISM", 201, 206], ["swine", "ORGANISM", 224, 229], ["CD4", "PROTEIN", 21, 24], ["swine", "SPECIES", 224, 229], ["swine", "SPECIES", 224, 229], ["a lower CD4 T-cell count", "TEST", 13, 37], ["Influenza", "PROBLEM", 83, 92], ["HLH", "PROBLEM", 111, 114], ["influenza", "PROBLEM", 120, 129], ["influenza", "PROBLEM", 245, 254], ["HLH", "OBSERVATION", 111, 114]]], ["It has also been associated with both immunocompromised [258] [259] [260] [261] and otherwise healthy children [122, 266] .", [["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["both", "OBSERVATION_MODIFIER", 33, 37], ["immunocompromised", "OBSERVATION", 38, 55]]], ["In a prospective pediatric study, which included 32 children hospitalized with seasonal influenza, one case had a fatal outcome [262] .", [["influenza", "DISEASE", 88, 97], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["a prospective pediatric study", "TEST", 3, 32], ["seasonal influenza", "PROBLEM", 79, 97]]], ["Interestingly, patients with severe H5N1 avian influenza have clinical pictures and laboratory findings similar to HLH; these consist mainly of encephalitis [267] , organ dysfunction with hemophagocytosis [268] , bone marrow suppression [268, 269] , and cytokine storm [270, 271] .", [["organ", "ANATOMY", 165, 170], ["bone marrow", "ANATOMY", 213, 224], ["avian influenza", "DISEASE", 41, 56], ["HLH", "DISEASE", 115, 118], ["encephalitis", "DISEASE", 144, 156], ["organ dysfunction", "DISEASE", 165, 182], ["hemophagocytosis", "DISEASE", 188, 204], ["bone marrow suppression", "DISEASE", 213, 236], ["patients", "ORGANISM", 15, 23], ["organ", "ORGAN", 165, 170], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 213, 224], ["cytokine", "PROTEIN", 254, 262], ["patients", "SPECIES", 15, 23], ["H5N1 avian influenza", "SPECIES", 36, 56], ["severe H5N1 avian influenza", "PROBLEM", 29, 56], ["laboratory findings", "TEST", 84, 103], ["HLH", "PROBLEM", 115, 118], ["encephalitis", "PROBLEM", 144, 156], ["organ dysfunction", "PROBLEM", 165, 182], ["hemophagocytosis", "PROBLEM", 188, 204], ["bone marrow suppression", "TEST", 213, 236], ["encephalitis", "OBSERVATION", 144, 156], ["hemophagocytosis", "OBSERVATION", 188, 204], ["bone", "ANATOMY", 213, 217]]], ["The most common characteristic pathological picture seen on autopsy and biopsy in such cases is hemophagocytosis [264, 271, 272] .InfluenzaClinical studies have found that mutations in some viral genes (NS1, PB2, HA, and NA) are significantly related to cytokine release, and it has been shown that recombinant hemagglutinin (H5) from H5N1 virus may suppress perforin expression and reduce the cytotoxicity of CD8 T cells, including their ability to kill H5-bearing cells leading to marked lymphoproliferation and IFN-\u03b3 hyperproduction with macrophage overactivation [273] .", [["CD8 T cells", "ANATOMY", 410, 421], ["cells", "ANATOMY", 466, 471], ["macrophage", "ANATOMY", 541, 551], ["hemophagocytosis", "DISEASE", 96, 112], ["lymphoproliferation", "DISEASE", 490, 509], ["NS1", "GENE_OR_GENE_PRODUCT", 203, 206], ["PB2", "GENE_OR_GENE_PRODUCT", 208, 211], ["HA", "GENE_OR_GENE_PRODUCT", 213, 215], ["NA", "GENE_OR_GENE_PRODUCT", 221, 223], ["recombinant hemagglutinin (H5", "ORGANISM", 299, 328], ["H5N1 virus", "ORGANISM", 335, 345], ["perforin", "GENE_OR_GENE_PRODUCT", 359, 367], ["CD8 T cells", "CELL", 410, 421], ["cells", "CELL", 466, 471], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 514, 519], ["macrophage", "CELL", 541, 551], ["viral genes", "DNA", 190, 201], ["NS1", "DNA", 203, 206], ["PB2", "DNA", 208, 211], ["HA", "DNA", 213, 215], ["NA", "DNA", 221, 223], ["cytokine", "PROTEIN", 254, 262], ["H5", "PROTEIN", 326, 328], ["perforin", "PROTEIN", 359, 367], ["CD8 T cells", "CELL_TYPE", 410, 421], ["H5-bearing cells", "CELL_LINE", 455, 471], ["IFN", "PROTEIN", 514, 517], ["H5N1 virus", "SPECIES", 335, 345], ["H5N1 virus", "SPECIES", 335, 345], ["autopsy", "TEST", 60, 67], ["biopsy", "TEST", 72, 78], ["hemophagocytosis", "PROBLEM", 96, 112], ["InfluenzaClinical studies", "TEST", 130, 155], ["mutations in some viral genes", "PROBLEM", 172, 201], ["NS1", "TEST", 203, 206], ["PB2", "TEST", 208, 211], ["HA", "PROBLEM", 213, 215], ["NA", "TEST", 221, 223], ["cytokine release", "TEST", 254, 270], ["recombinant hemagglutinin (H5)", "PROBLEM", 299, 329], ["H5N1 virus", "PROBLEM", 335, 345], ["perforin expression", "PROBLEM", 359, 378], ["the cytotoxicity of CD8 T cells", "PROBLEM", 390, 421], ["marked lymphoproliferation", "PROBLEM", 483, 509], ["IFN", "PROBLEM", 514, 517], ["hyperproduction", "PROBLEM", 520, 535], ["macrophage overactivation", "PROBLEM", 541, 566], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["pathological", "OBSERVATION", 31, 43], ["hemophagocytosis", "OBSERVATION", 96, 112], ["marked", "OBSERVATION_MODIFIER", 483, 489], ["lymphoproliferation", "OBSERVATION", 490, 509]]], ["Considering the high mortality caused by H5N1-HLH, the resistance to many antivirals by H5N1, and the similarity between HLH and severe flu infections have led some to suggest the use of a modified HLH-94 protocol [274] with a shorter course of etoposide and dexamethasone in such cases.", [["HLH", "DISEASE", 46, 49], ["H5N1", "DISEASE", 88, 92], ["HLH", "DISEASE", 121, 124], ["flu infections", "DISEASE", 136, 150], ["HLH", "DISEASE", 198, 201], ["etoposide", "CHEMICAL", 245, 254], ["dexamethasone", "CHEMICAL", 259, 272], ["HLH-94", "CHEMICAL", 198, 204], ["etoposide", "CHEMICAL", 245, 254], ["dexamethasone", "CHEMICAL", 259, 272], ["H5N1-HLH", "ORGANISM", 41, 49], ["H5N1", "ORGANISM", 88, 92], ["etoposide", "SIMPLE_CHEMICAL", 245, 254], ["dexamethasone", "SIMPLE_CHEMICAL", 259, 272], ["the high mortality", "PROBLEM", 12, 30], ["H5N1", "PROBLEM", 41, 45], ["HLH", "PROBLEM", 46, 49], ["many antivirals", "TREATMENT", 69, 84], ["H5N1", "PROBLEM", 88, 92], ["HLH", "PROBLEM", 121, 124], ["severe flu infections", "PROBLEM", 129, 150], ["a modified HLH", "TREATMENT", 187, 201], ["etoposide", "TREATMENT", 245, 254], ["dexamethasone", "TREATMENT", 259, 272], ["HLH", "OBSERVATION", 46, 49], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["flu", "OBSERVATION", 136, 139]]], ["However, in a randomized study from Vietnam, all patients with H5N1-HLH died despite receiving corticosteroids [275] .InfluenzaRecently, a study was done on 16 cases of fatal influenza A (H1N1) infection who met 44 and 81% of modified HLH-2004 and MAS criteria, respectively.", [["H5N1-", "DISEASE", 63, 68], ["HLH", "DISEASE", 68, 71], ["influenza A (H1N1) infection", "DISEASE", 175, 203], ["corticosteroids", "CHEMICAL", 95, 110], ["patients", "ORGANISM", 49, 57], ["influenza A", "ORGANISM", 175, 186], ["patients", "SPECIES", 49, 57], ["influenza A (H1N1", "SPECIES", 175, 192], ["a randomized study", "TEST", 12, 30], ["H5N1", "PROBLEM", 63, 67], ["HLH", "PROBLEM", 68, 71], ["corticosteroids", "TREATMENT", 95, 110], ["a study", "TEST", 137, 144], ["fatal influenza A (H1N1) infection", "PROBLEM", 169, 203], ["modified HLH", "TEST", 226, 238], ["fatal", "OBSERVATION_MODIFIER", 169, 174], ["influenza", "OBSERVATION", 175, 184]]], ["Five subjects (36%) carried one of three different heterozygous LYST mutations, two of whom also possessed the relatively common p.A91V PRF1 mutation, which was shown to mildly decrease NK cell cytolytic function.", [["NK cell", "ANATOMY", 186, 193], ["LYST", "GENE_OR_GENE_PRODUCT", 64, 68], ["p.A91V", "GENE_OR_GENE_PRODUCT", 129, 135], ["PRF1", "GENE_OR_GENE_PRODUCT", 136, 140], ["NK cell", "CELL", 186, 193], ["PRF1", "PROTEIN", 136, 140], ["different heterozygous LYST mutations", "PROBLEM", 41, 78], ["PRF1 mutation", "PROBLEM", 136, 149], ["mildly decrease NK cell cytolytic function", "PROBLEM", 170, 212], ["LYST mutations", "OBSERVATION", 64, 78], ["mildly", "OBSERVATION_MODIFIER", 170, 176], ["decrease NK cell", "OBSERVATION", 177, 193], ["cytolytic function", "OBSERVATION", 194, 212]]], ["Several patients also carried rare variants in other genes previously observed in patients with MAS.", [["MAS", "DISEASE", 96, 99], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 82, 90], ["rare variants", "PROBLEM", 30, 43]]], ["The high percentage of HLH gene mutations suggests they are risk factors for mortality among individuals with influenza A (H1N1) infection [276] .ParvovirusHLH has been reported in approximately 30 cases of parvovirus B19 infection; most of them had hereditary spherocytosis as the underlying disease, and less than 50% were children [106, 109, 110, 277, 278] .", [["HLH", "DISEASE", 23, 26], ["influenza A (H1N1) infection", "DISEASE", 110, 138], ["parvovirus B19 infection", "DISEASE", 207, 231], ["hereditary spherocytosis", "DISEASE", 250, 274], ["influenza A (H1N1)", "ORGANISM", 110, 128], ["ParvovirusHLH", "GENE_OR_GENE_PRODUCT", 146, 159], ["parvovirus B19", "ORGANISM", 207, 221], ["children", "ORGANISM", 325, 333], ["HLH gene", "DNA", 23, 31], ["influenza A (H1N1", "SPECIES", 110, 127], ["parvovirus B19", "SPECIES", 207, 221], ["children", "SPECIES", 325, 333], ["parvovirus B19", "SPECIES", 207, 221], ["HLH gene mutations", "PROBLEM", 23, 41], ["influenza A (H1N1) infection", "PROBLEM", 110, 138], ["parvovirus B19 infection", "PROBLEM", 207, 231], ["hereditary spherocytosis", "PROBLEM", 250, 274], ["the underlying disease", "PROBLEM", 278, 300], ["high", "OBSERVATION_MODIFIER", 4, 8], ["percentage", "OBSERVATION_MODIFIER", 9, 19], ["HLH", "OBSERVATION", 23, 26], ["parvovirus B19 infection", "OBSERVATION", 207, 231], ["hereditary", "OBSERVATION_MODIFIER", 250, 260], ["spherocytosis", "OBSERVATION", 261, 274], ["disease", "OBSERVATION", 293, 300]]], ["Of these patients, 22 survived, of whom 16 did not receive any treatment.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["any treatment", "TREATMENT", 59, 72]]], ["This suggests a better prognosis of parvovirus-HLH than that with other viral infections.Hepatitis VirusesFulminant viral hepatitis may mimic and even cause HLH.", [["parvovirus-HLH", "DISEASE", 36, 50], ["viral infections", "DISEASE", 72, 88], ["Hepatitis VirusesFulminant viral hepatitis", "DISEASE", 89, 131], ["HLH", "DISEASE", 157, 160], ["parvovirus-HLH", "ORGANISM", 36, 50], ["Hepatitis VirusesFulminant viral", "ORGANISM", 89, 121], ["parvovirus", "PROBLEM", 36, 46], ["HLH", "PROBLEM", 47, 50], ["other viral infections", "PROBLEM", 66, 88], ["Hepatitis VirusesFulminant viral hepatitis", "PROBLEM", 89, 131], ["HLH", "PROBLEM", 157, 160], ["parvovirus", "OBSERVATION", 36, 46], ["viral", "OBSERVATION_MODIFIER", 72, 77], ["infections", "OBSERVATION", 78, 88], ["viral hepatitis", "OBSERVATION", 116, 131]]], ["Hepatitis A virus (HAV) is more frequently associated with HLH than other hepato-tropic viruses, including HBV and HCV.", [["Hepatitis A", "DISEASE", 0, 11], ["HAV", "DISEASE", 19, 22], ["HLH", "DISEASE", 59, 62], ["HCV", "DISEASE", 115, 118], ["Hepatitis A virus", "ORGANISM", 0, 17], ["HAV", "ORGANISM", 19, 22], ["hepato-tropic viruses", "ORGANISM", 74, 95], ["HBV", "ORGANISM", 107, 110], ["HCV", "ORGANISM", 115, 118], ["Hepatitis A virus", "SPECIES", 0, 17], ["Hepatitis A virus", "SPECIES", 0, 17], ["HAV", "SPECIES", 19, 22], ["HBV", "SPECIES", 107, 110], ["HCV", "SPECIES", 115, 118], ["Hepatitis A virus (HAV", "PROBLEM", 0, 22], ["HLH", "PROBLEM", 59, 62], ["other hepato-tropic viruses", "PROBLEM", 68, 95], ["HBV", "PROBLEM", 107, 110], ["HCV", "PROBLEM", 115, 118], ["virus", "OBSERVATION", 12, 17], ["tropic viruses", "OBSERVATION", 81, 95], ["HCV", "OBSERVATION", 115, 118]]], ["Fifteen cases (including children) have been described in the literature, mainly in Asia; three of these patients also had a concurrent rheumatological disease (sJIA or the related adult onset Still disease), and two also had hepatitis C. Four patients survived without specific treatment.", [["rheumatological disease", "DISEASE", 136, 159], ["JIA", "DISEASE", 162, 165], ["Still disease", "DISEASE", 193, 206], ["hepatitis", "DISEASE", 226, 235], ["children", "ORGANISM", 25, 33], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 244, 252], ["children", "SPECIES", 25, 33], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 244, 252], ["a concurrent rheumatological disease", "PROBLEM", 123, 159], ["sJIA", "PROBLEM", 161, 165], ["Still disease)", "PROBLEM", 193, 207], ["hepatitis C.", "PROBLEM", 226, 238], ["specific treatment", "TREATMENT", 270, 288], ["rheumatological disease", "OBSERVATION", 136, 159]]], ["The others received corticosteroids with or without IVIg.", [["IVIg", "CHEMICAL", 52, 56], ["corticosteroids", "CHEMICAL", 20, 35], ["IVIg", "SIMPLE_CHEMICAL", 52, 56], ["corticosteroids", "TREATMENT", 20, 35], ["IVIg", "TREATMENT", 52, 56]]], ["Overall, 11 of the 15 had a good outcome [112, 113, 279] .EnterovirusTwelve cases of pediatric enterovirus-related HLH have been described.", [["enterovirus", "DISEASE", 95, 106], ["HLH", "DISEASE", 115, 118], ["Enterovirus", "ORGANISM", 58, 69], ["enterovirus", "ORGANISM", 95, 106], ["Enterovirus", "PROBLEM", 58, 69], ["pediatric enterovirus", "PROBLEM", 85, 106], ["HLH", "PROBLEM", 115, 118], ["HLH", "OBSERVATION", 115, 118]]], ["Four patients had an underlying disease (Hodgkin and non-Hodgkin lymphoma, acute lymphoblastic leukemia, JIA) and had a higher mortality rate (75%).", [["Hodgkin", "ANATOMY", 41, 48], ["non-Hodgkin lymphoma", "ANATOMY", 53, 73], ["acute lymphoblastic leukemia", "ANATOMY", 75, 103], ["Hodgkin and non-Hodgkin lymphoma", "DISEASE", 41, 73], ["acute lymphoblastic leukemia", "DISEASE", 75, 103], ["JIA", "DISEASE", 105, 108], ["patients", "ORGANISM", 5, 13], ["Hodgkin", "CANCER", 41, 48], ["non-Hodgkin lymphoma", "CANCER", 53, 73], ["acute lymphoblastic leukemia", "CANCER", 75, 103], ["patients", "SPECIES", 5, 13], ["an underlying disease", "PROBLEM", 18, 39], ["Hodgkin and non-Hodgkin lymphoma", "PROBLEM", 41, 73], ["acute lymphoblastic leukemia", "PROBLEM", 75, 103], ["disease", "OBSERVATION", 32, 39], ["Hodgkin", "OBSERVATION", 41, 48], ["non-Hodgkin lymphoma", "OBSERVATION", 53, 73], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["lymphoblastic leukemia", "OBSERVATION", 81, 103]]], ["Ten patients received IVIg (six in combination with corticosteroids), but only seven patients survived [132] .", [["IVIg", "CHEMICAL", 22, 26], ["patients", "ORGANISM", 4, 12], ["IVIg", "SIMPLE_CHEMICAL", 22, 26], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 85, 93], ["IVIg", "TREATMENT", 22, 26], ["corticosteroids", "TREATMENT", 52, 67]]], ["Other viruses associated have been associated with HLH (Table 14 .4), for most of which varying courses of corticosteroids and IVIg have been used.", [["HLH", "DISEASE", 51, 54], ["IVIg", "CHEMICAL", 127, 131], ["corticosteroids", "CHEMICAL", 107, 122], ["corticosteroids", "SIMPLE_CHEMICAL", 107, 122], ["IVIg", "SIMPLE_CHEMICAL", 127, 131], ["Other viruses", "PROBLEM", 0, 13], ["HLH", "PROBLEM", 51, 54], ["corticosteroids", "TREATMENT", 107, 122], ["IVIg", "TREATMENT", 127, 131], ["viruses", "OBSERVATION", 6, 13]]], ["Interestingly, HLH may contribute to the high mortality rate associated with certain hemorrhagic fever viruses, such as those causing Dengue fever and Ebola.Bacteria-Associated Hemophagocytic SyndromeOf the bacterial pathogens, intracellular organisms have most commonly been the precipitating bacterial agents of HLH.", [["intracellular", "ANATOMY", 228, 241], ["HLH", "DISEASE", 15, 18], ["hemorrhagic fever", "DISEASE", 85, 102], ["Dengue fever", "DISEASE", 134, 146], ["Ebola", "DISEASE", 151, 156], ["HLH", "DISEASE", 314, 317], ["Ebola", "ORGANISM", 151, 156], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 228, 241], ["Dengue fever", "SPECIES", 134, 146], ["HLH", "PROBLEM", 15, 18], ["the high mortality rate", "PROBLEM", 37, 60], ["certain hemorrhagic fever viruses", "PROBLEM", 77, 110], ["Dengue fever", "PROBLEM", 134, 146], ["Ebola", "PROBLEM", 151, 156], ["Bacteria", "PROBLEM", 157, 165], ["Hemophagocytic SyndromeOf", "PROBLEM", 177, 202], ["the bacterial pathogens", "PROBLEM", 203, 226], ["intracellular organisms", "PROBLEM", 228, 251], ["HLH", "PROBLEM", 314, 317], ["HLH", "OBSERVATION", 15, 18], ["hemorrhagic", "OBSERVATION_MODIFIER", 85, 96], ["fever", "OBSERVATION", 97, 102], ["Hemophagocytic SyndromeOf", "OBSERVATION", 177, 202], ["bacterial pathogens", "OBSERVATION", 207, 226], ["HLH", "OBSERVATION", 314, 317]]], ["The pathophysiology is probably related to the host lymphocytes and monocytes producing high levels of activating cytokines.", [["lymphocytes", "ANATOMY", 52, 63], ["monocytes", "ANATOMY", 68, 77], ["host lymphocytes", "CELL", 47, 63], ["monocytes", "CELL", 68, 77], ["host lymphocytes", "CELL_TYPE", 47, 63], ["monocytes", "CELL_TYPE", 68, 77], ["activating cytokines", "PROTEIN", 103, 123], ["the host lymphocytes", "TEST", 43, 63], ["monocytes", "TEST", 68, 77], ["activating cytokines", "PROBLEM", 103, 123], ["probably related to", "UNCERTAINTY", 23, 42], ["host lymphocytes", "OBSERVATION", 47, 63], ["high", "OBSERVATION_MODIFIER", 88, 92], ["levels", "OBSERVATION_MODIFIER", 93, 99]]], ["Defective NK cell and cytotoxic T-cell function is also hypothesized to play a role in the pathophysiology [2] .Bacteria-Associated Hemophagocytic SyndromeHLH has been reported with disseminated Mycobacterium tuberculosis (TB) infection.", [["NK cell", "ANATOMY", 10, 17], ["T-cell", "ANATOMY", 32, 38], ["Hemophagocytic SyndromeHLH", "DISEASE", 132, 158], ["Mycobacterium tuberculosis (TB) infection", "DISEASE", 195, 236], ["NK cell", "CELL", 10, 17], ["cytotoxic T-cell", "CELL", 22, 38], ["Mycobacterium tuberculosis", "ORGANISM", 195, 221], ["NK cell", "CELL_TYPE", 10, 17], ["Mycobacterium tuberculosis", "SPECIES", 195, 221], ["Mycobacterium tuberculosis", "SPECIES", 195, 221], ["Defective NK cell", "PROBLEM", 0, 17], ["cytotoxic T-cell function", "TEST", 22, 47], ["Bacteria", "PROBLEM", 112, 120], ["Hemophagocytic SyndromeHLH", "PROBLEM", 132, 158], ["disseminated Mycobacterium tuberculosis (TB) infection", "PROBLEM", 182, 236], ["NK cell", "OBSERVATION", 10, 17], ["cytotoxic", "OBSERVATION_MODIFIER", 22, 31], ["Hemophagocytic SyndromeHLH", "OBSERVATION", 132, 158], ["disseminated", "OBSERVATION_MODIFIER", 182, 194], ["Mycobacterium tuberculosis", "OBSERVATION", 195, 221], ["infection", "OBSERVATION", 227, 236]]], ["It can occur in otherwise healthy patients [280] , in end-stage renal disease patients receiving hemodialysis [281] , in those who had undergone renal transplantation [164] , or who had malignancy [282] , HIV/AIDS [283] , or sarcoidosis [284] .", [["renal", "ANATOMY", 64, 69], ["renal", "ANATOMY", 145, 150], ["end-stage renal disease", "DISEASE", 54, 77], ["malignancy", "DISEASE", 186, 196], ["HIV/AIDS", "DISEASE", 205, 213], ["sarcoidosis", "DISEASE", 225, 236], ["patients", "ORGANISM", 34, 42], ["renal", "ORGAN", 64, 69], ["patients", "ORGANISM", 78, 86], ["renal", "ORGAN", 145, 150], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 78, 86], ["HIV", "SPECIES", 205, 208], ["HIV", "SPECIES", 205, 208], ["end-stage renal disease", "PROBLEM", 54, 77], ["hemodialysis", "TREATMENT", 97, 109], ["renal transplantation", "TREATMENT", 145, 166], ["malignancy", "PROBLEM", 186, 196], ["HIV/AIDS", "PROBLEM", 205, 213], ["sarcoidosis", "PROBLEM", 225, 236], ["renal", "ANATOMY", 64, 69], ["disease", "OBSERVATION", 70, 77], ["renal", "ANATOMY", 145, 150], ["transplantation", "OBSERVATION", 151, 166], ["malignancy", "OBSERVATION", 186, 196], ["sarcoidosis", "OBSERVATION", 225, 236]]], ["In a review of 36 cases by Brastianos et al., 83% of cases had evidence of extrapulmonary tuberculo-sis.", [["extrapulmonary tuberculo-sis", "DISEASE", 75, 103], ["extrapulmonary tuberculo-sis", "PROBLEM", 75, 103], ["extrapulmonary", "ANATOMY", 75, 89], ["tuberculo", "OBSERVATION", 90, 99]]], ["The mortality rate was approximately 50% which portrays the poor outcome of TB-HLH, although antituberculous and immunomodulatory therapy (consisting of high-dose corticosteroids, IVIg, antithymocyte globulin, cyclosporine A, epipodophyllotoxin, or plasma exchange) may lead to better outcomes [155] .", [["plasma", "ANATOMY", 249, 255], ["TB", "DISEASE", 76, 78], ["HLH", "DISEASE", 79, 82], ["IVIg", "CHEMICAL", 180, 184], ["antithymocyte globulin", "CHEMICAL", 186, 208], ["cyclosporine A", "CHEMICAL", 210, 224], ["epipodophyllotoxin", "CHEMICAL", 226, 244], ["cyclosporine A", "CHEMICAL", 210, 224], ["epipodophyllotoxin", "CHEMICAL", 226, 244], ["IVIg", "SIMPLE_CHEMICAL", 180, 184], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 186, 208], ["cyclosporine A", "SIMPLE_CHEMICAL", 210, 224], ["epipodophyllotoxin", "SIMPLE_CHEMICAL", 226, 244], ["plasma", "ORGANISM_SUBSTANCE", 249, 255], ["The mortality rate", "TEST", 0, 18], ["TB", "PROBLEM", 76, 78], ["HLH", "PROBLEM", 79, 82], ["antituberculous", "TREATMENT", 93, 108], ["immunomodulatory therapy", "TREATMENT", 113, 137], ["high-dose corticosteroids", "TREATMENT", 153, 178], ["IVIg", "TREATMENT", 180, 184], ["antithymocyte globulin", "TREATMENT", 186, 208], ["cyclosporine A", "TREATMENT", 210, 224], ["epipodophyllotoxin", "TREATMENT", 226, 244], ["plasma exchange", "TREATMENT", 249, 264], ["HLH", "OBSERVATION", 79, 82]]], ["Early diagnosis and timely administration of antituberculous treatment are crucial in these patients.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["antituberculous treatment", "TREATMENT", 45, 70]]], ["Moreover, one reported case of HLH occurred after childhood vaccination with the bacillus Calmette-Gu\u00e9rin [157] .", [["HLH", "DISEASE", 31, 34], ["bacillus Calmette-Gu\u00e9rin", "CHEMICAL", 81, 105], ["bacillus Calmette-Gu\u00e9rin", "SPECIES", 81, 105], ["HLH", "PROBLEM", 31, 34], ["childhood vaccination", "TREATMENT", 50, 71], ["the bacillus Calmette", "TREATMENT", 77, 98]]], ["HLH has also been described in association with brucellosis, with Brucella melitensis being the most frequently isolated species [168] .", [["HLH", "DISEASE", 0, 3], ["brucellosis", "DISEASE", 48, 59], ["Brucella melitensis", "DISEASE", 66, 85], ["Brucella melitensis", "ORGANISM", 66, 85], ["HLH", "PROTEIN", 0, 3], ["Brucella melitensis", "SPECIES", 66, 85], ["Brucella melitensis", "SPECIES", 66, 85], ["HLH", "PROBLEM", 0, 3], ["brucellosis", "PROBLEM", 48, 59], ["Brucella melitensis", "PROBLEM", 66, 85], ["brucellosis", "OBSERVATION", 48, 59]]], ["Leptospirosis has been reported with HLH and has required treatment with corticosteroids, IVIg, or etoposide, in addition to antibiotic treatment [179] .", [["Leptospirosis", "DISEASE", 0, 13], ["HLH", "DISEASE", 37, 40], ["IVIg", "CHEMICAL", 90, 94], ["etoposide", "CHEMICAL", 99, 108], ["corticosteroids", "CHEMICAL", 73, 88], ["etoposide", "CHEMICAL", 99, 108], ["corticosteroids", "SIMPLE_CHEMICAL", 73, 88], ["IVIg", "SIMPLE_CHEMICAL", 90, 94], ["etoposide", "SIMPLE_CHEMICAL", 99, 108], ["Leptospirosis", "PROBLEM", 0, 13], ["HLH", "PROBLEM", 37, 40], ["treatment", "TREATMENT", 58, 67], ["corticosteroids", "TREATMENT", 73, 88], ["IVIg", "TREATMENT", 90, 94], ["etoposide", "TREATMENT", 99, 108], ["antibiotic treatment", "TREATMENT", 125, 145], ["HLH", "OBSERVATION", 37, 40]]], ["Reports have also related Rickettsia and Ehrlichia to HLH, and the prognosis seems to be influenced by the specific Rickettsia species, patient's immunologic status, and delay in antibiotic therapy or corticosteroid therapy [184] .", [["Ehrlichia", "DISEASE", 41, 50], ["HLH", "DISEASE", 54, 57], ["Ehrlichia", "ORGANISM", 41, 50], ["Rickettsia species", "ORGANISM", 116, 134], ["patient", "ORGANISM", 136, 143], ["corticosteroid", "SIMPLE_CHEMICAL", 201, 215], ["patient", "SPECIES", 136, 143], ["Rickettsia", "PROBLEM", 26, 36], ["Ehrlichia", "PROBLEM", 41, 50], ["HLH", "PROBLEM", 54, 57], ["the specific Rickettsia species", "PROBLEM", 103, 134], ["antibiotic therapy", "TREATMENT", 179, 197], ["corticosteroid therapy", "TREATMENT", 201, 223], ["Rickettsia", "OBSERVATION", 26, 36]]], ["Also, MAS following urinary tract infection with Acinetobacter baumannii was reported for the first time in a previously healthy 3-year-old child; recovery occurred without any cytotoxic treatment or immunotherapy, using only multiple doses of GCSF and red blood cell/platelet transfusions [159] .", [["urinary tract", "ANATOMY", 20, 33], ["red blood cell", "ANATOMY", 253, 267], ["platelet", "ANATOMY", 268, 276], ["urinary tract infection", "DISEASE", 20, 43], ["Acinetobacter baumannii", "CHEMICAL", 49, 72], ["GCSF", "CHEMICAL", 244, 248], ["urinary tract", "ORGANISM_SUBDIVISION", 20, 33], ["Acinetobacter baumannii", "ORGANISM", 49, 72], ["child", "ORGANISM", 140, 145], ["GCSF", "SIMPLE_CHEMICAL", 244, 248], ["red blood cell", "CELL", 253, 267], ["platelet", "CELL", 268, 276], ["GCSF", "PROTEIN", 244, 248], ["red blood cell", "CELL_TYPE", 253, 267], ["Acinetobacter baumannii", "SPECIES", 49, 72], ["Acinetobacter baumannii", "SPECIES", 49, 72], ["urinary tract infection", "PROBLEM", 20, 43], ["Acinetobacter baumannii", "PROBLEM", 49, 72], ["any cytotoxic treatment", "TREATMENT", 173, 196], ["immunotherapy", "TREATMENT", 200, 213], ["GCSF", "TREATMENT", 244, 248], ["red blood cell", "TEST", 253, 267], ["platelet transfusions", "TREATMENT", 268, 289], ["urinary tract", "ANATOMY", 20, 33], ["infection", "OBSERVATION", 34, 43], ["Acinetobacter baumannii", "OBSERVATION", 49, 72]]], ["Just like viruses, a large array of additional bacterial infections has been associated with HLH (Table 14 .4), but a propensity for intracellular invasion is a common theme to many of these triggers.Parasitic and Fungal Infection-Associated Hemophagocytic SyndromeLeishmania infection has been associated with HLH (particularly Leishmania donovani and Leishmania infantum), but considering that it presents with organomegaly and pancytopenia, it can also just mimic the syndrome of HLH.", [["intracellular", "ANATOMY", 133, 146], ["bacterial infections", "DISEASE", 47, 67], ["HLH", "DISEASE", 93, 96], ["Fungal Infection", "DISEASE", 214, 230], ["Hemophagocytic SyndromeLeishmania infection", "DISEASE", 242, 285], ["HLH", "DISEASE", 311, 314], ["Leishmania donovani and Leishmania infantum", "DISEASE", 329, 372], ["organomegaly", "DISEASE", 413, 425], ["pancytopenia", "DISEASE", 430, 442], ["HLH", "DISEASE", 483, 486], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 146], ["Leishmania donovani", "ORGANISM", 329, 348], ["Leishmania infantum", "ORGANISM", 353, 372], ["Leishmania donovani", "SPECIES", 329, 348], ["Leishmania infantum", "SPECIES", 353, 372], ["Leishmania donovani", "SPECIES", 329, 348], ["Leishmania infantum", "SPECIES", 353, 372], ["Just like viruses", "PROBLEM", 0, 17], ["additional bacterial infections", "PROBLEM", 36, 67], ["HLH", "PROBLEM", 93, 96], ["intracellular invasion", "PROBLEM", 133, 155], ["Parasitic and Fungal Infection", "PROBLEM", 200, 230], ["Hemophagocytic SyndromeLeishmania infection", "PROBLEM", 242, 285], ["HLH", "PROBLEM", 311, 314], ["Leishmania donovani and Leishmania infantum", "PROBLEM", 329, 372], ["organomegaly", "PROBLEM", 413, 425], ["pancytopenia", "PROBLEM", 430, 442], ["HLH", "PROBLEM", 483, 486], ["viruses", "OBSERVATION", 10, 17], ["large", "OBSERVATION_MODIFIER", 21, 26], ["array", "OBSERVATION_MODIFIER", 27, 32], ["bacterial", "OBSERVATION_MODIFIER", 47, 56], ["infections", "OBSERVATION", 57, 67], ["invasion", "OBSERVATION", 147, 155], ["Fungal", "OBSERVATION_MODIFIER", 214, 220], ["Infection", "OBSERVATION", 221, 230], ["Hemophagocytic SyndromeLeishmania", "OBSERVATION", 242, 275], ["infection", "OBSERVATION", 276, 285], ["associated with", "UNCERTAINTY", 295, 310], ["HLH", "OBSERVATION", 311, 314], ["organomegaly", "OBSERVATION", 413, 425], ["pancytopenia", "OBSERVATION", 430, 442], ["HLH", "OBSERVATION", 483, 486]]], ["This is of importance in non-endemic areas, where visceral leishmaniasis is unlikely considered as a differential diagnosis, and repeated bone marrow smears are often required to identify Leishmania species by means of PCR with species-specific probes [285] .", [["visceral leishmaniasis", "ANATOMY", 50, 72], ["bone marrow", "ANATOMY", 138, 149], ["visceral leishmaniasis", "DISEASE", 50, 72], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 138, 149], ["visceral leishmaniasis", "PROBLEM", 50, 72], ["repeated bone marrow smears", "TEST", 129, 156], ["Leishmania species", "PROBLEM", 188, 206], ["PCR", "TEST", 219, 222], ["non-endemic", "OBSERVATION_MODIFIER", 25, 36], ["visceral", "ANATOMY", 50, 58], ["leishmaniasis", "OBSERVATION", 59, 72], ["unlikely considered", "UNCERTAINTY", 76, 95]]], ["While specific treatment with amphotericin B is usually sufficient to control HLH, fatal outcomes have been seen with undiagnosed Leishmania cases treated as HLH [188] .", [["amphotericin B", "CHEMICAL", 30, 44], ["HLH", "DISEASE", 78, 81], ["HLH", "DISEASE", 158, 161], ["amphotericin B", "CHEMICAL", 30, 44], ["amphotericin B", "SIMPLE_CHEMICAL", 30, 44], ["amphotericin B", "TREATMENT", 30, 44], ["HLH", "PROBLEM", 78, 81], ["undiagnosed Leishmania cases", "PROBLEM", 118, 146], ["HLH", "PROBLEM", 158, 161]]], ["History of travel to endemic areas is also of utmost importance for suspecting HLH secondary to certain parasitic infections such as malaria, toxoplasma, babesia, and strongyloides.Parasitic and Fungal Infection-Associated Hemophagocytic SyndromeYeast infections (Candida sp., Cryptococcus sp., and Pneumocystis sp.) and molds (Histoplasma sp., Aspergillus sp., and Fusarium sp.) have been associated with HLH, most commonly during HIV infection, malignancy, prolonged corticosteroid administration, and transplantation [196, 286, 287] .", [["HLH", "DISEASE", 79, 82], ["parasitic infections", "DISEASE", 104, 124], ["malaria", "DISEASE", 133, 140], ["toxoplasma, babesia", "DISEASE", 142, 161], ["Fungal Infection", "DISEASE", 195, 211], ["Hemophagocytic SyndromeYeast infections", "DISEASE", 223, 262], ["Candida sp.", "DISEASE", 264, 275], ["Cryptococcus sp.", "DISEASE", 277, 293], ["Pneumocystis sp.)", "DISEASE", 299, 316], ["Histoplasma sp.", "DISEASE", 328, 343], ["Fusarium sp.", "DISEASE", 366, 378], ["HLH", "DISEASE", 406, 409], ["HIV infection", "DISEASE", 432, 445], ["malignancy", "DISEASE", 447, 457], ["Candida sp.", "ORGANISM", 264, 275], ["Cryptococcus sp.", "ORGANISM", 277, 293], ["Pneumocystis sp.", "ORGANISM", 299, 315], ["Histoplasma sp.", "ORGANISM", 328, 343], ["Aspergillus sp.", "ORGANISM", 345, 360], ["Fusarium sp.", "ORGANISM", 366, 378], ["Candida sp.", "SPECIES", 264, 275], ["Cryptococcus sp.", "SPECIES", 277, 293], ["Pneumocystis sp.", "SPECIES", 299, 315], ["Histoplasma sp.", "SPECIES", 328, 343], ["Aspergillus sp.", "SPECIES", 345, 360], ["Fusarium sp.", "SPECIES", 366, 378], ["HIV", "SPECIES", 432, 435], ["Candida sp.", "SPECIES", 264, 275], ["Cryptococcus sp.", "SPECIES", 277, 293], ["Pneumocystis sp.", "SPECIES", 299, 315], ["Histoplasma sp.", "SPECIES", 328, 343], ["Aspergillus sp.", "SPECIES", 345, 360], ["Fusarium sp.", "SPECIES", 366, 378], ["HIV", "SPECIES", 432, 435], ["HLH", "PROBLEM", 79, 82], ["certain parasitic infections", "PROBLEM", 96, 124], ["malaria", "PROBLEM", 133, 140], ["toxoplasma", "PROBLEM", 142, 152], ["babesia", "PROBLEM", 154, 161], ["strongyloides", "PROBLEM", 167, 180], ["Parasitic and Fungal Infection", "PROBLEM", 181, 211], ["Hemophagocytic SyndromeYeast infections", "PROBLEM", 223, 262], ["Candida sp.", "PROBLEM", 264, 275], ["Cryptococcus sp.", "PROBLEM", 277, 293], ["Pneumocystis sp.", "PROBLEM", 299, 315], ["molds (Histoplasma sp.", "PROBLEM", 321, 343], ["Aspergillus sp.", "PROBLEM", 345, 360], ["Fusarium", "PROBLEM", 366, 374], ["HLH", "PROBLEM", 406, 409], ["HIV infection", "PROBLEM", 432, 445], ["malignancy", "PROBLEM", 447, 457], ["prolonged corticosteroid administration", "TREATMENT", 459, 498], ["parasitic", "OBSERVATION_MODIFIER", 104, 113], ["infections", "OBSERVATION", 114, 124], ["strongyloides", "OBSERVATION", 167, 180], ["Fungal Infection", "OBSERVATION", 195, 211], ["Hemophagocytic SyndromeYeast infections", "OBSERVATION", 223, 262], ["Cryptococcus sp.", "OBSERVATION", 277, 293], ["Pneumocystis sp.", "OBSERVATION", 299, 315], ["Histoplasma sp.", "OBSERVATION", 328, 343], ["associated with", "UNCERTAINTY", 390, 405], ["HLH", "OBSERVATION", 406, 409], ["infection", "OBSERVATION", 436, 445], ["malignancy", "OBSERVATION", 447, 457]]], ["Disseminated Penicillium marneffei infection is common among HIV-infected patients in Southeast Asia.", [["Penicillium marneffei infection", "DISEASE", 13, 44], ["HIV-infected", "DISEASE", 61, 73], ["Penicillium marneffei", "ORGANISM", 13, 34], ["HIV", "ORGANISM", 61, 64], ["patients", "ORGANISM", 74, 82], ["Penicillium marneffei", "SPECIES", 13, 34], ["HIV", "SPECIES", 61, 64], ["patients", "SPECIES", 74, 82], ["Penicillium marneffei", "SPECIES", 13, 34], ["HIV", "SPECIES", 61, 64], ["Disseminated Penicillium marneffei infection", "PROBLEM", 0, 44], ["Penicillium", "OBSERVATION", 13, 24], ["marneffei infection", "OBSERVATION", 25, 44], ["infected", "OBSERVATION_MODIFIER", 65, 73]]], ["The first case of penicilliosis-HLH was reported in a Thai HIV-infected child in 2001, with complete recovery after antifungal and IVIg therapy [200] .Treatment Options for MAS/HLHIn addition to treating any underlying infection, treatment designed to dampen the cytokine storm associated with MAS/HLH is critical for improving survival (Table 14 .5).", [["penicilliosis", "DISEASE", 18, 31], ["HLH", "DISEASE", 32, 35], ["HIV-infected", "DISEASE", 59, 71], ["IVIg", "CHEMICAL", 131, 135], ["infection", "DISEASE", 219, 228], ["HLH", "DISEASE", 298, 301], ["child", "ORGANISM", 72, 77], ["IVIg", "SIMPLE_CHEMICAL", 131, 135], ["cytokine", "PROTEIN", 263, 271], ["HIV", "SPECIES", 59, 62], ["HIV", "SPECIES", 59, 62], ["penicilliosis", "PROBLEM", 18, 31], ["HLH", "PROBLEM", 32, 35], ["antifungal", "TREATMENT", 116, 126], ["IVIg therapy", "TREATMENT", 131, 143], ["MAS/HLHIn addition", "TREATMENT", 173, 191], ["any underlying infection", "PROBLEM", 204, 228], ["treatment", "TREATMENT", 230, 239], ["the cytokine storm", "PROBLEM", 259, 277], ["MAS/HLH", "PROBLEM", 294, 301], ["HLH", "OBSERVATION", 32, 35], ["infection", "OBSERVATION", 219, 228], ["HLH", "OBSERVATION", 298, 301]]], ["Some researchers reported the success of high-dose corticosteroids alone [25, 288] in treating sJIA-MAS.", [["MAS", "DISEASE", 100, 103], ["corticosteroids", "CHEMICAL", 51, 66], ["high-dose corticosteroids", "TREATMENT", 41, 66]]], ["While the fundamental role of corticosteroids in the therapy of this disease is not doubted [25, 69, 70] , current regimens usually add more aggressive treatment to corticosteroids including cyclophosphamide [289] , which has not gained wide use in this condition; cyclosporine A (CsA), which is currently the most commonly added medicine to corticosteroids [290, 291] ; and etoposide-based regimens, such as HLH-94 and HLH-2004 [11] , which have their not insignificant mortality rates during the pre-and postbone marrow transplant periods [292] .", [["postbone marrow", "ANATOMY", 506, 521], ["corticosteroids", "CHEMICAL", 30, 45], ["cyclophosphamide", "CHEMICAL", 191, 207], ["cyclosporine A", "CHEMICAL", 265, 279], ["CsA", "CHEMICAL", 281, 284], ["etoposide", "CHEMICAL", 375, 384], ["corticosteroids", "CHEMICAL", 30, 45], ["corticosteroids", "CHEMICAL", 165, 180], ["cyclophosphamide", "CHEMICAL", 191, 207], ["cyclosporine A", "CHEMICAL", 265, 279], ["CsA", "CHEMICAL", 281, 284], ["corticosteroids", "CHEMICAL", 342, 357], ["etoposide", "CHEMICAL", 375, 384], ["corticosteroids", "SIMPLE_CHEMICAL", 30, 45], ["corticosteroids", "SIMPLE_CHEMICAL", 165, 180], ["cyclophosphamide", "SIMPLE_CHEMICAL", 191, 207], ["cyclosporine A", "SIMPLE_CHEMICAL", 265, 279], ["CsA", "SIMPLE_CHEMICAL", 281, 284], ["etoposide", "SIMPLE_CHEMICAL", 375, 384], ["postbone marrow", "MULTI-TISSUE_STRUCTURE", 506, 521], ["corticosteroids", "TREATMENT", 30, 45], ["this disease", "PROBLEM", 64, 76], ["current regimens", "TREATMENT", 107, 123], ["aggressive treatment to corticosteroids", "TREATMENT", 141, 180], ["cyclophosphamide", "TREATMENT", 191, 207], ["cyclosporine A (CsA)", "TREATMENT", 265, 285], ["corticosteroids", "TREATMENT", 342, 357], ["etoposide", "TREATMENT", 375, 384], ["HLH", "TEST", 409, 412], ["HLH", "TEST", 420, 423], ["the pre-and postbone marrow transplant periods", "TREATMENT", 494, 540], ["corticosteroids", "OBSERVATION", 30, 45]]], ["Of the biologics, IVIg has been used, particularly for infection-associated sHLH, but IVIg must be given early in disease to be effective [293] .", [["sHLH", "ANATOMY", 76, 80], ["IVIg", "CHEMICAL", 18, 22], ["infection", "DISEASE", 55, 64], ["sHLH", "DISEASE", 76, 80], ["IVIg", "CHEMICAL", 86, 90], ["IVIg", "SIMPLE_CHEMICAL", 18, 22], ["sHLH", "CANCER", 76, 80], ["IVIg", "SIMPLE_CHEMICAL", 86, 90], ["the biologics", "TREATMENT", 3, 16], ["IVIg", "TREATMENT", 18, 22], ["infection", "PROBLEM", 55, 64], ["IVIg", "TREATMENT", 86, 90]]], ["Furthermore, IVIg has been shown to be ineffective in some reports [17] .", [["IVIg", "CHEMICAL", 13, 17], ["IVIg", "SIMPLE_CHEMICAL", 13, 17], ["IVIg", "PROTEIN", 13, 17], ["IVIg", "TREATMENT", 13, 17]]], ["Antithymocyte globulin has been used successfully in two patients with probable MAS [294] , but it carries a significant risk of serious infections and mortality.Treatment Options for MAS/HLHRecently, newer more targeted biologic therapies have provided a more targeted and effective option in treating sJIA-MAS.", [["Antithymocyte globulin", "CHEMICAL", 0, 22], ["MAS", "DISEASE", 80, 83], ["infections", "DISEASE", 137, 147], ["MAS", "DISEASE", 308, 311], ["Antithymocyte globulin", "GENE_OR_GENE_PRODUCT", 0, 22], ["patients", "ORGANISM", 57, 65], ["Antithymocyte globulin", "PROTEIN", 0, 22], ["patients", "SPECIES", 57, 65], ["Antithymocyte globulin", "TREATMENT", 0, 22], ["serious infections", "PROBLEM", 129, 147], ["MAS/HLHRecently", "PROBLEM", 184, 199], ["biologic therapies", "TREATMENT", 221, 239], ["significant risk of", "UNCERTAINTY", 109, 128], ["serious", "OBSERVATION_MODIFIER", 129, 136], ["infections", "OBSERVATION", 137, 147]]], ["While there was some initial excitement about TNF blockers with reports on their success in treating many cases of MAS including several children with sJIA [295] [296] [297] [298] [299] [300] [301] [302] [303] , reports of TNF inhibitors triggering MAS diminished enthusiasm for this therapy [304] [305] [306] [307] [308] [309] [310] .", [["MAS", "DISEASE", 115, 118], ["sJIA [295] [296] [297] [298] [299]", "CHEMICAL", 151, 185], ["TNF", "GENE_OR_GENE_PRODUCT", 46, 49], ["children", "ORGANISM", 137, 145], ["TNF", "GENE_OR_GENE_PRODUCT", 223, 226], ["TNF", "PROTEIN", 46, 49], ["TNF", "PROTEIN", 223, 226], ["children", "SPECIES", 137, 145], ["TNF blockers", "TREATMENT", 46, 58], ["TNF inhibitors", "TREATMENT", 223, 237], ["MAS diminished enthusiasm", "PROBLEM", 249, 274], ["this therapy", "TREATMENT", 279, 291]]], ["Knowing that cause and effect is certainly difficult to prove in these situations, the fact that MAS did develop in the setting of TNF inhibition is concerning [311, 312] .", [["TNF", "GENE_OR_GENE_PRODUCT", 131, 134], ["TNF", "PROTEIN", 131, 134], ["MAS", "PROBLEM", 97, 100], ["TNF inhibition", "PROBLEM", 131, 145]]], ["This has led to focusing on therapy directed at two other pro-inflammatory cytokines, IL-1 and IL-6.Treatment Options for MAS/HLHThe IL-1 receptor antagonist anakinra was shown to be highly effective for sJIA [313, 314] .", [["anakinra", "CHEMICAL", 158, 166], ["IL-1", "GENE_OR_GENE_PRODUCT", 86, 90], ["IL-6", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 133, 146], ["anakinra", "SIMPLE_CHEMICAL", 158, 166], ["pro-inflammatory cytokines", "PROTEIN", 58, 84], ["IL-1 and IL-6", "PROTEIN", 86, 99], ["therapy", "TREATMENT", 28, 35], ["IL", "TEST", 86, 88], ["Treatment Options", "TREATMENT", 100, 117], ["MAS/HLHThe IL-1 receptor antagonist anakinra", "TREATMENT", 122, 166], ["sJIA", "PROBLEM", 204, 208]]], ["MAS and sJIA flare share many clinical and laboratory features.", [["MAS and sJIA flare", "PROBLEM", 0, 18], ["sJIA flare", "OBSERVATION", 8, 18]]], ["Moreover in addition to the 10% risk of developing overt MAS as part of sJIA, another 30-40% of sJIA patients may have occult or subclinical MAS during flare that can eventually lead to overt MAS [68, 83] .", [["MAS", "DISEASE", 57, 60], ["sJIA", "DISEASE", 72, 76], ["sJIA", "DISEASE", 96, 100], ["MAS", "DISEASE", 141, 144], ["MAS", "DISEASE", 192, 195], ["sJIA", "CANCER", 72, 76], ["sJIA", "ORGANISM", 96, 100], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["developing overt MAS", "PROBLEM", 40, 60], ["sJIA", "PROBLEM", 72, 76], ["subclinical MAS during flare", "PROBLEM", 129, 157], ["overt MAS", "PROBLEM", 186, 195]]], ["This suggested that anakinra would also be a valuable treatment for sJIA-MAS.", [["anakinra", "CHEMICAL", 20, 28], ["MAS", "DISEASE", 73, 76], ["anakinra", "SIMPLE_CHEMICAL", 20, 28], ["anakinra", "TREATMENT", 20, 28], ["a valuable treatment", "TREATMENT", 43, 63], ["sJIA", "PROBLEM", 68, 72], ["MAS", "PROBLEM", 73, 76], ["anakinra", "OBSERVATION", 20, 28]]], ["There are several reports of dramatically successful use of anakinra in cases of sJIA-MAS after failing to respond to corticosteroids and CsA [313, [315] [316] [317] .Treatment Options for MAS/HLHAnakinra is regarded as a generally safe drug because it is a recombinant human protein with a short half-life (approximately 4 h) [318] and a wide therapeutic window (1-48 mg/kg/day) [35, 317] .", [["anakinra", "CHEMICAL", 60, 68], ["sJIA", "CHEMICAL", 81, 85], ["CsA", "CHEMICAL", 138, 141], ["HLHAnakinra", "CHEMICAL", 193, 204], ["anakinra", "CHEMICAL", 60, 68], ["corticosteroids", "CHEMICAL", 118, 133], ["CsA", "CHEMICAL", 138, 141], ["anakinra", "SIMPLE_CHEMICAL", 60, 68], ["corticosteroids", "SIMPLE_CHEMICAL", 118, 133], ["CsA", "SIMPLE_CHEMICAL", 138, 141], ["human", "ORGANISM", 270, 275], ["recombinant human protein", "PROTEIN", 258, 283], ["human", "SPECIES", 270, 275], ["human", "SPECIES", 270, 275], ["anakinra", "TREATMENT", 60, 68], ["sJIA", "PROBLEM", 81, 85], ["MAS", "PROBLEM", 86, 89], ["corticosteroids", "TREATMENT", 118, 133], ["CsA", "TEST", 138, 141], ["MAS/HLHAnakinra", "PROBLEM", 189, 204], ["a wide therapeutic window", "TREATMENT", 337, 362], ["dramatically", "OBSERVATION_MODIFIER", 29, 41]]], ["However, cases of hepatitis attributed to anakinra in children with sJIA have been reported [319] .", [["hepatitis", "DISEASE", 18, 27], ["anakinra", "CHEMICAL", 42, 50], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["hepatitis", "PROBLEM", 18, 27], ["anakinra", "TREATMENT", 42, 50], ["sJIA", "PROBLEM", 68, 72], ["hepatitis", "OBSERVATION", 18, 27]]], ["Moreover, though cause and effect are difficult to establish, there has been a suggestion that anakinra triggered MAS in two children with sJIA [320, 321] .", [["anakinra", "CHEMICAL", 95, 103], ["MAS", "DISEASE", 114, 117], ["sJIA", "DISEASE", 139, 143], ["anakinra", "CHEMICAL", 95, 103], ["anakinra", "SIMPLE_CHEMICAL", 95, 103], ["children", "ORGANISM", 125, 133], ["children", "SPECIES", 125, 133], ["anakinra triggered MAS", "PROBLEM", 95, 117], ["anakinra", "OBSERVATION", 95, 103]]], ["In a large case series of 46 sJIA patients treated with anakinra at disease onset, anakinra was a potential MAS trigger in five children at doses of 1-2 mg/kg/day [313] .", [["sJIA", "DISEASE", 29, 33], ["anakinra", "CHEMICAL", 56, 64], ["anakinra", "CHEMICAL", 83, 91], ["anakinra", "CHEMICAL", 83, 91], ["patients", "ORGANISM", 34, 42], ["anakinra", "SIMPLE_CHEMICAL", 56, 64], ["anakinra", "SIMPLE_CHEMICAL", 83, 91], ["children", "ORGANISM", 128, 136], ["patients", "SPECIES", 34, 42], ["children", "SPECIES", 128, 136], ["anakinra at disease onset", "PROBLEM", 56, 81], ["anakinra", "TREATMENT", 83, 91], ["large", "OBSERVATION_MODIFIER", 5, 10]]], ["However, dose escalation of anakinra often seemed to help control MAS, and none of the children had to permanently stop the anakinra [313] .", [["anakinra", "CHEMICAL", 28, 36], ["MAS", "DISEASE", 66, 69], ["anakinra", "CHEMICAL", 124, 132], ["anakinra", "SIMPLE_CHEMICAL", 28, 36], ["children", "ORGANISM", 87, 95], ["children", "SPECIES", 87, 95], ["anakinra", "TREATMENT", 28, 36]]], ["More research is needed to define the role of anakinra in sJIA-MAS and other forms of sHLH.Treatment Options for MAS/HLHIL-6 blockade, via an anti-IL-6 receptor monoclonal antibody (tocilizumab), has also proven successful in treating sJIA [322] .", [["anakinra", "CHEMICAL", 46, 54], ["MAS", "DISEASE", 63, 66], ["sHLH", "DISEASE", 86, 90], ["tocilizumab", "CHEMICAL", 182, 193], ["anakinra", "SIMPLE_CHEMICAL", 46, 54], ["sHLH", "CANCER", 86, 90], ["HLHIL-6", "SIMPLE_CHEMICAL", 117, 124], ["anti-IL-6 receptor", "GENE_OR_GENE_PRODUCT", 142, 160], ["tocilizumab", "SIMPLE_CHEMICAL", 182, 193], ["anti-IL-6 receptor monoclonal antibody", "PROTEIN", 142, 180], ["anakinra", "TREATMENT", 46, 54], ["MAS", "PROBLEM", 63, 66], ["sHLH", "PROBLEM", 86, 90], ["MAS/HLHIL-6 blockade", "TREATMENT", 113, 133], ["an anti-IL-6 receptor monoclonal antibody (tocilizumab", "TREATMENT", 139, 193]]], ["However, a case report of MAS attributed to IL-6 blockade [323] underscores the need for further studies to define its role in the treatment of sJIA-MAS.", [["MAS", "DISEASE", 26, 29], ["MAS", "DISEASE", 149, 152], ["IL-6", "GENE_OR_GENE_PRODUCT", 44, 48], ["IL", "PROTEIN", 44, 46], ["MAS", "PROBLEM", 26, 29], ["IL-6 blockade", "TREATMENT", 44, 57], ["further studies", "TEST", 89, 104], ["sJIA", "PROBLEM", 144, 148], ["MAS", "PROBLEM", 149, 152], ["sJIA", "OBSERVATION", 144, 148]]], ["IL-6 blockade, however, has been successfully used in treating cytokine storm syndrome associated with chimeric antigen receptor (CAR) T-cell-directed therapy against resistant leukemia [324] .", [["T-cell", "ANATOMY", 135, 141], ["leukemia", "ANATOMY", 177, 185], ["leukemia", "DISEASE", 177, 185], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 103, 128], ["CAR", "GENE_OR_GENE_PRODUCT", 130, 133], ["leukemia", "CANCER", 177, 185], ["IL-6", "PROTEIN", 0, 4], ["cytokine", "PROTEIN", 63, 71], ["chimeric antigen receptor", "PROTEIN", 103, 128], ["CAR", "PROTEIN", 130, 133], ["IL-6 blockade", "TREATMENT", 0, 13], ["cytokine storm syndrome", "PROBLEM", 63, 86], ["chimeric antigen receptor", "TREATMENT", 103, 128], ["T-cell-directed therapy", "TREATMENT", 135, 158], ["resistant leukemia", "PROBLEM", 167, 185], ["cytokine storm", "OBSERVATION", 63, 77], ["leukemia", "OBSERVATION", 177, 185]]], ["Other biologic therapies are being explored.", [["Other biologic therapies", "TREATMENT", 0, 24]]], ["Co-stimulatory blockade with cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA-4-Ig) has been anecdotally beneficial in children with severe sJIA [317] , but its role in treating MAS is unknown.", [["CTLA-4-Ig", "CHEMICAL", 89, 98], ["MAS", "DISEASE", 194, 197], ["cytotoxic T-lymphocyte-associated protein 4", "GENE_OR_GENE_PRODUCT", 29, 72], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 73, 87], ["CTLA-4-Ig", "GENE_OR_GENE_PRODUCT", 89, 98], ["children", "ORGANISM", 135, 143], ["cytotoxic T-lymphocyte-associated protein 4", "PROTEIN", 29, 72], ["immunoglobulin", "PROTEIN", 73, 87], ["CTLA", "PROTEIN", 89, 93], ["Ig", "PROTEIN", 96, 98], ["children", "SPECIES", 135, 143], ["Co-stimulatory blockade", "TREATMENT", 0, 23], ["cytotoxic T", "TEST", 29, 40], ["lymphocyte", "TEST", 41, 51], ["protein", "TEST", 63, 70], ["immunoglobulin", "TEST", 73, 87], ["CTLA", "TEST", 89, 93], ["severe sJIA", "PROBLEM", 149, 160], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["sJIA", "OBSERVATION", 156, 160]]], ["Nevertheless, there is building evidence that biologic therapies, particularly IL-1 inhibitors, are a welcome addition to corticosteroids and CsA in treating MAS associated with sJIA [17] .", [["CsA", "CHEMICAL", 142, 145], ["MAS", "DISEASE", 158, 161], ["corticosteroids", "CHEMICAL", 122, 137], ["CsA", "CHEMICAL", 142, 145], ["IL-1", "GENE_OR_GENE_PRODUCT", 79, 83], ["corticosteroids", "SIMPLE_CHEMICAL", 122, 137], ["CsA", "SIMPLE_CHEMICAL", 142, 145], ["biologic therapies", "TREATMENT", 46, 64], ["IL-1 inhibitors", "TREATMENT", 79, 94], ["corticosteroids", "TREATMENT", 122, 137], ["CsA", "TREATMENT", 142, 145], ["MAS", "PROBLEM", 158, 161], ["sJIA", "PROBLEM", 178, 182]]], ["Finally, rituximab has recently been reported to lead to remission in a sizable percentage of children with refractory sJIA [325] , in addition to its effectiveness in treating EBV-HLH [230, 326] .HSCTThe first report of successful HSCT in HLH was reported in 1986 [327] .", [["rituximab", "CHEMICAL", 9, 18], ["sJIA", "DISEASE", 119, 123], ["EBV-HLH", "DISEASE", 177, 184], ["HLH", "DISEASE", 240, 243], ["rituximab", "SIMPLE_CHEMICAL", 9, 18], ["children", "ORGANISM", 94, 102], ["EBV", "ORGANISM", 177, 180], ["children", "SPECIES", 94, 102], ["rituximab", "TREATMENT", 9, 18], ["refractory sJIA", "PROBLEM", 108, 123], ["HLH", "PROBLEM", 240, 243], ["HLH", "OBSERVATION", 240, 243]]], ["HSCT tends to be more frequently used in familial cases of HLH, but it is used in secondary cases as well.", [["HLH", "DISEASE", 59, 62], ["HLH", "PROBLEM", 59, 62], ["HLH", "OBSERVATION", 59, 62]]], ["While several studies have shown that HSCT is the best option for permanent disease control or cure [328] [329] [330] [331] [332] , the overall transplant morbidity and mortality is still high (~45%) and it is not uncommon for patients to develop recurrence of HLH before a suitable donor is identified.", [["HLH", "DISEASE", 261, 264], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["several studies", "TEST", 6, 21], ["HSCT", "TEST", 38, 42], ["permanent disease control", "TREATMENT", 66, 91], ["the overall transplant morbidity", "PROBLEM", 132, 164], ["mortality", "TEST", 169, 178], ["recurrence of HLH", "PROBLEM", 247, 264], ["a suitable donor", "TREATMENT", 272, 288], ["transplant", "OBSERVATION_MODIFIER", 144, 154], ["morbidity", "OBSERVATION", 155, 164], ["high", "OBSERVATION_MODIFIER", 188, 192], ["HLH", "OBSERVATION", 261, 264]]], ["Moreover, autologous and allogeneic HSCT have been reported to induce HLH in transplanted patients, probably due to the increased risk of infection imposed by the immunosuppressive conditioning regimen with an estimated risk of 4% in a recent cohort [333] .", [["HLH", "DISEASE", 70, 73], ["infection", "DISEASE", 138, 147], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["autologous and allogeneic HSCT", "TREATMENT", 10, 40], ["HLH", "PROBLEM", 70, 73], ["infection", "PROBLEM", 138, 147], ["the immunosuppressive conditioning regimen", "TREATMENT", 159, 201], ["HLH", "OBSERVATION", 70, 73], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["infection", "OBSERVATION", 138, 147]]], ["This risk appeared to be reduced in etoposide-containing conditioning regimens [333] .", [["etoposide", "CHEMICAL", 36, 45], ["etoposide", "CHEMICAL", 36, 45], ["etoposide", "SIMPLE_CHEMICAL", 36, 45], ["etoposide", "TREATMENT", 36, 45], ["conditioning regimens", "TREATMENT", 57, 78], ["appeared to be", "UNCERTAINTY", 10, 24], ["reduced", "OBSERVATION_MODIFIER", 25, 32]]], ["The current era of biologic therapies has reduced the need for HSCT.HSCTIn the future, autologous HSCT combined with gene therapy to correct the genetic defects might be applicable.", [["biologic therapies", "TREATMENT", 19, 37], ["HSCT", "TREATMENT", 63, 67], ["autologous HSCT", "TREATMENT", 87, 102], ["gene therapy", "TREATMENT", 117, 129], ["the genetic defects", "PROBLEM", 141, 160]]], ["Carmo et al. have shown that transfer of a functional perforin gene (Prf1) into autologous hematopoietic stem cells from perforin-deficient mice restored perforin expression, partially repaired the cytotoxic defect, and attenuated HLH symptoms after viral challenge, provided that at least 30% engraftment was attained [334] .", [["hematopoietic stem cells", "ANATOMY", 91, 115], ["HLH", "DISEASE", 231, 234], ["perforin", "GENE_OR_GENE_PRODUCT", 54, 62], ["Prf1", "GENE_OR_GENE_PRODUCT", 69, 73], ["hematopoietic stem cells", "CELL", 91, 115], ["perforin", "GENE_OR_GENE_PRODUCT", 121, 129], ["mice", "ORGANISM", 140, 144], ["perforin", "GENE_OR_GENE_PRODUCT", 154, 162], ["perforin gene", "DNA", 54, 67], ["Prf1", "DNA", 69, 73], ["autologous hematopoietic stem cells", "CELL_TYPE", 80, 115], ["perforin", "PROTEIN", 121, 129], ["perforin", "PROTEIN", 154, 162], ["mice", "SPECIES", 140, 144], ["a functional perforin gene (Prf1)", "TREATMENT", 41, 74], ["autologous hematopoietic stem cells", "TREATMENT", 80, 115], ["perforin-deficient mice", "TREATMENT", 121, 144], ["the cytotoxic defect", "PROBLEM", 194, 214], ["attenuated HLH symptoms", "PROBLEM", 220, 243], ["viral challenge", "TREATMENT", 250, 265], ["hematopoietic stem cells", "OBSERVATION", 91, 115], ["cytotoxic defect", "OBSERVATION", 198, 214]]], ["Similarly, Rivat et al. showed that in a mouse model of XLP, gene transfer also restored SAP expression and normalized cytotoxic function [335] .IFN-\u03b3 BlockadeIFN-\u03b3 has been shown to play a pivotal role in several HLH models.", [["BlockadeIFN-\u03b3", "CHEMICAL", 151, 164], ["HLH", "DISEASE", 214, 217], ["mouse", "ORGANISM", 41, 46], ["XLP", "GENE_OR_GENE_PRODUCT", 56, 59], ["SAP", "GENE_OR_GENE_PRODUCT", 89, 92], ["BlockadeIFN-\u03b3", "GENE_OR_GENE_PRODUCT", 151, 164], ["SAP", "PROTEIN", 89, 92], ["IFN", "PROTEIN", 145, 148], ["BlockadeIFN", "PROTEIN", 151, 162], ["\u03b3", "PROTEIN", 163, 164], ["mouse", "SPECIES", 41, 46], ["mouse", "SPECIES", 41, 46]]], ["Its neutralization has substantially improved survival in HLH animal models [336, 337] and an MAS model using IL-6 transgenic mice [338] .", [["HLH", "DISEASE", 58, 61], ["IL-6", "GENE_OR_GENE_PRODUCT", 110, 114], ["mice", "ORGANISM", 126, 130], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["HLH animal models", "TEST", 58, 75], ["an MAS model", "TEST", 91, 103], ["IL", "TEST", 110, 112], ["neutralization", "OBSERVATION_MODIFIER", 4, 18], ["substantially", "OBSERVATION_MODIFIER", 23, 36], ["improved", "OBSERVATION_MODIFIER", 37, 45], ["survival", "OBSERVATION_MODIFIER", 46, 54]]], ["Levels of both IFN-\u03b3 and IFN-\u03b3 -induced chemokines such as CXCL10 and CXCL9 are elevated in children with HLH [339] .", [["HLH", "DISEASE", 106, 109], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 15, 20], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 25, 30], ["CXCL10", "GENE_OR_GENE_PRODUCT", 59, 65], ["CXCL9", "GENE_OR_GENE_PRODUCT", 70, 75], ["children", "ORGANISM", 92, 100], ["IFN", "PROTEIN", 15, 18], ["IFN-\u03b3", "PROTEIN", 25, 30], ["chemokines", "PROTEIN", 40, 50], ["CXCL10", "PROTEIN", 59, 65], ["CXCL9", "PROTEIN", 70, 75], ["children", "SPECIES", 92, 100], ["Levels", "TEST", 0, 6], ["IFN", "TEST", 15, 18], ["\u03b3", "TEST", 19, 20], ["IFN", "TEST", 25, 28], ["induced chemokines", "PROBLEM", 32, 50], ["CXCL10", "TEST", 59, 65], ["CXCL9", "TEST", 70, 75], ["HLH", "PROBLEM", 106, 109]]], ["Moreover, sJIA-MAS is commonly triggered by viral infections which are known to activate IFN\u03b3-associated pathways.", [["sJIA", "CHEMICAL", 10, 14], ["viral infections", "DISEASE", 44, 60], ["sJIA", "GENE_OR_GENE_PRODUCT", 10, 14], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 89, 93], ["sJIA", "PROTEIN", 10, 14], ["IFN\u03b3", "PROTEIN", 89, 93], ["sJIA", "PROBLEM", 10, 14], ["MAS", "PROBLEM", 15, 18], ["viral infections", "PROBLEM", 44, 60], ["sJIA", "OBSERVATION", 10, 14], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["infections", "OBSERVATION", 50, 60]]], ["Furthermore, numerous IFN-\u03b3-producing T cells were found in close proximity to activated hemophagocytic histiocytes in a study of inflammatory infiltrates in tissues affected by MAS [340] , and children with MAS show increased levels of neopterin, which is known to be released by interferon-stimulated macrophages [26] .", [["T cells", "ANATOMY", 38, 45], ["hemophagocytic histiocytes", "ANATOMY", 89, 115], ["tissues", "ANATOMY", 158, 165], ["macrophages", "ANATOMY", 303, 314], ["hemophagocytic histiocytes", "DISEASE", 89, 115], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 22, 28], ["T cells", "CELL", 38, 45], ["hemophagocytic histiocytes", "CELL", 89, 115], ["tissues", "TISSUE", 158, 165], ["children", "ORGANISM", 194, 202], ["neopterin", "GENE_OR_GENE_PRODUCT", 237, 246], ["interferon", "GENE_OR_GENE_PRODUCT", 281, 291], ["macrophages", "CELL", 303, 314], ["IFN", "PROTEIN", 22, 25], ["T cells", "CELL_TYPE", 38, 45], ["neopterin", "PROTEIN", 237, 246], ["interferon", "PROTEIN", 281, 291], ["stimulated macrophages", "CELL_TYPE", 292, 314], ["children", "SPECIES", 194, 202], ["T cells", "PROBLEM", 38, 45], ["activated hemophagocytic histiocytes", "PROBLEM", 79, 115], ["a study", "TEST", 119, 126], ["inflammatory infiltrates in tissues", "PROBLEM", 130, 165], ["MAS", "PROBLEM", 208, 211], ["increased levels of neopterin", "PROBLEM", 217, 246], ["hemophagocytic histiocytes", "OBSERVATION", 89, 115], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142], ["infiltrates", "OBSERVATION", 143, 154]]], ["A longitudinal study of the cytokine changes in patients with sJIA showed that levels of IFN-\u03b3 and IFN-\u03b3-induced chemokines (particularly, CXCL9) markedly increased with the beginning of clinical MAS and returned to normal with its resolution.", [["patients", "ORGANISM", 48, 56], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 89, 94], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 99, 105], ["CXCL9", "GENE_OR_GENE_PRODUCT", 139, 144], ["cytokine", "PROTEIN", 28, 36], ["IFN", "PROTEIN", 89, 92], ["IFN", "PROTEIN", 99, 102], ["chemokines", "PROTEIN", 113, 123], ["CXCL9", "PROTEIN", 139, 144], ["patients", "SPECIES", 48, 56], ["A longitudinal study", "TEST", 0, 20], ["the cytokine changes", "TEST", 24, 44], ["sJIA", "PROBLEM", 62, 66], ["IFN", "TEST", 89, 92], ["\u03b3", "TEST", 93, 94], ["IFN", "TEST", 99, 102], ["induced chemokines", "PROBLEM", 105, 123], ["CXCL9", "TEST", 139, 144], ["clinical MAS", "TEST", 187, 199], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["normal", "OBSERVATION", 216, 222]]], ["These findings highlighted IFN-\u03b3 as an appealing targeted and potentially less toxic therapeutic option in HLH, and a clinical trial evaluating NI-0501, which is an anti-IFN-\u03b3 monoclonal antibody that binds to and neutralizes human IFN-\u03b3, is underway [341] .", [["HLH", "DISEASE", 107, 110], ["NI-0501", "CHEMICAL", 144, 151], ["NI-0501", "CHEMICAL", 144, 151], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 27, 32], ["NI-0501", "SIMPLE_CHEMICAL", 144, 151], ["anti-IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 165, 175], ["human", "ORGANISM", 226, 231], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 232, 237], ["IFN", "PROTEIN", 27, 30], ["anti-IFN-\u03b3 monoclonal antibody", "PROTEIN", 165, 195], ["human IFN-\u03b3", "PROTEIN", 226, 237], ["human", "SPECIES", 226, 231], ["NI-0501", "SPECIES", 144, 151], ["human", "SPECIES", 226, 231], ["IFN", "TEST", 27, 30], ["HLH", "PROBLEM", 107, 110], ["NI", "TEST", 144, 146], ["an anti-IFN", "TEST", 162, 173], ["monoclonal antibody", "PROBLEM", 176, 195], ["neutralizes human IFN", "TEST", 214, 235]]], ["Recently, a report on this trial showed promising results [18] .IFN-\u03b3 BlockadeHowever, some recent studies question the potential of IFN-\u03b3 blocking therapy in MAS.", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 64, 69], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 133, 138], ["IFN", "PROTEIN", 64, 67], ["IFN", "PROTEIN", 133, 136], ["this trial", "TEST", 22, 32], ["some recent studies", "TEST", 87, 106], ["IFN-\u03b3 blocking therapy", "TREATMENT", 133, 155]]], ["First, Tesi et al. reported two cases of HLH in children with novel IFN-\u03b3 receptor mutations associated with IFN-\u03b3 deficiency, findings which highlight the significance of IFN-\u03b3-independent mechanisms in the immune pathology of HLH and warrant that other novel therapies, beside anti-IFN-\u03b3 therapy, be investigated [342] .", [["HLH", "DISEASE", 41, 44], ["HLH", "DISEASE", 228, 231], ["anti-IFN-\u03b3", "CHEMICAL", 279, 289], ["children", "ORGANISM", 48, 56], ["IFN-\u03b3 receptor", "GENE_OR_GENE_PRODUCT", 68, 82], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 109, 114], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 172, 178], ["anti-IFN-\u03b3", "SIMPLE_CHEMICAL", 279, 289], ["IFN", "PROTEIN", 68, 71], ["\u03b3 receptor", "PROTEIN", 72, 82], ["IFN", "PROTEIN", 109, 112], ["IFN", "PROTEIN", 172, 175], ["anti-IFN", "PROTEIN", 279, 287], ["children", "SPECIES", 48, 56], ["HLH", "PROBLEM", 41, 44], ["novel IFN", "PROBLEM", 62, 71], ["receptor mutations", "PROBLEM", 74, 92], ["IFN-\u03b3 deficiency", "PROBLEM", 109, 125], ["IFN", "PROBLEM", 172, 175], ["HLH", "PROBLEM", 228, 231], ["other novel therapies", "TREATMENT", 249, 270], ["anti-IFN", "TREATMENT", 279, 287], ["therapy", "TREATMENT", 290, 297], ["HLH", "OBSERVATION", 41, 44], ["HLH", "OBSERVATION", 228, 231]]], ["Additionally, sJIA patients were found to have normal levels of IFN-\u03b3 independent of disease activity [343] , which suggests that this cytokine does not always play an essential role in disease pathogenesis.Janus Kinase InhibitionBecause targeting individual cytokines might be insufficient during severe hypercytokinemia, cytokine signaling pathways can be targeted to avoid an imbalance in the cytokine network.", [["hypercytokinemia", "DISEASE", 305, 321], ["patients", "ORGANISM", 19, 27], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 64, 69], ["Janus Kinase", "GENE_OR_GENE_PRODUCT", 207, 219], ["IFN", "PROTEIN", 64, 67], ["cytokine", "PROTEIN", 135, 143], ["Janus Kinase", "PROTEIN", 207, 219], ["cytokines", "PROTEIN", 259, 268], ["cytokine", "PROTEIN", 323, 331], ["cytokine network", "PROTEIN", 396, 412], ["patients", "SPECIES", 19, 27], ["IFN", "TEST", 64, 67], ["disease activity", "PROBLEM", 85, 101], ["disease pathogenesis", "PROBLEM", 186, 206], ["Janus Kinase", "TREATMENT", 207, 219], ["individual cytokines", "PROBLEM", 248, 268], ["severe hypercytokinemia", "PROBLEM", 298, 321], ["cytokine signaling pathways", "PROBLEM", 323, 350], ["an imbalance in the cytokine network", "PROBLEM", 376, 412], ["normal", "OBSERVATION", 47, 53], ["severe", "OBSERVATION_MODIFIER", 298, 304], ["hypercytokinemia", "OBSERVATION", 305, 321]]], ["Janus kinases control the signaling of many cytokines, notably IFN-\u03b3, IL-2, and IL-6.", [["Janus kinases", "GENE_OR_GENE_PRODUCT", 0, 13], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 63, 68], ["IL-2", "GENE_OR_GENE_PRODUCT", 70, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 80, 84], ["Janus kinases", "PROTEIN", 0, 13], ["cytokines", "PROTEIN", 44, 53], ["IFN", "PROTEIN", 63, 66], ["IL", "PROTEIN", 70, 72], ["IL-6", "PROTEIN", 80, 84], ["Janus kinases", "TREATMENT", 0, 13], ["many cytokines", "TEST", 39, 53], ["IFN", "TEST", 63, 66], ["IL", "TEST", 70, 72]]], ["Thus, inhibition of Janus kinases via ruxolitinib for example may serve this purpose.", [["ruxolitinib", "CHEMICAL", 38, 49], ["ruxolitinib", "CHEMICAL", 38, 49], ["Janus kinases", "GENE_OR_GENE_PRODUCT", 20, 33], ["ruxolitinib", "SIMPLE_CHEMICAL", 38, 49], ["Janus kinases", "PROTEIN", 20, 33], ["inhibition of Janus kinases", "TREATMENT", 6, 33], ["ruxolitinib", "TREATMENT", 38, 49]]], ["Das et al. reported that in rodent models of primary and secondary HLH, treatment with the JAK1/2 inhibitor ruxolitinib significantly lessened the clinical and laboratory manifestations, including weight loss, organomegaly, anemia, thrombocytopenia, hypercytokinemia, and tissue inflammation.", [["tissue", "ANATOMY", 272, 278], ["HLH", "DISEASE", 67, 70], ["ruxolitinib", "CHEMICAL", 108, 119], ["weight loss", "DISEASE", 197, 208], ["organomegaly", "DISEASE", 210, 222], ["anemia", "DISEASE", 224, 230], ["thrombocytopenia", "DISEASE", 232, 248], ["hypercytokinemia", "DISEASE", 250, 266], ["inflammation", "DISEASE", 279, 291], ["ruxolitinib", "CHEMICAL", 108, 119], ["JAK1/2", "GENE_OR_GENE_PRODUCT", 91, 97], ["ruxolitinib", "SIMPLE_CHEMICAL", 108, 119], ["tissue", "TISSUE", 272, 278], ["JAK1", "PROTEIN", 91, 95], ["secondary HLH", "PROBLEM", 57, 70], ["treatment", "TREATMENT", 72, 81], ["the JAK1/2 inhibitor ruxolitinib", "TREATMENT", 87, 119], ["weight loss", "PROBLEM", 197, 208], ["organomegaly", "PROBLEM", 210, 222], ["anemia", "PROBLEM", 224, 230], ["thrombocytopenia", "PROBLEM", 232, 248], ["hypercytokinemia", "PROBLEM", 250, 266], ["tissue inflammation", "PROBLEM", 272, 291], ["secondary HLH", "OBSERVATION", 57, 70], ["organomegaly", "OBSERVATION", 210, 222], ["anemia", "OBSERVATION", 224, 230], ["thrombocytopenia", "OBSERVATION", 232, 248], ["tissue", "ANATOMY", 272, 278], ["inflammation", "OBSERVATION", 279, 291]]], ["Importantly, ruxolitinib treatment also significantly improved survival in this model [344] .", [["ruxolitinib", "CHEMICAL", 13, 24], ["ruxolitinib", "CHEMICAL", 13, 24], ["ruxolitinib", "SIMPLE_CHEMICAL", 13, 24], ["ruxolitinib treatment", "TREATMENT", 13, 34]]], ["Similarly, Maschalidi et al. reported that JAK1/2 inhibition in Prf1 \u2212/\u2212 and Rab27a \u2212/\u2212 mice with full-blown HLH syndrome has led to recovery in both models [345] .Other TargetsPeroxisome proliferator-activated receptor-\u03b3 agonists have also been presented as potential agents.", [["Prf1 \u2212/\u2212", "ANATOMY", 64, 72], ["HLH syndrome", "DISEASE", 109, 121], ["JAK1", "GENE_OR_GENE_PRODUCT", 43, 47], ["2", "GENE_OR_GENE_PRODUCT", 48, 49], ["Prf1", "GENE_OR_GENE_PRODUCT", 64, 68], ["\u2212", "GENE_OR_GENE_PRODUCT", 71, 72], ["Rab27a", "GENE_OR_GENE_PRODUCT", 77, 83], ["Peroxisome proliferator-activated receptor-\u03b3", "GENE_OR_GENE_PRODUCT", 177, 221], ["JAK1", "PROTEIN", 43, 47], ["Prf1", "PROTEIN", 64, 68], ["Rab27a", "PROTEIN", 77, 83], ["Peroxisome proliferator-activated receptor", "PROTEIN", 177, 219], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["JAK1", "TEST", 43, 47], ["Rab27a", "TEST", 77, 83], ["blown HLH syndrome", "PROBLEM", 103, 121], ["Peroxisome proliferator", "TEST", 177, 200], ["activated receptor-\u03b3 agonists", "TREATMENT", 201, 230], ["blown HLH syndrome", "OBSERVATION", 103, 121], ["Peroxisome proliferator", "OBSERVATION", 177, 200]]], ["They interfere with the activation of the NF\u03baB pathway and exert both a broad antiinflammatory effect and antiviral capacities [346, 347] .", [["NF\u03baB", "GENE_OR_GENE_PRODUCT", 42, 46], ["NF\u03baB", "PROTEIN", 42, 46], ["the NF\u03baB pathway", "TREATMENT", 38, 54], ["a broad antiinflammatory effect", "TREATMENT", 70, 101], ["antiviral capacities", "PROBLEM", 106, 126]]], ["Based on research in HLH animal models, other targets for future therapy have been proposed.", [["HLH", "DISEASE", 21, 24], ["future therapy", "TREATMENT", 58, 72]]], ["These include the induction of T-cell exhaustion through the stimulation of inhibitory receptors like programmed cell death 1 (PDCD1/ PD-1), restoring cytokine balances by the antiinflammatory IL-10 or IL-18BP, halting chronic TLR activation by TLR antagonists or blocking TLR signaling pathways, and targeting dendritic cells as the main drivers of ongoing antigen stimulation or suppressing antigen presentation itself [348, 349] .Other TargetsOver the past few years, more has been revealed about the role of IL-18 in the pathogenesis of sJIA and MAS.", [["T-cell", "ANATOMY", 31, 37], ["cell", "ANATOMY", 113, 117], ["dendritic cells", "ANATOMY", 311, 326], ["MAS", "DISEASE", 550, 553], ["T-cell", "CELL", 31, 37], ["programmed cell death 1", "GENE_OR_GENE_PRODUCT", 102, 125], ["PDCD1", "GENE_OR_GENE_PRODUCT", 127, 132], ["PD-1", "GENE_OR_GENE_PRODUCT", 134, 138], ["IL-10", "GENE_OR_GENE_PRODUCT", 193, 198], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 202, 209], ["TLR", "GENE_OR_GENE_PRODUCT", 227, 230], ["TLR antagonists", "GENE_OR_GENE_PRODUCT", 245, 260], ["TLR", "GENE_OR_GENE_PRODUCT", 273, 276], ["dendritic cells", "CELL", 311, 326], ["IL-18", "GENE_OR_GENE_PRODUCT", 512, 517], ["sJIA", "CANCER", 541, 545], ["inhibitory receptors", "PROTEIN", 76, 96], ["programmed cell death 1", "PROTEIN", 102, 125], ["PDCD1", "PROTEIN", 127, 132], ["cytokine", "PROTEIN", 151, 159], ["antiinflammatory IL-10", "PROTEIN", 176, 198], ["IL-18BP", "PROTEIN", 202, 209], ["TLR", "PROTEIN", 227, 230], ["TLR", "PROTEIN", 245, 248], ["TLR", "PROTEIN", 273, 276], ["dendritic cells", "CELL_TYPE", 311, 326], ["IL-18", "PROTEIN", 512, 517], ["T-cell exhaustion", "TREATMENT", 31, 48], ["the stimulation of inhibitory receptors", "TREATMENT", 57, 96], ["programmed cell death", "PROBLEM", 102, 123], ["PDCD1/ PD", "TREATMENT", 127, 136], ["restoring cytokine balances", "PROBLEM", 141, 168], ["the antiinflammatory IL", "TREATMENT", 172, 195], ["IL", "TREATMENT", 202, 204], ["halting chronic TLR activation", "TREATMENT", 211, 241], ["TLR antagonists", "TREATMENT", 245, 260], ["blocking TLR signaling pathways", "TREATMENT", 264, 295], ["ongoing antigen stimulation", "TREATMENT", 350, 377], ["sJIA", "PROBLEM", 541, 545], ["dendritic cells", "OBSERVATION", 311, 326], ["sJIA", "OBSERVATION", 541, 545]]], ["It has been shown that patients with sJIA have significantly higher levels of IL-18 [85] [86] [87] as opposed to other rheumatic diseases such as SLE or rheumatoid arthritis [350, 351] . sJIA patients with high levels of IL-18 are more likely to develop systemic features of the disease and are more prone to develop MAS [85] .", [["rheumatic diseases", "DISEASE", 119, 137], ["SLE", "DISEASE", 146, 149], ["rheumatoid arthritis", "DISEASE", 153, 173], ["MAS", "DISEASE", 317, 320], ["patients", "ORGANISM", 23, 31], ["sJIA", "CANCER", 37, 41], ["IL-18", "GENE_OR_GENE_PRODUCT", 78, 83], ["patients", "ORGANISM", 192, 200], ["IL-18", "GENE_OR_GENE_PRODUCT", 221, 226], ["IL-18", "PROTEIN", 221, 226], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 192, 200], ["sJIA", "PROBLEM", 37, 41], ["IL", "TEST", 78, 80], ["other rheumatic diseases", "PROBLEM", 113, 137], ["SLE", "PROBLEM", 146, 149], ["rheumatoid arthritis", "PROBLEM", 153, 173], ["the disease", "PROBLEM", 275, 286], ["MAS", "TEST", 317, 320], ["rheumatic", "OBSERVATION_MODIFIER", 119, 128], ["diseases", "OBSERVATION", 129, 137], ["rheumatoid arthritis", "OBSERVATION", 153, 173], ["disease", "OBSERVATION", 279, 286]]], ["Interestingly, the development of MAS in these patients is associated with a further rise in IL-18 levels [85] .", [["MAS", "DISEASE", 34, 37], ["patients", "ORGANISM", 47, 55], ["IL-18", "GENE_OR_GENE_PRODUCT", 93, 98], ["IL", "PROTEIN", 93, 95], ["patients", "SPECIES", 47, 55], ["MAS", "PROBLEM", 34, 37], ["a further rise in IL", "PROBLEM", 75, 95], ["MAS", "OBSERVATION", 34, 37], ["rise", "OBSERVATION_MODIFIER", 85, 89]]], ["IL-18 has also been found to correlate with ferritin in adult onset Still disease [86] .", [["Still disease", "DISEASE", 68, 81], ["IL-18", "GENE_OR_GENE_PRODUCT", 0, 5], ["ferritin", "GENE_OR_GENE_PRODUCT", 44, 52], ["IL-18", "PROTEIN", 0, 5], ["ferritin", "PROTEIN", 44, 52], ["ferritin", "TEST", 44, 52]]], ["Therefore, IL-18 has been suggested as a promising biomarker for MAS.", [["IL-18", "GENE_OR_GENE_PRODUCT", 11, 16], ["IL-18", "PROTEIN", 11, 16], ["MAS", "PROBLEM", 65, 68]]], ["Another interesting field of growing research is in the role of IL-18-binding protein (IL-18BP) which is a naturally occurring protein that counter-regulates the activity of IL-18.", [["IL-18-binding protein", "GENE_OR_GENE_PRODUCT", 64, 85], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 87, 94], ["IL-18", "GENE_OR_GENE_PRODUCT", 174, 179], ["IL-18-binding protein", "PROTEIN", 64, 85], ["IL", "PROTEIN", 87, 89], ["18BP", "PROTEIN", 90, 94], ["IL-18", "PROTEIN", 174, 179], ["IL", "TEST", 64, 66], ["field", "OBSERVATION_MODIFIER", 20, 25], ["growing", "OBSERVATION_MODIFIER", 29, 36]]], ["Imbalance between IL-18 and IL-18BP, leading to higher levels of unbound IL-18, has been found in patients with increased disease severity [33, 86, 352] .", [["IL-18", "GENE_OR_GENE_PRODUCT", 18, 23], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 28, 35], ["IL-18", "GENE_OR_GENE_PRODUCT", 73, 78], ["patients", "ORGANISM", 98, 106], ["IL-18", "PROTEIN", 18, 23], ["IL-18BP", "PROTEIN", 28, 35], ["IL-18", "PROTEIN", 73, 78], ["patients", "SPECIES", 98, 106], ["IL", "TEST", 18, 20], ["IL", "TREATMENT", 28, 30], ["unbound IL", "TEST", 65, 75], ["increased disease severity", "PROBLEM", 112, 138], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["disease", "OBSERVATION", 122, 129]]], ["The administration of synthetic IL-18BP in perforin-deficient mice infected with murine CMV ameliorated liver damage but has not shown an effect on the pro-inflammatory cytokine levels or on the overall survival [353] .", [["liver", "ANATOMY", 104, 109], ["liver damage", "DISEASE", 104, 116], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 32, 39], ["perforin", "GENE_OR_GENE_PRODUCT", 43, 51], ["mice", "ORGANISM", 62, 66], ["murine", "ORGANISM", 81, 87], ["CMV", "ORGANISM", 88, 91], ["liver", "ORGAN", 104, 109], ["IL-18BP", "PROTEIN", 32, 39], ["perforin", "PROTEIN", 43, 51], ["pro-inflammatory cytokine", "PROTEIN", 152, 177], ["mice", "SPECIES", 62, 66], ["murine", "SPECIES", 81, 87], ["mice", "SPECIES", 62, 66], ["CMV", "SPECIES", 88, 91], ["synthetic IL", "TREATMENT", 22, 34], ["murine CMV ameliorated liver damage", "PROBLEM", 81, 116], ["the pro-inflammatory cytokine levels", "TEST", 148, 184], ["CMV", "OBSERVATION", 88, 91], ["liver", "ANATOMY", 104, 109], ["damage", "OBSERVATION", 110, 116]]], ["Based on these findings, further work is needed to demonstrate the role of IL-18 and IL-18BP in MAS.", [["IL-18", "GENE_OR_GENE_PRODUCT", 75, 80], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 85, 92], ["IL-18", "PROTEIN", 75, 80], ["IL-18BP", "PROTEIN", 85, 92], ["IL", "TEST", 75, 77]]], ["Along these lines, IL-18BP was shown to be beneficial in treating refractory MAS in a child with an NLRC4 mutation [354] .Other TargetsRecently, neutralizing antibodies and antagonists targeting the alarmin HMGB1 (high mobility group box 1) were proposed as potential therapeutic options, aiming to reduce the immunostimulatory load of necrosis-and pyroptosisderived danger signals.", [["MAS", "DISEASE", 77, 80], ["necrosis", "DISEASE", 336, 344], ["lines", "CELL", 12, 17], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 19, 26], ["NLRC4", "GENE_OR_GENE_PRODUCT", 100, 105], ["alarmin HMGB1", "GENE_OR_GENE_PRODUCT", 199, 212], ["high mobility group box 1", "GENE_OR_GENE_PRODUCT", 214, 239], ["IL-18BP", "PROTEIN", 19, 26], ["NLRC4", "PROTEIN", 100, 105], ["neutralizing antibodies", "PROTEIN", 145, 168], ["alarmin HMGB1", "PROTEIN", 199, 212], ["high mobility group box 1", "PROTEIN", 214, 239], ["refractory MAS", "PROBLEM", 66, 80], ["an NLRC4 mutation", "PROBLEM", 97, 114], ["neutralizing antibodies", "TREATMENT", 145, 168], ["antagonists", "TREATMENT", 173, 184], ["the alarmin HMGB1", "TREATMENT", 195, 212], ["high mobility group box", "TREATMENT", 214, 237], ["necrosis", "PROBLEM", 336, 344], ["lines", "OBSERVATION_MODIFIER", 12, 17], ["NLRC4 mutation", "OBSERVATION", 100, 114], ["necrosis", "OBSERVATION", 336, 344]]], ["Models of systemic sterile and infectious inflammation have demonstrated the efficacy of this strategy [355] .", [["inflammation", "DISEASE", 42, 54], ["systemic sterile and infectious inflammation", "PROBLEM", 10, 54], ["systemic", "OBSERVATION_MODIFIER", 10, 18], ["infectious", "OBSERVATION_MODIFIER", 31, 41]]], ["Moreover, blocking the alarmin IL-33, via its receptor ST2/IL-1RL1, is also a potential therapy [356] [43] .", [["IL-33", "GENE_OR_GENE_PRODUCT", 31, 36], ["ST2", "GENE_OR_GENE_PRODUCT", 55, 58], ["IL-1RL1", "GENE_OR_GENE_PRODUCT", 59, 66], ["alarmin IL-33", "PROTEIN", 23, 36], ["ST2", "PROTEIN", 55, 58], ["IL", "PROTEIN", 59, 61], ["1RL1", "PROTEIN", 62, 66], ["the alarmin IL", "TREATMENT", 19, 33]]], ["Overall, the future is looking brighter for a variety of potential therapeutics to treat HLH/MAS in a patient-specific fashion.", [["HLH", "DISEASE", 89, 92], ["MAS", "DISEASE", 93, 96], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["potential therapeutics", "TREATMENT", 57, 79], ["HLH", "PROBLEM", 89, 92], ["MAS", "PROBLEM", 93, 96]]]]}